
<html lang="en"     class="pb-page"  data-request-id="b311f33b-5dad-4e42-8ce8-d5f5894836e5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.0c00829;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-22"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon" /></meta><meta name="dc.Creator" content="Tanaji T.  Talele" /></meta><meta name="dc.Description" content="A quaternary carbon bears four other carbon substituents or combination of four non-hydrogen substituents at four vertices of a tetrahedron. The spirocyclic quaternary carbon positioned at the cent..." /></meta><meta name="Description" content="A quaternary carbon bears four other carbon substituents or combination of four non-hydrogen substituents at four vertices of a tetrahedron. The spirocyclic quaternary carbon positioned at the cent..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 17, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00829" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00829" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00829" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00829" /></link>
        
    
    

<title>Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00829" /></meta><meta property="og:title" content="Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0051.jpeg" /></meta><meta property="og:description" content="A quaternary carbon bears four other carbon substituents or combination of four non-hydrogen substituents at four vertices of a tetrahedron. The spirocyclic quaternary carbon positioned at the center of a bioactive molecule offers conformational rigidity, which in turn reduces the penalty for conformational entropy. The quaternary carbon is a predominant feature of natural product structures and has been associated with more effective and selective binding to target proteins compared to planar compounds with a high sp2 count. The presence of a quaternary carbon stereocenter allows the exploration of novel chemical space to obtain new molecules with enhanced three-dimensionality. These characteristics, coupled to an increasing awareness to develop sp3-rich molecules, boosted utility of quaternary carbon stereocenters in bioactive compounds. It is hoped that this Perspective will inspire the chemist to utilize quaternary carbon stereocenters to enhance potency, selectivity, and other drug-like properties." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00829"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00829">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00829&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00829&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00829&amp;href=/doi/10.1021/acs.jmedchem.0c00829" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 13291-13315</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00780" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c00884" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Tanaji T. Talele</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tanaji T. Talele</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, New York 11439, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#a9ddc8c5ccc5ccdde9daddc3c6c1c7da87cccddc"><span class="__cf_email__" data-cfemail="6b1f0a070e070e1f2b181f0104030518450e0f1e">[email protected]</span></a>. Phone: (718) 990-5405. Fax: (718) 990-1877.</span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tanaji+T.++Talele">Tanaji T. Talele</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5938-6505" title="Orcid link">http://orcid.org/0000-0002-5938-6505</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00829&amp;href=/doi/10.1021%2Facs.jmedchem.0c00829" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 13291–13315</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 17, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 May 2020</li><li><span class="item_label"><b>Published</b> online</span>17 August 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 November 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00829" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00829</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 <span class="NLM_copyright-holder">American Chemical Society</span></strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D13291%26pageCount%3D25%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTanaji%2BT.%2BTalele%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D22%26contentID%3Dacs.jmedchem.0c00829%26title%3DOpportunities%2Bfor%2BTapping%2Binto%2BThree-Dimensional%2BChemical%2BSpace%2Bthrough%2Ba%2BQuaternary%2BCarbon%26numPages%3D25%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D13315%26publicationDate%3DNovember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00829"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3714</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">10</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00829" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Tanaji&quot;,&quot;last_name&quot;:&quot;T. Talele&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;17&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;13291-13315&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00829&quot;},&quot;abstract&quot;:&quot;A quaternary carbon bears four other carbon substituents or combination of four non-hydrogen substituents at four vertices of a tetrahedron. The spirocyclic quaternary carbon positioned at the center of a bioactive molecule offers conformational rigidity, which in turn reduces the penalty for conformational entropy. The quaternary carbon is a predominant feature of natural product structures and has been associated with more effective and selective binding to target proteins compared to planar compounds with a high sp2 count. The presence of a quaternary carbon stereocenter allows the exploration of novel chemical space to obtain new molecules with enhanced three-dimensionality. These characteristics, coupled to an increasing awareness to develop sp3-rich molecules, boosted utility of quaternary carbon stereocenters in bioactive compounds. It is hoped that this Perspective will inspire the chemist to utilize quaternary carbon stereocenters to enhance potency, selectivity, and other drug-like properties.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00829&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00829" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00829&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00829" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00829&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00829" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00829&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00829&amp;href=/doi/10.1021/acs.jmedchem.0c00829" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00829" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00829" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00829%26sid%3Dliteratum%253Aachs%26pmid%3D32805118%26genre%3Darticle%26aulast%3DTalele%26date%3D2020%26atitle%3DOpportunities%2Bfor%2BTapping%2Binto%2BThree-Dimensional%2BChemical%2BSpace%2Bthrough%2Ba%2BQuaternary%2BCarbon%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D22%26spage%3D13291%26epage%3D13315%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=291445" title="Chemical structure">Chemical structure</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/jmcmar.2020.63.issue-22/20201125/jmcmar.2020.63.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0051.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0051.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A quaternary carbon bears four other carbon substituents or combination of four non-hydrogen substituents at four vertices of a tetrahedron. The spirocyclic quaternary carbon positioned at the center of a bioactive molecule offers conformational rigidity, which in turn reduces the penalty for conformational entropy. The quaternary carbon is a predominant feature of natural product structures and has been associated with more effective and selective binding to target proteins compared to planar compounds with a high sp<sup>2</sup> count. The presence of a quaternary carbon stereocenter allows the exploration of novel chemical space to obtain new molecules with enhanced three-dimensionality. These characteristics, coupled to an increasing awareness to develop sp<sup>3</sup>-rich molecules, boosted utility of quaternary carbon stereocenters in bioactive compounds. It is hoped that this Perspective will inspire the chemist to utilize quaternary carbon stereocenters to enhance potency, selectivity, and other drug-like properties.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Relevance of a Quaternary Carbon in Modern Drug Design</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42706" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42706" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Traditionally medicinal chemists have been inclined to create architecturally simple flat molecules.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> This is not surprising because the commercial compound screening libraries employed in several high-throughput screening (HTS) campaigns are enriched with flat and linear (hetero)aromatic compounds with a limited number of sp<sup>3</sup> carbon centers.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4−6)</a> Moreover, (hetero)aromatic rings provide numerous vectors that can be functionalized by a robust aromatic chemistry without introducing stereochemical complexity.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Substituents, appended to sp<sup>2</sup>-rich (hetero)aromatic rings, are often projected outward along the perimeter of a disk shaped molecular skeleton.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> On the contrary, substituents, appended to a diversity oriented synthesis-derived globular/spherical sp<sup>3</sup>-rich compound, are projected out-of-plane of a spherically shaped skeleton.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Although (hetero)aromatic rings appear to be attractive in terms of synthetic feasibility and SAR analysis compared to the sp<sup>3</sup>-rich scaffolds, too many in a given lead compound will have negative consequences (poor solubility, increased plasma protein binding, CYP450 inhibition/activation, and hERG (human ether-a-go-go-related gene) channel inhibition) in terms of clinical development.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> For example, highly planar molecular features result in higher packing in a three-dimensional periodic lattice through π-stacking, a characteristic that, in turn, can lead to compounds with poor aqueous solubility.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8−10)</a> Flat molecules are metabolically labile largely due to the presence of unhindered metabolically labile sites. Furthermore, flat molecules occupy only a tiny fraction of synthetically feasible small molecule entities within the universe of astronomically large (>10<sup>60</sup>) collection of molecules with drug-like properties.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> Increased molecular planarity (mostly two-dimensional) provides limited shape diversity and less efficient interaction toward a three-dimensional target binding site.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The high (hetero)aromatic ring count has been associated with the inhibition/activation of the major drug metabolizing CYP450 enzymes.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Additionally, flat molecules are prone to a high chance of off-target effects.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14−16)</a> Aforementioned shortcomings of largely two-dimensional molecules collectively contribute to a higher rate of late stage attrition of sp<sup>2</sup>-rich drug candidates.<a onclick="showRef(event, 'ref1 ref2 ref14'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref14">(1,2,14)</a></div><div class="NLM_p">The molecular planarity can be effectively disrupted by increasing the fraction of sp<sup>3</sup> (Fsp<sup>3</sup>)-hybridized carbons while removing aromatic rings from a planar structure.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> This topic has been the subject of many reviews.<a onclick="showRef(event, 'ref15 ref16 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref19 ref20 ref21">(15,16,19−21)</a> Fsp<sup>3</sup> is a measure of molecular complexity and is defined as a ratio of the number of sp<sup>3</sup> hybridized carbon atoms to the total carbon atom count.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Alicyclic ring systems are more water-soluble because of increased solvation and poor solid state crystal lattice packing compared to flat (hetero)aromatic ring systems.<a onclick="showRef(event, 'ref1 ref16 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref1 ref16 ref23 ref24">(1,16,23,24)</a> Consequently, efforts in drug discovery have been directed to incorporate sp<sup>3</sup>-hybridized carbon centers to allow for more efficient sampling of a larger fraction of chemical space and on target selectivity.<a onclick="showRef(event, 'ref7 ref15 ref16 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref7 ref15 ref16 ref25 ref26 ref27">(7,15,16,25−27)</a> Small drug molecules enriched with sp<sup>3</sup>-hybridized carbon atoms with minimal aromatic/heteroaromatic rings are likely to be clinically successful.<a onclick="showRef(event, 'ref15 ref16 ref28'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref28">(15,16,28)</a> It has been shown that an increase in sp<sup>3</sup> count in small molecules resulted in reduced promiscuity and inhibition of drug metabolizing CYP450 enzymes.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Further sp<sup>3</sup>-rich molecules may enable targeting of those therapeutic proteins that are otherwise difficult to target.<a onclick="showRef(event, 'ref6 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref6 ref29 ref30">(6,29,30)</a></div><div class="NLM_p">The presence of a sterically hindered quaternary carbon in bioactive small molecules promotes an element of conformational restriction and architecturally complex structures that are shown to impart increased potency, selectivity, and metabolic stability.<a onclick="showRef(event, 'ref4 ref15 ref16 ref23 ref31 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref4 ref15 ref16 ref23 ref31 ref32 ref33">(4,15,16,23,31−33)</a> A quaternary carbon bears four other carbon substituents or combination of four non-hydrogen substituents that form the vertices of a tetrahedron. A quaternary carbon (spiroatom) is also present in spirocyclic molecules. A quaternary carbon-containing small molecule possesses inherent three-dimensionality that allows for the simultaneous projection/optimization of substituents at the four vertices of a tetrahedral carbon atom.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> By virtue of chain growth in all four directions from the sp<sup>3</sup> tetrahedral carbon atom, quaternary carbon-containing small molecules will allow medicinal chemists to tap into a previously unexplored chemical space.<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34,35)</a> Although a precise definition of chemical space is more complex, a simplified definition states that it is a collection of all possible organic compounds.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Construction of quaternary carbon-containing small molecules is a formidable synthetic challenge due to inherently unfavorable steric hindrance.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> The paucity of efficient and generally applicable synthetic methods for the construction of quaternary carbon-containing small molecules has restricted its application in drug discovery. Nonetheless, recent publications disclosing synthetic methodologies for the construction of quaternary-carbon containing small molecules are expected to spur further interest in this area of drug discovery.<a onclick="showRef(event, 'ref13 ref37 ref39 ref40 ref41 ref42 ref43 ref44 ref45 ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref13 ref37 ref39 ref40 ref41 ref42 ref43 ref44 ref45 ref46 ref47 ref48">(13,37,39−48)</a></div><div class="NLM_p last">A major objective of this Perspective is to encourage exploration of three-dimensional space in small molecules through the use of a quaternary-carbon center by providing rather selected examples and by no means an exhaustive review of the field. Where possible, matched molecular pairs with a concise discussion are provided, and the reader is referred to the original citations for a more detailed information. The last sections of this Perspective will highlight (i) the contribution of a quaternary carbon in terms of drug-like property optimization, (ii) potential caveats of quaternary carbon insertion in bioactive compounds, (iii) examples of quaternary carbon-containing compounds that entered development, and (iv) the summary.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Matched Molecular Pairs of Quaternary versus Secondary/Tertiary Carbon Compounds</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46632" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46632" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Discovery of Oxytocin Receptor (OTR) Antagonists <b>1</b> and <b>2</b></h3><div class="NLM_p">The OTR antagonism in the brain has been shown to present a potential treatment for premature ejaculation,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> which prompted Li and co-workers to develop OTR antagonists.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Early lead compounds such as <b>1</b>, featuring a phenyl substituted pyrrolidine ring, demonstrated low nanomolar potency against human OTR, but it showed poor selectivity over vasopressin. It also exhibited poor rat pharmacokinetic (PK) profile (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). To circumvent the shortcomings of <b>1</b>, the pyrrolidine ring of this compound was converted into a more rigid ring system such as 3-azabicyclo[3.1.0]hexane to obtain a quaternary carbon-containing (<i>S</i>,<i>S</i>) analogue <b>2</b> (SHR1653)<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> with marginally improved human OTR antagonist activity. <b>2</b> manifested a significantly improved rat PK profile and selectivity over human vasopressin compared to <b>1</b>. Furthermore, <b>2</b> demonstrated excellent blood–brain barrier (BBB) permeability as evidenced from its concentration (229 ng/g) in rat brain tissue.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures, in vitro potency, and PK profiles of OTR antagonists <b>1</b> and <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Development of Lysine Specific Demethylase 1 (LSD1) Inhibitors <b>3</b> and <b>4</b></h3><div class="NLM_p">LSD1 plays a key role in cancer and other diseases. Consequently, Mould and co-workers synthesized several <i>N</i>-arylglycinamides as reversible LSD1 inhibitors.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> They reported that the early lead <b>3</b> was a potent reversible inhibitor of LSD1 with acceptable in vitro ADME profile and off-target hERG activity. Lead optimization efforts led these authors to conclude that the presence of a <i>para</i>-cyanophenyl (the cyano group forming a key hydrogen bond with Lys661) and the side chain basic nitrogen center (which forms a network of ionic interactions with acidic residues Asp555 and Asp556) were critical for LSD1 inhibition. Further improvement in in vitro ADME and hERG inhibition liability profile and in vitro potency was accomplished by rigidifying the 4-aminomethylpiperidine into the 2,7-diazaspiro[3.5]nonane spiro ring system as in <b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures, in vitro potency, and PK profiles of LSD1 inhibitors <b>3</b> and <b>4</b>. SPR, surface plasmon resonance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Development of G-Protein-Coupled Bile Acid Receptor 1 (GP-BAR1/TGR5) Agonists <b>5</b>–<b>7</b></h3><div class="NLM_p">Zhang et al. began optimization of an initial lead <b>5</b> as TGR5 agonists for the treatment of type 2 diabetes.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Chemical modification of <b>5</b> involved incorporation of a methyl group at the 7-position of a tetrahydrobenzimidazole scaffold, leading to <b>6</b> with a quaternary center at C7 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). This modification resulted in modestly improved activity toward mouse TGR5 with no improvement in aqueous solubility and potency toward human TGR5. To increase the kinetic solubility and human TGR5 potency of <b>6</b>, a favorable C7-methyl group was retained and a <i>tert</i>-amine capped polyethylene glycol group was inserted at the <i>para</i>-position of the eastern phenyl ring to obtain <b>7</b> with increased kinetic solubility and potency at both mouse and human TGR5. Furthermore, <b>7</b> showed desirable in vivo DMPK profile in mouse.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures, in vitro potency, and DMPK profiles of TGR5 agonists <b>5</b>–<b>7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Discovery of Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitors <b>8</b>–<b>10</b></h3><div class="NLM_p">DGAT1 is an emerging target for the development of treatments for metabolic disorders. Consequently, Cheung and co-workers developed tetralone derivatives as potent and selective inhibitors of DGAT1.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> They began with the tetralone derivative <b>8</b>, which showed single-digit micromolar DGAT1 inhibitory potency. However, the C2-monosubstituted tetralone, as in <b>8</b>, may undergo racemization due to the presence of an enolizable C1-ketone function, and the electrophilic ketone group is further susceptible to nucleophilic attack. These observations prompted the authors to introduce a quaternary center next to the ketone functionality as exemplified by the trifluoroethyl substituted tetralone derivative rac-<b>9</b> with a >900-fold increased DGAT1 inhibitory potency. While retaining the tetralone scaffold of <b>9</b>, they optimized the central and the terminal phenyl rings to obtain <b>10</b> with in vitro potency akin to that of <b>9</b>.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Because of its excellent PK/PD profile, <b>10</b> was selected as a candidate for further development (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures, in vitro potency, and PK properties of DGAT1 inhibitors <b>8</b>–<b>10</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Discovery of Inhibitors of the PI3K-AKT-mTOR Pathway</h3><div class="NLM_p">The phosphoinositide-3-kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) pathway is involved in a number of cellular processes such as proliferation, metabolism, autophagy, differentiation, and survival.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Therefore, Hobbs et al. synthesized compound <b>12</b>, characterized by the presence of a 3-oxabicyclo[4.1.0]heptane all-carbon quaternary morpholine surrogate, as a multitarget (PI3K/AKT/MTOR) inhibitor.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The X-ray structure of <b>12</b> revealed coplanarity between the pyrimidine ring and the 3-oxabicyclo[4.1.0]heptane moiety. The authors postulated that the oxygen atom in a 3-oxabicyclo[4.1.0]heptane ring is oriented optimally to engage in a key hydrogen bonding interaction with the target enzymes. On the basis of biochemical potency and physicochemical properties, <b>12</b> manifested a comparable profile to that of the previously reported morpholine analogue <b>11</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures, in vitro potency, and physicochemical properties of PI3K-AKT-mTOR pathway inhibitors <b>11</b> and <b>12</b>. Chrom logP, chromatographic log <i>P</i>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Development of P2Y<sub>12</sub> Antagonists <b>13</b> and <b>14</b> as Antiplatelet Agents</h3><div class="NLM_p">P2Y<sub>12</sub> antagonists were reported by Kong et al. to act as antiplatelet agents.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> They introduced a methyl substituent at the 4-position of the piperidine ring of <b>13</b> to obtain a quaternary carbon-containing piperidine analogue <b>14</b> with comparable in vitro potency and encouraging DMPK profile (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures and in vitro potency of <b>13</b> and <b>14</b> and DMPK properties of P2Y<sub>12</sub> antagonist <b>14</b>. hPRP, human platelet-rich plasma aggregation; MRT, mean residence time.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Development of Benzocyclobutene Derivatives <b>16</b> and <b>17</b> as General Anesthetics</h3><div class="NLM_p">Zhang and co-workers reported the synthesis of a novel class of benzocyclobutene-based general anesthetics by fusing the isopropyl moiety to the <i>meta</i>-position of the phenolic ring in <b>15</b> (propofol).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> This has led to the identification of the methyl substituted benzocyclobutene analogue <b>16</b> with marginally improved therapeutic efficacy and index compared to <b>15</b>. Incorporation of the cyano group on a methyl substituted <i>tert</i>-carbon center led to a quaternary carbon-containing analogue <b>17</b> with increased efficacy and therapeutic index (TI) evaluated using a mice model of anesthesia (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures and in vivo efficacy of general anesthetics <b>15</b>–<b>17</b> in a mice model of anesthesia. TI, LD<sub>50</sub>/ED<sub>50</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Discovery of BCL-X<sub>L</sub> Inhibitors <b>18</b> and <b>19</b></h3><div class="NLM_p">Highly selective BCL-X<sub>L</sub> inhibitors are useful in the treatment of solid tumors. Since BCL-2 inhibition is associated with neutropenic toxicity, Wang and colleagues decided to develop a novel class of highly selective BCL-X<sub>L</sub> inhibitors.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> They synthesized <b>18</b> bearing the P<sub>4</sub>-pocket targeted sp<sup>3</sup>-rich cyclohexane ring. <b>18</b> showed exceptional selectivity toward BCL-X<sub>L</sub> and MOLT-4 cells over BCL-2 and RS4;11 cell lines, respectively (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Subsequently, they replaced the cyclohexane ring with a bulkier sp<sup>3</sup>-rich adamantyl moiety to obtain <b>19</b> with improved functional efficacy against MOLT-4 cells.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structures and in vitro potency of BCL-X<sub>L</sub> inhibitors <b>18</b> and <b>19</b>. HS, human serum.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Naphthalene Derivatives as Antifungal Agents <b>20</b>–<b>22</b></h3><div class="NLM_p">Nussbaumer and colleagues converted inactive secondary benzylic carbon bearing analogue <b>20</b> to a quaternary carbon derivative <b>21</b> by inserting a <i>gem</i>-dimethyl substituent.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a><b>21</b> had a significant improvement in antifungal activity against <i>Aspergillus fumigatus</i> and <i>Candida albicans</i> strains. Replacement of a <i>gem</i>-dimethyl group with a spirocyclopropane led to <b>22</b> with detrimental effect on antifungal activity, which reinforces the fact that quaternization is not a universal panacea for improving drug properties (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structures and in vitro potency of antifungal agents <b>20</b>–<b>22</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> A<sub>1</sub>-Adenosine Receptor Antagonists <b>23</b> and <b>24</b></h3><div class="NLM_p">Adenosine receptors are drug targets for numerous disease conditions.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Shimada and co-workers<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> began optimization of previously reported lead <b>23</b>,<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> which had a low nanomolar antagonist potency against A<sub>1</sub> and high selectivity over A<sub>2</sub>. Subsequent optimization involved replacement of a C8-cyclopentyl moiety with a conformationally restricted quaternary carbon-containing 2,2,5,5-tetramethylcyclopentyl moiety to obtain <b>24</b> with retention of antagonist potency against A<sub>1</sub> but with substantial boost in selectivity over A<sub>2</sub> (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures and in vitro binding affinity of adenosine receptor antagonists <b>23</b> and <b>24</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Two Quaternary Carbon-Containing Bicyclo[1.1.1]pentane (BCP) System as a Phenyl Ring Isostere</h3><div class="NLM_p last">Although BCP has a different stereoelectronic property compared to the 1,4-disubstituted phenyl ring, it shares comparable dihedral angles and similar distance and coplanar linear disposition of the substituents.<a onclick="showRef(event, 'ref64 ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref64 ref65 ref66">(64−66)</a> BCP system significantly increases aqueous solubility and noticeably decreases nonspecific binding.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> Consequently, the sp<sup>3</sup>-rich BCP system serves as a nonclassical phenyl bioisostere to “escape from flatland” imposed by high aromatic ring count and modulate physicochemical properties during lead optimization.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> For example, isosteric replacement of the 1,4-disubstituted phenyl ring with BCP has been shown to confer significantly improved passive permeability and aqueous solubility.<a onclick="showRef(event, 'ref66 ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref66 ref69 ref70">(66,69,70)</a> Further mGluR1 antagonist development work successfully utilized BCP as an isostere of a 1,4-disubstituted phenyl ring as evidenced from retention of mGluR1 antagonist potency.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64,65)</a> It should be noted that such bioisosteric replacement strategy will not be effective in lead compounds where a 1,4-disubstituted phenyl ring plays a pharmacophore role such as π–π stacking or π–cation interactions with the aromatic or positively charged residues of the target protein.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></div></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Isosteric Replacement of the Phenyl Ring by BCP System in Lipoprotein-Associated Phospholipase A<sub>2</sub> (LpPLA<sub>2</sub>) Inhibitor</h3><div class="NLM_p">LpPLA<sub>2</sub> is a therapeutic target for the development of antiatherosclerotic drugs. Comparison of the structures of <b>25</b> and <b>26</b> revealed successful isosterism between the phenyl ring and the two quaternary carbon-containing BCP system (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Although <b>26</b> underwent noticeable loss of potency, it exhibited improved physicochemical profile (including permeability, kinetic solubility, and thermodynamic fasted state simulated intestinal fluid solubility) and a comparable property forecast index (PFI)<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> (a risk indicator of developability). Despite a rise in ChromLogD<sub>7.4</sub> for <b>26</b> compared to <b>25</b>, it exhibited increased solubility and thus reinforces the contribution of disruption of the molecular planarity. <b>26</b> also showed low clearance based on human liver microsomal stability test. On the basis of the physicochemical properties of <b>26</b>, it is reasonable to assume that by disrupting the molecular planarity and decreasing the aromatic ring count, the solubility and other PK related properties can be improved.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structures, in vitro potency, and physicochemical properties of LpPLA<sub>2</sub> inhibitors <b>25</b> and <b>26</b>. CLIND, kinetic solubility; FaSSIF, thermodynamic fasted state simulated intestinal fluid solubility; AMP, artificial membrane permeability; chromLogD, chromatographic log <i>D</i>; PFI, property forecast index.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> γ-Secretase Inhibitors <b>27</b> and <b>28</b></h3><div class="NLM_p">γ-Secretase inhibitors have a potential for the treatment of Alzheimer’s disease. Stepan and co-workers bioisosterically replaced the <i>para</i>-substituted fluorophenyl ring in <b>27</b> with the BCP system, which led to <b>28</b> with retention of enzymatic potency but significantly improved biopharmaceutical properties, including human liver microsomal clearance, passive permeability, and aqueous solubility.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Further <b>28</b> showed superior oral absorption in a mouse model compared to <b>27</b> (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structures, in vitro potency, physicochemical properties, and DMPK profiles of γ-secretase inhibitors <b>27</b> and <b>28</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Resveratrol and Its BCP Isostere</h3><div class="NLM_p">True potential of resveratrol as a drug has been hampered due to its undesirable bioavailability. To address this drawback, Goh and colleagues<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> replaced the 1,4-disubstituted phenolic ring with bioisosteric BCP system, which led to <b>30</b> with improved in vivo PK profile compared to that of <b>29</b> (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>).<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Structures and in vivo PK profiles of <b>29</b> and <b>30</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Carbon–Oxygen/Sulfur/Nitrogen/Halogen Tetrasubstituted Center in Medicinal Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57427" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57427" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Discovery of GPR40 Superagonists <b>31</b> and <b>32</b></h3><div class="NLM_p">GPR40 agonism is a novel strategy for the development of therapeutics to treat type 2 diabetes. Huang et al. reported the synthesis of the <i>trans</i>-cyclohexane ring-containing fatty acid mimicking arylpropionic acid superagonist <b>31</b> that showed low nanomolar potency in a fluorometric imaging plate reader (FLIPR)-based intracellular calcium mobilization assay and inositol monophosphate (IP1) assay; however, its PK profile was less than optimal.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Insertion of an α-methyl in <b>31</b> led to a tetrasubstituted carbon-containing analogue <b>32</b> with improved potency and overall PK profile (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). Although <b>32</b> produced a potentially hepatotoxic acyl glucuronide (AG) conjugate, it was deemed safe because of the increased stability of AG conjugate (half-life of >7 h).</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structures, in vitro potency, and rat PK profiles of GPR40 agonists <b>31</b> and <b>32</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Discovery of Benzoazepine-quinolines as Orally Bioavailable Respiratory Syncytial Virus (RSV) Fusion (F) Protein Inhibitors <b>33</b> and <b>34</b></h3><div class="NLM_p">RSV F protein, a surface glycoprotein, is expressed on the RSV envelope and plays a key role for the entry of the virus into host cells.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> RSV F promotes the formation of syncytia between an infected cell and neighboring healthy cells, an effect that leads to the rapid spread of the viral infection.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Therefore, RSV F serves as a molecular target to halt viral entry and spread and thus to a treatment of a RSV infected patient. Zheng and colleagues applied 2D/3D similarity-based virtual screening to obtain several promising benzoazepine-quinoline lead compounds such as <b>33</b> with a potent and selective RSV F inhibitory activity.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Conformational analysis of <b>33</b> concluded that the benzoazepine ring and the quinoline ring must be orthogonal (90° dihedral angle) to each other for activity against RSV F. Further investigation of <b>33</b> revealed its poor PAMPA permeability and oral exposure. The reduced permeability of <b>33</b> was rationalized based on the presence of a highly basic (p<i>K</i><sub>b</sub>) terminal amine functionality. Therefore, addition of an oxetane ring, a carbonyl surrogate, adjacent to the basic amine in the form of a spiro ring would be expected to reduce the basicity (p<i>K</i><sub>b</sub>) as in <b>34</b>. Overall <b>34</b> demonstrated promising in vitro potency, selectivity, PAMPA permeability, and improved oral exposure compared to <b>33</b> (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). Docking of <b>34</b> into the RSV F protein indicated that the oxetane moiety primarily contributed toward restricting the conformation of the ethylamine head group such that it can effectively engage in salt bridge formation with the side chain of Asp486.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structures, in vitro potency, and PK profiles of RSV fusion protein inhibitors <b>33</b> and <b>34</b>. PAMPA, parallel artificial membrane permeability assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Identification of IKKβ Inhibitors <b>35</b> and <b>36</b></h3><div class="NLM_p">IκB kinase β (IKKβ), a major regulator of nuclear factor κB (NF-κB), is a therapeutic target for the development of nonsteroidal anti-inflammatory agents.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Kerns et al. described the optimization of 3,5-disubstituted indole-7-carboxamides as inhibitors of IKKβ.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Compound <b>35</b> showed promising in vitro potency and PAMPA permeability, but it suffered from moderate oral exposure and short half-life. To address these issues, a <i>gem</i>-dimethyl substituent was inserted on a carbon adjacent to the sulfone group, thus leading to <b>36</b> with comparable in vitro potency but improved PK profile than <b>35</b> (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>).</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Structures, in vitro potency, and PK profiles of IKKβ inhibitors <b>35</b> and <b>36</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Discovery of ERK Inhibitors <b>37</b>–<b>39</b></h3><div class="NLM_p">The extracellular signal-regulated kinase 1/2 (ERK1/2) has been established as a target for oncology drug discovery.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Promising in vitro biochemical and cell-based potency and selectivity were demonstrated by a pyrrolidine-based dual ERK1/2 inhibitor <b>37</b> (SCH-772984).<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> However, because <b>37</b> exhibited poor Caco2 cell permeability and high plasma clearance, it suffered from poor oral absorption and bioavailability. Metabolite identification studies on <b>37</b> showed hydrolytic degradation of the pyrrolidine-3-carboxamide group.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> The authors proposed that the poor PK profile of <b>37</b> was perhaps due to its hydrolysis. Therefore, they introduced a more sterically bulky (<i>S</i>)-methylthio group at the C3-position of the pyrrolidine ring to protect the amide group from undergoing hydrolysis. Other chemical modifications involved replacement of the pyridine and piperazine rings with 4-fluorophenyl and tetrahydropyridine rings, respectively. This strategy resulted in the identification of <b>38</b> with improved PK profile compared to <b>37</b>. The hydrolytically stable pyrrolidine core was retained while conducting chemical modifications on either end of <b>38</b> to obtain the dual ERK1/2 inhibitory orally bioavailable, clinical candidate <b>39</b> (MK-8353) (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>).<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a></div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structures, in vitro potency, and PK profiles of ERK1/2 inhibitors <b>37</b>–<b>39</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Identification of Pim Kinase Inhibitors <b>40</b> and <b>41</b></h3><div class="NLM_p">Since Pim kinases play a role in cancers, Wang et al. decided to develop pan-Pim kinase inhibitors.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> They began with the optimized quinazolinone-pyrrolodihydropyrrolone lead scaffold <b>40</b>, which showed potent pan-Pim kinase inhibitory activity. The authors suspected that the poor aqueous solubility exhibited by this scaffold was due to the coplanar arrangement of the quinazolinone and the pyrrole ring, a situation that is reinforced by an intramolecular hydrogen bond (IMHB) between the pyrrole-NH and the quinazolinone-N. To offset this liability, they decided to explore various substituents at the more tolerant N3-position of the quinazolinone core. Consequently, they replaced the <i>N</i>3-cyclopropyl group in <b>40</b> with the 1-methylcyclopropyl moiety, which led to the identification of <b>41</b>, showing improved enzymatic and cellular potencies and PK profile (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>). The X-ray crystal structure data revealed binding of the two methylcyclopropyl moieties into small hydrophobic pockets positioned under the glycine-rich loop of Pim-1 kinase. The authors concluded that this interaction may be responsible for the high potency and selectivity of <b>41</b> over other related kinases.</div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Structures, in vitro potency, and PK profiles of Pim kinase inhibitors <b>40</b> and <b>41</b>. KMS-12 pBAD, inhibition of phosphorylation of BAD at Ser112 in KMS-12 BM cells; LLC-PK1, single layer of LLC-PK1 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Discovery of Veliparib (<b>44</b>)</h3><div class="NLM_p">Poly(ADP-ribose)polymerase 1 (PARP1) inhibitors are useful for the treatment of various cancers as single agents or in combination with established chemotherapeutic agents. To this end, a series of cyclic amine-containing benzimidazole-4-carboxamide (BI-4-CONH<sub>2</sub>) catalytic inhibitors of PARP1 was reported by Penning and colleagues.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> They found that the pyrrolidin-2-yl at the 2-position of the BI-4-CONH<sub>2</sub> scaffold was a promising moiety to achieve low nanomolar biochemical and cellular potency as exemplified by compound <b>42</b> (PK profile not available). Next, they inserted the methyl substituent at C-2 position of the pyrrolidine ring, which ultimately led to the discovery of two tetrasubstituted carbon-containing enantiomers (<i>S</i>)-<b>43</b> and (<i>R</i>)-<b>44</b> (ABT-888/veliparib)<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> with marginally improved biochemical and cellular potencies. Though both enantiomers exhibited comparable in vitro potency, only the (<i>R</i>)-enantiomer (<b>44</b>) had a superior PK profile (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).</div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Structures and in vitro potency of <b>42</b>–<b>44</b> and PK profiles of PARP1 inhibitors <b>43</b> and <b>44</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Development of Leukotriene C4 Synthase (LTC4S) Inhibitors <b>45</b> and <b>46</b></h3><div class="NLM_p">LTC4S catalyzes the conversion of LTA4 to LTC4 in a cascade that leads to asthma.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Munck Af Rosenschold et al. reported the synthesis of a pyrazine derivative containing an <i>N</i>-isobutyl group with picomolar potency against LTC4S and showing attractive cell-based potency, distribution coefficient, and low human hepatocyte intrinsic clearance.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Incorporation of a fluorine atom at the 2-position of the <i>N</i>-isobutyl group led to a tetrasubstituted carbon-containing analogue <b>46</b> (AZD9898) with retention of picomolar potency against LTC4S and improved hepatocyte clearance compared to <b>45</b> (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>).<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> It may be noted that favorable hepatocyte clearance is a result of bioisosteric replacement of the hydrogen with a fluorine rather than the effect of quaternization.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a></div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Structures, in vitro potency, and physicochemical properties of LTC4S inhibitors <b>45</b> and <b>46</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Discovery of β-Arrestin Biased CNS Penetrating Neurotensin Receptor 1 (NTR1) Allosteric Modulators <b>47</b> and <b>48</b></h3><div class="NLM_p">Since NTR1 is an emerging target for a wide range of CNS disorders, Pinkerton et al. pursued optimization of quinazoline derivatives as potent and CNS penetrating NTR1 allosteric modulators.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Of the various derivatives prepared, <b>47</b>, bearing the <i>N</i>-methyl-2-hydroxyethylamine substituent at the C6-position of the quinazoline ring, demonstrated submicromolar efficacy against NTR1 and also demonstrated a promising response in terms of <i>E</i><sub>max</sub> (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>). Next, they converted the <i>tert</i>-C1-cyclopropyl ring to the 1-fluoro substituted cyclopropyl ring (-H to -F isosteric replacement)<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a>-containing analogue <b>48</b> (SBI-553) that showed marginally increased potency and response in addition to PK parameters that were suitable for further development.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a></div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Structures and in vitro potency of <b>47</b> and <b>48</b> and PK profile of NTR1 modulator <b>48</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Development of <i>N</i>-Methyl-<span class="smallcaps smallerCapital">d</span>-Aspartate Receptor (NMDAR) Positive Allosteric Modulators (PAMs)</h3><div class="NLM_p">NMDA receptors are implicated in a wide range of CNS disorders. Consequently, an endogenously produced neuroactive 24(<i>S</i>)-hydroxycholesterol <b>49</b>, serving as an initial lead, was optimized by La and colleagues to develop more potent NMDA receptor PAMs with favorable PK profile.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> The poor metabolic stability of <b>49</b> was suspected to be due to the phase 2 conjugation of the C3-OH group. Considering the essential role played by C3-OH group toward potency, the authors decided to sterically shield it by adding a methyl substituent to mitigate phase 2 metabolic inactivation. This has led to the identification of a metabolically stable C3-tetrasubstituted analogue <b>50</b>, demonstrating a >4-fold increase in potency toward GluN2 and improved in vivo PK properties compared to <b>49</b>. Further modification of <b>50</b> at the C24-position wherein an isopropyl group was replaced with a <i>gem</i>-dimethyl group led to the identification of <b>51</b> (SGE-301) bearing a second tetrasubstituted carbon (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>).<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Relative to <b>50</b>, compound <b>51</b> displayed further improvement in PK properties and also enhanced long-term potentiation and cognition in rat models.</div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Structures of neuroactive steroids <b>49</b>–<b>51</b> as NMDA receptor PAMs along with PK properties in SD rats.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Discovery of Estrogen Receptor α (ERα) Degraders <b>52</b> and <b>53</b></h3><div class="NLM_p">Burks and co-workers reported the synthesis of various tetrahydroisoquinoline derivatives as potent ERα antagonists with the ability to selectively degrade ERα.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> One of the early leads was compound <b>52</b>, bearing a quaternary benzylic carbon and demonstrating an acceptable potency against ERα (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>). Subsequently, they probed the significance of a methyl group connected to the benzylic carbon on ERα binding affinity by synthesizing and testing a des-methyl analogue of <b>52</b>, but this proved to be a weaker ERα antagonist compared to <b>52</b> (the authors did not show these data). It was reasoned that the weaker activity of a des-methyl analogue was the result of the loss of van der Waals interactions between the methyl group and Leu346 within the ligand binding site of ERα as confirmed by subsequent X-ray crystal structure analysis. Therefore, they retained a tetrasubstituted benzylic carbon center in subsequent optimization work, leading to the potent ERα degrader <b>53</b>. Although the (<i>R</i>)-stereochemistry at the tetrasubstituted benzylic chiral center of <b>53</b> demonstrated favorable affinity toward ERα, both the (<i>R</i>)- and (<i>S</i>)-isomers were shown to undergo fast racemization in a number of physiological conditions.</div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Structures and in vitro potency of ERα degraders <b>52</b> and <b>53</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Identification of Selective Estrogen Receptor Downregulator (SERD) Antagonists <b>54</b>–<b>57</b></h3><div class="NLM_p">Incorporation of 1-methyl substituent in a promising SERD hit <b>54</b> led to a tetrasubstituted carbon-containing <b>55</b> with a drop in potency while gaining lipophilicity by 0.9 log unit.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Addition of a second methyl group at C3-position led to a quaternary carbon-containing <b>57</b> with decreased potency but noticeable advantages in terms of turnover in both rat and human hepatocytes compared to C3-tertiary analogue <b>56</b> (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>).</div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Structures, in vitro potency, and in vitro DMPK properties of ER downregulator antagonists <b>54</b>–<b>57</b>. ER DR, estrogen receptor downregulation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In a follow-on work, Scott and colleagues demonstrated the impact of quaternization of C1-position in <b>58</b>.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> For example, insertion of 1-methyl substituent led to a tetrasubstituted carbon-containing <b>59</b> with retention of ER binding potency, but the degradation potency was substantially dropped. Moreover, quaternization also resulted in a noticeable drop in the stability of <b>59</b> as assessed by <sup>1</sup>H NMR and LC–MS analyses. To circumvent the stability concerns associated with <b>59</b>, the authors subsequently decided to bridge the diaxial 1,3-methyl groups leading to the identification of a bridged tetracyclic indole scaffold <b>60</b> with improved stability; however, it showed lowered ER binding and ER degradation potencies compared to <b>59</b> (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>). Thus, ER degrader examples indicate that quaternization of a secondary or a tertiary carbon does not always lead to improved pharmacodynamic or pharmacokinetic properties.</div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Structures, in vitro potency, in vitro DMPK properties, and stability of ER downregulator antagonists <b>58</b>–<b>60</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Synthesis of Phenylindole-Based Inhibitors of AAA+ ATPase p97 Inhibitors <b>61</b> and <b>62</b></h3><div class="NLM_p">Since p97 is as a potential anticancer target, LaPorte et al., optimized their early lead compound <b>61</b>, which showed submicromolar potency against p97 (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>).<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> They made two chemical modifications to <b>61</b>: (1) insertion of a fluorine atom at the 5-position of the indole nucleus and (2) installation of a spirocyclobutane ring at the α-carbon adjacent to the <i>N</i>-methylpiperazine ring. These modifications led to the identification of <b>62</b> with a 14-fold increase in potency. On the basis of SAR studies around 2-phenylindole derivatives, it was reasoned that the enhanced potency of <b>62</b> was due to the combined contribution of (1) a hydrogen bond between a 5-fluorine and the side chain of Thr509 and (2) a spirocyclobutane providing a kinked <i>N</i>-methylpiperazine side chain that effectively occupies a deep hydrophobic pocket enclosed by residues Val493 and Ile531 of p97. The authors hypothesized that the more buried binding of the <i>N</i>-methylpiperazine could be the result of desolvation of the spirocyclobutyl moiety.</div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Structures and in vitro potency of p97 inhibitors <b>61</b> and <b>62</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Development of Cell Active SET and MYND Domain-Containing Protein 2 (SMYD2) Inhibitory Chemical Probes</h3><div class="NLM_p">Since increased expression of SMYD2 has been shown in a number of cancer types,<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Taylor and colleagues began the search for efficient cell active chemical probes targeted to SMYD2.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Toward this objective, the first lead compound <b>63</b> showed a low nanomolar biochemical inhibitory activity against SMYD2, but it exhibited poor cell-based activity in MCF7 cells (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>). Consequently, <b>63</b> was not regarded as a useful chemical probe. This limitation was addressed by exploiting a small lipophilic notch observed in the crystal structure of the SMYD2-<b>63</b> complex. To effectively fill this, they introduced a methyl group at the 3-position of the azetidine ring while simultaneously increasing compound lipophilicity for cellular permeability as in <b>64</b>. Compound <b>64</b> exhibited increased cell-based potency while retaining the <i>S</i>-adenosylmethionine-competitive inhibitory biochemical potency of <b>63</b>.</div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Structures and in vitro potency of SMYD2 inhibitors <b>63</b> and <b>64</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Discovery of Human Neuromedin U Receptor 1 (NMUR1) Agonists <b>65</b> and <b>66</b></h3><div class="NLM_p">NMUR1 is an emerging target for the development of antiobesity drugs. Takayama and co-workers reported the synthesis of 2-thienylacetyl hexapeptides as selective NMUR1 agonists with enhanced serum stability.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> The hexapeptide analogue <b>65</b> showed highly selective agonist activity toward NMUR1 (EC<sub>50</sub> > 0.25 nM), which was greater than toward NMUR2 (EC<sub>50</sub> > 100 nM), but it suffered from rapid degradation by rat and human serum thrombin. To overcome this limitation, they synthesized the new hexapeptide analogue <b>66</b> bearing an α-methyl at Trp<sup>2</sup>, which not only improved potency and selectivity toward NMUR1 (EC<sub>50</sub> = 0.25 nM) over NMUR2 (EC<sub>50</sub> > 100 nM) but also enhanced stability in rat and human serum (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>). The authors concluded that the α-methylation at Trp<sup>2</sup> prevented efficient binding of this modified residue to the thrombin P<sub>4</sub> aryl binding site. Furthermore, <b>66</b> significantly reduced the body weight of male ddY mice upon subcutaneous administration.</div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0028.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Structures, in vitro potency, and DMPK profiles of NMUR1 agonists <b>65</b> and <b>66</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Development of β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors <b>67</b>–<b>69</b></h3><div class="NLM_p">BACE1, an aspartyl protease enzyme, plays a crucial role in the production of amyloid β in the brain. Therefore, it has been widely explored as a therapeutic target for the development of anti-Alzheimer’s drugs. A cyclopropylthiazine analogue <b>67</b> manifested low nanomolar biochemical and cell (HEK)-based potency against BACE1, but it lacked selectivity as evidenced from its potent inhibitory action on BACE2 activity. Therefore, it was optimized first at the P<sub>1′</sub> and then at the P<sub>3</sub> regions to enhance selectivity toward BACE1 and also to obtain new analogues with a CNS drug-like profile. Although insertion of a methoxymethyl substituent in the P<sub>1′</sub> region as in <b>68</b> resulted in improved enzymatic and cell-based BACE1 inhibitory activity and P-gp efflux ratio, it retained high affinity toward BACE2. While retaining the P<sub>1′</sub> methoxymethyl substituent on the tetrasubstituted carbon of the cyclopropylthiazine, the authors replaced the 5-chloropyridine P<sub>3</sub> motif with a 5-propargyloxypyrazine ring to effectively fill the deeper S<sub>3</sub> pocket of BACE1. These efforts resulted in the identification of <b>69</b> (AM-6494) with increased biochemical and cellular potency against BACE1, desirable selectivity over BACE2 and CatD and exhibited in vitro and in vivo CNS drug-like properties and efficacy (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>).<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a></div><figure id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0029.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Structures, in vitro potency, and physicochemical properties of BACE1 inhibitors <b>67</b>–<b>69</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Design of <b>71</b> (Misoprostol)</h3><div class="NLM_p">Nonsteroidal anti-inflammatory drug (NSAID)-induced damage to gastric mucosa is a common problem associated with the chronic use of nonselective NSAIDs.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> An exogenously administered natural prostaglandin PGE<sub>1</sub> (<b>70</b>) was shown to reduce gastric damage. However, it was ineffective orally and parenteral administration led to the rapid degradation by prostaglandin-15-hydroxydehydrogenase-mediated oxidation of the C15-secondary alcohol group to an inactive C15-ketone metabolite. To address this concern, the prostaglandin derivative <b>71</b> (misoprostol) was developed for oral administration. Specifically, three chemical modifications were performed on <b>70</b>: (1) the carboxyl group was converted to the methyl ester, which upon oral administration undergoes an esterase-mediated hydrolysis to the active carboxylic acid metabolite, (2) the hydroxyl group was relocated from the C15 to the C16 position to thwart the enzyme prostaglandin-15-hydroxydehydrogenase, and (3) successive insertion of a methyl group at the C16 was done, thus generating the stable <i>tert</i>-alcohol-containing derivative <b>71</b> (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>).</div><figure id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0030.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Structures of gastric mucosa protecting prostaglandins <b>70</b> and <b>71</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Discovery of HCV NS5B Polymerase Inhibitor <b>72</b> (Sofosbuvir)</h3><div class="NLM_p">The nucleoside phosphoramidate prodrug <b>72</b> (sofosbuvir), a hepatitis C virus (HCV) NS5B polymerase inhibitor discovered by Sofia and co-workers, has been used for the treatment of chronic HCV infections (<a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>).<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Although <b>72</b> carries a 3′-hydroxyl group to serve as a nucleophile for an incoming nucleotide substrate, it acts as a terminator of the nascent RNA product. The chain termination activity of <b>72</b> is analogous to that of other related C2′-modified nucleoside analogues (<a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>), i.e., the steric clash between the congested C2′-tetrasubstituted stereocenter and the incoming nucleoside triphosphate as well as the side chain of Ser282/Thr282 within the active site of HCV NS5B polymerase.<a onclick="showRef(event, 'ref99 ref100'); return false;" href="javascript:void(0);" class="ref ref99 ref100">(99,100)</a> The C2′-tetrasubstituted stereocenter also allowed downward orientation of a fluorine atom to engage in favorable interactions with the side chain of Asn291. This interaction was critical for the recognition of the active form of <b>72</b> at the active site of HCV NS5B polymerase.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Several other tetrasubstituted C2’ motifs such as 2′-α-hydroxy-2′-β-methyl, 2′-α-fluoro-2′-β-chloro, 2′-deoxy-2′-spirooxetane, and 2′-deoxy-2′-spirocyclopropane are also shown to potently inhibit HCV NS5B polymerase by a similar mechanism (<a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig31" id="" class=" internalNav">31</a></a>).<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a></div><figure id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0031.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Structures of HCV NS5B polymerase inhibitor <b>72</b> and the general tetrasubstituted C2′-ribose modification strategy employed in HCV NS5B polymerase inhibitor design.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Bromodomain and Extra-Terminal Protein (BET) Inhibitors <b>73</b> and <b>74</b></h3><div class="NLM_p">BET is a well-established target for anticancer drug development. Although benzhydryl-containing <b>73</b> showed potent biochemical and cell-based potency, it suffered from unfavorable ligand lipophilic efficiency (LLE). To improve LLE, the diphenyl moiety in <b>73</b> was replaced with a bipyridyl moiety while simultaneously adding a methyl substituent at the benzylic carbon, which led to a tetrasubstituted carbon-containing derivative <b>74</b> with improved potency and LLE (<a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig32" id="" class=" internalNav">32</a></a>).<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></div><figure id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0032.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Structures and in vitro potency of BET inhibitors <b>73</b> and <b>74</b>. TR-FRET BD1, measurement of binding to BRD4-BD1 domain using time-resolved fluorescence energy transfer TR-FRET binding assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Discovery of Toll-like Receptor 8 (TLR8) Agonists <b>75</b>–<b>77</b></h3><div class="NLM_p">Activation of TLR8 by small molecules has been hypothesized to stimulate host immune response, which in turn will provide a novel treatment strategy for chronic hepatitis B.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> On the basis of this concept, Mackman and colleagues synthesized TLR8 selective derivative <b>75</b> showing submicromolar potency against IL-12p40 (TLR8 cytokine), but it had no effect on TLR7-mediated induction of IFN-α up to 50 μM and showed only 10-fold MT-4 cytotoxicity window.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> To completely fill the lipophilic pocket of TLR8 from the α-branch point and minimize entropic penalty of the flexible hydroxymethyl substituent, the authors introduced an α-methyl group to obtain a tetrasubstituted carbon-containing <b>76</b> with improved potency and selectivity toward TLR8 which also resulted in significantly improved MT-4 cytotoxicity window. To mitigate metabolic modification of the pyridopyrimidine core, a 7-fluoro group was added, which gave rise to a clinical candidate <b>77</b> (GS-9688, selgantolimod) (<a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig33" id="" class=" internalNav">33</a></a>).<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a></div><figure id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0033.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Structures and in vitro potency of TLR8 agonists <b>75</b>–<b>77</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 1,5-Benzodiazepines as Cholecystokinin A (CCK-A) Agonists <b>78</b> and <b>79</b></h3><div class="NLM_p">Selective CCK-A agonists are useful in obese patients as satiety agents.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Willson and co-workers began optimization of one of the leads, <b>78</b>, by inserting a methyl group at C3-position of the benzodiazepine scaffold, which led to quaternary carbon-containing <b>79</b> with increased functional efficacy and selectivity.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> In contrast, incorporation of a methyl group at C3 in urea series as exemplified by <b>80</b> resulted in loss of functional efficacy and selectivity (<a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig34" id="" class=" internalNav">34</a></a>). Thus, <b>80</b> highlights a potential caveat that incorporation of a quaternary center does not always lead to improved ligand properties.</div><figure id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0034.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Structures and in vitro potency of CCK-A agonists <b>78</b>–<b>80</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39">Examples of Spirocycles in Drug Discovery</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12371" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12371" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Zheng et al. briefly reviewed the application of spirocyclic scaffolds in drug discovery with an emphasis on biological activities and provided examples reported during 2011–2015.<a onclick="showRef(event, 'ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref107 ref108">(107,108)</a> Muller et al. recently described the analysis of sp<sup>3</sup>-rich spirocycle-containing bioactive compounds and concluded that spirocyclic chemical space can be further expanded for drug discovery.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a></div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Discovery of Cyclophilin (CyP) A Inhibitors <b>81</b> and <b>82</b> with Potent Anti-HCV Activity</h3><div class="NLM_p">Interaction of host CyP A and HCV NS5a protein has been suggested to play a role in the replication of HCV.<a onclick="showRef(event, 'ref110 ref111'); return false;" href="javascript:void(0);" class="ref ref110 ref111">(110,111)</a> Therefore, disruption of host CyP A and HCV NS5a interaction represents a viable strategy to minimize HCV replication. Targeting CyP A by small molecules will also ensure high barrier to resistance and pan-genotypic activity. To that end, Mackman and co-workers decided to develop orally bioavailable nonimmunosuppressive small molecule CyP A inhibitors with potent anti-HCV efficacy.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> They began with a sanglifehrin A inspired 22-membered macrocyclic lead <b>81</b>, which, although a highly potent CyP A inhibitor, exhibited moderate anti-HCV potency and a poor PK profile. Therefore, <b>81</b> was subjected to further optimization to <b>82</b> by employing a number of modification strategies: (1) reducing the macrocycle ring size from 22 to 21, (2) swapping the lactone and the lactam groups, (3) replacing the styryl moiety with the quinoline ring, which resulted in the introduction of an intramolecular hydrogen bond (IMHB) and resultant increase in cell permeability, and (4) transforming a tertiary C14 to a quaternary C14 (spiro-1,3-dioxane) that resulted in a number of beneficial properties, including reduced oxidative metabolism, lowered log <i>D</i> value, and reduced liability of drug–drug interaction due to decreased activity toward pregnane X receptor. Additionally, <b>82</b> contains two less chiral centers and improved in vitro potency and PK profile compared to <b>81</b> (<a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig35" id="" class=" internalNav">35</a></a>).</div><figure id="fig35" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0035.jpeg" id="gr35" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 35. Structures, in vitro potency, and PK profiles of CyP A inhibitors <b>81</b> and <b>82</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig35"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Discovery of Selective Tankyrase Inhibitors <b>83</b>–<b>86</b></h3><div class="NLM_p">Similar to PARP1 inhibitors, tankyrase (TNKS1/PARP-5a and TNKS2/PARP-5b) inhibitors are also useful for the treatment of cancers. Shirai and colleagues began with the HTS hit optimized lead compound <b>83</b> that showed selective inhibition of TNKS1 and TNKS2 over PARP1 (<a data-tab="pane-pcw-Figures" href="#fig36" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig36" id="" class=" internalNav">36</a></a>).<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> From the X-ray crystal study, the authors observed that the tetrahydroquinazolinone core and the terminal phenyl ring were orthogonal to each other. These observations prompted them to lock this orthogonality via installation of a spiroindoline ring at the 4-position of the piperidine ring to obtain <b>84</b> with improved enzyme potency, selectivity, aqueous solubility, and metabolic stability but slightly diminished cell-based potency. Subsequently, <b>84</b> was optimized by addition of fluorine and hydroxyethyl substituents on the spiroindoline ring to obtain <b>85</b> (RK-287107)<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> with further increase in enzymatic potency, selectivity, cell-based potency, and aqueous solubility; however, its metabolic stability was lower than that of <b>84</b>. To improve microsomal stability and P-gp efflux ratio of <b>85</b>, it was investigated further by subjecting it to chemical derivatization that led to the discovery of <b>86</b> (RK-582) with improved microsomal stability and P-gp efflux ratio (<a data-tab="pane-pcw-Figures" href="#fig36" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig36" id="" class=" internalNav">36</a></a>).<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Additionally, when administered orally <b>86</b> showed improved inhibition of tumor growth in a mouse xenograft model. The X-ray crystal structure of <b>86</b> bound to TNKS2 highlighted productive interactions between the spiroindolinone moiety and the TNKS2 residues. For instance, the phenyl portion of the indolinone moiety was engaged in T-shaped π–π and CH−π interactions with the side chains of Phe1035 and Ile1075, respectively. The carbonyl oxygen of the indolinone forms a water-mediated hydrogen bonding interaction with the backbone −NH– of Tyr1060. The 2,6-dimethylmorpholine moiety at the 6-position of the spiroindolinone core is localized outside the enzyme binding pocket.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a></div><figure id="fig36" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0036.jpeg" id="gr36" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 36. Structures, in vitro potency, and PK profiles of tankyrase inhibitors <b>83</b>–<b>86</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig36"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Development of β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors <b>87</b>–<b>91</b></h3><div class="NLM_p">Thomas and co-workers reported the development of chroman derivatives as potent and selective BACE1 inhibitors.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> A des-methyl (<i>tert</i>-carbon-containing) analogue <b>87</b> showed moderate biochemical- and cell-based potency. Insertion of a β-methyl group gave rise to a tetrasubstituted carbon-containing analogue <b>88</b>, which demonstrated significant improvement in biochemical- and cell-based potency and also exhibited noticeable selectivity over physiologically important CatD. On the basis of the results obtained from the X-ray crystal structure, the authors concluded that the increase in potency of <b>88</b> toward BACE1 was the result of a favorable hydrophobic contact between the side chain of Thr132 and the β-methyl group. The greater selectivity of <b>88</b> toward BACE1 than toward CatD was reasoned to be due to the severe steric clash of the β-methyl group with the flexible loop of CatD. Because <b>88</b> had unfavorable P-gp efflux ratio, it was further modified by replacing the fluoropyridine ring with the cyanophenyl ring to obtain <b>89</b>, which demonstrated further increase in potency and selectivity and a desirable efflux ratio (<a data-tab="pane-pcw-Figures" href="#fig37" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig37" id="" class=" internalNav">37</a></a>).</div><figure id="fig37" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Figure 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0037.jpeg" id="gr37" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 37. Structures, in vitro potency, and physicochemical properties of BACE1 inhibitors <b>87</b>–<b>91</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig37"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Fujimoto and colleagues undertook optimization of lead compound <b>90</b>, which showed low nanomolar potency against BACE1 but moderate selectivity over BACE2.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> On the basis of the X-ray crystal study, the authors found that a greater selectivity for BACE1 over BACE2 was achievable by adding a spirocyclic ring at the 5-position of the thiazine ring as in <b>91</b>, which led to a significant jump in BACE1 selectivity. The X-ray structure of <b>91</b> bound to BACE1 demonstrated a favorable interaction between the 5-spirotetrahydro-2<i>H</i>-thiopyran 1,1-dioxide and the side chain of Tyr71 in the flap region. The binding of <b>91</b> to BACE2 revealed a significant movement of the flap region, which could account for its greater selectivity for BACE1 than for BACE2 (<a data-tab="pane-pcw-Figures" href="#fig37" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig37" id="" class=" internalNav">37</a></a>). A marginal drop in cell-based potency of <b>91</b> was attributed to its less lipophilic nature (log <i>D</i> pH<sub>7.4</sub> = 0.62).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Development of the Potent and Metabolically Stable κ-Opioid Receptor Agonist <b>93</b></h3><div class="NLM_p">Sherwood and colleagues began their search for a potent κ-opioid receptor agonist using naturally occurring non-nitrogenous salvinorin A (<b>92</b>) scaffold as a starting point, which showed potent agonist activity toward the κ-opioid receptor.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Nevertheless, one of the major liabilities associated with <b>92</b> is the presence of a readily hydrolyzable acetate ester group on A ring and ensuing short half-life that precludes in vivo evaluation. Since the C2-acetoxy group has been shown to engage in activity-favoring hydrogen bonding interaction with the κ-opioid receptor, the authors decided to protect it through the formation of a conformationally constrained tetrasubstituted carbon-containing spirobutyrolactone. This chemical modification gave <b>93</b> with a potency comparable to that of <b>92</b> but with a greater resistance to metabolism by rat liver microsomes (<a data-tab="pane-pcw-Figures" href="#fig38" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig38" id="" class=" internalNav">38</a></a>). <b>93</b> also demonstrated potent attenuation of nociceptive and inflammatory pain in mice.</div><figure id="fig38" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Figure 38</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0038.jpeg" id="gr38" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 38. Structures, in vitro potency, and physicochemical properties of κ-opioid receptor agonists <b>92</b> and <b>93</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig38"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Discovery of Histone Acetyltransferase (HAT) Inhibitors <b>94</b>–<b>96</b></h3><div class="NLM_p">Since the inhibition of HAT is considered a strategy for anticancer drug development, Michaelides et al. optimized a virtual screening hit that culminated in lead <b>94</b> with micromolar inhibitory activity against HAT.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Subsequently they decided to restrict the conformational flexibility of the pendant phenyl ring in an effort to improve potency. This resulted in the identification of a constrained spiroindene hydantoin derivative <b>95</b> with a >4-fold increase in potency. Further optimization of <b>95</b> led to urea substituted spiroindene oxazolidinedione <b>96</b> (A-485)<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> with nanomolar potency against HAT (<a data-tab="pane-pcw-Figures" href="#fig39" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig39" id="" class=" internalNav">39</a></a>).</div><figure id="fig39" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Figure 39</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0039.jpeg" id="gr39" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 39. Structures and in vitro potency of HAT inhibitors <b>94</b>–<b>96</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig39"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Human Mitochondrial Peptide Deformylase (HsPDF) Inhibitors <b>97</b>–<b>99</b></h3><div class="NLM_p">HsPDF catalyzes the deformylation of N-terminal formylmethionines of newly synthesized mitochondrial proteins.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> HsPDF has been shown to be overexpressed in a variety of cancer cells, including breast, lung, and colon cancer.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Hu and co-workers identified a quaternary carbon-containing 5-azaspiro[2.4]heptane derivative <b>97</b> via screening of their compound collection.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a><b>97</b> showed single-digit nanomolar enzyme potency against HsPDF and a double-digit micromolar cytotoxicity toward HCT116 cells. They verified the beneficial effect of the P<sub>2</sub>-binding spirocyclopropane moiety by testing <b>98</b> and found it to be less effective compared to <b>97</b>. By retaining P<sub>1</sub>- and P<sub>2</sub>-binding motifs intact, they replaced the P<sub>3</sub>-binding 5-fluoropyridine ring and the carboxamide group with a 4-fluoro-2-trifluoromethylphenyl ring and amide isostere 1,2,4-oxadiazole, respectively, to obtain <b>99</b> with further increase in enzymatic and cell-based potencies (<a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig40" id="" class=" internalNav">40</a></a>).</div><figure id="fig40" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Figure 40</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0040.jpeg" id="gr40" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 40. Structures and in vitro potency of HsPDF inhibitors <b>97</b>–<b>99</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig40"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Discovery of Calcitonin Gene-Related Peptide Receptor (CGRPR) Antagonist <b>100</b> (Ubrogepant)</h3><div class="NLM_p">CGRPR and its ligand CGRP are implicated in the pathophysiology of migraine and thus serve as targets for the development of antimigraine drugs.<a onclick="showRef(event, 'ref122 ref123'); return false;" href="javascript:void(0);" class="ref ref122 ref123">(122,123)</a> A complete report on the discovery of <b>100</b> is not available, but based on a series of structurally related derivatives, it can be concluded that the spirocyclic 4-azaindene nucleus locks the hydrogen bond acceptor–donor pair in a favorable geometry to form productive hydrogen bonding interactions with the backbone Thr122 on CGRPR (<a data-tab="pane-pcw-Figures" href="#fig41" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig41" id="" class=" internalNav">41</a></a>).<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a></div><figure id="fig41" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Figure 41</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0041.jpeg" id="gr41" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 41. Structure and binding affinity of CGRP receptor antagonist <b>100</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig41"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Aldose Reductase (AR) Inhibitors <b>101</b>–<b>103</b></h3><div class="NLM_p">AR inhibitors are useful for the treatment of diabetic complications.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> AR inhibitors typically consist of an acetic acid group or five-membered cyclic imides such as hydantoin or succinimide. Because of the poor in vivo activity of the acetic acid class, newer AR inhibitors instead contain tetrasubstituted carbon stereocenter-containing spirocyclic succinimide (e.g., <b>101</b><a onclick="showRef(event, 'ref126 ref127'); return false;" href="javascript:void(0);" class="ref ref126 ref127">(126,127)</a> and <b>102</b> (AS-3201)<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a>) or hydantoin (e.g., <b>103</b>)<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> acidic functionalities (<a data-tab="pane-pcw-Figures" href="#fig42" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig42" id="" class=" internalNav">42</a></a>). The anionic spirosuccinimide or spirohydantoin motif has been considered as a quintessential structural feature to efficiently bind to the anionic binding site surrounded by positively charged amino acids and nicotinamide portion of NADP<sup>+</sup> within the active site of AR. These spirocycles drive the bioactive conformational shape by arranging the hydantoin/succinimide moiety and the bicyclic ring system perpendicular to each other.<a onclick="showRef(event, 'ref126 ref129 ref130'); return false;" href="javascript:void(0);" class="ref ref126 ref129 ref130">(126,129,130)</a></div><figure id="fig42" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Figure 42</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0042.jpeg" id="gr42" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 42. Structures of aldose reductase inhibitors <b>101</b>–<b>103</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig42"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Discovery of <b>105</b> (Tofogliflozin)</h3><div class="NLM_p">Inhibition of sodium glucose cotransporter 2 (SGLT2) leads to the excretion of glucose into the urine. Therefore, SGLT2 inhibitors are used as type 2 antidiabetic drugs. Ohtake and co-workers conducted active ligand-based virtual screening of compound database using two-point pharmacophore model (encompassing the sugar moiety and the aromatic ring), which led to the identification of the spiroketal C-arylglucoside <b>104</b>.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Subsequent removal of unnecessary acyl groups and addition of a <i>para</i>-ethylbenzyl moiety on the spiro-dihydroisobenzofuran core yielded the highly selective and potent SGLT2 inhibitor <b>105</b> (CSG452/tofogliflozin) (<a data-tab="pane-pcw-Figures" href="#fig43" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig43" id="" class=" internalNav">43</a></a>).<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></div><figure id="fig43" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Figure 43</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0043.jpeg" id="gr43" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 43. Structures and in vitro potency of SGLT2 inhibitor <b>105</b> and a virtual screening hit <b>104</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig43"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Discovery of Ibutamoren (<b>107</b>) and Capromorelin (<b>108</b>)</h3><div class="NLM_p"><b>107</b> and <b>108</b> are orally active peptidomimetic agonists of growth hormone secretagogue receptor (GHSR). The spiropiperidine core of lead <b>106</b> is a privileged scaffold for a number of GPCR targeted ligands. Consequently, Patchett and colleagues chemically modified <b>106</b> by replacing tryptophan, quinuclidinyl urea, and spiroindene with (<span class="smallcaps smallerCapital">d</span>)-benzyloxyserine, α-aminoisobutyramide, and N-substituted spiroindoline, respectively, to obtain <b>107</b> (MK-0677, ibutamoren) with significantly improved efficacy (<a data-tab="pane-pcw-Figures" href="#fig44" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig44" id="" class=" internalNav">44</a></a>).<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a></div><figure id="fig44" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Figure 44</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0044.jpeg" id="gr44" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 44. Structure and in vitro potency of GHSR agonists <b>106</b>–<b>108</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig44"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Compound <b>107</b> had a poor PK profile due to the presence of a dipeptidyl backbone. Since the dipeptidyl backbone is essential for GHSR agonist activity, Carpino et al. decided to pursue a PK-driven optimization strategy to improve the physicochemical properties of <b>107</b> by focusing on the C-terminal region while retaining the essential dipeptide pharmacophore.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> Replacing the N-substituted spiroindolinepiperidine core by the 3a<i>R</i>-benzyl substituted piperidinopyrazolinone scaffold gave <b>108</b> with increased lipophilicity to compensate the hydrophilicity imposed by the dipeptidyl backbone (<a data-tab="pane-pcw-Figures" href="#fig44" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig44" id="" class=" internalNav">44</a></a>).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Discovery of Transient Receptor Potential Vanilloid Subtype 4 (TRPV4) Inhibitors <b>109</b>–<b>111</b></h3><div class="NLM_p">TRPV4-mediates Ca<sup>2+</sup> influx across the plasma membrane, and thus it serves as a target for the treatment of pulmonary edema.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> Brooks and co-workers reported the synthesis of a benzimidazole-based spirocyclic multiple quaternary carbon-containing clinical candidate as a potent inhibitor of TRPV4.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> They began with the HTS screening hit molecule <b>109</b> that showed potent TRPV4 inhibition with attractive physicochemical properties but exhibited undesirably short mean residence time (MRT) in rat model (<a data-tab="pane-pcw-Figures" href="#fig45" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig45" id="" class=" internalNav">45</a></a>). To improve MRT and potency, they installed a methyl group onto the cyclohexane ring to sterically block potential metabolism at the methylene bridge. These efforts led to the identification of <b>110</b>, which demonstrated a 32-fold increase in potency but no improvement in MRT. The improved potency was ascribed to a reduced conformational flexibility at the cyclohexane or benzimidazole rings and to the ensuing reduced entropic penalty upon binding to TRPV4. To remove potential oxidation liability of the neopentyl moiety on the oxazolidinone ring nitrogen, they introduced a <i>gem</i>-dimethylcarbinol substituted pyrazine ring to obtain a clinical candidate <b>111</b> (GSK2798745) with increased MRT and desirable rat PK profile.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a></div><figure id="fig45" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Figure 45</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0045.jpeg" id="gr45" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 45. Structure, in vitro potency, and PK profiles of TRPV4 inhibitors <b>109</b>–<b>111</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig45"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Discovery of Polo-like Kinase 4 (PLK4) Inhibitors <b>112</b>–<b>114</b></h3><div class="NLM_p">PLK4 is a serine–threonine kinase that is implicated in triple-negative breast cancer and other tumor types.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Sampson and colleagues began a PLK4 inhibitor development effort with the early lead compound (<i>E</i>)-<b>112</b> that showed potent PLK4 inhibition but demonstrated poor oral exposure.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Furthermore, the (<i>E</i>)-C3-arylidene double bond in <b>112</b> was prone to undergo <i>E</i>/<i>Z</i> isomerization under in vivo conditions. To address this problem, the authors decided to introduce configurational stability while simultaneously improving physicochemical properties by replacing the double bond with an isosteric cyclopropane ring. This strategy resulted in the <i>trans</i>-locked <b>113</b> with improved potency, KDR selectivity, and DMPK profile. The cyclopropane ring of <b>113</b> is orthogonal to the plane of the oxindole ring, which caused disruption of crystal packing forces and thus increased aqueous solubility. The addition of a 5-methoxy group to the oxindole ring resulted in <b>114</b> with further increase in potency, selectivity, and oral exposure (<a data-tab="pane-pcw-Figures" href="#fig46" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig46" id="" class=" internalNav">46</a></a>).</div><figure id="fig46" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Figure 46</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0046.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0046.jpeg" id="gr46" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 46. Structures, in vitro potency, and DMPK profiles of PLK4 inhibitors <b>112</b>–<b>114</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig46"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Discovery of Signal Peptide Peptidase-like 2a (SPPL2a) Inhibitors <b>115</b>–<b>117</b></h3><div class="NLM_p">SPPL2a, an aspartyl intramembrane protease, plays a key role in antigen presenting B cell maturation.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Therefore, inhibition of SPPL2a is a strategy for the treatment of autoimmune diseases. Velcicky and colleagues synthesized the tricyclic benzopyrazolodiazepinone lead <b>115</b>, which showed reasonable potency and selectivity toward SPPL2a over γ-secretase and an acceptable PK profile.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> The tricyclic ring system of <b>115</b> was successively optimized to block a metabolically prone benzylic carbon by converting it into a carbonyl group. However, since this modification will produce a relatively polar molecule, they also replaced the methyl group by a cyclopropyl group to obtain <b>116</b>, possessing a log <i>P</i> value comparable to that of <b>115</b>. Unfortunately, <b>116</b> was less potent than <b>115</b>. Finally, the addition of a spirocyclopropane moiety to the tricyclic scaffold of <b>116</b> led to the identification of <b>117</b> possessing greater lipophilicity, comparable potency, and improved PK profile compared to <b>115</b> (<a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig47" id="" class=" internalNav">47</a></a>).</div><figure id="fig47" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Figure 47</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0047.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0047.jpeg" id="gr47" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 47. Structures, in vitro potency, and PK profiles of hSPPL2a inhibitors <b>115</b>–<b>117</b>. RGA, receptor gene assay; CD74/p8, inhibition of accumulation of CD74/p8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0047.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig47"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Spirocycle/Quaternary Carbon-Containing MDM2-p53 Interaction Inhibitors</h3><div class="NLM_p">The MDM2 (murine double minute 2) oncogene antagonizes tumor suppressor protein p53 via a protein–protein interaction. Inhibition of the MDM2-p53 interaction by small molecules would be expected to release p53 from MDM2 and thus activate wild-type p53 pathway and produce an antitumor effect.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> Interaction of p53 with the MDM2 occurs primarily through three hydrophobic residues Phe19, Trp23, and Leu26. Thus, MDM2 has three docking pockets (Phe19, Trp23, and Leu26) for p53 that could be exploited by nonpeptidic small molecules to block the MDM2-p53 interaction. Consequently, a large number of MDM2 directed small molecules bearing spirocycles/quaternary carbon centers have been developed and of which only selected examples are shown in <a data-tab="pane-pcw-Figures" href="#fig48" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig48" id="" class=" internalNav">48</a></a>. Spirooxindole-based MDM2 inhibitors <b>118</b> (MI-888)<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> and <b>119</b> (MI-77301/SAR405838)<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> wherein the two halogenated phenyl moieties are held in a <i>trans</i>-arrangement by a rigid spirooxindolylpyrrolidine have been developed by the Wang group. A quaternary stereocenter-containing piperidinone MDM2 inhibitor exemplified by <b>120</b> (AMG 232), also analogously featuring two essential halogenated phenyl moieties in the <i>trans</i>-orientation, was developed by Rew and colleagues.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a></div><figure id="fig48" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Figure 48</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0048.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0048.jpeg" id="gr48" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 48. Structures and in vitro potency of selected MDM2 inhibitors <b>118</b>–<b>120</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig48"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Synthesis of Lysine-Specific Demethylase 1 (LSD1) Inhibitors <b>121</b> and <b>122</b></h3><div class="NLM_p">Overexpression of LSD1 is implicated in a wide range of cancers. Therefore, Gehling and colleagues decided to identify a novel class of covalent inhibitors of LSD1.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> One of the early lead compounds <b>121</b>, typified by the LSD1 bound flavin adenine dinucleotide (FAD) cofactor targeted warhead styrenylcyclopropylamine, showed low nanomolar potency in biochemical enzyme, lymphocyte antigen 96 (<i>LY96</i>) gene, and phenotypic Kasumi-1 cell assays. Since <b>121</b> manifested less than desirable microsomal clearance in mouse, rat, dog, and human microsomes, it was optimized by replacing the piperidine ring with its surrogate 2-azaspiro[3.3]heptane ring to obtain <b>122</b> with overall improved potency and liver microsomal clearance profile (<a data-tab="pane-pcw-Figures" href="#fig49" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig49" id="" class=" internalNav">49</a></a>).</div><figure id="fig49" data-index="49" class="article__inlineFigure"><h2 class="fig-label">Figure 49</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0049.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0049.jpeg" id="gr49" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 49. Structures, in vitro potency, and microsomal clearance of LSD1 inhibitors <b>121</b> and <b>122</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0049.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig49"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55">General Principles That Can Be Gathered from a Quaternary or Tetrasubstituted Carbon in Terms of Potency, Selectivity, Metabolism, Lipophilicity, Solubility, Enthalpy, and Entropy</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66418" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66418" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">(1) It is generally anticipated that quaternization of a secondary or tertiary carbon will enhance binding affinity and selectivity to target receptor simply via gaining an access to the unique out-of-plane vacant target pocket and capturing specific favorable interactions. This exercise may allow medicinal chemists to tune the three-dimensional molecular shape to achieve desirable on target binding profile. However, it should be noted that substitution at the vacant vertices of a secondary or tertiary carbon occasionally becomes counterproductive and outcomes of which vary based on the individual binding site topology as described in the potential caveat section.</div><div class="NLM_p">(2) Metabolic hydroxylation of tertiary −C–H bonds with increased s-character in a quaternary carbon-containing BCP system is less likely to occur compared to the aromatic −C–H bonds. Numerous examples described in this Perspective indicate that quaternization of a secondary or tertiary carbon led to improvement in in vitro and in vivo DMPK profiles.</div><div class="NLM_p">(3) Addition of a hydrophobic quaternary or tetrasubstituted (sp<sup>3</sup>) carbon in lead compounds may increase lipophilicity, but aqueous solubility may increase, if not decrease, by a potential disruption of molecular planarity as evidenced from examples <b>12</b>, <b>26</b>, and <b>113</b>. Converting the benzylic carbon into a quaternary center may give rise to compounds with improved aqueous solubility by increased solvation and poorer solid state crystal lattice packing, e.g., <b>12</b>, <b>41</b>, and <b>113</b>. Occasionally medicinal chemists need to increase both solubility and hydrophobicity to achieve the desired oral bioavailability, a task that may potentially be achieved by replacing the aromatic ring with a quaternary carbon aliphatic ring system such as BCP.</div><div class="NLM_p">(4) A quaternary carbon in the form of a spiro atom, when present in the core structure, inherently provides an opportunity to project substituents in all three dimensions to maximize ligand interactions with a three-dimensional target binding site. The other prominent feature of spirocyclic compounds is the conformational rigidity, which allows ligands to bind to the target protein in an entropically favorable manner. Increased sp<sup>3</sup> character of spirocycles further favors aqueous solubility.</div><div class="NLM_p">(5) Entropy gain through quaternization of a secondary or tertiary carbon may be derived from a high degree of steric congestion in preorganized lead compounds. However, it remains to be validated by comparing relevant quaternary/tetrasubstituted carbon-containing MMPs.</div><div class="NLM_p">(6) Although predicting the effect of a structural modification on enthalpy or entropy of binding is difficult, some general trends can be gathered from structural modification at the sp<sup>3</sup> carbon center. For example, addition of a polar group such as amino or hydroxyl at a tertiary carbon-containing lead molecule may result in favorable enthalpy, provided these groups are engaged in hydrogen bonding interaction with out-of-plane active site residues. Similarly, addition of a small hydrophobic group such as methyl, ethyl, isopropyl, or cyclopropyl may contribute to a favorable enthalpy via van der Waals contacts and by decreasing desolvation enthalpy while simultaneously gaining favorable entropy by the expulsion of a weakly bound active site water molecule(s). Additionally, increase in LLE strongly correlates with the quality of lead compounds as assessed by enthalpy-driven binding<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> and evidenced from at least one example, i.e., BET inhibitor <b>74</b>.</div><div class="NLM_p last">(7) Quaternization has also been shown to impart stability of peptidic compounds against proteolytic cleavage (e.g., NMUR1 agonist <b>66</b>). A strategy to install tetrasubstituted carbon as in <b>71</b> resulted in enhanced chemical and enzymatic stability. However, occasionally quaternization may result in chemical instability of the compound, e.g., ER degrader <b>59</b>).</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i56">Potential Caveats of a Tetrasubstituted or Quaternary Carbon</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15853" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15853" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">(1) Synthesis and SAR optimization of quaternary carbon-containing lead molecules may potentially pose limitations in terms of slowness of parallel synthesis due to stereochemical complexity.</div><div class="NLM_p">(2) Construction of quaternary carbon-containing small molecules presents a formidable synthetic challenge due to its inherent sterically crowded nature. It is important to distinguish quaternary carbons located within the core structure from those that arise due to peripheral quaternization, of which the former would be more challenging to construct and more difficult in terms of SAR interpretation.</div><div class="NLM_p">(3) Replacing the (hetero)aromatic ring participating in favorable π–π interactions or π–cation interactions with the sp<sup>3</sup>-rich ring may be counterproductive. Thus, it is imperative to identify such pharmacophoric rings prior to initiating drug-like property optimization program.</div><div class="NLM_p">(4) Large-scale production of architecturally complex quaternary carbon-containing GMP quality clinical candidates with several chiral centers will be challenging and may not be cost-effective. However, a growing list of the quaternary/tetrasubstituted carbon-containing compounds entering development or the clinic highlights the growth in this area (see subsequent section).</div><div class="NLM_p">(5) It is evident from this Perspective that quaternization of a secondary or a tertiary carbon does not always lead to improved pharmacodynamic or pharmacokinetic properties.</div><div class="NLM_p last">(6) A simple quaternization by insertion of a methyl group at a tertiary carbon may result in increased lipophilicity, introduce potential sites for metabolism, and potentially lower potency due to a steric clash with protein or causing the conformation to deviate from the bioactive one.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i57">Quaternary or Tetrasubstituted Carbon-Containing Molecules That Entered Development</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51101" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51101" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A noticeable number of quaternary or tetrasubstituted carbon-containing compounds that entered the development stage show the feasibility of clinical development of such architecturally complex molecules (<a data-tab="pane-pcw-Figures" href="#fig50" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig50" id="" class=" internalNav">50</a></a>). For example, (<i>R</i>)-<b>44</b> (veliparib) is undergoing phase 3 clinical trials in combination with numerous chemotherapeutic agents to treat a wide range of cancer patients.<a onclick="showRef(event, 'ref146 ref147 ref148 ref149'); return false;" href="javascript:void(0);" class="ref ref146 ref147 ref148 ref149">(146−149)</a> MDM2 inhibitor <b>120</b> is in phase 1b/2a clinical trial for the treatment of metastatic melanoma (NCT02110355). <b>111</b>, a TRPV4 inhibitor, is undergoing phase 2 clinical trial in participants with chronic cough (NCT03372603). <b>39</b>, an ERK1/2 inhibitor, is undergoing phase 1 clinical trial in combination with pembrolizumab in participants with colorectal cancer (NCT02972034). Ibutamoren (<b>107</b>), an investigational new drug, has been clinically evaluated in phase 2 clinical trial, last updated in 2012 (NCT00116129), but no information is available on its further development. Selgantolimod (<b>77</b>), a TLR8 agonist, is undergoing phase 2 clinical trial in chronic hepatitis B patients (NCT03491553). Delgocitinib (<b>123</b>), a spirocycle-containing JAK inhibitor, has been approved for the treatment of atopic dermatitis in Japan. A tetrasubstituted stereocenter-containing nonsteroidal glucocorticoid receptor modulator, <b>124</b>, has completed phase 1 clinical trial as a topical agent for psoriasis (NCT02940002). Numerous quaternary or tetrasubstituted carbon-containing drugs are in the clinic, including misoprostol (<b>71</b>), sofosbuvir (<b>72</b>), ubrogepant (<b>100</b>), tofogliflozin (<b>105</b>), aliskiren (<b>125</b>), lemborexant (<b>126</b>), and rolapitant (<b>127</b>).</div><figure id="fig50" data-index="50" class="article__inlineFigure"><h2 class="fig-label">Figure 50</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0050.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0050.jpeg" id="gr50" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 50. Structures of quaternary or tetrasubstituted carbon-containing compounds that entered clinical development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0050.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig50"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Large-scale production of GMP quality quaternary or tetrasubstituted carbon-containing clinical candidates strengthens the feasibility of developing these types of molecules (<a data-tab="pane-pcw-Figures" href="#fig50" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig50" id="" class=" internalNav">50</a></a>). For example, the scale-up of a potential macrocyclic clinical candidate <b>128</b> (DZ-2384) bearing a quaternary stereocenter has been reported using electrochemical macrocyclization.<a onclick="showRef(event, 'ref150 ref151'); return false;" href="javascript:void(0);" class="ref ref150 ref151">(150,151)</a> Maddess et al. reported the synthesis of multikilogram quantities of a quaternary carbon-containing estrogen receptor β agonist, <b>129</b>, to facilitate early preclinical and clinical studies.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> Sclafani et al. reported asymmetric pilot scale synthesis of a quaternary stereocenter-containing Nav<sub>1.7</sub> and Nav<sub>1.8</sub> voltage-gated sodium channel blocker funapide (<b>130</b>, TV-45070).<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> Cumming et al. reported multikilogram scale stereoselective synthesis of a novel anti-inflammatory agent (<b>131</b>, PH46A),<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> which has completed phase 1 clinical trial (BioMed Central ISRCTN Registry, 2014). Dillon et al. developed a kilogram-scale synthesis of tetrasubstituted carbon-containing muscarinic antagonist <b>132</b> (PF-3635659) to support clinical studies.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> This compound has been investigated in phase 2 clinical trial in COPD patients (NCT01033487). A multikilogram scale synthesis of BACE inhibitor (<b>133</b>, LY2886721) has been reported using a pilot scale flow synthesis.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> This compound has been evaluated in a number of clinical trials in healthy participants and participants with Alzheimer’s disease (NCT01807026).</div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i58">Summary</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27061" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27061" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Although combinatorial synthesis of small molecule libraries has been in place since the 1990s, it did not deliver clinically viable lead compounds.<a onclick="showRef(event, 'ref157 ref158 ref159 ref160 ref161'); return false;" href="javascript:void(0);" class="ref ref157 ref158 ref159 ref160 ref161">(157−161)</a> This situation could be attributed to the use of synthetically tractable random/flat building blocks to generate combinatorial libraries.<a onclick="showRef(event, 'ref157 ref158 ref159 ref160 ref161'); return false;" href="javascript:void(0);" class="ref ref157 ref158 ref159 ref160 ref161">(157−161)</a> On the contrary, the utilization of quaternary carbon stereocenters in small bioactive molecules is expected to pave the way for tapping into untrammeled patentable chemical space with a high likelihood of finding novel clinical candidate(s).<a onclick="showRef(event, 'ref7 ref15 ref16 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref7 ref15 ref16 ref26 ref27">(7,15,16,26,27)</a> For this to become a reality, we need a quantum leap in the development of novel synthetic methods to construct quaternary carbon stereocenters in an enantiomerically pure form. The use of quaternary or tetrasubstituted carbon center during lead optimization will continue to grow owing to an increased awareness of the need for useful and potent drugs with a larger fraction of sp<sup>3</sup> carbons.<a onclick="showRef(event, 'ref7 ref15 ref16 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref7 ref15 ref16 ref26 ref27">(7,15,16,26,27)</a> The addition of one or more quaternary carbon centers in bioactive molecules will undoubtedly increase the cost of lead optimization and will slow down the process of lead-to-drug optimization. However, we may not require exhaustive SAR to arrive at a potentially viable clinical candidate because such molecules are expected to provide desirable three-dimensionality and drug-like property profiles. In addition, quaternary or tetrasubstituted carbon stereocenters will afford molecules that are relatively more resistant to racemization compared to the molecules bearing tertiary carbon stereocenters. This is of particular interest in situations where one isomer is a eutomer (pharmacologically active) but the other is a distomer (potentially harmful).</div><div class="NLM_p">The other type of quaternary carbon stereocenter, present as a spirocyclic ring system, is found in a number of synthetic, semisynthetic, and naturally occurring bioactive compounds. Spirocyclic compounds are denoted by molecules wherein two rings are connected by a single quaternary carbon center, referred to as a spiroatom. The spiroatom is expected to offer an element of chirality when the two rings are of different size, atomic composition, or substitution pattern. Because of its rigid three-dimensionality, a spirocycle has been widely employed in drug discovery to the extent that it has become a privileged scaffold for a number of therapeutic targets, including the CGRP receptor, BACE1, aldose reductase, protein–protein interaction (MDM2-p53), and HCV NS3/4a protease/NS5B polymerase/NS5A replication complex. When the spirocycle is present in the center of bioactive molecules, it imparts significant conformational rigidity, which in turn contributes to their entropically favorable binding to target proteins.</div><div class="NLM_p last">It is hoped that this Perspective will encourage the practicing chemist to develop novel enantioselective methods for constructing quaternary or tetrasubstituted carbon stereocenters and for using them in the development of new drugs that will satisfy pressing therapeutic needs.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00829" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76532" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76532" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tanaji T. Talele</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Sciences,
College of Pharmacy and Health Sciences, St. John’s University, Queens, New York 11439, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5938-6505" title="Orcid link">http://orcid.org/0000-0002-5938-6505</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d2a6b3beb7beb7a692a1a6b8bdbabca1fcb7b6a7"><span class="__cf_email__" data-cfemail="65110409000900112516110f0a0d0b164b000110">[email protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The author declares the following competing financial interest(s): Tanaji T. Talele cofounded Hysplex LLC.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i59">Biography</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84584" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84584" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="51" class="article__inlineFigure"><h2 class="fig-label">Tanaji T. Talele</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=BIO-d7e3453-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Tanaji T. Talele</b> received his Ph.D. (1998) in Medicinal Chemistry from the University of Mumbai, India. After completing his postdoctoral training at New Jersey Medical School, Louisiana State University and Moffitt Cancer Center, he joined St. John’s University in 2005, where he is currently a Full Professor. He has contributed 96 peer-reviewed papers in various journals, including <i>Science</i> and <i>Journal of Medicinal Chemistry</i>. Since 2016, he has been serving as an editorial advisory board member of the <i>European Journal of Medicinal Chemistry</i>. Since 2018, he has been serving as an Editor of <i>Bioorganic Chemistry</i>. In 2019, he cofounded start-up company Hysplex LLC. His current research efforts are directed toward the development of small-molecule inhibitors of PARP/HDAC/RAD51.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i60">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11427" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11427" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The author is thankful to Dr. Cesar A. Lau-Cam (St. John’s University), Dr. Dana V. Ferraris (McDaniel College), and Dr. Vijay M. Gokhale (The University of Arizona) for reviewing the manuscript.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">BACE</td><td class="NLM_def"><p class="first last">β-site amyloid precursor protein cleaving enzyme</p></td></tr><tr><td class="NLM_term">BCP</td><td class="NLM_def"><p class="first last">bicyclopentane</p></td></tr><tr><td class="NLM_term">BET</td><td class="NLM_def"><p class="first last">bromodomain and extra-terminal protein</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">ligand lipophilic efficiency</p></td></tr><tr><td class="NLM_term">CCK-A</td><td class="NLM_def"><p class="first last">cholecystokinin A</p></td></tr><tr><td class="NLM_term">CGRPR</td><td class="NLM_def"><p class="first last">calcitonin gene-related peptide receptor</p></td></tr><tr><td class="NLM_term">DGAT1</td><td class="NLM_def"><p class="first last">diacylglycerol acyltransferase 1</p></td></tr><tr><td class="NLM_term">ERα</td><td class="NLM_def"><p class="first last">estrogen receptor α</p></td></tr><tr><td class="NLM_term">ER DR</td><td class="NLM_def"><p class="first last">estrogen receptor downregulator</p></td></tr><tr><td class="NLM_term">ERK1/2</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase 1/2</p></td></tr><tr><td class="NLM_term">FLIPR</td><td class="NLM_def"><p class="first last">fluorometric imaging plate reader</p></td></tr><tr><td class="NLM_term">GHSR</td><td class="NLM_def"><p class="first last">growth hormone secretagogue receptor</p></td></tr><tr><td class="NLM_term">GP-BAR1/TGR5</td><td class="NLM_def"><p class="first last">G-protein-coupled bile acid receptor 1</p></td></tr><tr><td class="NLM_term">HAT</td><td class="NLM_def"><p class="first last">histone acetyltransferase</p></td></tr><tr><td class="NLM_term">HCV</td><td class="NLM_def"><p class="first last">hepatitis C virus</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">HsPDF</td><td class="NLM_def"><p class="first last">human mitochondrial peptide deformylase</p></td></tr><tr><td class="NLM_term">IKKβ</td><td class="NLM_def"><p class="first last">IκB kinase β</p></td></tr><tr><td class="NLM_term">IP1</td><td class="NLM_def"><p class="first last">inositol monophosphate</p></td></tr><tr><td class="NLM_term">LpPLA<sub>2</sub></td><td class="NLM_def"><p class="first last">lipoprotein-associated phospholipase A<sub>2</sub></p></td></tr><tr><td class="NLM_term">LSD1</td><td class="NLM_def"><p class="first last">lysine-specific demethylase 1</p></td></tr><tr><td class="NLM_term">LTC4S</td><td class="NLM_def"><p class="first last">leukotriene C4 synthase</p></td></tr><tr><td class="NLM_term">MRT</td><td class="NLM_def"><p class="first last">mean residence time</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">NMDAR</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate receptor</p></td></tr><tr><td class="NLM_term">NMUR</td><td class="NLM_def"><p class="first last">neuromedin U receptor</p></td></tr><tr><td class="NLM_term">NSAID</td><td class="NLM_def"><p class="first last">nonsteroidal anti-inflammatory drug</p></td></tr><tr><td class="NLM_term">NTR1</td><td class="NLM_def"><p class="first last">neurotensin receptor 1</p></td></tr><tr><td class="NLM_term">OTR</td><td class="NLM_def"><p class="first last">oxytocin receptor</p></td></tr><tr><td class="NLM_term">PAM</td><td class="NLM_def"><p class="first last">positive allosteric modulator</p></td></tr><tr><td class="NLM_term">PARP1</td><td class="NLM_def"><p class="first last">poly(ADP-ribose)polymerase 1</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide-3-kinase</p></td></tr><tr><td class="NLM_term">PLK4</td><td class="NLM_def"><p class="first last">polo-like kinase 4</p></td></tr><tr><td class="NLM_term">RSV</td><td class="NLM_def"><p class="first last">respiratory syncytial virus</p></td></tr><tr><td class="NLM_term">SERD</td><td class="NLM_def"><p class="first last">selective estrogen receptor downregulator</p></td></tr><tr><td class="NLM_term">SGLT2</td><td class="NLM_def"><p class="first last">sodium glucose cotransporter 2</p></td></tr><tr><td class="NLM_term">SMYD2</td><td class="NLM_def"><p class="first last">SET and MYND domain-containing protein 2</p></td></tr><tr><td class="NLM_term">SPPL2a</td><td class="NLM_def"><p class="first last">signal peptide peptidase-like 2a</p></td></tr><tr><td class="NLM_term">TLR8</td><td class="NLM_def"><p class="first last">Toll-like receptor 8</p></td></tr><tr><td class="NLM_term">TNKS</td><td class="NLM_def"><p class="first last">tankyrase</p></td></tr><tr><td class="NLM_term">TRPV4</td><td class="NLM_def"><p class="first last">transient receptor potential vanilloid 4</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41805" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41805" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 161 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J.</span></span> <span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1011</span>– <span class="NLM_lpage">1020</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2009.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.drudis.2009.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=19729075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1011-1020&author=T.+J.+Ritchieauthor=S.+J.+Macdonald&title=The+impact+of+aromatic+ring+count+on+compound+developability%2D%2Dare+too+many+aromatic+rings+a+liability+in+drug+design%3F&doi=10.1016%2Fj.drudis.2009.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: Are too many aromatic rings a liability in drug design?</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">21/22</span>),
    <span class="NLM_cas:pages">1011-1020</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of arom. ring count (the no. of arom. and heteroarom. rings) in mols. has been analyzed against various developability parameters, aq. soly., lipophilicity, serum albumin binding, CyP450 inhibition and hERG inhibition.  On the basis of this anal., it was concluded that the fewer arom. rings contained in an oral drug candidate, the more developable that candidate is probably to be; in addn., more than three arom. rings in a mol. correlates with poorer compd. developability and, thus, an increased risk of attrition in development.  Data are also presented that demonstrate that even within a defined lipophilicity range, increased arom. ring count leads to decreased aq. soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2hOeD6TNGUbVg90H21EOLACvtfcHk0lg-3J794F8g0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP&md5=48454c9809e8225b4336ea76aad3f3ba</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability--are%2520too%2520many%2520aromatic%2520rings%2520a%2520liability%2520in%2520drug%2520design%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D1011%26epage%3D1020%26doi%3D10.1016%2Fj.drudis.2009.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span> <span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">171</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2010.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.drudis.2010.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=21129497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=164-171&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonaldauthor=R.+J.+Youngauthor=S.+D.+Pickett&title=The+impact+of+aromatic+ring+count+on+compound+developability%3A+further+insights+by+examining+carbo-+and+hetero-aromatic+and+-aliphatic+ring+types&doi=10.1016%2Fj.drudis.2010.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.; Young, Robert J.; Pickett, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3/4</span>),
    <span class="NLM_cas:pages">164-171</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of carboarom., heteroarom., carboaliph. and heteroaliph. ring counts and fused arom. ring count on several developability measures (soly., lipophilicity, protein binding, P 450 inhibition and hERG binding) is the topic for this review article.  Recent results indicate that increasing ring counts have detrimental effects on developability in the order carboaroms. » heteroaroms. > carboaliphatics > heteroaliphatics, with heteroaliphatics exerting a beneficial effect in many cases.  Increasing arom. ring count exerts effects on several developability parameters that are lipophilicity- and size-independent, and fused arom. systems have a beneficial effect relative to their nonfused counterparts.  Increasing arom. ring count has a detrimental effect on human bioavailability parameters, and heteroarom. ring count (but not other ring counts) has increased over time in marketed oral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJYPC7hkoyv7Vg90H21EOLACvtfcHk0lg-3J794F8g0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D&md5=8e2d0e4e499d2f07d66ca2f385defb2d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%253A%2520further%2520insights%2520by%2520examining%2520carbo-%2520and%2520hetero-aromatic%2520and%2520-aliphatic%2520ring%2520types%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D164%26epage%3D171%26doi%3D10.1016%2Fj.drudis.2010.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span> <span> </span><span class="NLM_article-title">Molecular obesity, potency and other addictions in drug discovery</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">355</span>, <span class="refDoi"> DOI: 10.1039/C1MD00017A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1039%2FC1MD00017A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Kht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=349-355&author=M.+M.+Hann&title=Molecular+obesity%2C+potency+and+other+addictions+in+drug+discovery&doi=10.1039%2FC1MD00017A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular obesity, potency and other addictions in drug discovery</span></div><div class="casAuthors">Hann, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">349-355</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Despite the increase in global biol. and chem. knowledge the discovery of effective and safe new drugs seems to become harder rather than easier.  Some of this challenge is due to increasing demands for safety and novelty, but some of the risk involved in this should be controllable if we had more effectively learned from our failures.  This perspective reflects on some of the learnings of recent years in relation to the causes of attrition.  The term Mol. Obesity is introduced to describe our tendency to build potency into mols. by the inappropriate use of lipophilicity which leads to the premature demise of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSlF7TPy6fHLVg90H21EOLACvtfcHk0lgsOLix-gRFTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Kht7g%253D&md5=954870db4b1d9e846612c3bb256582f7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1039%2FC1MD00017A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC1MD00017A%26sid%3Dliteratum%253Aachs%26aulast%3DHann%26aufirst%3DM.%2BM.%26atitle%3DMolecular%2520obesity%252C%2520potency%2520and%2520other%2520addictions%2520in%2520drug%2520discovery%26jtitle%3DMedChemComm%26date%3D2011%26volume%3D2%26spage%3D349%26epage%3D355%26doi%3D10.1039%2FC1MD00017A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dancik, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrinski, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">Quantifying structure and performance diversity for sets of small molecules comprising small-molecule screening collections</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">6817</span>– <span class="NLM_lpage">6822</span>, <span class="refDoi"> DOI: 10.1073/pnas.1015024108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1073%2Fpnas.1015024108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=21482810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlslyru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=6817-6822&author=P.+A.+Clemonsauthor=J.+A.+Wilsonauthor=V.+Dancikauthor=S.+Mullerauthor=H.+A.+Carrinskiauthor=B.+K.+Wagnerauthor=A.+N.+Koehlerauthor=S.+L.+Schreiber&title=Quantifying+structure+and+performance+diversity+for+sets+of+small+molecules+comprising+small-molecule+screening+collections&doi=10.1073%2Fpnas.1015024108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Quantifying structure and performance diversity for sets of small molecules comprising small-molecule screening collections</span></div><div class="casAuthors">Clemons, Paul A.; Wilson, J. Anthony; Dancik, Vlado; Muller, Sandrine; Carrinski, Hyman A.; Wagner, Bridget K.; Koehler, Angela N.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6817-6822, S6817/1-S6817/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Using a diverse collection of small mols. we recently found that compd. sets from different sources (com.; academic; natural) have different protein-binding behaviors, and these behaviors correlate with trends in stereochem. complexity for these compd. sets.  These results lend insight into structural features that synthetic chemists might target when synthesizing screening collections for biol. discovery.  We report extensive characterization of structural properties and diversity of biol. performance for these compds. and expand comparative analyses to include physicochem. properties and three-dimensional shapes of predicted conformers.  The results highlight addnl. similarities and differences between the sets, but also the dependence of such comparisons on the choice of mol. descriptors.  Using a protein-binding dataset, we introduce an information-theoretic measure to assess diversity of performance with a constraint on specificity.  Rather than relying on finding individual active compds., this measure allows rational judgment of compd. subsets as groups.  We also apply this measure to publicly available data from ChemBank for the same compd. sets across a diverse group of functional assays.  We find that performance diversity of compd. sets is relatively stable across a range of property values as judged by this measure, both in protein-binding studies and functional assays.  Because building screening collections with improved performance depends on efficient use of synthetic org. chem. resources, these studies illustrate an important quant. framework to help prioritize choices made in building such collections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTV-EsmSsjP7Vg90H21EOLACvtfcHk0lgsOLix-gRFTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlslyru7c%253D&md5=d83343549289415060ea55d45118d31f</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1015024108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1015024108%26sid%3Dliteratum%253Aachs%26aulast%3DClemons%26aufirst%3DP.%2BA.%26aulast%3DWilson%26aufirst%3DJ.%2BA.%26aulast%3DDancik%26aufirst%3DV.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DCarrinski%26aufirst%3DH.%2BA.%26aulast%3DWagner%26aufirst%3DB.%2BK.%26aulast%3DKoehler%26aufirst%3DA.%2BN.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DQuantifying%2520structure%2520and%2520performance%2520diversity%2520for%2520sets%2520of%2520small%2520molecules%2520comprising%2520small-molecule%2520screening%2520collections%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D6817%26epage%3D6822%26doi%3D10.1073%2Fpnas.1015024108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boström, J.</span></span> <span> </span><span class="NLM_article-title">Analysis of past and present synthetic methodologies on medicinal chemistry: Where have all the new reactions gone?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4443</span>– <span class="NLM_lpage">4458</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01409</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01409" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4443-4458&author=D.+G.+Brownauthor=J.+Bostr%C3%B6m&title=Analysis+of+past+and+present+synthetic+methodologies+on+medicinal+chemistry%3A+Where+have+all+the+new+reactions+gone%3F&doi=10.1021%2Facs.jmedchem.5b01409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone?</span></div><div class="casAuthors">Brown, Dean G.; Bostrom, Jonas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4443-4458</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  An anal. of chem. reactions used in current medicinal chem. (2014), three decades ago (1984), and in natural product total synthesis has been conducted.  The anal. revealed that of the current most frequently used synthetic reactions, none were discovered within the past 20 years and only two in the 1980s and 1990s (Suzuki-Miyaura and Buchwald-Hartwig).  This suggests an inherent high bar of impact for new synthetic reactions in drug discovery.  The most frequently used reactions were amide bond formation, Suzuki-Miyaura coupling, and SNAr reactions, most likely due to com. availability of reagents, high chemoselectivity, and a pressure on delivery.  The authors show that these practices result in overpopulation of certain types of mol. shapes to the exclusion of others using simple PMI plots.  The authors hope that these results will help catalyze improvements in integration of new synthetic methodologies as well as new library design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLWvt5DxktAbVg90H21EOLACvtfcHk0lgsOLix-gRFTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsrzM&md5=fd56ba8418f6d4e8c271f4e977ee2a93</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01409%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DBostr%25C3%25B6m%26aufirst%3DJ.%26atitle%3DAnalysis%2520of%2520past%2520and%2520present%2520synthetic%2520methodologies%2520on%2520medicinal%2520chemistry%253A%2520Where%2520have%2520all%2520the%2520new%2520reactions%2520gone%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4443%26epage%3D4458%26doi%3D10.1021%2Facs.jmedchem.5b01409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">Molecular diversity by design</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>457</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1038/457153a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2F457153a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=19129834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlSgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=457&publication_year=2009&pages=153-154&author=S.+L.+Schreiber&title=Molecular+diversity+by+design&doi=10.1038%2F457153a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular diversity by design</span></div><div class="casAuthors">Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">457</span>
        (<span class="NLM_cas:issue">7226</span>),
    <span class="NLM_cas:pages">153-154</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Many org. syntheses are target-oriented - each multi-step route is designed to make just one compd.  But now a diversity-oriented synthesis can make 80 different mol. skeletons in just a few steps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNnW8LJ03ahbVg90H21EOLACvtfcHk0lgX_xMnwZq1kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlSgug%253D%253D&md5=2ddc5e57f47d2e83598e644fb0259245</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2F457153a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F457153a%26sid%3Dliteratum%253Aachs%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DMolecular%2520diversity%2520by%2520design%26jtitle%3DNature%26date%3D2009%26volume%3D457%26spage%3D153%26epage%3D154%26doi%3D10.1038%2F457153a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burke, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">A planning strategy for diversity-oriented synthesis</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1002/anie.200300626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fanie.200300626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=14694470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsVeksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=46-58&author=M.+D.+Burkeauthor=S.+L.+Schreiber&title=A+planning+strategy+for+diversity-oriented+synthesis&doi=10.1002%2Fanie.200300626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">A planning strategy for diversity-oriented synthesis</span></div><div class="casAuthors">Burke, Martin D.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-58</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  In contrast to target-oriented synthesis (TOS) and medicinal or combinatorial chem., which aim to access precise or dense regions of chem. space, diversity-oriented synthesis (DOS) populates chem. space broadly with small-mols., having diverse structures.  The goals of DOS include the development of pathways leading to the efficient (three- to five-step) synthesis of collections of small mols. having skeletal and stereochem. diversity with defined coordinates in chem. space.  Ideally, these pathways also yield compds. having the potential to attach appendages site- and stereoselectively to a variety of attachment sites during a post-screening, maturation stage.  The diverse skeletons and stereochemistries ensure that the appendages can be positioned in multiple orientations about the surface of the mols.  TOS as well as medicinal and combinatorial chemistries have been advanced by the development of retrosynthetic anal.  Although the distinct goals of DOS do not permit the application of retrosynthetic concepts and thinking, these foundations are being built on, by using parallel logic, to develop a complementary procedure known as forward-synthetic anal.  This anal. facilitates synthetic planning, communication, and teaching in this evolving discipline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8zavQvQH3GLVg90H21EOLACvtfcHk0lgX_xMnwZq1kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsVeksQ%253D%253D&md5=e556604e2e248ff7a86121d8c2383182</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fanie.200300626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200300626%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DM.%2BD.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DA%2520planning%2520strategy%2520for%2520diversity-oriented%2520synthesis%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2004%26volume%3D43%26spage%3D46%26epage%3D58%26doi%3D10.1002%2Fanie.200300626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wassvik, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmén, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Draheim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergström, C. A. S.</span></span> <span> </span><span class="NLM_article-title">Molecular characteristics for solid-state limited solubility</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">3035</span>– <span class="NLM_lpage">3039</span>, <span class="refDoi"> DOI: 10.1021/jm701587d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701587d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksVSgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3035-3039&author=C.+M.+Wassvikauthor=A.+G.+Holm%C3%A9nauthor=R.+Draheimauthor=P.+Arturssonauthor=C.+A.+S.+Bergstr%C3%B6m&title=Molecular+characteristics+for+solid-state+limited+solubility&doi=10.1021%2Fjm701587d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Characteristics for Solid-State Limited Solubility</span></div><div class="casAuthors">Wassvik, Carola M.; Holmen, Anders G.; Draheim, Rieke; Artursson, Per; Bergstroem, Christel A. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3035-3039</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Soly. and solid-state characteristics were detd. and multivariate data anal. was used to deduce structural features important for solid-state limited soly. of marketed drugs.  Mols. with extended ring structures and large conjugated systems were less sol., indicating that structural features related to rigidity and aromaticity result in soly. restricted by stable crystal structures.  These descriptors successfully predicted the applied test set and can be useful for avoiding synthesis of compds. behaving like "brick dust".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4YD2_Ul4qabVg90H21EOLACvtfcHk0lgX_xMnwZq1kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksVSgt7o%253D&md5=f27982a173dfbc1491b6ce1749f486a8</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm701587d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701587d%26sid%3Dliteratum%253Aachs%26aulast%3DWassvik%26aufirst%3DC.%2BM.%26aulast%3DHolm%25C3%25A9n%26aufirst%3DA.%2BG.%26aulast%3DDraheim%26aufirst%3DR.%26aulast%3DArtursson%26aufirst%3DP.%26aulast%3DBergstr%25C3%25B6m%26aufirst%3DC.%2BA.%2BS.%26atitle%3DMolecular%2520characteristics%2520for%2520solid-state%2520limited%2520solubility%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3035%26epage%3D3039%26doi%3D10.1021%2Fjm701587d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamanna, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westerberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maccari, L.</span></span> <span> </span><span class="NLM_article-title">Straightforward Recursive Partitioning Model for Discarding Insoluble Compounds in the Drug Discovery Process</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">2891</span>– <span class="NLM_lpage">2897</span>, <span class="refDoi"> DOI: 10.1021/jm701407x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701407x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvVChu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2891-2897&author=C.+Lamannaauthor=M.+Belliniauthor=A.+Padovaauthor=G.+Westerbergauthor=L.+Maccari&title=Straightforward+Recursive+Partitioning+Model+for+Discarding+Insoluble+Compounds+in+the+Drug+Discovery+Process&doi=10.1021%2Fjm701407x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Straightforward Recursive Partitioning Model for Discarding Insoluble Compounds in the Drug Discovery Process</span></div><div class="casAuthors">Lamanna, Claudia; Bellini, Marta; Padova, Alessandro; Westerberg, Goran; Maccari, Laura</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2891-2897</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Poor aq. soly. is one of the major issues in drug discovery and development, impacting neg. on all aspects of the research and development process.  The pharmaceutical industry has realized that soly. issues need to be resolved at the discovery stage.  We here present an innovative way to address this problem via a model designed to address the simple question, "Is the compd. likely to be sufficiently sol. to provide interpretable data in biol. screening assays" A recursive partitioning (RP) method was applied to a set of 3563 mols., with in house detd. aq. soly. values.  Five models were generated on the basis of a small no. of descriptors affording intuitive information regarding structural features influencing soly.  The final model was based on only two descriptors: the mol. wt. (MW) and the arom. proportion (AP).  This model provided satisfactory values of accuracy (81%) and precision (75%) for a test set of 1200 compds., suggesting that the model may add value in compd. selection and library design during early drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPk-CmrXXXLrVg90H21EOLACvtfcHk0ljH-C722drbEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvVChu70%253D&md5=aa20e98714f60f9820fe3e26d871de10</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm701407x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701407x%26sid%3Dliteratum%253Aachs%26aulast%3DLamanna%26aufirst%3DC.%26aulast%3DBellini%26aufirst%3DM.%26aulast%3DPadova%26aufirst%3DA.%26aulast%3DWesterberg%26aufirst%3DG.%26aulast%3DMaccari%26aufirst%3DL.%26atitle%3DStraightforward%2520Recursive%2520Partitioning%2520Model%2520for%2520Discarding%2520Insoluble%2520Compounds%2520in%2520the%2520Drug%2520Discovery%2520Process%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2891%26epage%3D2897%26doi%3D10.1021%2Fjm701407x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span> <span> </span><span class="NLM_article-title">Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2010.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.drudis.2010.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=20570751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVeksb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=648-655&author=A.+P.+Hillauthor=R.+J.+Young&title=Getting+physical+in+drug+discovery%3A+a+contemporary+perspective+on+solubility+and+hydrophobicity&doi=10.1016%2Fj.drudis.2010.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity</span></div><div class="casAuthors">Hill, Alan P.; Young, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">15/16</span>),
    <span class="NLM_cas:pages">648-655</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Suboptimal phys. properties have been identified as a particular shortcoming of compds. in contemporary drug discovery, contributing to high attrition levels.  An anal. of the relationship between hydrophobicity (calcd. and measured) and ∼100 k measured kinetic soly. values has been undertaken.  In line with the General Soly. Equation, ests. of hydrophobicity, particularly ACD c log D pH7.4, give a useful indication of the likely soly. classification of particular mols.  Taking ACD c log D pH7.4 values together with the no. of arom. rings in a given mol. provides enhanced prediction.  The Soly. Forecast Index' (SFI = c log D pH7.4 + #Ar) is proposed as a simple, yet effective, guide to predicting soly.  Moreover, anal. of measured distribution/partition coeff. values highlighted statistically significant shortcomings in the applicability of octanol/water as a model system for hydrophobicity detn. with poorly sol. compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdtQyfNjbFUrVg90H21EOLACvtfcHk0ljH-C722drbEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVeksb3P&md5=7b201081c5586a6ea4b7af00d507d462</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DA.%2BP.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26atitle%3DGetting%2520physical%2520in%2520drug%2520discovery%253A%2520a%2520contemporary%2520perspective%2520on%2520solubility%2520and%2520hydrophobicity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2010%26volume%3D15%26spage%3D648%26epage%3D655%26doi%3D10.1016%2Fj.drudis.2010.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(96)00423-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings&doi=10.1016%2FS0169-409X%2896%2900423-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0ljH-C722drbEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26spage%3D3%26epage%3D25%26doi%3D10.1016%2FS0169-409X%2896%2900423-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohacek, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMartin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, W. C.</span></span> <span> </span><span class="NLM_article-title">The art and practice of structure-based drug design: a molecular modeling perspective</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1098-1128(199601)16:1<3::AID-MED1>3.0.CO;2-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2F%28SICI%291098-1128%28199601%2916%3A1%3C3%3A%3AAID-MED1%3E3.0.CO%3B2-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=8788213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaK28XhtFyls78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1996&pages=3-50&author=R.+S.+Bohacekauthor=C.+McMartinauthor=W.+C.+Guida&title=The+art+and+practice+of+structure-based+drug+design%3A+a+molecular+modeling+perspective&doi=10.1002%2F%28SICI%291098-1128%28199601%2916%3A1%3C3%3A%3AAID-MED1%3E3.0.CO%3B2-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The art and practice of structure-based drug design: a molecular modeling perspective</span></div><div class="casAuthors">Bohacek, Regine S.; McMartin, Colin; Guida, Wayne C.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-50</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">Wiley</span>)
        </div><div class="casAbstract">A review with 120 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmfrWdtPosdrVg90H21EOLACvtfcHk0ljH-C722drbEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhtFyls78%253D&md5=edfa592791c111479117feed600dead6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291098-1128%28199601%2916%3A1%3C3%3A%3AAID-MED1%3E3.0.CO%3B2-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291098-1128%2528199601%252916%253A1%253C3%253A%253AAID-MED1%253E3.0.CO%253B2-6%26sid%3Dliteratum%253Aachs%26aulast%3DBohacek%26aufirst%3DR.%2BS.%26aulast%3DMcMartin%26aufirst%3DC.%26aulast%3DGuida%26aufirst%3DW.%2BC.%26atitle%3DThe%2520art%2520and%2520practice%2520of%2520structure-based%2520drug%2520design%253A%2520a%2520molecular%2520modeling%2520perspective%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D1996%26volume%3D16%26spage%3D3%26epage%3D50%26doi%3D10.1002%2F%28SICI%291098-1128%28199601%2916%3A1%3C3%3A%3AAID-MED1%3E3.0.CO%3B2-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoltz, B. M.</span></span> <span> </span><span class="NLM_article-title">Catalytic enantioselective construction of quaternary stereocenters: assembly of key building blocks for the synthesis of biologically active molecules</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">740</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1021/ar5004658</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar5004658" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtlChtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2015&pages=740-751&author=Y.+Liuauthor=S.+J.+Hanauthor=W.+B.+Liuauthor=B.+M.+Stoltz&title=Catalytic+enantioselective+construction+of+quaternary+stereocenters%3A+assembly+of+key+building+blocks+for+the+synthesis+of+biologically+active+molecules&doi=10.1021%2Far5004658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic Enantioselective Construction of Quaternary Stereocenters: Assembly of Key Building Blocks for the Synthesis of Biologically Active Molecules</span></div><div class="casAuthors">Liu, Yiyang; Han, Seo-Jung; Liu, Wen-Bo; Stoltz, Brian M.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">740-751</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ever-present demand for drugs with better efficacy and fewer side effects continually motivates scientists to explore the vast chem. space.  Traditionally, medicinal chemists have focused much attention on achiral or so-called "flat" mols.  More recently, attention has shifted towards mols. with stereogenic centers since their three-dimensional structures represent a much larger fraction of the chem. space and have a no. of superior properties compared with flat arom. compds.  Quaternary stereocenters, in particular, add greatly to the three-dimensionality and novelty of the mol.  Nevertheless, synthetic challenges in building quaternary stereocenters have largely prevented their implementation in drug discovery.  The lack of effective and broadly general methods for enantioselective formation of quaternary stereocenters in simple mol. scaffolds has prompted the authors to investigate new chem. and develop innovative tools and solns.  In this account, the authors describe three approaches to constructing quaternary stereocenters: nucleophilic substitution of 3-halooxindoles, conjugate addn. of boronic acids to cyclic enones, and allylic alkylation of enolates.  In the first approach, malonic ester nucleophiles attack electrophilic 3-halooxindoles, mediated by a copper(II)-bisoxazoline catalyst.  A variety of oxindoles contg. a benzylic quaternary stereocenter can be accessed through this method.  However, it is only applicable to the specialized 3,3-disubstituted oxindole system.  To access benzylic quaternary stereocenters in a more general context, the authors turned their attention to the enantioselective conjugate addn. of carbon nucleophiles to α,β-unsatd. carbonyl acceptors.  The authors discovered that in the presence of catalytic palladium-pyridinooxazoline complex, arylboronic acids add smoothly to β-substituted cyclic enones to furnish ketones with a β-benzylic quaternary stereocenter in high yields and enantioselectivities.  The reaction is compatible with a wide range of arylboronic acids, β-substituents, and ring sizes.  Aside from benzylic quaternary stereocenters, a more challenging motif is a quaternary stereocenter not adjacent to an arom. group.  Such centers represent more general structures in chem. space but are more difficult to form by asym. catalysis.  To address this greater challenge, and motivated by the greater reward, the authors entered the field of palladium-catalyzed asym. allylic alkylation of prochiral enolate nucleophiles about a decade ago.  On the basis of Tsuji's work, which solved the issue of positional selectivity for unsym. ketones, the authors discovered that the phosphinooxazoline ligand effectively rendered this reaction enantioselective.  Extensive investigations since then have revealed that the reaction exhibits broad scope and accepts a range of substrate classes, each with its unique advantage in synthetic applications.  A diverse array of carbonyl compds. bearing α-quaternary stereocenters are obtained in excellent yields and enantioselectivities, and more possibilities have yet to be explored.  As an alternative to palladium catalysis, the authors also studied iridium-catalyzed asym. allylic alkylations that generate vicinal quaternary and tertiary stereocenters in a single transformation.  Overall, these methods provide access to small mol. building blocks with a single quaternary stereocenter, can be applied to various mol. scaffolds, and tolerate a wide range of functional groups.  The authors envision that the chem. reported in this account will be increasingly useful in drug discovery and design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreBoLUz4vn8bVg90H21EOLACvtfcHk0lhDOTcdxqK3Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtlChtrw%253D&md5=9a6705502b6db17067d3f3b011e5803b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Far5004658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far5004658%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DS.%2BJ.%26aulast%3DLiu%26aufirst%3DW.%2BB.%26aulast%3DStoltz%26aufirst%3DB.%2BM.%26atitle%3DCatalytic%2520enantioselective%2520construction%2520of%2520quaternary%2520stereocenters%253A%2520assembly%2520of%2520key%2520building%2520blocks%2520for%2520the%2520synthesis%2520of%2520biologically%2520active%2520molecules%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2015%26volume%3D48%26spage%3D740%26epage%3D751%26doi%3D10.1021%2Far5004658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaraz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chohan, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butlin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elebring, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guile, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St-Gallay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swahn, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swallow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenlock, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span> <span> </span><span class="NLM_article-title">Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5673</span>– <span class="NLM_lpage">5679</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.07.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.bmcl.2011.07.074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=21852131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFKju77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=5673-5679&author=T.+Lukerauthor=L.+Alcarazauthor=K.+K.+Chohanauthor=N.+Blombergauthor=D.+S.+Brownauthor=R.+J.+Butlinauthor=T.+Elebringauthor=A.+M.+Griffinauthor=S.+Guileauthor=S.+St-Gallayauthor=B.+M.+Swahnauthor=S.+Swallowauthor=M.+J.+Waringauthor=M.+C.+Wenlockauthor=P.+D.+Leeson&title=Strategies+to+improve+in+vivo+toxicology+outcomes+for+basic+candidate+drug+molecules&doi=10.1016%2Fj.bmcl.2011.07.074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules</span></div><div class="casAuthors">Luker, Tim; Alcaraz, Lilian; Chohan, Kamaldeep K.; Blomberg, Niklas; Brown, Dearg S.; Butlin, Roger J.; Elebring, Thomas; Griffin, Andrew M.; Guile, Simon; St-Gallay, Stephen; Swahn, Britt-Marie; Swallow, Steve; Waring, Michael J.; Wenlock, Mark C.; Leeson, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5673-5679</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A valid PLS-DA model to predict attrition in pre-clin. toxicol. for basic oral candidate drugs was built.  A combination of arom./aliph. balance, flatness, charge distribution and size descriptors helped predict the successful progression of compds. through a wide range of toxicity testing.  Eighty percent of an independent test set of marketed post-2000 basic drugs could be successfully classified using the model, indicating useful forward predictivity.  The themes within this work provide addnl. guidance for medicinal design chemists and complement other literature property guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_8ruOOUvvQ7Vg90H21EOLACvtfcHk0lhDOTcdxqK3Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFKju77E&md5=7fa177a686eaa7a9868798028bce3043</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.07.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.07.074%26sid%3Dliteratum%253Aachs%26aulast%3DLuker%26aufirst%3DT.%26aulast%3DAlcaraz%26aufirst%3DL.%26aulast%3DChohan%26aufirst%3DK.%2BK.%26aulast%3DBlomberg%26aufirst%3DN.%26aulast%3DBrown%26aufirst%3DD.%2BS.%26aulast%3DButlin%26aufirst%3DR.%2BJ.%26aulast%3DElebring%26aufirst%3DT.%26aulast%3DGriffin%26aufirst%3DA.%2BM.%26aulast%3DGuile%26aufirst%3DS.%26aulast%3DSt-Gallay%26aufirst%3DS.%26aulast%3DSwahn%26aufirst%3DB.%2BM.%26aulast%3DSwallow%26aufirst%3DS.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWenlock%26aufirst%3DM.%2BC.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26atitle%3DStrategies%2520to%2520improve%2520in%2520vivo%2520toxicology%2520outcomes%2520for%2520basic%2520candidate%2520drug%2520molecules%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D5673%26epage%3D5679%26doi%3D10.1016%2Fj.bmcl.2011.07.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland 2: complexity and promiscuity</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">519</span>, <span class="refDoi"> DOI: 10.1039/c2md20347b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1039%2Fc2md20347b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=515-519&author=F.+Lovering&title=Escape+from+flatland+2%3A+complexity+and+promiscuity&doi=10.1039%2Fc2md20347b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland 2: complexity and promiscuity</span></div><div class="casAuthors">Lovering, Frank</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">515-519</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Toxicity plays a major role in attrition in the clinic and promiscuity has been linked to toxicity.  A no. of mol. descriptors have been identified that contribute to promiscuity including ionization and logP.  In this study we report on the relationship between complexity, as measured by two descriptors [fraction sp3 (Fsp3) where Fsp3 = (no. of sp3 hybridized carbons/total carbon count) and chiral carbon count], and promiscuity as well as Cyp450 inhibition.  We find that increasing complexity reduces promiscuity and Cyp450 inhibition.  As an understanding of key property descriptors has helped the pharmaceutical industry to address some of the deficiencies of compds. as pertains to bioavailability, awareness of the descriptors that impact promiscuity should allow us to better address toxicity in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJfDH0430P-bVg90H21EOLACvtfcHk0lgJiwYLJWUaTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D&md5=c03d3b99da22a684cbbbb00fb1633342</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1039%2Fc2md20347b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20347b%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26atitle%3DEscape%2520from%2520flatland%25202%253A%2520complexity%2520and%2520promiscuity%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26spage%3D515%26epage%3D519%26doi%3D10.1039%2Fc2md20347b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0lgJiwYLJWUaTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span> <span> </span><span class="NLM_article-title">Physicochemical Descriptors of Aromatic Character and Their Use in Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7206</span>– <span class="NLM_lpage">7215</span>, <span class="refDoi"> DOI: 10.1021/jm500515d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500515d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1Wmsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7206-7215&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonald&title=Physicochemical+Descriptors+of+Aromatic+Character+and+Their+Use+in+Drug+Discovery&doi=10.1021%2Fjm500515d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical Descriptors of Aromatic Character and Their Use in Drug Discovery</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7206-7215</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Published physicochem. descriptors of mols. that convey aromaticity-related character are reviewed in the context of drug design and discovery.  Studies that have employed arom. descriptors are discussed, and several descriptors are compared and contrasted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogc1vxNtUQl7Vg90H21EOLACvtfcHk0lgJiwYLJWUaTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1Wmsbw%253D&md5=7aca9f7309bb5dd806aeb4c2b4ff8eab</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm500515d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500515d%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DPhysicochemical%2520Descriptors%2520of%2520Aromatic%2520Character%2520and%2520Their%2520Use%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7206%26epage%3D7215%26doi%3D10.1021%2Fjm500515d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span> <span> </span><span class="NLM_article-title">Molecular complexity and fragment-based drug discovery: ten years on</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2011.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.cbpa.2011.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=21665521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFCltrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=489-496&author=A.+R.+Leachauthor=M.+M.+Hann&title=Molecular+complexity+and+fragment-based+drug+discovery%3A+ten+years+on&doi=10.1016%2Fj.cbpa.2011.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular complexity and fragment-based drug discovery: ten years on</span></div><div class="casAuthors">Leach, Andrew R.; Hann, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">489-496</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We review the concept of mol. complexity in the context of the very simple model of mol. interactions that we introduced over 10 years ago.  A summary is presented of efforts to validate this simple model using screening data.  The relationship between the complexity model and the problem of sampling chem. space is discussed, together with the relevance of these theor. concepts to fragment-based drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNcMgTT6eLC7Vg90H21EOLACvtfcHk0lghI7WrRjPjaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFCltrg%253D&md5=19c2d65de80a8bab1059468828da6ce2</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2011.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2011.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DHann%26aufirst%3DM.%2BM.%26atitle%3DMolecular%2520complexity%2520and%2520fragment-based%2520drug%2520discovery%253A%2520ten%2520years%2520on%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D15%26spage%3D489%26epage%3D496%26doi%3D10.1016%2Fj.cbpa.2011.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Measom, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Down, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manas, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somers, D. O.</span></span> <span> </span><span class="NLM_article-title">Investigation of a bicyclo[1.1.1]pentane as a phenyl replacement within an LpPLA2 inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00281</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00281" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCqtbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=43-48&author=N.+D.+Measomauthor=K.+D.+Downauthor=D.+J.+Hirstauthor=C.+Jamiesonauthor=E.+S.+Manasauthor=V.+K.+Patelauthor=D.+O.+Somers&title=Investigation+of+a+bicyclo%5B1.1.1%5Dpentane+as+a+phenyl+replacement+within+an+LpPLA2+inhibitor&doi=10.1021%2Facsmedchemlett.6b00281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of a Bicyclo[1.1.1]pentane as a Phenyl Replacement within an LpPLA2 Inhibitor</span></div><div class="casAuthors">Measom, Nicholas D.; Down, Kenneth D.; Hirst, David J.; Jamieson, Craig; Manas, Eric S.; Patel, Vipulkumar K.; Somers, Don O.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-48</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors describe the incorporation of a bicyclo[1.1.1]pentane moiety within two known LpPLA2 inhibitors to act as bioisosteric Ph replacements.  An efficient synthesis to the target compds. was enabled with a dichlorocarbene insertion into a bicyclo[1.1.0]butane system being the key transformation.  Potency, physicochem., and x-ray crystallog. data were obtained to compare the known inhibitors to their bioisosteric counterparts, which showed the isostere was well tolerated and pos. impacted on the physicochem. profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouQjyZ5QbhWbVg90H21EOLACvtfcHk0lghI7WrRjPjaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCqtbjK&md5=5d8edc57e03090b6680bd819fc5ed67a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00281%26sid%3Dliteratum%253Aachs%26aulast%3DMeasom%26aufirst%3DN.%2BD.%26aulast%3DDown%26aufirst%3DK.%2BD.%26aulast%3DHirst%26aufirst%3DD.%2BJ.%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DManas%26aufirst%3DE.%2BS.%26aulast%3DPatel%26aufirst%3DV.%2BK.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26atitle%3DInvestigation%2520of%2520a%2520bicyclo%255B1.1.1%255Dpentane%2520as%2520a%2520phenyl%2520replacement%2520within%2520an%2520LpPLA2%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D43%26epage%3D48%26doi%3D10.1021%2Facsmedchemlett.6b00281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stockdale, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C. M.</span></span> <span> </span><span class="NLM_article-title">Pharmaceuticals that contain polycyclic hydrocarbon scaffolds</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">7737</span>– <span class="NLM_lpage">7763</span>, <span class="refDoi"> DOI: 10.1039/C4CS00477A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1039%2FC4CS00477A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=26171466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFKitr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2015&pages=7737-7763&author=T.+P.+Stockdaleauthor=C.+M.+Williams&title=Pharmaceuticals+that+contain+polycyclic+hydrocarbon+scaffolds&doi=10.1039%2FC4CS00477A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmaceuticals that contain polycyclic hydrocarbon scaffolds</span></div><div class="casAuthors">Stockdale, Tegan P.; Williams, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7737-7763</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Numerous variations on structural motifs exist within pharmaceutical compds. that have entered the clinic.  These variations have amounted over many decades based on years of drug development assocd. with screening natural products and de novo synthetic systems.  Caged (or bridged) bicyclic structural elements offer a variety of diverse features, encompassing three-dimensional shape, and assorted pharmacokinetic properties.  This review highlights approx. 20 all carbon cage contg. pharmaceuticals, ranging in structure from bicyclo[2.2.1] through to adamantane, including some in the top-selling pharmaceutical bracket.  Although, a wide variety of human diseases, illnesses and conditions are treated with drugs contg. the bicyclic motif, a common feature is that many of these lipophilic systems display CNS and/or neurol. activity.  In addn., to an extensive overview of the history and biol. assocd. with each drug, a survey of synthetic methods used to construct these entities is presented.  An anal. section compares natural products to synthetics in drug discovery, and entertains the classical caged hydrocarbon systems potentially missing from the clinic.  Lastly, this unprecedented review is highly pertinent at a time when big pharma is desperately trying to escape flatland drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopp0z3Mk5xj7Vg90H21EOLACvtfcHk0lghI7WrRjPjaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFKitr7O&md5=b9b825abdcc6b98c8d409014983370ae</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2FC4CS00477A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CS00477A%26sid%3Dliteratum%253Aachs%26aulast%3DStockdale%26aufirst%3DT.%2BP.%26aulast%3DWilliams%26aufirst%3DC.%2BM.%26atitle%3DPharmaceuticals%2520that%2520contain%2520polycyclic%2520hydrocarbon%2520scaffolds%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2015%26volume%3D44%26spage%3D7737%26epage%3D7763%26doi%3D10.1039%2FC4CS00477A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tajabadi, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campitelli, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, R. J.</span></span> <span> </span><span class="NLM_article-title">Scaffold Flatness: Reversing the Trend</span>. <i>Springer Science Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1007/s40362-013-0014-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1007%2Fs40362-013-0014-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=141-151&author=F.+M.+Tajabadiauthor=M.+R.+Campitelliauthor=R.+J.+Quinn&title=Scaffold+Flatness%3A+Reversing+the+Trend&doi=10.1007%2Fs40362-013-0014-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs40362-013-0014-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40362-013-0014-7%26sid%3Dliteratum%253Aachs%26aulast%3DTajabadi%26aufirst%3DF.%2BM.%26aulast%3DCampitelli%26aufirst%3DM.%2BR.%26aulast%3DQuinn%26aufirst%3DR.%2BJ.%26atitle%3DScaffold%2520Flatness%253A%2520Reversing%2520the%2520Trend%26jtitle%3DSpringer%2520Science%2520Rev.%26date%3D2013%26volume%3D1%26spage%3D141%26epage%3D151%26doi%3D10.1007%2Fs40362-013-0014-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasteiger, J.</span></span> <span> </span><span class="NLM_article-title">Prediction of aqueous solubility of organic compounds based on a 3D structure representation</span>. <i>J. Chem. Inf. Comput. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">434</span>, <span class="refDoi"> DOI: 10.1021/ci025590u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci025590u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD38Xps1GgsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2003&pages=429-434&author=A.+Yanauthor=J.+Gasteiger&title=Prediction+of+aqueous+solubility+of+organic+compounds+based+on+a+3D+structure+representation&doi=10.1021%2Fci025590u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Aqueous Solubility of Organic Compounds Based on a 3D Structure Representation</span></div><div class="casAuthors">Yan, Aixia; Gasteiger, Johann</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">429-434</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two quant. models for the prediction of aq. soly. of 1293 org. compds. were developed by a Multilinear Regression (MLR) anal. and a Back-Propagation (BPG) neural network.  The mols. were described by a set of 32 values of a Radial Distribution Function (RDF) code representing the 3D structure and eight addnl. descriptors.  The 1293 compds. were divided into a training set of 797 compds. and a test set of 496 compds. based on a Kohonen self-organizing neural network map.  The obtained models show a good predictive power: for the test set, a correlation coeff. of 0.96 and a std. deviation of 0.59 were achieved by the back-propagation neural network approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXUOcOYAjstrVg90H21EOLACvtfcHk0lghI7WrRjPjaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xps1GgsLc%253D&md5=17a31099dbdf8759952227315af1a633</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fci025590u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci025590u%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DA.%26aulast%3DGasteiger%26aufirst%3DJ.%26atitle%3DPrediction%2520of%2520aqueous%2520solubility%2520of%2520organic%2520compounds%2520based%2520on%2520a%25203D%2520structure%2520representation%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comput.%2520Sci.%26date%3D2003%26volume%3D43%26spage%3D429%26epage%3D434%26doi%3D10.1021%2Fci025590u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span> <span> </span><span class="NLM_article-title">Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1539</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1021/jm101356p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101356p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1539-1554&author=M.+Ishikawaauthor=Y.+Hashimoto&title=Improvement+in+aqueous+solubility+in+small+molecule+drug+discovery+programs+by+disruption+of+molecular+planarity+and+symmetry&doi=10.1021%2Fjm101356p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry</span></div><div class="casAuthors">Ishikawa, Minoru; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1539-1554</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKbtbfvqKZjrVg90H21EOLACvtfcHk0liyv67wnZcCuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D&md5=a88804b3850625ef9c3f7424366acb91</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm101356p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101356p%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DImprovement%2520in%2520aqueous%2520solubility%2520in%2520small%2520molecule%2520drug%2520discovery%2520programs%2520by%2520disruption%2520of%2520molecular%2520planarity%2520and%2520symmetry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1539%26epage%3D1554%26doi%3D10.1021%2Fjm101356p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engkvist, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">Beyond size, ionization state, and lipophilicity: influence of molecular topology on absorption, distribution, metabolism, excretion, and toxicity for druglike compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3667</span>– <span class="NLM_lpage">3677</span>, <span class="refDoi"> DOI: 10.1021/jm201548z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201548z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVymtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3667-3677&author=Y.+Yangauthor=O.+Engkvistauthor=A.+Llinasauthor=H.+Chen&title=Beyond+size%2C+ionization+state%2C+and+lipophilicity%3A+influence+of+molecular+topology+on+absorption%2C+distribution%2C+metabolism%2C+excretion%2C+and+toxicity+for+druglike+compounds&doi=10.1021%2Fjm201548z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond Size, Ionization State, and Lipophilicity: Influence of Molecular Topology on Absorption, Distribution, Metabolism, Excretion, and Toxicity for Druglike Compounds</span></div><div class="casAuthors">Yang, Yidong; Engkvist, Ola; Llinas, Antonio; Chen, Hongming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3667-3677</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The absorption, distribution, metab., excretion, and toxicity (ADMET) of a compd. is dependent on physicochem. properties such as mol. size, lipophilicity, and ionization state.  However, much less is known regarding the relationship between ADMET and the mol. topol.  In this study two descriptors related to the mol. topol. have been investigated, the fraction of the mol. framework (fMF) and the fraction of sp3-hybridized carbon atoms (Fsp3). fMF and Fsp3, together with std. physicochem. properties (mol. size, ionization state, and lipophilicity), were analyzed for a set of ADMET assays.  It is shown that aq. soly., Caco-2 permeability, plasma protein binding, human ether-a-go-go-related potassium channel protein inhibition, and CYP3A4 (CYP = cytochrome P 450) inhibition are influenced by the mol. topol.  These findings are in most cases independent of the already well-established relationships between the properties and mol. size, lipophilicity, and ionization state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAjwI3Slwd37Vg90H21EOLACvtfcHk0liyv67wnZcCuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVymtL0%253D&md5=596f7685e87dc0f0178d7d70616e17de</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm201548z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201548z%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DEngkvist%26aufirst%3DO.%26aulast%3DLlinas%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DBeyond%2520size%252C%2520ionization%2520state%252C%2520and%2520lipophilicity%253A%2520influence%2520of%2520molecular%2520topology%2520on%2520absorption%252C%2520distribution%252C%2520metabolism%252C%2520excretion%252C%2520and%2520toxicity%2520for%2520druglike%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3667%26epage%3D3677%26doi%3D10.1021%2Fjm201548z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, C.</span></span> <span> </span><span class="NLM_article-title">Chemical space</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>432</i></span>,  <span class="NLM_fpage">823</span>– <span class="NLM_lpage">823</span>, <span class="refDoi"> DOI: 10.1038/432823a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2F432823a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVOht7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=432&publication_year=2004&pages=823-823&author=P.+Kirkpatrickauthor=C.+Ellis&title=Chemical+space&doi=10.1038%2F432823a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical space</span></div><div class="casAuthors">Kirkpatrick, Peter; Ellis, Clare</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">432</span>
        (<span class="NLM_cas:issue">7019</span>),
    <span class="NLM_cas:pages">823</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSXQH2kgCwfrVg90H21EOLACvtfcHk0liyv67wnZcCuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVOht7rI&md5=50a945a5b82429437d7745e619d628bf</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2F432823a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F432823a%26sid%3Dliteratum%253Aachs%26aulast%3DKirkpatrick%26aufirst%3DP.%26aulast%3DEllis%26aufirst%3DC.%26atitle%3DChemical%2520space%26jtitle%3DNature%26date%3D2004%26volume%3D432%26spage%3D823%26epage%3D823%26doi%3D10.1038%2F432823a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aldeghi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selwood, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A. W.</span></span> <span> </span><span class="NLM_article-title">Two- and three-dimensional rings in drugs</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">450</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1111/cbdd.12260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1111%2Fcbdd.12260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=24472495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktlCit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2014&pages=450-461&author=M.+Aldeghiauthor=S.+Malhotraauthor=D.+L.+Selwoodauthor=A.+W.+Chan&title=Two-+and+three-dimensional+rings+in+drugs&doi=10.1111%2Fcbdd.12260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Two- and Three-dimensional Rings in Drugs</span></div><div class="casAuthors">Aldeghi, Matteo; Malhotra, Shipra; Selwood, David L.; Chan, Ah Wing Edith</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">450-461</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Using small, flat arom. rings as components of fragments or mols. is a common practice in fragment-based drug discovery and lead optimization.  With an increasing focus on the exploration of novel biol. and chem. space, and their improved synthetic accessibility, 3D fragments are attracting increasing interest.  This study presents a detailed anal. of 3D and 2D ring fragments in marketed drugs.  Several measures of properties were used, such as the type of ring assemblies and mol. shapes.  The study also took into account the relationship between protein classes targeted by each ring fragment, providing target-specific information.  The anal. shows the high structural and shape diversity of 3D ring systems and their importance in bioactive compds.  Major differences in 2D and 3D fragments are apparent in ligands that bind to the major drug targets such as GPCRs, ion channels, and enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH07LvbUgiSrVg90H21EOLACvtfcHk0lgVSdoEjMLoLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktlCit7g%253D&md5=dc877976abbd6b5b7d25a6b8b96415bc</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12260%26sid%3Dliteratum%253Aachs%26aulast%3DAldeghi%26aufirst%3DM.%26aulast%3DMalhotra%26aufirst%3DS.%26aulast%3DSelwood%26aufirst%3DD.%2BL.%26aulast%3DChan%26aufirst%3DA.%2BW.%26atitle%3DTwo-%2520and%2520three-dimensional%2520rings%2520in%2520drugs%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2014%26volume%3D83%26spage%3D450%26epage%3D461%26doi%3D10.1111%2Fcbdd.12260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morley, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugliese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bower, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoelder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swarbrick, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span> <span> </span><span class="NLM_article-title">Fragment-based hit identification: thinking in 3D</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1221</span>– <span class="NLM_lpage">1227</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.07.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.drudis.2013.07.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=23906694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A280%3ADC%252BC3sflvFSnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=1221-1227&author=A.+D.+Morleyauthor=A.+Puglieseauthor=K.+Birchallauthor=J.+Bowerauthor=P.+Brennanauthor=N.+Brownauthor=T.+Chapmanauthor=M.+Drysdaleauthor=I.+H.+Gilbertauthor=S.+Hoelderauthor=A.+Jordanauthor=S.+V.+Leyauthor=A.+Merrittauthor=D.+Millerauthor=M.+E.+Swarbrickauthor=P.+G.+Wyatt&title=Fragment-based+hit+identification%3A+thinking+in+3D&doi=10.1016%2Fj.drudis.2013.07.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-based hit identification: thinking in 3D</span></div><div class="casAuthors">Morley Andrew D; Pugliese Angelo; Birchall Kristian; Bower Justin; Brennan Paul; Brown Nathan; Chapman Tim; Drysdale Martin; Gilbert Ian H; Hoelder Swen; Jordan Allan; Ley Steven V; Merritt Andy; Miller David; Swarbrick Martin E; Wyatt Paul G</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">1221-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs.  As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science.  The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSiou0I6dpmUhgd2Wuil24tfW6udTcc2eZZl1bRJtVMKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sflvFSnuw%253D%253D&md5=74c6c81bfa12018554c0d1cfab894501</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.07.011%26sid%3Dliteratum%253Aachs%26aulast%3DMorley%26aufirst%3DA.%2BD.%26aulast%3DPugliese%26aufirst%3DA.%26aulast%3DBirchall%26aufirst%3DK.%26aulast%3DBower%26aufirst%3DJ.%26aulast%3DBrennan%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DN.%26aulast%3DChapman%26aufirst%3DT.%26aulast%3DDrysdale%26aufirst%3DM.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DHoelder%26aufirst%3DS.%26aulast%3DJordan%26aufirst%3DA.%26aulast%3DLey%26aufirst%3DS.%2BV.%26aulast%3DMerritt%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DD.%26aulast%3DSwarbrick%26aufirst%3DM.%2BE.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26atitle%3DFragment-based%2520hit%2520identification%253A%2520thinking%2520in%25203D%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D1221%26epage%3D1227%26doi%3D10.1016%2Fj.drudis.2013.07.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kombo, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallapragada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazurov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speake, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toler, S.</span></span> <span> </span><span class="NLM_article-title">3D molecular descriptors important for clinical success</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.1021/ci300445e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci300445e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCjurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=327-342&author=D.+C.+Komboauthor=K.+Tallapragadaauthor=R.+Jainauthor=J.+Chewningauthor=A.+A.+Mazurovauthor=J.+D.+Speakeauthor=T.+A.+Hauserauthor=S.+Toler&title=3D+molecular+descriptors+important+for+clinical+success&doi=10.1021%2Fci300445e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">3D Molecular Descriptors Important for Clinical Success</span></div><div class="casAuthors">Kombo, David C.; Tallapragada, Kartik; Jain, Rachit; Chewning, Joseph; Mazurov, Anatoly A.; Speake, Jason D.; Hauser, Terry A.; Toler, Steve</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">327-342</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pharmacokinetic and safety profiles of clin. drug candidates are greatly influenced by their requisite physicochem. properties.  In particular, it has been shown that 2D mol. descriptors such as fraction of Sp3 carbon atoms (Fsp3) and no. of stereo centers correlate with clin. success.  Using the proteomic off-target hit rate of nicotinic ligands, we found that shape-based 3D descriptors such as the radius of gyration and shadow indexes discriminate off-target promiscuity better than do Fsp3 and the no. of stereo centers.  We have deduced the relevant descriptor values required for a ligand to be nonpromiscuous.  Investigating the MDL Drug Data Report (MDDR) database as compds. move from the preclin. stage toward the market, we have found that these shape-based 3D descriptors predict clin. success of compds. at preclin. and phase1 stages vs compds. withdrawn from the market better than do Fsp3 and LogD.  Further, these computed 3D mol. descriptors correlate well with exptl. obsd. soly., which is among well-known physicochem. properties that drive clin. success.  We also found that about 84% of launched drugs satisfy either Shadow index or Fsp3 criteria, whereas withdrawn and discontinued compds. fail to meet the same criteria.  Our studies suggest that spherical compds. (rather than their elongated counterparts) with a minimal no. of arom. rings may exhibit a high propensity to advance from clin. trials to market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNRhBgMppmbbVg90H21EOLACvtfcHk0lgVSdoEjMLoLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCjurnE&md5=c750cdc150c2ba3626d98e2eea8c3144</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fci300445e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci300445e%26sid%3Dliteratum%253Aachs%26aulast%3DKombo%26aufirst%3DD.%2BC.%26aulast%3DTallapragada%26aufirst%3DK.%26aulast%3DJain%26aufirst%3DR.%26aulast%3DChewning%26aufirst%3DJ.%26aulast%3DMazurov%26aufirst%3DA.%2BA.%26aulast%3DSpeake%26aufirst%3DJ.%2BD.%26aulast%3DHauser%26aufirst%3DT.%2BA.%26aulast%3DToler%26aufirst%3DS.%26atitle%3D3D%2520molecular%2520descriptors%2520important%2520for%2520clinical%2520success%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D327%26epage%3D342%26doi%3D10.1021%2Fci300445e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hung, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, D. W.</span></span> <span> </span><span class="NLM_article-title">Route to three-dimensional fragments using diversity-oriented synthesis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">6799</span>– <span class="NLM_lpage">6804</span>, <span class="refDoi"> DOI: 10.1073/pnas.1015271108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1073%2Fpnas.1015271108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=21482811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlslyru7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=6799-6804&author=A.+W.+Hungauthor=A.+Ramekauthor=Y.+Wangauthor=T.+Kayaauthor=J.+A.+Wilsonauthor=P.+A.+Clemonsauthor=D.+W.+Young&title=Route+to+three-dimensional+fragments+using+diversity-oriented+synthesis&doi=10.1073%2Fpnas.1015271108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Route to three-dimensional fragments using diversity-oriented synthesis</span></div><div class="casAuthors">Hung, Alvin W.; Ramek, Alex; Wang, Yikai; Kaya, Taner; Wilson, J. Anthony; Clemons, Paul A.; Young, Damian W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6799-6804, S6799/1-S6799/41</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Fragment-based drug discovery (FBDD) has proven to be an effective means of producing high-quality chem. ligands as starting points for drug-discovery pursuits.  The increasing no. of clin. candidate drugs developed using FBDD approaches is a testament of the efficacy of this approach.  The success of fragment-based methods is highly dependent on the identity of the fragment library used for screening.  The vast majority of FBDD has centered on the use of sp2-rich arom. compds.  An expanded set of fragments that possess more 3D character would provide access to a larger chem. space of fragments than those currently used.  Diversity-oriented synthesis (DOS) aims to efficiently generate a set of mols. diverse in skeletal and stereochem. properties.  Mols. derived from DOS have also displayed significant success in the modulation of function of various difficult targets.  Herein, the authors describe the application of DOS toward the construction of a unique set of fragments contg. highly sp3-rich skeletons for fragment-based screening.  Using chemoinformatics anal., the authors quantified the shapes and phys. properties of the new 3D fragments and compared them with a database contg. known fragment-like mols.  The synthesis of the target compds. was achieved using as starting materials (2R)-2-(2-propen-1-yl)-1,2-pyrrolidinedicarboxylic acid 1-(1,1-dimethylethyl) ester, (5R)-5-(2-propen-1-yl)-L-proline 1,1-dimethylethyl ester and (5S)-5-(2-propen-1-yl)-L-proline 1,1-dimethylethyl ester and com. available reactants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIEcByQ3cnmbVg90H21EOLACvtfcHk0li-74yZz1dsfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlslyru7k%253D&md5=400419b262a4541a6bad66f64d461211</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1015271108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1015271108%26sid%3Dliteratum%253Aachs%26aulast%3DHung%26aufirst%3DA.%2BW.%26aulast%3DRamek%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKaya%26aufirst%3DT.%26aulast%3DWilson%26aufirst%3DJ.%2BA.%26aulast%3DClemons%26aufirst%3DP.%2BA.%26aulast%3DYoung%26aufirst%3DD.%2BW.%26atitle%3DRoute%2520to%2520three-dimensional%2520fragments%2520using%2520diversity-oriented%2520synthesis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D6799%26epage%3D6804%26doi%3D10.1073%2Fpnas.1015271108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krautler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liskamp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samori, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwalbe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toniolo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Boeckel, C. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, C. T.</span></span> <span> </span><span class="NLM_article-title">The state of the art of chemical biology</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1002/cbic.200800758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fcbic.200800758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=19115274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFOgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=16-29&author=K.-H.+Altmannauthor=J.+Buchnerauthor=H.+Kesslerauthor=F.+Diederichauthor=B.+Krautlerauthor=S.+Lippardauthor=R.+Liskampauthor=K.+Mullerauthor=E.+M.+Nolanauthor=B.+Samoriauthor=G.+Schneiderauthor=S.+L.+Schreiberauthor=H.+Schwalbeauthor=C.+Tonioloauthor=C.+A.+A.+van+Boeckelauthor=H.+Waldmannauthor=C.+T.+Walsh&title=The+state+of+the+art+of+chemical+biology&doi=10.1002%2Fcbic.200800758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The state of the art of chemical biology</span></div><div class="casAuthors">Altmann, Karl-Heinz; Buchner, Johannes; Kessler, Horst; Diederich, Francois; Krautler, Bernhard; Lippard, Stephen; Liskamp, Rob; Muller, Klaus; Nolan, Elizabeth M.; Samori, Bruno; Schneider, Gisbert; Schreiber, Stuart L.; Schwalbe, Harald; Toniolo, Claudio; van Boeckel, Constant A. A.; Waldmann, Herbert; Walsh, Christopher T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-29</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Individual commentaries by each of the authors are given on the development and growth in the field of chem. biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0dnOb6qYHPrVg90H21EOLACvtfcHk0li-74yZz1dsfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFOgtLc%253D&md5=3a4d305e6dea4857f5de343acbde4a2d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200800758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200800758%26sid%3Dliteratum%253Aachs%26aulast%3DAltmann%26aufirst%3DK.-H.%26aulast%3DBuchner%26aufirst%3DJ.%26aulast%3DKessler%26aufirst%3DH.%26aulast%3DDiederich%26aufirst%3DF.%26aulast%3DKrautler%26aufirst%3DB.%26aulast%3DLippard%26aufirst%3DS.%26aulast%3DLiskamp%26aufirst%3DR.%26aulast%3DMuller%26aufirst%3DK.%26aulast%3DNolan%26aufirst%3DE.%2BM.%26aulast%3DSamori%26aufirst%3DB.%26aulast%3DSchneider%26aufirst%3DG.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DSchwalbe%26aufirst%3DH.%26aulast%3DToniolo%26aufirst%3DC.%26aulast%3Dvan%2BBoeckel%26aufirst%3DC.%2BA.%2BA.%26aulast%3DWaldmann%26aufirst%3DH.%26aulast%3DWalsh%26aufirst%3DC.%2BT.%26atitle%3DThe%2520state%2520of%2520the%2520art%2520of%2520chemical%2520biology%26jtitle%3DChemBioChem%26date%3D2009%26volume%3D10%26spage%3D16%26epage%3D29%26doi%3D10.1002%2Fcbic.200800758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Conformational restriction: an effective tactic in ‘follow-on’-based drug discovery</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">901</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.4155%2Ffmc.14.50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=24962281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVemsrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=885-901&author=Z.+Fangauthor=Y.+Songauthor=P.+Zhanauthor=Q.+Zhangauthor=X.+Liu&title=Conformational+restriction%3A+an+effective+tactic+in+%E2%80%98follow-on%E2%80%99-based+drug+discovery&doi=10.4155%2Ffmc.14.50"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational restriction: an effective tactic in 'follow-on'-based drug discovery</span></div><div class="casAuthors">Fang, Zengjun; Song, Yu'ning; Zhan, Peng; Zhang, Qingzhu; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">885-901</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The conformational restriction (rigidification) of a flexible ligand has often been a commonly used strategy in drug design, as it can minimize the entropic loss assocd. with the ligand adopting a preferred conformation for binding, which leads to enhanced potency for a given physiol. target, improved selectivity for isoforms and reduced the possibility of drug metab.  Therefore, the application of conformational restriction strategy is a core aspect of drug discovery and development that is widely practiced by medicinal chemists either deliberately or subliminally.  The present review will highlight current representative examples and a brief overview on the rational design of conformationally restricted agents as well as discuss its advantages over the flexible counterparts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoupMomfg9J_bVg90H21EOLACvtfcHk0lip-VKXDIrAyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVemsrzE&md5=dcf5fa6cead84c77b3603c7e0800f49b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.50%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DZ.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DConformational%2520restriction%253A%2520an%2520effective%2520tactic%2520in%2520%25E2%2580%2598follow-on%25E2%2580%2599-based%2520drug%2520discovery%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D885%26epage%3D901%26doi%3D10.4155%2Ffmc.14.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodycombe, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrinski, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamji, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">18787</span>– <span class="NLM_lpage">18792</span>, <span class="refDoi"> DOI: 10.1073/pnas.1012741107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1073%2Fpnas.1012741107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=20956335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVCqsb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=18787-18792&author=P.+A.+Clemonsauthor=N.+E.+Bodycombeauthor=H.+A.+Carrinskiauthor=J.+A.+Wilsonauthor=A.+F.+Shamjiauthor=B.+K.+Wagnerauthor=A.+N.+Koehlerauthor=S.+L.+Schreiber&title=Small+molecules+of+different+origins+have+distinct+distributions+of+structural+complexity+that+correlate+with+protein-binding+profiles&doi=10.1073%2Fpnas.1012741107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles</span></div><div class="casAuthors">Clemons, Paul A.; Bodycombe, Nicole E.; Carrinski, Hyman A.; Wilson, J. Anthony; Shamji, Alykhan F.; Wagner, Bridget K.; Koehler, Angela N.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">18787-18792, S18787/1-S18787/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Using a diverse collection of small mols. generated from a variety of sources, we measured protein-binding activities of each individual compd. against each of 100 diverse (sequence-unrelated) proteins using small-mol. microarrays.  We also analyzed structural features, including complexity, of the small mols.  We found that compds. from different sources (com., academic, natural) have different protein-binding behaviors and that these behaviors correlate with general trends in stereochem. and shape descriptors for these compd. collections.  Increasing the content of sp3-hybridized and stereogenic atoms relative to compds. from com. sources, which comprise the majority of current screening collections, improved binding selectivity and frequency.  The results suggest structural features that synthetic chemists can target when synthesizing screening collections for biol. discovery.  Because binding proteins selectively can be a key feature of high-value probes and drugs, synthesizing com- pounds having features identified in this study may result in improved performance of screening collections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBrE7Js72yZrVg90H21EOLACvtfcHk0lip-VKXDIrAyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVCqsb%252FN&md5=198e298ca5391d7dfd91184680e3c2ec</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1012741107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1012741107%26sid%3Dliteratum%253Aachs%26aulast%3DClemons%26aufirst%3DP.%2BA.%26aulast%3DBodycombe%26aufirst%3DN.%2BE.%26aulast%3DCarrinski%26aufirst%3DH.%2BA.%26aulast%3DWilson%26aufirst%3DJ.%2BA.%26aulast%3DShamji%26aufirst%3DA.%2BF.%26aulast%3DWagner%26aufirst%3DB.%2BK.%26aulast%3DKoehler%26aufirst%3DA.%2BN.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DSmall%2520molecules%2520of%2520different%2520origins%2520have%2520distinct%2520distributions%2520of%2520structural%2520complexity%2520that%2520correlate%2520with%2520protein-binding%2520profiles%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D18787%26epage%3D18792%26doi%3D10.1073%2Fpnas.1012741107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zdorichenko, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker-Milburn, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paumier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson-Ralph, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, G.</span></span> <span> </span><span class="NLM_article-title">Escaping from flatland: Substituted bridged pyrrolidine fragments with inherent three-dimensional character</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1185</span>– <span class="NLM_lpage">1190</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlvVGmtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1185-1190&author=B.+Coxauthor=V.+Zdorichenkoauthor=P.+B.+Coxauthor=K.+I.+Booker-Milburnauthor=R.+Paumierauthor=L.+D.+Elliottauthor=M.+Robertson-Ralphauthor=G.+Bloomfield&title=Escaping+from+flatland%3A+Substituted+bridged+pyrrolidine+fragments+with+inherent+three-dimensional+character&doi=10.1021%2Facsmedchemlett.0c00039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Escaping from flatland: Substituted bridged pyrrolidine fragments with inherent three-dimensional character</span></div><div class="casAuthors">Cox, Brian; Zdorichenko, Victor; Cox, Philip B.; Booker-Milburn, Kevin I.; Paumier, Romain; Elliott, Luke D.; Robertson-Ralph, Michael; Bloomfield, Graham</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1185-1190</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pressure to deliver new medicines to the patient continues to grow along with increases in compd. failure rate, thus putting the current R&D model at risk.  Anal. has shown that increasing the three-dimensionality of potential drug candidates decreases the risk of failure and improves binding selectivity and frequency.  For this reason many workers have taken a new look at the power of photochem. as a means to generate novel sp3 rich scaffolds for use in drug discovery programs.  Here we report the design, synthesis, and computational structural anal. of a series of 2,4-methanoprolines having inherent 3D character (PMI and PBF scores) significantly higher than that of the broader AbbVie Rule of 3 (Ro3) collection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbrR6OWJMH3bVg90H21EOLACvtfcHk0lip-VKXDIrAyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlvVGmtrc%253D&md5=f6d85595552e87671c7261e841d33146</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00039%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DB.%26aulast%3DZdorichenko%26aufirst%3DV.%26aulast%3DCox%26aufirst%3DP.%2BB.%26aulast%3DBooker-Milburn%26aufirst%3DK.%2BI.%26aulast%3DPaumier%26aufirst%3DR.%26aulast%3DElliott%26aufirst%3DL.%2BD.%26aulast%3DRobertson-Ralph%26aufirst%3DM.%26aulast%3DBloomfield%26aufirst%3DG.%26atitle%3DEscaping%2520from%2520flatland%253A%2520Substituted%2520bridged%2520pyrrolidine%2520fragments%2520with%2520inherent%2520three-dimensional%2520character%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1185%26epage%3D1190%26doi%3D10.1021%2Facsmedchemlett.0c00039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. B.</span></span> <span> </span><span class="NLM_article-title">Privileged structures: Efficient chemical “navigators” toward unexplored biologically relevant chemical spaces</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">14629</span>– <span class="NLM_lpage">14638</span>, <span class="refDoi"> DOI: 10.1021/ja508343a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja508343a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsleksrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=14629-14638&author=J.+Kimauthor=H.+Kimauthor=S.+B.+Park&title=Privileged+structures%3A+Efficient+chemical+%E2%80%9Cnavigators%E2%80%9D+toward+unexplored+biologically+relevant+chemical+spaces&doi=10.1021%2Fja508343a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Privileged Structures: Efficient Chemical "Navigators" toward Unexplored Biologically Relevant Chemical Spaces</span></div><div class="casAuthors">Kim, Jonghoon; Kim, Heejun; Park, Seung Bum</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">14629-14638</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In the search for new therapeutic agents for currently incurable diseases, attention has turned to traditionally "undruggable" targets, and collections of drug-like small mols. with high diversity and quality have become a prerequisite for new breakthroughs.  To generate such collections, the diversity-oriented synthesis (DOS) strategy was developed, which aims to populate new chem. space with drug-like compds. contg. a high degree of mol. diversity.  The resulting DOS-derived libraries have been of great value for the discovery of various bioactive small mols. and therapeutic agents, and thus DOS has emerged as an essential tool in chem. biol. and drug discovery.  However, the key challenge has become how to design and synthesize drug-like small-mol. libraries with improved biol. relevancy as well as max. mol. diversity.  This Perspective presents the development of privileged substructure-based DOS (pDOS), an efficient strategy for the construction of polyheterocyclic compd. libraries with high biol. relevancy.  We envisioned the specific interaction of drug-like small mols. with certain biopolymers via the incorporation of privileged substructures into polyheterocyclic core skeletons.  The importance of privileged substructures such as benzopyran, pyrimidine, and oxopiperazine in rigid skeletons was clearly demonstrated through the discovery of bioactive small mols. and the subsequent identification of appropriate target biomol. using a method called "fluorescence difference in two-dimensional gel electrophoresis".  Focusing on examples of pDOS-derived bioactive compds. with exceptional specificity, we discuss the capability of privileged structures to serve as chem. "navigators" toward biol. relevant chem. spaces.  We also provide an outlook on chem. biol. research and drug discovery using biol. relevant compd. libraries constructed by pDOS, biol.-oriented synthesis, or natural product-inspired DOS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTYO_xHDuDQLVg90H21EOLACvtfcHk0li6nPG6L9QmdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsleksrjM&md5=27672b927e95b898a7f95cb0f2bd1ef8</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fja508343a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja508343a%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DS.%2BB.%26atitle%3DPrivileged%2520structures%253A%2520Efficient%2520chemical%2520%25E2%2580%259Cnavigators%25E2%2580%259D%2520toward%2520unexplored%2520biologically%2520relevant%2520chemical%2520spaces%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D14629%26epage%3D14638%26doi%3D10.1021%2Fja508343a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cordier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murrison, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Leary-Steele, C.</span></span> <span> </span><span class="NLM_article-title">Natural products as an inspiration in the diversity-oriented synthesis of bioactive compound libraries</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">737</span>, <span class="refDoi"> DOI: 10.1039/b706296f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1039%2Fb706296f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=18663392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVCmsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2008&pages=719-737&author=C.+Cordierauthor=D.+Mortonauthor=S.+Murrisonauthor=A.+Nelsonauthor=C.+O%E2%80%99Leary-Steele&title=Natural+products+as+an+inspiration+in+the+diversity-oriented+synthesis+of+bioactive+compound+libraries&doi=10.1039%2Fb706296f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Natural products as an inspiration in the diversity-oriented synthesis of bioactive compound libraries</span></div><div class="casAuthors">Cordier, Christopher; Morton, Daniel; Murrison, Sarah; Nelson, Adam; O'Leary-Steele, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">719-737</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The purpose of diversity-oriented synthesis is to drive the discovery of small mols. with previously unknown biol. functions.  Natural products necessarily populate biol. relevant chem. space, since they bind both their biosynthetic enzymes and their target macromols.  Natural product families are, therefore, libraries of pre-validated, functionally diverse structures in which individual compds. selectively modulate unrelated macromol. targets.  This review described examples of diversity-oriented syntheses which were, to some extent, inspired by the structures of natural products.  Particular emphasis was placed on innovations that allow the synthesis of compd. libraries that, like natural products, are skeletally diverse.  Mimicking the broad structural features of natural products may allow the discovery of compds. that modulate the functions of macromols. for which ligands are not known.  The ability of innovations in diversity-oriented synthesis to deliver such compds. is critically assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe3y9-D0jDCLVg90H21EOLACvtfcHk0li6nPG6L9QmdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVCmsrk%253D&md5=a53c08a650f68989cb177cb954ec352b</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1039%2Fb706296f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb706296f%26sid%3Dliteratum%253Aachs%26aulast%3DCordier%26aufirst%3DC.%26aulast%3DMorton%26aufirst%3DD.%26aulast%3DMurrison%26aufirst%3DS.%26aulast%3DNelson%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Leary-Steele%26aufirst%3DC.%26atitle%3DNatural%2520products%2520as%2520an%2520inspiration%2520in%2520the%2520diversity-oriented%2520synthesis%2520of%2520bioactive%2520compound%2520libraries%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2008%26volume%3D25%26spage%3D719%26epage%3D737%26doi%3D10.1039%2Fb706296f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A.</span></span> <span> </span><span class="NLM_article-title">Navigating chemical space for biology and medicine</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>432</i></span>,  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">861</span>, <span class="refDoi"> DOI: 10.1038/nature03193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2Fnature03193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=15602551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVOht7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=432&publication_year=2004&pages=855-861&author=C.+Lipinskiauthor=A.+Hopkins&title=Navigating+chemical+space+for+biology+and+medicine&doi=10.1038%2Fnature03193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Navigating chemical space for biology and medicine</span></div><div class="casAuthors">Lipinski, Christopher; Hopkins, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">432</span>
        (<span class="NLM_cas:issue">7019</span>),
    <span class="NLM_cas:pages">855-861</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite over a century of applying org. synthesis to the search for drugs, the authors are still far from even a cursory examn. of the vast no. of possible small mols. that could be created.  Indeed, a thorough examn. of all 'chem. space' is practically impossible.  Given this, what are the best strategies for identifying small mols. that modulate biol. targets And how might such strategies differ, depending on whether the primary goal is to understand biol. systems or to develop potential drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3hQm7xaX5MLVg90H21EOLACvtfcHk0li6nPG6L9QmdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVOht7jO&md5=077237d55fa1225fd0aaee481e376172</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnature03193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03193%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%26aulast%3DHopkins%26aufirst%3DA.%26atitle%3DNavigating%2520chemical%2520space%2520for%2520biology%2520and%2520medicine%26jtitle%3DNature%26date%3D2004%26volume%3D432%26spage%3D855%26epage%3D861%26doi%3D10.1038%2Fnature03193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quasdorf, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overman, L. E.</span></span> <span> </span><span class="NLM_article-title">Catalytic enantioselective synthesis of quaternary carbon stereocentres</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>516</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1038/nature14007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2Fnature14007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=25503231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFams7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=516&publication_year=2014&pages=181-191&author=K.+W.+Quasdorfauthor=L.+E.+Overman&title=Catalytic+enantioselective+synthesis+of+quaternary+carbon+stereocentres&doi=10.1038%2Fnature14007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic enantioselective synthesis of quaternary carbon stereocentres</span></div><div class="casAuthors">Quasdorf, Kyle W.; Overman, Larry E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">516</span>
        (<span class="NLM_cas:issue">7530</span>),
    <span class="NLM_cas:pages">181-191</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Quaternary carbon stereocenters, carbon atoms to which four distinct carbon substituents are attached, are common features of mols. found in nature.  However, before recent advances in chem. catalysis, there were few methods of constructing single stereoisomers of this important structural motif.  Here, the authors discuss the many catalytic enantioselective reactions developed during the past decade for the synthesis of single stereoisomers of such org. mols.  This progress now makes it possible to incorporate quaternary stereocenters selectively in many org. mols. that are useful in medicine, agriculture and potentially other areas such as flavoring, fragrances and materials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWZnnX-pFyE7Vg90H21EOLACvtfcHk0li6nPG6L9QmdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFams7jK&md5=0ed7950ca837a1ed1fde6af538c25c95</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnature14007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14007%26sid%3Dliteratum%253Aachs%26aulast%3DQuasdorf%26aufirst%3DK.%2BW.%26aulast%3DOverman%26aufirst%3DL.%2BE.%26atitle%3DCatalytic%2520enantioselective%2520synthesis%2520of%2520quaternary%2520carbon%2520stereocentres%26jtitle%3DNature%26date%3D2014%26volume%3D516%26spage%3D181%26epage%3D191%26doi%3D10.1038%2Fnature14007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marek, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minko, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mejuch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilboa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chechik, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, J. P.</span></span> <span> </span><span class="NLM_article-title">All-carbon quaternary stereogenic centers in acyclic systems through the creation of several C-C bonds per chemical step</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">2682</span>– <span class="NLM_lpage">2694</span>, <span class="refDoi"> DOI: 10.1021/ja410424g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja410424g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1OhsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=2682-2694&author=I.+Marekauthor=Y.+Minkoauthor=M.+Pascoauthor=T.+Mejuchauthor=N.+Gilboaauthor=H.+Chechikauthor=J.+P.+Das&title=All-carbon+quaternary+stereogenic+centers+in+acyclic+systems+through+the+creation+of+several+C-C+bonds+per+chemical+step&doi=10.1021%2Fja410424g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">All-Carbon Quaternary Stereogenic Centers in Acyclic Systems through the Creation of Several C-C Bonds per Chemical Step</span></div><div class="casAuthors">Marek, Ilan; Minko, Yury; Pasco, Morgane; Mejuch, Tom; Gilboa, Noga; Chechik, Helena; Das, Jaya P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2682-2694</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In the past few decades, it has become clear that asym. catalysis is one of the most powerful methods for the construction of carbon-carbon as well as carbon-heteroatom bonds in a stereoselective manner.  However, when structural complexity increases (i.e., all-carbon quaternary stereogenic center), the difficulty in reaching the desired adducts through asym. catalytic reactions leads to a single carbon-carbon bond-forming event per chem. step between two components.  Issues of efficiency and convergence should therefore be addressed to avoid extraneous chem. steps.  In this perspective, the authors present approaches that tackle the stimulating problem of efficiency while answering interesting synthetic challenges.  Ideally, if one could create all-carbon quaternary stereogenic centers via the creation of several new carbon-carbon bonds in an acyclic system and in a single-pot operation from simple precursors, it would certainly open new horizons toward solving the synthetic problems.  Even more important for any further design, the presence of polyreactive intermediates in synthesis (bismetalated, carbenoid, and oxenoids species) becomes now an indispensable tool, as it creates consecutively the same no. of carbon-carbon bonds as in a multi-step process, but in a single-pot operation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm5zTezd7iT7Vg90H21EOLACvtfcHk0lh0Y7pY9FeswQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1OhsLw%253D&md5=24d1bae788830c25bdd29817a87dbcf3</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fja410424g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja410424g%26sid%3Dliteratum%253Aachs%26aulast%3DMarek%26aufirst%3DI.%26aulast%3DMinko%26aufirst%3DY.%26aulast%3DPasco%26aufirst%3DM.%26aulast%3DMejuch%26aufirst%3DT.%26aulast%3DGilboa%26aufirst%3DN.%26aulast%3DChechik%26aufirst%3DH.%26aulast%3DDas%26aufirst%3DJ.%2BP.%26atitle%3DAll-carbon%2520quaternary%2520stereogenic%2520centers%2520in%2520acyclic%2520systems%2520through%2520the%2520creation%2520of%2520several%2520C-C%2520bonds%2520per%2520chemical%2520step%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D2682%26epage%3D2694%26doi%3D10.1021%2Fja410424g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marek, I.</span></span> <span> </span><span class="NLM_article-title">Enantioselective synthesis of all-carbon quaternary stereogenic centers in acyclic systems</span>. <i>Chem. Commun. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">4593</span>– <span class="NLM_lpage">4623</span>, <span class="refDoi"> DOI: 10.1039/c0cc05222a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1039%2Fc0cc05222a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=21359322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktF2ntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=4593-4623&author=J.+P.+Dasauthor=I.+Marek&title=Enantioselective+synthesis+of+all-carbon+quaternary+stereogenic+centers+in+acyclic+systems&doi=10.1039%2Fc0cc05222a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective synthesis of all-carbon quaternary stereogenic centers in acyclic systems</span></div><div class="casAuthors">Das, Jaya Prakash; Marek, Ilan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4593-4623</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Most of the methods for the creation of all-carbon quaternary stereogenic centers in acyclic systems were developed in the last decade showing the contemporary interest of this field of research.  Initial strategies, where chiral entities were linked to carbon skeleton, to enantioselective catalysis and finally to strategies where several carbon-carbon bonds were created in a single-pot operation, reflect the const. strive and creativity in the design and execution of synthetic sequences.  This review summarizes these sequences and is divided into sections on substitution and addns. reactions, alkylation, aldol, Mannich and rearrangements reactions.  It is safe to predict that this field of chem. will continue to grow exponentially in the coming decades and the ready availability of a wide range of these chiral entities will provide an excellent opportunity to further enrich mainstream synthetic methodologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozUlshUFovp7Vg90H21EOLACvtfcHk0lh0Y7pY9FeswQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktF2ntr4%253D&md5=9d864f6b868bdd87c44031252c68b12e</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1039%2Fc0cc05222a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0cc05222a%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DJ.%2BP.%26aulast%3DMarek%26aufirst%3DI.%26atitle%3DEnantioselective%2520synthesis%2520of%2520all-carbon%2520quaternary%2520stereogenic%2520centers%2520in%2520acyclic%2520systems%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2011%26volume%3D47%26spage%3D4593%26epage%3D4623%26doi%3D10.1039%2Fc0cc05222a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Y. Q.</span></span> <span> </span><span class="NLM_article-title">Stereoselective construction of quaternary carbon stereocenters via a semipinacol rearrangement strategy</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1207</span>– <span class="NLM_lpage">1222</span>, <span class="refDoi"> DOI: 10.1021/ar200082p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar200082p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVCqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2011&pages=1207-1222&author=B.+Wangauthor=Y.+Q.+Tu&title=Stereoselective+construction+of+quaternary+carbon+stereocenters+via+a+semipinacol+rearrangement+strategy&doi=10.1021%2Far200082p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Stereoselective construction of quaternary carbon stereocenters via a semipinacol rearrangement strategy</span></div><div class="casAuthors">Wang, Baomin; Tu, Yong Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1207-1222</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Quaternary carbon stereocenters are found in a broad range of org. compds., including important bioactive natural products and medicinal agents.  Given their ubiquity and the significant synthetic challenges they present, quaternary carbon stereocenters have long attracted great interest from synthetic org. chemists.  Numerous efforts have been devoted to their construction, leading to a spectrum of strategies for creating stereogenic quaternary carbon centers.  In this context, the semipinacol rearrangement has proven successful.  In this extension of the pinacol rearrangement, the 1,2-carbon-to-carbon migration in a 1,2-diol has been expanded to include leaving groups other than the hydroxyl group.  Over the past decade, our lab. has explored the semipinacol rearrangement strategy for the stereoselective construction of quaternary carbon stereocenters.  We have investigated various substrates, including 2,3-epoxy alcs. (also termed α-hydroxy epoxides), 2,3-aziridino alcs., and allylic alcs.  Several promoters that effect the semipinacol rearrangement have been identified, including Lewis acids based on Al, Sm, B, Zn, and Ti for the rearrangement of α-hydroxy epoxides and 2,3-aziridino alcs.; cationic halogen species for the rearrangement of allylic alcs.; and cinchona alkaloids and chiral phosphoric acid for the asym. semipinacol rearrangement.  Our research efforts have led to a series of valuable synthetic methods, including (1) a tandem semipinacol rearrangement and Meerwein-Ponndorf-Verley redn., (2) a tandem semipinacol rearrangement and Tishchenko reaction, (3) a tandem semipinacol rearrangement with either an allylation or a propargylation, (4) a tandem semipinacol rearrangement and Schmidt reaction, (5) a semipinacol rearrangement of 2,3-aziridino alcs., (6) a semipinacol rearrangement of allylic alcs. induced by halogen cation, (7) a tandem aziridination and semipinacol rearrangement of allylic alcs., and (8) asym. semipinacol rearrangements with chiral org. catalysts.  One hallmark of these reactions is the creation of stereogenic quaternary carbon centers with high levels of stereocontrol.  In this account, we describe the development of these synthetically useful methodologies and their successful application to the total syntheses of natural products.  Our results demonstrate that the semipinacol rearrangement of carefully designed substrates constitutes an efficient approach to the stereoselective construction of quaternary carbon centers.  These reactions have produced a broad array of useful compds. that lend themselves to further elaboration.  Furthermore, the total synthesis of a series of alkaloids, with significant bioactivity and intriguing mol. architecture, was achieved through these semipinacol rearrangement strategies, highlighting their synthetic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq822oVgbG0qbVg90H21EOLACvtfcHk0lh0Y7pY9FeswQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVCqtrw%253D&md5=096b3c728019cd43c6365a3a9f50b898</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Far200082p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far200082p%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%26aulast%3DTu%26aufirst%3DY.%2BQ.%26atitle%3DStereoselective%2520construction%2520of%2520quaternary%2520carbon%2520stereocenters%2520via%2520a%2520semipinacol%2520rearrangement%2520strategy%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2011%26volume%3D44%26spage%3D1207%26epage%3D1222%26doi%3D10.1021%2Far200082p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruoka, K.</span></span> <span> </span><span class="NLM_article-title">Construction of a chiral quaternary carbon center by catalytic asymmetric alkylation of 2-arylcyclohexanones under phase-transfer conditions</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">7134</span>– <span class="NLM_lpage">7137</span>, <span class="refDoi"> DOI: 10.1021/ja403340r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja403340r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvVygsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=7134-7137&author=T.+Kanoauthor=Y.+Hayashiauthor=K.+Maruoka&title=Construction+of+a+chiral+quaternary+carbon+center+by+catalytic+asymmetric+alkylation+of+2-arylcyclohexanones+under+phase-transfer+conditions&doi=10.1021%2Fja403340r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Construction of a Chiral Quaternary Carbon Center by Catalytic Asymmetric Alkylation of 2-Arylcyclohexanones under Phase-Transfer Conditions</span></div><div class="casAuthors">Kano, Taichi; Hayashi, Yumi; Maruoka, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7134-7137</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, the authors present an asym. alkylation of modified 2-arylcyclohexanones.  A novel chiral ammonium bromide is employed as a phase-transfer catalyst and an achiral diphenylaminomethylene auxiliary is utilized as a controller to improve the enantioselectivity to afford optically enriched products having a chiral quaternary carbon center.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSOi-RTlj5iLVg90H21EOLACvtfcHk0lhw8DnQ2SDQvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvVygsbs%253D&md5=f9243ec3ac78f7cb04b2fc22529ac7a6</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fja403340r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja403340r%26sid%3Dliteratum%253Aachs%26aulast%3DKano%26aufirst%3DT.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DMaruoka%26aufirst%3DK.%26atitle%3DConstruction%2520of%2520a%2520chiral%2520quaternary%2520carbon%2520center%2520by%2520catalytic%2520asymmetric%2520alkylation%2520of%25202-arylcyclohexanones%2520under%2520phase-transfer%2520conditions%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26spage%3D7134%26epage%3D7137%26doi%3D10.1021%2Fja403340r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span> <span> </span><span class="NLM_article-title">Enantioselective formation of all-carbon quaternary stereocenters from indoles and tertiary alcohols bearing a directing group</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1910</span>– <span class="NLM_lpage">1913</span>, <span class="refDoi"> DOI: 10.1002/anie.201405252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fanie.201405252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1GqsLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=1910-1913&author=W.+Zhaoauthor=Z.+Wangauthor=B.+Chuauthor=J.+Sun&title=Enantioselective+formation+of+all-carbon+quaternary+stereocenters+from+indoles+and+tertiary+alcohols+bearing+a+directing+group&doi=10.1002%2Fanie.201405252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective Formation of All-Carbon Quaternary Stereocenters from Indoles and Tertiary Alcohols Bearing A Directing Group</span></div><div class="casAuthors">Zhao, Wanxiang; Wang, Zhaobin; Chu, Boyang; Sun, Jianwei</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1910-1913</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Described is an efficient catalytic asym. intermol. C-C bond-formation process to generate acyclic all-carbon quaternary stereocenters.  The reactions overcome the unfavorable steric hindrance around reactive centers, and the competitive elimination (E1), to form a range of useful indole products I [R1 = 5-OMe, 5-OBn, 5-OTBS, etc; R2 = Me, Et; R3 = H, 5-Me, 6-F, etc; Ar = Ph, 4-MeC6H4, 4-FC6H4, etc] with excellent efficiency and enantioselectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhmZ-uY-dbV7Vg90H21EOLACvtfcHk0lhw8DnQ2SDQvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1GqsLbP&md5=678a101f8eba32fdca077cf8086c239a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fanie.201405252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201405252%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChu%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DJ.%26atitle%3DEnantioselective%2520formation%2520of%2520all-carbon%2520quaternary%2520stereocenters%2520from%2520indoles%2520and%2520tertiary%2520alcohols%2520bearing%2520a%2520directing%2520group%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D1910%26epage%3D1913%26doi%3D10.1002%2Fanie.201405252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.-F.</span></span> <span> </span><span class="NLM_article-title">Recent developments in the synthesis of chiral compounds with quaternary centers by organocatalytic cascade reactions</span>. <i>Asian J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">580</span>– <span class="NLM_lpage">607</span>, <span class="refDoi"> DOI: 10.1002/ajoc.201500486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fajoc.201500486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsF2ru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=580-607&author=L.+Tianauthor=Y.-C.+Luoauthor=X.-Q.+Huauthor=P.-F.+Xu&title=Recent+developments+in+the+synthesis+of+chiral+compounds+with+quaternary+centers+by+organocatalytic+cascade+reactions&doi=10.1002%2Fajoc.201500486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Developments in the Synthesis of Chiral Compounds with Quaternary Centers by Organocatalytic Cascade Reactions</span></div><div class="casAuthors">Tian, Li; Luo, Yong-Chun; Hu, Xiu-Qin; Xu, Peng-Fei</div><div class="citationInfo"><span class="NLM_cas:title">Asian Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">580-607</span>CODEN:
                <span class="NLM_cas:coden">AJOCC7</span>;
        ISSN:<span class="NLM_cas:issn">2193-5807</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Quaternary carbon stereocenters were present in a wide variety of org. compds. and drug mols.  Highly enantioselective construction of such quaternary carbon stereocenters had received considerable attention owing to the great challenges in their syntheses.  With the development of asym. organocatalytic cascade reactions, several efficient methods for the construction of optically pure compds. with quaternary carbon centers were developed.  This focused review highlighted the asym. synthesis of chiral compds. with quaternary centers through organocatalytic cascade reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx4tKOCTxcxbVg90H21EOLACvtfcHk0lhw8DnQ2SDQvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsF2ru74%253D&md5=f2bfcb67e49b4779e3006ce35484c644</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fajoc.201500486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajoc.201500486%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DY.-C.%26aulast%3DHu%26aufirst%3DX.-Q.%26aulast%3DXu%26aufirst%3DP.-F.%26atitle%3DRecent%2520developments%2520in%2520the%2520synthesis%2520of%2520chiral%2520compounds%2520with%2520quaternary%2520centers%2520by%2520organocatalytic%2520cascade%2520reactions%26jtitle%3DAsian%2520J.%2520Org.%2520Chem.%26date%3D2016%26volume%3D5%26spage%3D580%26epage%3D607%26doi%3D10.1002%2Fajoc.201500486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krische, M. J.</span></span> <span> </span><span class="NLM_article-title">Acyclic quaternary carbon stereocenters via enantioselective transition metal catalysis</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">12564</span>– <span class="NLM_lpage">12580</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.7b00385</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.7b00385" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVyqt77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=12564-12580&author=J.+Fengauthor=M.+Holmesauthor=M.+J.+Krische&title=Acyclic+quaternary+carbon+stereocenters+via+enantioselective+transition+metal+catalysis&doi=10.1021%2Facs.chemrev.7b00385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Acyclic Quaternary Carbon Stereocenters via Enantioselective Transition Metal Catalysis</span></div><div class="casAuthors">Feng, Jiajie; Holmes, Michael; Krische, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">12564-12580</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The enantioselective methods for the construction of acyclic quaternary carbon stereocenters from achiral or chiral racemic reactants via transition metal catalysis were summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoufRx1t1h1srVg90H21EOLACvtfcHk0lhw8DnQ2SDQvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVyqt77O&md5=299bce81c9a0aaabb6d5ac1a5014d7d4</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.7b00385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.7b00385%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DHolmes%26aufirst%3DM.%26aulast%3DKrische%26aufirst%3DM.%2BJ.%26atitle%3DAcyclic%2520quaternary%2520carbon%2520stereocenters%2520via%2520enantioselective%2520transition%2520metal%2520catalysis%26jtitle%3DChem.%2520Rev.%26date%3D2017%26volume%3D117%26spage%3D12564%26epage%3D12580%26doi%3D10.1021%2Facs.chemrev.7b00385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mateu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidd, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalash, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sore, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">Synthesis of structurally diverse <i>N</i>-substituted quaternary-carbon-containing small molecules from alpha, alpha-disubstituted propargyl amino esters</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">13681</span>– <span class="NLM_lpage">13687</span>, <span class="refDoi"> DOI: 10.1002/chem.201803143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fchem.201803143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=30011115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2ltLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=13681-13687&author=N.+Mateuauthor=S.+L.+Kiddauthor=L.+Kalashauthor=H.+F.+Soreauthor=A.+Madinauthor=A.+Benderauthor=D.+R.+Spring&title=Synthesis+of+structurally+diverse+N-substituted+quaternary-carbon-containing+small+molecules+from+alpha%2C+alpha-disubstituted+propargyl+amino+esters&doi=10.1002%2Fchem.201803143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Structurally Diverse N-Substituted Quaternary-Carbon-Containing Small Molecules from α,α-Disubstituted Propargyl Amino Esters</span></div><div class="casAuthors">Mateu, Natalia; Kidd, Sarah L.; Kalash, Leen; Sore, Hannah F.; Madin, Andrew; Bender, Andreas; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">13681-13687</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Herein, the diversity-oriented synthesis (DOS) of quaternary carbon contg. nitrogen heterocycles using α-Me propargylglycine as starting material was described.  The subsequent derivatization and the stereoselective synthesis exemplified the versatility of this strategy for drug discovery and library enrichment.  Chemoinformatic anal. revealed the enhanced sp3 character of the target library and demonstrated that it represented an attractive collection of biol. diverse small mols. with high scaffold diversity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojZ_5wCM10_rVg90H21EOLACvtfcHk0lioZTBG-ulTSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2ltLfF&md5=04075c8c49ce1182006292f4a0fea96d</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fchem.201803143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201803143%26sid%3Dliteratum%253Aachs%26aulast%3DMateu%26aufirst%3DN.%26aulast%3DKidd%26aufirst%3DS.%2BL.%26aulast%3DKalash%26aufirst%3DL.%26aulast%3DSore%26aufirst%3DH.%2BF.%26aulast%3DMadin%26aufirst%3DA.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DSynthesis%2520of%2520structurally%2520diverse%2520N-substituted%2520quaternary-carbon-containing%2520small%2520molecules%2520from%2520alpha%252C%2520alpha-disubstituted%2520propargyl%2520amino%2520esters%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2018%26volume%3D24%26spage%3D13681%26epage%3D13687%26doi%3D10.1002%2Fchem.201803143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wendlandt, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, E. N.</span></span> <span> </span><span class="NLM_article-title">Quaternary stereocentres via an enantioconvergent catalytic SN1 reaction</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>556</i></span>,  <span class="NLM_fpage">447</span>– <span class="NLM_lpage">451</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0042-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2Fs41586-018-0042-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=29695848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVWrtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=556&publication_year=2018&pages=447-451&author=A.+E.+Wendlandtauthor=P.+Vangalauthor=E.+N.+Jacobsen&title=Quaternary+stereocentres+via+an+enantioconvergent+catalytic+SN1+reaction&doi=10.1038%2Fs41586-018-0042-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Quaternary stereocentres via an enantioconvergent catalytic SN1 reaction</span></div><div class="casAuthors">Wendlandt, Alison E.; Vangal, Prithvi; Jacobsen, Eric N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">556</span>
        (<span class="NLM_cas:issue">7702</span>),
    <span class="NLM_cas:pages">447-451</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The unimol. nucleophilic substitution (SN1) mechanism features prominently in every introductory org. chem. course.  In principle, stepwise displacement of a leaving group by a nucleophile via a carbocationic intermediate enables the construction of highly congested carbon centers.  However, the intrinsic instability and high reactivity of the carbocationic intermediates make it very difficult to control product distributions and stereoselectivity in reactions that proceed via SN1 pathways.  Here the asym. catalysis of an SN1-type reaction mechanism that results in the enantioselective construction of quaternary stereocentres from racemic precursors is reported.  The transformation relies on the synergistic action of a chiral hydrogen-bond-donor catalyst with a strong Lewis-acid promoter to mediate the formation of tertiary carbocationic intermediates at low temp. and to achieve high levels of control over reaction enantioselectivity and product distribution.  This work provides a foundation for the enantioconvergent synthesis of other fully substituted carbon stereocentres.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5F7L6qtrn7LVg90H21EOLACvtfcHk0lioZTBG-ulTSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVWrtrY%253D&md5=8a0c8ee971d4b69d70c3cd1c598e5068</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0042-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0042-1%26sid%3Dliteratum%253Aachs%26aulast%3DWendlandt%26aufirst%3DA.%2BE.%26aulast%3DVangal%26aufirst%3DP.%26aulast%3DJacobsen%26aufirst%3DE.%2BN.%26atitle%3DQuaternary%2520stereocentres%2520via%2520an%2520enantioconvergent%2520catalytic%2520SN1%2520reaction%26jtitle%3DNature%26date%3D2018%26volume%3D556%26spage%3D447%26epage%3D451%26doi%3D10.1038%2Fs41586-018-0042-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span> <span> </span><span class="NLM_article-title">Catalytic enantioselective House-Meinwald rearrangement: Efficient construction of all-carbon quaternary stereocenters</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">13783</span>– <span class="NLM_lpage">13787</span>, <span class="refDoi"> DOI: 10.1021/jacs.9b07514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.9b07514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1ajtLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=13783-13787&author=D.+Maauthor=C.+B.+Miaoauthor=J.+Sun&title=Catalytic+enantioselective+House-Meinwald+rearrangement%3A+Efficient+construction+of+all-carbon+quaternary+stereocenters&doi=10.1021%2Fjacs.9b07514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic Enantioselective House-Meinwald Rearrangement: Efficient Construction of All-Carbon Quaternary Stereocenters</span></div><div class="casAuthors">Ma, Dengke; Miao, Chun-Bao; Sun, Jianwei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">13783-13787</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A catalytic asym. House-Meinwald rearrangement for the synthesis of both cyclic and acyclic ketones is disclosed.  From readily accessible racemic tetrasubstituted epoxides, this approach provides efficient access to chiral ketones bearing α all-carbon quaternary stereocenters with high enantiocontrol.  The observation of pos. nonlinear effects and nontrivial kinetic feature provided important insights into the mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt5TGyhQECCbVg90H21EOLACvtfcHk0lioZTBG-ulTSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1ajtLnL&md5=afc0efb44dea52ff69d1de267d6c2a2a</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjacs.9b07514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.9b07514%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DD.%26aulast%3DMiao%26aufirst%3DC.%2BB.%26aulast%3DSun%26aufirst%3DJ.%26atitle%3DCatalytic%2520enantioselective%2520House-Meinwald%2520rearrangement%253A%2520Efficient%2520construction%2520of%2520all-carbon%2520quaternary%2520stereocenters%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D13783%26epage%3D13787%26doi%3D10.1021%2Fjacs.9b07514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span> <span> </span><span class="NLM_article-title">Catalytic enantioselective pinacol and Meinwald rearrangements for the construction of quaternary stereocenters</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">11372</span>– <span class="NLM_lpage">11377</span>, <span class="refDoi"> DOI: 10.1021/jacs.9b04551</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.9b04551" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlamsLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=11372-11377&author=H.+Wuauthor=Q.+Wangauthor=J.+Zhu&title=Catalytic+enantioselective+pinacol+and+Meinwald+rearrangements+for+the+construction+of+quaternary+stereocenters&doi=10.1021%2Fjacs.9b04551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic Enantioselective Pinacol and Meinwald Rearrangements for the Construction of Quaternary Stereocenters</span></div><div class="casAuthors">Wu, Hua; Wang, Qian; Zhu, Jieping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">11372-11377</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of enantioselective pinacol rearrangement is extremely challenging due to the likelihood involvement of the carbenium intermediate that renders the stereochem. communication between catalyst and substrate difficult to achieve.  Herein, the authors report chiral N-triflyl phosphoramide-catalyzed enantioselective pinacol rearrangement of 1,2-tertiary diols and mechanistically related Meinwald rearrangement of tetrasubstituted epoxides for the synthesis of enantioenriched 2-alkynyl-2-arylcyclohexanones and 2,2-diarylcyclohexanones, resp.  Total synthesis of (+)-mesembrane featuring the catalytic enantioselective pinacol rearrangement as a key strategic step is also documented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqolZB-_NmIE7Vg90H21EOLACvtfcHk0lioZTBG-ulTSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlamsLrM&md5=be407f3e4a984188c9d219ce339896d9</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjacs.9b04551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.9b04551%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DJ.%26atitle%3DCatalytic%2520enantioselective%2520pinacol%2520and%2520Meinwald%2520rearrangements%2520for%2520the%2520construction%2520of%2520quaternary%2520stereocenters%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D11372%26epage%3D11377%26doi%3D10.1021%2Fjacs.9b04551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serefoglu, E. C.</span></span> <span> </span><span class="NLM_article-title">Oxytocin antagonists: the next frontier in PE treatment</span>. <i>Nat. Rev. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">696</span>– <span class="NLM_lpage">697</span>, <span class="refDoi"> DOI: 10.1038/s41585-019-0238-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2Fs41585-019-0238-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=31551585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A280%3ADC%252BB3MnhvVSiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=696-697&author=M.+Gulauthor=E.+C.+Serefoglu&title=Oxytocin+antagonists%3A+the+next+frontier+in+PE+treatment&doi=10.1038%2Fs41585-019-0238-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Oxytocin antagonists: the next frontier in PE treatment</span></div><div class="casAuthors">Gul Murat; Gul Murat; Serefoglu Ege Can; Serefoglu Ege Can; Serefoglu Ege Can</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Urology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">696-697</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnXmondofHviA3UY9EwTNrfW6udTcc2ebbOgzG714Vlrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnhvVSiug%253D%253D&md5=adb52da2df4907dad9cf4f7a60e09d65</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fs41585-019-0238-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41585-019-0238-7%26sid%3Dliteratum%253Aachs%26aulast%3DGul%26aufirst%3DM.%26aulast%3DSerefoglu%26aufirst%3DE.%2BC.%26atitle%3DOxytocin%2520antagonists%253A%2520the%2520next%2520frontier%2520in%2520PE%2520treatment%26jtitle%3DNat.%2520Rev.%2520Urol.%26date%3D2019%26volume%3D16%26spage%3D696%26epage%3D697%26doi%3D10.1038%2Fs41585-019-0238-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of SHR1653, a highly potent and selective OTR antagonist with improved blood-brain barrier penetration</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">996</span>– <span class="NLM_lpage">1001</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00186</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00186" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKgtrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=996-1001&author=X.+Liauthor=Z.+Zhangauthor=Y.+Chenauthor=H.+Wanauthor=J.+Sunauthor=B.+Wangauthor=B.+Fengauthor=B.+Huauthor=X.+Shiauthor=J.+Fengauthor=L.+Zhangauthor=F.+Heauthor=C.+Baiauthor=L.+Zhangauthor=W.+Tao&title=Discovery+of+SHR1653%2C+a+highly+potent+and+selective+OTR+antagonist+with+improved+blood-brain+barrier+penetration&doi=10.1021%2Facsmedchemlett.9b00186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of SHR1653, a Highly Potent and Selective OTR Antagonist with Improved Blood-Brain Barrier Penetration</span></div><div class="casAuthors">Li, Xin; Zhang, Zhigao; Chen, Yang; Wan, Hong; Sun, Jiakang; Wang, Bin; Feng, Bingqiang; Hu, Bing; Shi, Xingxing; Feng, Jun; Zhang, Lei; He, Feng; Bai, Chang; Zhang, Lianshan; Tao, Weikang</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">996-1001</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The oxytocin receptor (OTR) plays a major role in the control of male sexual responses.  Antagonists of the OTR have been reported to inhibit ejaculation in animal models and serve as a potential treatment for premature ejaculation (PE).  Herein, we describe a novel scaffold featuring an aryl substituted 3-azabicyclo [3.1.0] hexane structure.  The lead compd., SHR1653(I), was shown to be a highly potent OTR antagonist, which exhibited excellent selectivity over V1AR, V1BR, and V2R.  This novel mol. was shown to have a favorable pharmacokinetic profile across species, as well as robust in vivo efficacy in a rat uterine contraction model.  Interestingly, SHR1653 exhibited excellent blood-brain barrier penetration, which might be beneficial for the treatment of CNS-related PE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWBfusb6HbE7Vg90H21EOLACvtfcHk0ljE1V07b5MHzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKgtrzF&md5=f952da6ce79ac33c1c61652a0dd40ddb</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00186%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DBai%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DTao%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520SHR1653%252C%2520a%2520highly%2520potent%2520and%2520selective%2520OTR%2520antagonist%2520with%2520improved%2520blood-brain%2520barrier%2520penetration%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D996%26epage%3D1001%26doi%3D10.1021%2Facsmedchemlett.9b00186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mould, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremberg, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geitmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiques-Diaz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGonagle, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somervaille, T. C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turlais, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogilvie, D.</span></span> <span> </span><span class="NLM_article-title">Development of (4-cyanophenyl)glycine derivatives as reversible inhibitors of lysine specific demethylase 1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7984</span>– <span class="NLM_lpage">7999</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00462</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00462" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKqsrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7984-7999&author=D.+P.+Mouldauthor=C.+Alliauthor=U.+Brembergauthor=S.+Carticauthor=A.+M.+Jordanauthor=M.+Geitmannauthor=A.+Maiques-Diazauthor=A.+E.+McGonagleauthor=T.+C.+P.+Somervailleauthor=G.+J.+Spencerauthor=F.+Turlaisauthor=D.+Ogilvie&title=Development+of+%284-cyanophenyl%29glycine+derivatives+as+reversible+inhibitors+of+lysine+specific+demethylase+1&doi=10.1021%2Facs.jmedchem.7b00462"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1</span></div><div class="casAuthors">Mould, Daniel P.; Alli, Cristina; Bremberg, Ulf; Cartic, Sharon; Jordan, Allan M.; Geitmann, Matthis; Maiques-Diaz, Alba; McGonagle, Alison E.; Somervaille, Tim C. P.; Spencer, Gary J.; Turlais, Fabrice; Ogilvie, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7984-7999</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of lysine specific demethylase 1 (LSD1) has been shown to induce the differentiation of leukemia stem cells in acute myeloid leukemia (AML).  Irreversible inhibitors developed from the nonspecific inhibitor tranylcypromine have entered clin. trials; however, the development of effective reversible inhibitors has proved more challenging.  Herein, we describe our efforts to identify reversible inhibitors of LSD1 from a high throughput screen and subsequent in silico modeling approaches.  From a single hit (12) validated by biochem. and biophys. assays, we describe our efforts to develop acyclic scaffold-hops from GSK-690 (1).  A further scaffold modification to a (4-cyanophenyl)glycinamide (e.g., 29a) led to the development of compd. 32, with a Kd value of 32 nM and an EC50 value of 0.67 μM in a surrogate cellular biomarker assay.  Moreover, this deriv. does not display the same level of hERG liability as obsd. with 1 and represents a promising lead for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5NyXkmZPOqrVg90H21EOLACvtfcHk0ljE1V07b5MHzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKqsrrJ&md5=af673e7b3a2815aa09fe7264a3e4247b</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00462&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00462%26sid%3Dliteratum%253Aachs%26aulast%3DMould%26aufirst%3DD.%2BP.%26aulast%3DAlli%26aufirst%3DC.%26aulast%3DBremberg%26aufirst%3DU.%26aulast%3DCartic%26aufirst%3DS.%26aulast%3DJordan%26aufirst%3DA.%2BM.%26aulast%3DGeitmann%26aufirst%3DM.%26aulast%3DMaiques-Diaz%26aufirst%3DA.%26aulast%3DMcGonagle%26aufirst%3DA.%2BE.%26aulast%3DSomervaille%26aufirst%3DT.%2BC.%2BP.%26aulast%3DSpencer%26aufirst%3DG.%2BJ.%26aulast%3DTurlais%26aufirst%3DF.%26aulast%3DOgilvie%26aufirst%3DD.%26atitle%3DDevelopment%2520of%2520%25284-cyanophenyl%2529glycine%2520derivatives%2520as%2520reversible%2520inhibitors%2520of%2520lysine%2520specific%2520demethylase%25201%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7984%26epage%3D7999%26doi%3D10.1021%2Facs.jmedchem.7b00462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, W. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demarest, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of orally efficacious tetrahydrobenzimidazoles as TGR5 agonists for type 2 diabetes</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">565</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00116</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00116" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlCmt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=560-565&author=X.+Zhangauthor=M.+Wallauthor=Z.+Suiauthor=J.+Kauffmanauthor=C.+Houauthor=C.+Chenauthor=F.+Duauthor=T.+Kirchnerauthor=Y.+Liangauthor=D.+L.+Johnsonauthor=W.+V.+Murrayauthor=K.+Demarest&title=Discovery+of+orally+efficacious+tetrahydrobenzimidazoles+as+TGR5+agonists+for+type+2+diabetes&doi=10.1021%2Facsmedchemlett.7b00116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Orally Efficacious Tetrahydrobenzimidazoles as TGR5 Agonists for Type 2 Diabetes</span></div><div class="casAuthors">Zhang, Xuqing; Wall, Mark; Sui, Zhihua; Kauffman, Jack; Hou, Cuifen; Chen, Cailin; Du, Fuyong; Kirchner, Thomas; Liang, Yin; Johnson, Dana L.; Murray, William V.; Demarest, Keith</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">560-565</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors have discovered a novel series of tetrahydrobenzimidazoles as TGR5 agonists.  Initial structure-activity relationship studies with an assay that measured cAMP levels in murine enteroendocrine cells (STC-1 cells) led to the discovery of potent agonists with submicromolar EC50 values for mTGR5.  Subsequent optimization through methylation of the 7-position of the core tetrahydrobenzimidazole ring resulted in the identification of potent agonists for both mTGR5 and hTGR5 (human enteroendocrine NCI-H716 cells).  While the lead compds. displayed low to moderate exposure after oral dosing, they significantly reduced blood glucose levels in C57 BL/6 mice at 30 mg/kg and induced a 13-22% redn. in the area under the blood glucose curve (AUC)0-120 min in oral glucose tolerance tests (OGTT).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5WtpgL4cFsbVg90H21EOLACvtfcHk0lgCGbTb5m3dZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlCmt70%253D&md5=409d84adc97e9860d7ab8bbf4863f007</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00116%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWall%26aufirst%3DM.%26aulast%3DSui%26aufirst%3DZ.%26aulast%3DKauffman%26aufirst%3DJ.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DDu%26aufirst%3DF.%26aulast%3DKirchner%26aufirst%3DT.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DD.%2BL.%26aulast%3DMurray%26aufirst%3DW.%2BV.%26aulast%3DDemarest%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520orally%2520efficacious%2520tetrahydrobenzimidazoles%2520as%2520TGR5%2520agonists%2520for%2520type%25202%2520diabetes%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D560%26epage%3D565%26doi%3D10.1021%2Facsmedchemlett.7b00116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tangirala, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethi, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariazi, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirunagaru, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of tetralones as potent and selective inhibitors of acyl-CoA:diacylglycerol acyltransferase 1</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00450</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00450" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXoslCktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=103-108&author=M.+Cheungauthor=R.+S.+Tangiralaauthor=S.+R.+Bethiauthor=H.+V.+Joshiauthor=J.+L.+Ariaziauthor=V.+G.+Tirunagaruauthor=S.+Kumar&title=Discovery+of+tetralones+as+potent+and+selective+inhibitors+of+acyl-CoA%3Adiacylglycerol+acyltransferase+1&doi=10.1021%2Facsmedchemlett.7b00450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tetralones as Potent and Selective Inhibitors of Acyl-CoA:Diacylglycerol Acyltransferase 1</span></div><div class="casAuthors">Cheung, Mui; Tangirala, Raghuram S.; Bethi, Sridhar R.; Joshi, Hemant V.; Ariazi, Jennifer L.; Tirunagaru, Vijaya G.; Kumar, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-108</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) plays an important role in triglyceride synthesis and is a target of interest for the treatment of metabolic disorders.  Herein we describe the structure-activity relationship of a novel tetralone series of DGAT1 inhibitors and our strategies for overcoming genotoxic liability of the anilines embedded in the chem. structures, leading to the discovery of a candidate compd., (S)-2-(6-(5-(3-(3,4-difluorophenyl)ureido)pyrazin-2-yl)-1-oxo-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydronaphthalen-2-yl)acetic acid (GSK2973980A, 26d).  Compd. 26d is a potent and selective DGAT1 inhibitor with excellent DMPK profiles and in vivo efficacy in a postprandial lipid excursion model in mice.  Based on the overall biol. and developability profiles and acceptable safety profiles in the 7-day toxicity studies in rats and dogs, compd. 26d was selected as a candidate compd. for further development in the treatment of metabolic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYk8N30-oo-7Vg90H21EOLACvtfcHk0lgCGbTb5m3dZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXoslCktQ%253D%253D&md5=e2395ae7529b07224ab604b54e89ca93</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00450%26sid%3Dliteratum%253Aachs%26aulast%3DCheung%26aufirst%3DM.%26aulast%3DTangirala%26aufirst%3DR.%2BS.%26aulast%3DBethi%26aufirst%3DS.%2BR.%26aulast%3DJoshi%26aufirst%3DH.%2BV.%26aulast%3DAriazi%26aufirst%3DJ.%2BL.%26aulast%3DTirunagaru%26aufirst%3DV.%2BG.%26aulast%3DKumar%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520tetralones%2520as%2520potent%2520and%2520selective%2520inhibitors%2520of%2520acyl-CoA%253Adiacylglycerol%2520acyltransferase%25201%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D103%26epage%3D108%26doi%3D10.1021%2Facsmedchemlett.7b00450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walton, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span> <span> </span><span class="NLM_article-title">Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2008.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.coph.2008.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=18721898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFCktL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=393-412&author=T.+A.+Yapauthor=M.+D.+Garrettauthor=M.+I.+Waltonauthor=F.+Raynaudauthor=J.+S.+de+Bonoauthor=P.+Workman&title=Targeting+the+PI3K-AKT-mTOR+pathway%3A+progress%2C+pitfalls%2C+and+promises&doi=10.1016%2Fj.coph.2008.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises</span></div><div class="casAuthors">Yap, Timothy A.; Garrett, Michelle D.; Walton, Mike I.; Raynaud, Florence; de Bono, Johann S.; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">393-412</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The strategy of drugging the cancer kinome' has led to the successful development and regulatory approval of several novel mol. targeted agents.  The spotlight is now shifting to the phosphatidylinositide 3-kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) pathway as a key potential target.  This review details the role of the pathway in oncogenesis and the rationale for inhibiting its vital components.  The focus will be on the progress made in the development of novel therapies for cancer treatment, with emphasis placed on agents that have entered clin. development.  Strategies involving horizontal and vertical blockade of the pathway, as well as the use of biomarkers to select appropriate patients and to provide proof of target modulation will also be highlighted.  Finally, we discuss the issues and limitations involved with targeting the PI3K-AKT-mTOR pathway, and predict what the future may hold for these novel anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnmwezNSKUfbVg90H21EOLACvtfcHk0lgCGbTb5m3dZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFCktL7E&md5=b6a4f3c01a6776977d61cde8222d7201</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2008.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2008.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DTargeting%2520the%2520PI3K-AKT-mTOR%2520pathway%253A%2520progress%252C%2520pitfalls%252C%2520and%2520promises%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2008%26volume%3D8%26spage%3D393%26epage%3D412%26doi%3D10.1016%2Fj.coph.2008.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Convery, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peace, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redmond, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summers, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-oxabicyclo[4.1.0]heptane, a non-nitrogen containing morpholine isostere, and its application in novel inhibitors of the PI3K-AKT-mTOR pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6972</span>– <span class="NLM_lpage">6984</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00348</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00348" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlamsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6972-6984&author=H.+Hobbsauthor=G.+Braviauthor=I.+Campbellauthor=M.+Converyauthor=H.+Daviesauthor=G.+Inglisauthor=S.+Palauthor=S.+Peaceauthor=J.+Redmondauthor=D.+Summers&title=Discovery+of+3-oxabicyclo%5B4.1.0%5Dheptane%2C+a+non-nitrogen+containing+morpholine+isostere%2C+and+its+application+in+novel+inhibitors+of+the+PI3K-AKT-mTOR+pathway&doi=10.1021%2Facs.jmedchem.9b00348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-Oxabicyclo[4.1.0]heptane, a Non-nitrogen Containing Morpholine Isostere, and Its Application in Novel Inhibitors of the PI3K-AKT-mTOR Pathway</span></div><div class="casAuthors">Hobbs, Heather; Bravi, Gianpaolo; Campbell, Ian; Convery, Maire; Davies, Hannah; Inglis, Graham; Pal, Sandeep; Peace, Simon; Redmond, Joanna; Summers, Declan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6972-6984</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4-(Pyrimidin-4-yl)morpholines are privileged pharmacophores for PI3K and PIKKs inhibition by virtue of the morpholine oxygen, both forming the key hydrogen bonding interaction and conveying selectivity over the broader kinome.  Key to the morpholine utility as a kinase hinge binder is its ability to adopt a coplanar conformation with an adjacent arom. core favored by the morpholine nitrogen nonbonding pair of electrons interacting with the electron deficient pyrimidine π-system.  Few selective morpholine replacements have been identified to date.  Herein we describe the discovery of a potent non-nitrogen contg. morpholine isostere with the ability to mimic this conformation and its application in a potent selective dual inhibitor of mTORC1 and mTORC2 (29b).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJxxyzMER0yLVg90H21EOLACvtfcHk0liNMKJH4vid7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlamsbzP&md5=4c8c01c4f3fc20f3f776b4752dee5d80</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00348%26sid%3Dliteratum%253Aachs%26aulast%3DHobbs%26aufirst%3DH.%26aulast%3DBravi%26aufirst%3DG.%26aulast%3DCampbell%26aufirst%3DI.%26aulast%3DConvery%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DInglis%26aufirst%3DG.%26aulast%3DPal%26aufirst%3DS.%26aulast%3DPeace%26aufirst%3DS.%26aulast%3DRedmond%26aufirst%3DJ.%26aulast%3DSummers%26aufirst%3DD.%26atitle%3DDiscovery%2520of%25203-oxabicyclo%255B4.1.0%255Dheptane%252C%2520a%2520non-nitrogen%2520containing%2520morpholine%2520isostere%252C%2520and%2520its%2520application%2520in%2520novel%2520inhibitors%2520of%2520the%2520PI3K-AKT-mTOR%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6972%26epage%3D6984%26doi%3D10.1021%2Facs.jmedchem.9b00348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruston, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demeritt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culshaw, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blades, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eden, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, S. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of AZD3147: a potent, selective dual inhibitor of mTORC1 and mTORC2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2326</span>– <span class="NLM_lpage">2349</span>, <span class="refDoi"> DOI: 10.1021/jm501778s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501778s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFeitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2326-2349&author=K.+G.+Pikeauthor=J.+Morrisauthor=L.+Rustonauthor=S.+L.+Passauthor=R.+Greenwoodauthor=E.+J.+Williamsauthor=J.+Demerittauthor=J.+D.+Culshawauthor=K.+Gillauthor=M.+Passauthor=M.+R.+Finlayauthor=C.+J.+Goodauthor=C.+A.+Robertsauthor=G.+S.+Currieauthor=K.+Bladesauthor=J.+M.+Edenauthor=S.+E.+Pearson&title=Discovery+of+AZD3147%3A+a+potent%2C+selective+dual+inhibitor+of+mTORC1+and+mTORC2&doi=10.1021%2Fjm501778s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AZD3147: A Potent, Selective Dual Inhibitor of mTORC1 and mTORC2</span></div><div class="casAuthors">Pike, Kurt G.; Morris, Jeff; Ruston, Linette; Pass, Sarah L.; Greenwood, Ryan; Williams, Emma J.; Demeritt, Julie; Culshaw, Janet D.; Gill, Kristy; Pass, Martin; Finlay, M. Raymond V.; Good, Catherine J.; Roberts, Craig A.; Currie, Gordon S.; Blades, Kevin; Eden, Jonathan M.; Pearson, Stuart E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2326-2349</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">High throughput screening followed by a lead generation campaign uncovered a novel series of urea contg. morpholinopyrimidine compds. which act as potent and selective dual inhibitors of mTORC1 and mTORC2.  The authors describe the continued compd. optimization campaign for this series, in particular focused on identifying compds. with improved cellular potency, improved aq. soly., and good stability in human hepatocyte incubations.  Knowledge from empirical SAR investigations was combined with an understanding of the mol. interactions in the crystal lattice to improve both cellular potency and soly., and the composite parameters of LLE and pIC50-pSoly. were used to assess compd. quality and progress.  Predictive models were employed to efficiently mine the attractive chem. space identified resulting in the discovery of I (AZD3147), an extremely potent and selective dual inhibitor of mTORC1 and mTORC2 with physicochem. and pharmacokinetic properties suitable for development as a potential clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVFrPEX3khBbVg90H21EOLACvtfcHk0liNMKJH4vid7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFeitL0%253D&md5=92d9596bf3c160bcde73fd9c586d6b84</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm501778s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501778s%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DRuston%26aufirst%3DL.%26aulast%3DPass%26aufirst%3DS.%2BL.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DE.%2BJ.%26aulast%3DDemeritt%26aufirst%3DJ.%26aulast%3DCulshaw%26aufirst%3DJ.%2BD.%26aulast%3DGill%26aufirst%3DK.%26aulast%3DPass%26aufirst%3DM.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DGood%26aufirst%3DC.%2BJ.%26aulast%3DRoberts%26aufirst%3DC.%2BA.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DBlades%26aufirst%3DK.%26aulast%3DEden%26aufirst%3DJ.%2BM.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26atitle%3DDiscovery%2520of%2520AZD3147%253A%2520a%2520potent%252C%2520selective%2520dual%2520inhibitor%2520of%2520mTORC1%2520and%2520mTORC2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2326%26epage%3D2349%26doi%3D10.1021%2Fjm501778s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Optimization of P2Y12 antagonist ethyl 6-(4-((benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) led to the discovery of an oral antiplatelet agent with improved druglike properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3088</span>– <span class="NLM_lpage">3106</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01971</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01971" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXksFens7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3088-3106&author=D.+Kongauthor=T.+Xueauthor=B.+Guoauthor=J.+Chengauthor=S.+Liuauthor=J.+Weiauthor=Z.+Luauthor=H.+Liuauthor=G.+Gongauthor=T.+Lanauthor=W.+Huauthor=Y.+Yang&title=Optimization+of+P2Y12+antagonist+ethyl+6-%284-%28%28benzylsulfonyl%29carbamoyl%29piperidin-1-yl%29-5-cyano-2-methylnicotinate+%28AZD1283%29+led+to+the+discovery+of+an+oral+antiplatelet+agent+with+improved+druglike+properties&doi=10.1021%2Facs.jmedchem.8b01971"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of P2Y12 Antagonist Ethyl 6-(4-((Benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties</span></div><div class="casAuthors">Kong, Deyu; Xue, Tao; Guo, Bin; Cheng, Jianjun; Liu, Shunyin; Wei, Jianhai; Lu, Zhengyu; Liu, Haoran; Gong, Guoqing; Lan, Tian; Hu, Wenhao; Yang, Yushe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3088-3106</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P2Y12 antagonists are widely used as antiplatelet agents for the prevention and treatment of arterial thrombosis.  Based on the scaffold of a known P2Y12 antagonist AZD1283 (I), a series of novel bicyclic pyridine derivs. were designed and synthesized.  The cyclization of the ester substituent on the pyridine ring to the ortho-Me group led to lactone analogs of AZD1283 that showed significantly enhanced metabolic stability in subsequent structure-pharmacokinetic relationship studies.  The metabolic stability was further enhanced by adding a 4-Me substituent to the piperidinyl moiety.  Compd. II displayed potent inhibition of platelet aggregation in vitro as well as antithrombotic efficacy in a rat ferric chloride model.  Moreover, II showed a safety profile that was superior to what was obsd. for clopidogrel in a rat tail-bleeding model.  These results support the further evaluation of compd. II as a promising drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3aElj92vWULVg90H21EOLACvtfcHk0ljtqsN-LuG8Qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXksFens7w%253D&md5=40577f34468ef13d6eea4a7a76dcaab8</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01971%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DD.%26aulast%3DXue%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DGong%26aufirst%3DG.%26aulast%3DLan%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DOptimization%2520of%2520P2Y12%2520antagonist%2520ethyl%25206-%25284-%2528%2528benzylsulfonyl%2529carbamoyl%2529piperidin-1-yl%2529-5-cyano-2-methylnicotinate%2520%2528AZD1283%2529%2520led%2520to%2520the%2520discovery%2520of%2520an%2520oral%2520antiplatelet%2520agent%2520with%2520improved%2520druglike%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3088%26epage%3D3106%26doi%3D10.1021%2Facs.jmedchem.8b01971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of a series of novel benzocyclobutene derivatives as general anesthetics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3618</span>– <span class="NLM_lpage">3625</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00253</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00253" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlCmtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3618-3625&author=C.+Zhangauthor=F.+Liauthor=Y.+Yuauthor=A.+Huangauthor=P.+Heauthor=M.+Leiauthor=J.+Wangauthor=L.+Huangauthor=Z.+Liuauthor=J.+Liuauthor=Y.+Wei&title=Design%2C+synthesis%2C+and+evaluation+of+a+series+of+novel+benzocyclobutene+derivatives+as+general+anesthetics&doi=10.1021%2Facs.jmedchem.7b00253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of a Series of Novel Benzocyclobutene Derivatives as General Anesthetics</span></div><div class="casAuthors">Zhang, Chen; Li, Fangqiong; Yu, Yan; Huang, Anbang; He, Ping; Lei, Ming; Wang, Jianmin; Huang, Longbin; Liu, Zhenhong; Liu, Jianyu; Wei, Yonggang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3618-3625</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the present work, a series of structurally novel benzocyclobutene derivs. were identified as general anesthetics through the loss of righting reflex (LORR) expt. on mice.  Our initial efforts found compd. 1a with a fused four-membered ring on the 2,3-position of the phenol ring could significantly improve the safety profile.  Further SAR study revealed that small hydrogen bond acceptor (HBA) groups are optimal for good ED50 along with much broader therapeutic windows, such as compds. 16b and 17.  Present work demonstrates the superiority of this novel benzocyclobutene scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_Lx2o14M9RrVg90H21EOLACvtfcHk0ljtqsN-LuG8Qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlCmtrg%253D&md5=9d38f93456f724429b2937e42f13fc68</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00253%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DHe%26aufirst%3DP.%26aulast%3DLei%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520a%2520series%2520of%2520novel%2520benzocyclobutene%2520derivatives%2520as%2520general%2520anesthetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D3618%26epage%3D3625%26doi%3D10.1021%2Facs.jmedchem.7b00253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judd, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Z.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruncko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunzer, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catron, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judge, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shekhar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimmer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahir, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitten, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boghaert, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairbrother, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmore, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souers, A. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of A-1331852, a first-in-class, potent, and orally-bioavailable BCL-XL inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00568</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00568" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=L.+Wangauthor=G.+A.+Dohertyauthor=A.+S.+Juddauthor=Z.-F.+Taoauthor=T.+M.+Hansenauthor=R.+R.+Freyauthor=X.+Songauthor=M.+Brunckoauthor=A.+R.+Kunzerauthor=X.+Wangauthor=M.+D.+Wendtauthor=J.+A.+Flygareauthor=N.+D.+Catronauthor=R.+A.+Judgeauthor=C.+H.+Parkauthor=S.+Shekharauthor=D.+C.+Phillipsauthor=P.+Nimmerauthor=M.+L.+Smithauthor=S.+K.+Tahirauthor=Y.+Xiaoauthor=J.+Xueauthor=H.+Zhangauthor=P.+N.+Leauthor=M.+J.+Mittenauthor=E.+R.+Boghaertauthor=W.+Gaoauthor=P.+Kovarauthor=E.+F.+Chooauthor=D.+Diazauthor=W.+J.+Fairbrotherauthor=S.+W.+Elmoreauthor=D.+Sampathauthor=J.+D.+Leversonauthor=A.+J.+Souers&title=Discovery+of+A-1331852%2C+a+first-in-class%2C+potent%2C+and+orally-bioavailable+BCL-XL+inhibitor&doi=10.1021%2Facsmedchemlett.9b00568"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00568%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DDoherty%26aufirst%3DG.%2BA.%26aulast%3DJudd%26aufirst%3DA.%2BS.%26aulast%3DTao%26aufirst%3DZ.-F.%26aulast%3DHansen%26aufirst%3DT.%2BM.%26aulast%3DFrey%26aufirst%3DR.%2BR.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DBruncko%26aufirst%3DM.%26aulast%3DKunzer%26aufirst%3DA.%2BR.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWendt%26aufirst%3DM.%2BD.%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DCatron%26aufirst%3DN.%2BD.%26aulast%3DJudge%26aufirst%3DR.%2BA.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DShekhar%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DD.%2BC.%26aulast%3DNimmer%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DM.%2BL.%26aulast%3DTahir%26aufirst%3DS.%2BK.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DXue%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLe%26aufirst%3DP.%2BN.%26aulast%3DMitten%26aufirst%3DM.%2BJ.%26aulast%3DBoghaert%26aufirst%3DE.%2BR.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DKovar%26aufirst%3DP.%26aulast%3DChoo%26aufirst%3DE.%2BF.%26aulast%3DDiaz%26aufirst%3DD.%26aulast%3DFairbrother%26aufirst%3DW.%2BJ.%26aulast%3DElmore%26aufirst%3DS.%2BW.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DLeverson%26aufirst%3DJ.%2BD.%26aulast%3DSouers%26aufirst%3DA.%2BJ.%26atitle%3DDiscovery%2520of%2520A-1331852%252C%2520a%2520first-in-class%252C%2520potent%252C%2520and%2520orally-bioavailable%2520BCL-XL%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26doi%3D10.1021%2Facsmedchemlett.9b00568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nussbaumer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorfstätter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grassberger, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leitner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meingassner, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thirring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stütz, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2115</span>– <span class="NLM_lpage">2120</span>, <span class="refDoi"> DOI: 10.1021/jm00067a010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00067a010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaK3sXlvVSnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=2115-2120&author=P.+Nussbaumerauthor=G.+Dorfst%C3%A4tterauthor=M.+A.+Grassbergerauthor=I.+Leitnerauthor=J.+G.+Meingassnerauthor=K.+Thirringauthor=A.+St%C3%BCtz&title=Synthesis+and+structure-activity+relationships+of+phenyl-substituted+benzylamine+antimycotics%3A+a+novel+benzylbenzylamine+antifungal+agent+for+systemic+treatment&doi=10.1021%2Fjm00067a010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatment</span></div><div class="casAuthors">Nussbaumer, Peter; Dorfstaetter, Gerhard; Grassberger, Maximilian A.; Leitner, Ingrid; Meingassner, Josef G.; Thirring, Klaus; Stuetz, Anton</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2115-20</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Derivs. of the benzylamine antimycotics with an extra Ph ring incorporated in the side chain have been prepd. and their antifungal activity evaluated.  Thus, alkylation of N-methyl-1-naphthalenemethanamine with benzyl halides I (R = CH:CH, X = Cl; R = bond, X = Cl; R = O, X = Br; etc.) gave benzylamine derivs. II which were tested for antifungal activity.  The potency is strongly dependent on the distance between the two Ph groups and the type of spacer.  Linking the aryl rings with a quaternary carbon atom resulted in the identification of highly active compds. II (R = CMe2) (III) and benzothienyl deriv. IV, having a novel 4-benzylbenzylamine side chain.  III and its 7-benzo[b]thienyl analog IV show significantly enhanced efficacy, in particular against Candida albicans, and are among the most potent allyl/benzylamine antimycotics identified so far.  Extended investigations with the benzylbenzylamine deriv. III revealed that, in addn. to the enhanced antimycotic profile, the compd. is the first representative of the benzylamine antimycotics suitable for systemic treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHbLSfXBkJvbVg90H21EOLACvtfcHk0liZbKtRk-qShA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlvVSnu70%253D&md5=e66050d2306b171bc06097e92f6759a2</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm00067a010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00067a010%26sid%3Dliteratum%253Aachs%26aulast%3DNussbaumer%26aufirst%3DP.%26aulast%3DDorfst%25C3%25A4tter%26aufirst%3DG.%26aulast%3DGrassberger%26aufirst%3DM.%2BA.%26aulast%3DLeitner%26aufirst%3DI.%26aulast%3DMeingassner%26aufirst%3DJ.%2BG.%26aulast%3DThirring%26aufirst%3DK.%26aulast%3DSt%25C3%25BCtz%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%2520phenyl-substituted%2520benzylamine%2520antimycotics%253A%2520a%2520novel%2520benzylbenzylamine%2520antifungal%2520agent%2520for%2520systemic%2520treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D2115%26epage%3D2120%26doi%3D10.1021%2Fjm00067a010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z. G.</span></span> <span> </span><span class="NLM_article-title">Adenosine receptors as therapeutic targets</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1038/nrd1983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2Fnrd1983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=16518376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFOlsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=247-264&author=K.+A.+Jacobsonauthor=Z.+G.+Gao&title=Adenosine+receptors+as+therapeutic+targets&doi=10.1038%2Fnrd1983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine receptors as therapeutic targets</span></div><div class="casAuthors">Jacobson, Kenneth A.; Gao, Zhan-Guo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">247-264</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Adenosine receptors are major targets of caffeine, the most commonly consumed drug in the world.  There is growing evidence that they could also be promising therapeutic targets in a wide range of conditions, including cerebral and cardiac ischemic diseases, sleep disorders, immune and inflammatory disorders and cancer.  After more than three decades of medicinal chem. research, a considerable no. of selective agonists and antagonists of adenosine receptors have been discovered, and some have been clin. evaluated, although none has yet received regulatory approval.  However, recent advances in the understanding of the roles of the various adenosine receptor subtypes, and in the development of selective and potent ligands, as discussed in this review, have brought the goal of therapeutic application of adenosine receptor modulators considerably closer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoG29EyQFoSbVg90H21EOLACvtfcHk0liZbKtRk-qShA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFOlsr4%253D&md5=85ad553154bd61f24a6bb594f960f9bc</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fnrd1983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1983%26sid%3Dliteratum%253Aachs%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DGao%26aufirst%3DZ.%2BG.%26atitle%3DAdenosine%2520receptors%2520as%2520therapeutic%2520targets%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D247%26epage%3D264%26doi%3D10.1038%2Fnrd1983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, A.</span></span> <span> </span><span class="NLM_article-title">8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">924</span>– <span class="NLM_lpage">930</span>, <span class="refDoi"> DOI: 10.1021/jm00083a018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00083a018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaK38XhvVOntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=924-930&author=J.+Shimadaauthor=F.+Suzukiauthor=H.+Nonakaauthor=A.+Ishii&title=8-Polycycloalkyl-1%2C3-dipropylxanthines+as+potent+and+selective+antagonists+for+A1-adenosine+receptors&doi=10.1021%2Fjm00083a018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors</span></div><div class="casAuthors">Shimada, Junichi; Suzuki, Fumio; Nonaka, Hiromi; Ishii, Akio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">924-30</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">With the aim of characterizing the hydrophobic interactions between xanthines and the A1 receptor site, 1,3-dipropyl-8-substituted xanthines (I, R = e.g., heteraryl, alkyl, alicyclic, or noradamantyl group) were prepd.  Introduction of a quaternary carbon and the conformationally restricted cyclopental moiety into the 8-position of xanthine enhanced the adenosine A1 antagonism.  1,3-Dipropyl-8-(3-noradamantyl)xanthine was identified to be a selective and the most potent A1 receptor antagonist reported to date.  Under the structure-activity relation study, the 8-substituent of xanthine antagonists and the N6-substituent of adenosine agonists appears to bind to the same region of the A1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1zxD_KlyFpLVg90H21EOLACvtfcHk0liZbKtRk-qShA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhvVOntbY%253D&md5=fad39d18bb9720d99c31dbbe9b808b2c</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm00083a018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00083a018%26sid%3Dliteratum%253Aachs%26aulast%3DShimada%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DF.%26aulast%3DNonaka%26aufirst%3DH.%26aulast%3DIshii%26aufirst%3DA.%26atitle%3D8-Polycycloalkyl-1%252C3-dipropylxanthines%2520as%2520potent%2520and%2520selective%2520antagonists%2520for%2520A1-adenosine%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D924%26epage%3D930%26doi%3D10.1021%2Fjm00083a018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. N.</span></span> <span> </span><span class="NLM_article-title">Potent adenosine receptor antagonists that are selective for the A1 receptor subtype</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">252</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=3561384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaL2sXktVSht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1987&pages=247-252&author=E.+A.+Martinsonauthor=R.+A.+Johnsonauthor=J.+N.+Wells&title=Potent+adenosine+receptor+antagonists+that+are+selective+for+the+A1+receptor+subtype"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Potent adenosine receptor antagonists that are selective for the A1 receptor subtype</span></div><div class="casAuthors">Martinson, Elizabeth A.; Johnson, Roger A.; Wells, Jack N.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">247-52</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">A systematic study of xanthine structure-activity relationships that compared antagonist potency at the A1 receptor of adipocytes with potency at the A2 receptor of platelets was conducted.  Since adenosine receptors are coupled to adenylate cyclase in these tissues, inhibition of adenylate cyclase via A1 receptors and stimulation via A2 receptors were used as models of receptor activation.  Antagonist potency was quantitated by Schild anal., which yields an est. of affinity (Ki) for the drug-receptor interaction.  Ki Values of a series of xanthine analogs made it possible to identify structural modifications than enhanced antagonist selectivity for one receptor subtype over the other.  Changes in the substituent at position 8 of the xanthine nucleus influenced antagonist potency at the A1 adenosine receptor more than at the A2 receptor.  In particular, an 8-cyclohexyl or 8-cyclopentyl substituent promoted antagonist selectivity for the A1 receptor subtype.  Thus, 1,3-dipropyl-8-cyclopentylxanthine (I) had comparatively high affinity (Ki = 0.47 nM) at the A1 receptor, and was roughly 150-fold more potent as an antagonist of the A1- than of the A2-adenosine receptor subtype.  In addn., the cycloalkylxanthines were relatively ineffective as inhibitors of cyclic nucleotide phosphodiesterase when used at concns. that produce marked adenosine receptor antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppuWrKG7BhtbVg90H21EOLACvtfcHk0liwHq59fW2lGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXktVSht7c%253D&md5=15f9f261071b96c164b935635806f6fa</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartinson%26aufirst%3DE.%2BA.%26aulast%3DJohnson%26aufirst%3DR.%2BA.%26aulast%3DWells%26aufirst%3DJ.%2BN.%26atitle%3DPotent%2520adenosine%2520receptor%2520antagonists%2520that%2520are%2520selective%2520for%2520the%2520A1%2520receptor%2520subtype%26jtitle%3DMol.%2520Pharmacol.%26date%3D1987%26volume%3D31%26spage%3D247%26epage%3D252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costantino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maltoni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinozzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camaioni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prezeau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pin, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicciari, R.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 2-(3′-(1H-tetrazol-5-yl)bicyclo[1.1.1]pent-1-yl)glycine (S-TBPG), a novel mGlu1 receptor antagonist</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(00)00270-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2FS0968-0896%2800%2900270-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=11249114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhs1artLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2001&pages=221-227&author=G.+Costantinoauthor=K.+Maltoniauthor=M.+Marinozziauthor=E.+Camaioniauthor=L.+Prezeauauthor=J.-P.+Pinauthor=R.+Pellicciari&title=Synthesis+and+biological+evaluation+of+2-%283%E2%80%B2-%281H-tetrazol-5-yl%29bicyclo%5B1.1.1%5Dpent-1-yl%29glycine+%28S-TBPG%29%2C+a+novel+mGlu1+receptor+antagonist&doi=10.1016%2FS0968-0896%2800%2900270-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 2-(3'-(1H-tetrazol-5-yl)bicyclo[1.1.1]pent-1-yl)glycine (S-TBPG), a novel mGlu1 receptor antagonist</span></div><div class="casAuthors">Costantino, G.; Maltoni, K.; Marinozzi, M.; Camaioni, E.; Prezeau, L.; Pin, J.-P.; Pellicciari, R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-227</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The design and synthesis of 2-(3'-(1H-tetrazol-5-yl)bicyclo[1.1.1]pent-1-yl)glycine (S-TBPG), a novel mGluR1 antagonist is reported.  S-TBPG is characterized by the bioisosteric replacement of the distal carboxy group of 2-(3'-carboxybicyclo[1.1.1]pent-1-yl)glycine (S-CBPG) by a tetrazolyl moiety.  Despite a moderate redn. in potency, S-TBPG is a selective mGluR1 antagonist (69 μM), with no activity at other mGluR subtypes.  The interesting biol. profile of S-TBPG, coupled with its peculiar chem. structure, is discussed in terms of the structure-activity relationship (SAR) of mGluR1 antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCrXubb8ywTLVg90H21EOLACvtfcHk0liwHq59fW2lGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhs1artLs%253D&md5=3a6eec857310855b4e67dd5d37dbc7e8</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2800%2900270-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252800%252900270-4%26sid%3Dliteratum%253Aachs%26aulast%3DCostantino%26aufirst%3DG.%26aulast%3DMaltoni%26aufirst%3DK.%26aulast%3DMarinozzi%26aufirst%3DM.%26aulast%3DCamaioni%26aufirst%3DE.%26aulast%3DPrezeau%26aufirst%3DL.%26aulast%3DPin%26aufirst%3DJ.-P.%26aulast%3DPellicciari%26aufirst%3DR.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25202-%25283%25E2%2580%25B2-%25281H-tetrazol-5-yl%2529bicyclo%255B1.1.1%255Dpent-1-yl%2529glycine%2520%2528S-TBPG%2529%252C%2520a%2520novel%2520mGlu1%2520receptor%2520antagonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2001%26volume%3D9%26spage%3D221%26epage%3D227%26doi%3D10.1016%2FS0968-0896%2800%2900270-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pellicciari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raimondo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinozzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natalini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costantino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, C.</span></span> <span> </span><span class="NLM_article-title">(S)-(+)-2-(3′-Carboxybicyclo[1.1.1]pentyl)- glycine, a structurally new group I metabotropic glutamate receptor antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2874</span>– <span class="NLM_lpage">2876</span>, <span class="refDoi"> DOI: 10.1021/jm960254o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960254o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaK28XjvVejtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=2874-2876&author=R.+Pellicciariauthor=M.+Raimondoauthor=M.+Marinozziauthor=B.+Nataliniauthor=G.+Costantinoauthor=C.+Thomsen&title=%28S%29-%28%2B%29-2-%283%E2%80%B2-Carboxybicyclo%5B1.1.1%5Dpentyl%29-+glycine%2C+a+structurally+new+group+I+metabotropic+glutamate+receptor+antagonist&doi=10.1021%2Fjm960254o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">(S)-(+)-2-(3'-Carboxybicyclo[1.1.1]pentyl)- glycine, a Structurally New Group I Metabotropic Glutamate Receptor Antagonist</span></div><div class="casAuthors">Pellicciari, Roberto; Raimondo, Mariarosa; Marinozzi, Maura; Natalini, Benedetto; Costantino, Gabriele; Thomsen, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2874-2876</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A no. of carboxyphenylglycine (CPG) derivs. are known to act at metabotropic glutamate receptors (mGluRs) with a wide range of potency and functional selectivities toward mGluR subtypes depending on the substitution pattern.  With the aim of defining the role of the Ph moiety in this class of compds., the authors report the synthesis of S-(+)- and R-(-)-2-(3'-carboxybicyclo[1.1.1]pentyl)glycine, I and II, resp., in which the Ph ring is replaced by a [1.1.1]propellane moiety as a new, unusual spacer featuring a still coplanar disposition of the substitution inserted at the bridgehead positions.  The (S)-enantiomer I was a potent antagonist at the cloned phosphoinositide coupled mGluR1 subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi6ImMXIWB4LVg90H21EOLACvtfcHk0liwHq59fW2lGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjvVejtr0%253D&md5=ff6b601f76372da3228974fed84e9088</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm960254o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960254o%26sid%3Dliteratum%253Aachs%26aulast%3DPellicciari%26aufirst%3DR.%26aulast%3DRaimondo%26aufirst%3DM.%26aulast%3DMarinozzi%26aufirst%3DM.%26aulast%3DNatalini%26aufirst%3DB.%26aulast%3DCostantino%26aufirst%3DG.%26aulast%3DThomsen%26aufirst%3DC.%26atitle%3D%2528S%2529-%2528%252B%2529-2-%25283%25E2%2580%25B2-Carboxybicyclo%255B1.1.1%255Dpentyl%2529-%2520glycine%252C%2520a%2520structurally%2520new%2520group%2520I%2520metabotropic%2520glutamate%2520receptor%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D2874%26epage%3D2876%26doi%3D10.1021%2Fjm960254o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutra, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiRico, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorff, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pustilnik, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kormos, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capetta, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atchison, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallgren, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oborski, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robshaw, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sneed, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3414</span>– <span class="NLM_lpage">3424</span>, <span class="refDoi"> DOI: 10.1021/jm300094u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300094u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVyntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3414-3424&author=A.+F.+Stepanauthor=C.+Subramanyamauthor=I.+V.+Efremovauthor=J.+K.+Dutraauthor=T.+J.+O%E2%80%99Sullivanauthor=K.+J.+DiRicoauthor=W.+S.+McDonaldauthor=A.+Wonauthor=P.+H.+Dorffauthor=C.+E.+Nolanauthor=S.+L.+Beckerauthor=L.+R.+Pustilnikauthor=D.+R.+Riddellauthor=G.+W.+Kauffmanauthor=B.+L.+Kormosauthor=L.+Zhangauthor=Y.+Luauthor=S.+H.+Capettaauthor=M.+E.+Greenauthor=K.+Karkiauthor=E.+Sibleyauthor=K.+P.+Atchisonauthor=A.+J.+Hallgrenauthor=C.+E.+Oborskiauthor=A.+E.+Robshawauthor=B.+Sneedauthor=C.+J.+O%E2%80%99Donnell&title=Application+of+the+bicyclo%5B1.1.1%5Dpentane+motif+as+a+nonclassical+phenyl+ring+bioisostere+in+the+design+of+a+potent+and+orally+active+%CE%B3-secretase+inhibitor&doi=10.1021%2Fjm300094u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor</span></div><div class="casAuthors">Stepan, Antonia F.; Subramanyam, Chakrapani; Efremov, Ivan V.; Dutra, Jason K.; O'Sullivan, Theresa J.; DiRico, Kenneth J.; McDonald, W. Scott; Won, Annie; Dorff, Peter H.; Nolan, Charles E.; Becker, Stacey L.; Pustilnik, Leslie R.; Riddell, David R.; Kauffman, Gregory W.; Kormos, Bethany L.; Zhang, Liming; Lu, Yasong; Capetta, Steven H.; Green, Michael E.; Karki, Kapil; Sibley, Evelyn; Atchison, Kevin P.; Hallgren, Andrew J.; Oborski, Christine E.; Robshaw, Ashley E.; Sneed, Blossom; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3414-3424</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Replacement of the central, para-substituted fluorophenyl ring in the γ-secretase inhibitor BMS-708,163 with the bicyclo[1.1.1]pentane motif led to the discovery of compd. (I), an equipotent enzyme inhibitor with significant improvements in passive permeability and aq. soly.  The modified biopharmaceutical properties of I translated into excellent oral absorption characteristics (∼4-fold ↑ Cmax and AUC values relative to BMS-708,163) in a mouse model of γ-secretase inhibition.  In addn., SAR studies into other fluorophenyl replacements indicate the intrinsic advantages of the bicyclo[1.1.1]pentane moiety over conventional Ph ring replacements with respect to achieving an optimal balance of properties (e.g., γ-secretase inhibition, aq. soly./permeability, in vitro metabolic stability).  Overall, this work enhances the scope of the [1.1.1]-bicycle beyond that of a mere "spacer" unit and presents a compelling case for its broader application as a Ph group replacement in scenarios where the arom. ring count impacts physicochem. parameters and overall drug-likeness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYTrCHjtRbgbVg90H21EOLACvtfcHk0lht2913t0UPPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVyntLo%253D&md5=4bbcac4eb20d974696833df5f86f9c34</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fjm300094u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300094u%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DEfremov%26aufirst%3DI.%2BV.%26aulast%3DDutra%26aufirst%3DJ.%2BK.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DT.%2BJ.%26aulast%3DDiRico%26aufirst%3DK.%2BJ.%26aulast%3DMcDonald%26aufirst%3DW.%2BS.%26aulast%3DWon%26aufirst%3DA.%26aulast%3DDorff%26aufirst%3DP.%2BH.%26aulast%3DNolan%26aufirst%3DC.%2BE.%26aulast%3DBecker%26aufirst%3DS.%2BL.%26aulast%3DPustilnik%26aufirst%3DL.%2BR.%26aulast%3DRiddell%26aufirst%3DD.%2BR.%26aulast%3DKauffman%26aufirst%3DG.%2BW.%26aulast%3DKormos%26aufirst%3DB.%2BL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DCapetta%26aufirst%3DS.%2BH.%26aulast%3DGreen%26aufirst%3DM.%2BE.%26aulast%3DKarki%26aufirst%3DK.%26aulast%3DSibley%26aufirst%3DE.%26aulast%3DAtchison%26aufirst%3DK.%2BP.%26aulast%3DHallgren%26aufirst%3DA.%2BJ.%26aulast%3DOborski%26aufirst%3DC.%2BE.%26aulast%3DRobshaw%26aufirst%3DA.%2BE.%26aulast%3DSneed%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DApplication%2520of%2520the%2520bicyclo%255B1.1.1%255Dpentane%2520motif%2520as%2520a%2520nonclassical%2520phenyl%2520ring%2520bioisostere%2520in%2520the%2520design%2520of%2520a%2520potent%2520and%2520orally%2520active%2520%25CE%25B3-secretase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3414%26epage%3D3424%26doi%3D10.1021%2Fjm300094u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Auberson, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brocklehurst, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furegati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fessard, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Vecchia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briard, E.</span></span> <span> </span><span class="NLM_article-title">Improving nonspecific binding and solubility: Bicycloalkyl groups and cubanes as para-phenyl bioisosteres</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">590</span>– <span class="NLM_lpage">598</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fcmdc.201700082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=28319646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvV2gsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=590-598&author=Y.+P.+Aubersonauthor=C.+Brocklehurstauthor=M.+Furegatiauthor=T.+C.+Fessardauthor=G.+Kochauthor=A.+Deckerauthor=L.+La+Vecchiaauthor=E.+Briard&title=Improving+nonspecific+binding+and+solubility%3A+Bicycloalkyl+groups+and+cubanes+as+para-phenyl+bioisosteres&doi=10.1002%2Fcmdc.201700082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Nonspecific Binding and Solubility: Bicycloalkyl Groups and Cubanes as para-Phenyl Bioisosteres</span></div><div class="casAuthors">Auberson, Yves P.; Brocklehurst, Cara; Furegati, Markus; Fessard, Thomas C.; Koch, Guido; Decker, Andrea; La Vecchia, Luigi; Briard, Emmanuelle</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">590-598</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Bicycloalkyl groups have been previously described as Ph group bioisosteres.  This article describes the synthesis of new building blocks allowing their introduction into complex mols., and explores their use as a means to modify the physicochem. properties of drug candidates and improve the quality of imaging agents.  In particular, the replacement of an arom. ring with a bicyclo[1.1.1]pentane-1,3-diyl (BCP) group improves aq. soly. by at least 50-fold, and markedly decreases nonspecific binding (NSB) as measured by CHI(IAM), the chromatog. hydrophobicity index on immobilized artificial membranes.  Structural variations with the bicyclo[2.2.2]octane-1,4-diyl group led to more lipophilic mols. and did not show the same benefits regarding NSB or soly., whereas substitutions with cubane-1,4-diyl showed improvements for both parameters.  These results confirm the potential advantages of both BCP and cubane motifs as bioisosteric replacements for optimizing para-phenyl-substituted mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod2zUqkK78vLVg90H21EOLACvtfcHk0lht2913t0UPPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvV2gsr8%253D&md5=7827a1866afae8b98b04ac03deaf5d2b</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700082%26sid%3Dliteratum%253Aachs%26aulast%3DAuberson%26aufirst%3DY.%2BP.%26aulast%3DBrocklehurst%26aufirst%3DC.%26aulast%3DFuregati%26aufirst%3DM.%26aulast%3DFessard%26aufirst%3DT.%2BC.%26aulast%3DKoch%26aufirst%3DG.%26aulast%3DDecker%26aufirst%3DA.%26aulast%3DLa%2BVecchia%26aufirst%3DL.%26aulast%3DBriard%26aufirst%3DE.%26atitle%3DImproving%2520nonspecific%2520binding%2520and%2520solubility%253A%2520Bicycloalkyl%2520groups%2520and%2520cubanes%2520as%2520para-phenyl%2520bioisosteres%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D590%26epage%3D598%26doi%3D10.1002%2Fcmdc.201700082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dilmaç, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spuling, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Meijere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bräse, S.</span></span> <span> </span><span class="NLM_article-title">Propellanes—From a chemical curiosity to “explosive” materials and natural products</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5684</span>– <span class="NLM_lpage">5718</span>, <span class="refDoi"> DOI: 10.1002/anie.201603951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fanie.201603951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlslOgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=5684-5718&author=A.+M.+Dilma%C3%A7author=E.+Spulingauthor=A.+de+Meijereauthor=S.+Br%C3%A4se&title=Propellanes%E2%80%94From+a+chemical+curiosity+to+%E2%80%9Cexplosive%E2%80%9D+materials+and+natural+products&doi=10.1002%2Fanie.201603951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Propellanes-From a Chemical Curiosity to "Explosive" Materials and Natural Products</span></div><div class="casAuthors">Dilmac, Alicia M.; Spuling, Eduard; de Meijere, Armin; Braese, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5684-5718</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Propellanes are a unique class of compds. currently consisting of well over 10 000 representatives, all featuring two more or less inverted tetrahedral carbon atoms that are common to three bridging rings.  The central single bond between the two bridgeheads is significantly weakened in the smaller entities, which leads to unusual reactivities of these structurally interesting propeller-like mols.  This Review highlights the synthesis of such propellanes and their occurrence in material sciences, natural products, and medicinal chem.  The conversion of [1.1.1]propellane into bridgehead derivs. of bicyclo[1.1.1]pentane, including oligomers and polymers with bicyclo[1.1.1]penta-1,3-diyl repeat units, is also featured.  A selection of natural products with larger propellane subunits are discussed in detail.  Heteropropellanes and inorg. propellanes are also addressed.  The historical background is touched in brief to show the pioneering work of David Ginsburg, Guenther Snatzke, Kenneth B. Wiberg, Guenter Szeimies, and others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPNBS1CEPKurVg90H21EOLACvtfcHk0ljxhWYTOEM8TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlslOgsrg%253D&md5=b9da3c7dc8d9cf7e8ef30b847569e8c6</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1002%2Fanie.201603951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201603951%26sid%3Dliteratum%253Aachs%26aulast%3DDilma%25C3%25A7%26aufirst%3DA.%2BM.%26aulast%3DSpuling%26aufirst%3DE.%26aulast%3Dde%2BMeijere%26aufirst%3DA.%26aulast%3DBr%25C3%25A4se%26aufirst%3DS.%26atitle%3DPropellanes%25E2%2580%2594From%2520a%2520chemical%2520curiosity%2520to%2520%25E2%2580%259Cexplosive%25E2%2580%259D%2520materials%2520and%2520natural%2520products%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D5684%26epage%3D5718%26doi%3D10.1002%2Fanie.201603951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicolaou, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vourloumis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totokotsopoulos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papakyriakou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karsunky, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernando, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavrilyuk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biopharmaceutical evaluation of imatinib analogues featuring unusual structural motifs</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fcmdc.201500510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=26585829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOmu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=31-37&author=K.+C.+Nicolaouauthor=D.+Vourloumisauthor=S.+Totokotsopoulosauthor=A.+Papakyriakouauthor=H.+Karsunkyauthor=H.+Fernandoauthor=J.+Gavrilyukauthor=D.+Webbauthor=A.+F.+Stepan&title=Synthesis+and+biopharmaceutical+evaluation+of+imatinib+analogues+featuring+unusual+structural+motifs&doi=10.1002%2Fcmdc.201500510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biopharmaceutical Evaluation of Imatinib Analogues Featuring Unusual Structural Motifs</span></div><div class="casAuthors">Nicolaou, Kyriacos C.; Vourloumis, Dionisios; Totokotsopoulos, Sotirios; Papakyriakou, Athanasios; Karsunky, Holger; Fernando, Hanan; Gavrilyuk, Julia; Webb, Damien; Stepan, Antonia F.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-37</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A convenient synthesis of imatinib, a potent inhibitor of ABL1 kinase and widely prescribed drug for the treatment of a variety of leukemias, was devised and applied to the construction of a series of novel imatinib analogs featuring a no. of nonarom. structural motifs in place of the parent mol.'s Ph moiety.  These analogs were subsequently evaluated for their biopharmaceutical properties (e.g., ABL1 kinase inhibitory activity, cytotoxicity).  The bicyclo[1.1.1]pentane- and cubane-contg. analogs were found to possess higher thermodn. soly., whereas cubane- and cyclohexyl-contg. analogs exhibited the highest inhibitory activity against ABL1 kinase and the most potent cytotoxicity values against cancer cell lines K562 and SUP-B15.  Mol. modeling was employed to rationalize the weak activity of the compds. against ABL1 kinase, and it is likely that the obsd. cytotoxicity of these agents arises through off-target effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryhdZvrPlg2rVg90H21EOLACvtfcHk0ljxhWYTOEM8TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOmu7nK&md5=012acd486d981afe4a4afe9d924fd696</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500510%26sid%3Dliteratum%253Aachs%26aulast%3DNicolaou%26aufirst%3DK.%2BC.%26aulast%3DVourloumis%26aufirst%3DD.%26aulast%3DTotokotsopoulos%26aufirst%3DS.%26aulast%3DPapakyriakou%26aufirst%3DA.%26aulast%3DKarsunky%26aufirst%3DH.%26aulast%3DFernando%26aufirst%3DH.%26aulast%3DGavrilyuk%26aufirst%3DJ.%26aulast%3DWebb%26aufirst%3DD.%26aulast%3DStepan%26aufirst%3DA.%2BF.%26atitle%3DSynthesis%2520and%2520biopharmaceutical%2520evaluation%2520of%2520imatinib%2520analogues%2520featuring%2520unusual%2520structural%2520motifs%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D31%26epage%3D37%26doi%3D10.1002%2Fcmdc.201500510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goh, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendharkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adsool, V. A.</span></span> <span> </span><span class="NLM_article-title">Toward resolving the resveratrol conundrum: Synthesis and in vivo pharmacokinetic evaluation of BCP-resveratrol</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">516</span>– <span class="NLM_lpage">520</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsFajsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=516-520&author=Y.+L.+Gohauthor=Y.+T.+Cuiauthor=V.+Pendharkarauthor=V.+A.+Adsool&title=Toward+resolving+the+resveratrol+conundrum%3A+Synthesis+and+in+vivo+pharmacokinetic+evaluation+of+BCP-resveratrol&doi=10.1021%2Facsmedchemlett.7b00018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Resolving the Resveratrol Conundrum: Synthesis and in Vivo Pharmacokinetic Evaluation of BCP-Resveratrol</span></div><div class="casAuthors">Goh, Yi Ling; Cui, Yan Ting; Pendharkar, Vishal; Adsool, Vikrant A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">516-520</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Over the last few decades, resveratrol has gained significance due to its impressive array of biol. activities; however, its true potential as a drug has been severely constrained by its poor bioavailability.  Indeed, several studies have implicated this bioavailability trait as a major road-block to resveratrol's potential clin. applications.  To mitigate this pharmacokinetic issue, we envisioned a tactical bioisosteric modification of resveratrol to bicyclo[1.1.1]pentane (BCP) resveratrol.  Relying on the beneficial bioisosteric potential demonstrated by the BCP-scaffold, we hypothesized that BCP-resveratrol would have an inherently better in vivo PK profile as compared to its natural counterpart.  To validate such a hypothesis, it was necessary to secure a synthetic access to this novel structure.  Herein we describe the first synthesis of BCP-resveratrol and disclose its PK properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN7vEKGcbeDLVg90H21EOLACvtfcHk0ljxhWYTOEM8TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsFajsrs%253D&md5=4bba7ca841dabab453237b0294239de8</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00018%26sid%3Dliteratum%253Aachs%26aulast%3DGoh%26aufirst%3DY.%2BL.%26aulast%3DCui%26aufirst%3DY.%2BT.%26aulast%3DPendharkar%26aufirst%3DV.%26aulast%3DAdsool%26aufirst%3DV.%2BA.%26atitle%3DToward%2520resolving%2520the%2520resveratrol%2520conundrum%253A%2520Synthesis%2520and%2520in%2520vivo%2520pharmacokinetic%2520evaluation%2520of%2520BCP-resveratrol%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D516%26epage%3D520%26doi%3D10.1021%2Facsmedchemlett.7b00018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Locke, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhard, S. S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senge, M. O.</span></span> <span> </span><span class="NLM_article-title">Nonconjugated hydrocarbons as rigid-linear motifs: Isosteres for material sciences and bioorganic and medicinal chemistry</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4590</span>– <span class="NLM_lpage">4647</span>, <span class="refDoi"> DOI: 10.1002/chem.201804225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fchem.201804225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=30387906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFSjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=4590-4647&author=G.+M.+Lockeauthor=S.+S.+R.+Bernhardauthor=M.+O.+Senge&title=Nonconjugated+hydrocarbons+as+rigid-linear+motifs%3A+Isosteres+for+material+sciences+and+bioorganic+and+medicinal+chemistry&doi=10.1002%2Fchem.201804225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Nonconjugated Hydrocarbons as Rigid-Linear Motifs: Isosteres for Material Sciences and Bioorganic and Medicinal Chemistry</span></div><div class="casAuthors">Locke, Gemma M.; Bernhard, Stefan S. R.; Senge, Mathias O.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4590-4647</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Nonconjugated hydrocarbons, like bicyclo[1.1.1]pentane, bicyclo[2.2.2]octane, triptycene, and cubane are a unique class of rigid linkers.  Due to their similarity in size and shape they are useful mimics of classic benzene moieties in drugs, so-called bioisosteres.  Moreover, they also fulfill an important role in material sciences as linear linkers, in order to arrange various functionalities in a defined spatial manner.  In this Review article, recent developments and usages of these special, rectilinear systems are discussed.  Furthermore, we focus on covalently linked, nonconjugated linear arrangements and discuss the phys. and chem. properties and differences of individual linkers, as well as their application in material and medicinal sciences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-6fMC92ObjbVg90H21EOLACvtfcHk0liBvzdgxPzxQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFSjtbg%253D&md5=9b22ee3b2a90132ab2e9cb5471f63ac1</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1002%2Fchem.201804225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201804225%26sid%3Dliteratum%253Aachs%26aulast%3DLocke%26aufirst%3DG.%2BM.%26aulast%3DBernhard%26aufirst%3DS.%2BS.%2BR.%26aulast%3DSenge%26aufirst%3DM.%2BO.%26atitle%3DNonconjugated%2520hydrocarbons%2520as%2520rigid-linear%2520motifs%253A%2520Isosteres%2520for%2520material%2520sciences%2520and%2520bioorganic%2520and%2520medicinal%2520chemistry%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2019%26volume%3D25%26spage%3D4590%26epage%3D4647%26doi%3D10.1002%2Fchem.201804225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span> <span> </span><span class="NLM_article-title">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">822</span>– <span class="NLM_lpage">830</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.drudis.2011.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=21704184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=822-830&author=R.+J.+Youngauthor=D.+V.+Greenauthor=C.+N.+Luscombeauthor=A.+P.+Hill&title=Getting+physical+in+drug+discovery+II%3A+the+impact+of+chromatographic+hydrophobicity+measurements+and+aromaticity&doi=10.1016%2Fj.drudis.2011.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span></div><div class="casAuthors">Young, Robert J.; Green, Darren V. S.; Luscombe, Christopher N.; Hill, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17/18</span>),
    <span class="NLM_cas:pages">822-830</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here, we review the performance of chromatog. hydrophobicity measurements in a data set of 100 000 GlaxoSmithKline compds., demonstrating the advantages of the method over octanol-water partitioning and highlighting new insights for drug discovery.  The value of chromatog. measurements, vs. other hydrophobicity ests., was supported by improved relationships with soly., permeation, cytochrome P450s, intrinsic clearance, hERG binding and promiscuity.  We also obsd. marked differentiation of the relative influence of intrinsic and effective hydrophobicity.  The summing of hydrophobicity values plus arom. ring count [log D pH7.4 (or log P) + #Ar], indicated a wide relevance for simplistic property forecast indexes' in developability assays, clearly enhanced by chromatog. values; therefore establishing new foundations for enriching property-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmIJyWi-DBW7Vg90H21EOLACvtfcHk0liBvzdgxPzxQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF&md5=22788603a45aa77537e8666433473d14</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DGreen%26aufirst%3DD.%2BV.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DHill%26aufirst%3DA.%2BP.%26atitle%3DGetting%2520physical%2520in%2520drug%2520discovery%2520II%253A%2520the%2520impact%2520of%2520chromatographic%2520hydrophobicity%2520measurements%2520and%2520aromaticity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D822%26epage%3D830%26doi%3D10.1016%2Fj.drudis.2011.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asensi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carretero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baño, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obrador, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrela, J. M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cancer growth by resveratrol is related to its low bioavailability</span>. <i>Free Radical Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1016/S0891-5849(02)00911-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2FS0891-5849%2802%2900911-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=12126761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt12kurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2002&pages=387-398&author=M.+Asensiauthor=I.+Medinaauthor=A.+Ortegaauthor=J.+Carreteroauthor=M.+C.+Ba%C3%B1oauthor=E.+Obradorauthor=J.+M.+Estrela&title=Inhibition+of+cancer+growth+by+resveratrol+is+related+to+its+low+bioavailability&doi=10.1016%2FS0891-5849%2802%2900911-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cancer growth by resveratrol is related to its low bioavailability</span></div><div class="casAuthors">Asensi, Miguel; Medina, Ignacio; Ortega, Angel; Carretero, Julian; Bano, M. Carmen; Obrador, Elena; Estrela, Jose M.</div><div class="citationInfo"><span class="NLM_cas:title">Free Radical Biology & Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">387-398</span>CODEN:
                <span class="NLM_cas:coden">FRBMEH</span>;
        ISSN:<span class="NLM_cas:issn">0891-5849</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The relationship between resveratrol (RES) bioavailability and its effect on tumor growth was investigated.  Tissue levels of RES were studied after i.v. and oral administration of trans-resveratrol (t-RES) to rabbits, rats, and mice.  Half-life of RES in plasma, after i.v. administration of 20 mg t-RES/kg b.wt., was very short (e.g., 14.4 min in rabbits).  The highest concn. of RES in plasma, either after i.v. or oral administration (e.g., 2.6 ± 1.0 μM in mice 2.5 min after receiving 20 mg t-RES/kg orally), was reached within the first 5 min in all animals studied.  Extravascular levels (brain, lung, liver, and kidney) of RES, which paralleled those in plasma, were always < 1 nmol/g fresh tissue.  RES measured in plasma or tissues was in the trans form (at least 99%).  Hepatocytes metabolized t-RES in a dose-dependent fashion (e.g., 43 nmol of t-RES/g × min in the presence of 20 μM tRES), which means that the liver can remove circulating RES very rapidly.  In vitro B16 melanoma (B16M) cell proliferation and generation of reactive oxygen species (ROS) was inhibited by t-RES in a concn.-dependent fashion (100% inhibition of tumor growth was found in the presence of 5 μM t-RES).  Addn. of 10 μM H2O2 to B16M cells, cultured in the presence of 5 μM t-RES, reactivated cell growth.  Oral administration of t-RES (20 mg/kg twice per day; or included in the drinking water at 23 mg/l) did not inhibit growth of B16M inoculated into the footpad of mice (solid growth).  However, oral administration of t-RES (as above) decreased hepatic metastatic invasion of B16M cells inoculated intrasplenically.  The antimetastatic mechanism involves a t-RES (1 μM)-induced inhibition of vascular adhesion mol. 1 (VCAM-1) expression in the hepatic sinusoidal endothelium (HSE), which consequently decreased in vitro B16M cell adhesion to the endothelium via very late activation antigen 4 (VLA-4).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP11sw2kyBFLVg90H21EOLACvtfcHk0liBvzdgxPzxQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt12kurk%253D&md5=c49ba5325c94060101d69c3e1640c1b3</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2FS0891-5849%2802%2900911-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0891-5849%252802%252900911-5%26sid%3Dliteratum%253Aachs%26aulast%3DAsensi%26aufirst%3DM.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DOrtega%26aufirst%3DA.%26aulast%3DCarretero%26aufirst%3DJ.%26aulast%3DBa%25C3%25B1o%26aufirst%3DM.%2BC.%26aulast%3DObrador%26aufirst%3DE.%26aulast%3DEstrela%26aufirst%3DJ.%2BM.%26atitle%3DInhibition%2520of%2520cancer%2520growth%2520by%2520resveratrol%2520is%2520related%2520to%2520its%2520low%2520bioavailability%26jtitle%3DFree%2520Radical%2520Biol.%2520Med.%26date%3D2002%26volume%3D33%26spage%3D387%26epage%3D398%26doi%3D10.1016%2FS0891-5849%2802%2900911-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meegalla, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanter, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winters, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littrell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rady, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilde, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otieno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Player, M. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of a GPR40 superagonist: The impact of aryl propionic acid alpha-fluorination</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00444</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00444" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVSgs7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=16-21&author=H.+Huangauthor=S.+K.+Meegallaauthor=J.+C.+Lanterauthor=M.+P.+Wintersauthor=S.+Zhaoauthor=J.+Littrellauthor=J.+Qiauthor=B.+Radyauthor=P.+S.+Leeauthor=J.+Liuauthor=T.+Martinauthor=W.+W.+Lamauthor=F.+Xuauthor=H.+K.+Limauthor=T.+Wildeauthor=J.+Silvaauthor=M.+Otienoauthor=A.+Pocaiauthor=M.+R.+Player&title=Discovery+of+a+GPR40+superagonist%3A+The+impact+of+aryl+propionic+acid+alpha-fluorination&doi=10.1021%2Facsmedchemlett.8b00444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a GPR40 Superagonist: The Impact of Aryl Propionic Acid α-Fluorination</span></div><div class="casAuthors">Huang, Hui; Meegalla, Sanath K.; Lanter, James C.; Winters, Michael P.; Zhao, Shuyuan; Littrell, James; Qi, Jenson; Rady, Brian; Lee, Paul S.; Liu, Jianying; Martin, Tonya; Lam, Wing W.; Xu, Fran; Lim, Heng Keang; Wilde, Thomas; Silva, Jose; Otieno, Monicah; Pocai, Alessandro; Player, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-21</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">GPR40 is a G-protein-coupled receptor which mediates fatty acid-induced glucose-stimulated insulin secretion from pancreatic beta cells and incretion release from enteroendocrine cells of the small intestine.  GPR40 full agonists exhibit superior glucose lowering compared to partial agonists in preclin. species due to increased insulin and GLP-1 secretion, with the added benefit of promoting wt. loss.  In our search for potent GPR40 full agonists, we discovered a superagonist which displayed excellent in vitro potency and superior efficacy in the Gαs-mediated signaling pathway.  Most synthetic GPR40 agonists have a carboxylic acid headgroup, which may cause idiosyncratic toxicities, including drug-induced-liver-injury (DILI).  With a Me group and a fluorine atom substituted at the α-C of the carboxylic acid group, 19 is not only highly efficacious in lowering glucose and body wt. in rodent models but also has a low DILI risk due to its stable acylglucuronide metabolite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQJ_WYP9f76rVg90H21EOLACvtfcHk0liHXAOdZqXCrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVSgs7fN&md5=1e9b9412b6438351528162aab15351eb</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00444%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DMeegalla%26aufirst%3DS.%2BK.%26aulast%3DLanter%26aufirst%3DJ.%2BC.%26aulast%3DWinters%26aufirst%3DM.%2BP.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLittrell%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DRady%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DP.%2BS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DLam%26aufirst%3DW.%2BW.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DLim%26aufirst%3DH.%2BK.%26aulast%3DWilde%26aufirst%3DT.%26aulast%3DSilva%26aufirst%3DJ.%26aulast%3DOtieno%26aufirst%3DM.%26aulast%3DPocai%26aufirst%3DA.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26atitle%3DDiscovery%2520of%2520a%2520GPR40%2520superagonist%253A%2520The%2520impact%2520of%2520aryl%2520propionic%2520acid%2520alpha-fluorination%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D16%26epage%3D21%26doi%3D10.1021%2Facsmedchemlett.8b00444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malashkevich, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, P. S.</span></span> <span> </span><span class="NLM_article-title">Structural characterization of the human respiratory syncytial virus fusion protein core</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">14172</span>– <span class="NLM_lpage">14177</span>, <span class="refDoi"> DOI: 10.1073/pnas.260499197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1073%2Fpnas.260499197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=11106388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVCguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=14172-14177&author=X.+Zhaoauthor=M.+Singhauthor=V.+N.+Malashkevichauthor=P.+S.+Kim&title=Structural+characterization+of+the+human+respiratory+syncytial+virus+fusion+protein+core&doi=10.1073%2Fpnas.260499197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Structural characterization of the human respiratory syncytial virus fusion protein core</span></div><div class="casAuthors">Zhao, Xun; Singh, Mona; Malashkevich, Vladimir N.; Kim, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">14172-14177</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Human respiratory syncytial virus (HRSV) is a major cause of a no. of severe respiratory diseases, including bronchiolitis and pneumonia, in infants and young children.  The HRSV F protein, a glycoprotein essential for viral entry, is a primary target for vaccine and drug development.  Two heptad-repeat regions within the HRSV F sequence were predicted by the computer program Learn-Coil-VMF.  These regions are thought to form trimer-of-hairpins-like structures, similar to those found in the fusion proteins of several enveloped viruses.  The hairpin structure likely brings the viral and cellular membranes into close apposition, thereby facilitating membrane fusion and subsequent viral entry.  Here, we show that peptides, denoted HR-N and HR-C, corresponding to the heptad-repeat regions from the N-terminal and C-terminal segments of the HRSV F protein, resp., form a stable α-helical trimer of heterodimers.  The HRSV N/C complex was crystd. and its x-ray structure was detd. at 2.3-Å resoln.  As anticipated, the complex is a six-helix bundle in which the HR-N peptides form a three-stranded, central coiled coil, and the HR-C peptides pack in an antiparallel manner into hydrophobic grooves on the coiled-coil surface.  There is remarkable structural similarity between the HRSV N/C complex and the fusion protein core of other viruses, including HIV-1 gp41.  In addn., earlier work has shown that HRSV HR-C peptides, like the HIV-1 gp41 C peptides, inhibit viral infection.  Thus, drug discovery and vaccine development strategies aimed at inhibiting viral entry by blocking hairpin formation may be applied to the inhibition of HRSV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKEUNin9nZSLVg90H21EOLACvtfcHk0liHXAOdZqXCrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVCguw%253D%253D&md5=9e4655323f6d5264a7e51913843e41eb</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1073%2Fpnas.260499197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.260499197%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DMalashkevich%26aufirst%3DV.%2BN.%26aulast%3DKim%26aufirst%3DP.%2BS.%26atitle%3DStructural%2520characterization%2520of%2520the%2520human%2520respiratory%2520syncytial%2520virus%2520fusion%2520protein%2520core%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2000%26volume%3D97%26spage%3D14172%26epage%3D14177%26doi%3D10.1073%2Fpnas.260499197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svabek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewah, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanjuan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patera, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolbeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, G. P.</span></span> <span> </span><span class="NLM_article-title">RAGE inhibits human respiratory syncytial virus syncytium formation by interfering with F-protein function</span>. <i>J. Gen. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">1691</span>– <span class="NLM_lpage">1700</span>, <span class="refDoi"> DOI: 10.1099/vir.0.049254-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1099%2Fvir.0.049254-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=23559480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht12gs7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2013&pages=1691-1700&author=J.+Tianauthor=K.+Huangauthor=S.+Krishnanauthor=C.+Svabekauthor=D.+C.+Roweauthor=Y.+Brewahauthor=M.+Sanjuanauthor=A.+C.+Pateraauthor=R.+Kolbeckauthor=R.+Herbstauthor=G.+P.+Sims&title=RAGE+inhibits+human+respiratory+syncytial+virus+syncytium+formation+by+interfering+with+F-protein+function&doi=10.1099%2Fvir.0.049254-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">RAGE inhibits human respiratory syncytial virus syncytium formation by interfering with F-protein function</span></div><div class="casAuthors">Tian, Jane; Huang, Kelly; Krishnan, Subramaniam; Svabek, Catherine; Rowe, Daniel C.; Brewah, Yambasu; Sanjuan, Miguel; Patera, Andriani C.; Kolbeck, Roland; Herbst, Ronald; Sims, Gary P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1691-1700</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    
            (<span class="NLM_cas:orgname">Society for General Microbiology</span>)
        </div><div class="casAbstract">Human respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infection.  Infection is critically dependent on the RSV fusion (F) protein, which mediates fusion between the viral envelope and airway epithelial cells.  The F protein is also expressed on infected cells and is responsible for fusion of infected cells with adjacent cells, giving multinucleate syncytia.  The receptor for advanced glycation end products (RAGE) is a pattern-recognition receptor that is constitutively highly expressed by type I alveolar epithelial cells.  Here, the authors report that RAGE protected HEK cells from RSV-induced cell death and reduced viral titers in vitro.  RAGE appeared to interact directly with the F protein, but, rather than inhibiting RSV entry into host cells, virus replication and budding, membrane-expressed RAGE or sol. RAGE blocked F-protein-mediated syncytium formation and sloughing.  RAGE may contribute to protecting the lower airways from RSV by inhibiting the formation of syncytia, viral spread, epithelial damage and airway obstruction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgLBX4XC_ZBbVg90H21EOLACvtfcHk0liHXAOdZqXCrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht12gs7zP&md5=df838540c1c9ccbe96b0db4a6e3aed72</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1099%2Fvir.0.049254-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fvir.0.049254-0%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DK.%26aulast%3DKrishnan%26aufirst%3DS.%26aulast%3DSvabek%26aufirst%3DC.%26aulast%3DRowe%26aufirst%3DD.%2BC.%26aulast%3DBrewah%26aufirst%3DY.%26aulast%3DSanjuan%26aufirst%3DM.%26aulast%3DPatera%26aufirst%3DA.%2BC.%26aulast%3DKolbeck%26aufirst%3DR.%26aulast%3DHerbst%26aufirst%3DR.%26aulast%3DSims%26aufirst%3DG.%2BP.%26atitle%3DRAGE%2520inhibits%2520human%2520respiratory%2520syncytial%2520virus%2520syncytium%2520formation%2520by%2520interfering%2520with%2520F-protein%2520function%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2013%26volume%3D94%26spage%3D1691%26epage%3D1700%26doi%3D10.1099%2Fvir.0.049254-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of benzoazepinequinoline (BAQ) derivatives as novel, potent, orally bioavailable respiratory syncytial virus fusion inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">10228</span>– <span class="NLM_lpage">10241</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01394</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01394" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOgu7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=10228-10241&author=X.+Zhengauthor=C.+Liangauthor=L.+Wangauthor=B.+Wangauthor=Y.+Liuauthor=S.+Fengauthor=J.+Z.+Wuauthor=L.+Gaoauthor=L.+Fengauthor=L.+Chenauthor=T.+Guoauthor=H.+C.+Shenauthor=H.+Yun&title=Discovery+of+benzoazepinequinoline+%28BAQ%29+derivatives+as+novel%2C+potent%2C+orally+bioavailable+respiratory+syncytial+virus+fusion+inhibitors&doi=10.1021%2Facs.jmedchem.8b01394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Benzoazepinequinoline (BAQ) Derivatives as Novel, Potent, Orally Bioavailable Respiratory Syncytial Virus Fusion Inhibitors</span></div><div class="casAuthors">Zheng, Xiufang; Liang, Chungen; Wang, Lisha; Wang, Baoxia; Liu, Yongfu; Feng, Song; Wu, Jim Zhen; Gao, Lu; Feng, Lichun; Chen, Li; Guo, Tao; Shen, Hong C.; Yun, Hongying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10228-10241</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel benzoazepinequnoline (BAQ) series was discovered as RSV fusion inhibitors.  BAQ series originated from a hit from similarity-based virtual screening.  In SAR exploration, benzoazepine allowed modifications in the head moiety.  Benzylic sulfonyl on benzoazepine and 6-Me on quinoline were crucial for good anti-RSV activity.  Although the basic amine in the head portion was crucial for anti-RSV activity, the attenuated basicity was required to reduce Vss.  Introducing oxetane to the head portion led to discovery of compd. I, which demonstrated single-digit nM anti-RSV activity against different RSV strains, reasonable oral exposure in plasma, and 78-fold higher exposure in lung.  Compd. I also displayed 1 log viral redn. in a female BALB/c mice RSV model by b.i.d. oral dosing at 12.5 mg/kg.  A single resistant mutant at L138F in fusion protein proved compd. I to be a RSV fusion inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppxigxpJ_FyLVg90H21EOLACvtfcHk0lijLZonvHvbRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOgu7%252FJ&md5=19190642aedb03d40eb530140530ffaf</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01394%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DJ.%2BZ.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DYun%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520benzoazepinequinoline%2520%2528BAQ%2529%2520derivatives%2520as%2520novel%252C%2520potent%252C%2520orally%2520bioavailable%2520respiratory%2520syncytial%2520virus%2520fusion%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D10228%26epage%3D10241%26doi%3D10.1021%2Facs.jmedchem.8b01394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rothschild, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaniel, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringel-Scaia, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, I. C.</span></span> <span> </span><span class="NLM_article-title">Modulating inflammation through the negative regulation of NF-κB signaling</span>. <i>J. Leukocyte Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1131</span>– <span class="NLM_lpage">1150</span>, <span class="refDoi"> DOI: 10.1002/JLB.3MIR0817-346RRR</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2FJLB.3MIR0817-346RRR" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlaltr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2018&pages=1131-1150&author=D.+E.+Rothschildauthor=D.+K.+McDanielauthor=V.+M.+Ringel-Scaiaauthor=I.+C.+Allen&title=Modulating+inflammation+through+the+negative+regulation+of+NF-%CE%BAB+signaling&doi=10.1002%2FJLB.3MIR0817-346RRR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Modulating inflammation through the negative regulation of NF-κB signaling</span></div><div class="casAuthors">Rothschild, Daniel E.; McDaniel, Dylan K.; Ringel-Scaia, Veronica M.; Allen, Irving C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1131-1150</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">1938-3673</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Immune system activation is essential to thwart the invasion of pathogens and respond appropriately to tissue damage.  However, uncontrolled inflammation can result in extensive collateral damage underlying a diverse range of auto-inflammatory, hyper-inflammatory, and neoplastic diseases.  The NF-κB signaling pathway lies at the heart of the immune system and functions as a master regulator of gene transcription.  Thus, this signaling cascade is heavily targeted by mechanisms designed to attenuate overzealous inflammation and promote resoln.  Mechanisms assocd. with the neg. regulation of NF-κB signaling are currently under intense investigation and have yet to be fully elucidated.  Here, we provide an overview of mechanisms that neg. regulate NF-κB signaling through either attenuation of signal transduction, inhibition of posttranscriptional signaling, or interference with posttranslational modifications of key pathway components.  While the regulators discussed for each group are far from comprehensive, they exemplify common mechanistic approaches that inhibit this crit. biochem. signaling cascade.  Despite their diversity, a commonality among these regulators is their selection of specific targets at key inflection points in the pathway, such as TNF-receptor-assocd. factor family members or essential kinases.  A better understanding of these neg. regulatory mechanisms will be essential to gain greater insight related to the maintenance of immune system homeostasis and inflammation resoln.  These processes are vital elements of disease pathol. and have important implications for targeted therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAg41CDsjMGrVg90H21EOLACvtfcHk0lijLZonvHvbRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlaltr7E&md5=a9f54694e4b65078255cfac5b7123781</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1002%2FJLB.3MIR0817-346RRR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252FJLB.3MIR0817-346RRR%26sid%3Dliteratum%253Aachs%26aulast%3DRothschild%26aufirst%3DD.%2BE.%26aulast%3DMcDaniel%26aufirst%3DD.%2BK.%26aulast%3DRingel-Scaia%26aufirst%3DV.%2BM.%26aulast%3DAllen%26aufirst%3DI.%2BC.%26atitle%3DModulating%2520inflammation%2520through%2520the%2520negative%2520regulation%2520of%2520NF-%25CE%25BAB%2520signaling%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2018%26volume%3D103%26spage%3D1131%26epage%3D1150%26doi%3D10.1002%2FJLB.3MIR0817-346RRR" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busch-Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muratore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullion, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakdawala, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cousins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Field, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborn, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonchuk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rumsey, W. L.</span></span> <span> </span><span class="NLM_article-title">3,5-Disubstituted-indole-7-carboxamides as IKKbeta inhibitors: Optimization of oral activity via the C3 substituent</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1164</span>– <span class="NLM_lpage">1169</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00291</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00291" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVCisbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1164-1169&author=J.+K.+Kernsauthor=J.+Busch-Petersenauthor=W.+Fuauthor=J.+C.+Boehmauthor=H.+Nieauthor=M.+Muratoreauthor=A.+Bullionauthor=G.+Linauthor=H.+Liauthor=R.+Davisauthor=X.+Linauthor=A.+S.+Lakdawalaauthor=R.+Cousinsauthor=R.+Fieldauthor=J.+Payneauthor=D.+D.+Millerauthor=P.+Bamboroughauthor=J.+A.+Christopherauthor=I.+Baldwinauthor=R.+R.+Osbornauthor=J.+Yonchukauthor=E.+Webbauthor=W.+L.+Rumsey&title=3%2C5-Disubstituted-indole-7-carboxamides+as+IKKbeta+inhibitors%3A+Optimization+of+oral+activity+via+the+C3+substituent&doi=10.1021%2Facsmedchemlett.8b00291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">3,5-Disubstituted-indole-7-carboxamides as IKKβ Inhibitors: Optimization of Oral Activity via the C3 Substituent</span></div><div class="casAuthors">Kerns, Jeffrey K.; Busch-Petersen, Jakob; Fu, Wei; Boehm, Jeffrey C.; Nie, Hong; Muratore, Michael; Bullion, Ann; Lin, Guoliang; Li, Huijie; Davis, Roderick; Lin, Xichen; Lakdawala, Ami S.; Cousins, Rick; Field, Rita; Payne, Jeremy; Miller, David D.; Bamborough, Paul; Christopher, John A.; Baldwin, Ian; Osborn, Ruth R.; Yonchuk, John; Webb, Edward; Rumsey, William L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1164-1169</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">IκB kinase β (IKKβ or IKK2) is a key regulator of nuclear factor kappa B (NF-κB) and has received attention as a therapeutic target.  Herein the authors report on the optimization of a series of 3,5-disubstituted-indole-7-carboxamides for oral activity.  In doing so, the authors focused attention on potency, ligand efficiency (LE), and physicochem. properties and have identified compds. I and II as having robust in vivo activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHiHQpGSkcarVg90H21EOLACvtfcHk0lijLZonvHvbRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVCisbzF&md5=65b74893bd7ec4766dad7447f9b3dfda</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00291%26sid%3Dliteratum%253Aachs%26aulast%3DKerns%26aufirst%3DJ.%2BK.%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DBoehm%26aufirst%3DJ.%2BC.%26aulast%3DNie%26aufirst%3DH.%26aulast%3DMuratore%26aufirst%3DM.%26aulast%3DBullion%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DLakdawala%26aufirst%3DA.%2BS.%26aulast%3DCousins%26aufirst%3DR.%26aulast%3DField%26aufirst%3DR.%26aulast%3DPayne%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DChristopher%26aufirst%3DJ.%2BA.%26aulast%3DBaldwin%26aufirst%3DI.%26aulast%3DOsborn%26aufirst%3DR.%2BR.%26aulast%3DYonchuk%26aufirst%3DJ.%26aulast%3DWebb%26aufirst%3DE.%26aulast%3DRumsey%26aufirst%3DW.%2BL.%26atitle%3D3%252C5-Disubstituted-indole-7-carboxamides%2520as%2520IKKbeta%2520inhibitors%253A%2520Optimization%2520of%2520oral%2520activity%2520via%2520the%2520C3%2520substituent%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D1164%26epage%3D1169%26doi%3D10.1021%2Facsmedchemlett.8b00291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samatar, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">Targeting RAS-ERK signalling in cancer: promises and challenges</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">928</span>– <span class="NLM_lpage">942</span>, <span class="refDoi"> DOI: 10.1038/nrd4281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2Fnrd4281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=25435214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2lsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=928-942&author=A.+A.+Samatarauthor=P.+I.+Poulikakos&title=Targeting+RAS-ERK+signalling+in+cancer%3A+promises+and+challenges&doi=10.1038%2Fnrd4281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAS-ERK signalling in cancer: promises and challenges</span></div><div class="casAuthors">Samatar, Ahmed A.; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">928-942</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumors, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes.  Recently, the use of compds. targeting components of ERK signalling, such as RAF or MEK inhibitors, has led to substantial improvement in clin. outcome in metastatic melanoma and has shown promising clin. activity in addnl. tumor types.  However, response rates are highly variable and the efficacy of these drugs is primarily limited by the development of resistance.  Both intrinsic and acquired resistance to RAF and MEK inhibitors are frequently assocd. with the persistence of ERK signalling in the presence of the drug, implying the need for more innovative approaches to target the pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL4UeXNUJnYbVg90H21EOLACvtfcHk0ljBc2qwBQW2Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2lsrrI&md5=ab4038893612f438cf4406680ab2e4f4</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1038%2Fnrd4281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4281%26sid%3Dliteratum%253Aachs%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DTargeting%2520RAS-ERK%2520signalling%2520in%2520cancer%253A%2520promises%2520and%2520challenges%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D928%26epage%3D942%26doi%3D10.1038%2Fnrd4281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Restaino, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayananth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinunzio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windsor, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angagaw, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinheiro, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipps, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paliwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daublain, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutterbach, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philippar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siliphaivanh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschmeier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicklin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samatar, A. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1158%2F2159-8290.CD-13-0070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=23614898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=742-750&author=E.+J.+Morrisauthor=S.+Jhaauthor=C.+R.+Restainoauthor=P.+Dayananthauthor=H.+Zhuauthor=A.+Cooperauthor=D.+Carrauthor=Y.+Dengauthor=W.+Jinauthor=S.+Blackauthor=B.+Longauthor=J.+Liuauthor=E.+Dinunzioauthor=W.+Windsorauthor=R.+Zhangauthor=S.+Zhaoauthor=M.+H.+Angagawauthor=E.+M.+Pinheiroauthor=J.+Desaiauthor=L.+Xiaoauthor=G.+Shippsauthor=A.+Hruzaauthor=J.+Wangauthor=J.+Kellyauthor=S.+Paliwalauthor=X.+Gaoauthor=B.+S.+Babuauthor=L.+Zhuauthor=P.+Daublainauthor=L.+Zhangauthor=B.+A.+Lutterbachauthor=M.+R.+Pelletierauthor=U.+Philipparauthor=P.+Siliphaivanhauthor=D.+Witterauthor=P.+Kirschmeierauthor=W.+R.+Bishopauthor=D.+Hicklinauthor=D.+G.+Gillilandauthor=L.+Jayaramanauthor=L.+Zawelauthor=S.+Fawellauthor=A.+A.+Samatar&title=Discovery+of+a+novel+ERK+inhibitor+with+activity+in+models+of+acquired+resistance+to+BRAF+and+MEK+inhibitors&doi=10.1158%2F2159-8290.CD-13-0070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors</span></div><div class="casAuthors">Morris, Erick J.; Jha, Sharda; Restaino, Clifford R.; Dayananth, Priya; Zhu, Hugh; Cooper, Alan; Carr, Donna; Deng, Yongi; Jin, Weihong; Black, Stuart; Long, Brian; Liu, Jenny; DiNunzio, Edward; Windsor, William; Zhang, Rumin; Zhao, Shuxia; Angagaw, Minilik H.; Pinheiro, Elaine M.; Desai, Jagdish; Xiao, Li; Shipps, Gerald; Hruza, Alan; Wang, James; Kelly, Joe; Paliwal, Sunil; Gao, Xiaolei; Babu, Boga Sobhana; Zhu, Liang; Daublain, Pierre; Zhang, Ling; Lutterbach, Bart A.; Pelletier, Marc R.; Philippar, Ulrike; Siliphaivanh, Phieng; Witter, David; Kirschmeier, Paul; Bishop, W. Robert; Hicklin, Daniel; Gilliland, D. Gary; Jayaraman, Lata; Zawel, Leigh; Fawell, Stephen; Samatar, Ahmed A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">742-750</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The high frequency of activating RAS or BRAF mutations in cancer provides strong rationale for targeting the mitogen-activated protein kinase (MAPK) pathway.  Selective BRAF and MAP-ERK kinase (MEK) inhibitors have shown clin. efficacy in patients with melanoma.  However, the majority of responses are transient, and resistance is often assocd. with pathway reactivation of the extracellular signal-regulated kinase (ERK) signaling pathway.  Here, we describe the identification and characterization of SCH772984, a novel and selective inhibitor of ERK1/2 that displays behaviors of both type I and type II kinase inhibitors.  SCH772984 has nanomolar cellular potency in tumor cells with mutations in BRAF, NRA5, or KRAS and induces tumor regressions in xenograft models at tolerated doses.  Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in BRAF or MEK inhibitor-resistant models as well as in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors.  These data support the clin. development of ERK inhibitors for tumors refractory to MAPK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4HJ4HhYmLL7Vg90H21EOLACvtfcHk0ljBc2qwBQW2Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE&md5=1f26a4a5bb1fab64bdd6c38c16b3f4e3</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0070%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DE.%2BJ.%26aulast%3DJha%26aufirst%3DS.%26aulast%3DRestaino%26aufirst%3DC.%2BR.%26aulast%3DDayananth%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DW.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDinunzio%26aufirst%3DE.%26aulast%3DWindsor%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DAngagaw%26aufirst%3DM.%2BH.%26aulast%3DPinheiro%26aufirst%3DE.%2BM.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DShipps%26aufirst%3DG.%26aulast%3DHruza%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DBabu%26aufirst%3DB.%2BS.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDaublain%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLutterbach%26aufirst%3DB.%2BA.%26aulast%3DPelletier%26aufirst%3DM.%2BR.%26aulast%3DPhilippar%26aufirst%3DU.%26aulast%3DSiliphaivanh%26aufirst%3DP.%26aulast%3DWitter%26aufirst%3DD.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DBishop%26aufirst%3DW.%2BR.%26aulast%3DHicklin%26aufirst%3DD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DJayaraman%26aufirst%3DL.%26aulast%3DZawel%26aufirst%3DL.%26aulast%3DFawell%26aufirst%3DS.%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520ERK%2520inhibitor%2520with%2520activity%2520in%2520models%2520of%2520acquired%2520resistance%2520to%2520BRAF%2520and%2520MEK%2520inhibitors%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D742%26epage%3D750%26doi%3D10.1158%2F2159-8290.CD-13-0070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boga, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipps, G. W.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doll, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paliwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhassan, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muppalla, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudipati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buevich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayananth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherborne, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruza, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschmeier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windsor, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samatar, A. A.</span></span> <span> </span><span class="NLM_article-title">MK-8353: Discovery of an orally bioavailable dual mechanism ERK inhibitor for oncology</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">767</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00220</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00220" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFenur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=761-767&author=S.+B.+Bogaauthor=Y.+Dengauthor=L.+Zhuauthor=Y.+Nanauthor=A.+B.+Cooperauthor=G.+W.+Shippsauthor=R.+Dollauthor=N.+Y.+Shihauthor=H.+Zhuauthor=R.+Sunauthor=T.+Wangauthor=S.+Paliwalauthor=H.+C.+Tsuiauthor=X.+Gaoauthor=X.+Yaoauthor=J.+Desaiauthor=J.+Wangauthor=A.+B.+Alhassanauthor=J.+Kellyauthor=M.+Patelauthor=K.+Muppallaauthor=S.+Gudipatiauthor=L.+K.+Zhangauthor=A.+Buevichauthor=D.+Heskauthor=D.+Carrauthor=P.+Dayananthauthor=S.+Blackauthor=H.+Meiauthor=K.+Coxauthor=B.+Sherborneauthor=A.+W.+Hruzaauthor=L.+Xiaoauthor=W.+Jinauthor=B.+Longauthor=G.+Liuauthor=S.+A.+Taylorauthor=P.+Kirschmeierauthor=W.+T.+Windsorauthor=R.+Bishopauthor=A.+A.+Samatar&title=MK-8353%3A+Discovery+of+an+orally+bioavailable+dual+mechanism+ERK+inhibitor+for+oncology&doi=10.1021%2Facsmedchemlett.8b00220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology</span></div><div class="casAuthors">Boga, Sobhana Babu; Deng, Yongqi; Zhu, Liang; Nan, Yang; Cooper, Alan B.; Shipps, Gerald W.; Doll, Ronald; Shih, Neng-Yang; Zhu, Hugh; Sun, Robert; Wang, Tong; Paliwal, Sunil; Tsui, Hon-Chung; Gao, Xiaolei; Yao, Xin; Desai, Jagdish; Wang, James; Alhassan, Abdul Basit; Kelly, Joseph; Patel, Mehul; Muppalla, Kiran; Gudipati, Subrahmanyam; Zhang, Li-Kang; Buevich, Alexei; Hesk, David; Carr, Donna; Dayananth, Priya; Black, Stuart; Mei, Hong; Cox, Kathleen; Sherborne, Bradley; Hruza, Alan W.; Xiao, Li; Jin, Weihong; Long, Brian; Liu, Gongjie; Taylor, Stacey A.; Kirschmeier, Paul; Windsor, William T.; Bishop, Robert; Samatar, Ahmed A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">761-767</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The emergence and evolution of new immunol. cancer therapies has sparked a rapidly growing interest in discovering novel pathways to treat cancer.  Toward this aim, a novel series of pyrrolidine derivs. were identified as potent inhibitors of ERK1/2 with excellent kinase selectivity and dual mechanism of action but suffered from poor pharmacokinetics (PK).  The challenge of PK was overcome by the discovery of a novel 3(S)-thiomethyl pyrrolidine analog.  Lead optimization through focused SAR led to the discovery of a clin. candidate MK-8353 suitable for twice daily oral dosing as a potential new cancer therapeutic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzQqYMfaHvG7Vg90H21EOLACvtfcHk0ljxd_OqiT-yjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFenur7M&md5=60d002186bc44c1fc6f0eff8658e0163</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00220%26sid%3Dliteratum%253Aachs%26aulast%3DBoga%26aufirst%3DS.%2BB.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DNan%26aufirst%3DY.%26aulast%3DCooper%26aufirst%3DA.%2BB.%26aulast%3DShipps%26aufirst%3DG.%2BW.%26aulast%3DDoll%26aufirst%3DR.%26aulast%3DShih%26aufirst%3DN.%2BY.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DTsui%26aufirst%3DH.%2BC.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DX.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAlhassan%26aufirst%3DA.%2BB.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DMuppalla%26aufirst%3DK.%26aulast%3DGudipati%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%2BK.%26aulast%3DBuevich%26aufirst%3DA.%26aulast%3DHesk%26aufirst%3DD.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DDayananth%26aufirst%3DP.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DSherborne%26aufirst%3DB.%26aulast%3DHruza%26aufirst%3DA.%2BW.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DJin%26aufirst%3DW.%26aulast%3DLong%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DTaylor%26aufirst%3DS.%2BA.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DWindsor%26aufirst%3DW.%2BT.%26aulast%3DBishop%26aufirst%3DR.%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26atitle%3DMK-8353%253A%2520Discovery%2520of%2520an%2520orally%2520bioavailable%2520dual%2520mechanism%2520ERK%2520inhibitor%2520for%2520oncology%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D761%26epage%3D767%26doi%3D10.1021%2Facsmedchemlett.8b00220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez, F.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastwood, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herberich, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laszlo, J.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipford, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winston, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasker, A. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of (<i>R</i>)-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4- b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4 (3<i>H</i>)-one, a potent and selective Pim-1/2 kinase inhibitor for hematological malignancies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1523</span>– <span class="NLM_lpage">1540</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01733</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01733" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnslSksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1523-1540&author=H.+L.+Wangauthor=K.+L.+Andrewsauthor=S.+K.+Bookerauthor=J.+Canonauthor=V.+J.+Ceeauthor=F.+Chavezauthor=Y.+Chenauthor=H.+Eastwoodauthor=N.+Guerreroauthor=B.+Herberichauthor=D.+Hickmanauthor=B.+A.+Lanmanauthor=J.+Laszloauthor=M.+R.+Leeauthor=J.+R.+Lipfordauthor=B.+Mattsonauthor=C.+Mohrauthor=Y.+Nguyenauthor=M.+H.+Normanauthor=L.+H.+Pettusauthor=D.+Powersauthor=A.+B.+Reedauthor=K.+Rexauthor=C.+Sastriauthor=N.+Tamayoauthor=P.+Wangauthor=J.+T.+Winstonauthor=B.+Wuauthor=Q.+Wuauthor=T.+Wuauthor=R.+P.+Wurzauthor=Y.+Xuauthor=Y.+Zhouauthor=A.+S.+Tasker&title=Discovery+of+%28R%29-8-%286-methyl-4-oxo-1%2C4%2C5%2C6-tetrahydropyrrolo%5B3%2C4-+b%5Dpyrrol-2-yl%29-3-%281-methylcyclopropyl%29-2-%28%281-methylcyclopropyl%29amino%29quinazolin-4+%283H%29-one%2C+a+potent+and+selective+Pim-1%2F2+kinase+inhibitor+for+hematological+malignancies&doi=10.1021%2Facs.jmedchem.8b01733"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (R)-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3H)-one, a potent and selective Pim-1/2 kinase inhibitor for hematological malignancies</span></div><div class="casAuthors">Wang, Hui-Ling; Andrews, Kristin L.; Booker, Shon K.; Canon, Jude; Cee, Victor J.; Chavez, Frank, Jr.; Chen, Yuping; Eastwood, Heather; Guerrero, Nadia; Herberich, Brad; Hickman, Dean; Lanman, Brian A.; Laszlo, Jimmy, III; Lee, Matthew R.; Lipford, J. Russell; Mattson, Bethany; Mohr, Christopher; Nguyen, Yen; Norman, Mark H.; Pettus, Liping H.; Powers, David; Reed, Anthony B.; Rex, Karen; Sastri, Christine; Tamayo, Nuria; Wang, Paul; Winston, Jeffrey T.; Wu, Bin; Wu, Qiong; Wu, Tian; Wurz, Ryan P.; Xu, Yang; Zhou, Yihong; Tasker, Andrew S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1523-1540</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pim kinases are a family of constitutively active serine/threonine kinases that are partially redundant and regulate multiple pathways important for cell growth and survival.  In human disease, high expression of the three Pim isoforms has been implicated in the progression of hematopoietic and solid tumor cancers, which suggests that Pim kinase inhibitors could provide patients with therapeutic benefit.  Herein, we describe the structure-guided optimization of a series of quinazolinone-pyrrolodihydropyrrolone analogs leading to the identification of potent pan-Pim inhibitor I with improved potency, soly., and drug-like properties.  I demonstrated on-target Pim activity in an in vivo pharmacodynamic assay with significant inhibition of BAD phosphorylation in KMS-12-BM multiple myeloma tumors for 16 h postdose.  In a 2-wk mouse xenograft model, daily dosing of I resulted in 33% tumor regression at 100 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz60Rl1mRubrVg90H21EOLACvtfcHk0ljxd_OqiT-yjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnslSksw%253D%253D&md5=a7d7dbe1f106b6f5cf8c81bb5660cb3f</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01733%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%2BL.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DCanon%26aufirst%3DJ.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DChavez%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DEastwood%26aufirst%3DH.%26aulast%3DGuerrero%26aufirst%3DN.%26aulast%3DHerberich%26aufirst%3DB.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DLaszlo%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DLipford%26aufirst%3DJ.%2BR.%26aulast%3DMattson%26aufirst%3DB.%26aulast%3DMohr%26aufirst%3DC.%26aulast%3DNguyen%26aufirst%3DY.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DPowers%26aufirst%3DD.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSastri%26aufirst%3DC.%26aulast%3DTamayo%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWinston%26aufirst%3DJ.%2BT.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26atitle%3DDiscovery%2520of%2520%2528R%2529-8-%25286-methyl-4-oxo-1%252C4%252C5%252C6-tetrahydropyrrolo%255B3%252C4-%2520b%255Dpyrrol-2-yl%2529-3-%25281-methylcyclopropyl%2529-2-%2528%25281-methylcyclopropyl%2529amino%2529quinazolin-4%2520%25283H%2529-one%252C%2520a%2520potent%2520and%2520selective%2520Pim-1%252F2%2520kinase%2520inhibitor%2520for%2520hematological%2520malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1523%26epage%3D1540%26doi%3D10.1021%2Facs.jmedchem.8b01733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Penning, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinghofer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donawho, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bontcheva-Diaz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouska, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osterling, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giranda, V. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(<i>R</i>)-2-methylpyrrolidin-2-yl]-1<i>H</i>-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">514</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.1021/jm801171j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801171j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFals7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=514-523&author=T.+D.+Penningauthor=G.+D.+Zhuauthor=V.+B.+Gandhiauthor=J.+Gongauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=C.+K.+Donawhoauthor=D.+J.+Frostauthor=V.+Bontcheva-Diazauthor=J.+J.+Bouskaauthor=D.+J.+Osterlingauthor=A.+M.+Olsonauthor=K.+C.+Marshauthor=Y.+Luoauthor=V.+L.+Giranda&title=Discovery+of+the+poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+2-%5B%28R%29-2-methylpyrrolidin-2-yl%5D-1H-benzimidazole-4-carboxamide+%28ABT-888%29+for+the+treatment+of+cancer&doi=10.1021%2Fjm801171j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer</span></div><div class="casAuthors">Penning, Thomas D.; Zhu, Gui-Dong; Gandhi, Viraj B.; Gong, Jianchun; Liu, Xuesong; Shi, Yan; Klinghofer, Vered; Johnson, Eric F.; Donawho, Cherrie K.; Frost, David J.; Bontcheva-Diaz, Velitchka; Bouska, Jennifer J.; Osterling, Donald J.; Olson, Amanda M.; Marsh, Kennan C.; Luo, Yan; Giranda, Vincent L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">514-523</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of cyclic amine-contg. benzimidazole carboxamide PARP inhibitors with a methyl-substituted quaternary center at the point of attachment to the benzimidazole ring system has been developed.  These compds. exhibit excellent PARP enzyme potency as well as single-digit nanomolar cellular potency.  These efforts led to the identification of (I)·2HCl (2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, ABT-888), currently in human phase I clin. trials.  Compd. I·2HCl displayed excellent potency against both the PARP-1 and PARP-2 enzymes with a Ki of 5 nM and in a C41 whole cell assay with an EC50 of 2 nM.  In addn., I·2HCl is aq. sol., orally bioavailable across multiple species, and demonstrated good in vivo efficacy in a B16F10 s.c. murine melanoma model in combination with temozolomide (TMZ) and in an MX-1 breast cancer xenograft model in combination with either carboplatin or cyclophosphamide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaBVnNi7EZcbVg90H21EOLACvtfcHk0ljPT1egPq231A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFals7bL&md5=283eddd2e8220740c48865e4e8269a95</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Fjm801171j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801171j%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DDiscovery%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%25202-%255B%2528R%2529-2-methylpyrrolidin-2-yl%255D-1H-benzimidazole-4-carboxamide%2520%2528ABT-888%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D514%26epage%3D523%26doi%3D10.1021%2Fjm801171j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munck
Af Rosenschold, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johannesson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikitidis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrchan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikitidis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glader, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorkstrand, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swedin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreasson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergstrom, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundqvist, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, A. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of the oral leukotriene C4 synthase inhibitor (1S,2S)-2-({5-[(5-chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic acid (AZD9898) as a new treatment for asthma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7769</span>– <span class="NLM_lpage">7787</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00555</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00555" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A280%3ADC%252BB3Mvot1ehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7769-7787&author=M.+Munck%0AAf+Rosenscholdauthor=P.+Johannessonauthor=A.+Nikitidisauthor=C.+Tyrchanauthor=H.+F.+Changauthor=R.+Ronnauthor=D.+Chapmanauthor=V.+Ullahauthor=G.+Nikitidisauthor=P.+Gladerauthor=H.+Kackauthor=B.+Bonnauthor=F.+Wagbergauthor=E.+Bjorkstrandauthor=U.+Anderssonauthor=L.+Swedinauthor=M.+Rohmanauthor=T.+Andreassonauthor=E.+L.+Bergstromauthor=F.+Jiangauthor=X.+H.+Zhouauthor=A.+J.+Lundqvistauthor=A.+Malmbergauthor=M.+Ekauthor=E.+Gordonauthor=A.+Pettersenauthor=L.+Ripaauthor=A.+M.+Davis&title=Discovery+of+the+oral+leukotriene+C4+synthase+inhibitor+%281S%2C2S%29-2-%28%7B5-%5B%285-chloro-2%2C4-difluorophenyl%29%282-fluoro-2-methylpropyl%29amino%5D-3-methoxypyrazin-2-yl%7Dcarbonyl%29cyclopropanecarboxylic+acid+%28AZD9898%29+as+a+new+treatment+for+asthma&doi=10.1021%2Facs.jmedchem.9b00555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic Acid (AZD9898) as a New Treatment for Asthma</span></div><div class="casAuthors">Munck Af Rosenschold Magnus; Johannesson Petra; Nikitidis Antonios; Tyrchan Christian; Chang Hui-Fang; Chapman Dave; Ullah Victoria; Nikitidis Grigorios; Glader Pernilla; Kack Helena; Bonn Britta; Wagberg Fredrik; Andersson Ulf; Swedin Linda; Rohman Mattias; Andreasson Theresa; Bergstrom Eva Lamm; Jiang Fanyi; Zhou Xiao-Hong; Lundqvist Anders J; Malmberg Anna; Ek Margareta; Gordon Euan; Pettersen Anna; Ripa Lena; Davis Andrew M; Ronn Robert; Bjorkstrand Eva</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7769-7787</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">While bronchodilators and inhaled corticosteroids are the mainstay of asthma treatment, up to 50% of asthmatics remain uncontrolled.  Many studies show that the cysteinyl leukotriene cascade remains highly activated in some asthmatics, even those on high-dose inhaled or oral corticosteroids.  Hence, inhibition of the leukotriene C4 synthase (LTC4S) enzyme could provide a new and differentiated core treatment for patients with a highly activated cysteinyl leukotriene cascade.  Starting from a screening hit (3), a program to discover oral inhibitors of LTC4S led to (1S,2S)-2-({5-[(5-chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic acid (AZD9898) (36), a picomolar LTC4S inhibitor (IC50 = 0.28 nM) with high lipophilic ligand efficiency (LLE = 8.5), which displays nanomolar potency in cells (peripheral blood mononuclear cell, IC50,free = 6.2 nM) and good in vivo pharmacodynamics in a calcium ionophore-stimulated rat model after oral dosing (in vivo, IC50,free = 34 nM).  Compound 36 mitigates the GABA binding, hepatic toxicity signal, and in vivo toxicology findings of an early lead compound 7 with a human dose predicted to be 30 mg once daily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQUEHXJSfcFdwwxfk_AGB-EfW6udTcc2ebt4bBfC6z1krntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mvot1ehug%253D%253D&md5=cb13c3632bd4d56be5dd6acdc3638f8f</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00555%26sid%3Dliteratum%253Aachs%26aulast%3DMunck%2BAf%2BRosenschold%26aufirst%3DM.%26aulast%3DJohannesson%26aufirst%3DP.%26aulast%3DNikitidis%26aufirst%3DA.%26aulast%3DTyrchan%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DH.%2BF.%26aulast%3DRonn%26aufirst%3DR.%26aulast%3DChapman%26aufirst%3DD.%26aulast%3DUllah%26aufirst%3DV.%26aulast%3DNikitidis%26aufirst%3DG.%26aulast%3DGlader%26aufirst%3DP.%26aulast%3DKack%26aufirst%3DH.%26aulast%3DBonn%26aufirst%3DB.%26aulast%3DWagberg%26aufirst%3DF.%26aulast%3DBjorkstrand%26aufirst%3DE.%26aulast%3DAndersson%26aufirst%3DU.%26aulast%3DSwedin%26aufirst%3DL.%26aulast%3DRohman%26aufirst%3DM.%26aulast%3DAndreasson%26aufirst%3DT.%26aulast%3DBergstrom%26aufirst%3DE.%2BL.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DX.%2BH.%26aulast%3DLundqvist%26aufirst%3DA.%2BJ.%26aulast%3DMalmberg%26aufirst%3DA.%26aulast%3DEk%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DE.%26aulast%3DPettersen%26aufirst%3DA.%26aulast%3DRipa%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DA.%2BM.%26atitle%3DDiscovery%2520of%2520the%2520oral%2520leukotriene%2520C4%2520synthase%2520inhibitor%2520%25281S%252C2S%2529-2-%2528%257B5-%255B%25285-chloro-2%252C4-difluorophenyl%2529%25282-fluoro-2-methylpropyl%2529amino%255D-3-methoxypyrazin-2-yl%257Dcarbonyl%2529cyclopropanecarboxylic%2520acid%2520%2528AZD9898%2529%2520as%2520a%2520new%2520treatment%2520for%2520asthma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7769%26epage%3D7787%26doi%3D10.1021%2Facs.jmedchem.9b00555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5822</span>– <span class="NLM_lpage">5880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5822-5880&author=N.+A.+Meanwell&title=Fluorine+and+fluorinated+motifs+in+the+design+and+application+of+bioisosteres+for+drug+design&doi=10.1021%2Facs.jmedchem.7b01788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5822-5880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The electronic properties and relatively small size of fluorine endow it with considerable versatility as a bioisostere and it has found application as a substitute for lone pairs of electrons, the hydrogen atom, and the Me group while also acting as a functional mimetic of the carbonyl, carbinol, andnitrile moieties.  In this context, fluorine substitution can influence the potency, conformation, metab., membrane permeability, and P-gp recognition of a mol. and temper inhibition of the hERG channel by basic amines.  However, as a consequence of the unique properties of fluorine, it features prominently in the design of higher order structural metaphors that are more esoteric in their conception and which reflect a more sophisticated mol. construction that broadens biol. mimesis.  In this Perspective, applications of fluorine in the construction of bioisosteric elements designed to enhance the in vitro and in vivo properties of a mol. are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoQvY950L3LVg90H21EOLACvtfcHk0ljM9fPex3pZ5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D&md5=2d0ce3326c7ff932da8d7d26972ced14</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01788%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DFluorine%2520and%2520fluorinated%2520motifs%2520in%2520the%2520design%2520and%2520application%2520of%2520bioisosteres%2520for%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5822%26epage%3D5880%26doi%3D10.1021%2Facs.jmedchem.7b01788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinkerton, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peddibhotla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slosky, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hershberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falter, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardecky, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, T. D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barak, L. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of beta-arrestin biased, orally bioavailable, and CNS penetrant neurotensin receptor 1 (NTR1) allosteric modulators</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8357</span>– <span class="NLM_lpage">8363</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00340</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00340" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFemtLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8357-8363&author=A.+B.+Pinkertonauthor=S.+Peddibhotlaauthor=F.+Yamamotoauthor=L.+M.+Sloskyauthor=Y.+Baiauthor=P.+Maloneyauthor=P.+Hershbergerauthor=M.+P.+Hedrickauthor=B.+Falterauthor=R.+J.+Ardeckyauthor=L.+H.+Smithauthor=T.+D.+Y.+Chungauthor=M.+R.+Jacksonauthor=M.+G.+Caronauthor=L.+S.+Barak&title=Discovery+of+beta-arrestin+biased%2C+orally+bioavailable%2C+and+CNS+penetrant+neurotensin+receptor+1+%28NTR1%29+allosteric+modulators&doi=10.1021%2Facs.jmedchem.9b00340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators</span></div><div class="casAuthors">Pinkerton, Anthony B.; Peddibhotla, Satyamaheshwar; Yamamoto, Fusayo; Slosky, Lauren M.; Bai, Yushi; Maloney, Patrick; Hershberger, Paul; Hedrick, Michael P.; Falter, Bekhi; Ardecky, Robert J.; Smith, Layton H.; Chung, Thomas D. Y.; Jackson, Michael R.; Caron, Marc G.; Barak, Lawrence S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8357-8363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Neurotensin receptor 1 (NTR1) is a G protein coupled receptor that is widely expressed throughout the central nervous system where it acts as a neuromodulator.  Neurotensin receptors have been implicated in a wide variety of CNS disorders but despite extensive efforts to develop small mol. ligands there are few reports of such compds.  Herein we describe the optimization of a quinazoline based lead to give 18 (SBI-553(I)), a potent and brain penetrant NTR1 allosteric modulator.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomN2_a2gmsHLVg90H21EOLACvtfcHk0ljM9fPex3pZ5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFemtLfM&md5=aa466e6b4be397a8712d3b5ecf28457b</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00340%26sid%3Dliteratum%253Aachs%26aulast%3DPinkerton%26aufirst%3DA.%2BB.%26aulast%3DPeddibhotla%26aufirst%3DS.%26aulast%3DYamamoto%26aufirst%3DF.%26aulast%3DSlosky%26aufirst%3DL.%2BM.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DMaloney%26aufirst%3DP.%26aulast%3DHershberger%26aufirst%3DP.%26aulast%3DHedrick%26aufirst%3DM.%2BP.%26aulast%3DFalter%26aufirst%3DB.%26aulast%3DArdecky%26aufirst%3DR.%2BJ.%26aulast%3DSmith%26aufirst%3DL.%2BH.%26aulast%3DChung%26aufirst%3DT.%2BD.%2BY.%26aulast%3DJackson%26aufirst%3DM.%2BR.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DBarak%26aufirst%3DL.%2BS.%26atitle%3DDiscovery%2520of%2520beta-arrestin%2520biased%252C%2520orally%2520bioavailable%252C%2520and%2520CNS%2520penetrant%2520neurotensin%2520receptor%25201%2520%2528NTR1%2529%2520allosteric%2520modulators%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8357%26epage%3D8363%26doi%3D10.1021%2Facs.jmedchem.9b00340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">La, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez
Botella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazdoba, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quirk, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A. J.</span></span> <span> </span><span class="NLM_article-title">Neuroactive steroid N-methyl-D-aspartate receptor positive allosteric modulators: Synthesis, SAR, and pharmacological activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7526</span>– <span class="NLM_lpage">7542</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00591</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00591" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFemtL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7526-7542&author=D.+S.+Laauthor=F.+G.+Salituroauthor=G.+Martinez%0ABotellaauthor=A.+M.+Griffinauthor=Z.+Baiauthor=M.+A.+Ackleyauthor=J.+Daiauthor=J.+J.+Dohertyauthor=B.+L.+Harrisonauthor=E.+C.+Hoffmannauthor=T.+M.+Kazdobaauthor=M.+C.+Lewisauthor=M.+C.+Quirkauthor=A.+J.+Robichaud&title=Neuroactive+steroid+N-methyl-D-aspartate+receptor+positive+allosteric+modulators%3A+Synthesis%2C+SAR%2C+and+pharmacological+activity&doi=10.1021%2Facs.jmedchem.9b00591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroactive Steroid N-Methyl-D-aspartate Receptor Positive Allosteric Modulators: Synthesis, SAR, and Pharmacological Activity</span></div><div class="casAuthors">La, Daniel S.; Salituro, Francesco G.; Martinez Botella, Gabriel; Griffin, Andrew M.; Bai, Zhu; Ackley, Michael A.; Dai, Jing; Doherty, James J.; Harrison, Boyd L.; Hoffmann, Ethan C.; Kazdoba, Tatiana M.; Lewis, Michael C.; Quirk, Michael C.; Robichaud, Albert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7526-7542</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Neuroactive steroids (NASs) play a pivotal role in maintaining homeostasis is the CNS.  We have discovered that one NAS in particular, 24(S)-hydroxycholesterol (I, 24(S)-HC), is a pos. allosteric modulator (PAM) of NMDA receptors.  Using 24(S)-HC as a chem. starting point, we have identified other NASs that have good in vitro potency and efficacy.  Herein, we describe the structure activity relationship and pharmacokinetic optimization of this series that ultimately led to II (SGE-301).  We demonstrate that SGE-301 enhances long-term potentiation (LTP) in rat hippocampal slices and, in a dose-dependent manner, improves cognition in a rat social recognition study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbfB83uVi2QbVg90H21EOLACvtfcHk0ljM9fPex3pZ5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFemtL3E&md5=a5e35b2c292c746cc9e2d9b0014bcdcc</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00591%26sid%3Dliteratum%253Aachs%26aulast%3DLa%26aufirst%3DD.%2BS.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DMartinez%2BBotella%26aufirst%3DG.%26aulast%3DGriffin%26aufirst%3DA.%2BM.%26aulast%3DBai%26aufirst%3DZ.%26aulast%3DAckley%26aufirst%3DM.%2BA.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DDoherty%26aufirst%3DJ.%2BJ.%26aulast%3DHarrison%26aufirst%3DB.%2BL.%26aulast%3DHoffmann%26aufirst%3DE.%2BC.%26aulast%3DKazdoba%26aufirst%3DT.%2BM.%26aulast%3DLewis%26aufirst%3DM.%2BC.%26aulast%3DQuirk%26aufirst%3DM.%2BC.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26atitle%3DNeuroactive%2520steroid%2520N-methyl-D-aspartate%2520receptor%2520positive%2520allosteric%2520modulators%253A%2520Synthesis%252C%2520SAR%252C%2520and%2520pharmacological%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7526%26epage%3D7542%26doi%3D10.1021%2Facs.jmedchem.9b00591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burks, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekete, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubicka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peukert, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of an acrylic acid based tetrahydroisoquinoline as an orally bioavailable selective estrogen receptor degrader for ERalpha+ breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2790</span>– <span class="NLM_lpage">2818</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01468</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01468" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1WktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2790-2818&author=H.+E.+Burksauthor=T.+Abramsauthor=C.+A.+Kirbyauthor=J.+Bairdauthor=A.+Feketeauthor=L.+G.+Hamannauthor=S.+Kimauthor=F.+Lombardoauthor=A.+Looauthor=D.+Lubickaauthor=K.+Macchiauthor=D.+P.+McDonnellauthor=Y.+Mishinaauthor=J.+D.+Norrisauthor=J.+Nunezauthor=C.+Saranauthor=Y.+Sunauthor=N.+M.+Thomsenauthor=C.+Wangauthor=J.+Wangauthor=S.+Peukert&title=Discovery+of+an+acrylic+acid+based+tetrahydroisoquinoline+as+an+orally+bioavailable+selective+estrogen+receptor+degrader+for+ERalpha%2B+breast+cancer&doi=10.1021%2Facs.jmedchem.6b01468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer</span></div><div class="casAuthors">Burks, Heather E.; Abrams, Tinya; Kirby, Christina A.; Baird, Jason; Fekete, Alexander; Hamann, Lawrence G.; Kim, Sunkyu; Lombardo, Franco; Loo, Alice; Lubicka, Danuta; Macchi, Kaitlin; McDonnell, Donald P.; Mishina, Yuji; Norris, John D.; Nunez, Jill; Saran, Chitra; Sun, Yingchuan; Thomsen, Noel M.; Wang, Chunrong; Wang, Jianling; Peukert, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2790-2818</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tetrahydroisoquinoline 40 has been identified as a potent ERα antagonist and selective estrogen receptor degrader (SERD), exhibiting good oral bioavailability, antitumor efficacy, and SERD activity in vivo.  We outline the discovery and chem. optimization of the THIQ scaffold leading to THIQ 40 and showcase the racemization of the scaffold, pharmacokinetic studies in preclin. species, and the in vivo efficacy of THIQ 40 in a MCF-7 human breast cancer xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6N78pDzgcpLVg90H21EOLACvtfcHk0lgasl2INxT-GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1WktLc%253D&md5=51ce5c93fb6dcaebb3e81fbb3ca67657</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01468%26sid%3Dliteratum%253Aachs%26aulast%3DBurks%26aufirst%3DH.%2BE.%26aulast%3DAbrams%26aufirst%3DT.%26aulast%3DKirby%26aufirst%3DC.%2BA.%26aulast%3DBaird%26aufirst%3DJ.%26aulast%3DFekete%26aufirst%3DA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DLubicka%26aufirst%3DD.%26aulast%3DMacchi%26aufirst%3DK.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DMishina%26aufirst%3DY.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DNunez%26aufirst%3DJ.%26aulast%3DSaran%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DThomsen%26aufirst%3DN.%2BM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPeukert%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520an%2520acrylic%2520acid%2520based%2520tetrahydroisoquinoline%2520as%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520for%2520ERalpha%252B%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2790%26epage%3D2818%26doi%3D10.1021%2Facs.jmedchem.6b01468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. D.</span></span> <span> </span><span class="NLM_article-title">Tetrahydroisoquinoline phenols: Selective estrogen receptor downregulator antagonists with oral bioavailability in rat</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00413</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00413" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGku7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=94-99&author=J.+S.+Scottauthor=A.+Baileyauthor=R.+D.+Daviesauthor=S.+L.+Degorceauthor=P.+A.+MacFaulauthor=H.+Gingellauthor=T.+Mossauthor=R.+A.+Normanauthor=J.+H.+Pinkauthor=A.+A.+Rabowauthor=B.+Robertsauthor=P.+D.+Smith&title=Tetrahydroisoquinoline+phenols%3A+Selective+estrogen+receptor+downregulator+antagonists+with+oral+bioavailability+in+rat&doi=10.1021%2Facsmedchemlett.5b00413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat</span></div><div class="casAuthors">Scott, James S.; Bailey, Andrew; Davies, Robert D. M.; Degorce, Sebastien L.; MacFaul, Philip A.; Gingell, Helen; Moss, Thomas; Norman, Richard A.; Pink, Jennifer H.; Rabow, Alfred A.; Roberts, Bryan; Smith, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-99</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of tetrahydroisoquinoline phenols was modified to give an estrogen receptor downregulator-antagonist profile.  Optimization around the core, alkyl side chain, and pendant aryl ring resulted in compds. I [R = Ph, PhCH2, i-Bu, etc.] with subnanomolar levels of potency.  The phenol functionality was shown to be required to achieve highly potent compds., but unusually this was compatible with obtaining high oral bioavailabilities in rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXOiEPK5ofVLVg90H21EOLACvtfcHk0lgasl2INxT-GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGku7bK&md5=8c573b4e96e70cf61d40f349a7c19967</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00413%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DR.%2BD.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DMacFaul%26aufirst%3DP.%2BA.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DMoss%26aufirst%3DT.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DRoberts%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DTetrahydroisoquinoline%2520phenols%253A%2520Selective%2520estrogen%2520receptor%2520downregulator%2520antagonists%2520with%2520oral%2520bioavailability%2520in%2520rat%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D94%26epage%3D99%26doi%3D10.1021%2Facsmedchemlett.5b00413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbajo, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polanski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varnes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span> <span> </span><span class="NLM_article-title">Building bridges in a series of estrogen receptor degraders: An application of metathesis in medicinal chemistry</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1492</span>– <span class="NLM_lpage">1497</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00370</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00370" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVentr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1492-1497&author=J.+S.+Scottauthor=J.+Breedauthor=R.+J.+Carbajoauthor=P.+R.+Daveyauthor=R.+Greenwoodauthor=H.+K.+Huynhauthor=T.+Klinowskaauthor=C.+J.+Morrowauthor=T.+A.+Mossauthor=R.+Polanskiauthor=J.+W.+M.+Nissinkauthor=J.+Varnesauthor=B.+Yang&title=Building+bridges+in+a+series+of+estrogen+receptor+degraders%3A+An+application+of+metathesis+in+medicinal+chemistry&doi=10.1021%2Facsmedchemlett.9b00370"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry</span></div><div class="casAuthors">Scott, James S.; Breed, Jason; Carbajo, Rodrigo J.; Davey, Paul R.; Greenwood, Ryan; Huynh, Hoan K.; Klinowska, Teresa; Morrow, Christopher J.; Moss, Thomas A.; Polanski, Radoslaw; Nissink, J. Willem M.; Varnes, Jeffrey; Yang, Bin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1492-1497</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein the authors report the use of metathesis to construct a novel tetracyclic core in a series of estrogen receptor degraders.  This improved the chem. stability, as assessed using an NMR-MS based assay, and gave a mol. with excellent physicochem. properties and pharmacokinetics in rat.  X-ray crystallog. established minimal perturbation of the bridged compds. relative to the unbridged analogs in the receptor binding pocket.  Unfortunately, despite retaining excellent binding to ERα, this adversely affected the ability of the compds. to degrade the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEcZlsyjk417Vg90H21EOLACvtfcHk0lgasl2INxT-GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVentr3E&md5=76a10d7bedd883966fb7106ccf08a0f0</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00370%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DCarbajo%26aufirst%3DR.%2BJ.%26aulast%3DDavey%26aufirst%3DP.%2BR.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DHuynh%26aufirst%3DH.%2BK.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DMorrow%26aufirst%3DC.%2BJ.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPolanski%26aufirst%3DR.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DVarnes%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DB.%26atitle%3DBuilding%2520bridges%2520in%2520a%2520series%2520of%2520estrogen%2520receptor%2520degraders%253A%2520An%2520application%2520of%2520metathesis%2520in%2520medicinal%2520chemistry%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1492%26epage%3D1497%26doi%3D10.1021%2Facsmedchemlett.9b00370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaPorte, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulfer, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alverez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkin, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wipf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huryn, D. M.</span></span> <span> </span><span class="NLM_article-title">Optimization of phenyl indole inhibitors of the AAA+ ATPase p97</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1075</span>– <span class="NLM_lpage">1081</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00372</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00372" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslaqsbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1075-1081&author=M.+G.+LaPorteauthor=J.+C.+Burnettauthor=R.+Colomboauthor=S.+L.+Bulferauthor=C.+Alverezauthor=T.+F.+Chouauthor=R.+J.+Neitzauthor=N.+Greenauthor=W.+J.+Mooreauthor=Z.+Yueauthor=S.+Liauthor=M.+R.+Arkinauthor=P.+Wipfauthor=D.+M.+Huryn&title=Optimization+of+phenyl+indole+inhibitors+of+the+AAA%2B+ATPase+p97&doi=10.1021%2Facsmedchemlett.8b00372"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Phenyl Indole Inhibitors of the AAA+ ATPase p97</span></div><div class="casAuthors">LaPorte, Matthew G.; Burnett, James C.; Colombo, Raffaele; Bulfer, Stacie L.; Alverez, Celeste; Chou, Tsui-Fen; Neitz, R. Jeffrey; Green, Neal; Moore, William J.; Yue, Zhizhou; Li, Shan; Arkin, Michelle R.; Wipf, Peter; Huryn, Donna M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1075-1081</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Starting from a hit identified from a high-throughput screening campaign for inhibitors of the AAA+ ATPase p97, optimization of the side-chain of Ph indole scaffold, in particular the addn. of an N-alkyl piperazine, led to high potency of this series in a biochem. assay, activity in cell-based assays, and excellent pharmaceutical properties.  Mol. modeling based on a subsequently obtained cryo-EM structure of p97 in complex with a Ph indole was used to rationalize the potency of these allosteric inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroJA4x7rXttLVg90H21EOLACvtfcHk0lh9xSy6s9ngTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslaqsbnL&md5=e43c1732377a21bdc6f7253d1834f4c2</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00372%26sid%3Dliteratum%253Aachs%26aulast%3DLaPorte%26aufirst%3DM.%2BG.%26aulast%3DBurnett%26aufirst%3DJ.%2BC.%26aulast%3DColombo%26aufirst%3DR.%26aulast%3DBulfer%26aufirst%3DS.%2BL.%26aulast%3DAlverez%26aufirst%3DC.%26aulast%3DChou%26aufirst%3DT.%2BF.%26aulast%3DNeitz%26aufirst%3DR.%2BJ.%26aulast%3DGreen%26aufirst%3DN.%26aulast%3DMoore%26aufirst%3DW.%2BJ.%26aulast%3DYue%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DArkin%26aufirst%3DM.%2BR.%26aulast%3DWipf%26aufirst%3DP.%26aulast%3DHuryn%26aufirst%3DD.%2BM.%26atitle%3DOptimization%2520of%2520phenyl%2520indole%2520inhibitors%2520of%2520the%2520AAA%252B%2520ATPase%2520p97%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D1075%26epage%3D1081%26doi%3D10.1021%2Facsmedchemlett.8b00372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozaki, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muramatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizumi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuji, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inazawa, J.</span></span> <span> </span><span class="NLM_article-title">Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1139</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1093/carcin/bgp116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1093%2Fcarcin%2Fbgp116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=19423649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXot1CisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=1139-1146&author=S.+Komatsuauthor=I.+Imotoauthor=H.+Tsudaauthor=K.+I.+Kozakiauthor=T.+Muramatsuauthor=Y.+Shimadaauthor=S.+Aikoauthor=Y.+Yoshizumiauthor=D.+Ichikawaauthor=E.+Otsujiauthor=J.+Inazawa&title=Overexpression+of+SMYD2+relates+to+tumor+cell+proliferation+and+malignant+outcome+of+esophageal+squamous+cell+carcinoma&doi=10.1093%2Fcarcin%2Fbgp116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma</span></div><div class="casAuthors">Komatsu, Shuhei; Imoto, Issei; Tsuda, Hitoshi; Kozaki, Ken-ich; Muramatsu, Tomoki; Shimada, Yutaka; Aiko, Satoshi; Yoshizumi, Yutaka; Ichikawa, Daisuke; Otsuji, Eigo; Inazawa, Johji</div><div class="citationInfo"><span class="NLM_cas:title">Carcinogenesis</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1139-1146</span>CODEN:
                <span class="NLM_cas:coden">CRNGDP</span>;
        ISSN:<span class="NLM_cas:issn">0143-3334</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Although we have identified two putative targets, ATF3 and CENPF, for a frequently gained/amplified region around 1q32-q41 in esophageal squamous cell carcinoma (ESCC), it is possible that other amplification targets remain to be identified.  In this study, we tested whether SET and MYND domain-contg. protein 2 (SMYD2), located between those two genes and encoding a lysine methyltransferase for histone H3K36 and p53K370 that regulates transcription and inhibits transactivation activity, resp., acts as a cancer-promoting gene through activation/overexpression in ESCC.  Frequent overexpression of SMYD2 mRNA and protein was obsd. in KYSE150 cells with remarkable amplification at 1q32-41.1 and other ESCC cell lines (11/43 lines, 25.6%).  Overexpression of SMYD2 protein was frequently detected in primary tumor samples of ESCC (117/153 cases, 76.5%) as well and significantly correlated with gender, venous invasion, the pT category in the tumor-lymph node-metastases classification and status of recurrence.  Patients with SMYD2-overexpressing tumors had a worse overall rate of survival than those with non-expressing tumors, and SMYD2 positivity was independently assocd. with a worse outcome in the multivariate anal.  Knockdown of SMYD2 expression inhibited and ectopic overexpression of SMYD2 promoted the proliferation of ESCC cells in a TP53 mutation-independent but SMYD2 expression-dependent manner.  These findings suggest that SMYD2 plays an important role in tumor cell proliferation through its activation/overexpression and highlight its usefulness as a prognosticator and potential therapeutic target in ESCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGuuMnL7IjzbVg90H21EOLACvtfcHk0lh9xSy6s9ngTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXot1CisLs%253D&md5=7eb396b256c9ec2b182fd999796527b5</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgp116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgp116%26sid%3Dliteratum%253Aachs%26aulast%3DKomatsu%26aufirst%3DS.%26aulast%3DImoto%26aufirst%3DI.%26aulast%3DTsuda%26aufirst%3DH.%26aulast%3DKozaki%26aufirst%3DK.%2BI.%26aulast%3DMuramatsu%26aufirst%3DT.%26aulast%3DShimada%26aufirst%3DY.%26aulast%3DAiko%26aufirst%3DS.%26aulast%3DYoshizumi%26aufirst%3DY.%26aulast%3DIchikawa%26aufirst%3DD.%26aulast%3DOtsuji%26aufirst%3DE.%26aulast%3DInazawa%26aufirst%3DJ.%26atitle%3DOverexpression%2520of%2520SMYD2%2520relates%2520to%2520tumor%2520cell%2520proliferation%2520and%2520malignant%2520outcome%2520of%2520esophageal%2520squamous%2520cell%2520carcinoma%26jtitle%3DCarcinogenesis%26date%3D2009%26volume%3D30%26spage%3D1139%26epage%3D1146%26doi%3D10.1093%2Fcarcin%2Fbgp116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swewczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trush, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira de Freitas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatlock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumpf, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wythes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsyte-Lovejoy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, D. R.</span></span> <span> </span><span class="NLM_article-title">Selective, small-molecule co-factor binding site inhibition of a Su(var)3-9, enhancer of zeste, trithorax domain containing lysine methyltransferase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7669</span>– <span class="NLM_lpage">7683</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00112</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00112" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyrur7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7669-7683&author=A.+P.+Taylorauthor=M.+Swewczykauthor=S.+Kennedyauthor=V.+V.+Trushauthor=H.+Wuauthor=H.+Zengauthor=A.+Dongauthor=R.+Ferreira+de+Freitasauthor=J.+Tatlockauthor=R.+A.+Kumpfauthor=M.+Wythesauthor=A.+Casimiro-Garciaauthor=R.+A.+Dennyauthor=M.+D.+Parikhauthor=F.+Liauthor=D.+Barsyte-Lovejoyauthor=M.+Schapiraauthor=M.+Vedadiauthor=P.+J.+Brownauthor=C.+H.+Arrowsmithauthor=D.+R.+Owen&title=Selective%2C+small-molecule+co-factor+binding+site+inhibition+of+a+Su%28var%293-9%2C+enhancer+of+zeste%2C+trithorax+domain+containing+lysine+methyltransferase&doi=10.1021%2Facs.jmedchem.9b00112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3-9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase</span></div><div class="casAuthors">Taylor, Alexandria P.; Swewczyk, Magdalena; Kennedy, Steven; Trush, Viacheslav V.; Wu, Hong; Zeng, Hong; Dong, Aiping; Ferreira de Freitas, Renato; Tatlock, John; Kumpf, Robert A.; Wythes, Martin; Casimiro-Garcia, Agustin; Denny, Rajiah Aldrin; Parikh, Mihir D.; Li, Fengling; Barsyte-Lovejoy, Dalia; Schapira, Matthieu; Vedadi, Masoud; Brown, Peter J.; Arrowsmith, Cheryl H.; Owen, Dafydd R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7669-7683</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The first chem. probe to primarily occupy the co-factor binding site of a Su(var)3-9, enhancer of a zeste, trithorax (SET) domain contg. protein lysine methyltransferase (PKMT) is reported.  Protein methyltransferases require S-adenosylmethionine (SAM) as a co-factor (Me donor) for enzymic activity.  However, SAM itself represents a poor medicinal chem. starting point for a selective, cell-active inhibitor given its extreme physicochem. properties and its role in multiple cellular processes.  A previously untested medicinal chem. strategy of deliberate file enrichment around mols. bearing the hallmarks of SAM, but with improved lead-like properties from the outset, yielded viable hits against SET and MYND domain-contg. protein 2 (SMYD2) that were shown to bind in the co-factor site.  These leads were optimized to identify a highly biochem. potent, PKMT-selective, and cell-active chem. probe.  While substrate-based inhibitors of PKMTs are known, this represents a novel, co-factor-derived strategy for the inhibition of SMYD2 which may also prove applicable to lysine methyltransferase family members previously thought of as intractable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrayuqhEmC-MLVg90H21EOLACvtfcHk0lieofWlmVSE2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyrur7N&md5=6a9f875b93804141716a85d77b93c5ee</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00112%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DA.%2BP.%26aulast%3DSwewczyk%26aufirst%3DM.%26aulast%3DKennedy%26aufirst%3DS.%26aulast%3DTrush%26aufirst%3DV.%2BV.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DDong%26aufirst%3DA.%26aulast%3DFerreira%2Bde%2BFreitas%26aufirst%3DR.%26aulast%3DTatlock%26aufirst%3DJ.%26aulast%3DKumpf%26aufirst%3DR.%2BA.%26aulast%3DWythes%26aufirst%3DM.%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26aulast%3DDenny%26aufirst%3DR.%2BA.%26aulast%3DParikh%26aufirst%3DM.%2BD.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DBarsyte-Lovejoy%26aufirst%3DD.%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DP.%2BJ.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DOwen%26aufirst%3DD.%2BR.%26atitle%3DSelective%252C%2520small-molecule%2520co-factor%2520binding%2520site%2520inhibition%2520of%2520a%2520Su%2528var%25293-9%252C%2520enhancer%2520of%2520zeste%252C%2520trithorax%2520domain%2520containing%2520lysine%2520methyltransferase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7669%26epage%3D7683%26doi%3D10.1021%2Facs.jmedchem.9b00112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakane, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minamino, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kangawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of a human neuromedin U receptor 1-selective hexapeptide agonist with enhanced serum stability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5228</span>– <span class="NLM_lpage">5234</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00694</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00694" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1Sns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5228-5234&author=K.+Takayamaauthor=K.+Moriauthor=A.+Tanakaauthor=E.+Nomuraauthor=Y.+Sohmaauthor=M.+Moriauthor=A.+Taguchiauthor=A.+Taniguchiauthor=T.+Sakaneauthor=A.+Yamamotoauthor=N.+Minaminoauthor=M.+Miyazatoauthor=K.+Kangawaauthor=Y.+Hayashi&title=Discovery+of+a+human+neuromedin+U+receptor+1-selective+hexapeptide+agonist+with+enhanced+serum+stability&doi=10.1021%2Facs.jmedchem.7b00694"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Human Neuromedin U Receptor 1-Selective Hexapeptide Agonist with Enhanced Serum Stability</span></div><div class="casAuthors">Takayama, Kentaro; Mori, Kenji; Tanaka, Akiko; Nomura, Erina; Sohma, Yuko; Mori, Miwa; Taguchi, Akihiro; Taniguchi, Atsuhiko; Sakane, Toshiyasu; Yamamoto, Akira; Minamino, Naoto; Miyazato, Mikiya; Kangawa, Kenji; Hayashi, Yoshio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5228-5234</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Neuromedin U (NMU) activates two NMU receptors (NMUR1 and NMUR2) and is a useful antiobesity drug lead.  We report discovery of a hexapeptide agonist, 2-thienylacetyl-Trp1-Phe(4-F)2-Arg3-Pro4-Arg5-Asn6-NH2 (4).  However, the NMUR1 selectivity and serum stability of this agonist were unsatisfactory.  Through a structure-activity relationship study focused on residue 2 of agonist 4, serum stability, and pharmacokinetic properties, we report here the discovery of a novel NMUR1 selective hexapeptide agonist 7b that suppresses body wt. gain in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqONktrt1VB-LVg90H21EOLACvtfcHk0lieofWlmVSE2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1Sns7k%253D&md5=6bc1a560eff4c7b013fb9caccd0cd644</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00694%26sid%3Dliteratum%253Aachs%26aulast%3DTakayama%26aufirst%3DK.%26aulast%3DMori%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DNomura%26aufirst%3DE.%26aulast%3DSohma%26aufirst%3DY.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DTaguchi%26aufirst%3DA.%26aulast%3DTaniguchi%26aufirst%3DA.%26aulast%3DSakane%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DA.%26aulast%3DMinamino%26aufirst%3DN.%26aulast%3DMiyazato%26aufirst%3DM.%26aulast%3DKangawa%26aufirst%3DK.%26aulast%3DHayashi%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520a%2520human%2520neuromedin%2520U%2520receptor%25201-selective%2520hexapeptide%2520agonist%2520with%2520enhanced%2520serum%2520stability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5228%26epage%3D5234%26doi%3D10.1021%2Facs.jmedchem.7b00694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourbeau, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of AM-6494: A potent and orally efficacious β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with in vivo selectivity over BACE2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2263</span>– <span class="NLM_lpage">2281</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01034</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A280%3ADC%252BB3MnlsFemug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2263-2281&author=L.+H.+Pettusauthor=M.+P.+Bourbeauauthor=J.+Bradleyauthor=M.+D.+Bartbergerauthor=K.+Chenauthor=D.+Hickmanauthor=M.+Johnsonauthor=Q.+Liuauthor=J.+R.+Manningauthor=A.+Nanezauthor=A.+C.+Siegmundauthor=P.+H.+Wenauthor=D.+A.+Whittingtonauthor=J.+R.+Allenauthor=S.+Wood&title=Discovery+of+AM-6494%3A+A+potent+and+orally+efficacious+%CE%B2-site+amyloid+precursor+protein+cleaving+enzyme+1+%28BACE1%29+inhibitor+with+in+vivo+selectivity+over+BACE2&doi=10.1021%2Facs.jmedchem.9b01034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2</span></div><div class="casAuthors">Pettus Liping H; Bourbeau Matthew P; Bradley Jodi; Bartberger Michael D; Chen Kui; Hickman Dean; Johnson Michael; Liu Qingyian; Manning James R; Nanez Adrian; Siegmund Aaron C; Wen Paul H; Whittington Douglas A; Allen Jennifer R; Wood Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2263-2281</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) is an aspartyl protease that plays a key role in the production of amyloid β (Aβ) in the brain and has been extensively pursued as a target for the treatment of Alzheimer's disease (AD).  BACE2, an aspartyl protease that is structurally related to BACE1, has been recently reported to be involved in melanosome maturation and pigmentation.  Herein, we describe the development of a series of cyclopropylthiazines as potent and orally efficacious BACE1 inhibitors.  Lead optimization led to the identification of 20, a molecule with biochemical IC50 BACE2/BACE1 ratio of 47.  Administration of 20 resulted in no skin/fur color change in a 13-day mouse hypopigmentation study and demonstrated robust and sustained reduction of CSF and brain Aβ40 levels in rat and monkey pharmacodynamic models.  On the basis of a compelling data package, 20 (AM-6494) was advanced to preclinical development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmgrDHvGragzjk2McQZ6XmfW6udTcc2eb5iwUuE4z-obntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnlsFemug%253D%253D&md5=abc7ed1f6b97a705d9b43ea992712a97</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01034%26sid%3Dliteratum%253Aachs%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DBourbeau%26aufirst%3DM.%2BP.%26aulast%3DBradley%26aufirst%3DJ.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DManning%26aufirst%3DJ.%2BR.%26aulast%3DNanez%26aufirst%3DA.%26aulast%3DSiegmund%26aufirst%3DA.%2BC.%26aulast%3DWen%26aufirst%3DP.%2BH.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DAllen%26aufirst%3DJ.%2BR.%26aulast%3DWood%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520AM-6494%253A%2520A%2520potent%2520and%2520orally%2520efficacious%2520%25CE%25B2-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%25201%2520%2528BACE1%2529%2520inhibitor%2520with%2520in%2520vivo%2520selectivity%2520over%2520BACE2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D2263%26epage%3D2281%26doi%3D10.1021%2Facs.jmedchem.9b01034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsoi, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Threapleton, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, F. K.</span></span> <span> </span><span class="NLM_article-title">Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity</span>. <i>Aliment. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1262</span>– <span class="NLM_lpage">1275</span>, <span class="refDoi"> DOI: 10.1111/apt.13642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1111%2Fapt.13642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=27121479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsFWiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2016&pages=1262-1275&author=J.+Q.+Yuanauthor=K.+K.+Tsoiauthor=M.+Yangauthor=J.+Y.+Wangauthor=D.+E.+Threapletonauthor=Z.+Y.+Yangauthor=B.+Zouauthor=C.+Maoauthor=J.+L.+Tangauthor=F.+K.+Chan&title=Systematic+review+with+network+meta-analysis%3A+comparative+effectiveness+and+safety+of+strategies+for+preventing+NSAID-associated+gastrointestinal+toxicity&doi=10.1111%2Fapt.13642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity</span></div><div class="casAuthors">Yuan, J. Q.; Tsoi, K. K. F.; Yang, M.; Wang, J. Y.; Threapleton, D. E.; Yang, Z. Y.; Zou, B.; Mao, C.; Tang, J. L.; Chan, F. K. L.</div><div class="citationInfo"><span class="NLM_cas:title">Alimentary Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1262-1275</span>CODEN:
                <span class="NLM_cas:coden">APTHEN</span>;
        ISSN:<span class="NLM_cas:issn">0269-2813</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Many strategies are used to prevent nonsteroidal anti-inflammatory drug (NSAID)-assocd. gastrointestinal toxicity, but the comparative effectiveness remains unclear.  Aim : To evaluate the comparative effectiveness of clin. strategies for preventing gastrointestinal toxicity induced by NSAIDs.  Methods : MEDLINE, EMBASE and the Cochrane Library (from their inception to May 2015) were searched for randomized controlled trials comparing the risk of gastrointestinal adverse events in patients taking nonselective NSAIDs, selective cyclooxygenase(COX)-2 inhibitors or nonselective NSAIDs/COX-2 inhibitors plus gastroprotective agents [proton pump inhibitors (PPIs), histamine-2 receptor antagonists, misoprostol].  Both pairwise meta-anal. and Bayesian network meta-anal. were performed.  Results : Analyses were based on 82 trials including 125 053 participants.  Network meta-anal. demonstrated that selective COX-2 inhibitors + PPIs [Risk ratio (RR), 95% Credible Interval (CrI): ulcer complications 0.07, 0.02-0.18], selective COX-2 inhibitors (RR, 95% CrI: ulcer complications 0.25, 0.15- 0.38; symptomatic ulcer 0.12, 0.04-0.30), nonselective NSAIDs + PPIs (RR, 95% CrI: ulcer complications 0.28, 0.18-0.41; symptomatic ulcer 0.11, 0.04-0.23), nonselective NSAIDs + misoprostol (RR, 95% CrI: ulcer complications 0.47, 0.24-0.81; symptomatic ulcer 0.41, 0.13-1.00) were assocd. with significantly lower risk of clin. gastrointestinal events compared with nonselective NSAIDs.  For all effectiveness endpoints, selective COX-2 inhibitors + PPIs was assocd. with the lowest abs. event probability and the highest rank, followed by selective COX-2 inhibitors and thirdly by nonselective NSAIDs + PPIs.  Conclusion : The combination of selective COX-2 inhibitors plus PPIs provides the best gastrointestinal protection, followed by selective COX-2 inhibitors, and thirdly by nonselective NSAIDs plus PPIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJmKaEIMhfobVg90H21EOLACvtfcHk0lhGjk-p2Bx9HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsFWiur8%253D&md5=48e32a90a90f52070b11bab75b59705b</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1111%2Fapt.13642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fapt.13642%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DJ.%2BQ.%26aulast%3DTsoi%26aufirst%3DK.%2BK.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DJ.%2BY.%26aulast%3DThreapleton%26aufirst%3DD.%2BE.%26aulast%3DYang%26aufirst%3DZ.%2BY.%26aulast%3DZou%26aufirst%3DB.%26aulast%3DMao%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DJ.%2BL.%26aulast%3DChan%26aufirst%3DF.%2BK.%26atitle%3DSystematic%2520review%2520with%2520network%2520meta-analysis%253A%2520comparative%2520effectiveness%2520and%2520safety%2520of%2520strategies%2520for%2520preventing%2520NSAID-associated%2520gastrointestinal%2520toxicity%26jtitle%3DAliment.%2520Pharmacol.%2520Ther.%26date%3D2016%26volume%3D43%26spage%3D1262%26epage%3D1275%26doi%3D10.1111%2Fapt.13642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarathnam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachakonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espiritu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steuer, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7202</span>– <span class="NLM_lpage">7218</span>, <span class="refDoi"> DOI: 10.1021/jm100863x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100863x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKmtb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7202-7218&author=M.+J.+Sofiaauthor=D.+Baoauthor=W.+Changauthor=J.+Duauthor=D.+Nagarathnamauthor=S.+Rachakondaauthor=P.+G.+Reddyauthor=B.+S.+Rossauthor=P.+Wangauthor=H.+R.+Zhangauthor=S.+Bansalauthor=C.+Espirituauthor=M.+Keilmanauthor=A.+M.+Lamauthor=H.+M.+Steuerauthor=C.+Niuauthor=M.+J.+Ottoauthor=P.+A.+Furman&title=Discovery+of+a+beta-d-2%E2%80%B2-deoxy-2%E2%80%B2-alpha-fluoro-2%E2%80%B2-beta-C-methyluridine+nucleotide+prodrug+%28PSI-7977%29+for+the+treatment+of+hepatitis+C+virus&doi=10.1021%2Fjm100863x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a β-D-2'-Deoxy-2'-α-fluoro-2'-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus</span></div><div class="casAuthors">Sofia, Michael J.; Bao, Donghui; Chang, Wonsuk; Du, Jinfa; Nagarathnam, Dhanapalan; Rachakonda, Suguna; Reddy, P. Ganapati; Ross, Bruce S.; Wang, Peiyuan; Zhang, Hai-Ren; Bansal, Shalini; Espiritu, Christine; Keilman, Meg; Lam, Angela M.; Steuer, Holly M. Micolochick; Niu, Congrong; Otto, Michael J.; Furman, Phillip A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7202-7218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is a global health problem requiring novel approaches for effective treatment of this disease.  The HCV NS5B polymerase has been demonstrated to be a viable target for the development of HCV therapies.  β-D-2'-Deoxy-2'-α-fluoro-2'-β-C-Me nucleosides are selective inhibitors of the HCV NS5B polymerase and have demonstrated potent activity in the clinic.  Phosphoramidate prodrugs of the 5'-phosphate deriv. of the β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleoside were prepd. and showed significant potency in the HCV subgenomic replicon assay (<1 μM) and produced high levels of triphosphate 6 in primary hepatocytes and in the livers of rats, dogs, and monkeys when administered in vivo.  The single diastereomer 51 of diastereomeric mixt. 14 was crystd., and an X-ray structure was detd. establishing the phosphoramidate stereochem. as Sp, thus correlating for the first time the stereochem. of a phosphoramidate prodrug with biol. activity.  51 (PSI-7977) was selected as a clin. development candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWAkLi9-odWbVg90H21EOLACvtfcHk0lhGjk-p2Bx9HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKmtb%252FO&md5=33d371e557e9d70562a326f97798f45c</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fjm100863x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100863x%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DBao%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DRachakonda%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.%2BR.%26aulast%3DBansal%26aufirst%3DS.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DKeilman%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DSteuer%26aufirst%3DH.%2BM.%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520beta-d-2%25E2%2580%25B2-deoxy-2%25E2%2580%25B2-alpha-fluoro-2%25E2%2580%25B2-beta-C-methyluridine%2520nucleotide%2520prodrug%2520%2528PSI-7977%2529%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7202%26epage%3D7218%26doi%3D10.1021%2Fjm100863x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Migliaccio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomassini, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomew, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosserman, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceccacci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colwell, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Francesco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eldrup, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getty, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFemina, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludmerer, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacCoss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMasters, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlhut, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flores, O. A.</span></span> <span> </span><span class="NLM_article-title">Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">49164</span>– <span class="NLM_lpage">49170</span>, <span class="refDoi"> DOI: 10.1074/jbc.M305041200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1074%2Fjbc.M305041200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=12966103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptlGrsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=49164-49170&author=G.+Migliaccioauthor=J.+E.+Tomassiniauthor=S.+S.+Carrollauthor=L.+Tomeiauthor=S.+Altamuraauthor=B.+Bhatauthor=L.+Bartholomewauthor=M.+R.+Bossermanauthor=A.+Ceccacciauthor=L.+F.+Colwellauthor=R.+Corteseauthor=R.+De+Francescoauthor=A.+B.+Eldrupauthor=K.+L.+Gettyauthor=X.+S.+Houauthor=R.+L.+LaFeminaauthor=S.+W.+Ludmererauthor=M.+MacCossauthor=D.+R.+McMastersauthor=M.+W.+Stahlhutauthor=D.+B.+Olsenauthor=D.+J.+Hazudaauthor=O.+A.+Flores&title=Characterization+of+resistance+to+non-obligate+chain-terminating+ribonucleoside+analogs+that+inhibit+hepatitis+C+virus+replication+in+vitro&doi=10.1074%2Fjbc.M305041200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of Resistance to Non-obligate Chain-terminating Ribonucleoside Analogs That Inhibit Hepatitis C Virus Replication in Vitro</span></div><div class="casAuthors">Migliaccio, Giovanni; Tomassini, Joanne E.; Carroll, Steven S.; Tomei, Licia; Altamura, Sergio; Bhat, Balkrishen; Bartholomew, Linda; Bosserman, Michele R.; Ceccacci, Alessandra; Colwell, Lawrence F.; Cortese, Riccardo; De Francesco, Raffaele; Eldrup, Anne B.; Getty, Krista L.; Hou, Xiaoli S.; LaFemina, Robert L.; Ludmerer, Steven W.; MacCoss, Malcolm; McMasters, Daniel R.; Stahlhut, Mark W.; Olsen, David B.; Hazuda, Daria J.; Flores, Osvaldo A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">49164-49170</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The urgent need for efficacious drugs to treat chronic hepatitis C virus (HCV) infection requires a concerted effort to develop inhibitors specific for virally encoded enzymes.  We demonstrate that 2'-C-Me ribonucleosides are efficient chain-terminating inhibitors of HCV genome replication.  Characterization of drug-resistant HCV replicons defined a single S282T mutation within the active site of the viral polymerase that conferred loss of sensitivity to structurally related compds. in both replicon and isolated polymerase assays.  Biochem. analyses demonstrated that resistance at the level of the enzyme results from a combination of reduced affinity of the mutant polymerase for the drug and an increased ability to extend the incorporated nucleoside analog.  Importantly, the combination of these agents with interferon-α results in synergistic inhibition of HCV genome replication in cell culture.  Furthermore, 2'-C-methyl-substituted ribonucleosides also inhibited replication of genetically related viruses such as bovine diarrhea virus, yellow fever, and West African Nile viruses.  These observations, together with the finding that 2'-C-methyl-guanosine in particular has a favorable pharmacol. profile, suggest that this class of compds. may have broad utility in the treatment of HCV and other flavivirus infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7Zeuc5zFmbbVg90H21EOLACvtfcHk0lgtnytiyroAqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptlGrsL4%253D&md5=a7183ce208fe008e48c7a1a83ef66e85</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M305041200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M305041200%26sid%3Dliteratum%253Aachs%26aulast%3DMigliaccio%26aufirst%3DG.%26aulast%3DTomassini%26aufirst%3DJ.%2BE.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DTomei%26aufirst%3DL.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DBhat%26aufirst%3DB.%26aulast%3DBartholomew%26aufirst%3DL.%26aulast%3DBosserman%26aufirst%3DM.%2BR.%26aulast%3DCeccacci%26aufirst%3DA.%26aulast%3DColwell%26aufirst%3DL.%2BF.%26aulast%3DCortese%26aufirst%3DR.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DEldrup%26aufirst%3DA.%2BB.%26aulast%3DGetty%26aufirst%3DK.%2BL.%26aulast%3DHou%26aufirst%3DX.%2BS.%26aulast%3DLaFemina%26aufirst%3DR.%2BL.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMacCoss%26aufirst%3DM.%26aulast%3DMcMasters%26aufirst%3DD.%2BR.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DFlores%26aufirst%3DO.%2BA.%26atitle%3DCharacterization%2520of%2520resistance%2520to%2520non-obligate%2520chain-terminating%2520ribonucleoside%2520analogs%2520that%2520inhibit%2520hepatitis%2520C%2520virus%2520replication%2520in%2520vitro%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D49164%26epage%3D49170%26doi%3D10.1074%2Fjbc.M305041200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Appleby, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barauskas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, D.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetmore, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, T. E.</span></span> <span> </span><span class="NLM_article-title">Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase</span>. <i>Science (Washington, DC, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">771</span>– <span class="NLM_lpage">775</span>, <span class="refDoi"> DOI: 10.1126/science.1259210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1126%2Fscience.1259210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=25678663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitlKktrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2015&pages=771-775&author=T.+C.+Applebyauthor=J.+K.+Perryauthor=E.+Murakamiauthor=O.+Barauskasauthor=J.+Fengauthor=A.+Choauthor=D.+Foxauthor=D.+R.+Wetmoreauthor=M.+E.+McGrathauthor=A.+S.+Rayauthor=M.+J.+Sofiaauthor=S.+Swaminathanauthor=T.+E.+Edwards&title=Viral+replication.+Structural+basis+for+RNA+replication+by+the+hepatitis+C+virus+polymerase&doi=10.1126%2Fscience.1259210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for RNA replication by the hepatitis C virus polymerase</span></div><div class="casAuthors">Appleby, Todd C.; Perry, Jason K.; Murakami, Eisuke; Barauskas, Ona; Feng, Joy; Cho, Aesop; Fox, David, III; Wetmore, Diana R.; McGrath, Mary E.; Ray, Adrian S.; Sofia, Michael J.; Swaminathan, S.; Edwards, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">6223</span>),
    <span class="NLM_cas:pages">771-775</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Nucleotide analog inhibitors have shown clin. success in the treatment of hepatitis C virus (HCV) infection, despite an incomplete mechanistic understanding of NS5B, the viral RNA-dependent RNA polymerase.  Here we study the details of HCV RNA replication by detg. crystal structures of stalled polymerase ternary complexes with enzymes, RNA templates, RNA primers, incoming nucleotides, and catalytic metal ions during both primed initiation and elongation of RNA synthesis.  Our anal. revealed that highly conserved active-site residues in NS5B position the primer for in-line attack on the incoming nucleotide.  A β loop and a C-terminal membrane-anchoring linker occlude the active-site cavity in the apo state, retract in the primed initiation assembly to enforce replication of the HCV genome from the 3' terminus, and vacate the active-site cavity during elongation.  We investigated the incorporation of nucleotide analog inhibitors, including the clin. active metabolite formed by sofosbuvir, to elucidate key mol. interactions in the active site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvMC7Wt9bjr7Vg90H21EOLACvtfcHk0lgtnytiyroAqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitlKktrk%253D&md5=aeebcacedf36a44ae80c972100c80c24</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1126%2Fscience.1259210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1259210%26sid%3Dliteratum%253Aachs%26aulast%3DAppleby%26aufirst%3DT.%2BC.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DMurakami%26aufirst%3DE.%26aulast%3DBarauskas%26aufirst%3DO.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DA.%26aulast%3DFox%26aufirst%3DD.%26aulast%3DWetmore%26aufirst%3DD.%2BR.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DEdwards%26aufirst%3DT.%2BE.%26atitle%3DViral%2520replication.%2520Structural%2520basis%2520for%2520RNA%2520replication%2520by%2520the%2520hepatitis%2520C%2520virus%2520polymerase%26jtitle%3DScience%2520%2528Washington%252C%2520DC%252C%2520U.%2520S.%2529%26date%3D2015%26volume%3D347%26spage%3D771%26epage%3D775%26doi%3D10.1126%2Fscience.1259210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jonckers, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijgen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachau-Durand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoops, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeys, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leclercq, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tambuyzer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raboisson, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-((2<i>R</i>,4a<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-2-isopropoxy-2-oxidodihydro-4<i>H</i>,6<i>H</i>-spiro[furo[3,2-d][1,3,2]dioxaphosphinine-7,2′-oxetan]-6-yl)pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione (JNJ-54257099), a 3′-5′-cyclic phosphate ester prodrug of 2′-deoxy-2′-spirooxetane uridine triphosphate useful for HCV inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5790</span>– <span class="NLM_lpage">5798</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00382</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00382" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFKisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5790-5798&author=T.+H.+Jonckersauthor=A.+Tahriauthor=L.+Vijgenauthor=J.+M.+Berkeauthor=S.+Lachau-Durandauthor=B.+Stoopsauthor=J.+Snoeysauthor=L.+Leclercqauthor=L.+Tambuyzerauthor=T.+I.+Linauthor=K.+Simmenauthor=P.+Raboisson&title=Discovery+of+1-%28%282R%2C4aR%2C6R%2C7R%2C7aR%29-2-isopropoxy-2-oxidodihydro-4H%2C6H-spiro%5Bfuro%5B3%2C2-d%5D%5B1%2C3%2C2%5Ddioxaphosphinine-7%2C2%E2%80%B2-oxetan%5D-6-yl%29pyrimidine-2%2C4%281H%2C3H%29-dione+%28JNJ-54257099%29%2C+a+3%E2%80%B2-5%E2%80%B2-cyclic+phosphate+ester+prodrug+of+2%E2%80%B2-deoxy-2%E2%80%B2-spirooxetane+uridine+triphosphate+useful+for+HCV+inhibition&doi=10.1021%2Facs.jmedchem.6b00382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-((2R,4aR,6R,7R,7aR)-2-Isopropoxy-2-oxidodihydro-4H,6H-spiro[furo[3,2-d][1,3,2]dioxaphosphinine-7,2'-oxetan]-6-yl)pyrimidine-2,4(1H,3H)-dione (JNJ-54257099), a 3'-5'-Cyclic Phosphate Ester Prodrug of 2'-Deoxy-2'-Spirooxetane Uridine Triphosphate Useful for HCV Inhibition</span></div><div class="casAuthors">Jonckers, Tim H. M.; Tahri, Abdellah; Vijgen, Leen; Berke, Jan Martin; Lachau-Durand, Sophie; Stoops, Bart; Snoeys, Jan; Leclercq, Laurent; Tambuyzer, Lotke; Lin, Tse-I.; Simmen, Kenny; Raboisson, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5790-5798</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">JNJ-54257099 (9) is a novel cyclic phosphate ester deriv. that belongs to the class of 2'-deoxy-2'-spirooxetane uridine nucleotide prodrugs which are known as inhibitors of the HCV NS5B RNA-dependent RNA polymerase (RdRp).  In the Huh-7 HCV genotype (GT) 1b replicon-contg. cell line 9 is devoid of any anti-HCV activity, an observation attributable to inefficient prodrug metab. which was found to be CYP3A4-dependent.  In contrast, in vitro incubation of 9 in primary human hepatocytes as well as pharmacokinetic evaluation thereof in different preclin. species reveals the formation of substantial levels of 2'-deoxy-2'-spirooxetane uridine triphosphate (8), a potent inhibitor of the HCV NS5B polymerase.  Overall, it was found that 9 displays a superior profile compared to its phosphoramidate prodrug analogs (e.g., 4) described previously.  Of particular interest is the in vivo dose dependent redn. of HCV RNA obsd. in HCV infected (GT1a and GT3a) human hepatocyte chimeric mice after 7 days of oral administration of 9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpipEonNiweI7Vg90H21EOLACvtfcHk0lgtnytiyroAqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFKisLg%253D&md5=d7d294da5d1adb1e6d576a708e6779fe</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00382%26sid%3Dliteratum%253Aachs%26aulast%3DJonckers%26aufirst%3DT.%2BH.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DVijgen%26aufirst%3DL.%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26aulast%3DLachau-Durand%26aufirst%3DS.%26aulast%3DStoops%26aufirst%3DB.%26aulast%3DSnoeys%26aufirst%3DJ.%26aulast%3DLeclercq%26aufirst%3DL.%26aulast%3DTambuyzer%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.%2BI.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DRaboisson%26aufirst%3DP.%26atitle%3DDiscovery%2520of%25201-%2528%25282R%252C4aR%252C6R%252C7R%252C7aR%2529-2-isopropoxy-2-oxidodihydro-4H%252C6H-spiro%255Bfuro%255B3%252C2-d%255D%255B1%252C3%252C2%255Ddioxaphosphinine-7%252C2%25E2%2580%25B2-oxetan%255D-6-yl%2529pyrimidine-2%252C4%25281H%252C3H%2529-dione%2520%2528JNJ-54257099%2529%252C%2520a%25203%25E2%2580%25B2-5%25E2%2580%25B2-cyclic%2520phosphate%2520ester%2520prodrug%2520of%25202%25E2%2580%25B2-deoxy-2%25E2%2580%25B2-spirooxetane%2520uridine%2520triphosphate%2520useful%2520for%2520HCV%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5790%26epage%3D5798%26doi%3D10.1021%2Facs.jmedchem.6b00382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutgesell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskyi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, R.</span></span> <span> </span><span class="NLM_article-title">Novel pyrrolopyridone bromodomain and extra-terminal motif (BET) inhibitors effective in endocrine-resistant ER+ breast cancer with acquired resistance to fulvestrant and palbociclib</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">7186</span>– <span class="NLM_lpage">7210</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00456</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00456" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVSht7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=7186-7210&author=Y.+Liauthor=J.+Zhaoauthor=L.+M.+Gutgesellauthor=Z.+Shenauthor=K.+Ratiaauthor=K.+Dyeauthor=O.+Dubrovskyiauthor=H.+Zhaoauthor=F.+Huangauthor=D.+A.+Tonettiauthor=G.+R.+J.+Thatcherauthor=R.+Xiong&title=Novel+pyrrolopyridone+bromodomain+and+extra-terminal+motif+%28BET%29+inhibitors+effective+in+endocrine-resistant+ER%2B+breast+cancer+with+acquired+resistance+to+fulvestrant+and+palbociclib&doi=10.1021%2Facs.jmedchem.0c00456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib</span></div><div class="casAuthors">Li, Yangfeng; Zhao, Jiong; Gutgesell, Lauren M.; Shen, Zhengnan; Ratia, Kiira; Dye, Katherine; Dubrovskyi, Oleksii; Zhao, Huiping; Huang, Fei; Tonetti, Debra A.; Thatcher, Gregory R. J.; Xiong, Rui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">7186-7210</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acquired resistance to fulvestrant and palbociclib is a new challenge to treatment of estrogen receptor pos. (ER+) breast cancer.  ER is expressed in most resistance settings; thus, bromodomain and extra-terminal protein inhibitors (BETi) that target BET-amplified ER-mediated transcription have therapeutic potential.  Novel pyrrolopyridone BETi leveraged novel interactions with L92/L94 confirmed by a cocrystal structure of 27 with BRD4.  Optimization of BETi using growth inhibition in fulvestrant-resistant (MCF-7:CFR) cells was confirmed in endocrine-resistant, palbociclib-resistant, and ESR1 mutant cell lines. 27 was more potent in MCF-7:CFR cells than six BET inhibitors in clin. trials.  Transcriptomic anal. differentiated 27 from the benchmark BETi, JQ-1, showing downregulation of oncogenes and upregulation of tumor suppressors and apoptosis.  The therapeutic approach was validated by oral administration of 27 in orthotopic xenografts of endocrine-resistant breast cancer in monotherapy and in combination with fulvestrant.  Importantly, at an equiv. dose in rats, thrombocytopenia was mitigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDIuIaC34dxbVg90H21EOLACvtfcHk0lgo8CFoFo2Vdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVSht7jM&md5=b44638b7c6db7998abd72b50f09382ca</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00456%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DGutgesell%26aufirst%3DL.%2BM.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DRatia%26aufirst%3DK.%26aulast%3DDye%26aufirst%3DK.%26aulast%3DDubrovskyi%26aufirst%3DO.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26aulast%3DXiong%26aufirst%3DR.%26atitle%3DNovel%2520pyrrolopyridone%2520bromodomain%2520and%2520extra-terminal%2520motif%2520%2528BET%2529%2520inhibitors%2520effective%2520in%2520endocrine-resistant%2520ER%252B%2520breast%2520cancer%2520with%2520acquired%2520resistance%2520to%2520fulvestrant%2520and%2520palbociclib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D7186%26epage%3D7210%26doi%3D10.1021%2Facs.jmedchem.0c00456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertoletti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, C.</span></span> <span> </span><span class="NLM_article-title">Adaptive immunity in HBV infection</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">S71</span>– <span class="NLM_lpage">s83</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2016.01.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.jhep.2016.01.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=27084039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVart7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=S71-s83&author=A.+Bertolettiauthor=C.+Ferrari&title=Adaptive+immunity+in+HBV+infection&doi=10.1016%2Fj.jhep.2016.01.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Adaptive immunity in HBV infection</span></div><div class="casAuthors">Bertoletti, Antonio; Ferrari, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1_Suppl.</span>),
    <span class="NLM_cas:pages">S71-S83</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">During hepatitis B virus (HBV) infection, the presence of HBV-specific antibody producing B cells and functional HBV-specific T cells (with helper or cytotoxic effects) ultimately dets. HBV infection outcome.  In this review, in addn. to summarizing the present state of knowledge of HBV-adaptive immunity, we will highlight controversies and uncertainties concerning the HBV-specific B and T lymphocyte response, and propose future directions for research aimed at the generation of more efficient immunotherapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0DCzFYSMYqLVg90H21EOLACvtfcHk0lgo8CFoFo2Vdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVart7w%253D&md5=a212ced9423f2e1db502572b049290ad</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2016.01.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2016.01.026%26sid%3Dliteratum%253Aachs%26aulast%3DBertoletti%26aufirst%3DA.%26aulast%3DFerrari%26aufirst%3DC.%26atitle%3DAdaptive%2520immunity%2520in%2520HBV%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2016%26volume%3D64%26spage%3DS71%26epage%3Ds83%26doi%3D10.1016%2Fj.jhep.2016.01.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleby, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aktoudianakis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metobo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daffis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villasenor, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zablocki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suekawa-Pirrone, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaney, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of GS-9688 (Selgantolimod) as a potent and selective oral Toll-like receptor 8 agonist for the treatment of chronic hepatitis B</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00100</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00100" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=R.+L.+Mackmanauthor=M.+Mishauthor=G.+Chinauthor=J.+K.+Perryauthor=T.+Applebyauthor=V.+Aktoudianakisauthor=S.+Metoboauthor=P.+Pyunauthor=C.+Niuauthor=S.+Daffisauthor=H.+Yuauthor=J.+Zhengauthor=A.+G.+Villasenorauthor=J.+Zablockiauthor=J.+Chamberlainauthor=H.+Jinauthor=G.+Leeauthor=K.+Suekawa-Pirroneauthor=R.+Santosauthor=W.+E.+Delaneyauthor=S.+P.+Fletcher&title=Discovery+of+GS-9688+%28Selgantolimod%29+as+a+potent+and+selective+oral+Toll-like+receptor+8+agonist+for+the+treatment+of+chronic+hepatitis+B&doi=10.1021%2Facs.jmedchem.0c00100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00100%26sid%3Dliteratum%253Aachs%26aulast%3DMackman%26aufirst%3DR.%2BL.%26aulast%3DMish%26aufirst%3DM.%26aulast%3DChin%26aufirst%3DG.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DAppleby%26aufirst%3DT.%26aulast%3DAktoudianakis%26aufirst%3DV.%26aulast%3DMetobo%26aufirst%3DS.%26aulast%3DPyun%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DDaffis%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DVillasenor%26aufirst%3DA.%2BG.%26aulast%3DZablocki%26aufirst%3DJ.%26aulast%3DChamberlain%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DSuekawa-Pirrone%26aufirst%3DK.%26aulast%3DSantos%26aufirst%3DR.%26aulast%3DDelaney%26aufirst%3DW.%2BE.%26aulast%3DFletcher%26aufirst%3DS.%2BP.%26atitle%3DDiscovery%2520of%2520GS-9688%2520%2528Selgantolimod%2529%2520as%2520a%2520potent%2520and%2520selective%2520oral%2520Toll-like%2520receptor%25208%2520agonist%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520B%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26doi%3D10.1021%2Facs.jmedchem.0c00100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pi-Sunyer, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kissileff, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. P.</span></span> <span> </span><span class="NLM_article-title">C-terminal octapeptide of cholecystokinin decreases food intake in obese men</span>. <i>Physiol. Behav.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1016/0031-9384(82)90230-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2F0031-9384%2882%2990230-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=6294699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaL38XlvFemsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1982&pages=627-630&author=X.+Pi-Sunyerauthor=H.+R.+Kissileffauthor=J.+Thorntonauthor=G.+P.+Smith&title=C-terminal+octapeptide+of+cholecystokinin+decreases+food+intake+in+obese+men&doi=10.1016%2F0031-9384%2882%2990230-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">C-terminal octapeptide of cholecystokinin decreases food intake in obese men</span></div><div class="casAuthors">Pi-Sunyer, Xavier; Kissileff, Harry R.; Thornton, John; Smith, Gerard P.</div><div class="citationInfo"><span class="NLM_cas:title">Physiology & Behavior</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">627-30</span>CODEN:
                <span class="NLM_cas:coden">PHBHA4</span>;
        ISSN:<span class="NLM_cas:issn">0031-9384</span>.
    </div><div class="casAbstract">Six of 8 obese men ate less food during an i.v. infusion of the C-terminal octapeptide of cholecystokinin (CCK-8)  [25126-32-3] (4 ng/kg/min) than during a saline infusion.  Subjects stopped eating sooner during CCK-8.  CCK-8 did not change the rate of eating.  No overt side effects were reported or obsd.  This is the 1st report of the satiety effect of CCK-8 in obese humans and it suggests that the therapeutic potential of CCK-8 for the treatment of obesity deserves investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof8-0MPTyHYLVg90H21EOLACvtfcHk0lgE0HhlZU3hmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XlvFemsb8%253D&md5=a4e2a45bf5082f00b5efe25b7459b8eb</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2F0031-9384%2882%2990230-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0031-9384%252882%252990230-X%26sid%3Dliteratum%253Aachs%26aulast%3DPi-Sunyer%26aufirst%3DX.%26aulast%3DKissileff%26aufirst%3DH.%2BR.%26aulast%3DThornton%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DG.%2BP.%26atitle%3DC-terminal%2520octapeptide%2520of%2520cholecystokinin%2520decreases%2520food%2520intake%2520in%2520obese%2520men%26jtitle%3DPhysiol.%2520Behav.%26date%3D1982%26volume%3D29%26spage%3D627%26epage%3D630%26doi%3D10.1016%2F0031-9384%2882%2990230-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henke, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momtahen, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugg, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croom, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grizzle, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queen, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimele, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yingling, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M. K.</span></span> <span> </span><span class="NLM_article-title">3-[2-(N-phenylacetamide)]-1,5-benzodiazepines: orally active, binding selective CCK-A agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">3030</span>– <span class="NLM_lpage">3034</span>, <span class="refDoi"> DOI: 10.1021/jm960205b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960205b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaK28XjvVartbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=3030-3034&author=T.+M.+Willsonauthor=B.+R.+Henkeauthor=T.+M.+Momtahenauthor=P.+L.+Myersauthor=E.+E.+Suggauthor=R.+J.+Unwallaauthor=D.+K.+Croomauthor=R.+W.+Doughertyauthor=M.+K.+Grizzleauthor=M.+F.+Johnsonauthor=K.+L.+Queenauthor=T.+J.+Rimeleauthor=J.+D.+Yinglingauthor=M.+K.+James&title=3-%5B2-%28N-phenylacetamide%29%5D-1%2C5-benzodiazepines%3A+orally+active%2C+binding+selective+CCK-A+agonists&doi=10.1021%2Fjm960205b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">3-[2-(N-Phenylacetamide)]-1,5-benzodiazepines: Orally Active, Binding Selective CCK-A Agonists</span></div><div class="casAuthors">Willson, Timothy M.; Henke, Brad R.; Momtahen, Tanya M.; Myers, Peter L.; Sugg, Elizabeth E.; Unwalla, Rayomand J.; Croom, Dallas K.; Dougherty, Robert W.; Grizzle, Mary K.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3030-3034</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of modifications were made to the C-3 substituent of the 1,5-benzodiazepine CCK-A agonist I.  Replacement of the inner urea NH and addn. of a Me group to generate a C-3 quaternary carbon resulted in acetamide II, which showed CCK-A receptor binding selectivity and sub-micromolar agonist activity in vitro.  II was active in an in vivo mouse gallbladder emptying assay and represents a novel orally active, binding selective CCK-A agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-xv3tWIdKmLVg90H21EOLACvtfcHk0lgE0HhlZU3hmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjvVartbc%253D&md5=c2b8e49fc0307b720ef0256a72f05ee7</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fjm960205b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960205b%26sid%3Dliteratum%253Aachs%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DHenke%26aufirst%3DB.%2BR.%26aulast%3DMomtahen%26aufirst%3DT.%2BM.%26aulast%3DMyers%26aufirst%3DP.%2BL.%26aulast%3DSugg%26aufirst%3DE.%2BE.%26aulast%3DUnwalla%26aufirst%3DR.%2BJ.%26aulast%3DCroom%26aufirst%3DD.%2BK.%26aulast%3DDougherty%26aufirst%3DR.%2BW.%26aulast%3DGrizzle%26aufirst%3DM.%2BK.%26aulast%3DJohnson%26aufirst%3DM.%2BF.%26aulast%3DQueen%26aufirst%3DK.%2BL.%26aulast%3DRimele%26aufirst%3DT.%2BJ.%26aulast%3DYingling%26aufirst%3DJ.%2BD.%26aulast%3DJames%26aufirst%3DM.%2BK.%26atitle%3D3-%255B2-%2528N-phenylacetamide%2529%255D-1%252C5-benzodiazepines%253A%2520orally%2520active%252C%2520binding%2520selective%2520CCK-A%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D3030%26epage%3D3034%26doi%3D10.1021%2Fjm960205b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. B.</span></span> <span> </span><span class="NLM_article-title">The use of spirocyclic scaffolds in drug discovery</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3673</span>– <span class="NLM_lpage">3682</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.bmcl.2014.06.081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=25052427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFykt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3673-3682&author=Y.+Zhengauthor=C.+M.+Ticeauthor=S.+B.+Singh&title=The+use+of+spirocyclic+scaffolds+in+drug+discovery&doi=10.1016%2Fj.bmcl.2014.06.081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">The use of spirocyclic scaffolds in drug discovery</span></div><div class="casAuthors">Zheng, Yajun; Tice, Colin M.; Singh, Suresh B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3673-3682</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Owing to their inherent three-dimensionality and structural novelty, spiro scaffolds have been increasingly utilized in drug discovery.  In this brief review, we highlight selected examples from the primary medicinal chem. literature during the last three years to demonstrate the versatility of spiro scaffolds.  With recent progress in synthetic methods providing access to spiro building blocks, spiro scaffolds are likely to be used more frequently in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqzTjJrsRkyLVg90H21EOLACvtfcHk0lgE0HhlZU3hmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFykt7bM&md5=9a2a644cf2b97edf7876b43b6457f6d5</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.081%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DTice%26aufirst%3DC.%2BM.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26atitle%3DThe%2520use%2520of%2520spirocyclic%2520scaffolds%2520in%2520drug%2520discovery%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3673%26epage%3D3682%26doi%3D10.1016%2Fj.bmcl.2014.06.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, C. M.</span></span> <span> </span><span class="NLM_article-title">The utilization of spirocyclic scaffolds in novel drug discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">834</span>, <span class="refDoi"> DOI: 10.1080/17460441.2016.1195367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1080%2F17460441.2016.1195367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=27233084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FktVGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=831-834&author=Y.+J.+Zhengauthor=C.+M.+Tice&title=The+utilization+of+spirocyclic+scaffolds+in+novel+drug+discovery&doi=10.1080%2F17460441.2016.1195367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">The utilization of spirocyclic scaffolds in novel drug discovery</span></div><div class="casAuthors">Zheng Ya-Jun; Tice Colin M</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on drug discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">831-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYAtKgZnFeprYtC3U5jeOifW6udTcc2ea9iifzGbIn1bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FktVGkug%253D%253D&md5=a736a7ecb934f323069bef58eaed9bbe</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1195367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1195367%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%2BJ.%26aulast%3DTice%26aufirst%3DC.%2BM.%26atitle%3DThe%2520utilization%2520of%2520spirocyclic%2520scaffolds%2520in%2520novel%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26spage%3D831%26epage%3D834%26doi%3D10.1080%2F17460441.2016.1195367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkenbosch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benningshof, J. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumpfe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span> <span> </span><span class="NLM_article-title">Charting biologically relevant spirocyclic compound space</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">703</span>– <span class="NLM_lpage">710</span>, <span class="refDoi"> DOI: 10.1002/chem.201604714</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fchem.201604714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=27859909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVWmsb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=703-710&author=G.+M%C3%BCllerauthor=T.+Berkenboschauthor=J.+C.+J.+Benningshofauthor=D.+Stumpfeauthor=J.+Bajorath&title=Charting+biologically+relevant+spirocyclic+compound+space&doi=10.1002%2Fchem.201604714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Charting Biologically Relevant Spirocyclic Compound Space</span></div><div class="casAuthors">Mueller, Gerhard; Berkenbosch, Tim; Benningshof, Jorg C. J.; Stumpfe, Dagmar; Bajorath, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">703-710</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Spirocycles frequently occur in natural products and experience increasing interest in drug discovery, given their richness in Sp3 centers and distinct three-dimensionality.  The authors have systematically explored chem. space populated with currently available bioactive spirocycles.  Compds. contg. spiro systems were classified and their scaffolds and spirocyclic ring combinations analyzed.  Nearly 47,000 compds. were identified that contained spirocycles in different structural contexts and were active against roughly 200 targets, among which several pharmaceutically relevant members of the G protein-coupled receptor (GPCR) family were identified.  Spirocycles and corresponding compds. displayed notable scaffold diversity but contained only limited nos. of combinations of differently sized rings.  These observations indicate that there should be significant potential to further expand spirocyclic chem. space for drug discovery, exploiting the privileged substructure concept.  Inspired by those findings, the authors embarked on the design and chem. synthesis of three distinct novel spirocyclic scaffolds that qualify for downstream library synthesis, thus exploring principally new chem. space with high potential for pharmaceutical research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUvVwE8kzXULVg90H21EOLACvtfcHk0ljZ617HOzkZqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVWmsb3O&md5=92293477499539b602abd928891de11b</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1002%2Fchem.201604714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201604714%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DG.%26aulast%3DBerkenbosch%26aufirst%3DT.%26aulast%3DBenningshof%26aufirst%3DJ.%2BC.%2BJ.%26aulast%3DStumpfe%26aufirst%3DD.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DCharting%2520biologically%2520relevant%2520spirocyclic%2520compound%2520space%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2017%26volume%3D23%26spage%3D703%26epage%3D710%26doi%3D10.1002%2Fchem.201604714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flisiak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horban, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvarajah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiercinska-Drapalo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siwak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cielniak, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higersberger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kierkus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aeschlimann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosgurin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas-Métral, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumont, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porchet, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabbé, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scalfaro, P.</span></span> <span> </span><span class="NLM_article-title">The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">826</span>, <span class="refDoi"> DOI: 10.1002/hep.22131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fhep.22131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=18302285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktVOiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=817-826&author=R.+Flisiakauthor=A.+Horbanauthor=P.+Gallayauthor=M.+Bobardtauthor=S.+Selvarajahauthor=A.+Wiercinska-Drapaloauthor=E.+Siwakauthor=I.+Cielniakauthor=J.+Higersbergerauthor=J.+Kierkusauthor=C.+Aeschlimannauthor=P.+Grosgurinauthor=V.+Nicolas-M%C3%A9tralauthor=J.-M.+Dumontauthor=H.+Porchetauthor=R.+Crabb%C3%A9author=P.+Scalfaro&title=The+cyclophilin+inhibitor+Debio-025+shows+potent+anti-hepatitis+C+effect+in+patients+coinfected+with+hepatitis+C+and+human+immunodeficiency+virus&doi=10.1002%2Fhep.22131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">The cyclophilin inhibitor Debio-O25 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus</span></div><div class="casAuthors">Flisiak, Robert; Horban, Andrzej; Gallay, Philippe; Bobardt, Michael; Selvarajah, Suganya; Wiercinska-Drapalo, Alicja; Siwak, Ewa; Cielniak, Iwona; Higersberger, Jozef; Kierkus, Jarek; Aeschlimann, Christian; Grosgurin, Pierre; Nicolas-Metral, Valerie; Dumont, Jean-Maurice; Porchet, Herve; Crabbe, Raf; Scalfaro, Pietro</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">817-826</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Debio-025 is an oral cyclophilin (Cyp) inhibitor with potent anti-hepatitis C virus activity in vitro.  Its effect on viral load as well as its influence on intracellular Cyp levels was investigated in a randomized, double-blind, placebo-controlled study.  Mean hepatitis C viral load decreased significantly by 3.6 log10 after a 14-day oral treatment with 1200 mg twice daily (P < 0.0001) with an effect against the 3 genotypes (1, 3, and 4) represented in the study.  In addn., the absence of viral rebound during treatment indicates that Debio-025 has a high barrier for the selection of resistance.  In Debio-025-treated patients, cydophilin B (CypB) levels in peripheral blood mononuclear cells decreased from 67 ± 6 (std. error) ng/mg protein (baseline) to 5 ± 1 ng/mg protein at day 15 (P < 0.01).  Conclusion: Debio-025 induced a strong drop in CypB levels, coinciding with the decrease in hepatitis C viral load.  These are the first preliminary human data supporting the hypothesis that CypB may play an important role in hepatitis C virus replication and that Cyp inhibition is a valid target for the development of anti-hepatitis C drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxguJagRjm8bVg90H21EOLACvtfcHk0ljZ617HOzkZqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktVOiu7o%253D&md5=8b864afa2a4d2b55fc90650d5ac4e30b</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1002%2Fhep.22131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.22131%26sid%3Dliteratum%253Aachs%26aulast%3DFlisiak%26aufirst%3DR.%26aulast%3DHorban%26aufirst%3DA.%26aulast%3DGallay%26aufirst%3DP.%26aulast%3DBobardt%26aufirst%3DM.%26aulast%3DSelvarajah%26aufirst%3DS.%26aulast%3DWiercinska-Drapalo%26aufirst%3DA.%26aulast%3DSiwak%26aufirst%3DE.%26aulast%3DCielniak%26aufirst%3DI.%26aulast%3DHigersberger%26aufirst%3DJ.%26aulast%3DKierkus%26aufirst%3DJ.%26aulast%3DAeschlimann%26aufirst%3DC.%26aulast%3DGrosgurin%26aufirst%3DP.%26aulast%3DNicolas-M%25C3%25A9tral%26aufirst%3DV.%26aulast%3DDumont%26aufirst%3DJ.-M.%26aulast%3DPorchet%26aufirst%3DH.%26aulast%3DCrabb%25C3%25A9%26aufirst%3DR.%26aulast%3DScalfaro%26aufirst%3DP.%26atitle%3DThe%2520cyclophilin%2520inhibitor%2520Debio-025%2520shows%2520potent%2520anti-hepatitis%2520C%2520effect%2520in%2520patients%2520coinfected%2520with%2520hepatitis%2520C%2520and%2520human%2520immunodeficiency%2520virus%26jtitle%3DHepatology%26date%3D2008%26volume%3D47%26spage%3D817%26epage%3D826%26doi%3D10.1002%2Fhep.22131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMassimo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalezari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sluder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scorneaux, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalczyk, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeill, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baugh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallay, P.</span></span> <span> </span><span class="NLM_article-title">The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2012.02.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.jhep.2012.02.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=22425702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC38XovV2nsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2012&pages=47-54&author=S.+Hopkinsauthor=B.+DiMassimoauthor=P.+Rusnakauthor=D.+Heumanauthor=J.+Lalezariauthor=A.+Sluderauthor=B.+Scorneauxauthor=S.+Mosierauthor=P.+Kowalczykauthor=Y.+Ribeillauthor=J.+Baughauthor=P.+Gallay&title=The+cyclophilin+inhibitor+SCY-635+suppresses+viral+replication+and+induces+endogenous+interferons+in+patients+with+chronic+HCV+genotype+1+infection&doi=10.1016%2Fj.jhep.2012.02.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection</span></div><div class="casAuthors">Hopkins, Sam; DiMassimo, Betty; Rusnak, Pamela; Heuman, Douglas; Lalezari, Jacob; Sluder, Ann; Scorneaux, Bernard; Mosier, Sarah; Kowalczyk, Paul; Ribeill, Yves; Baugh, James; Gallay, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-54</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background & Aims: SCY-635 is a non-immunosuppressive analog of cyclosporin A that inhibits cyclophilins A and B and hepatitis C virus (HCV) replication in vitro.  In a phase 1b multi-dose escalation study, we evaluated the safety, plasma pharmacokinetics, and antiviral activity of 15 days of monotherapy with SCY-635 in adults with chronic genotype 1 HCV infection.  Methods: Twenty adults with chronic HCV genotype 1 were randomized to SCY-635 oral doses of 100, 200, or 300 mg three times daily for 15 days.  Results: No dose-limiting clin. or lab. toxicities were identified.  On day 15, the mean decline in plasma viremia was 2.24 ± 1.74 log10 IU/mL with SCY-635 900 mg/d.  Individual antiviral responses correlated with host IL28B genotype.  Post hoc analyses indicated treatment with SCY-635 increased plasma protein concns. of interferon α (IFNα), IFNs λ1 and λ3, and 2'5' oligoadenylate synthetase 1 (2'5'OAS-1), with the greatest increases in IL28B CC and CT subjects.  Changes in plasma concns. for all markers were coincident with changes in the plasma concn. of SCY-635.  Peaks of IFNs α, λ1, and λ3 and 2'5'OAS-1 were obsd. within 2 h after drug administration.  In replicon cells, SCY-635 enhanced secretion of type I and type III IFNs and increased the expression of IFN-stimulated genes (ISG).  Conclusions: These studies establish clin. proof of concept for SCY-635 as a novel antiviral agent and suggest that restoration of the host innate immune response to chronic hepatitis C infection may represent a major mechanism through which cyclophilin inhibitors exert clin. antiviral activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOeLKHF7TNQLVg90H21EOLACvtfcHk0lgy3qaobGLVzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovV2nsLc%253D&md5=43dcadacaaef7efd63d3d823f53ad514</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.02.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.02.024%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DS.%26aulast%3DDiMassimo%26aufirst%3DB.%26aulast%3DRusnak%26aufirst%3DP.%26aulast%3DHeuman%26aufirst%3DD.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DSluder%26aufirst%3DA.%26aulast%3DScorneaux%26aufirst%3DB.%26aulast%3DMosier%26aufirst%3DS.%26aulast%3DKowalczyk%26aufirst%3DP.%26aulast%3DRibeill%26aufirst%3DY.%26aulast%3DBaugh%26aufirst%3DJ.%26aulast%3DGallay%26aufirst%3DP.%26atitle%3DThe%2520cyclophilin%2520inhibitor%2520SCY-635%2520suppresses%2520viral%2520replication%2520and%2520induces%2520endogenous%2520interferons%2520in%2520patients%2520with%2520chronic%2520HCV%2520genotype%25201%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2012%26volume%3D57%26spage%3D47%26epage%3D54%26doi%3D10.1016%2Fj.jhep.2012.02.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steadman, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poullennec, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleby, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakemore, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannizzaro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiva, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunbar, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fliri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Highton, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarides, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liclican, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettit, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanvoisin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperandio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent and orally bioavailable cyclophilin inhibitor derived from the sanglifehrin macrocycle</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9473</span>– <span class="NLM_lpage">9499</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00802</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00802" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVChtbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9473-9499&author=R.+L.+Mackmanauthor=V.+A.+Steadmanauthor=D.+K.+Deanauthor=P.+Jansaauthor=K.+G.+Poullennecauthor=T.+Applebyauthor=C.+Austinauthor=C.+A.+Blakemoreauthor=R.+Caiauthor=C.+Cannizzaroauthor=G.+Chinauthor=J.+C.+Chivaauthor=N.+A.+Dunbarauthor=H.+Fliriauthor=A.+J.+Hightonauthor=H.+Huiauthor=M.+Jiauthor=H.+Jinauthor=K.+Karkiauthor=A.+J.+Keatsauthor=L.+Lazaridesauthor=Y.+J.+Leeauthor=A.+Liclicanauthor=M.+Mishauthor=B.+Murrayauthor=S.+B.+Pettitauthor=P.+Pyunauthor=M.+Sangiauthor=R.+Santosauthor=J.+Sanvoisinauthor=U.+Schmitzauthor=A.+Schrierauthor=D.+Siegelauthor=D.+Sperandioauthor=G.+Stepanauthor=Y.+Tianauthor=G.+M.+Wattauthor=H.+Yangauthor=B.+E.+Schultz&title=Discovery+of+a+potent+and+orally+bioavailable+cyclophilin+inhibitor+derived+from+the+sanglifehrin+macrocycle&doi=10.1021%2Facs.jmedchem.8b00802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a potent and orally bioavailable cyclophilin inhibitor derived from the sanglifehrin macrocycle</span></div><div class="casAuthors">Mackman, Richard L.; Steadman, Victoria A.; Dean, David K.; Jansa, Petr; Poullennec, Karine G.; Appleby, Todd; Austin, Carol; Blakemore, Caroline A.; Cai, Ruby; Cannizzaro, Carina; Chin, Gregory; Chiva, Jean-Yves C.; Dunbar, Neil A.; Fliri, Hans; Highton, Adrian J.; Hui, Hon; Ji, Mingzhe; Jin, Haolun; Karki, Kapil; Keats, Andrew J.; Lazarides, Linos; Lee, Yu-Jen; Liclican, Albert; Mish, Michael; Murray, Bernard; Pettit, Simon B.; Pyun, Peter; Sangi, Michael; Santos, Rex; Sanvoisin, Jonathan; Schmitz, Uli; Schrier, Adam; Siegel, Dustin; Sperandio, David; Stepan, George; Tian, Yang; Watt, Gregory M.; Yang, Hai; Schultz, Brian E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9473-9499</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclophilins are a family of peptidyl-prolyl isomerases that are implicated in a wide range of diseases including hepatitis C.  Our aim was to discover through total synthesis an orally bioavailable, non-immunosuppressive cyclophilin (Cyp) inhibitor with potent anti-hepatitis C virus (HCV) activity that could serve as part of an all oral antiviral combination therapy.  An initial lead (I) derived from the sanglifehrin A macrocycle was optimized using structure based design to produce a potent and orally bioavailable inhibitor (II).  The macrocycle ring size was reduced by one atom, and an internal hydrogen bond drove improved permeability and drug-like properties. II demonstrates potent Cyp inhibition (Kd = 5 nM), potent anti-HCV 2a activity (EC50 = 98 nM), and high oral bioavailability in rat (100%) and dog (55%).  The synthetic accessibility and properties of II support its potential as an anti-HCV agent and for interrogating the role of Cyp inhibition in a variety of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEpEZcwXK8z7Vg90H21EOLACvtfcHk0lgy3qaobGLVzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVChtbrI&md5=616cf72e0d2766e159769166c98a9e86</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00802%26sid%3Dliteratum%253Aachs%26aulast%3DMackman%26aufirst%3DR.%2BL.%26aulast%3DSteadman%26aufirst%3DV.%2BA.%26aulast%3DDean%26aufirst%3DD.%2BK.%26aulast%3DJansa%26aufirst%3DP.%26aulast%3DPoullennec%26aufirst%3DK.%2BG.%26aulast%3DAppleby%26aufirst%3DT.%26aulast%3DAustin%26aufirst%3DC.%26aulast%3DBlakemore%26aufirst%3DC.%2BA.%26aulast%3DCai%26aufirst%3DR.%26aulast%3DCannizzaro%26aufirst%3DC.%26aulast%3DChin%26aufirst%3DG.%26aulast%3DChiva%26aufirst%3DJ.%2BC.%26aulast%3DDunbar%26aufirst%3DN.%2BA.%26aulast%3DFliri%26aufirst%3DH.%26aulast%3DHighton%26aufirst%3DA.%2BJ.%26aulast%3DHui%26aufirst%3DH.%26aulast%3DJi%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DKarki%26aufirst%3DK.%26aulast%3DKeats%26aufirst%3DA.%2BJ.%26aulast%3DLazarides%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DY.%2BJ.%26aulast%3DLiclican%26aufirst%3DA.%26aulast%3DMish%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DB.%26aulast%3DPettit%26aufirst%3DS.%2BB.%26aulast%3DPyun%26aufirst%3DP.%26aulast%3DSangi%26aufirst%3DM.%26aulast%3DSantos%26aufirst%3DR.%26aulast%3DSanvoisin%26aufirst%3DJ.%26aulast%3DSchmitz%26aufirst%3DU.%26aulast%3DSchrier%26aufirst%3DA.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DSperandio%26aufirst%3DD.%26aulast%3DStepan%26aufirst%3DG.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DWatt%26aufirst%3DG.%2BM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520orally%2520bioavailable%2520cyclophilin%2520inhibitor%2520derived%2520from%2520the%2520sanglifehrin%2520macrocycle%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9473%26epage%3D9499%26doi%3D10.1021%2Facs.jmedchem.8b00802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsumura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yashiroda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niwa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chikada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washizuka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirama, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umehara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirouzu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shitara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muramatsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seimiya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel spiroindoline derivatives as selective tankyrase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3407</span>– <span class="NLM_lpage">3427</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01888</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01888" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltFertbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3407-3427&author=F.+Shiraiauthor=T.+Tsumuraauthor=Y.+Yashirodaauthor=H.+Yukiauthor=H.+Niwaauthor=S.+Satoauthor=T.+Chikadaauthor=Y.+Kodaauthor=K.+Washizukaauthor=N.+Yoshimotoauthor=M.+Abeauthor=T.+Onukiauthor=Y.+Mazakiauthor=C.+Hiramaauthor=T.+Fukamiauthor=H.+Watanabeauthor=T.+Honmaauthor=T.+Umeharaauthor=M.+Shirouzuauthor=M.+Okueauthor=Y.+Kanoauthor=T.+Watanabeauthor=K.+Kitamuraauthor=E.+Shitaraauthor=Y.+Muramatsuauthor=H.+Yoshidaauthor=A.+Mizutaniauthor=H.+Seimiyaauthor=M.+Yoshidaauthor=H.+Koyama&title=Discovery+of+novel+spiroindoline+derivatives+as+selective+tankyrase+inhibitors&doi=10.1021%2Facs.jmedchem.8b01888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors</span></div><div class="casAuthors">Shirai, Fumiyuki; Tsumura, Takeshi; Yashiroda, Yoko; Yuki, Hitomi; Niwa, Hideaki; Sato, Shin; Chikada, Tsubasa; Koda, Yasuko; Washizuka, Kenichi; Yoshimoto, Nobuko; Abe, Masako; Onuki, Tetsuo; Mazaki, Yui; Hirama, Chizuko; Fukami, Takehiro; Watanabe, Hirofumi; Honma, Teruki; Umehara, Takashi; Shirouzu, Mikako; Okue, Masayuki; Kano, Yuko; Watanabe, Takashi; Kitamura, Kouichi; Shitara, Eiki; Muramatsu, Yukiko; Yoshida, Haruka; Mizutani, Anna; Seimiya, Hiroyuki; Yoshida, Minoru; Koyama, Hiroo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3407-3427</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The canonical WNT pathway plays an important role in cancer pathogenesis.  Inhibition of poly(ADP-ribose) polymerase catalytic activity of the tankyrases (TNKS/TNKS2) has been reported to reduce the Wnt/β-catenin signal by preventing poly ADP-ribosylation dependent degrdn. of AXIN, a neg. regulator of Wnt/β-catenin signaling.  With the goal of investigating the effects of tankyrase and Wnt pathway inhibition on tumor growth, we set out to find small mol. inhibitors of TNKS/TNKS2 with suitable drug-like properties.  Starting from 1a(I), a high-throughput screening hit, the spiroindoline deriv. 40c(II) (RK-287107) was discovered as a potent TNKS/TNKS2 inhibitor with >7,000-fold selectivity against the PARP1 enzyme, which inhibits WNT-responsive TCF reporter activity and proliferation of human colorectal cancer cell line COLO-320DM.  II also demonstrated dose-dependent tumor growth inhibition in a mouse xenograft model.  These observations suggest that II is a promising lead compd. for the development of novel tankyrase inhibitors as anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb10HXpjf717Vg90H21EOLACvtfcHk0lgnstb1mwqCkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltFertbg%253D&md5=7877414ff5e5cfc908b1248017867639</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01888%26sid%3Dliteratum%253Aachs%26aulast%3DShirai%26aufirst%3DF.%26aulast%3DTsumura%26aufirst%3DT.%26aulast%3DYashiroda%26aufirst%3DY.%26aulast%3DYuki%26aufirst%3DH.%26aulast%3DNiwa%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DChikada%26aufirst%3DT.%26aulast%3DKoda%26aufirst%3DY.%26aulast%3DWashizuka%26aufirst%3DK.%26aulast%3DYoshimoto%26aufirst%3DN.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DOnuki%26aufirst%3DT.%26aulast%3DMazaki%26aufirst%3DY.%26aulast%3DHirama%26aufirst%3DC.%26aulast%3DFukami%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DHonma%26aufirst%3DT.%26aulast%3DUmehara%26aufirst%3DT.%26aulast%3DShirouzu%26aufirst%3DM.%26aulast%3DOkue%26aufirst%3DM.%26aulast%3DKano%26aufirst%3DY.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DKitamura%26aufirst%3DK.%26aulast%3DShitara%26aufirst%3DE.%26aulast%3DMuramatsu%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DMizutani%26aufirst%3DA.%26aulast%3DSeimiya%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DKoyama%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520novel%2520spiroindoline%2520derivatives%2520as%2520selective%2520tankyrase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3407%26epage%3D3427%26doi%3D10.1021%2Facs.jmedchem.8b01888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yashiroda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsumura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muramatsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chikada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niwa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washizuka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, M.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shitara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umehara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirouzu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seimiya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, H.</span></span> <span> </span><span class="NLM_article-title">Design and discovery of an orally efficacious spiroindolinone-based tankyrase inhibitor for the treatment of colon cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">4183</span>– <span class="NLM_lpage">4204</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00045</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00045" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BB3cXltl2mt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4183-4204&author=F.+Shiraiauthor=A.+Mizutaniauthor=Y.+Yashirodaauthor=T.+Tsumuraauthor=Y.+Kanoauthor=Y.+Muramatsuauthor=T.+Chikadaauthor=H.+Yukiauthor=H.+Niwaauthor=S.+Satoauthor=K.+Washizukaauthor=Y.+Kodaauthor=Y.+Mazakiauthor=M.-K.+Jangauthor=H.+Yoshidaauthor=A.+Nagamoriauthor=M.+Okueauthor=T.+Watanabeauthor=K.+Kitamuraauthor=E.+Shitaraauthor=T.+Honmaauthor=T.+Umeharaauthor=M.+Shirouzuauthor=T.+Fukamiauthor=H.+Seimiyaauthor=M.+Yoshidaauthor=H.+Koyama&title=Design+and+discovery+of+an+orally+efficacious+spiroindolinone-based+tankyrase+inhibitor+for+the+treatment+of+colon+cancer&doi=10.1021%2Facs.jmedchem.0c00045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer</span></div><div class="casAuthors">Shirai, Fumiyuki; Mizutani, Anna; Yashiroda, Yoko; Tsumura, Takeshi; Kano, Yuko; Muramatsu, Yukiko; Chikada, Tsubasa; Yuki, Hitomi; Niwa, Hideaki; Sato, Shin; Washizuka, Kenichi; Koda, Yasuko; Mazaki, Yui; Jang, Myung-Kyu; Yoshida, Haruka; Nagamori, Akiko; Okue, Masayuki; Watanabe, Takashi; Kitamura, Kouichi; Shitara, Eiki; Honma, Teruki; Umehara, Takashi; Shirouzu, Mikako; Fukami, Takehiro; Seimiya, Hiroyuki; Yoshida, Minoru; Koyama, Hiroo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4183-4204</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tankyrases (TNKS/TNKS2) belong to the poly(ADP-ribose) polymerase family.  Inhibition of their enzymic activities attenuates the Wnt/β-catenin signaling, which plays an important role in cancer pathogenesis.  We previously reported the discovery of RK-287107, a spiroindoline-based, highly selective, potent tankyrase inhibitor.  Herein we describe the optimization process of RK-287107 leading to RK-582, which exhibits a markedly improved robust tumor growth inhibition in a COLO-320DM mouse xenograft model when orally administered.  In addn. to the dose-dependent elevation and attenuation of the levels of biomarkers AXIN2 and β-catenin, resp., results of the TCF reporter and cell proliferation studies on COLO-320DM are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnxMuxDScpWLVg90H21EOLACvtfcHk0lgnstb1mwqCkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXltl2mt7g%253D&md5=8c55fd054daf7ccc91975379c2d8085b</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00045%26sid%3Dliteratum%253Aachs%26aulast%3DShirai%26aufirst%3DF.%26aulast%3DMizutani%26aufirst%3DA.%26aulast%3DYashiroda%26aufirst%3DY.%26aulast%3DTsumura%26aufirst%3DT.%26aulast%3DKano%26aufirst%3DY.%26aulast%3DMuramatsu%26aufirst%3DY.%26aulast%3DChikada%26aufirst%3DT.%26aulast%3DYuki%26aufirst%3DH.%26aulast%3DNiwa%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DWashizuka%26aufirst%3DK.%26aulast%3DKoda%26aufirst%3DY.%26aulast%3DMazaki%26aufirst%3DY.%26aulast%3DJang%26aufirst%3DM.-K.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DNagamori%26aufirst%3DA.%26aulast%3DOkue%26aufirst%3DM.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DKitamura%26aufirst%3DK.%26aulast%3DShitara%26aufirst%3DE.%26aulast%3DHonma%26aufirst%3DT.%26aulast%3DUmehara%26aufirst%3DT.%26aulast%3DShirouzu%26aufirst%3DM.%26aulast%3DFukami%26aufirst%3DT.%26aulast%3DSeimiya%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DKoyama%26aufirst%3DH.%26atitle%3DDesign%2520and%2520discovery%2520of%2520an%2520orally%2520efficacious%2520spiroindolinone-based%2520tankyrase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520colon%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D4183%26epage%3D4204%26doi%3D10.1021%2Facs.jmedchem.0c00045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newhouse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otten, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geck
Do, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutcher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLisle, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groneberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scearce-Levie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J. P.</span></span> <span> </span><span class="NLM_article-title">8-Tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">10112</span>– <span class="NLM_lpage">10129</span>, <span class="refDoi"> DOI: 10.1021/jm5015132</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5015132" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKqurnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10112-10129&author=A.+A.+Thomasauthor=K.+W.+Huntauthor=B.+Newhouseauthor=R.+J.+Wattsauthor=X.+Liuauthor=G.+Vigersauthor=D.+Smithauthor=S.+P.+Rhodesauthor=K.+D.+Brownauthor=J.+N.+Ottenauthor=M.+Burkardauthor=A.+A.+Coxauthor=M.+K.+Geck%0ADoauthor=D.+Dutcherauthor=S.+Ranaauthor=R.+K.+DeLisleauthor=K.+Regalauthor=A.+D.+Wrightauthor=R.+Gronebergauthor=J.+Liaoauthor=K.+Scearce-Levieauthor=M.+Siuauthor=H.+E.+Purkeyauthor=J.+P.+Lyssikatos&title=8-Tetrahydropyran-2-yl+chromans%3A+highly+selective+beta-site+amyloid+precursor+protein+cleaving+enzyme+1+%28BACE1%29+inhibitors&doi=10.1021%2Fjm5015132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">8-Tetrahydropyran-2-yl Chromans: Highly Selective Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors</span></div><div class="casAuthors">Thomas, Allen A.; Hunt, Kevin W.; Newhouse, Brad; Watts, Ryan J.; Liu, Xingrong; Vigers, Guy; Smith, Darin; Rhodes, Susan P.; Brown, Karin D.; Otten, Jennifer N.; Burkard, Michael; Cox, April A.; Geck Do, Mary K.; Dutcher, Darrin; Rana, Sumeet; DeLisle, Robert K.; Regal, Kelly; Wright, Albion D.; Groneberg, Robert; Liao, Jiangpeng; Scearce-Levie, Kimberly; Siu, Michael; Purkey, Hans E.; Lyssikatos, Joseph P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10112-10129</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hexahydropyrano[3,2-b]chromenes such as I were prepd. as inhibitors of β-site amyloid cleaving enzyme 1 (BACE1) selective for BACE1 over cathepsin D (CatD).  Three different Asp-binding moieties were examd. (spirocyclic acyl guanidines, spirocyclic aminooxazolines, and spirocyclic aminothiazolines) in order to modulate potency, selectivity, efflux, and permeability; changes to the aryl substituents of the pyranochromene moiety and substitution of a ring junction proton with a Me group were also studied.  In particular, spirocyclic aminooxazoline and aminothiazoline inhibitors with Me substituents possessed excellent cellular potency (37-137 nM) for inhibiting BACE1 and high selectivity (435 to >2000-fold) for BACE1 vs CatD.  These efforts led to nonracemic I, which demonstrated a 69% redn. in rat CSF Aβ1-40 at a dosage of 60 mg/kg (PO).  The complexes of four hexahydropyrano[3,2-b]chromenes bound to BACE-1 were detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKJ3ssfyhPHrVg90H21EOLACvtfcHk0li8bA4UrH2a_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKqurnK&md5=827f89cabdaa149283d04f030a3d5568</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Fjm5015132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5015132%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DA.%2BA.%26aulast%3DHunt%26aufirst%3DK.%2BW.%26aulast%3DNewhouse%26aufirst%3DB.%26aulast%3DWatts%26aufirst%3DR.%2BJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DRhodes%26aufirst%3DS.%2BP.%26aulast%3DBrown%26aufirst%3DK.%2BD.%26aulast%3DOtten%26aufirst%3DJ.%2BN.%26aulast%3DBurkard%26aufirst%3DM.%26aulast%3DCox%26aufirst%3DA.%2BA.%26aulast%3DGeck%2BDo%26aufirst%3DM.%2BK.%26aulast%3DDutcher%26aufirst%3DD.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DDeLisle%26aufirst%3DR.%2BK.%26aulast%3DRegal%26aufirst%3DK.%26aulast%3DWright%26aufirst%3DA.%2BD.%26aulast%3DGroneberg%26aufirst%3DR.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DScearce-Levie%26aufirst%3DK.%26aulast%3DSiu%26aufirst%3DM.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26atitle%3D8-Tetrahydropyran-2-yl%2520chromans%253A%2520highly%2520selective%2520beta-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%25201%2520%2528BACE1%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10112%26epage%3D10129%26doi%3D10.1021%2Fjm5015132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanegawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moechars, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusakabe, K. I.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: Targeting the flap to gain selectivity over BACE2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5080</span>– <span class="NLM_lpage">5095</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00309</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotl2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5080-5095&author=K.+Fujimotoauthor=E.+Matsuokaauthor=N.+Asadaauthor=G.+Tadanoauthor=T.+Yamamotoauthor=K.+Nakaharaauthor=K.+Fuchinoauthor=H.+Itoauthor=N.+Kanegawaauthor=D.+Moecharsauthor=H.+J.+M.+Gijsenauthor=K.+I.+Kusakabe&title=Structure-based+design+of+selective+beta-site+amyloid+precursor+protein+cleaving+enzyme+1+%28BACE1%29+inhibitors%3A+Targeting+the+flap+to+gain+selectivity+over+BACE2&doi=10.1021%2Facs.jmedchem.9b00309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Selective β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2</span></div><div class="casAuthors">Fujimoto, Kazuki; Matsuoka, Eriko; Asada, Naoya; Tadano, Genta; Yamamoto, Takahiko; Nakahara, Kenji; Fuchino, Kouki; Ito, Hisanori; Kanegawa, Naoki; Moechars, Diederik; Gijsen, Harrie J. M.; Kusakabe, Ken-ichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5080-5095</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">BACE1 inhibitors hold potential as agents in disease-modifying treatment for Alzheimer's disease.  BACE2 cleaves the melanocyte protein PMEL in pigment cells of the skin and eye, generating melanin pigments.  This role of BACE2 implies that nonselective and chronic inhibition of BACE1 may cause side effects derived from BACE2.  Herein, we describe the discovery of potent and selective BACE1 inhibitors using structure-based drug design.  We targeted the flap region, where the shape and flexibility differ between these enzymes.  Anal. of the cocrystal structures of an initial lead 8 prompted us to incorporate spirocycles followed by its fine-tuning, culminating in highly selective compds. 21 and 22.  The structures of 22 bound to BACE1 and BACE2 revealed that a relatively high energetic penalty in the flap of the 22-bound BACE2 structure may cause a loss in BACE2 potency, thereby leading to its high selectivity.  These findings and insights should contribute to responding to the challenges in exploring selective BACE1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGdAN0ejWNyrVg90H21EOLACvtfcHk0li8bA4UrH2a_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotl2nt7w%253D&md5=9ceba959612bdac96dfdda689ad6f0e8</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00309%26sid%3Dliteratum%253Aachs%26aulast%3DFujimoto%26aufirst%3DK.%26aulast%3DMatsuoka%26aufirst%3DE.%26aulast%3DAsada%26aufirst%3DN.%26aulast%3DTadano%26aufirst%3DG.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DNakahara%26aufirst%3DK.%26aulast%3DFuchino%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DH.%26aulast%3DKanegawa%26aufirst%3DN.%26aulast%3DMoechars%26aufirst%3DD.%26aulast%3DGijsen%26aufirst%3DH.%2BJ.%2BM.%26aulast%3DKusakabe%26aufirst%3DK.%2BI.%26atitle%3DStructure-based%2520design%2520of%2520selective%2520beta-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%25201%2520%2528BACE1%2529%2520inhibitors%253A%2520Targeting%2520the%2520flap%2520to%2520gain%2520selectivity%2520over%2520BACE2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5080%26epage%3D5095%26doi%3D10.1021%2Facs.jmedchem.9b00309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sherwood, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paton, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggerstaff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuenswander, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivell, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prisinzano, T. E.</span></span> <span> </span><span class="NLM_article-title">Addressing structural flexibility at the A-ring on salvinorin A: Discovery of a potent kappa-opioid agonist with enhanced metabolic stability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3866</span>– <span class="NLM_lpage">3878</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00148</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00148" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1Gls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3866-3878&author=A.+M.+Sherwoodauthor=R.+S.+Crowleyauthor=K.+F.+Patonauthor=A.+Biggerstaffauthor=B.+Neuenswanderauthor=V.+W.+Dayauthor=B.+M.+Kivellauthor=T.+E.+Prisinzano&title=Addressing+structural+flexibility+at+the+A-ring+on+salvinorin+A%3A+Discovery+of+a+potent+kappa-opioid+agonist+with+enhanced+metabolic+stability&doi=10.1021%2Facs.jmedchem.7b00148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability</span></div><div class="casAuthors">Sherwood, Alexander M.; Crowley, Rachel Saylor; Paton, Kelly F.; Biggerstaff, Andrew; Neuenswander, Benjamin; Day, Victor W.; Kivell, Bronwyn M.; Prisinzano, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3866-3878</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Previous structure-activity studies on the neoclerodane diterpenoid salvinorin A have demonstrated the importance of the acetoxy functionality on the A-ring in its activity as a kappa opioid receptor agonist.  Few studies have focused on understanding the role of conformation in these interactions.  Herein we describe the synthesis and evaluation of both flexible and conformationally restricted compds. derived from salvinorin A.  One such compd., spirobutyrolactone (I), was synthesized in a single step from salvinorin B and had similar potency and selectivity to salvinorin A (EC50 = 0.6 ± 0.2 nM at κ >10,000 nM at μ and δ).  Microsomal stability studies demonstrated that 14 was more metabolically resistant than salvinorin A.  Evaluation of analgesic and anti-inflammatory properties revealed similar in vivo effects between 14 and salvinorin A.  To our knowledge, this study represents the first example of bioisosteric replacement of an acetate group by a spirobutyrolactone to produce a metabolically resistant deriv.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphQfDVKsiZz7Vg90H21EOLACvtfcHk0li8bA4UrH2a_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1Gls7s%253D&md5=32073a4c5da4fb19e2d9adc0bba34d2d</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00148%26sid%3Dliteratum%253Aachs%26aulast%3DSherwood%26aufirst%3DA.%2BM.%26aulast%3DCrowley%26aufirst%3DR.%2BS.%26aulast%3DPaton%26aufirst%3DK.%2BF.%26aulast%3DBiggerstaff%26aufirst%3DA.%26aulast%3DNeuenswander%26aufirst%3DB.%26aulast%3DDay%26aufirst%3DV.%2BW.%26aulast%3DKivell%26aufirst%3DB.%2BM.%26aulast%3DPrisinzano%26aufirst%3DT.%2BE.%26atitle%3DAddressing%2520structural%2520flexibility%2520at%2520the%2520A-ring%2520on%2520salvinorin%2520A%253A%2520Discovery%2520of%2520a%2520potent%2520kappa-opioid%2520agonist%2520with%2520enhanced%2520metabolic%2520stability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D3866%26epage%3D3878%26doi%3D10.1021%2Facs.jmedchem.7b00148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michaelides, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluge, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Drie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risi, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karukurichi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nesterov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElligott, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmorstein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bromberg, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesicki, E. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of spiro oxazolidinediones as selective, orally bioavailable inhibitors of p300/CBP histone acetyltransferases</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00395</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00395" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOqsrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=28-33&author=M.+R.+Michaelidesauthor=A.+Klugeauthor=M.+Pataneauthor=J.+H.+Van+Drieauthor=C.+Wangauthor=T.+M.+Hansenauthor=R.+M.+Risiauthor=R.+Manteiauthor=C.+Hertelauthor=K.+Karukurichiauthor=A.+Nesterovauthor=D.+McElligottauthor=P.+de+Vriesauthor=J.+W.+Langstonauthor=P.+A.+Coleauthor=R.+Marmorsteinauthor=H.+Liuauthor=L.+Laskoauthor=K.+D.+Brombergauthor=A.+Laiauthor=E.+A.+Kesicki&title=Discovery+of+spiro+oxazolidinediones+as+selective%2C+orally+bioavailable+inhibitors+of+p300%2FCBP+histone+acetyltransferases&doi=10.1021%2Facsmedchemlett.7b00395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases</span></div><div class="casAuthors">Michaelides, Michael R.; Kluge, Arthur; Patane, Michael; Van Drie, John H.; Wang, Ce; Hansen, T. Matthew; Risi, Roberto M.; Mantei, Robert; Hertel, Carmen; Karukurichi, Kannan; Nesterov, Alexandre; McElligott, David; de Vries, Peter; Langston, J. William; Cole, Philip A.; Marmorstein, Ronen; Liu, Hong; Lasko, Loren; Bromberg, Kenneth D.; Lai, Albert; Kesicki, Edward A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-33</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P300 and its paralog CBP can acetylate histones and other proteins and have been implicated in a no. of diseases characterized by aberrant gene activation, such as cancer.  A novel, highly selective, orally bioavailable histone acetyltransferase (HAT) domain inhibitor has been identified through virtual ligand screening and subsequent optimization of a unique hydantoin screening hit.  Conformational restraint in the form of a spirocyclization followed by substitution with a urea led to a significant improvement in potency.  Replacement of the hydantoin moiety with an oxazolidinedione followed by fluoro substitution led to A-485, which exhibits potent cell activity, low clearance, and high oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ091OW0sfXbVg90H21EOLACvtfcHk0liurG9bPVYQdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOqsrnE&md5=3ba083fc5e148d06457d2e4015ac7475</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00395%26sid%3Dliteratum%253Aachs%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26aulast%3DKluge%26aufirst%3DA.%26aulast%3DPatane%26aufirst%3DM.%26aulast%3DVan%2BDrie%26aufirst%3DJ.%2BH.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHansen%26aufirst%3DT.%2BM.%26aulast%3DRisi%26aufirst%3DR.%2BM.%26aulast%3DMantei%26aufirst%3DR.%26aulast%3DHertel%26aufirst%3DC.%26aulast%3DKarukurichi%26aufirst%3DK.%26aulast%3DNesterov%26aufirst%3DA.%26aulast%3DMcElligott%26aufirst%3DD.%26aulast%3Dde%2BVries%26aufirst%3DP.%26aulast%3DLangston%26aufirst%3DJ.%2BW.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DMarmorstein%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLasko%26aufirst%3DL.%26aulast%3DBromberg%26aufirst%3DK.%2BD.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DKesicki%26aufirst%3DE.%2BA.%26atitle%3DDiscovery%2520of%2520spiro%2520oxazolidinediones%2520as%2520selective%252C%2520orally%2520bioavailable%2520inhibitors%2520of%2520p300%252FCBP%2520histone%2520acetyltransferases%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D28%26epage%3D33%26doi%3D10.1021%2Facsmedchemlett.7b00395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Escobar-Alvarez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouerfelli, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaney, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheinberg, D. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of human peptide deformylase disrupts mitochondrial function</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">5099</span>– <span class="NLM_lpage">5109</span>, <span class="refDoi"> DOI: 10.1128/MCB.00469-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1128%2FMCB.00469-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=20805355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVams77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=5099-5109&author=S.+Escobar-Alvarezauthor=J.+Gardnerauthor=A.+Shethauthor=G.+Manfrediauthor=G.+Yangauthor=O.+Ouerfelliauthor=M.+L.+Heaneyauthor=D.+A.+Scheinberg&title=Inhibition+of+human+peptide+deformylase+disrupts+mitochondrial+function&doi=10.1128%2FMCB.00469-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human peptide deformylase disrupts mitochondrial function</span></div><div class="casAuthors">Escobar-Alvarez, Sindy; Gardner, Jeffrey; Sheth, Aneesh; Manfredi, Giovanni; Yang, Guangli; Ouerfelli, Ouathek; Heaney, Mark L.; Scheinberg, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5099-5109</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Deformylases are metalloproteases in bacteria, plants, and humans that remove the N-formyl-methionine off peptides in vitro.  The human homolog of peptide deformylase (HsPDF) resides in the mitochondria, along with its putative formylated substrates; however, the cellular function of HsPDF remains elusive.  Here we report on the function of HsPDF in mitochondrial translation and oxidative phosphorylation complex biogenesis.  Functional HsPDF appears to be necessary for the accumulation of mitochondrial DNA-encoded proteins and assembly of new respiratory complexes contg. these proteins.  Consequently, inhibition of HsPDF reduces respiratory function and cellular ATP levels, causing dependence on aerobic glycolysis for cell survival.  A series of structurally different HsPDF inhibitors and control peptidase inhibitors confirmed that inhibition of HsPDF decreases mtDNA-encoded protein accumulation.  Therefore, HsPDF appears to have a role in maintenance of mitochondrial respiratory function, and this function is analogous to that of chloroplast PDF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZERhqg9LoibVg90H21EOLACvtfcHk0liurG9bPVYQdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVams77N&md5=e10c8db4910169d431baa07f6d6a2675</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1128%2FMCB.00469-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00469-10%26sid%3Dliteratum%253Aachs%26aulast%3DEscobar-Alvarez%26aufirst%3DS.%26aulast%3DGardner%26aufirst%3DJ.%26aulast%3DSheth%26aufirst%3DA.%26aulast%3DManfredi%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DOuerfelli%26aufirst%3DO.%26aulast%3DHeaney%26aufirst%3DM.%2BL.%26aulast%3DScheinberg%26aufirst%3DD.%2BA.%26atitle%3DInhibition%2520of%2520human%2520peptide%2520deformylase%2520disrupts%2520mitochondrial%2520function%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2010%26volume%3D30%26spage%3D5099%26epage%3D5109%26doi%3D10.1128%2FMCB.00469-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Randhawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chikara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehring, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yildirim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reindl, K. M.</span></span> <span> </span><span class="NLM_article-title">Overexpression of peptide deformylase in breast, colon, and lung cancers</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">321</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-13-321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1186%2F1471-2407-13-321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=23815882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1ert7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=321&author=H.+Randhawaauthor=S.+Chikaraauthor=D.+Gehringauthor=T.+Yildirimauthor=J.+Menonauthor=K.+M.+Reindl&title=Overexpression+of+peptide+deformylase+in+breast%2C+colon%2C+and+lung+cancers&doi=10.1186%2F1471-2407-13-321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of peptide deformylase in breast, colon, and lung cancers</span></div><div class="casAuthors">Randhawa, Harsharan; Chikara, Shireen; Gehring, Drew; Yildirim, Tuba; Menon, Jyotsana; Reindl, Katie M.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">321</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Human mitochondrial peptide deformylase (PDF) has been proposed as a novel cancer therapeutic target.  However, very little is known about its expression and regulation in human tissues.  The purpose of this study was to characterize the expression pattern of PDF in cancerous tissues and to identify mechanisms that regulate its expression.  Methods: The mRNA expression levels of PDF and methionine aminopeptidase 1D (MAP1D), an enzyme involved in a related pathway with PDF, were detd. using tissue panels contg. cDNA from patients with various types of cancer (breast, colon, kidney, liver, lung, ovarian, prostate, or thyroid) and human cell lines.  Protein levels of PDF were also detd. in 2 colon cancer patients via western blotting.  Colon cancer cells were treated with inhibitors of ERK, Akt, and mTOR signaling pathways and the resulting effects on PDF and MAP1D mRNA levels were detd. by qPCR for colon and lung cancer cell lines.  Finally, the effects of a PDF inhibitor, actinonin, on the proliferation of breast, colon, and prostate cell lines were detd. using the CyQUANT assay.  Results: PDF and MAP1D mRNA levels were elevated in cancer cell lines compared to non-cancer lines.  PDF mRNA levels were significantly increased in breast, colon, and lung cancer samples while MAP1D mRNA levels were increased in just colon cancers.  The expression of PDF and MAP1D varied with stage in these cancers.  Further, PDF protein expression was elevated in colon cancer tissue samples.  Inhibition of the MEK/ERK, but not PI3K or mTOR, pathway reduced the expression of PDF and MAP1D in both colon and lung cancer cell lines.  Further, inhibition of PDF with actinonin resulted in greater redn. of breast, colon, and prostate cancer cell proliferation than non-cancer cell lines.  Conclusions: This is the first report showing that PDF is over-expressed in breast, colon, and lung cancers, and the first evidence that the MEK/ERK pathway plays a role in regulating the expression of PDF and MAP1D.  The over expression of PDF in several cancers and the inhibition of cancer cell growth by a PDF inhibitor suggest this enzyme may act as an oncogene to promote cancer cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4-itOPYaIi7Vg90H21EOLACvtfcHk0liurG9bPVYQdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1ert7fM&md5=525b45c0c0147d4abf2a25c8ce7e3191</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-13-321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-13-321%26sid%3Dliteratum%253Aachs%26aulast%3DRandhawa%26aufirst%3DH.%26aulast%3DChikara%26aufirst%3DS.%26aulast%3DGehring%26aufirst%3DD.%26aulast%3DYildirim%26aufirst%3DT.%26aulast%3DMenon%26aufirst%3DJ.%26aulast%3DReindl%26aufirst%3DK.%2BM.%26atitle%3DOverexpression%2520of%2520peptide%2520deformylase%2520in%2520breast%252C%2520colon%252C%2520and%2520lung%2520cancers%26jtitle%3DBMC%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D321%26doi%3D10.1186%2F1471-2407-13-321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and anticancer activity of novel actinonin derivatives as HsPDF inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">6959</span>– <span class="NLM_lpage">6978</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00079</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00079" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Slt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=6959-6978&author=L.+Huauthor=X.+Caiauthor=S.+Dongauthor=Y.+Zhenauthor=J.+Huauthor=S.+Wangauthor=J.+Jiangauthor=J.+Huangauthor=Y.+Hanauthor=Y.+Qianauthor=Y.+Yuanauthor=W.+Hu&title=Synthesis+and+anticancer+activity+of+novel+actinonin+derivatives+as+HsPDF+inhibitors&doi=10.1021%2Facs.jmedchem.0c00079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and anticancer activity of novel Actinonin derivatives as HsPDF inhibitors</span></div><div class="casAuthors">Hu, Liu; Cai, Xing; Dong, Suzhen; Zhen, Yongjia; Hu, Jidi; Wang, Shenjun; Jiang, Jingwen; Huang, Jiawu; Han, Yuqiao; Qian, Yu; Yuan, Yanqiu; Hu, Wenhao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6959-6978</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human mitochondrial peptide deformylase (HsPDF) is responsible for removing the formyl group from N-terminal formylmethionines of newly synthesized mitochondrial proteins and plays important roles in maintaining mitochondria function.  It is overexpressed in various cancers and has been proposed as a novel therapeutic target.  Actinonin, a naturally occurring peptidomimetic HsPDF inhibitor, was reported to inhibit the proliferation of a broad spectrum of human cancer cells in vitro.  However, its efficacy and pharmacokinetic profile requires significant improvement for therapeutic purposes.  To obtain HsPDF inhibitors as anticancer therapeutics, we screened an inhouse collection of actinonin derivs. and found two initial hits with antiproliferation activity.  Further optimization along the peptidomimetic backbone lead to two series of compds. contg. substituted Ph moieties.  They are potent HsPDF inhibitors and exhibited greatly improved antiproliferation activity in selected cancer cell lines.  Finally, compd. (I) significantly inhibited the growth of human colon cancer in xenograft animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVqwuMEsV71bVg90H21EOLACvtfcHk0lhQqzHLRbxvmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Slt7vP&md5=33ed3163f3be5502ca7f3be61de48a96</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00079%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DL.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DS.%26aulast%3DZhen%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DW.%26atitle%3DSynthesis%2520and%2520anticancer%2520activity%2520of%2520novel%2520actinonin%2520derivatives%2520as%2520HsPDF%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D6959%26epage%3D6978%26doi%3D10.1021%2Facs.jmedchem.0c00079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goadsby, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edvinsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekman, R.</span></span> <span> </span><span class="NLM_article-title">Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1002/ana.410230214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fana.410230214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=2454066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaL1cXhsVeqsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1988&pages=193-196&author=P.+J.+Goadsbyauthor=L.+Edvinssonauthor=R.+Ekman&title=Release+of+vasoactive+peptides+in+the+extracerebral+circulation+of+humans+and+the+cat+during+activation+of+the+trigeminovascular+system&doi=10.1002%2Fana.410230214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system</span></div><div class="casAuthors">Goadsby, P. J.; Edvinsson, L.; Ekman, R.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">193-6</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    </div><div class="casAbstract">The trigeminal ganglion was activated, in humans by thermocoagulation as part of the treatment of trigeminal neuralgia and in cats by elec. stimulation, and blood samples were taken from the external jugular vein for ests. of plasma levels of substance P and calcitonin gene-related peptide (CGRP).  In those patients who were noted at the time of coagulation to have flushed there were marked elevations of the local (cranial) levels of both peptides.  However, in the nonflushing patients no changes in the peptide levels were obsd.  Parallel expts. in the cat revealed that the levels of substance P-like and CGRP-like immunoreactivity were increased during elec. stimulation of the trigeminal ganglion.  The observation of elevation of substance P-like and CGRP-like immunoreactivity after activation of the nociceptive afferent system of the head provides new insights into a putative role of peptides in the pathophysiol. of migraine and cluster headache, and suggests new areas of possible therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPF6kxitFWh7Vg90H21EOLACvtfcHk0lhQqzHLRbxvmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXhsVeqsLo%253D&md5=429d3f356dca62e015608b76b40ac533</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1002%2Fana.410230214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.410230214%26sid%3Dliteratum%253Aachs%26aulast%3DGoadsby%26aufirst%3DP.%2BJ.%26aulast%3DEdvinsson%26aufirst%3DL.%26aulast%3DEkman%26aufirst%3DR.%26atitle%3DRelease%2520of%2520vasoactive%2520peptides%2520in%2520the%2520extracerebral%2520circulation%2520of%2520humans%2520and%2520the%2520cat%2520during%2520activation%2520of%2520the%2520trigeminovascular%2520system%26jtitle%3DAnn.%2520Neurol.%26date%3D1988%26volume%3D23%26spage%3D193%26epage%3D196%26doi%3D10.1002%2Fana.410230214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edvinsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanes, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warfvinge, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, D. N.</span></span> <span> </span><span class="NLM_article-title">CGRP as the target of new migraine therapies - successful translation from bench to clinic</span>. <i>Nat. Rev. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">350</span>, <span class="refDoi"> DOI: 10.1038/s41582-018-0003-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2Fs41582-018-0003-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=29691490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXos1Knsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=338-350&author=L.+Edvinssonauthor=K.+A.+Haanesauthor=K.+Warfvingeauthor=D.+N.+Krause&title=CGRP+as+the+target+of+new+migraine+therapies+-+successful+translation+from+bench+to+clinic&doi=10.1038%2Fs41582-018-0003-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">CGRP as the target of new migraine therapies - successful translation from bench to clinic</span></div><div class="casAuthors">Edvinsson, Lars; Haanes, Kristian Agmund; Warfvinge, Karin; Krause, Diana N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neurology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">338-350</span>CODEN:
                <span class="NLM_cas:coden">NRNACP</span>;
        ISSN:<span class="NLM_cas:issn">1759-4758</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Treatment of migraine is on the cusp of a new era with the development of drugs that target the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its receptor.  Several of these drugs are expected to receive approval for use in migraine headache in 2018 and 2019.  CGRP-related therapies offer considerable improvements over existing drugs as they are the first to be designed specifically to act on the trigeminal pain system, they are more specific and they seem to have few or no adverse effects.  CGRP receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively prevent migraine attacks.  As these drugs come into clin. use, we provide an overview of knowledge that has led to successful development of these drugs.  We describe the biol. of CGRP signalling, summarize key clin. evidence for the role of CGRP in migraine headache, including the efficacy of CGRP-targeted treatment, and synthesize what is known about the role of CGRP in the trigeminovascular system.  Finally, we consider how the latest findings provide new insight into the central role of the trigeminal ganglion in the pathophysiol. of migraine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMGVuYa3fHurVg90H21EOLACvtfcHk0lhQqzHLRbxvmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXos1Knsrk%253D&md5=bd946d0558d71beb2cf78ca43d56c78c</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fs41582-018-0003-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41582-018-0003-1%26sid%3Dliteratum%253Aachs%26aulast%3DEdvinsson%26aufirst%3DL.%26aulast%3DHaanes%26aufirst%3DK.%2BA.%26aulast%3DWarfvinge%26aufirst%3DK.%26aulast%3DKrause%26aufirst%3DD.%2BN.%26atitle%3DCGRP%2520as%2520the%2520target%2520of%2520new%2520migraine%2520therapies%2520-%2520successful%2520translation%2520from%2520bench%2520to%2520clinic%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2018%26volume%3D14%26spage%3D338%26epage%3D350%26doi%3D10.1038%2Fs41582-018-0003-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubowchik, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, A. W.</span></span> <span> </span><span class="NLM_article-title">Blocking the CGRP pathway for acute and preventive treatment of migraine: The evolution of success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">6600</span>– <span class="NLM_lpage">6623</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01810</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01810" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFGitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=6600-6623&author=G.+M.+Dubowchikauthor=C.+M.+Conwayauthor=A.+W.+Xin&title=Blocking+the+CGRP+pathway+for+acute+and+preventive+treatment+of+migraine%3A+The+evolution+of+success&doi=10.1021%2Facs.jmedchem.9b01810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success</span></div><div class="casAuthors">Dubowchik, Gene M.; Conway, Charles M.; Xin, Alison W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6600-6623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The pivotal role of calcitonin gene-related peptide (CGRP) in migraine pathophysiol. was identified over 30 years ago, but the successful clin. development of targeted therapies has only recently been realized.  This Perspective traces the decades long evolution of medicinal chem. required to advance small mol. CGRP receptor antagonists, also called gepants, including the current clin. agents rimegepant, vazegepant, ubrogepant, and atogepant.  Providing clin. effective blockade of CGRP signaling required surmounting multiple challenging hurdles, including defeating a sizable ligand with subnanomolar affinity for its receptor, designing antagonists with an extended confirmation and multiple pharmacophores while retaining soly. and oral bioavailability, and achieving circulating free plasma levels that provided near maximal CGRP receptor coverage.  The clin. efficacy of oral and intranasal gepants and the injectable CGRP monoclonal antibodies (mAbs) are described, as are recent synthetic developments that have benefited from new structural biol. data.  The first oral gepant was recently approved and heralds a new era in the treatment of migraine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM4FYBpPD8oLVg90H21EOLACvtfcHk0lgpzMKW8DUxuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFGitLY%253D&md5=f275362ece230e78851612557fec04f8</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01810%26sid%3Dliteratum%253Aachs%26aulast%3DDubowchik%26aufirst%3DG.%2BM.%26aulast%3DConway%26aufirst%3DC.%2BM.%26aulast%3DXin%26aufirst%3DA.%2BW.%26atitle%3DBlocking%2520the%2520CGRP%2520pathway%2520for%2520acute%2520and%2520preventive%2520treatment%2520of%2520migraine%253A%2520The%2520evolution%2520of%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D6600%26epage%3D6623%26doi%3D10.1021%2Facs.jmedchem.9b01810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, D.</span></span> <span> </span><span class="NLM_article-title">Sorbinil, an aldose reductase inhibitor, in fighting against diabetic complications</span>. <i>Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.2174/1573406414666180524082445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.2174%2F1573406414666180524082445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=29792152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2ht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=3-7&author=Q.+Huangauthor=Q.+Liuauthor=D.+Ouyang&title=Sorbinil%2C+an+aldose+reductase+inhibitor%2C+in+fighting+against+diabetic+complications&doi=10.2174%2F1573406414666180524082445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Sorbinil, an Aldose Reductase Inhibitor, in Fighting Against Diabetic Complications</span></div><div class="casAuthors">Huang, Qi; Liu, Qiong; Ouyang, Dongsheng</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-7</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: Aldose reductase (AR) is involved in the pathogenesis of diabetes, which is one of the major threats to global public health.  Objective: In this review article, we have discussed the role of sorbinil, an AR inhibitor (ARI), in preventing diabetic complications.  Results: AR contributes in diabetes by generating excess intracellular superoxide and other mediators of oxidative stress through polyol pathway.  Inhibition of AR activity thus might be a potential approach for the management of diabetic complications.  Exptl. evidences indicated that sorbinil can decrease AR activity and inhibit polyol pathway.  Both in vitro and animal model studies reported the efficacy of sorbinil in controlling the progression of diabetes.  Moreover, Sorbinil has been found to be comparatively safer than other ARIs for human use.  But, it is still in earlyphase testing for the treatment of diabetic complications clin.  Conclusion: Sorbinil is an effective ARI, which could play therapeutic role in treating diabetes and diabetic complications.  However, advanced clin. trials are required for sorbinil so that it could be applied with the lowest efficacious dose in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo868R204lrp7Vg90H21EOLACvtfcHk0lgpzMKW8DUxuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2ht70%253D&md5=ade5a79e7b1f01c47cc9367854103714</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.2174%2F1573406414666180524082445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1573406414666180524082445%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DOuyang%26aufirst%3DD.%26atitle%3DSorbinil%252C%2520an%2520aldose%2520reductase%2520inhibitor%252C%2520in%2520fighting%2520against%2520diabetic%2520complications%26jtitle%3DMed.%2520Chem.%26date%3D2019%26volume%3D15%26spage%3D3%26epage%3D7%26doi%3D10.2174%2F1573406414666180524082445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El-Kabbani, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darmanin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazemann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joachimiak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze-Briese, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomizaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitschler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podjarny, A.</span></span> <span> </span><span class="NLM_article-title">Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with fidarestat and minalrestat: Implications for the binding of cyclic imide inhibitors</span>. <i>Proteins: Struct., Funct., Genet.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">805</span>– <span class="NLM_lpage">813</span>, <span class="refDoi"> DOI: 10.1002/prot.20001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fprot.20001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=15146479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkslCjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2004&pages=805-813&author=O.+El-Kabbaniauthor=C.+Darmaninauthor=T.+R.+Schneiderauthor=I.+Hazemannauthor=F.+Ruizauthor=M.+Okaauthor=A.+Joachimiakauthor=C.+Schulze-Brieseauthor=T.+Tomizakiauthor=A.+Mitschlerauthor=A.+Podjarny&title=Ultrahigh+resolution+drug+design.+II.+Atomic+resolution+structures+of+human+aldose+reductase+holoenzyme+complexed+with+fidarestat+and+minalrestat%3A+Implications+for+the+binding+of+cyclic+imide+inhibitors&doi=10.1002%2Fprot.20001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: Implications for the binding of cyclic imide inhibitors</span></div><div class="casAuthors">El-Kabbani, Ossama; Darmanin, Connie; Schneider, Thomas R.; Hazemann, Isabelle; Ruiz, Federico; Oka, Mitsuru; Joachimiak, Andrzejj; Schulze-Briese, Clemens; Tomizaki, Takashi; Mitschler, Andre; Podjarny, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">805-813</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The x-ray structures of human aldose reductase holoenzyme in complex with the inhibitors Fidarestat (SNK-860) and Minalrestat (WAY-509) were detd. at at. resolns. of 0.92 Å and 1.1 Å, resp.  The hydantoin and succinimide moieties of the inhibitors interacted with the conserved anion-binding site located between the nicotinamide ring of the coenzyme and active site residues Tyr48, His110, and Trp111.  Minalrestat's hydrophobic isoquinoline ring was bound in an adjacent pocket lined by residues Trp20, Phe122, and Trp219, with the bromo-fluorobenzyl group inside the "specificity" pocket.  The interactions between Minalrestat's bromo-fluorobenzyl group and the enzyme include the stacking against the side-chain of Trp111 as well as hydrogen bonding distances with residues Leu300 and Thr113.  The carbamoyl group in Fidarestat formed a hydrogen bond with the main-chain nitrogen atom of Leu300.  The at. resoln. refinement allowed the positioning of hydrogen atoms and accurate detn. of bond lengths of the inhibitors, coenzyme NADP+ and active-site residue His110.  The 1'-position nitrogen atom in the hydantoin and succinimide moieties of Fidarestat and Minalrestat, resp., form a hydrogen bond with the Nε2 atom of His 110.  For Fidarestat, the electron d. indicated two possible positions for the H-atom in this bond.  Furthermore, both native and anomalous difference maps indicated the replacement of a water mol. linked to His110 by a CI-ion.  These observations suggest a mechanism in which Fidarestat is bound protonated and becomes neg. charged by donating the proton to His110, which may have important implications on drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9xAk-M-tpubVg90H21EOLACvtfcHk0lgpzMKW8DUxuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkslCjtLo%253D&md5=de972dd5f58825024773742f346de1cc</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1002%2Fprot.20001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.20001%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Kabbani%26aufirst%3DO.%26aulast%3DDarmanin%26aufirst%3DC.%26aulast%3DSchneider%26aufirst%3DT.%2BR.%26aulast%3DHazemann%26aufirst%3DI.%26aulast%3DRuiz%26aufirst%3DF.%26aulast%3DOka%26aufirst%3DM.%26aulast%3DJoachimiak%26aufirst%3DA.%26aulast%3DSchulze-Briese%26aufirst%3DC.%26aulast%3DTomizaki%26aufirst%3DT.%26aulast%3DMitschler%26aufirst%3DA.%26aulast%3DPodjarny%26aufirst%3DA.%26atitle%3DUltrahigh%2520resolution%2520drug%2520design.%2520II.%2520Atomic%2520resolution%2520structures%2520of%2520human%2520aldose%2520reductase%2520holoenzyme%2520complexed%2520with%2520fidarestat%2520and%2520minalrestat%253A%2520Implications%2520for%2520the%2520binding%2520of%2520cyclic%2520imide%2520inhibitors%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2004%26volume%3D55%26spage%3D805%26epage%3D813%26doi%3D10.1002%2Fprot.20001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El-Kabbani, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbone, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darmanin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitschler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podjarny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze-Briese, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, R. P.</span></span> <span> </span><span class="NLM_article-title">Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">5536</span>– <span class="NLM_lpage">5542</span>, <span class="refDoi"> DOI: 10.1021/jm050412o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050412o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmsFWntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5536-5542&author=O.+El-Kabbaniauthor=V.+Carboneauthor=C.+Darmaninauthor=M.+Okaauthor=A.+Mitschlerauthor=A.+Podjarnyauthor=C.+Schulze-Brieseauthor=R.+P.+Chung&title=Structure+of+aldehyde+reductase+holoenzyme+in+complex+with+the+potent+aldose+reductase+inhibitor+fidarestat%3A+implications+for+inhibitor+binding+and+selectivity&doi=10.1021%2Fjm050412o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of Aldehyde Reductase Holoenzyme in Complex with the Potent Aldose Reductase Inhibitor Fidarestat: Implications for Inhibitor Binding and Selectivity</span></div><div class="casAuthors">El-Kabbani, Ossama; Carbone, Vincenzo; Darmanin, Connie; Oka, Mitsuru; Mitschler, Andre; Podjarny, Alberto; Schulze-Briese, Clemens; Chung, Roland P.-T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5536-5542</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure detn. of porcine aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat was carried out to explain the difference in the potency of the inhibitor for aldose and aldehyde reductases.  The hydrogen bonds between the active-site residues Tyr50, His113, and Trp114 and fidarestat are conserved in the two enzymes.  In aldose reductase, Leu300 forms a hydrogen bond through its main-chain nitrogen atom with the exocyclic amide group of the inhibitor, which when replaced with a Pro in aldehyde reductase, cannot form a hydrogen bond, thus causing a loss in binding energy.  Furthermore, in aldehyde reductase, the side chain of Trp220 occupies a disordered split conformation that is not obsd. in aldose reductase.  Mol. modeling and inhibitory activity measurements suggest that the difference in the interaction between the side chain of Trp220 and fidarestat may contribute to the difference in the binding of the inhibitor to the enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgas3h39we_rVg90H21EOLACvtfcHk0lgcCNVL7maL5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmsFWntr4%253D&md5=675d54ec62f286d84e31b9b0a5ab03e3</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Fjm050412o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050412o%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Kabbani%26aufirst%3DO.%26aulast%3DCarbone%26aufirst%3DV.%26aulast%3DDarmanin%26aufirst%3DC.%26aulast%3DOka%26aufirst%3DM.%26aulast%3DMitschler%26aufirst%3DA.%26aulast%3DPodjarny%26aufirst%3DA.%26aulast%3DSchulze-Briese%26aufirst%3DC.%26aulast%3DChung%26aufirst%3DR.%2BP.%26atitle%3DStructure%2520of%2520aldehyde%2520reductase%2520holoenzyme%2520in%2520complex%2520with%2520the%2520potent%2520aldose%2520reductase%2520inhibitor%2520fidarestat%253A%2520implications%2520for%2520inhibitor%2520binding%2520and%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5536%26epage%3D5542%26doi%3D10.1021%2Fjm050412o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Negoro, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujitani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuromiya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komiya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, J.</span></span> <span> </span><span class="NLM_article-title">Novel, highly potent aldose reductase inhibitors: (<i>R</i>)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3′-pyrrolidine-1,2′,3,5′-tetrone (AS-3201) and its congeners</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">4118</span>– <span class="NLM_lpage">4129</span>, <span class="refDoi"> DOI: 10.1021/jm9802968</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9802968" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaK1cXlvFGitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=4118-4129&author=T.+Negoroauthor=M.+Murataauthor=S.+Uedaauthor=B.+Fujitaniauthor=Y.+Onoauthor=A.+Kuromiyaauthor=M.+Komiyaauthor=K.+Suzukiauthor=J.+Matsumoto&title=Novel%2C+highly+potent+aldose+reductase+inhibitors%3A+%28R%29-%28-%29-2-%284-bromo-2-fluorobenzyl%29-1%2C2%2C3%2C4-tetrahydropyrrolo%5B1%2C2-a%5Dpyrazine-4-spiro-3%E2%80%B2-pyrrolidine-1%2C2%E2%80%B2%2C3%2C5%E2%80%B2-tetrone+%28AS-3201%29+and+its+congeners&doi=10.1021%2Fjm9802968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Novel, Highly Potent Aldose Reductase Inhibitors: (R)-(-)-2-(4-Bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine- 4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and Its Congeners</span></div><div class="casAuthors">Negoro, Toshiyuki; Murata, Makoto; Ueda, Shozo; Fujitani, Buichi; Ono, Yoshiyuki; Kuromiya, Akemi; Komiya, Masanobu; Suzuki, Kenji; Matsumoto, Jun-ichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4118-4129</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel tetrahydropyrrolo[1,2-a]pyrazine derivs. were synthesized and evaluated as aldose reductase inhibitors on the basis of their abilities to inhibit porcine lens aldose reductase in vitro and to inhibit sorbitol accumulation in the sciatic nerve of streptozotocin-induced diabetic rats in vivo.  Of these compds., spirosuccinimide-fused tetrahydropyrrolo[1,2-a]pyrazine-1,3-dione derivs. showed significantly potent aldose reductase inhibitory activity.  In the in vivo activity of these derivs., 2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (I) (SX-3030) showed the best oral activity.  The enantiomers of I were synthesized, and the biol. activities were evaluated.  It was found that aldose reductase inhibitory activity resides in the (-)-I (AS-3201), which was 10 times more potent in inhibition of the aldose reductase (IC50 = 1.5 × 10-8 M) and 500 times more potent in the in vivo activity (ED50 = 0.18 mg/kg/day for 5 days) than the corresponding (+)-I (SX-3202).  From these results, AS-3201 was selected as the candidate for clin. development.  The abs. configuration of AS-3201 was also established to be (R)-form by single-crystal X-ray anal.  In this article we report the prepn. and structure-activity relationship of tetrahydropyrrolopyrazine derivs. including a novel aldose reductase inhibitor, AS-3201.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxzCKd8YdPTbVg90H21EOLACvtfcHk0lgcCNVL7maL5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlvFGitL4%253D&md5=6793771a43992b477d2fbf48caf7f207</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Fjm9802968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9802968%26sid%3Dliteratum%253Aachs%26aulast%3DNegoro%26aufirst%3DT.%26aulast%3DMurata%26aufirst%3DM.%26aulast%3DUeda%26aufirst%3DS.%26aulast%3DFujitani%26aufirst%3DB.%26aulast%3DOno%26aufirst%3DY.%26aulast%3DKuromiya%26aufirst%3DA.%26aulast%3DKomiya%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DMatsumoto%26aufirst%3DJ.%26atitle%3DNovel%252C%2520highly%2520potent%2520aldose%2520reductase%2520inhibitors%253A%2520%2528R%2529-%2528-%2529-2-%25284-bromo-2-fluorobenzyl%2529-1%252C2%252C3%252C4-tetrahydropyrrolo%255B1%252C2-a%255Dpyrazine-4-spiro-3%25E2%2580%25B2-pyrrolidine-1%252C2%25E2%2580%25B2%252C3%252C5%25E2%2580%25B2-tetrone%2520%2528AS-3201%2529%2520and%2520its%2520congeners%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D4118%26epage%3D4129%26doi%3D10.1021%2Fjm9802968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urzhumtsev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tete-Favier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitschler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbanton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urzhumtseva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biellmann, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podjarny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moras, D.</span></span> <span> </span><span class="NLM_article-title">A ‘specificity’ pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">612</span>, <span class="refDoi"> DOI: 10.1016/S0969-2126(97)00216-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2FS0969-2126%2897%2900216-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=9195881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaK2sXjvFamt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1997&pages=601-612&author=A.+Urzhumtsevauthor=F.+Tete-Favierauthor=A.+Mitschlerauthor=J.+Barbantonauthor=P.+Barthauthor=L.+Urzhumtsevaauthor=J.+F.+Biellmannauthor=A.+Podjarnyauthor=D.+Moras&title=A+%E2%80%98specificity%E2%80%99+pocket+inferred+from+the+crystal+structures+of+the+complexes+of+aldose+reductase+with+the+pharmaceutically+important+inhibitors+tolrestat+and+sorbinil&doi=10.1016%2FS0969-2126%2897%2900216-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">A "specificity" pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil</span></div><div class="casAuthors">Urzhumtsev, A.; Tete-Favier, F.; Mitschler, A.; Barbanton, J.; Barth, P.; Urzhumtseva, L.; Biellmann, J.F.; Podjarny, A.D.; Moras, D.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">601-612</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Current Biology</span>)
        </div><div class="casAbstract">Aldose reductase (AR) is an NADPH-dependent enzyme implicated in long-term diabetic complications.  Buried at the bottom of a deep hydrophobic cleft, the NADPH coenzyme is surrounded by the conserved hydrophilic residues of the AR active site.  The existence of an anionic binding site near the NADP+ has been detd. from the structures of the complexes of AR with citrate, cacodylate and glucose-6-phosphate.  The inhibitor zopolrestat binds to this anionic site, and in the hydrophobic cleft, after a change of conformation which opens a "specificity" pocket.  The crystal structures of the porcine AR holoenzyme and its complexes with the inhibitors tolrestat and sorbinil have been solved; these structures are important as tolrestat and sorbinil are, pharmaceutically, the most well-studied AR inhibitors.  The active site of the holoenzyme was analyzed, and binding of the inhibitors was found to involve two contact zones in the active site; first, a recognition region for hydrogen-bond acceptors near the coenzyme, with three centers, including the anionic site; and second, a hydrophobic contact zone in the active-site cleft, which in the case of tolrestat includes the specificity pocket.  The conformational change leading to the opening of the specificity pocket upon tolrestat binding is different to the one seen upon zopolrestat binding; this pocket binds inhibitors that are more effective against AR than against aldehyde reductase.  The active site of AR adapts itself to bind tightly to different inhibitors; this happens both upon binding to the inhibitor's hydrophilic heads, and at the hydrophobic and specificity pockets of AR, which can change their shape through different conformational change of the same residues.  This flexibility could explain the large variety of possible substrates of AR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryQrSqGzZR_7Vg90H21EOLACvtfcHk0lgcCNVL7maL5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjvFamt7o%253D&md5=309b86f73d9cacb2667c6b8d609fca28</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2FS0969-2126%2897%2900216-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-2126%252897%252900216-5%26sid%3Dliteratum%253Aachs%26aulast%3DUrzhumtsev%26aufirst%3DA.%26aulast%3DTete-Favier%26aufirst%3DF.%26aulast%3DMitschler%26aufirst%3DA.%26aulast%3DBarbanton%26aufirst%3DJ.%26aulast%3DBarth%26aufirst%3DP.%26aulast%3DUrzhumtseva%26aufirst%3DL.%26aulast%3DBiellmann%26aufirst%3DJ.%2BF.%26aulast%3DPodjarny%26aufirst%3DA.%26aulast%3DMoras%26aufirst%3DD.%26atitle%3DA%2520%25E2%2580%2598specificity%25E2%2580%2599%2520pocket%2520inferred%2520from%2520the%2520crystal%2520structures%2520of%2520the%2520complexes%2520of%2520aldose%2520reductase%2520with%2520the%2520pharmaceutically%2520important%2520inhibitors%2520tolrestat%2520and%2520sorbinil%26jtitle%3DStructure%26date%3D1997%26volume%3D5%26spage%3D601%26epage%3D612%26doi%3D10.1016%2FS0969-2126%2897%2900216-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El-Kabbani, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darmanin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze-Briese, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomizaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazemann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitschler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podjarny, A.</span></span> <span> </span><span class="NLM_article-title">High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor Fidarestat: stereospecific interaction between the enzyme and a cyclic imide type inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">4530</span>– <span class="NLM_lpage">4537</span>, <span class="refDoi"> DOI: 10.1021/jm0497794</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0497794" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVeiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=4530-4537&author=O.+El-Kabbaniauthor=C.+Darmaninauthor=M.+Okaauthor=C.+Schulze-Brieseauthor=T.+Tomizakiauthor=I.+Hazemannauthor=A.+Mitschlerauthor=A.+Podjarny&title=High-resolution+structures+of+human+aldose+reductase+holoenzyme+in+complex+with+stereoisomers+of+the+potent+inhibitor+Fidarestat%3A+stereospecific+interaction+between+the+enzyme+and+a+cyclic+imide+type+inhibitor&doi=10.1021%2Fjm0497794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">High-Resolution Structures of Human Aldose Reductase Holoenzyme in Complex with Stereoisomers of the Potent Inhibitor Fidarestat: Stereospecific Interaction between the Enzyme and a Cyclic Imide Type Inhibitor</span></div><div class="casAuthors">El-Kabbani, Ossama; Darmanin, Connie; Oka, Mitsuru; Schulze-Briese, Clemens; Tomizaki, Takashi; Hazemann, Isabelle; Mitschler, Andre; Podjarny, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4530-4537</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure detns. of human aldose reductase holoenzyme in complex with the 2S,4R-, 2R,4S- and 2R,4R-isomers of the potent inhibitor Fidarestat ((2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazoline]-2-carboxamide) were carried out to elucidate the binding modes responsible for the differences in their inhibitory potencies.  In the complex structure with the 2R4S-isomer the cyclic imide moiety formed hydrogen bonds with the side-chains of Trp-111, Tyr-48 and His-110.  In the attempt to det. the complex structure with the least potent 2R4R-isomer this ligand was not obsd., and instead, the active site was simultaneously occupied by two citrate mols. (occupancies of 60% and 40%).  In the case of 2S4R, the active site was occupied by a citrate mol. which anchors the 2S4R-isomer from its carbamoyl group.  The structures of the complexes suggest that the differences in the interactions between the cyclic imide rings and carbamoyl groups of the compds. with residues His-110, Trp-111, Trp-219 and Cys-298 account for differences in their inhibitory potencies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-nKSIwDdmorVg90H21EOLACvtfcHk0lhmjlagQ6mfQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVeiur8%253D&md5=3e66fa908fcb38393800c7d33e5d916f</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Fjm0497794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0497794%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Kabbani%26aufirst%3DO.%26aulast%3DDarmanin%26aufirst%3DC.%26aulast%3DOka%26aufirst%3DM.%26aulast%3DSchulze-Briese%26aufirst%3DC.%26aulast%3DTomizaki%26aufirst%3DT.%26aulast%3DHazemann%26aufirst%3DI.%26aulast%3DMitschler%26aufirst%3DA.%26aulast%3DPodjarny%26aufirst%3DA.%26atitle%3DHigh-resolution%2520structures%2520of%2520human%2520aldose%2520reductase%2520holoenzyme%2520in%2520complex%2520with%2520stereoisomers%2520of%2520the%2520potent%2520inhibitor%2520Fidarestat%253A%2520stereospecific%2520interaction%2520between%2520the%2520enzyme%2520and%2520a%2520cyclic%2520imide%2520type%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D4530%26epage%3D4537%26doi%3D10.1021%2Fjm0497794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohtake, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of tofogliflozin, a novel C-arylglucoside with an <i>O</i>-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7828</span>– <span class="NLM_lpage">7840</span>, <span class="refDoi"> DOI: 10.1021/jm300884k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300884k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOrurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7828-7840&author=Y.+Ohtakeauthor=T.+Satoauthor=T.+Kobayashiauthor=M.+Nishimotoauthor=N.+Takaauthor=K.+Takanoauthor=K.+Yamamotoauthor=M.+Ohmoriauthor=M.+Yamaguchiauthor=K.+Takamiauthor=S.+Y.+Yeuauthor=K.+H.+Ahnauthor=H.+Matsuokaauthor=K.+Morikawaauthor=M.+Suzukiauthor=H.+Hagitaauthor=K.+Ozawaauthor=K.+Yamaguchiauthor=M.+Katoauthor=S.+Ikeda&title=Discovery+of+tofogliflozin%2C+a+novel+C-arylglucoside+with+an+O-spiroketal+ring+system%2C+as+a+highly+selective+sodium+glucose+cotransporter+2+%28SGLT2%29+inhibitor+for+the+treatment+of+type+2+diabetes&doi=10.1021%2Fjm300884k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tofogliflozin, a Novel C-Arylglucoside with an O-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes</span></div><div class="casAuthors">Ohtake, Yoshihito; Sato, Tsutomu; Kobayashi, Takamitsu; Nishimoto, Masahiro; Taka, Naoki; Takano, Koji; Yamamoto, Keisuke; Ohmori, Masayuki; Yamaguchi, Marina; Takami, Kyoko; Yeu, Sang-Yong; Ahn, Koo-Hyeon; Matsuoka, Hiroharu; Morikawa, Kazumi; Suzuki, Masayuki; Hagita, Hitoshi; Ozawa, Kazuharu; Yamaguchi, Koji; Kato, Motohiro; Ikeda, Sachiya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7828-7840</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of sodium glucose cotransporter 2 (SGLT2) has been proposed as a novel therapeutic approach to treat type 2 diabetes.  In our efforts to discover novel inhibitors of SGLT2, we first generated a 3D pharmacophore model based on the superposition of known inhibitors.  A search of the Cambridge Structural Database using a series of pharmacophore queries led to the discovery of an O-spiroketal C-arylglucoside scaffold.  Subsequent chem. examn. combined with computational modeling resulted in the identification of the clin. candidate CSG452 (tofogliflozin), which is currently under phase III clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeIDNjd6qaWLVg90H21EOLACvtfcHk0lhmjlagQ6mfQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOrurfN&md5=174a0538c13a286dd320a52395e1dd85</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Fjm300884k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300884k%26sid%3Dliteratum%253Aachs%26aulast%3DOhtake%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DNishimoto%26aufirst%3DM.%26aulast%3DTaka%26aufirst%3DN.%26aulast%3DTakano%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DOhmori%26aufirst%3DM.%26aulast%3DYamaguchi%26aufirst%3DM.%26aulast%3DTakami%26aufirst%3DK.%26aulast%3DYeu%26aufirst%3DS.%2BY.%26aulast%3DAhn%26aufirst%3DK.%2BH.%26aulast%3DMatsuoka%26aufirst%3DH.%26aulast%3DMorikawa%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DHagita%26aufirst%3DH.%26aulast%3DOzawa%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DIkeda%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520tofogliflozin%252C%2520a%2520novel%2520C-arylglucoside%2520with%2520an%2520O-spiroketal%2520ring%2520system%252C%2520as%2520a%2520highly%2520selective%2520sodium%2520glucose%2520cotransporter%25202%2520%2528SGLT2%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7828%26epage%3D7840%26doi%3D10.1021%2Fjm300884k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patchett, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nargund, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tata, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barakat, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacks, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pong, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaung, L. Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, S. H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. G.</span></span> <span> </span><span class="NLM_article-title">Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">7001</span>– <span class="NLM_lpage">7005</span>, <span class="refDoi"> DOI: 10.1073/pnas.92.15.7001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1073%2Fpnas.92.15.7001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=7624358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaK2MXntVSktLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1995&pages=7001-7005&author=A.+A.+Patchettauthor=R.+P.+Nargundauthor=J.+R.+Tataauthor=M.+H.+Chenauthor=K.+J.+Barakatauthor=D.+B.+Johnstonauthor=K.+Chengauthor=W.+W.+Chanauthor=B.+Butlerauthor=G.+Hickeyauthor=T.+Jacksauthor=K.+Schleimauthor=S.+S.+Pongauthor=L.+Y.+P.+Chaungauthor=H.+Y.+Chenauthor=E.+Frazierauthor=K.+H.+Leungauthor=S.+H.+L.+Chiuauthor=R.+G.+Smith&title=Design+and+biological+activities+of+L-163%2C191+%28MK-0677%29%3A+a+potent%2C+orally+active+growth+hormone+secretagogue&doi=10.1073%2Fpnas.92.15.7001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue</span></div><div class="casAuthors">Patchett, A. A.; Nargund, R. P.; Tata, J. R.; Chen, M.-H.; Barakat, K. J.; Johnston, D. B. R.; Cheng, K.; Chan, W. W.-S.; Butler, B.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7001-5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A potent, orally active growth hormone (GH) secretagogue L-163,191 belonging to a recently synthesized structural class has been characterized.  L-163,191 releases GH from rat pituitary cells in culture with EC50 = 1.3 nM and is mechanistically indistinguishable from the GH-releasing peptide GHRP-6 and the prototypical nonpeptide GH secretagogue L-692,429 but clearly distinguishable from the natural GH secretagogue, GH-releasing hormone.  L-163,191 elevates GH in dogs after oral doses as low as 0.125 mg/kg and was shown to be specific in its release of GH without significant effect on plasma levels of aldosterone, LH, thyroxine, and prolactin after oral administration of 1 mg/kg.  Only modest increases in cortisol were obsd.  Based on these properties, L-163,191 has been selected for clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3UFEi4P46gbVg90H21EOLACvtfcHk0lgyGAs7UjgzGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXntVSktLw%253D&md5=4e008b20d4713e41d2f0ee4b2113d851</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1073%2Fpnas.92.15.7001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.92.15.7001%26sid%3Dliteratum%253Aachs%26aulast%3DPatchett%26aufirst%3DA.%2BA.%26aulast%3DNargund%26aufirst%3DR.%2BP.%26aulast%3DTata%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DM.%2BH.%26aulast%3DBarakat%26aufirst%3DK.%2BJ.%26aulast%3DJohnston%26aufirst%3DD.%2BB.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DW.%2BW.%26aulast%3DButler%26aufirst%3DB.%26aulast%3DHickey%26aufirst%3DG.%26aulast%3DJacks%26aufirst%3DT.%26aulast%3DSchleim%26aufirst%3DK.%26aulast%3DPong%26aufirst%3DS.%2BS.%26aulast%3DChaung%26aufirst%3DL.%2BY.%2BP.%26aulast%3DChen%26aufirst%3DH.%2BY.%26aulast%3DFrazier%26aufirst%3DE.%26aulast%3DLeung%26aufirst%3DK.%2BH.%26aulast%3DChiu%26aufirst%3DS.%2BH.%2BL.%26aulast%3DSmith%26aufirst%3DR.%2BG.%26atitle%3DDesign%2520and%2520biological%2520activities%2520of%2520L-163%252C191%2520%2528MK-0677%2529%253A%2520a%2520potent%252C%2520orally%2520active%2520growth%2520hormone%2520secretagogue%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1995%26volume%3D92%26spage%3D7001%26epage%3D7005%26doi%3D10.1073%2Fpnas.92.15.7001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carpino, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefker, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toler, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadcock, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiBrino, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campeta, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeNinno, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chidsey-Frink, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hada, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inthavongsay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangano, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullins, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickerson, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirie, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tess, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawistoski, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DaSilva-Jardine, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D. D.</span></span> <span> </span><span class="NLM_article-title">Pyrazolinone-piperidine dipeptide growth hormone secretagogues (GHSs). Discovery of capromorelin</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">590</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(02)00433-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2FS0968-0896%2802%2900433-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=12538023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlt1OltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=581-590&author=P.+A.+Carpinoauthor=B.+A.+Lefkerauthor=S.+M.+Tolerauthor=L.+C.+Panauthor=J.+R.+Hadcockauthor=E.+R.+Cookauthor=J.+N.+DiBrinoauthor=A.+M.+Campetaauthor=S.+L.+DeNinnoauthor=K.+L.+Chidsey-Frinkauthor=W.+A.+Hadaauthor=J.+Inthavongsayauthor=F.+M.+Manganoauthor=M.+A.+Mullinsauthor=D.+F.+Nickersonauthor=O.+Ngauthor=C.+M.+Pirieauthor=J.+A.+Raganauthor=C.+R.+Roseauthor=D.+A.+Tessauthor=A.+S.+Wrightauthor=L.+Yuauthor=M.+P.+Zawistoskiauthor=P.+A.+DaSilva-Jardineauthor=T.+C.+Wilsonauthor=D.+D.+Thompson&title=Pyrazolinone-piperidine+dipeptide+growth+hormone+secretagogues+%28GHSs%29.+Discovery+of+capromorelin&doi=10.1016%2FS0968-0896%2802%2900433-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolinone-piperidine dipeptide growth hormone secretagogues (GHSs): discovery of capromorelin</span></div><div class="casAuthors">Carpino, Philip A.; Lefker, Bruce A.; Toler, Steven M.; Pan, Lydia C.; Hadcock, John R.; Cook, Ewell R.; DiBrino, Joseph N.; Campeta, Anthony M.; DeNinno, Shari L.; Chidsey-Frink, Kristin L.; Hada, William A.; Inthavongsay, John; Mangano, F. Michael; Mullins, Michelle A.; Nickerson, David F.; Ng, Oicheng; Pirie, Christine M.; Ragan, John A.; Rose, Colin R.; Tess, David A.; Wright, Ann S.; Yu, Li; Zawistoski, Michael P.; DaSilva-Jardine, Paul A.; Wilson, Theresa C.; Thompson, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">581-590</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Novel pyrazolinone-piperidine dipeptide derivs. were synthesized and evaluated as growth hormone secretagogues (GHSs).  Two analogs, capromorelin (5, CP-424391-18, hGHS-R1a Ki=7 nM, rat pituicyte EC50=3 nM) and the des-Me analog 5c (hGHS-R1a Ki=17 nM, rat pituicyte EC50=3 nM), increased plasma GH levels in an anesthetized rat model, with ED50 values less than 0.05 mg/kg iv.  Capromorelin showed enhanced intestinal absorption in rodent models and exhibited superior pharmacokinetic properties, including high bioavailabilities in two animal species [F(rat)=65%, F(dog)=44%].  This short-duration GHS was orally active in canine models and was selected as a development candidate for the treatment of musculoskeletal frailty in elderly adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomT-CMS1N-_7Vg90H21EOLACvtfcHk0lgyGAs7UjgzGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlt1OltQ%253D%253D&md5=bc0b258bb650a827188bf33fb1399cc1</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2802%2900433-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252802%252900433-9%26sid%3Dliteratum%253Aachs%26aulast%3DCarpino%26aufirst%3DP.%2BA.%26aulast%3DLefker%26aufirst%3DB.%2BA.%26aulast%3DToler%26aufirst%3DS.%2BM.%26aulast%3DPan%26aufirst%3DL.%2BC.%26aulast%3DHadcock%26aufirst%3DJ.%2BR.%26aulast%3DCook%26aufirst%3DE.%2BR.%26aulast%3DDiBrino%26aufirst%3DJ.%2BN.%26aulast%3DCampeta%26aufirst%3DA.%2BM.%26aulast%3DDeNinno%26aufirst%3DS.%2BL.%26aulast%3DChidsey-Frink%26aufirst%3DK.%2BL.%26aulast%3DHada%26aufirst%3DW.%2BA.%26aulast%3DInthavongsay%26aufirst%3DJ.%26aulast%3DMangano%26aufirst%3DF.%2BM.%26aulast%3DMullins%26aufirst%3DM.%2BA.%26aulast%3DNickerson%26aufirst%3DD.%2BF.%26aulast%3DNg%26aufirst%3DO.%26aulast%3DPirie%26aufirst%3DC.%2BM.%26aulast%3DRagan%26aufirst%3DJ.%2BA.%26aulast%3DRose%26aufirst%3DC.%2BR.%26aulast%3DTess%26aufirst%3DD.%2BA.%26aulast%3DWright%26aufirst%3DA.%2BS.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DZawistoski%26aufirst%3DM.%2BP.%26aulast%3DDaSilva-Jardine%26aufirst%3DP.%2BA.%26aulast%3DWilson%26aufirst%3DT.%2BC.%26aulast%3DThompson%26aufirst%3DD.%2BD.%26atitle%3DPyrazolinone-piperidine%2520dipeptide%2520growth%2520hormone%2520secretagogues%2520%2528GHSs%2529.%2520Discovery%2520of%2520capromorelin%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D581%26epage%3D590%26doi%3D10.1016%2FS0968-0896%2802%2900433-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorneloe, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsaid, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenhard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jian, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maniscalco-Hauk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawiec, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olzinski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozinskaya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elefante, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matasic, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tunstead, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waszkiewicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casillas, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquis, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidam, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toomey, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roethke, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jucker, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnackenberg, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsley, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepore, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willette, R. N.</span></span> <span> </span><span class="NLM_article-title">An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">159ra148</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.3004276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1126%2Fscitranslmed.3004276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=23136043" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&author=K.+S.+Thorneloeauthor=M.+Cheungauthor=W.+Baoauthor=H.+Alsaidauthor=S.+Lenhardauthor=M.+Y.+Jianauthor=M.+Costellauthor=K.+Maniscalco-Haukauthor=J.+A.+Krawiecauthor=A.+Olzinskiauthor=E.+Gordonauthor=I.+Lozinskayaauthor=L.+Elefanteauthor=P.+Qinauthor=D.+S.+Matasicauthor=C.+Jamesauthor=J.+Tunsteadauthor=B.+Donovanauthor=L.+Kallalauthor=A.+Waszkiewiczauthor=K.+Vaidyaauthor=E.+A.+Davenportauthor=J.+Larkinauthor=M.+Burgertauthor=L.+N.+Casillasauthor=R.+W.+Marquisauthor=G.+Yeauthor=H.+S.+Eidamauthor=K.+B.+Goodmanauthor=J.+R.+Toomeyauthor=T.+J.+Roethkeauthor=B.+M.+Juckerauthor=C.+G.+Schnackenbergauthor=M.+I.+Townsleyauthor=J.+J.+Leporeauthor=R.+N.+Willette&title=An+orally+active+TRPV4+channel+blocker+prevents+and+resolves+pulmonary+edema+induced+by+heart+failure&doi=10.1126%2Fscitranslmed.3004276"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3004276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3004276%26sid%3Dliteratum%253Aachs%26aulast%3DThorneloe%26aufirst%3DK.%2BS.%26aulast%3DCheung%26aufirst%3DM.%26aulast%3DBao%26aufirst%3DW.%26aulast%3DAlsaid%26aufirst%3DH.%26aulast%3DLenhard%26aufirst%3DS.%26aulast%3DJian%26aufirst%3DM.%2BY.%26aulast%3DCostell%26aufirst%3DM.%26aulast%3DManiscalco-Hauk%26aufirst%3DK.%26aulast%3DKrawiec%26aufirst%3DJ.%2BA.%26aulast%3DOlzinski%26aufirst%3DA.%26aulast%3DGordon%26aufirst%3DE.%26aulast%3DLozinskaya%26aufirst%3DI.%26aulast%3DElefante%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DP.%26aulast%3DMatasic%26aufirst%3DD.%2BS.%26aulast%3DJames%26aufirst%3DC.%26aulast%3DTunstead%26aufirst%3DJ.%26aulast%3DDonovan%26aufirst%3DB.%26aulast%3DKallal%26aufirst%3DL.%26aulast%3DWaszkiewicz%26aufirst%3DA.%26aulast%3DVaidya%26aufirst%3DK.%26aulast%3DDavenport%26aufirst%3DE.%2BA.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DBurgert%26aufirst%3DM.%26aulast%3DCasillas%26aufirst%3DL.%2BN.%26aulast%3DMarquis%26aufirst%3DR.%2BW.%26aulast%3DYe%26aufirst%3DG.%26aulast%3DEidam%26aufirst%3DH.%2BS.%26aulast%3DGoodman%26aufirst%3DK.%2BB.%26aulast%3DToomey%26aufirst%3DJ.%2BR.%26aulast%3DRoethke%26aufirst%3DT.%2BJ.%26aulast%3DJucker%26aufirst%3DB.%2BM.%26aulast%3DSchnackenberg%26aufirst%3DC.%2BG.%26aulast%3DTownsley%26aufirst%3DM.%2BI.%26aulast%3DLepore%26aufirst%3DJ.%2BJ.%26aulast%3DWillette%26aufirst%3DR.%2BN.%26atitle%3DAn%2520orally%2520active%2520TRPV4%2520channel%2520blocker%2520prevents%2520and%2520resolves%2520pulmonary%2520edema%2520induced%2520by%2520heart%2520failure%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26doi%3D10.1126%2Fscitranslmed.3004276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behm, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidam, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilfiker, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawhorn, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roethke, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorneloe, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of GSK2798745: A clinical candidate for inhibition of transient receptor potential vanilloid 4 (TRPV4)</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1228</span>– <span class="NLM_lpage">1233</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00274</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00274" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOhurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1228-1233&author=C.+A.+Brooksauthor=L.+S.+Bartonauthor=D.+J.+Behmauthor=H.+S.+Eidamauthor=R.+M.+Foxauthor=M.+Hammondauthor=T.+H.+Hoangauthor=D.+A.+Holtauthor=M.+A.+Hilfikerauthor=B.+G.+Lawhornauthor=J.+R.+Pattersonauthor=P.+Stoyauthor=T.+J.+Roethkeauthor=G.+Yeauthor=S.+Zhaoauthor=K.+S.+Thorneloeauthor=K.+B.+Goodmanauthor=M.+Cheung&title=Discovery+of+GSK2798745%3A+A+clinical+candidate+for+inhibition+of+transient+receptor+potential+vanilloid+4+%28TRPV4%29&doi=10.1021%2Facsmedchemlett.9b00274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4)</span></div><div class="casAuthors">Brooks, Carl A.; Barton, Linda S.; Behm, David J.; Eidam, Hilary S.; Fox, Ryan M.; Hammond, Marlys; Hoang, Tram H.; Holt, Dennis A.; Hilfiker, Mark A.; Lawhorn, Brian G.; Patterson, Jaclyn R.; Stoy, Patrick; Roethke, Theresa J.; Ye, Guosen; Zhao, Steve; Thorneloe, Kevin S.; Goodman, Krista B.; Cheung, Mui</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1228-1233</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">GSK2798745, a clin. candidate, was identified as an inhibitor of the transient receptor potential vanilloid 4 (TRPV4) ion channel for the treatment of pulmonary edema assocd. with congestive heart failure.  The lead optimization of this novel spirocarbamate series and specifically focus on the authors' strategies and solns. for achieving desirable potency, rat pharmacokinetics, and physicochem. properties are discussed.  The authors highlight the use of conformational bias to deliver potency and optimization of vol. of distribution and unbound clearance to enable desirable in vivo mean residence times.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeTgvHBnx5ObVg90H21EOLACvtfcHk0lgXSqvQGInlDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOhurfK&md5=fce123551c6d6d336cfb1270c2513a18</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00274%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DC.%2BA.%26aulast%3DBarton%26aufirst%3DL.%2BS.%26aulast%3DBehm%26aufirst%3DD.%2BJ.%26aulast%3DEidam%26aufirst%3DH.%2BS.%26aulast%3DFox%26aufirst%3DR.%2BM.%26aulast%3DHammond%26aufirst%3DM.%26aulast%3DHoang%26aufirst%3DT.%2BH.%26aulast%3DHolt%26aufirst%3DD.%2BA.%26aulast%3DHilfiker%26aufirst%3DM.%2BA.%26aulast%3DLawhorn%26aufirst%3DB.%2BG.%26aulast%3DPatterson%26aufirst%3DJ.%2BR.%26aulast%3DStoy%26aufirst%3DP.%26aulast%3DRoethke%26aufirst%3DT.%2BJ.%26aulast%3DYe%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DThorneloe%26aufirst%3DK.%2BS.%26aulast%3DGoodman%26aufirst%3DK.%2BB.%26aulast%3DCheung%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520GSK2798745%253A%2520A%2520clinical%2520candidate%2520for%2520inhibition%2520of%2520transient%2520receptor%2520potential%2520vanilloid%25204%2520%2528TRPV4%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1228%26epage%3D1233%26doi%3D10.1021%2Facsmedchemlett.9b00274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span> <span> </span><span class="NLM_article-title">Expression of polo-like kinase 4 (PLK4) in breast cancer and its response to taxane-based neoadjuvant chemotherapy</span>. <i>J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1125</span>– <span class="NLM_lpage">1132</span>, <span class="refDoi"> DOI: 10.7150/jca.14307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.7150%2Fjca.14307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=27326256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsFGltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1125-1132&author=Z.+Liauthor=K.+Daiauthor=C.+Wangauthor=Y.+Songauthor=F.+Guauthor=F.+Liuauthor=L.+Fu&title=Expression+of+polo-like+kinase+4+%28PLK4%29+in+breast+cancer+and+its+response+to+taxane-based+neoadjuvant+chemotherapy&doi=10.7150%2Fjca.14307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of Polo-Like Kinase 4(PLK4) in breast cancer and its response to taxane-based neoadjuvant chemotherapy</span></div><div class="casAuthors">Li, Zhenhua; Dai, Kun; Wang, Chijuan; Song, Yawen; Gu, Feng; Liu, Fangfang; Li, Fu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer (Wyoming, Australia)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1125-1132</span>CODEN:
                <span class="NLM_cas:coden">JCWAAL</span>;
        ISSN:<span class="NLM_cas:issn">1837-9664</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher Pty Ltd.</span>)
        </div><div class="casAbstract">Purpose: Polo-like kinase 4(PLK4) is an important evolutionarily regulator involved in centrosome duplication.  We here investigated the expression of PLK4 mRNA and PLK4 in breast cancer, and evaluated its predictive value for response to taxane-based neoadjuvant chemotherapy.  Method: The PLK4 mRNA expression was measured in breast cancer tissues and corresponding normal breast tissues from 30 breast cancer patients by quant. real-time polymerase chain reaction (PCR).The assocn. of the expression of PLK4 with clinicopathol. parameters and prognostic significance was evaluated in 154 cases of invasive breast cancer.  In addn., we immunohistochem. examd. the changes of PLK4 expression in biopsy and postoperative tumor specimens of another 64 breast cancer patients who received taxane-based neoadjuvant chemotherapy.  Results: The level of PLK4 mRNA expression in cancerous tissues had a significant difference compared to the corresponding normal breast tissues (P=0.021).  There is a correlation of PLK4 expression with higher incidence of lymph node metastasis and distant metastasis or surrounding recurrence (P=0.043; P=0.006).  High PLK4 expression was found to be a detrimental prognostic factor measured by overall survival (OS) (P=0.003) and progress-free survival (PFS) (P=0.003).  Moreover, the results demonstrated that PLK4 expression was a neg. predictor of response to taxane-based neoadjuvant chemotherapy (rs= - 0.253, P=0.044).  Conclusion: The findings of this current study indicated that PLK4 expression in breast cancer could be a potential prognostic factor and a neg. predictor of response to taxane-based neoadjuvant chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAAGxqawou-7Vg90H21EOLACvtfcHk0lgXSqvQGInlDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsFGltrc%253D&md5=ba87450f801327b59e0efa3369750fce</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.7150%2Fjca.14307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fjca.14307%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DDai%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DFu%26aufirst%3DL.%26atitle%3DExpression%2520of%2520polo-like%2520kinase%25204%2520%2528PLK4%2529%2520in%2520breast%2520cancer%2520and%2520its%2520response%2520to%2520taxane-based%2520neoadjuvant%2520chemotherapy%26jtitle%3DJ.%2520Cancer%26date%3D2016%26volume%3D7%26spage%3D1125%26epage%3D1132%26doi%3D10.7150%2Fjca.14307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrest, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ban, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awrey, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiarash, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirgadze, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, H. W.</span></span> <span> </span><span class="NLM_article-title">The discovery of polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3′[3<i>H</i>]indol]-2′(1′<i>H</i>).ones as orally bioavailable antitumor agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1021/jm500537u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500537u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1Wktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=130-146&author=P.+B.+Sampsonauthor=Y.+Liuauthor=N.+K.+Patelauthor=M.+Feherauthor=B.+Forrestauthor=S.+W.+Liauthor=L.+Edwardsauthor=R.+Lauferauthor=Y.+Langauthor=F.+Banauthor=D.+E.+Awreyauthor=G.+Maoauthor=O.+Plotnikovaauthor=G.+Leungauthor=R.+Hodgsonauthor=J.+M.+Masonauthor=X.+Weiauthor=R.+Kiarashauthor=E.+Greenauthor=W.+Qiuauthor=N.+Y.+Chirgadzeauthor=T.+W.+Makauthor=G.+Panauthor=H.+W.+Pauls&title=The+discovery+of+polo-like+kinase+4+inhibitors%3A+design+and+optimization+of+spiro%5Bcyclopropane-1%2C3%E2%80%B2%5B3H%5Dindol%5D-2%E2%80%B2%281%E2%80%B2H%29.ones+as+orally+bioavailable+antitumor+agents&doi=10.1021%2Fjm500537u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of Polo-Like Kinase 4 Inhibitors: Design and Optimization of Spiro[cyclopropane-1,3'[3H]indol]-2'(1'H)-ones as Orally Bioavailable Antitumor Agents</span></div><div class="casAuthors">Sampson, Peter B.; Liu, Yong; Patel, Narendra Kumar; Feher, Miklos; Forrest, Bryan; Li, Sze-Wan; Edwards, Louise; Laufer, Radoslaw; Lang, Yunhui; Ban, Fuqiang; Awrey, Donald E.; Mao, Guodong; Plotnikova, Olga; Leung, Genie; Hodgson, Richard; Mason, Jacqueline; Wei, Xin; Kiarash, Reza; Green, Erin; Qiu, Wei; Chirgadze, Nickolay Y.; Mak, Tak W.; Pan, Guohua; Pauls, Henry W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">130-146</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polo-like kinase 4 (PLK4), a unique member of the polo-like kinase family of serine-threonine kinases, is a master regulator of centriole duplication that is important for maintaining genome integrity.  Overexpression of PLK4 is found in several human cancers and is linked with a predisposition to tumorigenesis.  Previous efforts to identify potent and efficacious PLK4 inhibitors resulted in the discovery of (E)-3-((1H-indazol-6-yl)methylene)indolin-2-ones, which are superseded by the bioisosteric 2-(1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones reported herein.  Optimization of this new cyclopropane-linked series was based on a computational model of a PLK4 x-ray structure and SAR attained from the analogous alkene-linked series.  The racemic cyclopropane-linked compds. showed PLK4 affinity and antiproliferative activity comparable to their alkene-linked congeners with improved physicochem., ADME, and pharmacokinetic properties.  Pos. xenograft results from the MDA-MB-468 human breast cancer xenograft model for compd. I support the investigation of PLK4 inhibitors as anticancer therapeutics.  A PLK4 x-ray co-structure with compd. I revealed preferential binding of the 1R,2S enantiomer to the PLK4 kinase domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_nQjbJy_sMLVg90H21EOLACvtfcHk0lhQdcY6EKEGaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1Wktro%253D&md5=90d60867ee5d6c27f597ebe32db64278</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Fjm500537u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500537u%26sid%3Dliteratum%253Aachs%26aulast%3DSampson%26aufirst%3DP.%2BB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPatel%26aufirst%3DN.%2BK.%26aulast%3DFeher%26aufirst%3DM.%26aulast%3DForrest%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%2BW.%26aulast%3DEdwards%26aufirst%3DL.%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DBan%26aufirst%3DF.%26aulast%3DAwrey%26aufirst%3DD.%2BE.%26aulast%3DMao%26aufirst%3DG.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DLeung%26aufirst%3DG.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DGreen%26aufirst%3DE.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DChirgadze%26aufirst%3DN.%2BY.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DPan%26aufirst%3DG.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DThe%2520discovery%2520of%2520polo-like%2520kinase%25204%2520inhibitors%253A%2520design%2520and%2520optimization%2520of%2520spiro%255Bcyclopropane-1%252C3%25E2%2580%25B2%255B3H%255Dindol%255D-2%25E2%2580%25B2%25281%25E2%2580%25B2H%2529.ones%2520as%2520orally%2520bioavailable%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D130%26epage%3D146%26doi%3D10.1021%2Fjm500537u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beisner, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langerak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otero, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirot, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiltshire, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodendorf, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martoglio, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, M. P.</span></span> <span> </span><span class="NLM_article-title">The intramembrane protease SPPL2a is required for B cell and DC development and survival via cleavage of the invariant chain</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1084/jem.20121072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1084%2Fjem.20121072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=23267013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Oitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2013&pages=23-30&author=D.+R.+Beisnerauthor=P.+Langerakauthor=A.+E.+Parkerauthor=C.+Dahlbergauthor=F.+J.+Oteroauthor=S.+E.+Suttonauthor=L.+Poirotauthor=W.+Barnesauthor=M.+A.+Youngauthor=S.+Niessenauthor=T.+Wiltshireauthor=U.+Bodendorfauthor=B.+Martoglioauthor=B.+Cravattauthor=M.+P.+Cooke&title=The+intramembrane+protease+SPPL2a+is+required+for+B+cell+and+DC+development+and+survival+via+cleavage+of+the+invariant+chain&doi=10.1084%2Fjem.20121072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">The intramembrane protease Sppl2a is required for B cell and DC development and survival via cleavage of the invariant chain</span></div><div class="casAuthors">Beisner, Daniel R.; Langerak, Petra; Parker, Albert E.; Dahlberg, Carol; Otero, Francella J.; Sutton, Sue E.; Poirot, Laurent; Barnes, Whitney; Young, Michael A.; Niessen, Sherry; Wiltshire, Tim; Bodendorf, Ursula; Martoglio, Bruno; Cravatt, Benjamin; Cooke, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-30</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">B cell development requires tight regulation to allow for the generation of a diverse repertoire while preventing the development of autoreactive cells.  We report, using N-ethyl-N-nitrosourea (ENU)-induced mutagenesis, the identification of a mutant mouse (chompB) with a block in early B cell development.  The blockade occurs after the transitional 1 (T1) stage and leads to a decrease in mature B cell subsets and deficits in T cell-dependent antibody responses.  Addnl., chompB mice have decreases in myeloid dendritic cells (DCs).  The mutation was mapped to the intramembrane protease signal peptide peptidase-like 2a (Sppl2a), a gene not previously implicated in immune cell development.  Proteomic anal. identified the invariant chain (CD74) as a key substrate of Sppl2a and suggests that regulated intramembrane proteolysis of CD74 by Sppl2a contributes to B cell and DC survival.  Moreover, these data suggest that modulation of Sppl2a may be a useful therapeutic strategy for treatment of B cell dependent autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz5IaIoDFCJrVg90H21EOLACvtfcHk0lhQdcY6EKEGaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Oitbs%253D&md5=001a2fe7aca2a8d5bb669833e155dff9</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1084%2Fjem.20121072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20121072%26sid%3Dliteratum%253Aachs%26aulast%3DBeisner%26aufirst%3DD.%2BR.%26aulast%3DLangerak%26aufirst%3DP.%26aulast%3DParker%26aufirst%3DA.%2BE.%26aulast%3DDahlberg%26aufirst%3DC.%26aulast%3DOtero%26aufirst%3DF.%2BJ.%26aulast%3DSutton%26aufirst%3DS.%2BE.%26aulast%3DPoirot%26aufirst%3DL.%26aulast%3DBarnes%26aufirst%3DW.%26aulast%3DYoung%26aufirst%3DM.%2BA.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DWiltshire%26aufirst%3DT.%26aulast%3DBodendorf%26aufirst%3DU.%26aulast%3DMartoglio%26aufirst%3DB.%26aulast%3DCravatt%26aufirst%3DB.%26aulast%3DCooke%26aufirst%3DM.%2BP.%26atitle%3DThe%2520intramembrane%2520protease%2520SPPL2a%2520is%2520required%2520for%2520B%2520cell%2520and%2520DC%2520development%2520and%2520survival%2520via%2520cleavage%2520of%2520the%2520invariant%2520chain%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2013%26volume%3D210%26spage%3D23%26epage%3D30%26doi%3D10.1084%2Fjem.20121072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velcicky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodendorf, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigollier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epple, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beisner, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feifel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wipfli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aichholz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couttet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widmer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandl, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of the first potent, selective, and orally bioavailable signal peptide peptidase-like 2a (SPPL2a) inhibitor displaying pronounced immunomodulatory effects in vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">865</span>– <span class="NLM_lpage">880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01371</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01371" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=865-880&author=J.+Velcickyauthor=U.+Bodendorfauthor=P.+Rigollierauthor=R.+Eppleauthor=D.+R.+Beisnerauthor=D.+Gueriniauthor=P.+Smithauthor=B.+Liuauthor=R.+Feifelauthor=P.+Wipfliauthor=R.+Aichholzauthor=P.+Couttetauthor=I.+Dixauthor=T.+Widmerauthor=B.+Wenauthor=T.+Brandl&title=Discovery+of+the+first+potent%2C+selective%2C+and+orally+bioavailable+signal+peptide+peptidase-like+2a+%28SPPL2a%29+inhibitor+displaying+pronounced+immunomodulatory+effects+in+vivo&doi=10.1021%2Facs.jmedchem.7b01371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In Vivo</span></div><div class="casAuthors">Velcicky, Juraj; Bodendorf, Ursula; Rigollier, Pascal; Epple, Robert; Beisner, Daniel R.; Guerini, Danilo; Smith, Philip; Liu, Bo; Feifel, Roland; Wipfli, Peter; Aichholz, Reiner; Couttet, Philippe; Dix, Ina; Widmer, Toni; Wen, Ben; Brandl, Trixi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">865-880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Signal Peptide Peptidase-Like 2a (SPPL2a) is an aspartic intramembrane protease which has recently been shown to play an important role in the development and function of antigen presenting cells such as B lymphocytes and dendritic cells.  In this paper the authors describe the discovery of the first selective and orally active SPPL2a inhibitor (S)-2-cyclopropyl-N1-((S)-5,11-dioxo-10,11-dihydro-1H,3H,5H-spiro[benzo[d]pyrazolo[1,2-a][1,2]diazepine-2,1'-cyclopropan]-10-yl)-N4-(5-fluoro-2-methylpyridin-3-yl)succinamide (40) (SPL-707).  This compd. shows adequate selectivity against the closely related enzymes γ secretase and SPP and a good pharmacokinetic profile in mouse and rat.  Compd. 40 significantly inhibited processing of the SPPL2a substrate CD74/p8 fragment in rodents at doses ≤10 mg/kg b.i.d. po.  Oral dosing of 40 for 11 days at ≥10 mg/kg b.i.d. recapitulated the phenotype seen in Sppl2a k.o. and ENU-mutant mice (reduced no. of specific B cells and myeloid dendritic cells).  Thus, the authors believe that SPPL2a represents an interesting and druggable pharmacol. target potentially providing a novel approach for the treatment of autoimmune diseases by targeting B cells and dendritic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-3mN1wPBrf7Vg90H21EOLACvtfcHk0liV3xR0c7LLWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyiuro%253D&md5=3076c11b3b83e2c3e1cf23ed69d8455e</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01371%26sid%3Dliteratum%253Aachs%26aulast%3DVelcicky%26aufirst%3DJ.%26aulast%3DBodendorf%26aufirst%3DU.%26aulast%3DRigollier%26aufirst%3DP.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DBeisner%26aufirst%3DD.%2BR.%26aulast%3DGuerini%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DFeifel%26aufirst%3DR.%26aulast%3DWipfli%26aufirst%3DP.%26aulast%3DAichholz%26aufirst%3DR.%26aulast%3DCouttet%26aufirst%3DP.%26aulast%3DDix%26aufirst%3DI.%26aulast%3DWidmer%26aufirst%3DT.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DBrandl%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520the%2520first%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520signal%2520peptide%2520peptidase-like%25202a%2520%2528SPPL2a%2529%2520inhibitor%2520displaying%2520pronounced%2520immunomodulatory%2520effects%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D865%26epage%3D880%26doi%3D10.1021%2Facs.jmedchem.7b01371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vassilev, L. T.</span></span> <span> </span><span class="NLM_article-title">p53 Activation by small molecules: application in oncology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">4491</span>– <span class="NLM_lpage">4499</span>, <span class="refDoi"> DOI: 10.1021/jm058174k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058174k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlarsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4491-4499&author=L.+T.+Vassilev&title=p53+Activation+by+small+molecules%3A+application+in+oncology&doi=10.1021%2Fjm058174k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">p53 Activation by Small Molecules: Application in Oncology</span></div><div class="casAuthors">Vassilev, Lyubomir T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4491-4499</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  P53 activation by small mols. and their application in chemoprevention are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO8McGVTfuxrVg90H21EOLACvtfcHk0liV3xR0c7LLWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlarsLc%253D&md5=44ee6a039c0c5ad69e218de742de0d53</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Fjm058174k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058174k%26sid%3Dliteratum%253Aachs%26aulast%3DVassilev%26aufirst%3DL.%2BT.%26atitle%3Dp53%2520Activation%2520by%2520small%2520molecules%253A%2520application%2520in%2520oncology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4491%26epage%3D4499%26doi%3D10.1021%2Fjm058174k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shargary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5553</span>– <span class="NLM_lpage">5561</span>, <span class="refDoi"> DOI: 10.1021/jm4005708</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4005708" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslCisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5553-5561&author=Y.+Zhaoauthor=S.+Yuauthor=W.+Sunauthor=L.+Liuauthor=J.+Luauthor=D.+McEachernauthor=S.+Shargaryauthor=D.+Bernardauthor=X.+Liauthor=T.+Zhaoauthor=P.+Zouauthor=D.+Sunauthor=S.+Wang&title=A+potent+small-molecule+inhibitor+of+the+MDM2-p53+interaction+%28MI-888%29+achieved+complete+and+durable+tumor+regression+in+mice&doi=10.1021%2Fjm4005708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">A Potent Small-Molecule Inhibitor of the MDM2-p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice</span></div><div class="casAuthors">Zhao, Yujun; Yu, Shanghai; Sun, Wei; Liu, Liu; Lu, Jianfeng; McEachern, Donna; Shargary, Sanjeev; Bernard, Denzil; Li, Xiaoqin; Zhao, Ting; Zou, Peng; Sun, Duxin; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5553-5561</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors previously reported the discovery of a class of spirooxindoles as potent and selective small-mol. inhibitors of the MDM2-p53 interaction (MDM2 inhibitors).  The authors report herein the authors' efforts to improve their pharmacokinetic properties and in vivo antitumor activity.  The authors' efforts led to the identification of MI-888 as a potent MDM2 inhibitor (Ki = 0.44 nM) with a superior pharmacokinetic profile and enhanced in vivo efficacy.  MI-888 is capable of achieving rapid, complete, and durable tumor regression in two types of xenograft models of human cancer with oral administration and represents the most potent and efficacious MDM2 inhibitor reported to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr06DpGqpt0TLVg90H21EOLACvtfcHk0liV3xR0c7LLWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslCisb4%253D&md5=a53931e3f91a1c1a302ac88bbb4d5c0d</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Fjm4005708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4005708%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DShargary%26aufirst%3DS.%26aulast%3DBernard%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DT.%26aulast%3DZou%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DA%2520potent%2520small-molecule%2520inhibitor%2520of%2520the%2520MDM2-p53%2520interaction%2520%2528MI-888%2529%2520achieved%2520complete%2520and%2520durable%2520tumor%2520regression%2520in%2520mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5553%26epage%3D5561%26doi%3D10.1021%2Fjm4005708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meaux, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barriere, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meagher, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman-Luca, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shangary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dos-Santos, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerif, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorge-Bernat, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debussche, L.</span></span> <span> </span><span class="NLM_article-title">SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">5855</span>– <span class="NLM_lpage">5865</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-0799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1158%2F0008-5472.CAN-14-0799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=25145672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGjsr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=5855-5865&author=S.+Wangauthor=W.+Sunauthor=Y.+Zhaoauthor=D.+McEachernauthor=I.+Meauxauthor=C.+Barriereauthor=J.+A.+Stuckeyauthor=J.+L.+Meagherauthor=L.+Baiauthor=L.+Liuauthor=C.+G.+Hoffman-Lucaauthor=J.+Luauthor=S.+Shangaryauthor=S.+Yuauthor=D.+Bernardauthor=A.+Aguilarauthor=O.+Dos-Santosauthor=L.+Besretauthor=S.+Guerifauthor=P.+Pannierauthor=D.+Gorge-Bernatauthor=L.+Debussche&title=SAR405838%3A+an+optimized+inhibitor+of+MDM2-p53+interaction+that+induces+complete+and+durable+tumor+regression&doi=10.1158%2F0008-5472.CAN-14-0799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression</span></div><div class="casAuthors">Wang, Shaomeng; Sun, Wei; Zhao, Yujun; McEachern, Donna; Meaux, Isabelle; Barriere, Cedric; Stuckey, Jeanne A.; Meagher, Jennifer L.; Bai, Longchuan; Liu, Liu; Hoffman-Luca, Cassandra Gianna; Lu, Jianfeng; Shangary, Sanjeev; Yu, Shanghai; Bernard, Denzil; Aguilar, Angelo; Dos-Santos, Odette; Besret, Laurent; Guerif, Stephane; Pannier, Pascal; Gorge-Bernat, Dimitri; Debussche, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5855-5865</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Despite the risk of applying a selection for p53 mutations that escape MDM2 control, blocking MDM2-p53 protein-protein interaction has long been considered by many to offer an attractive cancer therapeutic strategy, a position strongly supported by the findings of this preclin. study.  Blocking the oncoprotein murine double minute 2 (MDM2)-p53 protein-protein interaction has long been considered to offer a broad cancer therapeutic strategy, despite the potential risks of selecting tumors harboring p53 mutations that escape MDM2 control.  In this study, we report a novel small-mol. inhibitor of the MDM2-p53 interaction, SAR405838 (MI-77301), that has been advanced into phase I clin. trials.  SAR405838 binds to MDM2 with Ki = 0.88 nmol/L and has high specificity over other proteins.  A cocrystal structure of the SAR405838:MDM2 complex shows that, in addn. to mimicking three key p53 amino acid residues, the inhibitor captures addnl. interactions not obsd. in the p53-MDM2 complex and induces refolding of the short, unstructured MDM2 N-terminal region to achieve its high affinity.  SAR405838 effectively activates wild-type p53 in vitro and in xenograft tumor tissue of leukemia and solid tumors, leading to p53-dependent cell-cycle arrest and/or apoptosis.  At well-tolerated dose schedules, SAR405838 achieves either durable tumor regression or complete tumor growth inhibition in mouse xenograft models of SJSA-1 osteosarcoma, RS4;11 acute leukemia, LNCaP prostate cancer, and HCT-116 colon cancer.  Remarkably, a single oral dose of SAR405838 is sufficient to achieve complete tumor regression in the SJSA-1 model.  Mechanistically, robust transcriptional upregulation of PUMA induced by SAR405838 results in strong apoptosis in tumor tissue, leading to complete tumor regression.  Our findings provide a preclin. basis upon which to evaluate SAR405838 as a therapeutic agent in patients whose tumors retain wild-type p53.  Cancer Res; 74(20); 5855-65. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptKSwfNhNzNLVg90H21EOLACvtfcHk0ljwrBL7j3qghw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGjsr7M&md5=5b35759e14fe4c1ae4e734775c4334a0</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-0799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-0799%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DMeaux%26aufirst%3DI.%26aulast%3DBarriere%26aufirst%3DC.%26aulast%3DStuckey%26aufirst%3DJ.%2BA.%26aulast%3DMeagher%26aufirst%3DJ.%2BL.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DHoffman-Luca%26aufirst%3DC.%2BG.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DShangary%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DBernard%26aufirst%3DD.%26aulast%3DAguilar%26aufirst%3DA.%26aulast%3DDos-Santos%26aufirst%3DO.%26aulast%3DBesret%26aufirst%3DL.%26aulast%3DGuerif%26aufirst%3DS.%26aulast%3DPannier%26aufirst%3DP.%26aulast%3DGorge-Bernat%26aufirst%3DD.%26aulast%3DDebussche%26aufirst%3DL.%26atitle%3DSAR405838%253A%2520an%2520optimized%2520inhibitor%2520of%2520MDM2-p53%2520interaction%2520that%2520induces%2520complete%2520and%2520durable%2520tumor%2520regression%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D5855%26epage%3D5865%26doi%3D10.1158%2F0008-5472.CAN-14-0799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rew, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6332</span>– <span class="NLM_lpage">6341</span>, <span class="refDoi"> DOI: 10.1021/jm500627s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500627s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVGlu7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6332-6341&author=Y.+Rewauthor=D.+Sun&title=Discovery+of+a+small+molecule+MDM2+inhibitor+%28AMG+232%29+for+treating+cancer&doi=10.1021%2Fjm500627s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Small Molecule MDM2 Inhibitor (AMG 232) for Treating Cancer</span></div><div class="casAuthors">Rew, Yosup; Sun, Daqing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6332-6341</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  We recently reported the discovery of AMG 232 (1), a potent and selective piperidinone inhibitor of the MDM2-p53 protein-protein interaction.  Compd. 1 is currently being evaluated in human clin. trials for the treatment of cancer.  This article provides an overview of its discovery from the de novo design of the piperidinone series to the structure-activity studies leading to the identification of 1.  In addn., this article also describes the preclin. pharmacol. and pharmacokinetics of 1, along with its drug metab. and safety assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_6moQsRdmtLVg90H21EOLACvtfcHk0ljwrBL7j3qghw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVGlu7jM&md5=07628b602fba44634add7d235751daf7</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Fjm500627s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500627s%26sid%3Dliteratum%253Aachs%26aulast%3DRew%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520a%2520small%2520molecule%2520MDM2%2520inhibitor%2520%2528AMG%2520232%2529%2520for%2520treating%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6332%26epage%3D6341%26doi%3D10.1021%2Fjm500627s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gehling, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duplessis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brucelle, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaswani, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Côté, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levell, J. R.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of styrenylcyclopropylamine LSD1 inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1213</span>– <span class="NLM_lpage">1220</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00060</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00060" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BB3cXoslals78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1213-1220&author=V.+S.+Gehlingauthor=J.+P.+McGrathauthor=M.+Duplessisauthor=A.+Khannaauthor=F.+Brucelleauthor=R.+G.+Vaswaniauthor=A.+C%C3%B4t%C3%A9author=J.+Stuckeyauthor=V.+Watsonauthor=R.+T.+Cummingsauthor=S.+Balasubramanianauthor=P.+Iyerauthor=P.+Sawantauthor=A.+C.+Goodauthor=B.+K.+Albrechtauthor=J.-C.+Harmangeauthor=J.+E.+Audiaauthor=S.+F.+Bellonauthor=P.+Trojerauthor=J.+R.+Levell&title=Design+and+synthesis+of+styrenylcyclopropylamine+LSD1+inhibitors&doi=10.1021%2Facsmedchemlett.0c00060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Styrenylcyclopropylamine LSD1 Inhibitors</span></div><div class="casAuthors">Gehling, Victor S.; McGrath, John P.; Duplessis, Martin; Khanna, Avinash; Brucelle, Francois; Vaswani, Rishi G.; Cote, Alexandre; Stuckey, Jacob; Watson, Venita; Cummings, Richard T.; Balasubramanian, Srividya; Iyer, Priyadarshini; Sawant, Priyanka; Good, Andrew C.; Albrecht, Brian K.; Harmange, Jean-Christophe; Audia, James E.; Bellon, Steven F.; Trojer, Patrick; Levell, Julian R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1213-1220</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Leveraging the catalytic machinery of LSD1 (KDM1A), a series of covalent styrenylcyclopropane LSD1 inhibitors were identified.  These inhibitors represent a new class of mechanism-based inhibitors that target and covalently label the FAD cofactor of LSD1.  The series was rapidly progressed to potent biochem. and cellular LSD1 inhibitors with good phys. properties.  This effort resulted in the identification of 34, a highly potent (<4 nM biochem., 2 nM cell, and 1 nM GI50), and selective LSD1 inhibitor.  In-depth kinetic profiling of 34 confirmed its covalent mechanism of action, validated the styrenylcyclopropane as an FAD-directed warhead, and demonstrated that the potency of this inhibitor is driven by improved non-covalent binding (KI). 34 demonstrated robust cell-killing activity in a panel of AML cell lines and robust antitumor activity in a Kasumi-1 xenograft model of AML when dosed orally at 1.5 mg/kg once daily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXdKSi11wzG7Vg90H21EOLACvtfcHk0ljwrBL7j3qghw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXoslals78%253D&md5=77d6d1674b5ec70bcbf4627a20417120</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00060%26sid%3Dliteratum%253Aachs%26aulast%3DGehling%26aufirst%3DV.%2BS.%26aulast%3DMcGrath%26aufirst%3DJ.%2BP.%26aulast%3DDuplessis%26aufirst%3DM.%26aulast%3DKhanna%26aufirst%3DA.%26aulast%3DBrucelle%26aufirst%3DF.%26aulast%3DVaswani%26aufirst%3DR.%2BG.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DA.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DWatson%26aufirst%3DV.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DSawant%26aufirst%3DP.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DHarmange%26aufirst%3DJ.-C.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DTrojer%26aufirst%3DP.%26aulast%3DLevell%26aufirst%3DJ.%2BR.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520styrenylcyclopropylamine%2520LSD1%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1213%26epage%3D1220%26doi%3D10.1021%2Facsmedchemlett.0c00060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5992</span>– <span class="NLM_lpage">6000</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.08.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.bmcl.2013.08.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=24054120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVOns73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5992-6000&author=M.+D.+Shultz&title=The+thermodynamic+basis+for+the+use+of+lipophilic+efficiency+%28LipE%29+in+enthalpic+optimizations&doi=10.1016%2Fj.bmcl.2013.08.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5992-6000</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Approaches to improve the efficiency of mol. optimizations have received great attention and numerous efficiency metrics have been introduced to assist in this effort.  Optimization of properties is equally important to optimization of potency and therefore these metrics contain potency vs. property calcns.  Widespread use of a metric does not guarantee its accuracy and a further understanding of which, if any, metric increases the probability of success was sought.  An anal. of LE, LELP and LipE based on theor. and exptl. data was performed demonstrating that LipE most strongly correlates with compd. quality as defined by enthalpy-driven binding.  The basis for the prioritization of LipE over other metrics in enthalpic optimizations is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobuMO74LdKnbVg90H21EOLACvtfcHk0lju2z8sl8-pYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVOns73P&md5=23d948d1135eeefdfebc60846f28ec2b</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.030%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DThe%2520thermodynamic%2520basis%2520for%2520the%2520use%2520of%2520lipophilic%2520efficiency%2520%2528LipE%2529%2520in%2520enthalpic%2520optimizations%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5992%26epage%3D6000%26doi%3D10.1016%2Fj.bmcl.2013.08.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beumer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puhalla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owonikoko, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald Harvey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petro, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawbi, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argiris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strychor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouquet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiesel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belani, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span> <span> </span><span class="NLM_article-title">Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">1289</span>– <span class="NLM_lpage">1301</span>, <span class="refDoi"> DOI: 10.1007/s00280-019-03960-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1007%2Fs00280-019-03960-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=31549216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVarsbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2019&pages=1289-1301&author=L.+J.+Applemanauthor=J.+H.+Beumerauthor=Y.+Jiangauthor=Y.+Linauthor=F.+Dingauthor=S.+Puhallaauthor=L.+Swartzauthor=T.+K.+Owonikokoauthor=R.+Donald+Harveyauthor=R.+Stollerauthor=D.+P.+Petroauthor=H.+A.+Tawbiauthor=A.+Argirisauthor=S.+Strychorauthor=M.+Pouquetauthor=B.+Kieselauthor=A.+P.+Chenauthor=D.+Gandaraauthor=C.+P.+Belaniauthor=E.+Chuauthor=S.+S.+Ramalingam&title=Phase+1+study+of+veliparib+%28ABT-888%29%2C+a+poly+%28ADP-ribose%29+polymerase+inhibitor%2C+with+carboplatin+and+paclitaxel+in+advanced+solid+malignancies&doi=10.1007%2Fs00280-019-03960-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies</span></div><div class="casAuthors">Appleman, Leonard J.; Beumer, Jan H.; Jiang, Yixing; Lin, Yan; Ding, Fei; Puhalla, Shannon; Swartz, Leigh; Owonikoko, Taofeek K.; Donald Harvey, R.; Stoller, Ronald; Petro, Daniel P.; Tawbi, Hussein A.; Argiris, Athanassios; Strychor, Sandra; Pouquet, Marie; Kiesel, Brian; Chen, Alice P.; Gandara, David; Belani, Chandra P.; Chu, Edward; Ramalingam, Suresh S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1289-1301</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Veliparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP)-1 and -2.  We aimed to det. the recommended phase 2 dose (RP2D), max. tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics (PK) of veliparib combined with paclitaxel and carboplatin.  Methods: Eligibility criteria included patients with advanced solid tumors treated with = 3 prior regimens.  Paclitaxel and carboplatin were administered on day 3 of a 21-day cycle.  Veliparib was given PO BID days 1-7, except for cycle 1 in the first 46 patients to serve as control for toxicity and PK.  The pharmacokinetic (PK) disposition of veliparib, paclitaxel, and carboplatin was detd. by LC-MS/MS and AAS during cycles 1 and 2.  Results: Seventy-three patients were enrolled.  Toxicities were as expected with carboplatin/paclitaxel chemotherapy, including neutropenia, thrombocytopenia, and peripheral neuropathy.  DLTs were seen in two of seven evaluable patients at the max. administered dose (MAD): veliparib 120 mg BID, paclitaxel 200 mg/m2, and carboplatin AUC 6 (febrile neutropenia, hyponatremia).  The MTD and RP2D were detd. to be veliparib 100 mg BID, paclitaxel 200 mg/m2, and carboplatin AUC 6.  Median no. of cycles of the three-agent combination was 4 (1-16).  Veliparib did not affect paclitaxel or carboplatin PK disposition.  Conclusion: Veliparib, paclitaxel, and carboplatin were well tolerated and demonstrated promising antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtG2HmKirpWbVg90H21EOLACvtfcHk0lju2z8sl8-pYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVarsbvJ&md5=bea92fafcc14ba9047195eb3c149454a</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1007%2Fs00280-019-03960-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-019-03960-w%26sid%3Dliteratum%253Aachs%26aulast%3DAppleman%26aufirst%3DL.%2BJ.%26aulast%3DBeumer%26aufirst%3DJ.%2BH.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DF.%26aulast%3DPuhalla%26aufirst%3DS.%26aulast%3DSwartz%26aufirst%3DL.%26aulast%3DOwonikoko%26aufirst%3DT.%2BK.%26aulast%3DDonald%2BHarvey%26aufirst%3DR.%26aulast%3DStoller%26aufirst%3DR.%26aulast%3DPetro%26aufirst%3DD.%2BP.%26aulast%3DTawbi%26aufirst%3DH.%2BA.%26aulast%3DArgiris%26aufirst%3DA.%26aulast%3DStrychor%26aufirst%3DS.%26aulast%3DPouquet%26aufirst%3DM.%26aulast%3DKiesel%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DA.%2BP.%26aulast%3DGandara%26aufirst%3DD.%26aulast%3DBelani%26aufirst%3DC.%2BP.%26aulast%3DChu%26aufirst%3DE.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26atitle%3DPhase%25201%2520study%2520of%2520veliparib%2520%2528ABT-888%2529%252C%2520a%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520inhibitor%252C%2520with%2520carboplatin%2520and%2520paclitaxel%2520in%2520advanced%2520solid%2520malignancies%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2019%26volume%3D84%26spage%3D1289%26epage%3D1301%26doi%3D10.1007%2Fs00280-019-03960-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorbunova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofheinz, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Alfonso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nechaeva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cubillo Gracian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elez Fernandez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deming, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, J. D.</span></span> <span> </span><span class="NLM_article-title">A phase 2 randomised study of veliparib plus FOLFIRI+/-bevacizumab versus placebo plus FOLFIRI+/-bevacizumab in metastatic colorectal cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1038/s41416-018-0343-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2Fs41416-018-0343-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=30531832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFWrtbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2019&pages=183-189&author=V.+Gorbunovaauthor=J.+T.+Beckauthor=R.+D.+Hofheinzauthor=P.+Garcia-Alfonsoauthor=M.+Nechaevaauthor=A.+Cubillo+Gracianauthor=L.+Mangelauthor=E.+Elez+Fernandezauthor=D.+A.+Demingauthor=R.+K.+Ramanathanauthor=A.+H.+Torresauthor=D.+Sullivanauthor=Y.+Luoauthor=J.+D.+Berlin&title=A+phase+2+randomised+study+of+veliparib+plus+FOLFIRI%2B%2F-bevacizumab+versus+placebo+plus+FOLFIRI%2B%2F-bevacizumab+in+metastatic+colorectal+cancer&doi=10.1038%2Fs41416-018-0343-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer</span></div><div class="casAuthors">Gorbunova, Vera; Beck, J. Thaddeus; Hofheinz, Ralf-Dieter; Garcia-Alfonso, Pilar; Nechaeva, Marina; Cubillo Gracian, Antonio; Mangel, Laszlo; Elez Fernandez, Elena; Deming, Dustin A.; Ramanathan, Ramesh K.; Torres, Alison H.; Sullivan, Danielle; Luo, Yan; Berlin, Jordan D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">183-189</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Background: Metastatic colorectal cancer (mCRC) has low survival rates.  We assessed if addn. of veliparib, concurrent to FOLFIRI, improves survival in patients with previously untreated mCRC.  Methods: This study compared veliparib (200 mg BID for 7 days of each 14-day cycle) to placebo, each with FOLFIRI.  Bevacizumab was allowed in both arms.  The primary endpoint was progression-free survival (PFS).  Results: Patients were randomised to receive veliparib (n = 65) or placebo (n = 65) in combination with FOLFIRI.  Median PFS was 12 vs 11 mo (veliparib vs placebo) [HR = 0.94 (95% CI: 0.60, 1.48)].  Median OS was 25 vs 27 mo [HR = 1.26 (95% CI: 0.74, 2.16)].  Response rate was 57% vs 62%.  Median DOR was 11 vs 9 mo [HR = 0.73 (95% CI: 0.38, 1.40)].  AEs with significantly higher frequency (p < 0.05) in the veliparib group were anemia (39% vs 19%, p = 0.019) and neutropenia (66% vs 37%, p = 0.001) for common AEs (≥20%); neutropenia (59% vs 22%, p < 0.001) for common Grade 3/4 AEs (≥5%); none in serious AEs.  Haematopoietic cytopenias were more common with veliparib (79% vs 52%, p = 0.003).  Fourteen percent of patients on veliparib and 15% on placebo discontinued treatment due to AEs.  Conclusion: Veliparib added to FOLFIRI ± bevacizumab demonstrated similar efficacy as FOLFIRI ± bevacizumab in frontline mCRC patients.  No unexpected safety concerns occurred.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyqNMJBiQPG7Vg90H21EOLACvtfcHk0lh36P1YQ-_1Qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFWrtbvM&md5=07f1c62412daf5dca8627422a2b26d68</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1038%2Fs41416-018-0343-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41416-018-0343-z%26sid%3Dliteratum%253Aachs%26aulast%3DGorbunova%26aufirst%3DV.%26aulast%3DBeck%26aufirst%3DJ.%2BT.%26aulast%3DHofheinz%26aufirst%3DR.%2BD.%26aulast%3DGarcia-Alfonso%26aufirst%3DP.%26aulast%3DNechaeva%26aufirst%3DM.%26aulast%3DCubillo%2BGracian%26aufirst%3DA.%26aulast%3DMangel%26aufirst%3DL.%26aulast%3DElez%2BFernandez%26aufirst%3DE.%26aulast%3DDeming%26aufirst%3DD.%2BA.%26aulast%3DRamanathan%26aufirst%3DR.%2BK.%26aulast%3DTorres%26aufirst%3DA.%2BH.%26aulast%3DSullivan%26aufirst%3DD.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DBerlin%26aufirst%3DJ.%2BD.%26atitle%3DA%2520phase%25202%2520randomised%2520study%2520of%2520veliparib%2520plus%2520FOLFIRI%252B%252F-bevacizumab%2520versus%2520placebo%2520plus%2520FOLFIRI%252B%252F-bevacizumab%2520in%2520metastatic%2520colorectal%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2019%26volume%3D120%26spage%3D183%26epage%3D189%26doi%3D10.1038%2Fs41416-018-0343-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pishvaian, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hankin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsch-Vogel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukadiya, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiner, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brody, J. R.</span></span> <span> </span><span class="NLM_article-title">A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">2337</span>– <span class="NLM_lpage">2346</span>, <span class="refDoi"> DOI: 10.1002/cncr.31309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fcncr.31309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=29579325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOqsLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2018&pages=2337-2346&author=M.+J.+Pishvaianauthor=R.+S.+Slackauthor=W.+Jiangauthor=A.+R.+Heauthor=J.+J.+Hwangauthor=A.+Hankinauthor=K.+Dorsch-Vogelauthor=D.+Kukadiyaauthor=L.+M.+Weinerauthor=J.+L.+Marshallauthor=J.+R.+Brody&title=A+phase+2+study+of+the+PARP+inhibitor+veliparib+plus+temozolomide+in+patients+with+heavily+pretreated+metastatic+colorectal+cancer&doi=10.1002%2Fcncr.31309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer</span></div><div class="casAuthors">Pishvaian, Michael J.; Slack, Rebecca S.; Jiang, Wei; He, A. Ruth; Hwang, Jimmy J.; Hankin, Amy; Dorsch-Vogel, Karen; Kukadiya, Divyesh; Weiner, Louis M.; Marshall, John L.; Brody, Jonathan R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2337-2346</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : Poly(ADP ribose) polymerase (PARP) inhibitors such as veliparib are potent sensitizing agents and have been safely combined with DNA-damaging agents such as temozolomide.  The sensitizing effects of PARP inhibitors are magnified when cells harbor DNA repair defects.  METHODS : A single-arm, open-label, phase 2 study was performed to investigate the disease control rate (DCR) after 2 cycles of veliparib plus temozolomide in patients with metastatic colorectal cancer (mCRC) refractory to all std. therapies.  Fifty patients received temozolomide (150 mg/m2/d) on days 1 to 5 and veliparib (40 mg twice daily) on days 1 to 7 of each 28-day cycle.  Another 5 patients with mismatch repair-deficient (dMMR) tumors were also enrolled.  Twenty addnl. patients were then treated with temozolomide at 200 mg/m2/d.  Archived tumor specimens were used for immunohistochem. to assess mismatch repair, phosphatase and tensin homolog deleted on chromosome 10 (PTEN), and O(6)-methylguanine-DNA methyltransferase (MGMT) protein expression levels.  RESULTS : The combination was well tolerated, although some patients required dose redns. for myelosuppression.  The primary endpoint was successfully met with a DCR of 24% and 2 confirmed partial responses.  The median progression-free survival was 1.8 mo, and the median overall survival was 6.6 mo.  PTEN protein expression and MGMT protein expression were not predictors of DCR.  There was also a suggestion of worse outcomes for patients with dMMR tumors.  CONCLUSIONS : In this heavily pretreated mCRC population, a combination of veliparib and temozolomide was well tolerated with temozolomide doses up to 200 mg/m2/d, and it was clin. active.  PARP inhibitor-based therapy merits further exploration in patients with mCRC.  Cancer 2018;124:2337-46. © 2018 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0pPe3laOHHLVg90H21EOLACvtfcHk0lh36P1YQ-_1Qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOqsLzM&md5=6b3ed55b93609f62c5c4dc566da2bee0</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1002%2Fcncr.31309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.31309%26sid%3Dliteratum%253Aachs%26aulast%3DPishvaian%26aufirst%3DM.%2BJ.%26aulast%3DSlack%26aufirst%3DR.%2BS.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DA.%2BR.%26aulast%3DHwang%26aufirst%3DJ.%2BJ.%26aulast%3DHankin%26aufirst%3DA.%26aulast%3DDorsch-Vogel%26aufirst%3DK.%26aulast%3DKukadiya%26aufirst%3DD.%26aulast%3DWeiner%26aufirst%3DL.%2BM.%26aulast%3DMarshall%26aufirst%3DJ.%2BL.%26aulast%3DBrody%26aufirst%3DJ.%2BR.%26atitle%3DA%2520phase%25202%2520study%2520of%2520the%2520PARP%2520inhibitor%2520veliparib%2520plus%2520temozolomide%2520in%2520patients%2520with%2520heavily%2520pretreated%2520metastatic%2520colorectal%2520cancer%26jtitle%3DCancer%26date%3D2018%26volume%3D124%26spage%3D2337%26epage%3D2346%26doi%3D10.1002%2Fcncr.31309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loibl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shaughnessy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Untch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikov, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKee, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huober, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golshan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Minckwitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolmark, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponce Lorenzo, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger Filho, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastogi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symmans, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, C. E.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(18)30111-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2FS1470-2045%2818%2930111-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=29501363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=497-509&author=S.+Loiblauthor=J.+O%E2%80%99Shaughnessyauthor=M.+Untchauthor=W.+M.+Sikovauthor=H.+S.+Rugoauthor=M.+D.+McKeeauthor=J.+Huoberauthor=M.+Golshanauthor=G.+von+Minckwitzauthor=D.+Maagauthor=D.+Sullivanauthor=N.+Wolmarkauthor=K.+McIntyreauthor=J.+J.+Ponce+Lorenzoauthor=O.+Metzger+Filhoauthor=P.+Rastogiauthor=W.+F.+Symmansauthor=X.+Liuauthor=C.+E.+Geyer&title=Addition+of+the+PARP+inhibitor+veliparib+plus+carboplatin+or+carboplatin+alone+to+standard+neoadjuvant+chemotherapy+in+triple-negative+breast+cancer+%28BrighTNess%29%3A+a+randomised%2C+phase+3+trial&doi=10.1016%2FS1470-2045%2818%2930111-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomized, phase 3 trial</span></div><div class="casAuthors">Loibl, Sibylle; O'Shaughnessy, Joyce; Untch, Michael; Sikov, William M.; Rugo, Hope S.; McKee, Mark D.; Huober, Jens; Golshan, Mehra; von Minckwitz, Gunter; Maag, David; Sullivan, Danielle; Wolmark, Norman; McIntyre, Kristi; Ponce Lorenzo, Jose J.; Metzger Filho, Otto; Rastogi, Priya; Symmans, W. Fraser; Liu, Xuan; Geyer, Charles E., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">497-509</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Background: Although several randomized trials in patients with triple-neg. breast cancer have shown that the addn. of carboplatin, with or without poly(ADP-ribose) polymerase (PARP) inhibitors, to neoadjuvant chemotherapy increases the likelihood of achieving a pathol. complete response, the use of these therapies in this setting has remained controversial.  The BrighTNess trial was designed to assess the addn. of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to std. neoadjuvant chemotherapy in triple-neg. breast cancer.  Methods: We did a phase 3, randomized, double-blind, placebo-controlled trial (BrighTNess) across 145 sites in 15 countries.  Patients aged 18 years and older with previously untreated histol. or cytol. confirmed clin. stage II-III triple-neg. breast cancer, who were candidates for potentially curative surgery and had an Eastern Cooperative Oncol. Group performance status of 0 or 1, were randomly assigned (2:1:1) by an interactive response technol. system via permuted blocks (block size of four) within strata to receive one of three segment 1 regimens: paclitaxel (80 mg/m2 i.v. weekly for 12 doses) plus carboplatin (area under the curve 6 mg/mL per min, i.v. every 3 wk, for four cycles) plus veliparib (50 mg orally, twice a day); paclitaxel plus carboplatin plus veliparib placebo (twice a day); or paclitaxel plus carboplatin placebo (every 3 wk for four cycles) plus veliparib placebo.  Following segment 1, all patients were assigned to segment 2 in which they received doxorubicin and cyclophosphamide every 2-3 wk for four cycles.  Randomisation for segment 1 was stratified by germline BRCA mutation status, nodal stage, and planned schedule of doxorubicin and cyclophosphamide administration.  The primary endpoint was pathol. complete response in breast and lymph nodes as detd. by site pathologists following completion of neoadjuvant therapy.  Efficacy analyses were done by intention to treat and safety analyses included all patients who received at least one dose of study treatment.  These are the first results of an ongoing clin. trial; the data cutoff for the analyses presented was Dec 8, 2016.  This study is registered with ClinicalTrials.gov, no. NCT02032277.  Findings: Between Apr. 4, 2014, and March 18, 2016, 634 patients were randomly assigned: 316 to paclitaxel plus carboplatin plus veliparib, 160 to paclitaxel plus carboplatin, and 158 to paclitaxel alone.  The proportion of patients who achieved a pathol. complete response was higher in the paclitaxel, carboplatin, and veliparib group than in patients receiving paclitaxel alone (168 [53%] of 316 patients vs 49 [31%] of 158, p<0·0001), but not compared with patients receiving paclitaxel plus carboplatin (92 [58%] of 160 patients, p=0·36).  Grade 3 or 4 toxicities, and serious adverse events were more common in patients receiving carboplatin, whereas veliparib did not substantially increase toxicity.  The most common grade 3 or 4 events overall were neutropenia (352 [56%] of 628 patients), anemia (180 [29%]), and thrombocytopenia (75 [12%]) through complete treatment, and febrile neutropenia (88 [15%] of 601 patients) during segment 2.  The most common serious adverse events were febrile neutropenia (80 [13%] of 628 patients) and anemia (20 [3%]).  Interpretation: Although the addn. of veliparib and carboplatin to paclitaxel followed by doxorubicin and cyclophosphamide improved the proportion of patients with triple-neg. breast cancer who achieved a pathol. complete response, the addn. of veliparib to carboplatin and paclitaxel did not.  Increased toxicities with the addn. of carboplatin (with or without veliparib) to paclitaxel were manageable and did not substantially affect treatment delivery of paclitaxel followed by doxorubicin and cyclophosphamide.  Given the consistent results with previous studies, the addn. of carboplatin appears to have a favorable risk to benefit profile and might be considered as a potential component of neoadjuvant chemotherapy for patients with high-risk, triple-neg. breast cancer.AbbVie.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8o10fhEXh6LVg90H21EOLACvtfcHk0lhj7oUOwt6vYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGgur4%253D&md5=38b22907e32c3bab5faeaf9bf1a96719</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2818%2930111-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252818%252930111-6%26sid%3Dliteratum%253Aachs%26aulast%3DLoibl%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DUntch%26aufirst%3DM.%26aulast%3DSikov%26aufirst%3DW.%2BM.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DMcKee%26aufirst%3DM.%2BD.%26aulast%3DHuober%26aufirst%3DJ.%26aulast%3DGolshan%26aufirst%3DM.%26aulast%3Dvon%2BMinckwitz%26aufirst%3DG.%26aulast%3DMaag%26aufirst%3DD.%26aulast%3DSullivan%26aufirst%3DD.%26aulast%3DWolmark%26aufirst%3DN.%26aulast%3DMcIntyre%26aufirst%3DK.%26aulast%3DPonce%2BLorenzo%26aufirst%3DJ.%2BJ.%26aulast%3DMetzger%2BFilho%26aufirst%3DO.%26aulast%3DRastogi%26aufirst%3DP.%26aulast%3DSymmans%26aufirst%3DW.%2BF.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DGeyer%26aufirst%3DC.%2BE.%26atitle%3DAddition%2520of%2520the%2520PARP%2520inhibitor%2520veliparib%2520plus%2520carboplatin%2520or%2520carboplatin%2520alone%2520to%2520standard%2520neoadjuvant%2520chemotherapy%2520in%2520triple-negative%2520breast%2520cancer%2520%2528BrighTNess%2529%253A%2520a%2520randomised%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2018%26volume%3D19%26spage%3D497%26epage%3D509%26doi%3D10.1016%2FS1470-2045%2818%2930111-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horn, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baran, P. S.</span></span> <span> </span><span class="NLM_article-title">Synthetic organic electrochemistry: An enabling and innately sustainable method</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">302</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1021/acscentsci.6b00091</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.6b00091" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC28XntFyrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=302-308&author=E.+J.+Hornauthor=B.+R.+Rosenauthor=P.+S.+Baran&title=Synthetic+organic+electrochemistry%3A+An+enabling+and+innately+sustainable+method&doi=10.1021%2Facscentsci.6b00091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Organic Electrochemistry: An Enabling and Innately Sustainable Method</span></div><div class="casAuthors">Horn, Evan J.; Rosen, Brandon R.; Baran, Phil S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">302-308</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  While preparative electrolysis of org. mols. has been an active area of research over the past century, modern synthetic chemists have generally been reluctant to adopt this technol.  In fact, electrochem. methods possess many benefits over traditional reagent-based transformations, such as high functional group tolerance, mild conditions, and innate scalability and sustainability.  In this Outlook, we highlight illustrative examples of electrochem. reactions in the context of the synthesis of complex mols., showcasing the intrinsic benefits of electrochem. reactions vs. traditional reagent-based approaches.  Our hope is that this field will soon see widespread adoption in the synthetic community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGJWhmoi1pj7Vg90H21EOLACvtfcHk0lhj7oUOwt6vYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntFyrsLg%253D&md5=3ab155779f3a0a3b407e5197bcb67a37</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.6b00091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.6b00091%26sid%3Dliteratum%253Aachs%26aulast%3DHorn%26aufirst%3DE.%2BJ.%26aulast%3DRosen%26aufirst%3DB.%2BR.%26aulast%3DBaran%26aufirst%3DP.%2BS.%26atitle%3DSynthetic%2520organic%2520electrochemistry%253A%2520An%2520enabling%2520and%2520innately%2520sustainable%2520method%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2016%26volume%3D2%26spage%3D302%26epage%3D308%26doi%3D10.1021%2Facscentsci.6b00091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRoy, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perreault, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larivée, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harran, P. G.</span></span> <span> </span><span class="NLM_article-title">Electrolytic macrocyclizations: scalable synthesis of a diazonamide-based drug development candidate</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4818</span>– <span class="NLM_lpage">4822</span>, <span class="refDoi"> DOI: 10.1002/anie.201411663</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fanie.201411663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvF2nu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=4818-4822&author=H.+Dingauthor=P.+L.+DeRoyauthor=C.+Perreaultauthor=A.+Lariv%C3%A9eauthor=A.+Siddiquiauthor=C.+G.+Caldwellauthor=S.+Harranauthor=P.+G.+Harran&title=Electrolytic+macrocyclizations%3A+scalable+synthesis+of+a+diazonamide-based+drug+development+candidate&doi=10.1002%2Fanie.201411663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Electrolytic Macrocyclizations: Scalable Synthesis of a Diazonamide-Based Drug Development Candidate</span></div><div class="casAuthors">Ding, Hui; DeRoy, Patrick L.; Perreault, Christian; Larivee, Alexandre; Siddiqui, Arshad; Caldwell, Charles G.; Harran, Susan; Harran, Patrick G.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4818-4822</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An electrochem. method to synthesize the core macrolactam of diazonamides is described.  Large ring-forming dehydrogenation is initiated by anodic oxidn. at a graphite surface.  The reaction requires no tailoring of the substrate and occurs at ambient temp. in aq. DMF in an undivided cell open to air.  This unique chem. has enabled a concise, scalable prepn. of DZ-2384; a refined analog of diazonamide A slated for clin. development as a cancer therapeutic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR84QAkxXvorVg90H21EOLACvtfcHk0ljEVEbQPW5UxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvF2nu78%253D&md5=45c53b65fe3cf1b39f16e8966e6dfad9</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1002%2Fanie.201411663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201411663%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%26aulast%3DDeRoy%26aufirst%3DP.%2BL.%26aulast%3DPerreault%26aufirst%3DC.%26aulast%3DLariv%25C3%25A9e%26aufirst%3DA.%26aulast%3DSiddiqui%26aufirst%3DA.%26aulast%3DCaldwell%26aufirst%3DC.%2BG.%26aulast%3DHarran%26aufirst%3DS.%26aulast%3DHarran%26aufirst%3DP.%2BG.%26atitle%3DElectrolytic%2520macrocyclizations%253A%2520scalable%2520synthesis%2520of%2520a%2520diazonamide-based%2520drug%2520development%2520candidate%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D4818%26epage%3D4822%26doi%3D10.1002%2Fanie.201411663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maddess, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alorati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremeyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleator, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dieguez-Vazquez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klapars, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span> <span> </span><span class="NLM_article-title">Enantioselective synthesis of a highly substituted tetrahydrofluorene derivative as a potent and selective estrogen receptor beta agonist</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">528</span>– <span class="NLM_lpage">538</span>, <span class="refDoi"> DOI: 10.1021/op5000489</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op5000489" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlOksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=528-538&author=M.+L.+Maddessauthor=J.+P.+Scottauthor=A.+Aloratiauthor=C.+Baxterauthor=N.+Bremeyerauthor=S.+Brewerauthor=K.+Camposauthor=E.+Cleatorauthor=A.+Dieguez-Vazquezauthor=A.+Gibbauthor=A.+Gibsonauthor=M.+Howardauthor=S.+Keenauthor=A.+Klaparsauthor=J.+Leeauthor=J.+Liauthor=J.+Lynchauthor=P.+Mullensauthor=D.+Wallaceauthor=R.+Wilson&title=Enantioselective+synthesis+of+a+highly+substituted+tetrahydrofluorene+derivative+as+a+potent+and+selective+estrogen+receptor+beta+agonist&doi=10.1021%2Fop5000489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective Synthesis of a Highly Substituted Tetrahydrofluorene Derivative as a Potent and Selective Estrogen Receptor Beta Agonist</span></div><div class="casAuthors">Maddess, Matthew L.; Scott, Jeremy P.; Alorati, Anthony; Baxter, Carl; Bremeyer, Nadine; Brewer, Sarah; Campos, Kevin; Cleator, Ed; Dieguez-Vazquez, Alejandro; Gibb, Andrew; Gibson, Andrew; Howard, Melissa; Keen, Stephen; Klapars, Artis; Lee, Jaemoon; Li, Jing; Lynch, Joseph; Mullens, Peter; Wallace, Debra; Wilson, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">528-538</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A practical asym. synthesis of an estrogen receptor β-selective agonist methanocycloheptaindenotriazolone I on multikilogram scale was developed using the diastereoselective alkylation of a phenoxyethyl indenopyridooxazolone II incorporating an aminoindanol chiral auxiliary with a bromomethylbenzotriazole III as the key step.  More than 30 kg of I in >99% ee was prepd. by a route with a longest linear sequence of thirteen steps in 21% overall yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRZ1TGpTmOubVg90H21EOLACvtfcHk0ljEVEbQPW5UxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlOksbs%253D&md5=6b441a45b5955c68815aa77b3fda75da</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Fop5000489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop5000489%26sid%3Dliteratum%253Aachs%26aulast%3DMaddess%26aufirst%3DM.%2BL.%26aulast%3DScott%26aufirst%3DJ.%2BP.%26aulast%3DAlorati%26aufirst%3DA.%26aulast%3DBaxter%26aufirst%3DC.%26aulast%3DBremeyer%26aufirst%3DN.%26aulast%3DBrewer%26aufirst%3DS.%26aulast%3DCampos%26aufirst%3DK.%26aulast%3DCleator%26aufirst%3DE.%26aulast%3DDieguez-Vazquez%26aufirst%3DA.%26aulast%3DGibb%26aufirst%3DA.%26aulast%3DGibson%26aufirst%3DA.%26aulast%3DHoward%26aufirst%3DM.%26aulast%3DKeen%26aufirst%3DS.%26aulast%3DKlapars%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLynch%26aufirst%3DJ.%26aulast%3DMullens%26aufirst%3DP.%26aulast%3DWallace%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DR.%26atitle%3DEnantioselective%2520synthesis%2520of%2520a%2520highly%2520substituted%2520tetrahydrofluorene%2520derivative%2520as%2520a%2520potent%2520and%2520selective%2520estrogen%2520receptor%2520beta%2520agonist%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2014%26volume%3D18%26spage%3D528%26epage%3D538%26doi%3D10.1021%2Fop5000489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sclafani, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reese, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudipalli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neville, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakale, R. P.</span></span> <span> </span><span class="NLM_article-title">The first asymmetric pilot-scale synthesis of TV-45070</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1616</span>– <span class="NLM_lpage">1624</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.7b00237</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.7b00237" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGhsr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=1616-1624&author=J.+A.+Sclafaniauthor=J.+Chenauthor=D.+V.+Levyauthor=H.+Reeseauthor=M.+Dimitriauthor=P.+Mudipalliauthor=M.+Christieauthor=C.+J.+Nevilleauthor=M.+Olsenauthor=R.+P.+Bakale&title=The+first+asymmetric+pilot-scale+synthesis+of+TV-45070&doi=10.1021%2Facs.oprd.7b00237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">The First Asymmetric Pilot-Scale Synthesis of TV-45070</span></div><div class="casAuthors">Sclafani, Joseph A.; Chen, Jian; Levy, Daniel V.; Reese, Harlan; Dimitri, Mina; Mudipalli, Partha; Christie, Michael; Neville, Christopher J.; Olsen, Mark; Bakale, Roger P.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1616-1624</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">TV-45070 (formerly XEN-402) is a small-mol. lactam contg. a chiral spiro-ether that is reported as a potential topical therapy for pain assocd. with the Nav1.7 Na ion channel encoded by the gene SCN9A.  A pilot-scale synthesis is presented that is highlighted by an asym. aldol coupling at ambient temp., used to create a quaternary chiral center.  Although only a moderate ee was obtained, the removal of the undesired isomer is achieved through preferential pptn. of a near racemic mixt. from the reaction, leaving the enantiopure isomer in soln.  Cyclization to form the final API uses an uncommon diphenylphosphine-based leaving group which proved successful on the neopentyl system when other traditional leaving groups failed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvvJXHK7roRLVg90H21EOLACvtfcHk0ljEVEbQPW5UxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGhsr3E&md5=0be4812d90881ccd423f3b70a64ea395</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.7b00237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.7b00237%26sid%3Dliteratum%253Aachs%26aulast%3DSclafani%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLevy%26aufirst%3DD.%2BV.%26aulast%3DReese%26aufirst%3DH.%26aulast%3DDimitri%26aufirst%3DM.%26aulast%3DMudipalli%26aufirst%3DP.%26aulast%3DChristie%26aufirst%3DM.%26aulast%3DNeville%26aufirst%3DC.%2BJ.%26aulast%3DOlsen%26aufirst%3DM.%26aulast%3DBakale%26aufirst%3DR.%2BP.%26atitle%3DThe%2520first%2520asymmetric%2520pilot-scale%2520synthesis%2520of%2520TV-45070%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2017%26volume%3D21%26spage%3D1616%26epage%3D1624%26doi%3D10.1021%2Facs.oprd.7b00237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scalabrino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankish, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, H.</span></span> <span> </span><span class="NLM_article-title">Investigation of the stereoselective synthesis of the indane dimer PH46A, a new potential anti-inflammatory agent</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1972</span>– <span class="NLM_lpage">1979</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.7b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.7b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVKisrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=1972-1979&author=G.+R.+Cummingauthor=T.+Zhangauthor=G.+Scalabrinoauthor=N.+Frankishauthor=H.+Sheridan&title=Investigation+of+the+stereoselective+synthesis+of+the+indane+dimer+PH46A%2C+a+new+potential+anti-inflammatory+agent&doi=10.1021%2Facs.oprd.7b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of the Stereoselective Synthesis of the Indane Dimer PH46A, a New Potential Anti-inflammatory Agent</span></div><div class="casAuthors">Cumming, Graham R.; Zhang, Tao; Scalabrino, Gaia; Frankish, Neil; Sheridan, Helen</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1972-1979</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PH46A, belonging to a class of 1,2-Indane dimers, has been developed by our research group as a potential therapeutic agent for the treatment of inflammatory and autoimmune diseases.  The initial synthetic route to PH46A gave a low overall yield, due in large part to the generation of undesired diastereoisomer I and the unwanted enantiomer (R,R)-II during the synthesis.  The aim of this work was to carry out a comprehensive investigation into the stereoselective synthesis of PH46A.  Significant progress was made on the ketone redn. step, where the use of triisobutylaluminum [TiBA, Al(iBu)3] afforded high selectivity for the target diastereoisomer (rac)-III, compared to the unfavorable ratio obtained using a previous process.  This enabled a multikilo scale synthesis of PH46A in a GMP environment.  Further, a brief proof-of-principle investigation was carried out using an achiral phase transfer catalyst (PTC) for alkylation at the methine carbon of the parent indanone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow1yX3lGQF-7Vg90H21EOLACvtfcHk0ljCO-tX-5BqaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVKisrvI&md5=a48530087953d2ac9cadb6771cc46908</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.7b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.7b00258%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DG.%2BR.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DScalabrino%26aufirst%3DG.%26aulast%3DFrankish%26aufirst%3DN.%26aulast%3DSheridan%26aufirst%3DH.%26atitle%3DInvestigation%2520of%2520the%2520stereoselective%2520synthesis%2520of%2520the%2520indane%2520dimer%2520PH46A%252C%2520a%2520new%2520potential%2520anti-inflammatory%2520agent%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2017%26volume%3D21%26spage%3D1972%26epage%3D1979%26doi%3D10.1021%2Facs.oprd.7b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entwistle, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laity, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Praquin, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strang, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C. A. L.</span></span> <span> </span><span class="NLM_article-title">Development of a scaleable synthesis of a geminal dimethyl tertiary amine as an inhaled muscarinic antagonist for the treatment of COPD</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1021/op200233r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op200233r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVKlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=195-203&author=B.+R.+Dillonauthor=D.+F.+Robertsauthor=D.+A.+Entwistleauthor=P.+A.+Glossopauthor=C.+J.+Knightauthor=D.+A.+Laityauthor=K.+Jamesauthor=C.+F.+Praquinauthor=R.+S.+Strangauthor=C.+A.+L.+Watson&title=Development+of+a+scaleable+synthesis+of+a+geminal+dimethyl+tertiary+amine+as+an+inhaled+muscarinic+antagonist+for+the+treatment+of+COPD&doi=10.1021%2Fop200233r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a scaleable synthesis of a geminal dimethyl tertiary amine as an inhaled muscarinic antagonist for the treatment of COPD</span></div><div class="casAuthors">Dillon, Barry R.; Roberts, Dannielle F.; Entwistle, David A.; Glossop, Paul A.; Knight, Craig J.; Laity, Daniel A.; James, Kim; Praquin, Celine F.; Strang, Ross S.; Watson, Christine A. L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-203</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An efficient and scaleable process for the synthesis of muscarinic antagonist, PF-3635659 (I), is described, illustrating redesign of an analog-targeted synthesis which contained a scale-limiting rhodium-activated C-H amination step.  The final route includes a reproducible modified Bouveault reaction which has not previously been reported on a substrate of this complexity, or on such a scale with over 5 kg of the requisite gem-dimethylamine prepd. via this methodol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFXTINg0pelLVg90H21EOLACvtfcHk0ljCO-tX-5BqaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVKlug%253D%253D&md5=11262a71aaceed3259dc98bb73810bbe</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Fop200233r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop200233r%26sid%3Dliteratum%253Aachs%26aulast%3DDillon%26aufirst%3DB.%2BR.%26aulast%3DRoberts%26aufirst%3DD.%2BF.%26aulast%3DEntwistle%26aufirst%3DD.%2BA.%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DKnight%26aufirst%3DC.%2BJ.%26aulast%3DLaity%26aufirst%3DD.%2BA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DPraquin%26aufirst%3DC.%2BF.%26aulast%3DStrang%26aufirst%3DR.%2BS.%26aulast%3DWatson%26aufirst%3DC.%2BA.%2BL.%26atitle%3DDevelopment%2520of%2520a%2520scaleable%2520synthesis%2520of%2520a%2520geminal%2520dimethyl%2520tertiary%2520amine%2520as%2520an%2520inhaled%2520muscarinic%2520antagonist%2520for%2520the%2520treatment%2520of%2520COPD%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2012%26volume%3D16%26spage%3D195%26epage%3D203%26doi%3D10.1021%2Fop200233r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Polster, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burcham, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaborenko, N.</span></span> <span> </span><span class="NLM_article-title">Pilot-scale continuous production of LY2886721: Amide formation and reactive crystallization</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1295</span>– <span class="NLM_lpage">1309</span>, <span class="refDoi"> DOI: 10.1021/op500204z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op500204z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslChtr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=1295-1309&author=C.+S.+Polsterauthor=K.+P.+Coleauthor=C.+L.+Burchamauthor=B.+M.+Campbellauthor=A.+L.+Frederickauthor=M.+M.+Hansenauthor=M.+Hardingauthor=M.+R.+Hellerauthor=M.+T.+Millerauthor=J.+L.+Phillipsauthor=P.+M.+Pollockauthor=N.+Zaborenko&title=Pilot-scale+continuous+production+of+LY2886721%3A+Amide+formation+and+reactive+crystallization&doi=10.1021%2Fop500204z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Pilot-Scale Continuous Production of LY2886721: Amide Formation and Reactive Crystallization</span></div><div class="casAuthors">Polster, Christopher S.; Cole, Kevin P.; Burcham, Christopher L.; Campbell, Bradley M.; Frederick, Andrea L.; Hansen, Marvin M.; Harding, Molly; Heller, Michael R.; Miller, Michael T.; Phillips, Joseph L.; Pollock, Patrick M.; Zaborenko, Nikolay</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1295-1309</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, development, and implementation of a pilot-scale continuous Schotten-Baumann amide bond formation and reactive crystn. to afford LY2886721 is described.  The material met all API quality attributes and was comparable to material produced by a defined batch process.  The scalability of the reaction and crystn. processes was confirmed during the development process.  The pilot-scale equipment set was contained in a walk-in fume hood and operated at a prodn. rate of 3 kg/day in a 72 h continuous run.  Significant tech. and business drivers for running the process in continuous flow mode were proposed and examd. during development.  The continuous process provided for lab hood commercialization and provided for minimal material at risk in the process.  The demonstration also confirmed the risk inherent to operation of a tubular reactor under supersatd. conditions, and fouling occurred in the plug flow reactor.  Fouling also occurred in the crystallizer.  Recognizing these deficiencies, the process operated within the footprint of a std. walk-in fume hood, providing a successful demonstration of the opportunities afforded by continuous processing for low vol. pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzl8U-JufDgLVg90H21EOLACvtfcHk0ljCO-tX-5BqaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslChtr7E&md5=2777d9d7600b877872d5bc74e367daf9</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Fop500204z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop500204z%26sid%3Dliteratum%253Aachs%26aulast%3DPolster%26aufirst%3DC.%2BS.%26aulast%3DCole%26aufirst%3DK.%2BP.%26aulast%3DBurcham%26aufirst%3DC.%2BL.%26aulast%3DCampbell%26aufirst%3DB.%2BM.%26aulast%3DFrederick%26aufirst%3DA.%2BL.%26aulast%3DHansen%26aufirst%3DM.%2BM.%26aulast%3DHarding%26aufirst%3DM.%26aulast%3DHeller%26aufirst%3DM.%2BR.%26aulast%3DMiller%26aufirst%3DM.%2BT.%26aulast%3DPhillips%26aufirst%3DJ.%2BL.%26aulast%3DPollock%26aufirst%3DP.%2BM.%26aulast%3DZaborenko%26aufirst%3DN.%26atitle%3DPilot-scale%2520continuous%2520production%2520of%2520LY2886721%253A%2520Amide%2520formation%2520and%2520reactive%2520crystallization%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2014%26volume%3D18%26spage%3D1295%26epage%3D1309%26doi%3D10.1021%2Fop500204z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giulianotti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinilla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghten, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina-Franco, J. L.</span></span> <span> </span><span class="NLM_article-title">Chemoinformatic analysis of combinatorial libraries, drugs, natural products, and molecular libraries small molecule repository</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1010</span>– <span class="NLM_lpage">1024</span>, <span class="refDoi"> DOI: 10.1021/ci800426u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci800426u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsVKktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=1010-1024&author=N.+Singhauthor=R.+Guhaauthor=M.+A.+Giulianottiauthor=C.+Pinillaauthor=R.+A.+Houghtenauthor=J.+L.+Medina-Franco&title=Chemoinformatic+analysis+of+combinatorial+libraries%2C+drugs%2C+natural+products%2C+and+molecular+libraries+small+molecule+repository&doi=10.1021%2Fci800426u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoinformatic Analysis of Combinatorial Libraries, Drugs, Natural Products, and Molecular Libraries Small Molecule Repository</span></div><div class="casAuthors">Singh, Narender; Guha, Rajarshi; Giulianotti, Marc A.; Pinilla, Clemencia; Houghten, Richard A.; Medina-Franco, Jose L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1010-1024</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A multiple criteria approach is presented, that is used to perform a comparative anal. of four recently developed combinatorial libraries to drugs, Mol. Libraries Small Mol. Repository (MLSMR) and natural products.  The compd. databases were assessed in terms of physicochem. properties, scaffolds, and fingerprints.  The approach enables the anal. of property space coverage, degree of overlap between collections, scaffold and structural diversity, and overall structural novelty.  The degree of overlap between combinatorial libraries and drugs was assessed using the R-NN curve methodol., which measures the d. of chem. space around a query mol. embedded in the chem. space of a target collection.  The combinatorial libraries studied in this work exhibit scaffolds that were not obsd. in the drug, MLSMR, and natural products databases.  The fingerprint-based comparisons indicate that these combinatorial libraries are structurally different than current drugs.  The R-NN curve methodol. revealed that a proportion of mols. in the combinatorial libraries is located within the property space of the drugs.  However, the R-NN anal. also showed that there are a significant no. of mols. in several combinatorial libraries that are located in sparse regions of the drug space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcwu-N7ebOhLVg90H21EOLACvtfcHk0lhh8eaPwX6jwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsVKktLY%253D&md5=4c246e6c66780516f596a7b398fc337b</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Fci800426u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800426u%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DN.%26aulast%3DGuha%26aufirst%3DR.%26aulast%3DGiulianotti%26aufirst%3DM.%2BA.%26aulast%3DPinilla%26aufirst%3DC.%26aulast%3DHoughten%26aufirst%3DR.%2BA.%26aulast%3DMedina-Franco%26aufirst%3DJ.%2BL.%26atitle%3DChemoinformatic%2520analysis%2520of%2520combinatorial%2520libraries%252C%2520drugs%252C%2520natural%2520products%252C%2520and%2520molecular%2520libraries%2520small%2520molecule%2520repository%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26spage%3D1010%26epage%3D1024%26doi%3D10.1021%2Fci800426u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, J.</span></span> <span> </span><span class="NLM_article-title">Will combinatorial chemistry keep its promise?</span>. <i>Biotechnol. Healthcare</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">32</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=23393460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A280%3ADC%252BC3szmslWlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=26-32&author=J.+Carroll&title=Will+combinatorial+chemistry+keep+its+promise%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Will combinatorial chemistry keep its promise?</span></div><div class="casAuthors">Carroll John</div><div class="citationInfo"><span class="NLM_cas:title">Biotechnology healthcare</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">26-32</span>
        ISSN:<span class="NLM_cas:issn">1554-169X</span>.
    </div><div class="casAbstract">Although this technology has come under fire, it isn't being abandoned.  Biotechs that use combichem are developing new strategies - replacing diverse compound libraries with smaller, targeted libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS83ZdOHnrtdXO4gDb7JggCfW6udTcc2eZf2uNrXPNFQbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szmslWlsQ%253D%253D&md5=2de10527093d0e78140e7c3aa9d94478</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarroll%26aufirst%3DJ.%26atitle%3DWill%2520combinatorial%2520chemistry%2520keep%2520its%2520promise%253F%26jtitle%3DBiotechnol.%2520Healthcare%26date%3D2005%26volume%3D2%26spage%3D26%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kodadek, T.</span></span> <span> </span><span class="NLM_article-title">The rise, fall and reinvention of combinatorial chemistry</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">9757</span>– <span class="NLM_lpage">9763</span>, <span class="refDoi"> DOI: 10.1039/c1cc12102b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1039%2Fc1cc12102b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=21701754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVGms7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=9757-9763&author=T.+Kodadek&title=The+rise%2C+fall+and+reinvention+of+combinatorial+chemistry&doi=10.1039%2Fc1cc12102b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">The rise, fall and reinvention of combinatorial chemistry</span></div><div class="casAuthors">Kodadek, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">9757-9763</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Combinatorial chem. provides a powerful tool for the rapid creation of large nos. of synthetic compds.  Ideally, these libraries should be a rich source of bioactive mols., but there is the general feeling that the initial promise of combinatorial chem. has not yet been realized.  In particular, enthusiasm for conducting unbiased (non-structure-guided) screens of large libraries for protein or RNA ligands has waned.  A central challenge in this area is to devise methods for the synthesis of chem. diverse, high-quality libraries of mols. with many of the desirable features of natural products.  These include diverse functionality, a significant representation of chiral sp3 centers that provide conformational bias to the mol., significant skeletal diversity, and good pharmacokinetic properties.  However, these libraries must be easy to make from cheap, readily available building blocks, ideally those that would support convenient hit optimization/structure reactivity relationship studies.  Meeting these challenges will not be easy.  Here I review some recent advances in this area and provide some thoughts on likely important developments in the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ-foGwWRw_7Vg90H21EOLACvtfcHk0lhh8eaPwX6jwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVGms7rN&md5=7f511292a501b50ff78bb497021b87e0</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1039%2Fc1cc12102b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1cc12102b%26sid%3Dliteratum%253Aachs%26aulast%3DKodadek%26aufirst%3DT.%26atitle%3DThe%2520rise%252C%2520fall%2520and%2520reinvention%2520of%2520combinatorial%2520chemistry%26jtitle%3DChem.%2520Commun.%26date%3D2011%26volume%3D47%26spage%3D9757%26epage%3D9763%26doi%3D10.1039%2Fc1cc12102b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, D. S.</span></span> <span> </span><span class="NLM_article-title">Combinatorial chemistry: starting the second decade</span>. <i>Pharmacogenomics J.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1038/sj.tpj.6500045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2Fsj.tpj.6500045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=11908762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjtlamtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=229-232&author=D.+S.+Thorpe&title=Combinatorial+chemistry%3A+starting+the+second+decade&doi=10.1038%2Fsj.tpj.6500045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial chemistry: Starting the second decade</span></div><div class="casAuthors">Thorpe, D. S.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenomics Journal</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">229-233</span>CODEN:
                <span class="NLM_cas:coden">PJHOAZ</span>;
        ISSN:<span class="NLM_cas:issn">1470-269X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review introduces the basic concepts of combinatorial chem., describe its strengths and weaknesses with an eye to efficiencies, and emphasize some ongoing changes to enhance performance.  The scope is restricted to small compds. made by synthetic chem., and not biol. generated libraries such as phage display.  The first generation of combinatorial chem. was based on polymer chem.  The high-diversity second-generation libraries were effective in generating hits and leads for only certain types of screens.  The current third generation of combinatorial chem. is building on its strength.  Design of the collections now employs empirical knowledge, sophisticated algorithms, and medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx1sxCVdJh7bVg90H21EOLACvtfcHk0lhh8eaPwX6jwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjtlamtg%253D%253D&md5=f6e3e01f8b715b52827394d42fc038d3</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1038%2Fsj.tpj.6500045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.tpj.6500045%26sid%3Dliteratum%253Aachs%26aulast%3DThorpe%26aufirst%3DD.%2BS.%26atitle%3DCombinatorial%2520chemistry%253A%2520starting%2520the%2520second%2520decade%26jtitle%3DPharmacogenomics%2520J.%26date%3D2001%26volume%3D1%26spage%3D229%26epage%3D232%26doi%3D10.1038%2Fsj.tpj.6500045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P. J.</span></span> <span> </span><span class="NLM_article-title">Moving beyond combinatorial chemistry for greater efficiency in lead discovery</span>. <i>JALA</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1016/S1535-5535-04-00175-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2FS1535-5535-04-00175-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD38Xit1amtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2002&pages=59-63&author=P.+J.+Edwards&title=Moving+beyond+combinatorial+chemistry+for+greater+efficiency+in+lead+discovery&doi=10.1016%2FS1535-5535-04-00175-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Moving beyond combinatorial chemistry for greater efficiency in lead discovery</span></div><div class="casAuthors">Edwards, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">JALA</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-63</span>CODEN:
                <span class="NLM_cas:coden">JALLFO</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">JALA</span>)
        </div><div class="casAbstract">A review.  Pfizer Inc. is a research based global pharmaceutical company committed to the discovery and development of innovative medicines that improve the quality of life of individuals throughout the world.  In order to gain a competitive advantage over competitor companies in the discovery of new medicines, we must speed up drug discovery and drive down costs.  Using non-combinatorial chem. techniques increases the efficiency with which we discover new "leads," leveraging our drug discovery efforts through retaining complete control over the properties of each product made.  Compd. purifn., managed through inhouse software, augments the quality of data obtained upon biol. screening of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL8vaIVL65QrVg90H21EOLACvtfcHk0lg119aC_m6OyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xit1amtLY%253D&md5=ac35620cd2d245fa458331a2ee786b65</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2FS1535-5535-04-00175-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-5535-04-00175-3%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DP.%2BJ.%26atitle%3DMoving%2520beyond%2520combinatorial%2520chemistry%2520for%2520greater%2520efficiency%2520in%2520lead%2520discovery%26jtitle%3DJALA%26date%3D2002%26volume%3D7%26spage%3D59%26epage%3D63%26doi%3D10.1016%2FS1535-5535-04-00175-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 10 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xiaoyi Zhu, Ruibo Li, Hequan Yao, <span class="NLM_string-name hlFld-ContribAuthor">Aijun Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium-Catalyzed Allenamide Carbopalladation/Allylation with Active Methine Compounds. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (12)
                                     , 4630-4634. <a href="https://doi.org/10.1021/acs.orglett.1c01369" title="DOI URL">https://doi.org/10.1021/acs.orglett.1c01369</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.1c01369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.1c01369%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DPalladium-Catalyzed%252BAllenamide%252BCarbopalladation%25252FAllylation%252Bwith%252BActive%252BMethine%252BCompounds%26aulast%3DZhu%26aufirst%3DXiaoyi%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D20042021%26date%3D28052021%26volume%3D23%26issue%3D12%26spage%3D4630%26epage%3D4634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marta Serafini, Sarah Cargnin, Alberto Massarotti, Gian Cesare Tron, Tracey Pirali, <span class="NLM_string-name hlFld-ContribAuthor">Armando A. Genazzani</span>. </span><span class="cited-content_cbyCitation_article-title">What’s in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 4410-4429. <a href="https://doi.org/10.1021/acs.jmedchem.1c00181" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00181</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00181%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhat%2525E2%252580%252599s%252Bin%252Ba%252BName%25253F%252BDrug%252BNomenclature%252Band%252BMedicinal%252BChemistry%252BTrends%252Busing%252BINN%252BPublications%26aulast%3DSerafini%26aufirst%3DMarta%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D01022021%26date%3D13042021%26volume%3D64%26issue%3D8%26spage%3D4410%26epage%3D4429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kerstin Hiesinger, Dmitry Dar’in, Ewgenij Proschak, <span class="NLM_string-name hlFld-ContribAuthor">Mikhail Krasavin</span>. </span><span class="cited-content_cbyCitation_article-title">Spirocyclic Scaffolds in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 150-183. <a href="https://doi.org/10.1021/acs.jmedchem.0c01473" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01473</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01473%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSpirocyclic%252BScaffolds%252Bin%252BMedicinal%252BChemistry%26aulast%3DHiesinger%26aufirst%3DKerstin%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D24082020%26date%3D31122020%26volume%3D64%26issue%3D1%26spage%3D150%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yangyang Yang, Jet Tsien, Ayala Ben David, Jonathan M. E. Hughes, Rohan R. Merchant, <span class="NLM_string-name hlFld-ContribAuthor">Tian Qin</span>. </span><span class="cited-content_cbyCitation_article-title">Practical and Modular Construction of C(sp3)-Rich Alkyl Boron Compounds. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (1)
                                     , 471-480. <a href="https://doi.org/10.1021/jacs.0c11964" title="DOI URL">https://doi.org/10.1021/jacs.0c11964</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.0c11964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.0c11964%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DPractical%252Band%252BModular%252BConstruction%252Bof%252BC%252528sp3%252529-Rich%252BAlkyl%252BBoron%252BCompounds%26aulast%3DYang%26aufirst%3DYangyang%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D15112020%26date%3D21122020%26volume%3D143%26issue%3D1%26spage%3D471%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junki  Morimoto</span>, <span class="hlFld-ContribAuthor ">Kazunori  Miyamoto</span>, <span class="hlFld-ContribAuthor ">Yuki  Ichikawa</span>, <span class="hlFld-ContribAuthor ">Masanobu  Uchiyama</span>, <span class="hlFld-ContribAuthor ">Makoto  Makishima</span>, <span class="hlFld-ContribAuthor ">Yuichi  Hashimoto</span>, <span class="hlFld-ContribAuthor ">Minoru  Ishikawa</span>. </span><span class="cited-content_cbyCitation_article-title">Improvement in aqueous solubility of achiral symmetric cyclofenil by modification to a chiral asymmetric analog. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-021-92028-y" title="DOI URL">https://doi.org/10.1038/s41598-021-92028-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-021-92028-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-021-92028-y%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DImprovement%252Bin%252Baqueous%252Bsolubility%252Bof%252Bachiral%252Bsymmetric%252Bcyclofenil%252Bby%252Bmodification%252Bto%252Ba%252Bchiral%252Basymmetric%252Banalog%26aulast%3DMorimoto%26aufirst%3DJunki%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lucia  Furiassi</span>, <span class="hlFld-ContribAuthor ">Emily J.  Tonogai</span>, <span class="hlFld-ContribAuthor ">Paul J.  Hergenrother</span>. </span><span class="cited-content_cbyCitation_article-title">Limonin as a Starting Point for the Construction of Compounds with High Scaffold Diversity. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2021,</strong> <em>133 </em>
                                    (29)
                                     , 16255-16264. <a href="https://doi.org/10.1002/ange.202104228" title="DOI URL">https://doi.org/10.1002/ange.202104228</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202104228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202104228%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DLimonin%252Bas%252Ba%252BStarting%252BPoint%252Bfor%252Bthe%252BConstruction%252Bof%252BCompounds%252Bwith%252BHigh%252BScaffold%252BDiversity%26aulast%3DFuriassi%26aufirst%3DLucia%26date%3D2021%26date%3D2021%26volume%3D133%26issue%3D29%26spage%3D16255%26epage%3D16264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lucia  Furiassi</span>, <span class="hlFld-ContribAuthor ">Emily J.  Tonogai</span>, <span class="hlFld-ContribAuthor ">Paul J.  Hergenrother</span>. </span><span class="cited-content_cbyCitation_article-title">Limonin as a Starting Point for the Construction of Compounds with High Scaffold Diversity. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2021,</strong> <em>60 </em>
                                    (29)
                                     , 16119-16128. <a href="https://doi.org/10.1002/anie.202104228" title="DOI URL">https://doi.org/10.1002/anie.202104228</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202104228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202104228%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DLimonin%252Bas%252Ba%252BStarting%252BPoint%252Bfor%252Bthe%252BConstruction%252Bof%252BCompounds%252Bwith%252BHigh%252BScaffold%252BDiversity%26aulast%3DFuriassi%26aufirst%3DLucia%26date%3D2021%26date%3D2021%26volume%3D60%26issue%3D29%26spage%3D16119%26epage%3D16128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weijin  Wang</span>, <span class="hlFld-ContribAuthor ">Douglass F.  Taber</span>, <span class="hlFld-ContribAuthor ">Hans  Renata</span>. </span><span class="cited-content_cbyCitation_article-title">Practical Enzymatic Production of Carbocycles. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2021,</strong> <em>26 </em><a href="https://doi.org/10.1002/chem.202101232" title="DOI URL">https://doi.org/10.1002/chem.202101232</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.202101232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.202101232%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DPractical%252BEnzymatic%252BProduction%252Bof%252BCarbocycles%26aulast%3DWang%26aufirst%3DWeijin%26date%3D2021%26date%3D2021%26volume%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei W.  Chen</span>, <span class="hlFld-ContribAuthor ">Nahiane Pipaon  Fernández</span>, <span class="hlFld-ContribAuthor ">Marta Díaz  Baranda</span>, <span class="hlFld-ContribAuthor ">Anton  Cunillera</span>, <span class="hlFld-ContribAuthor ">Laura G.  Rodríguez</span>, <span class="hlFld-ContribAuthor ">Alexandr  Shafir</span>, <span class="hlFld-ContribAuthor ">Ana B.  Cuenca</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring benzylic
              gem
              -C(sp
              3
              )–boron–silicon and boron–tin centers as a synthetic platform. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2021,</strong> <em>96 </em><a href="https://doi.org/10.1039/D1SC01741A" title="DOI URL">https://doi.org/10.1039/D1SC01741A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1SC01741A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1SC01741A%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DExploring%252Bbenzylic%252Bgem%252B-C%252528sp%252B3%252B%252529%2525E2%252580%252593boron%2525E2%252580%252593silicon%252Band%252Bboron%2525E2%252580%252593tin%252Bcenters%252Bas%252Ba%252Bsynthetic%252Bplatform%26aulast%3DChen%26aufirst%3DWei%2BW.%26date%3D2021%26date%3D2021%26volume%3D96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen  Zhang</span>, <span class="hlFld-ContribAuthor ">Lingzi  Li</span>, <span class="hlFld-ContribAuthor ">Chuang-Chuang  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of natural products containing highly strained
              trans
              -fused bicyclo[3.3.0]octane: historical overview and future prospects. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2021,</strong> <em>79 </em><a href="https://doi.org/10.1039/D0CS01471K" title="DOI URL">https://doi.org/10.1039/D0CS01471K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CS01471K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CS01471K%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DSynthesis%252Bof%252Bnatural%252Bproducts%252Bcontaining%252Bhighly%252Bstrained%252Btrans%252B-fused%252Bbicyclo%25255B3.3.0%25255Doctane%25253A%252Bhistorical%252Boverview%252Band%252Bfuture%252Bprospects%26aulast%3DZhang%26aufirst%3DWen%26date%3D2021%26date%3D2021%26volume%3D79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0051.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0051.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures, in vitro potency, and PK profiles of OTR antagonists <b>1</b> and <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures, in vitro potency, and PK profiles of LSD1 inhibitors <b>3</b> and <b>4</b>. SPR, surface plasmon resonance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures, in vitro potency, and DMPK profiles of TGR5 agonists <b>5</b>–<b>7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures, in vitro potency, and PK properties of DGAT1 inhibitors <b>8</b>–<b>10</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures, in vitro potency, and physicochemical properties of PI3K-AKT-mTOR pathway inhibitors <b>11</b> and <b>12</b>. Chrom logP, chromatographic log <i>P</i>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures and in vitro potency of <b>13</b> and <b>14</b> and DMPK properties of P2Y<sub>12</sub> antagonist <b>14</b>. hPRP, human platelet-rich plasma aggregation; MRT, mean residence time.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures and in vivo efficacy of general anesthetics <b>15</b>–<b>17</b> in a mice model of anesthesia. TI, LD<sub>50</sub>/ED<sub>50</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Structures and in vitro potency of BCL-X<sub>L</sub> inhibitors <b>18</b> and <b>19</b>. HS, human serum.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Structures and in vitro potency of antifungal agents <b>20</b>–<b>22</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures and in vitro binding affinity of adenosine receptor antagonists <b>23</b> and <b>24</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structures, in vitro potency, and physicochemical properties of LpPLA<sub>2</sub> inhibitors <b>25</b> and <b>26</b>. CLIND, kinetic solubility; FaSSIF, thermodynamic fasted state simulated intestinal fluid solubility; AMP, artificial membrane permeability; chromLogD, chromatographic log <i>D</i>; PFI, property forecast index.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structures, in vitro potency, physicochemical properties, and DMPK profiles of γ-secretase inhibitors <b>27</b> and <b>28</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Structures and in vivo PK profiles of <b>29</b> and <b>30</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structures, in vitro potency, and rat PK profiles of GPR40 agonists <b>31</b> and <b>32</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structures, in vitro potency, and PK profiles of RSV fusion protein inhibitors <b>33</b> and <b>34</b>. PAMPA, parallel artificial membrane permeability assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Structures, in vitro potency, and PK profiles of IKKβ inhibitors <b>35</b> and <b>36</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structures, in vitro potency, and PK profiles of ERK1/2 inhibitors <b>37</b>–<b>39</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Structures, in vitro potency, and PK profiles of Pim kinase inhibitors <b>40</b> and <b>41</b>. KMS-12 pBAD, inhibition of phosphorylation of BAD at Ser112 in KMS-12 BM cells; LLC-PK1, single layer of LLC-PK1 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Structures and in vitro potency of <b>42</b>–<b>44</b> and PK profiles of PARP1 inhibitors <b>43</b> and <b>44</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Structures, in vitro potency, and physicochemical properties of LTC4S inhibitors <b>45</b> and <b>46</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Structures and in vitro potency of <b>47</b> and <b>48</b> and PK profile of NTR1 modulator <b>48</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Structures of neuroactive steroids <b>49</b>–<b>51</b> as NMDA receptor PAMs along with PK properties in SD rats.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Structures and in vitro potency of ERα degraders <b>52</b> and <b>53</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Structures, in vitro potency, and in vitro DMPK properties of ER downregulator antagonists <b>54</b>–<b>57</b>. ER DR, estrogen receptor downregulation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Structures, in vitro potency, in vitro DMPK properties, and stability of ER downregulator antagonists <b>58</b>–<b>60</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Structures and in vitro potency of p97 inhibitors <b>61</b> and <b>62</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Structures and in vitro potency of SMYD2 inhibitors <b>63</b> and <b>64</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0028.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Structures, in vitro potency, and DMPK profiles of NMUR1 agonists <b>65</b> and <b>66</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0029.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Structures, in vitro potency, and physicochemical properties of BACE1 inhibitors <b>67</b>–<b>69</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0030.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Structures of gastric mucosa protecting prostaglandins <b>70</b> and <b>71</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig31" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Figure 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0031.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 31. Structures of HCV NS5B polymerase inhibitor <b>72</b> and the general tetrasubstituted C2′-ribose modification strategy employed in HCV NS5B polymerase inhibitor design.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig32" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Figure 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0032.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 32. Structures and in vitro potency of BET inhibitors <b>73</b> and <b>74</b>. TR-FRET BD1, measurement of binding to BRD4-BD1 domain using time-resolved fluorescence energy transfer TR-FRET binding assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig33" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0033.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 33. Structures and in vitro potency of TLR8 agonists <b>75</b>–<b>77</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig34" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0034.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 34. Structures and in vitro potency of CCK-A agonists <b>78</b>–<b>80</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig35" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0035.jpeg" id="rightTab-gr35" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 35. Structures, in vitro potency, and PK profiles of CyP A inhibitors <b>81</b> and <b>82</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig35"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig36" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Figure 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0036.jpeg" id="rightTab-gr36" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 36. Structures, in vitro potency, and PK profiles of tankyrase inhibitors <b>83</b>–<b>86</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig36"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig37" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Figure 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0037.jpeg" id="rightTab-gr37" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 37. Structures, in vitro potency, and physicochemical properties of BACE1 inhibitors <b>87</b>–<b>91</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig37"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig38" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Figure 38</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0038.jpeg" id="rightTab-gr38" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 38. Structures, in vitro potency, and physicochemical properties of κ-opioid receptor agonists <b>92</b> and <b>93</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig38"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig39" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Figure 39</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0039.jpeg" id="rightTab-gr39" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 39. Structures and in vitro potency of HAT inhibitors <b>94</b>–<b>96</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig39"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig40" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Figure 40</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0040.jpeg" id="rightTab-gr40" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 40. Structures and in vitro potency of HsPDF inhibitors <b>97</b>–<b>99</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig40"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig41" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Figure 41</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0041.jpeg" id="rightTab-gr41" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 41. Structure and binding affinity of CGRP receptor antagonist <b>100</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig41"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig42" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Figure 42</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0042.jpeg" id="rightTab-gr42" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 42. Structures of aldose reductase inhibitors <b>101</b>–<b>103</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig42"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig43" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Figure 43</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0043.jpeg" id="rightTab-gr43" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 43. Structures and in vitro potency of SGLT2 inhibitor <b>105</b> and a virtual screening hit <b>104</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig43"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig44" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Figure 44</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0044.jpeg" id="rightTab-gr44" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 44. Structure and in vitro potency of GHSR agonists <b>106</b>–<b>108</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig44"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig45" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Figure 45</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0045.jpeg" id="rightTab-gr45" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 45. Structure, in vitro potency, and PK profiles of TRPV4 inhibitors <b>109</b>–<b>111</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig45"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig46" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Figure 46</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0046.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0046.jpeg" id="rightTab-gr46" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 46. Structures, in vitro potency, and DMPK profiles of PLK4 inhibitors <b>112</b>–<b>114</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig46"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig47" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Figure 47</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0047.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0047.jpeg" id="rightTab-gr47" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 47. Structures, in vitro potency, and PK profiles of hSPPL2a inhibitors <b>115</b>–<b>117</b>. RGA, receptor gene assay; CD74/p8, inhibition of accumulation of CD74/p8.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0047.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig47"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig48" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Figure 48</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0048.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0048.jpeg" id="rightTab-gr48" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 48. Structures and in vitro potency of selected MDM2 inhibitors <b>118</b>–<b>120</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig48"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig49" data-index="49" class="article__inlineFigure"><h2 class="fig-label">Figure 49</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0049.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0049.jpeg" id="rightTab-gr49" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 49. Structures, in vitro potency, and microsomal clearance of LSD1 inhibitors <b>121</b> and <b>122</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0049.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig49"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig50" data-index="50" class="article__inlineFigure"><h2 class="fig-label">Figure 50</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/medium/jm0c00829_0050.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0050.jpeg" id="rightTab-gr50" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 50. Structures of quaternary or tetrasubstituted carbon-containing compounds that entered clinical development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00829/20201120/images/large/jm0c00829_0050.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00829&amp;id=fig50"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i62">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70003" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70003" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 161 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J.</span></span> <span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1011</span>– <span class="NLM_lpage">1020</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2009.07.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.drudis.2009.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=19729075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1011-1020&author=T.+J.+Ritchieauthor=S.+J.+Macdonald&title=The+impact+of+aromatic+ring+count+on+compound+developability%2D%2Dare+too+many+aromatic+rings+a+liability+in+drug+design%3F&doi=10.1016%2Fj.drudis.2009.07.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: Are too many aromatic rings a liability in drug design?</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">21/22</span>),
    <span class="NLM_cas:pages">1011-1020</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of arom. ring count (the no. of arom. and heteroarom. rings) in mols. has been analyzed against various developability parameters, aq. soly., lipophilicity, serum albumin binding, CyP450 inhibition and hERG inhibition.  On the basis of this anal., it was concluded that the fewer arom. rings contained in an oral drug candidate, the more developable that candidate is probably to be; in addn., more than three arom. rings in a mol. correlates with poorer compd. developability and, thus, an increased risk of attrition in development.  Data are also presented that demonstrate that even within a defined lipophilicity range, increased arom. ring count leads to decreased aq. soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2hOeD6TNGUbVg90H21EOLACvtfcHk0liyZc465CRn8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP&md5=48454c9809e8225b4336ea76aad3f3ba</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability--are%2520too%2520many%2520aromatic%2520rings%2520a%2520liability%2520in%2520drug%2520design%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D1011%26epage%3D1020%26doi%3D10.1016%2Fj.drudis.2009.07.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span> <span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">171</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2010.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.drudis.2010.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=21129497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=164-171&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonaldauthor=R.+J.+Youngauthor=S.+D.+Pickett&title=The+impact+of+aromatic+ring+count+on+compound+developability%3A+further+insights+by+examining+carbo-+and+hetero-aromatic+and+-aliphatic+ring+types&doi=10.1016%2Fj.drudis.2010.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: further insights by examining carbo- and hetero-aromatic and -aliphatic ring types</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.; Young, Robert J.; Pickett, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3/4</span>),
    <span class="NLM_cas:pages">164-171</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of carboarom., heteroarom., carboaliph. and heteroaliph. ring counts and fused arom. ring count on several developability measures (soly., lipophilicity, protein binding, P 450 inhibition and hERG binding) is the topic for this review article.  Recent results indicate that increasing ring counts have detrimental effects on developability in the order carboaroms. » heteroaroms. > carboaliphatics > heteroaliphatics, with heteroaliphatics exerting a beneficial effect in many cases.  Increasing arom. ring count exerts effects on several developability parameters that are lipophilicity- and size-independent, and fused arom. systems have a beneficial effect relative to their nonfused counterparts.  Increasing arom. ring count has a detrimental effect on human bioavailability parameters, and heteroarom. ring count (but not other ring counts) has increased over time in marketed oral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJYPC7hkoyv7Vg90H21EOLACvtfcHk0liyZc465CRn8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVyqsr0%253D&md5=8e2d0e4e499d2f07d66ca2f385defb2d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%253A%2520further%2520insights%2520by%2520examining%2520carbo-%2520and%2520hetero-aromatic%2520and%2520-aliphatic%2520ring%2520types%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D164%26epage%3D171%26doi%3D10.1016%2Fj.drudis.2010.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span> <span> </span><span class="NLM_article-title">Molecular obesity, potency and other addictions in drug discovery</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">355</span>, <span class="refDoi"> DOI: 10.1039/C1MD00017A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1039%2FC1MD00017A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Kht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=349-355&author=M.+M.+Hann&title=Molecular+obesity%2C+potency+and+other+addictions+in+drug+discovery&doi=10.1039%2FC1MD00017A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular obesity, potency and other addictions in drug discovery</span></div><div class="casAuthors">Hann, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">349-355</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Despite the increase in global biol. and chem. knowledge the discovery of effective and safe new drugs seems to become harder rather than easier.  Some of this challenge is due to increasing demands for safety and novelty, but some of the risk involved in this should be controllable if we had more effectively learned from our failures.  This perspective reflects on some of the learnings of recent years in relation to the causes of attrition.  The term Mol. Obesity is introduced to describe our tendency to build potency into mols. by the inappropriate use of lipophilicity which leads to the premature demise of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSlF7TPy6fHLVg90H21EOLACvtfcHk0liyZc465CRn8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Kht7g%253D&md5=954870db4b1d9e846612c3bb256582f7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1039%2FC1MD00017A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC1MD00017A%26sid%3Dliteratum%253Aachs%26aulast%3DHann%26aufirst%3DM.%2BM.%26atitle%3DMolecular%2520obesity%252C%2520potency%2520and%2520other%2520addictions%2520in%2520drug%2520discovery%26jtitle%3DMedChemComm%26date%3D2011%26volume%3D2%26spage%3D349%26epage%3D355%26doi%3D10.1039%2FC1MD00017A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dancik, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrinski, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">Quantifying structure and performance diversity for sets of small molecules comprising small-molecule screening collections</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">6817</span>– <span class="NLM_lpage">6822</span>, <span class="refDoi"> DOI: 10.1073/pnas.1015024108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1073%2Fpnas.1015024108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=21482810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlslyru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=6817-6822&author=P.+A.+Clemonsauthor=J.+A.+Wilsonauthor=V.+Dancikauthor=S.+Mullerauthor=H.+A.+Carrinskiauthor=B.+K.+Wagnerauthor=A.+N.+Koehlerauthor=S.+L.+Schreiber&title=Quantifying+structure+and+performance+diversity+for+sets+of+small+molecules+comprising+small-molecule+screening+collections&doi=10.1073%2Fpnas.1015024108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Quantifying structure and performance diversity for sets of small molecules comprising small-molecule screening collections</span></div><div class="casAuthors">Clemons, Paul A.; Wilson, J. Anthony; Dancik, Vlado; Muller, Sandrine; Carrinski, Hyman A.; Wagner, Bridget K.; Koehler, Angela N.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6817-6822, S6817/1-S6817/8</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Using a diverse collection of small mols. we recently found that compd. sets from different sources (com.; academic; natural) have different protein-binding behaviors, and these behaviors correlate with trends in stereochem. complexity for these compd. sets.  These results lend insight into structural features that synthetic chemists might target when synthesizing screening collections for biol. discovery.  We report extensive characterization of structural properties and diversity of biol. performance for these compds. and expand comparative analyses to include physicochem. properties and three-dimensional shapes of predicted conformers.  The results highlight addnl. similarities and differences between the sets, but also the dependence of such comparisons on the choice of mol. descriptors.  Using a protein-binding dataset, we introduce an information-theoretic measure to assess diversity of performance with a constraint on specificity.  Rather than relying on finding individual active compds., this measure allows rational judgment of compd. subsets as groups.  We also apply this measure to publicly available data from ChemBank for the same compd. sets across a diverse group of functional assays.  We find that performance diversity of compd. sets is relatively stable across a range of property values as judged by this measure, both in protein-binding studies and functional assays.  Because building screening collections with improved performance depends on efficient use of synthetic org. chem. resources, these studies illustrate an important quant. framework to help prioritize choices made in building such collections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTV-EsmSsjP7Vg90H21EOLACvtfcHk0lgOEJgH4F66sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlslyru7c%253D&md5=d83343549289415060ea55d45118d31f</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1015024108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1015024108%26sid%3Dliteratum%253Aachs%26aulast%3DClemons%26aufirst%3DP.%2BA.%26aulast%3DWilson%26aufirst%3DJ.%2BA.%26aulast%3DDancik%26aufirst%3DV.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DCarrinski%26aufirst%3DH.%2BA.%26aulast%3DWagner%26aufirst%3DB.%2BK.%26aulast%3DKoehler%26aufirst%3DA.%2BN.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DQuantifying%2520structure%2520and%2520performance%2520diversity%2520for%2520sets%2520of%2520small%2520molecules%2520comprising%2520small-molecule%2520screening%2520collections%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D6817%26epage%3D6822%26doi%3D10.1073%2Fpnas.1015024108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boström, J.</span></span> <span> </span><span class="NLM_article-title">Analysis of past and present synthetic methodologies on medicinal chemistry: Where have all the new reactions gone?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4443</span>– <span class="NLM_lpage">4458</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01409</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01409" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4443-4458&author=D.+G.+Brownauthor=J.+Bostr%C3%B6m&title=Analysis+of+past+and+present+synthetic+methodologies+on+medicinal+chemistry%3A+Where+have+all+the+new+reactions+gone%3F&doi=10.1021%2Facs.jmedchem.5b01409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone?</span></div><div class="casAuthors">Brown, Dean G.; Bostrom, Jonas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4443-4458</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  An anal. of chem. reactions used in current medicinal chem. (2014), three decades ago (1984), and in natural product total synthesis has been conducted.  The anal. revealed that of the current most frequently used synthetic reactions, none were discovered within the past 20 years and only two in the 1980s and 1990s (Suzuki-Miyaura and Buchwald-Hartwig).  This suggests an inherent high bar of impact for new synthetic reactions in drug discovery.  The most frequently used reactions were amide bond formation, Suzuki-Miyaura coupling, and SNAr reactions, most likely due to com. availability of reagents, high chemoselectivity, and a pressure on delivery.  The authors show that these practices result in overpopulation of certain types of mol. shapes to the exclusion of others using simple PMI plots.  The authors hope that these results will help catalyze improvements in integration of new synthetic methodologies as well as new library design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLWvt5DxktAbVg90H21EOLACvtfcHk0lgOEJgH4F66sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVeqsrzM&md5=fd56ba8418f6d4e8c271f4e977ee2a93</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01409%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DBostr%25C3%25B6m%26aufirst%3DJ.%26atitle%3DAnalysis%2520of%2520past%2520and%2520present%2520synthetic%2520methodologies%2520on%2520medicinal%2520chemistry%253A%2520Where%2520have%2520all%2520the%2520new%2520reactions%2520gone%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4443%26epage%3D4458%26doi%3D10.1021%2Facs.jmedchem.5b01409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">Molecular diversity by design</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>457</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1038/457153a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2F457153a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=19129834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitlSgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=457&publication_year=2009&pages=153-154&author=S.+L.+Schreiber&title=Molecular+diversity+by+design&doi=10.1038%2F457153a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular diversity by design</span></div><div class="casAuthors">Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">457</span>
        (<span class="NLM_cas:issue">7226</span>),
    <span class="NLM_cas:pages">153-154</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Many org. syntheses are target-oriented - each multi-step route is designed to make just one compd.  But now a diversity-oriented synthesis can make 80 different mol. skeletons in just a few steps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNnW8LJ03ahbVg90H21EOLACvtfcHk0lgOEJgH4F66sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitlSgug%253D%253D&md5=2ddc5e57f47d2e83598e644fb0259245</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2F457153a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F457153a%26sid%3Dliteratum%253Aachs%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DMolecular%2520diversity%2520by%2520design%26jtitle%3DNature%26date%3D2009%26volume%3D457%26spage%3D153%26epage%3D154%26doi%3D10.1038%2F457153a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burke, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">A planning strategy for diversity-oriented synthesis</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1002/anie.200300626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fanie.200300626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=14694470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsVeksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2004&pages=46-58&author=M.+D.+Burkeauthor=S.+L.+Schreiber&title=A+planning+strategy+for+diversity-oriented+synthesis&doi=10.1002%2Fanie.200300626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">A planning strategy for diversity-oriented synthesis</span></div><div class="casAuthors">Burke, Martin D.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-58</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  In contrast to target-oriented synthesis (TOS) and medicinal or combinatorial chem., which aim to access precise or dense regions of chem. space, diversity-oriented synthesis (DOS) populates chem. space broadly with small-mols., having diverse structures.  The goals of DOS include the development of pathways leading to the efficient (three- to five-step) synthesis of collections of small mols. having skeletal and stereochem. diversity with defined coordinates in chem. space.  Ideally, these pathways also yield compds. having the potential to attach appendages site- and stereoselectively to a variety of attachment sites during a post-screening, maturation stage.  The diverse skeletons and stereochemistries ensure that the appendages can be positioned in multiple orientations about the surface of the mols.  TOS as well as medicinal and combinatorial chemistries have been advanced by the development of retrosynthetic anal.  Although the distinct goals of DOS do not permit the application of retrosynthetic concepts and thinking, these foundations are being built on, by using parallel logic, to develop a complementary procedure known as forward-synthetic anal.  This anal. facilitates synthetic planning, communication, and teaching in this evolving discipline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8zavQvQH3GLVg90H21EOLACvtfcHk0lgvALREakdEUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsVeksQ%253D%253D&md5=e556604e2e248ff7a86121d8c2383182</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fanie.200300626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200300626%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DM.%2BD.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DA%2520planning%2520strategy%2520for%2520diversity-oriented%2520synthesis%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2004%26volume%3D43%26spage%3D46%26epage%3D58%26doi%3D10.1002%2Fanie.200300626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wassvik, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmén, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Draheim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergström, C. A. S.</span></span> <span> </span><span class="NLM_article-title">Molecular characteristics for solid-state limited solubility</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">3035</span>– <span class="NLM_lpage">3039</span>, <span class="refDoi"> DOI: 10.1021/jm701587d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701587d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksVSgt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=3035-3039&author=C.+M.+Wassvikauthor=A.+G.+Holm%C3%A9nauthor=R.+Draheimauthor=P.+Arturssonauthor=C.+A.+S.+Bergstr%C3%B6m&title=Molecular+characteristics+for+solid-state+limited+solubility&doi=10.1021%2Fjm701587d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Characteristics for Solid-State Limited Solubility</span></div><div class="casAuthors">Wassvik, Carola M.; Holmen, Anders G.; Draheim, Rieke; Artursson, Per; Bergstroem, Christel A. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3035-3039</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Soly. and solid-state characteristics were detd. and multivariate data anal. was used to deduce structural features important for solid-state limited soly. of marketed drugs.  Mols. with extended ring structures and large conjugated systems were less sol., indicating that structural features related to rigidity and aromaticity result in soly. restricted by stable crystal structures.  These descriptors successfully predicted the applied test set and can be useful for avoiding synthesis of compds. behaving like "brick dust".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4YD2_Ul4qabVg90H21EOLACvtfcHk0lgvALREakdEUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksVSgt7o%253D&md5=f27982a173dfbc1491b6ce1749f486a8</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fjm701587d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701587d%26sid%3Dliteratum%253Aachs%26aulast%3DWassvik%26aufirst%3DC.%2BM.%26aulast%3DHolm%25C3%25A9n%26aufirst%3DA.%2BG.%26aulast%3DDraheim%26aufirst%3DR.%26aulast%3DArtursson%26aufirst%3DP.%26aulast%3DBergstr%25C3%25B6m%26aufirst%3DC.%2BA.%2BS.%26atitle%3DMolecular%2520characteristics%2520for%2520solid-state%2520limited%2520solubility%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D3035%26epage%3D3039%26doi%3D10.1021%2Fjm701587d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamanna, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westerberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maccari, L.</span></span> <span> </span><span class="NLM_article-title">Straightforward Recursive Partitioning Model for Discarding Insoluble Compounds in the Drug Discovery Process</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">2891</span>– <span class="NLM_lpage">2897</span>, <span class="refDoi"> DOI: 10.1021/jm701407x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701407x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvVChu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=2891-2897&author=C.+Lamannaauthor=M.+Belliniauthor=A.+Padovaauthor=G.+Westerbergauthor=L.+Maccari&title=Straightforward+Recursive+Partitioning+Model+for+Discarding+Insoluble+Compounds+in+the+Drug+Discovery+Process&doi=10.1021%2Fjm701407x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Straightforward Recursive Partitioning Model for Discarding Insoluble Compounds in the Drug Discovery Process</span></div><div class="casAuthors">Lamanna, Claudia; Bellini, Marta; Padova, Alessandro; Westerberg, Goran; Maccari, Laura</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2891-2897</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Poor aq. soly. is one of the major issues in drug discovery and development, impacting neg. on all aspects of the research and development process.  The pharmaceutical industry has realized that soly. issues need to be resolved at the discovery stage.  We here present an innovative way to address this problem via a model designed to address the simple question, "Is the compd. likely to be sufficiently sol. to provide interpretable data in biol. screening assays" A recursive partitioning (RP) method was applied to a set of 3563 mols., with in house detd. aq. soly. values.  Five models were generated on the basis of a small no. of descriptors affording intuitive information regarding structural features influencing soly.  The final model was based on only two descriptors: the mol. wt. (MW) and the arom. proportion (AP).  This model provided satisfactory values of accuracy (81%) and precision (75%) for a test set of 1200 compds., suggesting that the model may add value in compd. selection and library design during early drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPk-CmrXXXLrVg90H21EOLACvtfcHk0lgvALREakdEUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvVChu70%253D&md5=aa20e98714f60f9820fe3e26d871de10</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm701407x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701407x%26sid%3Dliteratum%253Aachs%26aulast%3DLamanna%26aufirst%3DC.%26aulast%3DBellini%26aufirst%3DM.%26aulast%3DPadova%26aufirst%3DA.%26aulast%3DWesterberg%26aufirst%3DG.%26aulast%3DMaccari%26aufirst%3DL.%26atitle%3DStraightforward%2520Recursive%2520Partitioning%2520Model%2520for%2520Discarding%2520Insoluble%2520Compounds%2520in%2520the%2520Drug%2520Discovery%2520Process%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D2891%26epage%3D2897%26doi%3D10.1021%2Fjm701407x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span> <span> </span><span class="NLM_article-title">Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">648</span>– <span class="NLM_lpage">655</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2010.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.drudis.2010.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=20570751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVeksb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=648-655&author=A.+P.+Hillauthor=R.+J.+Young&title=Getting+physical+in+drug+discovery%3A+a+contemporary+perspective+on+solubility+and+hydrophobicity&doi=10.1016%2Fj.drudis.2010.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Getting physical in drug discovery: a contemporary perspective on solubility and hydrophobicity</span></div><div class="casAuthors">Hill, Alan P.; Young, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">15/16</span>),
    <span class="NLM_cas:pages">648-655</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Suboptimal phys. properties have been identified as a particular shortcoming of compds. in contemporary drug discovery, contributing to high attrition levels.  An anal. of the relationship between hydrophobicity (calcd. and measured) and ∼100 k measured kinetic soly. values has been undertaken.  In line with the General Soly. Equation, ests. of hydrophobicity, particularly ACD c log D pH7.4, give a useful indication of the likely soly. classification of particular mols.  Taking ACD c log D pH7.4 values together with the no. of arom. rings in a given mol. provides enhanced prediction.  The Soly. Forecast Index' (SFI = c log D pH7.4 + #Ar) is proposed as a simple, yet effective, guide to predicting soly.  Moreover, anal. of measured distribution/partition coeff. values highlighted statistically significant shortcomings in the applicability of octanol/water as a model system for hydrophobicity detn. with poorly sol. compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdtQyfNjbFUrVg90H21EOLACvtfcHk0lgvALREakdEUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVeksb3P&md5=7b201081c5586a6ea4b7af00d507d462</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DA.%2BP.%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26atitle%3DGetting%2520physical%2520in%2520drug%2520discovery%253A%2520a%2520contemporary%2520perspective%2520on%2520solubility%2520and%2520hydrophobicity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2010%26volume%3D15%26spage%3D648%26epage%3D655%26doi%3D10.1016%2Fj.drudis.2010.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(96)00423-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings&doi=10.1016%2FS0169-409X%2896%2900423-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0limvhS2f2_PXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26spage%3D3%26epage%3D25%26doi%3D10.1016%2FS0169-409X%2896%2900423-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohacek, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMartin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, W. C.</span></span> <span> </span><span class="NLM_article-title">The art and practice of structure-based drug design: a molecular modeling perspective</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1098-1128(199601)16:1<3::AID-MED1>3.0.CO;2-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2F%28SICI%291098-1128%28199601%2916%3A1%3C3%3A%3AAID-MED1%3E3.0.CO%3B2-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=8788213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaK28XhtFyls78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1996&pages=3-50&author=R.+S.+Bohacekauthor=C.+McMartinauthor=W.+C.+Guida&title=The+art+and+practice+of+structure-based+drug+design%3A+a+molecular+modeling+perspective&doi=10.1002%2F%28SICI%291098-1128%28199601%2916%3A1%3C3%3A%3AAID-MED1%3E3.0.CO%3B2-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The art and practice of structure-based drug design: a molecular modeling perspective</span></div><div class="casAuthors">Bohacek, Regine S.; McMartin, Colin; Guida, Wayne C.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-50</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">Wiley</span>)
        </div><div class="casAbstract">A review with 120 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmfrWdtPosdrVg90H21EOLACvtfcHk0limvhS2f2_PXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhtFyls78%253D&md5=edfa592791c111479117feed600dead6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291098-1128%28199601%2916%3A1%3C3%3A%3AAID-MED1%3E3.0.CO%3B2-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291098-1128%2528199601%252916%253A1%253C3%253A%253AAID-MED1%253E3.0.CO%253B2-6%26sid%3Dliteratum%253Aachs%26aulast%3DBohacek%26aufirst%3DR.%2BS.%26aulast%3DMcMartin%26aufirst%3DC.%26aulast%3DGuida%26aufirst%3DW.%2BC.%26atitle%3DThe%2520art%2520and%2520practice%2520of%2520structure-based%2520drug%2520design%253A%2520a%2520molecular%2520modeling%2520perspective%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D1996%26volume%3D16%26spage%3D3%26epage%3D50%26doi%3D10.1002%2F%28SICI%291098-1128%28199601%2916%3A1%3C3%3A%3AAID-MED1%3E3.0.CO%3B2-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoltz, B. M.</span></span> <span> </span><span class="NLM_article-title">Catalytic enantioselective construction of quaternary stereocenters: assembly of key building blocks for the synthesis of biologically active molecules</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">740</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1021/ar5004658</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar5004658" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtlChtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2015&pages=740-751&author=Y.+Liuauthor=S.+J.+Hanauthor=W.+B.+Liuauthor=B.+M.+Stoltz&title=Catalytic+enantioselective+construction+of+quaternary+stereocenters%3A+assembly+of+key+building+blocks+for+the+synthesis+of+biologically+active+molecules&doi=10.1021%2Far5004658"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic Enantioselective Construction of Quaternary Stereocenters: Assembly of Key Building Blocks for the Synthesis of Biologically Active Molecules</span></div><div class="casAuthors">Liu, Yiyang; Han, Seo-Jung; Liu, Wen-Bo; Stoltz, Brian M.</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">740-751</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ever-present demand for drugs with better efficacy and fewer side effects continually motivates scientists to explore the vast chem. space.  Traditionally, medicinal chemists have focused much attention on achiral or so-called "flat" mols.  More recently, attention has shifted towards mols. with stereogenic centers since their three-dimensional structures represent a much larger fraction of the chem. space and have a no. of superior properties compared with flat arom. compds.  Quaternary stereocenters, in particular, add greatly to the three-dimensionality and novelty of the mol.  Nevertheless, synthetic challenges in building quaternary stereocenters have largely prevented their implementation in drug discovery.  The lack of effective and broadly general methods for enantioselective formation of quaternary stereocenters in simple mol. scaffolds has prompted the authors to investigate new chem. and develop innovative tools and solns.  In this account, the authors describe three approaches to constructing quaternary stereocenters: nucleophilic substitution of 3-halooxindoles, conjugate addn. of boronic acids to cyclic enones, and allylic alkylation of enolates.  In the first approach, malonic ester nucleophiles attack electrophilic 3-halooxindoles, mediated by a copper(II)-bisoxazoline catalyst.  A variety of oxindoles contg. a benzylic quaternary stereocenter can be accessed through this method.  However, it is only applicable to the specialized 3,3-disubstituted oxindole system.  To access benzylic quaternary stereocenters in a more general context, the authors turned their attention to the enantioselective conjugate addn. of carbon nucleophiles to α,β-unsatd. carbonyl acceptors.  The authors discovered that in the presence of catalytic palladium-pyridinooxazoline complex, arylboronic acids add smoothly to β-substituted cyclic enones to furnish ketones with a β-benzylic quaternary stereocenter in high yields and enantioselectivities.  The reaction is compatible with a wide range of arylboronic acids, β-substituents, and ring sizes.  Aside from benzylic quaternary stereocenters, a more challenging motif is a quaternary stereocenter not adjacent to an arom. group.  Such centers represent more general structures in chem. space but are more difficult to form by asym. catalysis.  To address this greater challenge, and motivated by the greater reward, the authors entered the field of palladium-catalyzed asym. allylic alkylation of prochiral enolate nucleophiles about a decade ago.  On the basis of Tsuji's work, which solved the issue of positional selectivity for unsym. ketones, the authors discovered that the phosphinooxazoline ligand effectively rendered this reaction enantioselective.  Extensive investigations since then have revealed that the reaction exhibits broad scope and accepts a range of substrate classes, each with its unique advantage in synthetic applications.  A diverse array of carbonyl compds. bearing α-quaternary stereocenters are obtained in excellent yields and enantioselectivities, and more possibilities have yet to be explored.  As an alternative to palladium catalysis, the authors also studied iridium-catalyzed asym. allylic alkylations that generate vicinal quaternary and tertiary stereocenters in a single transformation.  Overall, these methods provide access to small mol. building blocks with a single quaternary stereocenter, can be applied to various mol. scaffolds, and tolerate a wide range of functional groups.  The authors envision that the chem. reported in this account will be increasingly useful in drug discovery and design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreBoLUz4vn8bVg90H21EOLACvtfcHk0limvhS2f2_PXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtlChtrw%253D&md5=9a6705502b6db17067d3f3b011e5803b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Far5004658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far5004658%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DS.%2BJ.%26aulast%3DLiu%26aufirst%3DW.%2BB.%26aulast%3DStoltz%26aufirst%3DB.%2BM.%26atitle%3DCatalytic%2520enantioselective%2520construction%2520of%2520quaternary%2520stereocenters%253A%2520assembly%2520of%2520key%2520building%2520blocks%2520for%2520the%2520synthesis%2520of%2520biologically%2520active%2520molecules%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2015%26volume%3D48%26spage%3D740%26epage%3D751%26doi%3D10.1021%2Far5004658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcaraz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chohan, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butlin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elebring, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guile, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St-Gallay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swahn, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swallow, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenlock, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span> <span> </span><span class="NLM_article-title">Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5673</span>– <span class="NLM_lpage">5679</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.07.074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.bmcl.2011.07.074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=21852131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFKju77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=5673-5679&author=T.+Lukerauthor=L.+Alcarazauthor=K.+K.+Chohanauthor=N.+Blombergauthor=D.+S.+Brownauthor=R.+J.+Butlinauthor=T.+Elebringauthor=A.+M.+Griffinauthor=S.+Guileauthor=S.+St-Gallayauthor=B.+M.+Swahnauthor=S.+Swallowauthor=M.+J.+Waringauthor=M.+C.+Wenlockauthor=P.+D.+Leeson&title=Strategies+to+improve+in+vivo+toxicology+outcomes+for+basic+candidate+drug+molecules&doi=10.1016%2Fj.bmcl.2011.07.074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules</span></div><div class="casAuthors">Luker, Tim; Alcaraz, Lilian; Chohan, Kamaldeep K.; Blomberg, Niklas; Brown, Dearg S.; Butlin, Roger J.; Elebring, Thomas; Griffin, Andrew M.; Guile, Simon; St-Gallay, Stephen; Swahn, Britt-Marie; Swallow, Steve; Waring, Michael J.; Wenlock, Mark C.; Leeson, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5673-5679</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A valid PLS-DA model to predict attrition in pre-clin. toxicol. for basic oral candidate drugs was built.  A combination of arom./aliph. balance, flatness, charge distribution and size descriptors helped predict the successful progression of compds. through a wide range of toxicity testing.  Eighty percent of an independent test set of marketed post-2000 basic drugs could be successfully classified using the model, indicating useful forward predictivity.  The themes within this work provide addnl. guidance for medicinal design chemists and complement other literature property guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_8ruOOUvvQ7Vg90H21EOLACvtfcHk0ljRvP0Q37Z2cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFKju77E&md5=7fa177a686eaa7a9868798028bce3043</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.07.074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.07.074%26sid%3Dliteratum%253Aachs%26aulast%3DLuker%26aufirst%3DT.%26aulast%3DAlcaraz%26aufirst%3DL.%26aulast%3DChohan%26aufirst%3DK.%2BK.%26aulast%3DBlomberg%26aufirst%3DN.%26aulast%3DBrown%26aufirst%3DD.%2BS.%26aulast%3DButlin%26aufirst%3DR.%2BJ.%26aulast%3DElebring%26aufirst%3DT.%26aulast%3DGriffin%26aufirst%3DA.%2BM.%26aulast%3DGuile%26aufirst%3DS.%26aulast%3DSt-Gallay%26aufirst%3DS.%26aulast%3DSwahn%26aufirst%3DB.%2BM.%26aulast%3DSwallow%26aufirst%3DS.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWenlock%26aufirst%3DM.%2BC.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26atitle%3DStrategies%2520to%2520improve%2520in%2520vivo%2520toxicology%2520outcomes%2520for%2520basic%2520candidate%2520drug%2520molecules%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D5673%26epage%3D5679%26doi%3D10.1016%2Fj.bmcl.2011.07.074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland 2: complexity and promiscuity</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">519</span>, <span class="refDoi"> DOI: 10.1039/c2md20347b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1039%2Fc2md20347b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=515-519&author=F.+Lovering&title=Escape+from+flatland+2%3A+complexity+and+promiscuity&doi=10.1039%2Fc2md20347b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland 2: complexity and promiscuity</span></div><div class="casAuthors">Lovering, Frank</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">515-519</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Toxicity plays a major role in attrition in the clinic and promiscuity has been linked to toxicity.  A no. of mol. descriptors have been identified that contribute to promiscuity including ionization and logP.  In this study we report on the relationship between complexity, as measured by two descriptors [fraction sp3 (Fsp3) where Fsp3 = (no. of sp3 hybridized carbons/total carbon count) and chiral carbon count], and promiscuity as well as Cyp450 inhibition.  We find that increasing complexity reduces promiscuity and Cyp450 inhibition.  As an understanding of key property descriptors has helped the pharmaceutical industry to address some of the deficiencies of compds. as pertains to bioavailability, awareness of the descriptors that impact promiscuity should allow us to better address toxicity in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJfDH0430P-bVg90H21EOLACvtfcHk0ljRvP0Q37Z2cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFShtL0%253D&md5=c03d3b99da22a684cbbbb00fb1633342</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1039%2Fc2md20347b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20347b%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26atitle%3DEscape%2520from%2520flatland%25202%253A%2520complexity%2520and%2520promiscuity%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26spage%3D515%26epage%3D519%26doi%3D10.1039%2Fc2md20347b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1021/jm901241e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+increasing+saturation+as+an+approach+to+improving+clinical+success&doi=10.1021%2Fjm901241e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0ljRvP0Q37Z2cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756%26doi%3D10.1021%2Fjm901241e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span> <span> </span><span class="NLM_article-title">Physicochemical Descriptors of Aromatic Character and Their Use in Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7206</span>– <span class="NLM_lpage">7215</span>, <span class="refDoi"> DOI: 10.1021/jm500515d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500515d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1Wmsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7206-7215&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonald&title=Physicochemical+Descriptors+of+Aromatic+Character+and+Their+Use+in+Drug+Discovery&doi=10.1021%2Fjm500515d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical Descriptors of Aromatic Character and Their Use in Drug Discovery</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7206-7215</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Published physicochem. descriptors of mols. that convey aromaticity-related character are reviewed in the context of drug design and discovery.  Studies that have employed arom. descriptors are discussed, and several descriptors are compared and contrasted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogc1vxNtUQl7Vg90H21EOLACvtfcHk0lj8on8PX6KP4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1Wmsbw%253D&md5=7aca9f7309bb5dd806aeb4c2b4ff8eab</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm500515d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500515d%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DPhysicochemical%2520Descriptors%2520of%2520Aromatic%2520Character%2520and%2520Their%2520Use%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7206%26epage%3D7215%26doi%3D10.1021%2Fjm500515d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span> <span> </span><span class="NLM_article-title">Molecular complexity and fragment-based drug discovery: ten years on</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2011.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.cbpa.2011.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=21665521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFCltrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=489-496&author=A.+R.+Leachauthor=M.+M.+Hann&title=Molecular+complexity+and+fragment-based+drug+discovery%3A+ten+years+on&doi=10.1016%2Fj.cbpa.2011.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular complexity and fragment-based drug discovery: ten years on</span></div><div class="casAuthors">Leach, Andrew R.; Hann, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">489-496</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We review the concept of mol. complexity in the context of the very simple model of mol. interactions that we introduced over 10 years ago.  A summary is presented of efforts to validate this simple model using screening data.  The relationship between the complexity model and the problem of sampling chem. space is discussed, together with the relevance of these theor. concepts to fragment-based drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNcMgTT6eLC7Vg90H21EOLACvtfcHk0lj8on8PX6KP4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFCltrg%253D&md5=19c2d65de80a8bab1059468828da6ce2</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2011.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2011.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DHann%26aufirst%3DM.%2BM.%26atitle%3DMolecular%2520complexity%2520and%2520fragment-based%2520drug%2520discovery%253A%2520ten%2520years%2520on%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D15%26spage%3D489%26epage%3D496%26doi%3D10.1016%2Fj.cbpa.2011.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Measom, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Down, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manas, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somers, D. O.</span></span> <span> </span><span class="NLM_article-title">Investigation of a bicyclo[1.1.1]pentane as a phenyl replacement within an LpPLA2 inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00281</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00281" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVCqtbjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=43-48&author=N.+D.+Measomauthor=K.+D.+Downauthor=D.+J.+Hirstauthor=C.+Jamiesonauthor=E.+S.+Manasauthor=V.+K.+Patelauthor=D.+O.+Somers&title=Investigation+of+a+bicyclo%5B1.1.1%5Dpentane+as+a+phenyl+replacement+within+an+LpPLA2+inhibitor&doi=10.1021%2Facsmedchemlett.6b00281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of a Bicyclo[1.1.1]pentane as a Phenyl Replacement within an LpPLA2 Inhibitor</span></div><div class="casAuthors">Measom, Nicholas D.; Down, Kenneth D.; Hirst, David J.; Jamieson, Craig; Manas, Eric S.; Patel, Vipulkumar K.; Somers, Don O.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-48</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors describe the incorporation of a bicyclo[1.1.1]pentane moiety within two known LpPLA2 inhibitors to act as bioisosteric Ph replacements.  An efficient synthesis to the target compds. was enabled with a dichlorocarbene insertion into a bicyclo[1.1.0]butane system being the key transformation.  Potency, physicochem., and x-ray crystallog. data were obtained to compare the known inhibitors to their bioisosteric counterparts, which showed the isostere was well tolerated and pos. impacted on the physicochem. profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouQjyZ5QbhWbVg90H21EOLACvtfcHk0lj8on8PX6KP4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVCqtbjK&md5=5d8edc57e03090b6680bd819fc5ed67a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00281%26sid%3Dliteratum%253Aachs%26aulast%3DMeasom%26aufirst%3DN.%2BD.%26aulast%3DDown%26aufirst%3DK.%2BD.%26aulast%3DHirst%26aufirst%3DD.%2BJ.%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DManas%26aufirst%3DE.%2BS.%26aulast%3DPatel%26aufirst%3DV.%2BK.%26aulast%3DSomers%26aufirst%3DD.%2BO.%26atitle%3DInvestigation%2520of%2520a%2520bicyclo%255B1.1.1%255Dpentane%2520as%2520a%2520phenyl%2520replacement%2520within%2520an%2520LpPLA2%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D43%26epage%3D48%26doi%3D10.1021%2Facsmedchemlett.6b00281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stockdale, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C. M.</span></span> <span> </span><span class="NLM_article-title">Pharmaceuticals that contain polycyclic hydrocarbon scaffolds</span>. <i>Chem. Soc. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">7737</span>– <span class="NLM_lpage">7763</span>, <span class="refDoi"> DOI: 10.1039/C4CS00477A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1039%2FC4CS00477A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=26171466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFKitr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2015&pages=7737-7763&author=T.+P.+Stockdaleauthor=C.+M.+Williams&title=Pharmaceuticals+that+contain+polycyclic+hydrocarbon+scaffolds&doi=10.1039%2FC4CS00477A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmaceuticals that contain polycyclic hydrocarbon scaffolds</span></div><div class="casAuthors">Stockdale, Tegan P.; Williams, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Society Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7737-7763</span>CODEN:
                <span class="NLM_cas:coden">CSRVBR</span>;
        ISSN:<span class="NLM_cas:issn">0306-0012</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Numerous variations on structural motifs exist within pharmaceutical compds. that have entered the clinic.  These variations have amounted over many decades based on years of drug development assocd. with screening natural products and de novo synthetic systems.  Caged (or bridged) bicyclic structural elements offer a variety of diverse features, encompassing three-dimensional shape, and assorted pharmacokinetic properties.  This review highlights approx. 20 all carbon cage contg. pharmaceuticals, ranging in structure from bicyclo[2.2.1] through to adamantane, including some in the top-selling pharmaceutical bracket.  Although, a wide variety of human diseases, illnesses and conditions are treated with drugs contg. the bicyclic motif, a common feature is that many of these lipophilic systems display CNS and/or neurol. activity.  In addn., to an extensive overview of the history and biol. assocd. with each drug, a survey of synthetic methods used to construct these entities is presented.  An anal. section compares natural products to synthetics in drug discovery, and entertains the classical caged hydrocarbon systems potentially missing from the clinic.  Lastly, this unprecedented review is highly pertinent at a time when big pharma is desperately trying to escape flatland drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopp0z3Mk5xj7Vg90H21EOLACvtfcHk0liF3d_sk0t9Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFKitr7O&md5=b9b825abdcc6b98c8d409014983370ae</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2FC4CS00477A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CS00477A%26sid%3Dliteratum%253Aachs%26aulast%3DStockdale%26aufirst%3DT.%2BP.%26aulast%3DWilliams%26aufirst%3DC.%2BM.%26atitle%3DPharmaceuticals%2520that%2520contain%2520polycyclic%2520hydrocarbon%2520scaffolds%26jtitle%3DChem.%2520Soc.%2520Rev.%26date%3D2015%26volume%3D44%26spage%3D7737%26epage%3D7763%26doi%3D10.1039%2FC4CS00477A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tajabadi, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campitelli, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, R. J.</span></span> <span> </span><span class="NLM_article-title">Scaffold Flatness: Reversing the Trend</span>. <i>Springer Science Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1007/s40362-013-0014-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1007%2Fs40362-013-0014-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=141-151&author=F.+M.+Tajabadiauthor=M.+R.+Campitelliauthor=R.+J.+Quinn&title=Scaffold+Flatness%3A+Reversing+the+Trend&doi=10.1007%2Fs40362-013-0014-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs40362-013-0014-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40362-013-0014-7%26sid%3Dliteratum%253Aachs%26aulast%3DTajabadi%26aufirst%3DF.%2BM.%26aulast%3DCampitelli%26aufirst%3DM.%2BR.%26aulast%3DQuinn%26aufirst%3DR.%2BJ.%26atitle%3DScaffold%2520Flatness%253A%2520Reversing%2520the%2520Trend%26jtitle%3DSpringer%2520Science%2520Rev.%26date%3D2013%26volume%3D1%26spage%3D141%26epage%3D151%26doi%3D10.1007%2Fs40362-013-0014-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasteiger, J.</span></span> <span> </span><span class="NLM_article-title">Prediction of aqueous solubility of organic compounds based on a 3D structure representation</span>. <i>J. Chem. Inf. Comput. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">434</span>, <span class="refDoi"> DOI: 10.1021/ci025590u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci025590u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD38Xps1GgsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2003&pages=429-434&author=A.+Yanauthor=J.+Gasteiger&title=Prediction+of+aqueous+solubility+of+organic+compounds+based+on+a+3D+structure+representation&doi=10.1021%2Fci025590u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of Aqueous Solubility of Organic Compounds Based on a 3D Structure Representation</span></div><div class="casAuthors">Yan, Aixia; Gasteiger, Johann</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">429-434</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two quant. models for the prediction of aq. soly. of 1293 org. compds. were developed by a Multilinear Regression (MLR) anal. and a Back-Propagation (BPG) neural network.  The mols. were described by a set of 32 values of a Radial Distribution Function (RDF) code representing the 3D structure and eight addnl. descriptors.  The 1293 compds. were divided into a training set of 797 compds. and a test set of 496 compds. based on a Kohonen self-organizing neural network map.  The obtained models show a good predictive power: for the test set, a correlation coeff. of 0.96 and a std. deviation of 0.59 were achieved by the back-propagation neural network approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXUOcOYAjstrVg90H21EOLACvtfcHk0liF3d_sk0t9Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xps1GgsLc%253D&md5=17a31099dbdf8759952227315af1a633</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fci025590u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci025590u%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DA.%26aulast%3DGasteiger%26aufirst%3DJ.%26atitle%3DPrediction%2520of%2520aqueous%2520solubility%2520of%2520organic%2520compounds%2520based%2520on%2520a%25203D%2520structure%2520representation%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comput.%2520Sci.%26date%3D2003%26volume%3D43%26spage%3D429%26epage%3D434%26doi%3D10.1021%2Fci025590u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, Y.</span></span> <span> </span><span class="NLM_article-title">Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1539</span>– <span class="NLM_lpage">1554</span>, <span class="refDoi"> DOI: 10.1021/jm101356p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101356p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1539-1554&author=M.+Ishikawaauthor=Y.+Hashimoto&title=Improvement+in+aqueous+solubility+in+small+molecule+drug+discovery+programs+by+disruption+of+molecular+planarity+and+symmetry&doi=10.1021%2Fjm101356p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement in Aqueous Solubility in Small Molecule Drug Discovery Programs by Disruption of Molecular Planarity and Symmetry</span></div><div class="casAuthors">Ishikawa, Minoru; Hashimoto, Yuichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1539-1554</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKbtbfvqKZjrVg90H21EOLACvtfcHk0liF3d_sk0t9Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWltLw%253D&md5=a88804b3850625ef9c3f7424366acb91</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm101356p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101356p%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DY.%26atitle%3DImprovement%2520in%2520aqueous%2520solubility%2520in%2520small%2520molecule%2520drug%2520discovery%2520programs%2520by%2520disruption%2520of%2520molecular%2520planarity%2520and%2520symmetry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1539%26epage%3D1554%26doi%3D10.1021%2Fjm101356p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engkvist, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">Beyond size, ionization state, and lipophilicity: influence of molecular topology on absorption, distribution, metabolism, excretion, and toxicity for druglike compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3667</span>– <span class="NLM_lpage">3677</span>, <span class="refDoi"> DOI: 10.1021/jm201548z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201548z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVymtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3667-3677&author=Y.+Yangauthor=O.+Engkvistauthor=A.+Llinasauthor=H.+Chen&title=Beyond+size%2C+ionization+state%2C+and+lipophilicity%3A+influence+of+molecular+topology+on+absorption%2C+distribution%2C+metabolism%2C+excretion%2C+and+toxicity+for+druglike+compounds&doi=10.1021%2Fjm201548z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond Size, Ionization State, and Lipophilicity: Influence of Molecular Topology on Absorption, Distribution, Metabolism, Excretion, and Toxicity for Druglike Compounds</span></div><div class="casAuthors">Yang, Yidong; Engkvist, Ola; Llinas, Antonio; Chen, Hongming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3667-3677</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The absorption, distribution, metab., excretion, and toxicity (ADMET) of a compd. is dependent on physicochem. properties such as mol. size, lipophilicity, and ionization state.  However, much less is known regarding the relationship between ADMET and the mol. topol.  In this study two descriptors related to the mol. topol. have been investigated, the fraction of the mol. framework (fMF) and the fraction of sp3-hybridized carbon atoms (Fsp3). fMF and Fsp3, together with std. physicochem. properties (mol. size, ionization state, and lipophilicity), were analyzed for a set of ADMET assays.  It is shown that aq. soly., Caco-2 permeability, plasma protein binding, human ether-a-go-go-related potassium channel protein inhibition, and CYP3A4 (CYP = cytochrome P 450) inhibition are influenced by the mol. topol.  These findings are in most cases independent of the already well-established relationships between the properties and mol. size, lipophilicity, and ionization state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAjwI3Slwd37Vg90H21EOLACvtfcHk0liF3d_sk0t9Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVymtL0%253D&md5=596f7685e87dc0f0178d7d70616e17de</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm201548z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201548z%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DEngkvist%26aufirst%3DO.%26aulast%3DLlinas%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DBeyond%2520size%252C%2520ionization%2520state%252C%2520and%2520lipophilicity%253A%2520influence%2520of%2520molecular%2520topology%2520on%2520absorption%252C%2520distribution%252C%2520metabolism%252C%2520excretion%252C%2520and%2520toxicity%2520for%2520druglike%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3667%26epage%3D3677%26doi%3D10.1021%2Fjm201548z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, C.</span></span> <span> </span><span class="NLM_article-title">Chemical space</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>432</i></span>,  <span class="NLM_fpage">823</span>– <span class="NLM_lpage">823</span>, <span class="refDoi"> DOI: 10.1038/432823a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2F432823a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVOht7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=432&publication_year=2004&pages=823-823&author=P.+Kirkpatrickauthor=C.+Ellis&title=Chemical+space&doi=10.1038%2F432823a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical space</span></div><div class="casAuthors">Kirkpatrick, Peter; Ellis, Clare</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">432</span>
        (<span class="NLM_cas:issue">7019</span>),
    <span class="NLM_cas:pages">823</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSXQH2kgCwfrVg90H21EOLACvtfcHk0lgIhreFhLWm0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVOht7rI&md5=50a945a5b82429437d7745e619d628bf</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2F432823a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F432823a%26sid%3Dliteratum%253Aachs%26aulast%3DKirkpatrick%26aufirst%3DP.%26aulast%3DEllis%26aufirst%3DC.%26atitle%3DChemical%2520space%26jtitle%3DNature%26date%3D2004%26volume%3D432%26spage%3D823%26epage%3D823%26doi%3D10.1038%2F432823a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aldeghi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selwood, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A. W.</span></span> <span> </span><span class="NLM_article-title">Two- and three-dimensional rings in drugs</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">450</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1111/cbdd.12260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1111%2Fcbdd.12260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=24472495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktlCit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2014&pages=450-461&author=M.+Aldeghiauthor=S.+Malhotraauthor=D.+L.+Selwoodauthor=A.+W.+Chan&title=Two-+and+three-dimensional+rings+in+drugs&doi=10.1111%2Fcbdd.12260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Two- and Three-dimensional Rings in Drugs</span></div><div class="casAuthors">Aldeghi, Matteo; Malhotra, Shipra; Selwood, David L.; Chan, Ah Wing Edith</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">450-461</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Using small, flat arom. rings as components of fragments or mols. is a common practice in fragment-based drug discovery and lead optimization.  With an increasing focus on the exploration of novel biol. and chem. space, and their improved synthetic accessibility, 3D fragments are attracting increasing interest.  This study presents a detailed anal. of 3D and 2D ring fragments in marketed drugs.  Several measures of properties were used, such as the type of ring assemblies and mol. shapes.  The study also took into account the relationship between protein classes targeted by each ring fragment, providing target-specific information.  The anal. shows the high structural and shape diversity of 3D ring systems and their importance in bioactive compds.  Major differences in 2D and 3D fragments are apparent in ligands that bind to the major drug targets such as GPCRs, ion channels, and enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH07LvbUgiSrVg90H21EOLACvtfcHk0lgIhreFhLWm0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktlCit7g%253D&md5=dc877976abbd6b5b7d25a6b8b96415bc</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12260%26sid%3Dliteratum%253Aachs%26aulast%3DAldeghi%26aufirst%3DM.%26aulast%3DMalhotra%26aufirst%3DS.%26aulast%3DSelwood%26aufirst%3DD.%2BL.%26aulast%3DChan%26aufirst%3DA.%2BW.%26atitle%3DTwo-%2520and%2520three-dimensional%2520rings%2520in%2520drugs%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2014%26volume%3D83%26spage%3D450%26epage%3D461%26doi%3D10.1111%2Fcbdd.12260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morley, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugliese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birchall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bower, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drysdale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoelder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ley, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swarbrick, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span> <span> </span><span class="NLM_article-title">Fragment-based hit identification: thinking in 3D</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1221</span>– <span class="NLM_lpage">1227</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.07.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.drudis.2013.07.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=23906694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A280%3ADC%252BC3sflvFSnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=1221-1227&author=A.+D.+Morleyauthor=A.+Puglieseauthor=K.+Birchallauthor=J.+Bowerauthor=P.+Brennanauthor=N.+Brownauthor=T.+Chapmanauthor=M.+Drysdaleauthor=I.+H.+Gilbertauthor=S.+Hoelderauthor=A.+Jordanauthor=S.+V.+Leyauthor=A.+Merrittauthor=D.+Millerauthor=M.+E.+Swarbrickauthor=P.+G.+Wyatt&title=Fragment-based+hit+identification%3A+thinking+in+3D&doi=10.1016%2Fj.drudis.2013.07.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-based hit identification: thinking in 3D</span></div><div class="casAuthors">Morley Andrew D; Pugliese Angelo; Birchall Kristian; Bower Justin; Brennan Paul; Brown Nathan; Chapman Tim; Drysdale Martin; Gilbert Ian H; Hoelder Swen; Jordan Allan; Ley Steven V; Merritt Andy; Miller David; Swarbrick Martin E; Wyatt Paul G</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">1221-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The identification of high-quality hits during the early phases of drug discovery is essential if projects are to have a realistic chance of progressing into clinical development and delivering marketed drugs.  As the pharmaceutical industry goes through unprecedented change, there are increasing opportunities to collaborate via pre-competitive networks to marshal multifunctional resources and knowledge to drive impactful, innovative science.  The 3D Fragment Consortium is developing fragment-screening libraries with enhanced 3D characteristics and evaluating their effect on the quality of fragment-based hit identification (FBHI) projects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSiou0I6dpmUhgd2Wuil24tfW6udTcc2eZlPgKo9k5Nwbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sflvFSnuw%253D%253D&md5=74c6c81bfa12018554c0d1cfab894501</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.07.011%26sid%3Dliteratum%253Aachs%26aulast%3DMorley%26aufirst%3DA.%2BD.%26aulast%3DPugliese%26aufirst%3DA.%26aulast%3DBirchall%26aufirst%3DK.%26aulast%3DBower%26aufirst%3DJ.%26aulast%3DBrennan%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DN.%26aulast%3DChapman%26aufirst%3DT.%26aulast%3DDrysdale%26aufirst%3DM.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DHoelder%26aufirst%3DS.%26aulast%3DJordan%26aufirst%3DA.%26aulast%3DLey%26aufirst%3DS.%2BV.%26aulast%3DMerritt%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DD.%26aulast%3DSwarbrick%26aufirst%3DM.%2BE.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26atitle%3DFragment-based%2520hit%2520identification%253A%2520thinking%2520in%25203D%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D1221%26epage%3D1227%26doi%3D10.1016%2Fj.drudis.2013.07.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kombo, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallapragada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazurov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speake, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauser, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toler, S.</span></span> <span> </span><span class="NLM_article-title">3D molecular descriptors important for clinical success</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">342</span>, <span class="refDoi"> DOI: 10.1021/ci300445e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci300445e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCjurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=327-342&author=D.+C.+Komboauthor=K.+Tallapragadaauthor=R.+Jainauthor=J.+Chewningauthor=A.+A.+Mazurovauthor=J.+D.+Speakeauthor=T.+A.+Hauserauthor=S.+Toler&title=3D+molecular+descriptors+important+for+clinical+success&doi=10.1021%2Fci300445e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">3D Molecular Descriptors Important for Clinical Success</span></div><div class="casAuthors">Kombo, David C.; Tallapragada, Kartik; Jain, Rachit; Chewning, Joseph; Mazurov, Anatoly A.; Speake, Jason D.; Hauser, Terry A.; Toler, Steve</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">327-342</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pharmacokinetic and safety profiles of clin. drug candidates are greatly influenced by their requisite physicochem. properties.  In particular, it has been shown that 2D mol. descriptors such as fraction of Sp3 carbon atoms (Fsp3) and no. of stereo centers correlate with clin. success.  Using the proteomic off-target hit rate of nicotinic ligands, we found that shape-based 3D descriptors such as the radius of gyration and shadow indexes discriminate off-target promiscuity better than do Fsp3 and the no. of stereo centers.  We have deduced the relevant descriptor values required for a ligand to be nonpromiscuous.  Investigating the MDL Drug Data Report (MDDR) database as compds. move from the preclin. stage toward the market, we have found that these shape-based 3D descriptors predict clin. success of compds. at preclin. and phase1 stages vs compds. withdrawn from the market better than do Fsp3 and LogD.  Further, these computed 3D mol. descriptors correlate well with exptl. obsd. soly., which is among well-known physicochem. properties that drive clin. success.  We also found that about 84% of launched drugs satisfy either Shadow index or Fsp3 criteria, whereas withdrawn and discontinued compds. fail to meet the same criteria.  Our studies suggest that spherical compds. (rather than their elongated counterparts) with a minimal no. of arom. rings may exhibit a high propensity to advance from clin. trials to market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNRhBgMppmbbVg90H21EOLACvtfcHk0lgqWs-WgOZJWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCjurnE&md5=c750cdc150c2ba3626d98e2eea8c3144</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fci300445e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci300445e%26sid%3Dliteratum%253Aachs%26aulast%3DKombo%26aufirst%3DD.%2BC.%26aulast%3DTallapragada%26aufirst%3DK.%26aulast%3DJain%26aufirst%3DR.%26aulast%3DChewning%26aufirst%3DJ.%26aulast%3DMazurov%26aufirst%3DA.%2BA.%26aulast%3DSpeake%26aufirst%3DJ.%2BD.%26aulast%3DHauser%26aufirst%3DT.%2BA.%26aulast%3DToler%26aufirst%3DS.%26atitle%3D3D%2520molecular%2520descriptors%2520important%2520for%2520clinical%2520success%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2013%26volume%3D53%26spage%3D327%26epage%3D342%26doi%3D10.1021%2Fci300445e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hung, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, D. W.</span></span> <span> </span><span class="NLM_article-title">Route to three-dimensional fragments using diversity-oriented synthesis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">6799</span>– <span class="NLM_lpage">6804</span>, <span class="refDoi"> DOI: 10.1073/pnas.1015271108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1073%2Fpnas.1015271108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=21482811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlslyru7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=6799-6804&author=A.+W.+Hungauthor=A.+Ramekauthor=Y.+Wangauthor=T.+Kayaauthor=J.+A.+Wilsonauthor=P.+A.+Clemonsauthor=D.+W.+Young&title=Route+to+three-dimensional+fragments+using+diversity-oriented+synthesis&doi=10.1073%2Fpnas.1015271108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Route to three-dimensional fragments using diversity-oriented synthesis</span></div><div class="casAuthors">Hung, Alvin W.; Ramek, Alex; Wang, Yikai; Kaya, Taner; Wilson, J. Anthony; Clemons, Paul A.; Young, Damian W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6799-6804, S6799/1-S6799/41</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Fragment-based drug discovery (FBDD) has proven to be an effective means of producing high-quality chem. ligands as starting points for drug-discovery pursuits.  The increasing no. of clin. candidate drugs developed using FBDD approaches is a testament of the efficacy of this approach.  The success of fragment-based methods is highly dependent on the identity of the fragment library used for screening.  The vast majority of FBDD has centered on the use of sp2-rich arom. compds.  An expanded set of fragments that possess more 3D character would provide access to a larger chem. space of fragments than those currently used.  Diversity-oriented synthesis (DOS) aims to efficiently generate a set of mols. diverse in skeletal and stereochem. properties.  Mols. derived from DOS have also displayed significant success in the modulation of function of various difficult targets.  Herein, the authors describe the application of DOS toward the construction of a unique set of fragments contg. highly sp3-rich skeletons for fragment-based screening.  Using chemoinformatics anal., the authors quantified the shapes and phys. properties of the new 3D fragments and compared them with a database contg. known fragment-like mols.  The synthesis of the target compds. was achieved using as starting materials (2R)-2-(2-propen-1-yl)-1,2-pyrrolidinedicarboxylic acid 1-(1,1-dimethylethyl) ester, (5R)-5-(2-propen-1-yl)-L-proline 1,1-dimethylethyl ester and (5S)-5-(2-propen-1-yl)-L-proline 1,1-dimethylethyl ester and com. available reactants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIEcByQ3cnmbVg90H21EOLACvtfcHk0lgqWs-WgOZJWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlslyru7k%253D&md5=400419b262a4541a6bad66f64d461211</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1015271108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1015271108%26sid%3Dliteratum%253Aachs%26aulast%3DHung%26aufirst%3DA.%2BW.%26aulast%3DRamek%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKaya%26aufirst%3DT.%26aulast%3DWilson%26aufirst%3DJ.%2BA.%26aulast%3DClemons%26aufirst%3DP.%2BA.%26aulast%3DYoung%26aufirst%3DD.%2BW.%26atitle%3DRoute%2520to%2520three-dimensional%2520fragments%2520using%2520diversity-oriented%2520synthesis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D6799%26epage%3D6804%26doi%3D10.1073%2Fpnas.1015271108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krautler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liskamp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samori, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwalbe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toniolo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Boeckel, C. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, C. T.</span></span> <span> </span><span class="NLM_article-title">The state of the art of chemical biology</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1002/cbic.200800758</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fcbic.200800758" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=19115274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFOgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=16-29&author=K.-H.+Altmannauthor=J.+Buchnerauthor=H.+Kesslerauthor=F.+Diederichauthor=B.+Krautlerauthor=S.+Lippardauthor=R.+Liskampauthor=K.+Mullerauthor=E.+M.+Nolanauthor=B.+Samoriauthor=G.+Schneiderauthor=S.+L.+Schreiberauthor=H.+Schwalbeauthor=C.+Tonioloauthor=C.+A.+A.+van+Boeckelauthor=H.+Waldmannauthor=C.+T.+Walsh&title=The+state+of+the+art+of+chemical+biology&doi=10.1002%2Fcbic.200800758"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The state of the art of chemical biology</span></div><div class="casAuthors">Altmann, Karl-Heinz; Buchner, Johannes; Kessler, Horst; Diederich, Francois; Krautler, Bernhard; Lippard, Stephen; Liskamp, Rob; Muller, Klaus; Nolan, Elizabeth M.; Samori, Bruno; Schneider, Gisbert; Schreiber, Stuart L.; Schwalbe, Harald; Toniolo, Claudio; van Boeckel, Constant A. A.; Waldmann, Herbert; Walsh, Christopher T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-29</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Individual commentaries by each of the authors are given on the development and growth in the field of chem. biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0dnOb6qYHPrVg90H21EOLACvtfcHk0lgqWs-WgOZJWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFOgtLc%253D&md5=3a4d305e6dea4857f5de343acbde4a2d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200800758&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200800758%26sid%3Dliteratum%253Aachs%26aulast%3DAltmann%26aufirst%3DK.-H.%26aulast%3DBuchner%26aufirst%3DJ.%26aulast%3DKessler%26aufirst%3DH.%26aulast%3DDiederich%26aufirst%3DF.%26aulast%3DKrautler%26aufirst%3DB.%26aulast%3DLippard%26aufirst%3DS.%26aulast%3DLiskamp%26aufirst%3DR.%26aulast%3DMuller%26aufirst%3DK.%26aulast%3DNolan%26aufirst%3DE.%2BM.%26aulast%3DSamori%26aufirst%3DB.%26aulast%3DSchneider%26aufirst%3DG.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DSchwalbe%26aufirst%3DH.%26aulast%3DToniolo%26aufirst%3DC.%26aulast%3Dvan%2BBoeckel%26aufirst%3DC.%2BA.%2BA.%26aulast%3DWaldmann%26aufirst%3DH.%26aulast%3DWalsh%26aufirst%3DC.%2BT.%26atitle%3DThe%2520state%2520of%2520the%2520art%2520of%2520chemical%2520biology%26jtitle%3DChemBioChem%26date%3D2009%26volume%3D10%26spage%3D16%26epage%3D29%26doi%3D10.1002%2Fcbic.200800758" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Conformational restriction: an effective tactic in ‘follow-on’-based drug discovery</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">901</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.50</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.4155%2Ffmc.14.50" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=24962281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVemsrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=885-901&author=Z.+Fangauthor=Y.+Songauthor=P.+Zhanauthor=Q.+Zhangauthor=X.+Liu&title=Conformational+restriction%3A+an+effective+tactic+in+%E2%80%98follow-on%E2%80%99-based+drug+discovery&doi=10.4155%2Ffmc.14.50"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational restriction: an effective tactic in 'follow-on'-based drug discovery</span></div><div class="casAuthors">Fang, Zengjun; Song, Yu'ning; Zhan, Peng; Zhang, Qingzhu; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">885-901</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The conformational restriction (rigidification) of a flexible ligand has often been a commonly used strategy in drug design, as it can minimize the entropic loss assocd. with the ligand adopting a preferred conformation for binding, which leads to enhanced potency for a given physiol. target, improved selectivity for isoforms and reduced the possibility of drug metab.  Therefore, the application of conformational restriction strategy is a core aspect of drug discovery and development that is widely practiced by medicinal chemists either deliberately or subliminally.  The present review will highlight current representative examples and a brief overview on the rational design of conformationally restricted agents as well as discuss its advantages over the flexible counterparts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoupMomfg9J_bVg90H21EOLACvtfcHk0li-iozLY1-M9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVemsrzE&md5=dcf5fa6cead84c77b3603c7e0800f49b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.50&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.50%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DZ.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DConformational%2520restriction%253A%2520an%2520effective%2520tactic%2520in%2520%25E2%2580%2598follow-on%25E2%2580%2599-based%2520drug%2520discovery%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D885%26epage%3D901%26doi%3D10.4155%2Ffmc.14.50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clemons, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodycombe, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrinski, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamji, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">18787</span>– <span class="NLM_lpage">18792</span>, <span class="refDoi"> DOI: 10.1073/pnas.1012741107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1073%2Fpnas.1012741107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=20956335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVCqsb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=18787-18792&author=P.+A.+Clemonsauthor=N.+E.+Bodycombeauthor=H.+A.+Carrinskiauthor=J.+A.+Wilsonauthor=A.+F.+Shamjiauthor=B.+K.+Wagnerauthor=A.+N.+Koehlerauthor=S.+L.+Schreiber&title=Small+molecules+of+different+origins+have+distinct+distributions+of+structural+complexity+that+correlate+with+protein-binding+profiles&doi=10.1073%2Fpnas.1012741107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules of different origins have distinct distributions of structural complexity that correlate with protein-binding profiles</span></div><div class="casAuthors">Clemons, Paul A.; Bodycombe, Nicole E.; Carrinski, Hyman A.; Wilson, J. Anthony; Shamji, Alykhan F.; Wagner, Bridget K.; Koehler, Angela N.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">18787-18792, S18787/1-S18787/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Using a diverse collection of small mols. generated from a variety of sources, we measured protein-binding activities of each individual compd. against each of 100 diverse (sequence-unrelated) proteins using small-mol. microarrays.  We also analyzed structural features, including complexity, of the small mols.  We found that compds. from different sources (com., academic, natural) have different protein-binding behaviors and that these behaviors correlate with general trends in stereochem. and shape descriptors for these compd. collections.  Increasing the content of sp3-hybridized and stereogenic atoms relative to compds. from com. sources, which comprise the majority of current screening collections, improved binding selectivity and frequency.  The results suggest structural features that synthetic chemists can target when synthesizing screening collections for biol. discovery.  Because binding proteins selectively can be a key feature of high-value probes and drugs, synthesizing com- pounds having features identified in this study may result in improved performance of screening collections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBrE7Js72yZrVg90H21EOLACvtfcHk0li-iozLY1-M9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVCqsb%252FN&md5=198e298ca5391d7dfd91184680e3c2ec</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1012741107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1012741107%26sid%3Dliteratum%253Aachs%26aulast%3DClemons%26aufirst%3DP.%2BA.%26aulast%3DBodycombe%26aufirst%3DN.%2BE.%26aulast%3DCarrinski%26aufirst%3DH.%2BA.%26aulast%3DWilson%26aufirst%3DJ.%2BA.%26aulast%3DShamji%26aufirst%3DA.%2BF.%26aulast%3DWagner%26aufirst%3DB.%2BK.%26aulast%3DKoehler%26aufirst%3DA.%2BN.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DSmall%2520molecules%2520of%2520different%2520origins%2520have%2520distinct%2520distributions%2520of%2520structural%2520complexity%2520that%2520correlate%2520with%2520protein-binding%2520profiles%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D18787%26epage%3D18792%26doi%3D10.1073%2Fpnas.1012741107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cox, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zdorichenko, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker-Milburn, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paumier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson-Ralph, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, G.</span></span> <span> </span><span class="NLM_article-title">Escaping from flatland: Substituted bridged pyrrolidine fragments with inherent three-dimensional character</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1185</span>– <span class="NLM_lpage">1190</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlvVGmtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1185-1190&author=B.+Coxauthor=V.+Zdorichenkoauthor=P.+B.+Coxauthor=K.+I.+Booker-Milburnauthor=R.+Paumierauthor=L.+D.+Elliottauthor=M.+Robertson-Ralphauthor=G.+Bloomfield&title=Escaping+from+flatland%3A+Substituted+bridged+pyrrolidine+fragments+with+inherent+three-dimensional+character&doi=10.1021%2Facsmedchemlett.0c00039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Escaping from flatland: Substituted bridged pyrrolidine fragments with inherent three-dimensional character</span></div><div class="casAuthors">Cox, Brian; Zdorichenko, Victor; Cox, Philip B.; Booker-Milburn, Kevin I.; Paumier, Romain; Elliott, Luke D.; Robertson-Ralph, Michael; Bloomfield, Graham</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1185-1190</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pressure to deliver new medicines to the patient continues to grow along with increases in compd. failure rate, thus putting the current R&D model at risk.  Anal. has shown that increasing the three-dimensionality of potential drug candidates decreases the risk of failure and improves binding selectivity and frequency.  For this reason many workers have taken a new look at the power of photochem. as a means to generate novel sp3 rich scaffolds for use in drug discovery programs.  Here we report the design, synthesis, and computational structural anal. of a series of 2,4-methanoprolines having inherent 3D character (PMI and PBF scores) significantly higher than that of the broader AbbVie Rule of 3 (Ro3) collection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbrR6OWJMH3bVg90H21EOLACvtfcHk0li-iozLY1-M9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlvVGmtrc%253D&md5=f6d85595552e87671c7261e841d33146</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00039%26sid%3Dliteratum%253Aachs%26aulast%3DCox%26aufirst%3DB.%26aulast%3DZdorichenko%26aufirst%3DV.%26aulast%3DCox%26aufirst%3DP.%2BB.%26aulast%3DBooker-Milburn%26aufirst%3DK.%2BI.%26aulast%3DPaumier%26aufirst%3DR.%26aulast%3DElliott%26aufirst%3DL.%2BD.%26aulast%3DRobertson-Ralph%26aufirst%3DM.%26aulast%3DBloomfield%26aufirst%3DG.%26atitle%3DEscaping%2520from%2520flatland%253A%2520Substituted%2520bridged%2520pyrrolidine%2520fragments%2520with%2520inherent%2520three-dimensional%2520character%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1185%26epage%3D1190%26doi%3D10.1021%2Facsmedchemlett.0c00039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. B.</span></span> <span> </span><span class="NLM_article-title">Privileged structures: Efficient chemical “navigators” toward unexplored biologically relevant chemical spaces</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">14629</span>– <span class="NLM_lpage">14638</span>, <span class="refDoi"> DOI: 10.1021/ja508343a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja508343a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsleksrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=14629-14638&author=J.+Kimauthor=H.+Kimauthor=S.+B.+Park&title=Privileged+structures%3A+Efficient+chemical+%E2%80%9Cnavigators%E2%80%9D+toward+unexplored+biologically+relevant+chemical+spaces&doi=10.1021%2Fja508343a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Privileged Structures: Efficient Chemical "Navigators" toward Unexplored Biologically Relevant Chemical Spaces</span></div><div class="casAuthors">Kim, Jonghoon; Kim, Heejun; Park, Seung Bum</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">14629-14638</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In the search for new therapeutic agents for currently incurable diseases, attention has turned to traditionally "undruggable" targets, and collections of drug-like small mols. with high diversity and quality have become a prerequisite for new breakthroughs.  To generate such collections, the diversity-oriented synthesis (DOS) strategy was developed, which aims to populate new chem. space with drug-like compds. contg. a high degree of mol. diversity.  The resulting DOS-derived libraries have been of great value for the discovery of various bioactive small mols. and therapeutic agents, and thus DOS has emerged as an essential tool in chem. biol. and drug discovery.  However, the key challenge has become how to design and synthesize drug-like small-mol. libraries with improved biol. relevancy as well as max. mol. diversity.  This Perspective presents the development of privileged substructure-based DOS (pDOS), an efficient strategy for the construction of polyheterocyclic compd. libraries with high biol. relevancy.  We envisioned the specific interaction of drug-like small mols. with certain biopolymers via the incorporation of privileged substructures into polyheterocyclic core skeletons.  The importance of privileged substructures such as benzopyran, pyrimidine, and oxopiperazine in rigid skeletons was clearly demonstrated through the discovery of bioactive small mols. and the subsequent identification of appropriate target biomol. using a method called "fluorescence difference in two-dimensional gel electrophoresis".  Focusing on examples of pDOS-derived bioactive compds. with exceptional specificity, we discuss the capability of privileged structures to serve as chem. "navigators" toward biol. relevant chem. spaces.  We also provide an outlook on chem. biol. research and drug discovery using biol. relevant compd. libraries constructed by pDOS, biol.-oriented synthesis, or natural product-inspired DOS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTYO_xHDuDQLVg90H21EOLACvtfcHk0likpufkTOSLmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsleksrjM&md5=27672b927e95b898a7f95cb0f2bd1ef8</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fja508343a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja508343a%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DS.%2BB.%26atitle%3DPrivileged%2520structures%253A%2520Efficient%2520chemical%2520%25E2%2580%259Cnavigators%25E2%2580%259D%2520toward%2520unexplored%2520biologically%2520relevant%2520chemical%2520spaces%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D14629%26epage%3D14638%26doi%3D10.1021%2Fja508343a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cordier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murrison, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Leary-Steele, C.</span></span> <span> </span><span class="NLM_article-title">Natural products as an inspiration in the diversity-oriented synthesis of bioactive compound libraries</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">737</span>, <span class="refDoi"> DOI: 10.1039/b706296f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1039%2Fb706296f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=18663392" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptVCmsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2008&pages=719-737&author=C.+Cordierauthor=D.+Mortonauthor=S.+Murrisonauthor=A.+Nelsonauthor=C.+O%E2%80%99Leary-Steele&title=Natural+products+as+an+inspiration+in+the+diversity-oriented+synthesis+of+bioactive+compound+libraries&doi=10.1039%2Fb706296f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Natural products as an inspiration in the diversity-oriented synthesis of bioactive compound libraries</span></div><div class="casAuthors">Cordier, Christopher; Morton, Daniel; Murrison, Sarah; Nelson, Adam; O'Leary-Steele, Catherine</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">719-737</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The purpose of diversity-oriented synthesis is to drive the discovery of small mols. with previously unknown biol. functions.  Natural products necessarily populate biol. relevant chem. space, since they bind both their biosynthetic enzymes and their target macromols.  Natural product families are, therefore, libraries of pre-validated, functionally diverse structures in which individual compds. selectively modulate unrelated macromol. targets.  This review described examples of diversity-oriented syntheses which were, to some extent, inspired by the structures of natural products.  Particular emphasis was placed on innovations that allow the synthesis of compd. libraries that, like natural products, are skeletally diverse.  Mimicking the broad structural features of natural products may allow the discovery of compds. that modulate the functions of macromols. for which ligands are not known.  The ability of innovations in diversity-oriented synthesis to deliver such compds. is critically assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe3y9-D0jDCLVg90H21EOLACvtfcHk0likpufkTOSLmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptVCmsrk%253D&md5=a53c08a650f68989cb177cb954ec352b</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1039%2Fb706296f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb706296f%26sid%3Dliteratum%253Aachs%26aulast%3DCordier%26aufirst%3DC.%26aulast%3DMorton%26aufirst%3DD.%26aulast%3DMurrison%26aufirst%3DS.%26aulast%3DNelson%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Leary-Steele%26aufirst%3DC.%26atitle%3DNatural%2520products%2520as%2520an%2520inspiration%2520in%2520the%2520diversity-oriented%2520synthesis%2520of%2520bioactive%2520compound%2520libraries%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2008%26volume%3D25%26spage%3D719%26epage%3D737%26doi%3D10.1039%2Fb706296f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A.</span></span> <span> </span><span class="NLM_article-title">Navigating chemical space for biology and medicine</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>432</i></span>,  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">861</span>, <span class="refDoi"> DOI: 10.1038/nature03193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2Fnature03193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=15602551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVOht7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=432&publication_year=2004&pages=855-861&author=C.+Lipinskiauthor=A.+Hopkins&title=Navigating+chemical+space+for+biology+and+medicine&doi=10.1038%2Fnature03193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Navigating chemical space for biology and medicine</span></div><div class="casAuthors">Lipinski, Christopher; Hopkins, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">432</span>
        (<span class="NLM_cas:issue">7019</span>),
    <span class="NLM_cas:pages">855-861</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite over a century of applying org. synthesis to the search for drugs, the authors are still far from even a cursory examn. of the vast no. of possible small mols. that could be created.  Indeed, a thorough examn. of all 'chem. space' is practically impossible.  Given this, what are the best strategies for identifying small mols. that modulate biol. targets And how might such strategies differ, depending on whether the primary goal is to understand biol. systems or to develop potential drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3hQm7xaX5MLVg90H21EOLACvtfcHk0likpufkTOSLmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVOht7jO&md5=077237d55fa1225fd0aaee481e376172</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnature03193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03193%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%26aulast%3DHopkins%26aufirst%3DA.%26atitle%3DNavigating%2520chemical%2520space%2520for%2520biology%2520and%2520medicine%26jtitle%3DNature%26date%3D2004%26volume%3D432%26spage%3D855%26epage%3D861%26doi%3D10.1038%2Fnature03193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quasdorf, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overman, L. E.</span></span> <span> </span><span class="NLM_article-title">Catalytic enantioselective synthesis of quaternary carbon stereocentres</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>516</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1038/nature14007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2Fnature14007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=25503231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFams7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=516&publication_year=2014&pages=181-191&author=K.+W.+Quasdorfauthor=L.+E.+Overman&title=Catalytic+enantioselective+synthesis+of+quaternary+carbon+stereocentres&doi=10.1038%2Fnature14007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic enantioselective synthesis of quaternary carbon stereocentres</span></div><div class="casAuthors">Quasdorf, Kyle W.; Overman, Larry E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">516</span>
        (<span class="NLM_cas:issue">7530</span>),
    <span class="NLM_cas:pages">181-191</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Quaternary carbon stereocenters, carbon atoms to which four distinct carbon substituents are attached, are common features of mols. found in nature.  However, before recent advances in chem. catalysis, there were few methods of constructing single stereoisomers of this important structural motif.  Here, the authors discuss the many catalytic enantioselective reactions developed during the past decade for the synthesis of single stereoisomers of such org. mols.  This progress now makes it possible to incorporate quaternary stereocenters selectively in many org. mols. that are useful in medicine, agriculture and potentially other areas such as flavoring, fragrances and materials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWZnnX-pFyE7Vg90H21EOLACvtfcHk0ljbU1_SgEiEjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFams7jK&md5=0ed7950ca837a1ed1fde6af538c25c95</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fnature14007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14007%26sid%3Dliteratum%253Aachs%26aulast%3DQuasdorf%26aufirst%3DK.%2BW.%26aulast%3DOverman%26aufirst%3DL.%2BE.%26atitle%3DCatalytic%2520enantioselective%2520synthesis%2520of%2520quaternary%2520carbon%2520stereocentres%26jtitle%3DNature%26date%3D2014%26volume%3D516%26spage%3D181%26epage%3D191%26doi%3D10.1038%2Fnature14007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marek, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minko, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mejuch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilboa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chechik, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, J. P.</span></span> <span> </span><span class="NLM_article-title">All-carbon quaternary stereogenic centers in acyclic systems through the creation of several C-C bonds per chemical step</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">2682</span>– <span class="NLM_lpage">2694</span>, <span class="refDoi"> DOI: 10.1021/ja410424g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja410424g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1OhsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=2682-2694&author=I.+Marekauthor=Y.+Minkoauthor=M.+Pascoauthor=T.+Mejuchauthor=N.+Gilboaauthor=H.+Chechikauthor=J.+P.+Das&title=All-carbon+quaternary+stereogenic+centers+in+acyclic+systems+through+the+creation+of+several+C-C+bonds+per+chemical+step&doi=10.1021%2Fja410424g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">All-Carbon Quaternary Stereogenic Centers in Acyclic Systems through the Creation of Several C-C Bonds per Chemical Step</span></div><div class="casAuthors">Marek, Ilan; Minko, Yury; Pasco, Morgane; Mejuch, Tom; Gilboa, Noga; Chechik, Helena; Das, Jaya P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2682-2694</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In the past few decades, it has become clear that asym. catalysis is one of the most powerful methods for the construction of carbon-carbon as well as carbon-heteroatom bonds in a stereoselective manner.  However, when structural complexity increases (i.e., all-carbon quaternary stereogenic center), the difficulty in reaching the desired adducts through asym. catalytic reactions leads to a single carbon-carbon bond-forming event per chem. step between two components.  Issues of efficiency and convergence should therefore be addressed to avoid extraneous chem. steps.  In this perspective, the authors present approaches that tackle the stimulating problem of efficiency while answering interesting synthetic challenges.  Ideally, if one could create all-carbon quaternary stereogenic centers via the creation of several new carbon-carbon bonds in an acyclic system and in a single-pot operation from simple precursors, it would certainly open new horizons toward solving the synthetic problems.  Even more important for any further design, the presence of polyreactive intermediates in synthesis (bismetalated, carbenoid, and oxenoids species) becomes now an indispensable tool, as it creates consecutively the same no. of carbon-carbon bonds as in a multi-step process, but in a single-pot operation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm5zTezd7iT7Vg90H21EOLACvtfcHk0ljbU1_SgEiEjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1OhsLw%253D&md5=24d1bae788830c25bdd29817a87dbcf3</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fja410424g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja410424g%26sid%3Dliteratum%253Aachs%26aulast%3DMarek%26aufirst%3DI.%26aulast%3DMinko%26aufirst%3DY.%26aulast%3DPasco%26aufirst%3DM.%26aulast%3DMejuch%26aufirst%3DT.%26aulast%3DGilboa%26aufirst%3DN.%26aulast%3DChechik%26aufirst%3DH.%26aulast%3DDas%26aufirst%3DJ.%2BP.%26atitle%3DAll-carbon%2520quaternary%2520stereogenic%2520centers%2520in%2520acyclic%2520systems%2520through%2520the%2520creation%2520of%2520several%2520C-C%2520bonds%2520per%2520chemical%2520step%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D2682%26epage%3D2694%26doi%3D10.1021%2Fja410424g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marek, I.</span></span> <span> </span><span class="NLM_article-title">Enantioselective synthesis of all-carbon quaternary stereogenic centers in acyclic systems</span>. <i>Chem. Commun. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">4593</span>– <span class="NLM_lpage">4623</span>, <span class="refDoi"> DOI: 10.1039/c0cc05222a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1039%2Fc0cc05222a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=21359322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktF2ntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=4593-4623&author=J.+P.+Dasauthor=I.+Marek&title=Enantioselective+synthesis+of+all-carbon+quaternary+stereogenic+centers+in+acyclic+systems&doi=10.1039%2Fc0cc05222a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective synthesis of all-carbon quaternary stereogenic centers in acyclic systems</span></div><div class="casAuthors">Das, Jaya Prakash; Marek, Ilan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4593-4623</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Most of the methods for the creation of all-carbon quaternary stereogenic centers in acyclic systems were developed in the last decade showing the contemporary interest of this field of research.  Initial strategies, where chiral entities were linked to carbon skeleton, to enantioselective catalysis and finally to strategies where several carbon-carbon bonds were created in a single-pot operation, reflect the const. strive and creativity in the design and execution of synthetic sequences.  This review summarizes these sequences and is divided into sections on substitution and addns. reactions, alkylation, aldol, Mannich and rearrangements reactions.  It is safe to predict that this field of chem. will continue to grow exponentially in the coming decades and the ready availability of a wide range of these chiral entities will provide an excellent opportunity to further enrich mainstream synthetic methodologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozUlshUFovp7Vg90H21EOLACvtfcHk0ljbU1_SgEiEjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktF2ntr4%253D&md5=9d864f6b868bdd87c44031252c68b12e</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1039%2Fc0cc05222a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0cc05222a%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DJ.%2BP.%26aulast%3DMarek%26aufirst%3DI.%26atitle%3DEnantioselective%2520synthesis%2520of%2520all-carbon%2520quaternary%2520stereogenic%2520centers%2520in%2520acyclic%2520systems%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2011%26volume%3D47%26spage%3D4593%26epage%3D4623%26doi%3D10.1039%2Fc0cc05222a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Y. Q.</span></span> <span> </span><span class="NLM_article-title">Stereoselective construction of quaternary carbon stereocenters via a semipinacol rearrangement strategy</span>. <i>Acc. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1207</span>– <span class="NLM_lpage">1222</span>, <span class="refDoi"> DOI: 10.1021/ar200082p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ar200082p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVCqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2011&pages=1207-1222&author=B.+Wangauthor=Y.+Q.+Tu&title=Stereoselective+construction+of+quaternary+carbon+stereocenters+via+a+semipinacol+rearrangement+strategy&doi=10.1021%2Far200082p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Stereoselective construction of quaternary carbon stereocenters via a semipinacol rearrangement strategy</span></div><div class="casAuthors">Wang, Baomin; Tu, Yong Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Accounts of Chemical Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1207-1222</span>CODEN:
                <span class="NLM_cas:coden">ACHRE4</span>;
        ISSN:<span class="NLM_cas:issn">0001-4842</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Quaternary carbon stereocenters are found in a broad range of org. compds., including important bioactive natural products and medicinal agents.  Given their ubiquity and the significant synthetic challenges they present, quaternary carbon stereocenters have long attracted great interest from synthetic org. chemists.  Numerous efforts have been devoted to their construction, leading to a spectrum of strategies for creating stereogenic quaternary carbon centers.  In this context, the semipinacol rearrangement has proven successful.  In this extension of the pinacol rearrangement, the 1,2-carbon-to-carbon migration in a 1,2-diol has been expanded to include leaving groups other than the hydroxyl group.  Over the past decade, our lab. has explored the semipinacol rearrangement strategy for the stereoselective construction of quaternary carbon stereocenters.  We have investigated various substrates, including 2,3-epoxy alcs. (also termed α-hydroxy epoxides), 2,3-aziridino alcs., and allylic alcs.  Several promoters that effect the semipinacol rearrangement have been identified, including Lewis acids based on Al, Sm, B, Zn, and Ti for the rearrangement of α-hydroxy epoxides and 2,3-aziridino alcs.; cationic halogen species for the rearrangement of allylic alcs.; and cinchona alkaloids and chiral phosphoric acid for the asym. semipinacol rearrangement.  Our research efforts have led to a series of valuable synthetic methods, including (1) a tandem semipinacol rearrangement and Meerwein-Ponndorf-Verley redn., (2) a tandem semipinacol rearrangement and Tishchenko reaction, (3) a tandem semipinacol rearrangement with either an allylation or a propargylation, (4) a tandem semipinacol rearrangement and Schmidt reaction, (5) a semipinacol rearrangement of 2,3-aziridino alcs., (6) a semipinacol rearrangement of allylic alcs. induced by halogen cation, (7) a tandem aziridination and semipinacol rearrangement of allylic alcs., and (8) asym. semipinacol rearrangements with chiral org. catalysts.  One hallmark of these reactions is the creation of stereogenic quaternary carbon centers with high levels of stereocontrol.  In this account, we describe the development of these synthetically useful methodologies and their successful application to the total syntheses of natural products.  Our results demonstrate that the semipinacol rearrangement of carefully designed substrates constitutes an efficient approach to the stereoselective construction of quaternary carbon centers.  These reactions have produced a broad array of useful compds. that lend themselves to further elaboration.  Furthermore, the total synthesis of a series of alkaloids, with significant bioactivity and intriguing mol. architecture, was achieved through these semipinacol rearrangement strategies, highlighting their synthetic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq822oVgbG0qbVg90H21EOLACvtfcHk0ljbU1_SgEiEjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVCqtrw%253D&md5=096b3c728019cd43c6365a3a9f50b898</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Far200082p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Far200082p%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%26aulast%3DTu%26aufirst%3DY.%2BQ.%26atitle%3DStereoselective%2520construction%2520of%2520quaternary%2520carbon%2520stereocenters%2520via%2520a%2520semipinacol%2520rearrangement%2520strategy%26jtitle%3DAcc.%2520Chem.%2520Res.%26date%3D2011%26volume%3D44%26spage%3D1207%26epage%3D1222%26doi%3D10.1021%2Far200082p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruoka, K.</span></span> <span> </span><span class="NLM_article-title">Construction of a chiral quaternary carbon center by catalytic asymmetric alkylation of 2-arylcyclohexanones under phase-transfer conditions</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">7134</span>– <span class="NLM_lpage">7137</span>, <span class="refDoi"> DOI: 10.1021/ja403340r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja403340r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvVygsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=7134-7137&author=T.+Kanoauthor=Y.+Hayashiauthor=K.+Maruoka&title=Construction+of+a+chiral+quaternary+carbon+center+by+catalytic+asymmetric+alkylation+of+2-arylcyclohexanones+under+phase-transfer+conditions&doi=10.1021%2Fja403340r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Construction of a Chiral Quaternary Carbon Center by Catalytic Asymmetric Alkylation of 2-Arylcyclohexanones under Phase-Transfer Conditions</span></div><div class="casAuthors">Kano, Taichi; Hayashi, Yumi; Maruoka, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7134-7137</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, the authors present an asym. alkylation of modified 2-arylcyclohexanones.  A novel chiral ammonium bromide is employed as a phase-transfer catalyst and an achiral diphenylaminomethylene auxiliary is utilized as a controller to improve the enantioselectivity to afford optically enriched products having a chiral quaternary carbon center.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSOi-RTlj5iLVg90H21EOLACvtfcHk0lgrw1MEZbvwMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvVygsbs%253D&md5=f9243ec3ac78f7cb04b2fc22529ac7a6</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fja403340r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja403340r%26sid%3Dliteratum%253Aachs%26aulast%3DKano%26aufirst%3DT.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DMaruoka%26aufirst%3DK.%26atitle%3DConstruction%2520of%2520a%2520chiral%2520quaternary%2520carbon%2520center%2520by%2520catalytic%2520asymmetric%2520alkylation%2520of%25202-arylcyclohexanones%2520under%2520phase-transfer%2520conditions%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26spage%3D7134%26epage%3D7137%26doi%3D10.1021%2Fja403340r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span> <span> </span><span class="NLM_article-title">Enantioselective formation of all-carbon quaternary stereocenters from indoles and tertiary alcohols bearing a directing group</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1910</span>– <span class="NLM_lpage">1913</span>, <span class="refDoi"> DOI: 10.1002/anie.201405252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fanie.201405252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1GqsLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=1910-1913&author=W.+Zhaoauthor=Z.+Wangauthor=B.+Chuauthor=J.+Sun&title=Enantioselective+formation+of+all-carbon+quaternary+stereocenters+from+indoles+and+tertiary+alcohols+bearing+a+directing+group&doi=10.1002%2Fanie.201405252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective Formation of All-Carbon Quaternary Stereocenters from Indoles and Tertiary Alcohols Bearing A Directing Group</span></div><div class="casAuthors">Zhao, Wanxiang; Wang, Zhaobin; Chu, Boyang; Sun, Jianwei</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1910-1913</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Described is an efficient catalytic asym. intermol. C-C bond-formation process to generate acyclic all-carbon quaternary stereocenters.  The reactions overcome the unfavorable steric hindrance around reactive centers, and the competitive elimination (E1), to form a range of useful indole products I [R1 = 5-OMe, 5-OBn, 5-OTBS, etc; R2 = Me, Et; R3 = H, 5-Me, 6-F, etc; Ar = Ph, 4-MeC6H4, 4-FC6H4, etc] with excellent efficiency and enantioselectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhmZ-uY-dbV7Vg90H21EOLACvtfcHk0lgrw1MEZbvwMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1GqsLbP&md5=678a101f8eba32fdca077cf8086c239a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fanie.201405252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201405252%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DChu%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DJ.%26atitle%3DEnantioselective%2520formation%2520of%2520all-carbon%2520quaternary%2520stereocenters%2520from%2520indoles%2520and%2520tertiary%2520alcohols%2520bearing%2520a%2520directing%2520group%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D1910%26epage%3D1913%26doi%3D10.1002%2Fanie.201405252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.-F.</span></span> <span> </span><span class="NLM_article-title">Recent developments in the synthesis of chiral compounds with quaternary centers by organocatalytic cascade reactions</span>. <i>Asian J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">580</span>– <span class="NLM_lpage">607</span>, <span class="refDoi"> DOI: 10.1002/ajoc.201500486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fajoc.201500486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsF2ru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=580-607&author=L.+Tianauthor=Y.-C.+Luoauthor=X.-Q.+Huauthor=P.-F.+Xu&title=Recent+developments+in+the+synthesis+of+chiral+compounds+with+quaternary+centers+by+organocatalytic+cascade+reactions&doi=10.1002%2Fajoc.201500486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Developments in the Synthesis of Chiral Compounds with Quaternary Centers by Organocatalytic Cascade Reactions</span></div><div class="casAuthors">Tian, Li; Luo, Yong-Chun; Hu, Xiu-Qin; Xu, Peng-Fei</div><div class="citationInfo"><span class="NLM_cas:title">Asian Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">580-607</span>CODEN:
                <span class="NLM_cas:coden">AJOCC7</span>;
        ISSN:<span class="NLM_cas:issn">2193-5807</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Quaternary carbon stereocenters were present in a wide variety of org. compds. and drug mols.  Highly enantioselective construction of such quaternary carbon stereocenters had received considerable attention owing to the great challenges in their syntheses.  With the development of asym. organocatalytic cascade reactions, several efficient methods for the construction of optically pure compds. with quaternary carbon centers were developed.  This focused review highlighted the asym. synthesis of chiral compds. with quaternary centers through organocatalytic cascade reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx4tKOCTxcxbVg90H21EOLACvtfcHk0lgrw1MEZbvwMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsF2ru74%253D&md5=f2bfcb67e49b4779e3006ce35484c644</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fajoc.201500486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajoc.201500486%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DY.-C.%26aulast%3DHu%26aufirst%3DX.-Q.%26aulast%3DXu%26aufirst%3DP.-F.%26atitle%3DRecent%2520developments%2520in%2520the%2520synthesis%2520of%2520chiral%2520compounds%2520with%2520quaternary%2520centers%2520by%2520organocatalytic%2520cascade%2520reactions%26jtitle%3DAsian%2520J.%2520Org.%2520Chem.%26date%3D2016%26volume%3D5%26spage%3D580%26epage%3D607%26doi%3D10.1002%2Fajoc.201500486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krische, M. J.</span></span> <span> </span><span class="NLM_article-title">Acyclic quaternary carbon stereocenters via enantioselective transition metal catalysis</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">12564</span>– <span class="NLM_lpage">12580</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.7b00385</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.7b00385" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVyqt77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2017&pages=12564-12580&author=J.+Fengauthor=M.+Holmesauthor=M.+J.+Krische&title=Acyclic+quaternary+carbon+stereocenters+via+enantioselective+transition+metal+catalysis&doi=10.1021%2Facs.chemrev.7b00385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Acyclic Quaternary Carbon Stereocenters via Enantioselective Transition Metal Catalysis</span></div><div class="casAuthors">Feng, Jiajie; Holmes, Michael; Krische, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">12564-12580</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The enantioselective methods for the construction of acyclic quaternary carbon stereocenters from achiral or chiral racemic reactants via transition metal catalysis were summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoufRx1t1h1srVg90H21EOLACvtfcHk0lggY8w901wptg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVyqt77O&md5=299bce81c9a0aaabb6d5ac1a5014d7d4</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.7b00385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.7b00385%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DHolmes%26aufirst%3DM.%26aulast%3DKrische%26aufirst%3DM.%2BJ.%26atitle%3DAcyclic%2520quaternary%2520carbon%2520stereocenters%2520via%2520enantioselective%2520transition%2520metal%2520catalysis%26jtitle%3DChem.%2520Rev.%26date%3D2017%26volume%3D117%26spage%3D12564%26epage%3D12580%26doi%3D10.1021%2Facs.chemrev.7b00385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mateu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidd, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalash, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sore, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spring, D. R.</span></span> <span> </span><span class="NLM_article-title">Synthesis of structurally diverse <i>N</i>-substituted quaternary-carbon-containing small molecules from alpha, alpha-disubstituted propargyl amino esters</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">13681</span>– <span class="NLM_lpage">13687</span>, <span class="refDoi"> DOI: 10.1002/chem.201803143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fchem.201803143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=30011115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsV2ltLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=13681-13687&author=N.+Mateuauthor=S.+L.+Kiddauthor=L.+Kalashauthor=H.+F.+Soreauthor=A.+Madinauthor=A.+Benderauthor=D.+R.+Spring&title=Synthesis+of+structurally+diverse+N-substituted+quaternary-carbon-containing+small+molecules+from+alpha%2C+alpha-disubstituted+propargyl+amino+esters&doi=10.1002%2Fchem.201803143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Structurally Diverse N-Substituted Quaternary-Carbon-Containing Small Molecules from α,α-Disubstituted Propargyl Amino Esters</span></div><div class="casAuthors">Mateu, Natalia; Kidd, Sarah L.; Kalash, Leen; Sore, Hannah F.; Madin, Andrew; Bender, Andreas; Spring, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">13681-13687</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Herein, the diversity-oriented synthesis (DOS) of quaternary carbon contg. nitrogen heterocycles using α-Me propargylglycine as starting material was described.  The subsequent derivatization and the stereoselective synthesis exemplified the versatility of this strategy for drug discovery and library enrichment.  Chemoinformatic anal. revealed the enhanced sp3 character of the target library and demonstrated that it represented an attractive collection of biol. diverse small mols. with high scaffold diversity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojZ_5wCM10_rVg90H21EOLACvtfcHk0lggY8w901wptg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsV2ltLfF&md5=04075c8c49ce1182006292f4a0fea96d</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fchem.201803143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201803143%26sid%3Dliteratum%253Aachs%26aulast%3DMateu%26aufirst%3DN.%26aulast%3DKidd%26aufirst%3DS.%2BL.%26aulast%3DKalash%26aufirst%3DL.%26aulast%3DSore%26aufirst%3DH.%2BF.%26aulast%3DMadin%26aufirst%3DA.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DSpring%26aufirst%3DD.%2BR.%26atitle%3DSynthesis%2520of%2520structurally%2520diverse%2520N-substituted%2520quaternary-carbon-containing%2520small%2520molecules%2520from%2520alpha%252C%2520alpha-disubstituted%2520propargyl%2520amino%2520esters%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2018%26volume%3D24%26spage%3D13681%26epage%3D13687%26doi%3D10.1002%2Fchem.201803143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wendlandt, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, E. N.</span></span> <span> </span><span class="NLM_article-title">Quaternary stereocentres via an enantioconvergent catalytic SN1 reaction</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>556</i></span>,  <span class="NLM_fpage">447</span>– <span class="NLM_lpage">451</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0042-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2Fs41586-018-0042-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=29695848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVWrtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=556&publication_year=2018&pages=447-451&author=A.+E.+Wendlandtauthor=P.+Vangalauthor=E.+N.+Jacobsen&title=Quaternary+stereocentres+via+an+enantioconvergent+catalytic+SN1+reaction&doi=10.1038%2Fs41586-018-0042-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Quaternary stereocentres via an enantioconvergent catalytic SN1 reaction</span></div><div class="casAuthors">Wendlandt, Alison E.; Vangal, Prithvi; Jacobsen, Eric N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">556</span>
        (<span class="NLM_cas:issue">7702</span>),
    <span class="NLM_cas:pages">447-451</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The unimol. nucleophilic substitution (SN1) mechanism features prominently in every introductory org. chem. course.  In principle, stepwise displacement of a leaving group by a nucleophile via a carbocationic intermediate enables the construction of highly congested carbon centers.  However, the intrinsic instability and high reactivity of the carbocationic intermediates make it very difficult to control product distributions and stereoselectivity in reactions that proceed via SN1 pathways.  Here the asym. catalysis of an SN1-type reaction mechanism that results in the enantioselective construction of quaternary stereocentres from racemic precursors is reported.  The transformation relies on the synergistic action of a chiral hydrogen-bond-donor catalyst with a strong Lewis-acid promoter to mediate the formation of tertiary carbocationic intermediates at low temp. and to achieve high levels of control over reaction enantioselectivity and product distribution.  This work provides a foundation for the enantioconvergent synthesis of other fully substituted carbon stereocentres.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5F7L6qtrn7LVg90H21EOLACvtfcHk0lggY8w901wptg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVWrtrY%253D&md5=8a0c8ee971d4b69d70c3cd1c598e5068</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0042-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0042-1%26sid%3Dliteratum%253Aachs%26aulast%3DWendlandt%26aufirst%3DA.%2BE.%26aulast%3DVangal%26aufirst%3DP.%26aulast%3DJacobsen%26aufirst%3DE.%2BN.%26atitle%3DQuaternary%2520stereocentres%2520via%2520an%2520enantioconvergent%2520catalytic%2520SN1%2520reaction%26jtitle%3DNature%26date%3D2018%26volume%3D556%26spage%3D447%26epage%3D451%26doi%3D10.1038%2Fs41586-018-0042-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span> <span> </span><span class="NLM_article-title">Catalytic enantioselective House-Meinwald rearrangement: Efficient construction of all-carbon quaternary stereocenters</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">13783</span>– <span class="NLM_lpage">13787</span>, <span class="refDoi"> DOI: 10.1021/jacs.9b07514</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.9b07514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1ajtLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=13783-13787&author=D.+Maauthor=C.+B.+Miaoauthor=J.+Sun&title=Catalytic+enantioselective+House-Meinwald+rearrangement%3A+Efficient+construction+of+all-carbon+quaternary+stereocenters&doi=10.1021%2Fjacs.9b07514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic Enantioselective House-Meinwald Rearrangement: Efficient Construction of All-Carbon Quaternary Stereocenters</span></div><div class="casAuthors">Ma, Dengke; Miao, Chun-Bao; Sun, Jianwei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">13783-13787</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A catalytic asym. House-Meinwald rearrangement for the synthesis of both cyclic and acyclic ketones is disclosed.  From readily accessible racemic tetrasubstituted epoxides, this approach provides efficient access to chiral ketones bearing α all-carbon quaternary stereocenters with high enantiocontrol.  The observation of pos. nonlinear effects and nontrivial kinetic feature provided important insights into the mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt5TGyhQECCbVg90H21EOLACvtfcHk0lggY8w901wptg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1ajtLnL&md5=afc0efb44dea52ff69d1de267d6c2a2a</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjacs.9b07514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.9b07514%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DD.%26aulast%3DMiao%26aufirst%3DC.%2BB.%26aulast%3DSun%26aufirst%3DJ.%26atitle%3DCatalytic%2520enantioselective%2520House-Meinwald%2520rearrangement%253A%2520Efficient%2520construction%2520of%2520all-carbon%2520quaternary%2520stereocenters%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D13783%26epage%3D13787%26doi%3D10.1021%2Fjacs.9b07514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span> <span> </span><span class="NLM_article-title">Catalytic enantioselective pinacol and Meinwald rearrangements for the construction of quaternary stereocenters</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">11372</span>– <span class="NLM_lpage">11377</span>, <span class="refDoi"> DOI: 10.1021/jacs.9b04551</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.9b04551" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlamsLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2019&pages=11372-11377&author=H.+Wuauthor=Q.+Wangauthor=J.+Zhu&title=Catalytic+enantioselective+pinacol+and+Meinwald+rearrangements+for+the+construction+of+quaternary+stereocenters&doi=10.1021%2Fjacs.9b04551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Catalytic Enantioselective Pinacol and Meinwald Rearrangements for the Construction of Quaternary Stereocenters</span></div><div class="casAuthors">Wu, Hua; Wang, Qian; Zhu, Jieping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">11372-11377</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of enantioselective pinacol rearrangement is extremely challenging due to the likelihood involvement of the carbenium intermediate that renders the stereochem. communication between catalyst and substrate difficult to achieve.  Herein, the authors report chiral N-triflyl phosphoramide-catalyzed enantioselective pinacol rearrangement of 1,2-tertiary diols and mechanistically related Meinwald rearrangement of tetrasubstituted epoxides for the synthesis of enantioenriched 2-alkynyl-2-arylcyclohexanones and 2,2-diarylcyclohexanones, resp.  Total synthesis of (+)-mesembrane featuring the catalytic enantioselective pinacol rearrangement as a key strategic step is also documented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqolZB-_NmIE7Vg90H21EOLACvtfcHk0lhXuBqYq3tr8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlamsLrM&md5=be407f3e4a984188c9d219ce339896d9</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjacs.9b04551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.9b04551%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DJ.%26atitle%3DCatalytic%2520enantioselective%2520pinacol%2520and%2520Meinwald%2520rearrangements%2520for%2520the%2520construction%2520of%2520quaternary%2520stereocenters%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2019%26volume%3D141%26spage%3D11372%26epage%3D11377%26doi%3D10.1021%2Fjacs.9b04551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serefoglu, E. C.</span></span> <span> </span><span class="NLM_article-title">Oxytocin antagonists: the next frontier in PE treatment</span>. <i>Nat. Rev. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">696</span>– <span class="NLM_lpage">697</span>, <span class="refDoi"> DOI: 10.1038/s41585-019-0238-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2Fs41585-019-0238-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=31551585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A280%3ADC%252BB3MnhvVSiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=696-697&author=M.+Gulauthor=E.+C.+Serefoglu&title=Oxytocin+antagonists%3A+the+next+frontier+in+PE+treatment&doi=10.1038%2Fs41585-019-0238-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Oxytocin antagonists: the next frontier in PE treatment</span></div><div class="casAuthors">Gul Murat; Gul Murat; Serefoglu Ege Can; Serefoglu Ege Can; Serefoglu Ege Can</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Urology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">696-697</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnXmondofHviA3UY9EwTNrfW6udTcc2eYy0lSsPwIDrLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnhvVSiug%253D%253D&md5=adb52da2df4907dad9cf4f7a60e09d65</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fs41585-019-0238-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41585-019-0238-7%26sid%3Dliteratum%253Aachs%26aulast%3DGul%26aufirst%3DM.%26aulast%3DSerefoglu%26aufirst%3DE.%2BC.%26atitle%3DOxytocin%2520antagonists%253A%2520the%2520next%2520frontier%2520in%2520PE%2520treatment%26jtitle%3DNat.%2520Rev.%2520Urol.%26date%3D2019%26volume%3D16%26spage%3D696%26epage%3D697%26doi%3D10.1038%2Fs41585-019-0238-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of SHR1653, a highly potent and selective OTR antagonist with improved blood-brain barrier penetration</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">996</span>– <span class="NLM_lpage">1001</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00186</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00186" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKgtrzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=996-1001&author=X.+Liauthor=Z.+Zhangauthor=Y.+Chenauthor=H.+Wanauthor=J.+Sunauthor=B.+Wangauthor=B.+Fengauthor=B.+Huauthor=X.+Shiauthor=J.+Fengauthor=L.+Zhangauthor=F.+Heauthor=C.+Baiauthor=L.+Zhangauthor=W.+Tao&title=Discovery+of+SHR1653%2C+a+highly+potent+and+selective+OTR+antagonist+with+improved+blood-brain+barrier+penetration&doi=10.1021%2Facsmedchemlett.9b00186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of SHR1653, a Highly Potent and Selective OTR Antagonist with Improved Blood-Brain Barrier Penetration</span></div><div class="casAuthors">Li, Xin; Zhang, Zhigao; Chen, Yang; Wan, Hong; Sun, Jiakang; Wang, Bin; Feng, Bingqiang; Hu, Bing; Shi, Xingxing; Feng, Jun; Zhang, Lei; He, Feng; Bai, Chang; Zhang, Lianshan; Tao, Weikang</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">996-1001</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The oxytocin receptor (OTR) plays a major role in the control of male sexual responses.  Antagonists of the OTR have been reported to inhibit ejaculation in animal models and serve as a potential treatment for premature ejaculation (PE).  Herein, we describe a novel scaffold featuring an aryl substituted 3-azabicyclo [3.1.0] hexane structure.  The lead compd., SHR1653(I), was shown to be a highly potent OTR antagonist, which exhibited excellent selectivity over V1AR, V1BR, and V2R.  This novel mol. was shown to have a favorable pharmacokinetic profile across species, as well as robust in vivo efficacy in a rat uterine contraction model.  Interestingly, SHR1653 exhibited excellent blood-brain barrier penetration, which might be beneficial for the treatment of CNS-related PE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWBfusb6HbE7Vg90H21EOLACvtfcHk0lhXuBqYq3tr8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKgtrzF&md5=f952da6ce79ac33c1c61652a0dd40ddb</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00186%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DBai%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DTao%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520SHR1653%252C%2520a%2520highly%2520potent%2520and%2520selective%2520OTR%2520antagonist%2520with%2520improved%2520blood-brain%2520barrier%2520penetration%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D996%26epage%3D1001%26doi%3D10.1021%2Facsmedchemlett.9b00186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mould, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremberg, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geitmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiques-Diaz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGonagle, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somervaille, T. C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turlais, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogilvie, D.</span></span> <span> </span><span class="NLM_article-title">Development of (4-cyanophenyl)glycine derivatives as reversible inhibitors of lysine specific demethylase 1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7984</span>– <span class="NLM_lpage">7999</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00462</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00462" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKqsrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7984-7999&author=D.+P.+Mouldauthor=C.+Alliauthor=U.+Brembergauthor=S.+Carticauthor=A.+M.+Jordanauthor=M.+Geitmannauthor=A.+Maiques-Diazauthor=A.+E.+McGonagleauthor=T.+C.+P.+Somervailleauthor=G.+J.+Spencerauthor=F.+Turlaisauthor=D.+Ogilvie&title=Development+of+%284-cyanophenyl%29glycine+derivatives+as+reversible+inhibitors+of+lysine+specific+demethylase+1&doi=10.1021%2Facs.jmedchem.7b00462"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1</span></div><div class="casAuthors">Mould, Daniel P.; Alli, Cristina; Bremberg, Ulf; Cartic, Sharon; Jordan, Allan M.; Geitmann, Matthis; Maiques-Diaz, Alba; McGonagle, Alison E.; Somervaille, Tim C. P.; Spencer, Gary J.; Turlais, Fabrice; Ogilvie, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7984-7999</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of lysine specific demethylase 1 (LSD1) has been shown to induce the differentiation of leukemia stem cells in acute myeloid leukemia (AML).  Irreversible inhibitors developed from the nonspecific inhibitor tranylcypromine have entered clin. trials; however, the development of effective reversible inhibitors has proved more challenging.  Herein, we describe our efforts to identify reversible inhibitors of LSD1 from a high throughput screen and subsequent in silico modeling approaches.  From a single hit (12) validated by biochem. and biophys. assays, we describe our efforts to develop acyclic scaffold-hops from GSK-690 (1).  A further scaffold modification to a (4-cyanophenyl)glycinamide (e.g., 29a) led to the development of compd. 32, with a Kd value of 32 nM and an EC50 value of 0.67 μM in a surrogate cellular biomarker assay.  Moreover, this deriv. does not display the same level of hERG liability as obsd. with 1 and represents a promising lead for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5NyXkmZPOqrVg90H21EOLACvtfcHk0lgmA-iD3SiFnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKqsrrJ&md5=af673e7b3a2815aa09fe7264a3e4247b</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00462&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00462%26sid%3Dliteratum%253Aachs%26aulast%3DMould%26aufirst%3DD.%2BP.%26aulast%3DAlli%26aufirst%3DC.%26aulast%3DBremberg%26aufirst%3DU.%26aulast%3DCartic%26aufirst%3DS.%26aulast%3DJordan%26aufirst%3DA.%2BM.%26aulast%3DGeitmann%26aufirst%3DM.%26aulast%3DMaiques-Diaz%26aufirst%3DA.%26aulast%3DMcGonagle%26aufirst%3DA.%2BE.%26aulast%3DSomervaille%26aufirst%3DT.%2BC.%2BP.%26aulast%3DSpencer%26aufirst%3DG.%2BJ.%26aulast%3DTurlais%26aufirst%3DF.%26aulast%3DOgilvie%26aufirst%3DD.%26atitle%3DDevelopment%2520of%2520%25284-cyanophenyl%2529glycine%2520derivatives%2520as%2520reversible%2520inhibitors%2520of%2520lysine%2520specific%2520demethylase%25201%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7984%26epage%3D7999%26doi%3D10.1021%2Facs.jmedchem.7b00462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, W. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demarest, K.</span></span> <span> </span><span class="NLM_article-title">Discovery of orally efficacious tetrahydrobenzimidazoles as TGR5 agonists for type 2 diabetes</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">565</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00116</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00116" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlCmt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=560-565&author=X.+Zhangauthor=M.+Wallauthor=Z.+Suiauthor=J.+Kauffmanauthor=C.+Houauthor=C.+Chenauthor=F.+Duauthor=T.+Kirchnerauthor=Y.+Liangauthor=D.+L.+Johnsonauthor=W.+V.+Murrayauthor=K.+Demarest&title=Discovery+of+orally+efficacious+tetrahydrobenzimidazoles+as+TGR5+agonists+for+type+2+diabetes&doi=10.1021%2Facsmedchemlett.7b00116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Orally Efficacious Tetrahydrobenzimidazoles as TGR5 Agonists for Type 2 Diabetes</span></div><div class="casAuthors">Zhang, Xuqing; Wall, Mark; Sui, Zhihua; Kauffman, Jack; Hou, Cuifen; Chen, Cailin; Du, Fuyong; Kirchner, Thomas; Liang, Yin; Johnson, Dana L.; Murray, William V.; Demarest, Keith</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">560-565</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors have discovered a novel series of tetrahydrobenzimidazoles as TGR5 agonists.  Initial structure-activity relationship studies with an assay that measured cAMP levels in murine enteroendocrine cells (STC-1 cells) led to the discovery of potent agonists with submicromolar EC50 values for mTGR5.  Subsequent optimization through methylation of the 7-position of the core tetrahydrobenzimidazole ring resulted in the identification of potent agonists for both mTGR5 and hTGR5 (human enteroendocrine NCI-H716 cells).  While the lead compds. displayed low to moderate exposure after oral dosing, they significantly reduced blood glucose levels in C57 BL/6 mice at 30 mg/kg and induced a 13-22% redn. in the area under the blood glucose curve (AUC)0-120 min in oral glucose tolerance tests (OGTT).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5WtpgL4cFsbVg90H21EOLACvtfcHk0lgmA-iD3SiFnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlCmt70%253D&md5=409d84adc97e9860d7ab8bbf4863f007</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00116%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWall%26aufirst%3DM.%26aulast%3DSui%26aufirst%3DZ.%26aulast%3DKauffman%26aufirst%3DJ.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DDu%26aufirst%3DF.%26aulast%3DKirchner%26aufirst%3DT.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DJohnson%26aufirst%3DD.%2BL.%26aulast%3DMurray%26aufirst%3DW.%2BV.%26aulast%3DDemarest%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520orally%2520efficacious%2520tetrahydrobenzimidazoles%2520as%2520TGR5%2520agonists%2520for%2520type%25202%2520diabetes%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D560%26epage%3D565%26doi%3D10.1021%2Facsmedchemlett.7b00116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tangirala, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethi, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariazi, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirunagaru, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of tetralones as potent and selective inhibitors of acyl-CoA:diacylglycerol acyltransferase 1</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00450</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00450" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXoslCktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=103-108&author=M.+Cheungauthor=R.+S.+Tangiralaauthor=S.+R.+Bethiauthor=H.+V.+Joshiauthor=J.+L.+Ariaziauthor=V.+G.+Tirunagaruauthor=S.+Kumar&title=Discovery+of+tetralones+as+potent+and+selective+inhibitors+of+acyl-CoA%3Adiacylglycerol+acyltransferase+1&doi=10.1021%2Facsmedchemlett.7b00450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tetralones as Potent and Selective Inhibitors of Acyl-CoA:Diacylglycerol Acyltransferase 1</span></div><div class="casAuthors">Cheung, Mui; Tangirala, Raghuram S.; Bethi, Sridhar R.; Joshi, Hemant V.; Ariazi, Jennifer L.; Tirunagaru, Vijaya G.; Kumar, Sanjay</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-108</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) plays an important role in triglyceride synthesis and is a target of interest for the treatment of metabolic disorders.  Herein we describe the structure-activity relationship of a novel tetralone series of DGAT1 inhibitors and our strategies for overcoming genotoxic liability of the anilines embedded in the chem. structures, leading to the discovery of a candidate compd., (S)-2-(6-(5-(3-(3,4-difluorophenyl)ureido)pyrazin-2-yl)-1-oxo-2-(2,2,2-trifluoroethyl)-1,2,3,4-tetrahydronaphthalen-2-yl)acetic acid (GSK2973980A, 26d).  Compd. 26d is a potent and selective DGAT1 inhibitor with excellent DMPK profiles and in vivo efficacy in a postprandial lipid excursion model in mice.  Based on the overall biol. and developability profiles and acceptable safety profiles in the 7-day toxicity studies in rats and dogs, compd. 26d was selected as a candidate compd. for further development in the treatment of metabolic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYk8N30-oo-7Vg90H21EOLACvtfcHk0lgmA-iD3SiFnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXoslCktQ%253D%253D&md5=e2395ae7529b07224ab604b54e89ca93</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00450%26sid%3Dliteratum%253Aachs%26aulast%3DCheung%26aufirst%3DM.%26aulast%3DTangirala%26aufirst%3DR.%2BS.%26aulast%3DBethi%26aufirst%3DS.%2BR.%26aulast%3DJoshi%26aufirst%3DH.%2BV.%26aulast%3DAriazi%26aufirst%3DJ.%2BL.%26aulast%3DTirunagaru%26aufirst%3DV.%2BG.%26aulast%3DKumar%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520tetralones%2520as%2520potent%2520and%2520selective%2520inhibitors%2520of%2520acyl-CoA%253Adiacylglycerol%2520acyltransferase%25201%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D103%26epage%3D108%26doi%3D10.1021%2Facsmedchemlett.7b00450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walton, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span> <span> </span><span class="NLM_article-title">Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">393</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2008.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.coph.2008.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=18721898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFCktL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=393-412&author=T.+A.+Yapauthor=M.+D.+Garrettauthor=M.+I.+Waltonauthor=F.+Raynaudauthor=J.+S.+de+Bonoauthor=P.+Workman&title=Targeting+the+PI3K-AKT-mTOR+pathway%3A+progress%2C+pitfalls%2C+and+promises&doi=10.1016%2Fj.coph.2008.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises</span></div><div class="casAuthors">Yap, Timothy A.; Garrett, Michelle D.; Walton, Mike I.; Raynaud, Florence; de Bono, Johann S.; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">393-412</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The strategy of drugging the cancer kinome' has led to the successful development and regulatory approval of several novel mol. targeted agents.  The spotlight is now shifting to the phosphatidylinositide 3-kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) pathway as a key potential target.  This review details the role of the pathway in oncogenesis and the rationale for inhibiting its vital components.  The focus will be on the progress made in the development of novel therapies for cancer treatment, with emphasis placed on agents that have entered clin. development.  Strategies involving horizontal and vertical blockade of the pathway, as well as the use of biomarkers to select appropriate patients and to provide proof of target modulation will also be highlighted.  Finally, we discuss the issues and limitations involved with targeting the PI3K-AKT-mTOR pathway, and predict what the future may hold for these novel anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnmwezNSKUfbVg90H21EOLACvtfcHk0lh6JxY8UkvdPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFCktL7E&md5=b6a4f3c01a6776977d61cde8222d7201</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2008.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2008.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DTargeting%2520the%2520PI3K-AKT-mTOR%2520pathway%253A%2520progress%252C%2520pitfalls%252C%2520and%2520promises%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2008%26volume%3D8%26spage%3D393%26epage%3D412%26doi%3D10.1016%2Fj.coph.2008.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Convery, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peace, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redmond, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summers, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-oxabicyclo[4.1.0]heptane, a non-nitrogen containing morpholine isostere, and its application in novel inhibitors of the PI3K-AKT-mTOR pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6972</span>– <span class="NLM_lpage">6984</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00348</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00348" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlamsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6972-6984&author=H.+Hobbsauthor=G.+Braviauthor=I.+Campbellauthor=M.+Converyauthor=H.+Daviesauthor=G.+Inglisauthor=S.+Palauthor=S.+Peaceauthor=J.+Redmondauthor=D.+Summers&title=Discovery+of+3-oxabicyclo%5B4.1.0%5Dheptane%2C+a+non-nitrogen+containing+morpholine+isostere%2C+and+its+application+in+novel+inhibitors+of+the+PI3K-AKT-mTOR+pathway&doi=10.1021%2Facs.jmedchem.9b00348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-Oxabicyclo[4.1.0]heptane, a Non-nitrogen Containing Morpholine Isostere, and Its Application in Novel Inhibitors of the PI3K-AKT-mTOR Pathway</span></div><div class="casAuthors">Hobbs, Heather; Bravi, Gianpaolo; Campbell, Ian; Convery, Maire; Davies, Hannah; Inglis, Graham; Pal, Sandeep; Peace, Simon; Redmond, Joanna; Summers, Declan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6972-6984</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4-(Pyrimidin-4-yl)morpholines are privileged pharmacophores for PI3K and PIKKs inhibition by virtue of the morpholine oxygen, both forming the key hydrogen bonding interaction and conveying selectivity over the broader kinome.  Key to the morpholine utility as a kinase hinge binder is its ability to adopt a coplanar conformation with an adjacent arom. core favored by the morpholine nitrogen nonbonding pair of electrons interacting with the electron deficient pyrimidine π-system.  Few selective morpholine replacements have been identified to date.  Herein we describe the discovery of a potent non-nitrogen contg. morpholine isostere with the ability to mimic this conformation and its application in a potent selective dual inhibitor of mTORC1 and mTORC2 (29b).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJxxyzMER0yLVg90H21EOLACvtfcHk0lh6JxY8UkvdPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlamsbzP&md5=4c8c01c4f3fc20f3f776b4752dee5d80</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00348%26sid%3Dliteratum%253Aachs%26aulast%3DHobbs%26aufirst%3DH.%26aulast%3DBravi%26aufirst%3DG.%26aulast%3DCampbell%26aufirst%3DI.%26aulast%3DConvery%26aufirst%3DM.%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DInglis%26aufirst%3DG.%26aulast%3DPal%26aufirst%3DS.%26aulast%3DPeace%26aufirst%3DS.%26aulast%3DRedmond%26aufirst%3DJ.%26aulast%3DSummers%26aufirst%3DD.%26atitle%3DDiscovery%2520of%25203-oxabicyclo%255B4.1.0%255Dheptane%252C%2520a%2520non-nitrogen%2520containing%2520morpholine%2520isostere%252C%2520and%2520its%2520application%2520in%2520novel%2520inhibitors%2520of%2520the%2520PI3K-AKT-mTOR%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6972%26epage%3D6984%26doi%3D10.1021%2Facs.jmedchem.9b00348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruston, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demeritt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culshaw, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blades, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eden, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, S. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of AZD3147: a potent, selective dual inhibitor of mTORC1 and mTORC2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2326</span>– <span class="NLM_lpage">2349</span>, <span class="refDoi"> DOI: 10.1021/jm501778s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501778s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFeitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2326-2349&author=K.+G.+Pikeauthor=J.+Morrisauthor=L.+Rustonauthor=S.+L.+Passauthor=R.+Greenwoodauthor=E.+J.+Williamsauthor=J.+Demerittauthor=J.+D.+Culshawauthor=K.+Gillauthor=M.+Passauthor=M.+R.+Finlayauthor=C.+J.+Goodauthor=C.+A.+Robertsauthor=G.+S.+Currieauthor=K.+Bladesauthor=J.+M.+Edenauthor=S.+E.+Pearson&title=Discovery+of+AZD3147%3A+a+potent%2C+selective+dual+inhibitor+of+mTORC1+and+mTORC2&doi=10.1021%2Fjm501778s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AZD3147: A Potent, Selective Dual Inhibitor of mTORC1 and mTORC2</span></div><div class="casAuthors">Pike, Kurt G.; Morris, Jeff; Ruston, Linette; Pass, Sarah L.; Greenwood, Ryan; Williams, Emma J.; Demeritt, Julie; Culshaw, Janet D.; Gill, Kristy; Pass, Martin; Finlay, M. Raymond V.; Good, Catherine J.; Roberts, Craig A.; Currie, Gordon S.; Blades, Kevin; Eden, Jonathan M.; Pearson, Stuart E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2326-2349</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">High throughput screening followed by a lead generation campaign uncovered a novel series of urea contg. morpholinopyrimidine compds. which act as potent and selective dual inhibitors of mTORC1 and mTORC2.  The authors describe the continued compd. optimization campaign for this series, in particular focused on identifying compds. with improved cellular potency, improved aq. soly., and good stability in human hepatocyte incubations.  Knowledge from empirical SAR investigations was combined with an understanding of the mol. interactions in the crystal lattice to improve both cellular potency and soly., and the composite parameters of LLE and pIC50-pSoly. were used to assess compd. quality and progress.  Predictive models were employed to efficiently mine the attractive chem. space identified resulting in the discovery of I (AZD3147), an extremely potent and selective dual inhibitor of mTORC1 and mTORC2 with physicochem. and pharmacokinetic properties suitable for development as a potential clin. candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVFrPEX3khBbVg90H21EOLACvtfcHk0lh6JxY8UkvdPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFeitL0%253D&md5=92d9596bf3c160bcde73fd9c586d6b84</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm501778s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501778s%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DRuston%26aufirst%3DL.%26aulast%3DPass%26aufirst%3DS.%2BL.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DWilliams%26aufirst%3DE.%2BJ.%26aulast%3DDemeritt%26aufirst%3DJ.%26aulast%3DCulshaw%26aufirst%3DJ.%2BD.%26aulast%3DGill%26aufirst%3DK.%26aulast%3DPass%26aufirst%3DM.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DGood%26aufirst%3DC.%2BJ.%26aulast%3DRoberts%26aufirst%3DC.%2BA.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DBlades%26aufirst%3DK.%26aulast%3DEden%26aufirst%3DJ.%2BM.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26atitle%3DDiscovery%2520of%2520AZD3147%253A%2520a%2520potent%252C%2520selective%2520dual%2520inhibitor%2520of%2520mTORC1%2520and%2520mTORC2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2326%26epage%3D2349%26doi%3D10.1021%2Fjm501778s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Optimization of P2Y12 antagonist ethyl 6-(4-((benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) led to the discovery of an oral antiplatelet agent with improved druglike properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3088</span>– <span class="NLM_lpage">3106</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01971</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01971" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXksFens7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3088-3106&author=D.+Kongauthor=T.+Xueauthor=B.+Guoauthor=J.+Chengauthor=S.+Liuauthor=J.+Weiauthor=Z.+Luauthor=H.+Liuauthor=G.+Gongauthor=T.+Lanauthor=W.+Huauthor=Y.+Yang&title=Optimization+of+P2Y12+antagonist+ethyl+6-%284-%28%28benzylsulfonyl%29carbamoyl%29piperidin-1-yl%29-5-cyano-2-methylnicotinate+%28AZD1283%29+led+to+the+discovery+of+an+oral+antiplatelet+agent+with+improved+druglike+properties&doi=10.1021%2Facs.jmedchem.8b01971"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of P2Y12 Antagonist Ethyl 6-(4-((Benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties</span></div><div class="casAuthors">Kong, Deyu; Xue, Tao; Guo, Bin; Cheng, Jianjun; Liu, Shunyin; Wei, Jianhai; Lu, Zhengyu; Liu, Haoran; Gong, Guoqing; Lan, Tian; Hu, Wenhao; Yang, Yushe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3088-3106</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P2Y12 antagonists are widely used as antiplatelet agents for the prevention and treatment of arterial thrombosis.  Based on the scaffold of a known P2Y12 antagonist AZD1283 (I), a series of novel bicyclic pyridine derivs. were designed and synthesized.  The cyclization of the ester substituent on the pyridine ring to the ortho-Me group led to lactone analogs of AZD1283 that showed significantly enhanced metabolic stability in subsequent structure-pharmacokinetic relationship studies.  The metabolic stability was further enhanced by adding a 4-Me substituent to the piperidinyl moiety.  Compd. II displayed potent inhibition of platelet aggregation in vitro as well as antithrombotic efficacy in a rat ferric chloride model.  Moreover, II showed a safety profile that was superior to what was obsd. for clopidogrel in a rat tail-bleeding model.  These results support the further evaluation of compd. II as a promising drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3aElj92vWULVg90H21EOLACvtfcHk0lgoviSLYXqr-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXksFens7w%253D&md5=40577f34468ef13d6eea4a7a76dcaab8</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01971&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01971%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DD.%26aulast%3DXue%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DB.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DGong%26aufirst%3DG.%26aulast%3DLan%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DOptimization%2520of%2520P2Y12%2520antagonist%2520ethyl%25206-%25284-%2528%2528benzylsulfonyl%2529carbamoyl%2529piperidin-1-yl%2529-5-cyano-2-methylnicotinate%2520%2528AZD1283%2529%2520led%2520to%2520the%2520discovery%2520of%2520an%2520oral%2520antiplatelet%2520agent%2520with%2520improved%2520druglike%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3088%26epage%3D3106%26doi%3D10.1021%2Facs.jmedchem.8b01971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of a series of novel benzocyclobutene derivatives as general anesthetics</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3618</span>– <span class="NLM_lpage">3625</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00253</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00253" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlCmtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3618-3625&author=C.+Zhangauthor=F.+Liauthor=Y.+Yuauthor=A.+Huangauthor=P.+Heauthor=M.+Leiauthor=J.+Wangauthor=L.+Huangauthor=Z.+Liuauthor=J.+Liuauthor=Y.+Wei&title=Design%2C+synthesis%2C+and+evaluation+of+a+series+of+novel+benzocyclobutene+derivatives+as+general+anesthetics&doi=10.1021%2Facs.jmedchem.7b00253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Evaluation of a Series of Novel Benzocyclobutene Derivatives as General Anesthetics</span></div><div class="casAuthors">Zhang, Chen; Li, Fangqiong; Yu, Yan; Huang, Anbang; He, Ping; Lei, Ming; Wang, Jianmin; Huang, Longbin; Liu, Zhenhong; Liu, Jianyu; Wei, Yonggang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3618-3625</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the present work, a series of structurally novel benzocyclobutene derivs. were identified as general anesthetics through the loss of righting reflex (LORR) expt. on mice.  Our initial efforts found compd. 1a with a fused four-membered ring on the 2,3-position of the phenol ring could significantly improve the safety profile.  Further SAR study revealed that small hydrogen bond acceptor (HBA) groups are optimal for good ED50 along with much broader therapeutic windows, such as compds. 16b and 17.  Present work demonstrates the superiority of this novel benzocyclobutene scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_Lx2o14M9RrVg90H21EOLACvtfcHk0lgoviSLYXqr-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlCmtrg%253D&md5=9d38f93456f724429b2937e42f13fc68</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00253%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DHe%26aufirst%3DP.%26aulast%3DLei%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520a%2520series%2520of%2520novel%2520benzocyclobutene%2520derivatives%2520as%2520general%2520anesthetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D3618%26epage%3D3625%26doi%3D10.1021%2Facs.jmedchem.7b00253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judd, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Z.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frey, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruncko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunzer, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flygare, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catron, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judge, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shekhar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimmer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahir, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitten, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boghaert, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairbrother, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmore, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souers, A. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of A-1331852, a first-in-class, potent, and orally-bioavailable BCL-XL inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00568</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00568" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=L.+Wangauthor=G.+A.+Dohertyauthor=A.+S.+Juddauthor=Z.-F.+Taoauthor=T.+M.+Hansenauthor=R.+R.+Freyauthor=X.+Songauthor=M.+Brunckoauthor=A.+R.+Kunzerauthor=X.+Wangauthor=M.+D.+Wendtauthor=J.+A.+Flygareauthor=N.+D.+Catronauthor=R.+A.+Judgeauthor=C.+H.+Parkauthor=S.+Shekharauthor=D.+C.+Phillipsauthor=P.+Nimmerauthor=M.+L.+Smithauthor=S.+K.+Tahirauthor=Y.+Xiaoauthor=J.+Xueauthor=H.+Zhangauthor=P.+N.+Leauthor=M.+J.+Mittenauthor=E.+R.+Boghaertauthor=W.+Gaoauthor=P.+Kovarauthor=E.+F.+Chooauthor=D.+Diazauthor=W.+J.+Fairbrotherauthor=S.+W.+Elmoreauthor=D.+Sampathauthor=J.+D.+Leversonauthor=A.+J.+Souers&title=Discovery+of+A-1331852%2C+a+first-in-class%2C+potent%2C+and+orally-bioavailable+BCL-XL+inhibitor&doi=10.1021%2Facsmedchemlett.9b00568"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00568%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DDoherty%26aufirst%3DG.%2BA.%26aulast%3DJudd%26aufirst%3DA.%2BS.%26aulast%3DTao%26aufirst%3DZ.-F.%26aulast%3DHansen%26aufirst%3DT.%2BM.%26aulast%3DFrey%26aufirst%3DR.%2BR.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DBruncko%26aufirst%3DM.%26aulast%3DKunzer%26aufirst%3DA.%2BR.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWendt%26aufirst%3DM.%2BD.%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DCatron%26aufirst%3DN.%2BD.%26aulast%3DJudge%26aufirst%3DR.%2BA.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DShekhar%26aufirst%3DS.%26aulast%3DPhillips%26aufirst%3DD.%2BC.%26aulast%3DNimmer%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DM.%2BL.%26aulast%3DTahir%26aufirst%3DS.%2BK.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DXue%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLe%26aufirst%3DP.%2BN.%26aulast%3DMitten%26aufirst%3DM.%2BJ.%26aulast%3DBoghaert%26aufirst%3DE.%2BR.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DKovar%26aufirst%3DP.%26aulast%3DChoo%26aufirst%3DE.%2BF.%26aulast%3DDiaz%26aufirst%3DD.%26aulast%3DFairbrother%26aufirst%3DW.%2BJ.%26aulast%3DElmore%26aufirst%3DS.%2BW.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DLeverson%26aufirst%3DJ.%2BD.%26aulast%3DSouers%26aufirst%3DA.%2BJ.%26atitle%3DDiscovery%2520of%2520A-1331852%252C%2520a%2520first-in-class%252C%2520potent%252C%2520and%2520orally-bioavailable%2520BCL-XL%2520inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26doi%3D10.1021%2Facsmedchemlett.9b00568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nussbaumer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorfstätter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grassberger, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leitner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meingassner, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thirring, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stütz, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2115</span>– <span class="NLM_lpage">2120</span>, <span class="refDoi"> DOI: 10.1021/jm00067a010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00067a010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaK3sXlvVSnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=2115-2120&author=P.+Nussbaumerauthor=G.+Dorfst%C3%A4tterauthor=M.+A.+Grassbergerauthor=I.+Leitnerauthor=J.+G.+Meingassnerauthor=K.+Thirringauthor=A.+St%C3%BCtz&title=Synthesis+and+structure-activity+relationships+of+phenyl-substituted+benzylamine+antimycotics%3A+a+novel+benzylbenzylamine+antifungal+agent+for+systemic+treatment&doi=10.1021%2Fjm00067a010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationships of phenyl-substituted benzylamine antimycotics: a novel benzylbenzylamine antifungal agent for systemic treatment</span></div><div class="casAuthors">Nussbaumer, Peter; Dorfstaetter, Gerhard; Grassberger, Maximilian A.; Leitner, Ingrid; Meingassner, Josef G.; Thirring, Klaus; Stuetz, Anton</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2115-20</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Derivs. of the benzylamine antimycotics with an extra Ph ring incorporated in the side chain have been prepd. and their antifungal activity evaluated.  Thus, alkylation of N-methyl-1-naphthalenemethanamine with benzyl halides I (R = CH:CH, X = Cl; R = bond, X = Cl; R = O, X = Br; etc.) gave benzylamine derivs. II which were tested for antifungal activity.  The potency is strongly dependent on the distance between the two Ph groups and the type of spacer.  Linking the aryl rings with a quaternary carbon atom resulted in the identification of highly active compds. II (R = CMe2) (III) and benzothienyl deriv. IV, having a novel 4-benzylbenzylamine side chain.  III and its 7-benzo[b]thienyl analog IV show significantly enhanced efficacy, in particular against Candida albicans, and are among the most potent allyl/benzylamine antimycotics identified so far.  Extended investigations with the benzylbenzylamine deriv. III revealed that, in addn. to the enhanced antimycotic profile, the compd. is the first representative of the benzylamine antimycotics suitable for systemic treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHbLSfXBkJvbVg90H21EOLACvtfcHk0ljoZDL2QvZYeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlvVSnu70%253D&md5=e66050d2306b171bc06097e92f6759a2</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm00067a010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00067a010%26sid%3Dliteratum%253Aachs%26aulast%3DNussbaumer%26aufirst%3DP.%26aulast%3DDorfst%25C3%25A4tter%26aufirst%3DG.%26aulast%3DGrassberger%26aufirst%3DM.%2BA.%26aulast%3DLeitner%26aufirst%3DI.%26aulast%3DMeingassner%26aufirst%3DJ.%2BG.%26aulast%3DThirring%26aufirst%3DK.%26aulast%3DSt%25C3%25BCtz%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%2520phenyl-substituted%2520benzylamine%2520antimycotics%253A%2520a%2520novel%2520benzylbenzylamine%2520antifungal%2520agent%2520for%2520systemic%2520treatment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D2115%26epage%3D2120%26doi%3D10.1021%2Fjm00067a010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z. G.</span></span> <span> </span><span class="NLM_article-title">Adenosine receptors as therapeutic targets</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1038/nrd1983</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2Fnrd1983" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=16518376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD28XhvFOlsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=247-264&author=K.+A.+Jacobsonauthor=Z.+G.+Gao&title=Adenosine+receptors+as+therapeutic+targets&doi=10.1038%2Fnrd1983"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine receptors as therapeutic targets</span></div><div class="casAuthors">Jacobson, Kenneth A.; Gao, Zhan-Guo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">247-264</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Adenosine receptors are major targets of caffeine, the most commonly consumed drug in the world.  There is growing evidence that they could also be promising therapeutic targets in a wide range of conditions, including cerebral and cardiac ischemic diseases, sleep disorders, immune and inflammatory disorders and cancer.  After more than three decades of medicinal chem. research, a considerable no. of selective agonists and antagonists of adenosine receptors have been discovered, and some have been clin. evaluated, although none has yet received regulatory approval.  However, recent advances in the understanding of the roles of the various adenosine receptor subtypes, and in the development of selective and potent ligands, as discussed in this review, have brought the goal of therapeutic application of adenosine receptor modulators considerably closer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoG29EyQFoSbVg90H21EOLACvtfcHk0ljoZDL2QvZYeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhvFOlsr4%253D&md5=85ad553154bd61f24a6bb594f960f9bc</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fnrd1983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1983%26sid%3Dliteratum%253Aachs%26aulast%3DJacobson%26aufirst%3DK.%2BA.%26aulast%3DGao%26aufirst%3DZ.%2BG.%26atitle%3DAdenosine%2520receptors%2520as%2520therapeutic%2520targets%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D247%26epage%3D264%26doi%3D10.1038%2Fnrd1983" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, A.</span></span> <span> </span><span class="NLM_article-title">8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">924</span>– <span class="NLM_lpage">930</span>, <span class="refDoi"> DOI: 10.1021/jm00083a018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00083a018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaK38XhvVOntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=924-930&author=J.+Shimadaauthor=F.+Suzukiauthor=H.+Nonakaauthor=A.+Ishii&title=8-Polycycloalkyl-1%2C3-dipropylxanthines+as+potent+and+selective+antagonists+for+A1-adenosine+receptors&doi=10.1021%2Fjm00083a018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors</span></div><div class="casAuthors">Shimada, Junichi; Suzuki, Fumio; Nonaka, Hiromi; Ishii, Akio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">924-30</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">With the aim of characterizing the hydrophobic interactions between xanthines and the A1 receptor site, 1,3-dipropyl-8-substituted xanthines (I, R = e.g., heteraryl, alkyl, alicyclic, or noradamantyl group) were prepd.  Introduction of a quaternary carbon and the conformationally restricted cyclopental moiety into the 8-position of xanthine enhanced the adenosine A1 antagonism.  1,3-Dipropyl-8-(3-noradamantyl)xanthine was identified to be a selective and the most potent A1 receptor antagonist reported to date.  Under the structure-activity relation study, the 8-substituent of xanthine antagonists and the N6-substituent of adenosine agonists appears to bind to the same region of the A1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1zxD_KlyFpLVg90H21EOLACvtfcHk0ljoZDL2QvZYeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhvVOntbY%253D&md5=fad39d18bb9720d99c31dbbe9b808b2c</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm00083a018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00083a018%26sid%3Dliteratum%253Aachs%26aulast%3DShimada%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DF.%26aulast%3DNonaka%26aufirst%3DH.%26aulast%3DIshii%26aufirst%3DA.%26atitle%3D8-Polycycloalkyl-1%252C3-dipropylxanthines%2520as%2520potent%2520and%2520selective%2520antagonists%2520for%2520A1-adenosine%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D924%26epage%3D930%26doi%3D10.1021%2Fjm00083a018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. N.</span></span> <span> </span><span class="NLM_article-title">Potent adenosine receptor antagonists that are selective for the A1 receptor subtype</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">252</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=3561384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaL2sXktVSht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1987&pages=247-252&author=E.+A.+Martinsonauthor=R.+A.+Johnsonauthor=J.+N.+Wells&title=Potent+adenosine+receptor+antagonists+that+are+selective+for+the+A1+receptor+subtype"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Potent adenosine receptor antagonists that are selective for the A1 receptor subtype</span></div><div class="casAuthors">Martinson, Elizabeth A.; Johnson, Roger A.; Wells, Jack N.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">247-52</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">A systematic study of xanthine structure-activity relationships that compared antagonist potency at the A1 receptor of adipocytes with potency at the A2 receptor of platelets was conducted.  Since adenosine receptors are coupled to adenylate cyclase in these tissues, inhibition of adenylate cyclase via A1 receptors and stimulation via A2 receptors were used as models of receptor activation.  Antagonist potency was quantitated by Schild anal., which yields an est. of affinity (Ki) for the drug-receptor interaction.  Ki Values of a series of xanthine analogs made it possible to identify structural modifications than enhanced antagonist selectivity for one receptor subtype over the other.  Changes in the substituent at position 8 of the xanthine nucleus influenced antagonist potency at the A1 adenosine receptor more than at the A2 receptor.  In particular, an 8-cyclohexyl or 8-cyclopentyl substituent promoted antagonist selectivity for the A1 receptor subtype.  Thus, 1,3-dipropyl-8-cyclopentylxanthine (I) had comparatively high affinity (Ki = 0.47 nM) at the A1 receptor, and was roughly 150-fold more potent as an antagonist of the A1- than of the A2-adenosine receptor subtype.  In addn., the cycloalkylxanthines were relatively ineffective as inhibitors of cyclic nucleotide phosphodiesterase when used at concns. that produce marked adenosine receptor antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppuWrKG7BhtbVg90H21EOLACvtfcHk0lhhr2ZLmLPKFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXktVSht7c%253D&md5=15f9f261071b96c164b935635806f6fa</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartinson%26aufirst%3DE.%2BA.%26aulast%3DJohnson%26aufirst%3DR.%2BA.%26aulast%3DWells%26aufirst%3DJ.%2BN.%26atitle%3DPotent%2520adenosine%2520receptor%2520antagonists%2520that%2520are%2520selective%2520for%2520the%2520A1%2520receptor%2520subtype%26jtitle%3DMol.%2520Pharmacol.%26date%3D1987%26volume%3D31%26spage%3D247%26epage%3D252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costantino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maltoni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinozzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camaioni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prezeau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pin, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellicciari, R.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 2-(3′-(1H-tetrazol-5-yl)bicyclo[1.1.1]pent-1-yl)glycine (S-TBPG), a novel mGlu1 receptor antagonist</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(00)00270-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2FS0968-0896%2800%2900270-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=11249114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhs1artLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2001&pages=221-227&author=G.+Costantinoauthor=K.+Maltoniauthor=M.+Marinozziauthor=E.+Camaioniauthor=L.+Prezeauauthor=J.-P.+Pinauthor=R.+Pellicciari&title=Synthesis+and+biological+evaluation+of+2-%283%E2%80%B2-%281H-tetrazol-5-yl%29bicyclo%5B1.1.1%5Dpent-1-yl%29glycine+%28S-TBPG%29%2C+a+novel+mGlu1+receptor+antagonist&doi=10.1016%2FS0968-0896%2800%2900270-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 2-(3'-(1H-tetrazol-5-yl)bicyclo[1.1.1]pent-1-yl)glycine (S-TBPG), a novel mGlu1 receptor antagonist</span></div><div class="casAuthors">Costantino, G.; Maltoni, K.; Marinozzi, M.; Camaioni, E.; Prezeau, L.; Pin, J.-P.; Pellicciari, R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-227</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The design and synthesis of 2-(3'-(1H-tetrazol-5-yl)bicyclo[1.1.1]pent-1-yl)glycine (S-TBPG), a novel mGluR1 antagonist is reported.  S-TBPG is characterized by the bioisosteric replacement of the distal carboxy group of 2-(3'-carboxybicyclo[1.1.1]pent-1-yl)glycine (S-CBPG) by a tetrazolyl moiety.  Despite a moderate redn. in potency, S-TBPG is a selective mGluR1 antagonist (69 μM), with no activity at other mGluR subtypes.  The interesting biol. profile of S-TBPG, coupled with its peculiar chem. structure, is discussed in terms of the structure-activity relationship (SAR) of mGluR1 antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCrXubb8ywTLVg90H21EOLACvtfcHk0lhhr2ZLmLPKFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhs1artLs%253D&md5=3a6eec857310855b4e67dd5d37dbc7e8</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2800%2900270-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252800%252900270-4%26sid%3Dliteratum%253Aachs%26aulast%3DCostantino%26aufirst%3DG.%26aulast%3DMaltoni%26aufirst%3DK.%26aulast%3DMarinozzi%26aufirst%3DM.%26aulast%3DCamaioni%26aufirst%3DE.%26aulast%3DPrezeau%26aufirst%3DL.%26aulast%3DPin%26aufirst%3DJ.-P.%26aulast%3DPellicciari%26aufirst%3DR.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25202-%25283%25E2%2580%25B2-%25281H-tetrazol-5-yl%2529bicyclo%255B1.1.1%255Dpent-1-yl%2529glycine%2520%2528S-TBPG%2529%252C%2520a%2520novel%2520mGlu1%2520receptor%2520antagonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2001%26volume%3D9%26spage%3D221%26epage%3D227%26doi%3D10.1016%2FS0968-0896%2800%2900270-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pellicciari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raimondo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinozzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natalini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costantino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, C.</span></span> <span> </span><span class="NLM_article-title">(S)-(+)-2-(3′-Carboxybicyclo[1.1.1]pentyl)- glycine, a structurally new group I metabotropic glutamate receptor antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2874</span>– <span class="NLM_lpage">2876</span>, <span class="refDoi"> DOI: 10.1021/jm960254o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960254o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaK28XjvVejtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=2874-2876&author=R.+Pellicciariauthor=M.+Raimondoauthor=M.+Marinozziauthor=B.+Nataliniauthor=G.+Costantinoauthor=C.+Thomsen&title=%28S%29-%28%2B%29-2-%283%E2%80%B2-Carboxybicyclo%5B1.1.1%5Dpentyl%29-+glycine%2C+a+structurally+new+group+I+metabotropic+glutamate+receptor+antagonist&doi=10.1021%2Fjm960254o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">(S)-(+)-2-(3'-Carboxybicyclo[1.1.1]pentyl)- glycine, a Structurally New Group I Metabotropic Glutamate Receptor Antagonist</span></div><div class="casAuthors">Pellicciari, Roberto; Raimondo, Mariarosa; Marinozzi, Maura; Natalini, Benedetto; Costantino, Gabriele; Thomsen, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2874-2876</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A no. of carboxyphenylglycine (CPG) derivs. are known to act at metabotropic glutamate receptors (mGluRs) with a wide range of potency and functional selectivities toward mGluR subtypes depending on the substitution pattern.  With the aim of defining the role of the Ph moiety in this class of compds., the authors report the synthesis of S-(+)- and R-(-)-2-(3'-carboxybicyclo[1.1.1]pentyl)glycine, I and II, resp., in which the Ph ring is replaced by a [1.1.1]propellane moiety as a new, unusual spacer featuring a still coplanar disposition of the substitution inserted at the bridgehead positions.  The (S)-enantiomer I was a potent antagonist at the cloned phosphoinositide coupled mGluR1 subtype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi6ImMXIWB4LVg90H21EOLACvtfcHk0lhhr2ZLmLPKFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjvVejtr0%253D&md5=ff6b601f76372da3228974fed84e9088</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm960254o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960254o%26sid%3Dliteratum%253Aachs%26aulast%3DPellicciari%26aufirst%3DR.%26aulast%3DRaimondo%26aufirst%3DM.%26aulast%3DMarinozzi%26aufirst%3DM.%26aulast%3DNatalini%26aufirst%3DB.%26aulast%3DCostantino%26aufirst%3DG.%26aulast%3DThomsen%26aufirst%3DC.%26atitle%3D%2528S%2529-%2528%252B%2529-2-%25283%25E2%2580%25B2-Carboxybicyclo%255B1.1.1%255Dpentyl%2529-%2520glycine%252C%2520a%2520structurally%2520new%2520group%2520I%2520metabotropic%2520glutamate%2520receptor%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D2874%26epage%3D2876%26doi%3D10.1021%2Fjm960254o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Efremov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutra, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiRico, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorff, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pustilnik, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kormos, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capetta, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atchison, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallgren, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oborski, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robshaw, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sneed, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3414</span>– <span class="NLM_lpage">3424</span>, <span class="refDoi"> DOI: 10.1021/jm300094u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300094u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVyntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3414-3424&author=A.+F.+Stepanauthor=C.+Subramanyamauthor=I.+V.+Efremovauthor=J.+K.+Dutraauthor=T.+J.+O%E2%80%99Sullivanauthor=K.+J.+DiRicoauthor=W.+S.+McDonaldauthor=A.+Wonauthor=P.+H.+Dorffauthor=C.+E.+Nolanauthor=S.+L.+Beckerauthor=L.+R.+Pustilnikauthor=D.+R.+Riddellauthor=G.+W.+Kauffmanauthor=B.+L.+Kormosauthor=L.+Zhangauthor=Y.+Luauthor=S.+H.+Capettaauthor=M.+E.+Greenauthor=K.+Karkiauthor=E.+Sibleyauthor=K.+P.+Atchisonauthor=A.+J.+Hallgrenauthor=C.+E.+Oborskiauthor=A.+E.+Robshawauthor=B.+Sneedauthor=C.+J.+O%E2%80%99Donnell&title=Application+of+the+bicyclo%5B1.1.1%5Dpentane+motif+as+a+nonclassical+phenyl+ring+bioisostere+in+the+design+of+a+potent+and+orally+active+%CE%B3-secretase+inhibitor&doi=10.1021%2Fjm300094u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor</span></div><div class="casAuthors">Stepan, Antonia F.; Subramanyam, Chakrapani; Efremov, Ivan V.; Dutra, Jason K.; O'Sullivan, Theresa J.; DiRico, Kenneth J.; McDonald, W. Scott; Won, Annie; Dorff, Peter H.; Nolan, Charles E.; Becker, Stacey L.; Pustilnik, Leslie R.; Riddell, David R.; Kauffman, Gregory W.; Kormos, Bethany L.; Zhang, Liming; Lu, Yasong; Capetta, Steven H.; Green, Michael E.; Karki, Kapil; Sibley, Evelyn; Atchison, Kevin P.; Hallgren, Andrew J.; Oborski, Christine E.; Robshaw, Ashley E.; Sneed, Blossom; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3414-3424</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Replacement of the central, para-substituted fluorophenyl ring in the γ-secretase inhibitor BMS-708,163 with the bicyclo[1.1.1]pentane motif led to the discovery of compd. (I), an equipotent enzyme inhibitor with significant improvements in passive permeability and aq. soly.  The modified biopharmaceutical properties of I translated into excellent oral absorption characteristics (∼4-fold ↑ Cmax and AUC values relative to BMS-708,163) in a mouse model of γ-secretase inhibition.  In addn., SAR studies into other fluorophenyl replacements indicate the intrinsic advantages of the bicyclo[1.1.1]pentane moiety over conventional Ph ring replacements with respect to achieving an optimal balance of properties (e.g., γ-secretase inhibition, aq. soly./permeability, in vitro metabolic stability).  Overall, this work enhances the scope of the [1.1.1]-bicycle beyond that of a mere "spacer" unit and presents a compelling case for its broader application as a Ph group replacement in scenarios where the arom. ring count impacts physicochem. parameters and overall drug-likeness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYTrCHjtRbgbVg90H21EOLACvtfcHk0lgXzKP3OhL6jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVyntLo%253D&md5=4bbcac4eb20d974696833df5f86f9c34</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fjm300094u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300094u%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DEfremov%26aufirst%3DI.%2BV.%26aulast%3DDutra%26aufirst%3DJ.%2BK.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DT.%2BJ.%26aulast%3DDiRico%26aufirst%3DK.%2BJ.%26aulast%3DMcDonald%26aufirst%3DW.%2BS.%26aulast%3DWon%26aufirst%3DA.%26aulast%3DDorff%26aufirst%3DP.%2BH.%26aulast%3DNolan%26aufirst%3DC.%2BE.%26aulast%3DBecker%26aufirst%3DS.%2BL.%26aulast%3DPustilnik%26aufirst%3DL.%2BR.%26aulast%3DRiddell%26aufirst%3DD.%2BR.%26aulast%3DKauffman%26aufirst%3DG.%2BW.%26aulast%3DKormos%26aufirst%3DB.%2BL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DCapetta%26aufirst%3DS.%2BH.%26aulast%3DGreen%26aufirst%3DM.%2BE.%26aulast%3DKarki%26aufirst%3DK.%26aulast%3DSibley%26aufirst%3DE.%26aulast%3DAtchison%26aufirst%3DK.%2BP.%26aulast%3DHallgren%26aufirst%3DA.%2BJ.%26aulast%3DOborski%26aufirst%3DC.%2BE.%26aulast%3DRobshaw%26aufirst%3DA.%2BE.%26aulast%3DSneed%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DApplication%2520of%2520the%2520bicyclo%255B1.1.1%255Dpentane%2520motif%2520as%2520a%2520nonclassical%2520phenyl%2520ring%2520bioisostere%2520in%2520the%2520design%2520of%2520a%2520potent%2520and%2520orally%2520active%2520%25CE%25B3-secretase%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3414%26epage%3D3424%26doi%3D10.1021%2Fjm300094u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Auberson, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brocklehurst, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furegati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fessard, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Vecchia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briard, E.</span></span> <span> </span><span class="NLM_article-title">Improving nonspecific binding and solubility: Bicycloalkyl groups and cubanes as para-phenyl bioisosteres</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">590</span>– <span class="NLM_lpage">598</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fcmdc.201700082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=28319646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvV2gsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=590-598&author=Y.+P.+Aubersonauthor=C.+Brocklehurstauthor=M.+Furegatiauthor=T.+C.+Fessardauthor=G.+Kochauthor=A.+Deckerauthor=L.+La+Vecchiaauthor=E.+Briard&title=Improving+nonspecific+binding+and+solubility%3A+Bicycloalkyl+groups+and+cubanes+as+para-phenyl+bioisosteres&doi=10.1002%2Fcmdc.201700082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Nonspecific Binding and Solubility: Bicycloalkyl Groups and Cubanes as para-Phenyl Bioisosteres</span></div><div class="casAuthors">Auberson, Yves P.; Brocklehurst, Cara; Furegati, Markus; Fessard, Thomas C.; Koch, Guido; Decker, Andrea; La Vecchia, Luigi; Briard, Emmanuelle</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">590-598</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Bicycloalkyl groups have been previously described as Ph group bioisosteres.  This article describes the synthesis of new building blocks allowing their introduction into complex mols., and explores their use as a means to modify the physicochem. properties of drug candidates and improve the quality of imaging agents.  In particular, the replacement of an arom. ring with a bicyclo[1.1.1]pentane-1,3-diyl (BCP) group improves aq. soly. by at least 50-fold, and markedly decreases nonspecific binding (NSB) as measured by CHI(IAM), the chromatog. hydrophobicity index on immobilized artificial membranes.  Structural variations with the bicyclo[2.2.2]octane-1,4-diyl group led to more lipophilic mols. and did not show the same benefits regarding NSB or soly., whereas substitutions with cubane-1,4-diyl showed improvements for both parameters.  These results confirm the potential advantages of both BCP and cubane motifs as bioisosteric replacements for optimizing para-phenyl-substituted mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod2zUqkK78vLVg90H21EOLACvtfcHk0lgXzKP3OhL6jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvV2gsr8%253D&md5=7827a1866afae8b98b04ac03deaf5d2b</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700082%26sid%3Dliteratum%253Aachs%26aulast%3DAuberson%26aufirst%3DY.%2BP.%26aulast%3DBrocklehurst%26aufirst%3DC.%26aulast%3DFuregati%26aufirst%3DM.%26aulast%3DFessard%26aufirst%3DT.%2BC.%26aulast%3DKoch%26aufirst%3DG.%26aulast%3DDecker%26aufirst%3DA.%26aulast%3DLa%2BVecchia%26aufirst%3DL.%26aulast%3DBriard%26aufirst%3DE.%26atitle%3DImproving%2520nonspecific%2520binding%2520and%2520solubility%253A%2520Bicycloalkyl%2520groups%2520and%2520cubanes%2520as%2520para-phenyl%2520bioisosteres%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D590%26epage%3D598%26doi%3D10.1002%2Fcmdc.201700082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dilmaç, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spuling, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Meijere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bräse, S.</span></span> <span> </span><span class="NLM_article-title">Propellanes—From a chemical curiosity to “explosive” materials and natural products</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5684</span>– <span class="NLM_lpage">5718</span>, <span class="refDoi"> DOI: 10.1002/anie.201603951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fanie.201603951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlslOgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=5684-5718&author=A.+M.+Dilma%C3%A7author=E.+Spulingauthor=A.+de+Meijereauthor=S.+Br%C3%A4se&title=Propellanes%E2%80%94From+a+chemical+curiosity+to+%E2%80%9Cexplosive%E2%80%9D+materials+and+natural+products&doi=10.1002%2Fanie.201603951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Propellanes-From a Chemical Curiosity to "Explosive" Materials and Natural Products</span></div><div class="casAuthors">Dilmac, Alicia M.; Spuling, Eduard; de Meijere, Armin; Braese, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5684-5718</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Propellanes are a unique class of compds. currently consisting of well over 10 000 representatives, all featuring two more or less inverted tetrahedral carbon atoms that are common to three bridging rings.  The central single bond between the two bridgeheads is significantly weakened in the smaller entities, which leads to unusual reactivities of these structurally interesting propeller-like mols.  This Review highlights the synthesis of such propellanes and their occurrence in material sciences, natural products, and medicinal chem.  The conversion of [1.1.1]propellane into bridgehead derivs. of bicyclo[1.1.1]pentane, including oligomers and polymers with bicyclo[1.1.1]penta-1,3-diyl repeat units, is also featured.  A selection of natural products with larger propellane subunits are discussed in detail.  Heteropropellanes and inorg. propellanes are also addressed.  The historical background is touched in brief to show the pioneering work of David Ginsburg, Guenther Snatzke, Kenneth B. Wiberg, Guenter Szeimies, and others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPNBS1CEPKurVg90H21EOLACvtfcHk0lgXzKP3OhL6jA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlslOgsrg%253D&md5=b9da3c7dc8d9cf7e8ef30b847569e8c6</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1002%2Fanie.201603951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201603951%26sid%3Dliteratum%253Aachs%26aulast%3DDilma%25C3%25A7%26aufirst%3DA.%2BM.%26aulast%3DSpuling%26aufirst%3DE.%26aulast%3Dde%2BMeijere%26aufirst%3DA.%26aulast%3DBr%25C3%25A4se%26aufirst%3DS.%26atitle%3DPropellanes%25E2%2580%2594From%2520a%2520chemical%2520curiosity%2520to%2520%25E2%2580%259Cexplosive%25E2%2580%259D%2520materials%2520and%2520natural%2520products%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D5684%26epage%3D5718%26doi%3D10.1002%2Fanie.201603951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicolaou, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vourloumis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Totokotsopoulos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papakyriakou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karsunky, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernando, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavrilyuk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biopharmaceutical evaluation of imatinib analogues featuring unusual structural motifs</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fcmdc.201500510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=26585829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOmu7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=31-37&author=K.+C.+Nicolaouauthor=D.+Vourloumisauthor=S.+Totokotsopoulosauthor=A.+Papakyriakouauthor=H.+Karsunkyauthor=H.+Fernandoauthor=J.+Gavrilyukauthor=D.+Webbauthor=A.+F.+Stepan&title=Synthesis+and+biopharmaceutical+evaluation+of+imatinib+analogues+featuring+unusual+structural+motifs&doi=10.1002%2Fcmdc.201500510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biopharmaceutical Evaluation of Imatinib Analogues Featuring Unusual Structural Motifs</span></div><div class="casAuthors">Nicolaou, Kyriacos C.; Vourloumis, Dionisios; Totokotsopoulos, Sotirios; Papakyriakou, Athanasios; Karsunky, Holger; Fernando, Hanan; Gavrilyuk, Julia; Webb, Damien; Stepan, Antonia F.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-37</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A convenient synthesis of imatinib, a potent inhibitor of ABL1 kinase and widely prescribed drug for the treatment of a variety of leukemias, was devised and applied to the construction of a series of novel imatinib analogs featuring a no. of nonarom. structural motifs in place of the parent mol.'s Ph moiety.  These analogs were subsequently evaluated for their biopharmaceutical properties (e.g., ABL1 kinase inhibitory activity, cytotoxicity).  The bicyclo[1.1.1]pentane- and cubane-contg. analogs were found to possess higher thermodn. soly., whereas cubane- and cyclohexyl-contg. analogs exhibited the highest inhibitory activity against ABL1 kinase and the most potent cytotoxicity values against cancer cell lines K562 and SUP-B15.  Mol. modeling was employed to rationalize the weak activity of the compds. against ABL1 kinase, and it is likely that the obsd. cytotoxicity of these agents arises through off-target effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryhdZvrPlg2rVg90H21EOLACvtfcHk0liUbC0AVKmoIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOmu7nK&md5=012acd486d981afe4a4afe9d924fd696</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500510%26sid%3Dliteratum%253Aachs%26aulast%3DNicolaou%26aufirst%3DK.%2BC.%26aulast%3DVourloumis%26aufirst%3DD.%26aulast%3DTotokotsopoulos%26aufirst%3DS.%26aulast%3DPapakyriakou%26aufirst%3DA.%26aulast%3DKarsunky%26aufirst%3DH.%26aulast%3DFernando%26aufirst%3DH.%26aulast%3DGavrilyuk%26aufirst%3DJ.%26aulast%3DWebb%26aufirst%3DD.%26aulast%3DStepan%26aufirst%3DA.%2BF.%26atitle%3DSynthesis%2520and%2520biopharmaceutical%2520evaluation%2520of%2520imatinib%2520analogues%2520featuring%2520unusual%2520structural%2520motifs%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D31%26epage%3D37%26doi%3D10.1002%2Fcmdc.201500510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goh, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendharkar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adsool, V. A.</span></span> <span> </span><span class="NLM_article-title">Toward resolving the resveratrol conundrum: Synthesis and in vivo pharmacokinetic evaluation of BCP-resveratrol</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">516</span>– <span class="NLM_lpage">520</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsFajsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=516-520&author=Y.+L.+Gohauthor=Y.+T.+Cuiauthor=V.+Pendharkarauthor=V.+A.+Adsool&title=Toward+resolving+the+resveratrol+conundrum%3A+Synthesis+and+in+vivo+pharmacokinetic+evaluation+of+BCP-resveratrol&doi=10.1021%2Facsmedchemlett.7b00018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Resolving the Resveratrol Conundrum: Synthesis and in Vivo Pharmacokinetic Evaluation of BCP-Resveratrol</span></div><div class="casAuthors">Goh, Yi Ling; Cui, Yan Ting; Pendharkar, Vishal; Adsool, Vikrant A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">516-520</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Over the last few decades, resveratrol has gained significance due to its impressive array of biol. activities; however, its true potential as a drug has been severely constrained by its poor bioavailability.  Indeed, several studies have implicated this bioavailability trait as a major road-block to resveratrol's potential clin. applications.  To mitigate this pharmacokinetic issue, we envisioned a tactical bioisosteric modification of resveratrol to bicyclo[1.1.1]pentane (BCP) resveratrol.  Relying on the beneficial bioisosteric potential demonstrated by the BCP-scaffold, we hypothesized that BCP-resveratrol would have an inherently better in vivo PK profile as compared to its natural counterpart.  To validate such a hypothesis, it was necessary to secure a synthetic access to this novel structure.  Herein we describe the first synthesis of BCP-resveratrol and disclose its PK properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN7vEKGcbeDLVg90H21EOLACvtfcHk0liUbC0AVKmoIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsFajsrs%253D&md5=4bba7ca841dabab453237b0294239de8</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00018%26sid%3Dliteratum%253Aachs%26aulast%3DGoh%26aufirst%3DY.%2BL.%26aulast%3DCui%26aufirst%3DY.%2BT.%26aulast%3DPendharkar%26aufirst%3DV.%26aulast%3DAdsool%26aufirst%3DV.%2BA.%26atitle%3DToward%2520resolving%2520the%2520resveratrol%2520conundrum%253A%2520Synthesis%2520and%2520in%2520vivo%2520pharmacokinetic%2520evaluation%2520of%2520BCP-resveratrol%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D516%26epage%3D520%26doi%3D10.1021%2Facsmedchemlett.7b00018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Locke, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhard, S. S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senge, M. O.</span></span> <span> </span><span class="NLM_article-title">Nonconjugated hydrocarbons as rigid-linear motifs: Isosteres for material sciences and bioorganic and medicinal chemistry</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4590</span>– <span class="NLM_lpage">4647</span>, <span class="refDoi"> DOI: 10.1002/chem.201804225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fchem.201804225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=30387906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFSjtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=4590-4647&author=G.+M.+Lockeauthor=S.+S.+R.+Bernhardauthor=M.+O.+Senge&title=Nonconjugated+hydrocarbons+as+rigid-linear+motifs%3A+Isosteres+for+material+sciences+and+bioorganic+and+medicinal+chemistry&doi=10.1002%2Fchem.201804225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Nonconjugated Hydrocarbons as Rigid-Linear Motifs: Isosteres for Material Sciences and Bioorganic and Medicinal Chemistry</span></div><div class="casAuthors">Locke, Gemma M.; Bernhard, Stefan S. R.; Senge, Mathias O.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4590-4647</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Nonconjugated hydrocarbons, like bicyclo[1.1.1]pentane, bicyclo[2.2.2]octane, triptycene, and cubane are a unique class of rigid linkers.  Due to their similarity in size and shape they are useful mimics of classic benzene moieties in drugs, so-called bioisosteres.  Moreover, they also fulfill an important role in material sciences as linear linkers, in order to arrange various functionalities in a defined spatial manner.  In this Review article, recent developments and usages of these special, rectilinear systems are discussed.  Furthermore, we focus on covalently linked, nonconjugated linear arrangements and discuss the phys. and chem. properties and differences of individual linkers, as well as their application in material and medicinal sciences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-6fMC92ObjbVg90H21EOLACvtfcHk0liUbC0AVKmoIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFSjtbg%253D&md5=9b22ee3b2a90132ab2e9cb5471f63ac1</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1002%2Fchem.201804225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201804225%26sid%3Dliteratum%253Aachs%26aulast%3DLocke%26aufirst%3DG.%2BM.%26aulast%3DBernhard%26aufirst%3DS.%2BS.%2BR.%26aulast%3DSenge%26aufirst%3DM.%2BO.%26atitle%3DNonconjugated%2520hydrocarbons%2520as%2520rigid-linear%2520motifs%253A%2520Isosteres%2520for%2520material%2520sciences%2520and%2520bioorganic%2520and%2520medicinal%2520chemistry%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2019%26volume%3D25%26spage%3D4590%26epage%3D4647%26doi%3D10.1002%2Fchem.201804225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span> <span> </span><span class="NLM_article-title">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">822</span>– <span class="NLM_lpage">830</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.drudis.2011.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=21704184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2011&pages=822-830&author=R.+J.+Youngauthor=D.+V.+Greenauthor=C.+N.+Luscombeauthor=A.+P.+Hill&title=Getting+physical+in+drug+discovery+II%3A+the+impact+of+chromatographic+hydrophobicity+measurements+and+aromaticity&doi=10.1016%2Fj.drudis.2011.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity</span></div><div class="casAuthors">Young, Robert J.; Green, Darren V. S.; Luscombe, Christopher N.; Hill, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17/18</span>),
    <span class="NLM_cas:pages">822-830</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here, we review the performance of chromatog. hydrophobicity measurements in a data set of 100 000 GlaxoSmithKline compds., demonstrating the advantages of the method over octanol-water partitioning and highlighting new insights for drug discovery.  The value of chromatog. measurements, vs. other hydrophobicity ests., was supported by improved relationships with soly., permeation, cytochrome P450s, intrinsic clearance, hERG binding and promiscuity.  We also obsd. marked differentiation of the relative influence of intrinsic and effective hydrophobicity.  The summing of hydrophobicity values plus arom. ring count [log D pH7.4 (or log P) + #Ar], indicated a wide relevance for simplistic property forecast indexes' in developability assays, clearly enhanced by chromatog. values; therefore establishing new foundations for enriching property-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmIJyWi-DBW7Vg90H21EOLACvtfcHk0lgykBX3h6i-Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCru7vF&md5=22788603a45aa77537e8666433473d14</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%2BJ.%26aulast%3DGreen%26aufirst%3DD.%2BV.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DHill%26aufirst%3DA.%2BP.%26atitle%3DGetting%2520physical%2520in%2520drug%2520discovery%2520II%253A%2520the%2520impact%2520of%2520chromatographic%2520hydrophobicity%2520measurements%2520and%2520aromaticity%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2011%26volume%3D16%26spage%3D822%26epage%3D830%26doi%3D10.1016%2Fj.drudis.2011.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asensi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carretero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baño, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obrador, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrela, J. M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cancer growth by resveratrol is related to its low bioavailability</span>. <i>Free Radical Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1016/S0891-5849(02)00911-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2FS0891-5849%2802%2900911-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=12126761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt12kurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2002&pages=387-398&author=M.+Asensiauthor=I.+Medinaauthor=A.+Ortegaauthor=J.+Carreteroauthor=M.+C.+Ba%C3%B1oauthor=E.+Obradorauthor=J.+M.+Estrela&title=Inhibition+of+cancer+growth+by+resveratrol+is+related+to+its+low+bioavailability&doi=10.1016%2FS0891-5849%2802%2900911-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cancer growth by resveratrol is related to its low bioavailability</span></div><div class="casAuthors">Asensi, Miguel; Medina, Ignacio; Ortega, Angel; Carretero, Julian; Bano, M. Carmen; Obrador, Elena; Estrela, Jose M.</div><div class="citationInfo"><span class="NLM_cas:title">Free Radical Biology & Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">387-398</span>CODEN:
                <span class="NLM_cas:coden">FRBMEH</span>;
        ISSN:<span class="NLM_cas:issn">0891-5849</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The relationship between resveratrol (RES) bioavailability and its effect on tumor growth was investigated.  Tissue levels of RES were studied after i.v. and oral administration of trans-resveratrol (t-RES) to rabbits, rats, and mice.  Half-life of RES in plasma, after i.v. administration of 20 mg t-RES/kg b.wt., was very short (e.g., 14.4 min in rabbits).  The highest concn. of RES in plasma, either after i.v. or oral administration (e.g., 2.6 ± 1.0 μM in mice 2.5 min after receiving 20 mg t-RES/kg orally), was reached within the first 5 min in all animals studied.  Extravascular levels (brain, lung, liver, and kidney) of RES, which paralleled those in plasma, were always < 1 nmol/g fresh tissue.  RES measured in plasma or tissues was in the trans form (at least 99%).  Hepatocytes metabolized t-RES in a dose-dependent fashion (e.g., 43 nmol of t-RES/g × min in the presence of 20 μM tRES), which means that the liver can remove circulating RES very rapidly.  In vitro B16 melanoma (B16M) cell proliferation and generation of reactive oxygen species (ROS) was inhibited by t-RES in a concn.-dependent fashion (100% inhibition of tumor growth was found in the presence of 5 μM t-RES).  Addn. of 10 μM H2O2 to B16M cells, cultured in the presence of 5 μM t-RES, reactivated cell growth.  Oral administration of t-RES (20 mg/kg twice per day; or included in the drinking water at 23 mg/l) did not inhibit growth of B16M inoculated into the footpad of mice (solid growth).  However, oral administration of t-RES (as above) decreased hepatic metastatic invasion of B16M cells inoculated intrasplenically.  The antimetastatic mechanism involves a t-RES (1 μM)-induced inhibition of vascular adhesion mol. 1 (VCAM-1) expression in the hepatic sinusoidal endothelium (HSE), which consequently decreased in vitro B16M cell adhesion to the endothelium via very late activation antigen 4 (VLA-4).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP11sw2kyBFLVg90H21EOLACvtfcHk0lgykBX3h6i-Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt12kurk%253D&md5=c49ba5325c94060101d69c3e1640c1b3</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2FS0891-5849%2802%2900911-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0891-5849%252802%252900911-5%26sid%3Dliteratum%253Aachs%26aulast%3DAsensi%26aufirst%3DM.%26aulast%3DMedina%26aufirst%3DI.%26aulast%3DOrtega%26aufirst%3DA.%26aulast%3DCarretero%26aufirst%3DJ.%26aulast%3DBa%25C3%25B1o%26aufirst%3DM.%2BC.%26aulast%3DObrador%26aufirst%3DE.%26aulast%3DEstrela%26aufirst%3DJ.%2BM.%26atitle%3DInhibition%2520of%2520cancer%2520growth%2520by%2520resveratrol%2520is%2520related%2520to%2520its%2520low%2520bioavailability%26jtitle%3DFree%2520Radical%2520Biol.%2520Med.%26date%3D2002%26volume%3D33%26spage%3D387%26epage%3D398%26doi%3D10.1016%2FS0891-5849%2802%2900911-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meegalla, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanter, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winters, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littrell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rady, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilde, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otieno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pocai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Player, M. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of a GPR40 superagonist: The impact of aryl propionic acid alpha-fluorination</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00444</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00444" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVSgs7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=16-21&author=H.+Huangauthor=S.+K.+Meegallaauthor=J.+C.+Lanterauthor=M.+P.+Wintersauthor=S.+Zhaoauthor=J.+Littrellauthor=J.+Qiauthor=B.+Radyauthor=P.+S.+Leeauthor=J.+Liuauthor=T.+Martinauthor=W.+W.+Lamauthor=F.+Xuauthor=H.+K.+Limauthor=T.+Wildeauthor=J.+Silvaauthor=M.+Otienoauthor=A.+Pocaiauthor=M.+R.+Player&title=Discovery+of+a+GPR40+superagonist%3A+The+impact+of+aryl+propionic+acid+alpha-fluorination&doi=10.1021%2Facsmedchemlett.8b00444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a GPR40 Superagonist: The Impact of Aryl Propionic Acid α-Fluorination</span></div><div class="casAuthors">Huang, Hui; Meegalla, Sanath K.; Lanter, James C.; Winters, Michael P.; Zhao, Shuyuan; Littrell, James; Qi, Jenson; Rady, Brian; Lee, Paul S.; Liu, Jianying; Martin, Tonya; Lam, Wing W.; Xu, Fran; Lim, Heng Keang; Wilde, Thomas; Silva, Jose; Otieno, Monicah; Pocai, Alessandro; Player, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-21</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">GPR40 is a G-protein-coupled receptor which mediates fatty acid-induced glucose-stimulated insulin secretion from pancreatic beta cells and incretion release from enteroendocrine cells of the small intestine.  GPR40 full agonists exhibit superior glucose lowering compared to partial agonists in preclin. species due to increased insulin and GLP-1 secretion, with the added benefit of promoting wt. loss.  In our search for potent GPR40 full agonists, we discovered a superagonist which displayed excellent in vitro potency and superior efficacy in the Gαs-mediated signaling pathway.  Most synthetic GPR40 agonists have a carboxylic acid headgroup, which may cause idiosyncratic toxicities, including drug-induced-liver-injury (DILI).  With a Me group and a fluorine atom substituted at the α-C of the carboxylic acid group, 19 is not only highly efficacious in lowering glucose and body wt. in rodent models but also has a low DILI risk due to its stable acylglucuronide metabolite.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQJ_WYP9f76rVg90H21EOLACvtfcHk0lgykBX3h6i-Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVSgs7fN&md5=1e9b9412b6438351528162aab15351eb</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00444%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DMeegalla%26aufirst%3DS.%2BK.%26aulast%3DLanter%26aufirst%3DJ.%2BC.%26aulast%3DWinters%26aufirst%3DM.%2BP.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DLittrell%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DRady%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DP.%2BS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DLam%26aufirst%3DW.%2BW.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DLim%26aufirst%3DH.%2BK.%26aulast%3DWilde%26aufirst%3DT.%26aulast%3DSilva%26aufirst%3DJ.%26aulast%3DOtieno%26aufirst%3DM.%26aulast%3DPocai%26aufirst%3DA.%26aulast%3DPlayer%26aufirst%3DM.%2BR.%26atitle%3DDiscovery%2520of%2520a%2520GPR40%2520superagonist%253A%2520The%2520impact%2520of%2520aryl%2520propionic%2520acid%2520alpha-fluorination%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D16%26epage%3D21%26doi%3D10.1021%2Facsmedchemlett.8b00444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malashkevich, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, P. S.</span></span> <span> </span><span class="NLM_article-title">Structural characterization of the human respiratory syncytial virus fusion protein core</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">14172</span>– <span class="NLM_lpage">14177</span>, <span class="refDoi"> DOI: 10.1073/pnas.260499197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1073%2Fpnas.260499197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=11106388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVCguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=14172-14177&author=X.+Zhaoauthor=M.+Singhauthor=V.+N.+Malashkevichauthor=P.+S.+Kim&title=Structural+characterization+of+the+human+respiratory+syncytial+virus+fusion+protein+core&doi=10.1073%2Fpnas.260499197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Structural characterization of the human respiratory syncytial virus fusion protein core</span></div><div class="casAuthors">Zhao, Xun; Singh, Mona; Malashkevich, Vladimir N.; Kim, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">14172-14177</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Human respiratory syncytial virus (HRSV) is a major cause of a no. of severe respiratory diseases, including bronchiolitis and pneumonia, in infants and young children.  The HRSV F protein, a glycoprotein essential for viral entry, is a primary target for vaccine and drug development.  Two heptad-repeat regions within the HRSV F sequence were predicted by the computer program Learn-Coil-VMF.  These regions are thought to form trimer-of-hairpins-like structures, similar to those found in the fusion proteins of several enveloped viruses.  The hairpin structure likely brings the viral and cellular membranes into close apposition, thereby facilitating membrane fusion and subsequent viral entry.  Here, we show that peptides, denoted HR-N and HR-C, corresponding to the heptad-repeat regions from the N-terminal and C-terminal segments of the HRSV F protein, resp., form a stable α-helical trimer of heterodimers.  The HRSV N/C complex was crystd. and its x-ray structure was detd. at 2.3-Å resoln.  As anticipated, the complex is a six-helix bundle in which the HR-N peptides form a three-stranded, central coiled coil, and the HR-C peptides pack in an antiparallel manner into hydrophobic grooves on the coiled-coil surface.  There is remarkable structural similarity between the HRSV N/C complex and the fusion protein core of other viruses, including HIV-1 gp41.  In addn., earlier work has shown that HRSV HR-C peptides, like the HIV-1 gp41 C peptides, inhibit viral infection.  Thus, drug discovery and vaccine development strategies aimed at inhibiting viral entry by blocking hairpin formation may be applied to the inhibition of HRSV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKEUNin9nZSLVg90H21EOLACvtfcHk0liJRpZnNegS8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVCguw%253D%253D&md5=9e4655323f6d5264a7e51913843e41eb</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1073%2Fpnas.260499197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.260499197%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DMalashkevich%26aufirst%3DV.%2BN.%26aulast%3DKim%26aufirst%3DP.%2BS.%26atitle%3DStructural%2520characterization%2520of%2520the%2520human%2520respiratory%2520syncytial%2520virus%2520fusion%2520protein%2520core%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2000%26volume%3D97%26spage%3D14172%26epage%3D14177%26doi%3D10.1073%2Fpnas.260499197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svabek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewah, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanjuan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patera, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolbeck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, G. P.</span></span> <span> </span><span class="NLM_article-title">RAGE inhibits human respiratory syncytial virus syncytium formation by interfering with F-protein function</span>. <i>J. Gen. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">1691</span>– <span class="NLM_lpage">1700</span>, <span class="refDoi"> DOI: 10.1099/vir.0.049254-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1099%2Fvir.0.049254-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=23559480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht12gs7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2013&pages=1691-1700&author=J.+Tianauthor=K.+Huangauthor=S.+Krishnanauthor=C.+Svabekauthor=D.+C.+Roweauthor=Y.+Brewahauthor=M.+Sanjuanauthor=A.+C.+Pateraauthor=R.+Kolbeckauthor=R.+Herbstauthor=G.+P.+Sims&title=RAGE+inhibits+human+respiratory+syncytial+virus+syncytium+formation+by+interfering+with+F-protein+function&doi=10.1099%2Fvir.0.049254-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">RAGE inhibits human respiratory syncytial virus syncytium formation by interfering with F-protein function</span></div><div class="casAuthors">Tian, Jane; Huang, Kelly; Krishnan, Subramaniam; Svabek, Catherine; Rowe, Daniel C.; Brewah, Yambasu; Sanjuan, Miguel; Patera, Andriani C.; Kolbeck, Roland; Herbst, Ronald; Sims, Gary P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1691-1700</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    
            (<span class="NLM_cas:orgname">Society for General Microbiology</span>)
        </div><div class="casAbstract">Human respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infection.  Infection is critically dependent on the RSV fusion (F) protein, which mediates fusion between the viral envelope and airway epithelial cells.  The F protein is also expressed on infected cells and is responsible for fusion of infected cells with adjacent cells, giving multinucleate syncytia.  The receptor for advanced glycation end products (RAGE) is a pattern-recognition receptor that is constitutively highly expressed by type I alveolar epithelial cells.  Here, the authors report that RAGE protected HEK cells from RSV-induced cell death and reduced viral titers in vitro.  RAGE appeared to interact directly with the F protein, but, rather than inhibiting RSV entry into host cells, virus replication and budding, membrane-expressed RAGE or sol. RAGE blocked F-protein-mediated syncytium formation and sloughing.  RAGE may contribute to protecting the lower airways from RSV by inhibiting the formation of syncytia, viral spread, epithelial damage and airway obstruction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgLBX4XC_ZBbVg90H21EOLACvtfcHk0liJRpZnNegS8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht12gs7zP&md5=df838540c1c9ccbe96b0db4a6e3aed72</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1099%2Fvir.0.049254-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fvir.0.049254-0%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DK.%26aulast%3DKrishnan%26aufirst%3DS.%26aulast%3DSvabek%26aufirst%3DC.%26aulast%3DRowe%26aufirst%3DD.%2BC.%26aulast%3DBrewah%26aufirst%3DY.%26aulast%3DSanjuan%26aufirst%3DM.%26aulast%3DPatera%26aufirst%3DA.%2BC.%26aulast%3DKolbeck%26aufirst%3DR.%26aulast%3DHerbst%26aufirst%3DR.%26aulast%3DSims%26aufirst%3DG.%2BP.%26atitle%3DRAGE%2520inhibits%2520human%2520respiratory%2520syncytial%2520virus%2520syncytium%2520formation%2520by%2520interfering%2520with%2520F-protein%2520function%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2013%26volume%3D94%26spage%3D1691%26epage%3D1700%26doi%3D10.1099%2Fvir.0.049254-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of benzoazepinequinoline (BAQ) derivatives as novel, potent, orally bioavailable respiratory syncytial virus fusion inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">10228</span>– <span class="NLM_lpage">10241</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01394</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01394" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFOgu7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=10228-10241&author=X.+Zhengauthor=C.+Liangauthor=L.+Wangauthor=B.+Wangauthor=Y.+Liuauthor=S.+Fengauthor=J.+Z.+Wuauthor=L.+Gaoauthor=L.+Fengauthor=L.+Chenauthor=T.+Guoauthor=H.+C.+Shenauthor=H.+Yun&title=Discovery+of+benzoazepinequinoline+%28BAQ%29+derivatives+as+novel%2C+potent%2C+orally+bioavailable+respiratory+syncytial+virus+fusion+inhibitors&doi=10.1021%2Facs.jmedchem.8b01394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Benzoazepinequinoline (BAQ) Derivatives as Novel, Potent, Orally Bioavailable Respiratory Syncytial Virus Fusion Inhibitors</span></div><div class="casAuthors">Zheng, Xiufang; Liang, Chungen; Wang, Lisha; Wang, Baoxia; Liu, Yongfu; Feng, Song; Wu, Jim Zhen; Gao, Lu; Feng, Lichun; Chen, Li; Guo, Tao; Shen, Hong C.; Yun, Hongying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10228-10241</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel benzoazepinequnoline (BAQ) series was discovered as RSV fusion inhibitors.  BAQ series originated from a hit from similarity-based virtual screening.  In SAR exploration, benzoazepine allowed modifications in the head moiety.  Benzylic sulfonyl on benzoazepine and 6-Me on quinoline were crucial for good anti-RSV activity.  Although the basic amine in the head portion was crucial for anti-RSV activity, the attenuated basicity was required to reduce Vss.  Introducing oxetane to the head portion led to discovery of compd. I, which demonstrated single-digit nM anti-RSV activity against different RSV strains, reasonable oral exposure in plasma, and 78-fold higher exposure in lung.  Compd. I also displayed 1 log viral redn. in a female BALB/c mice RSV model by b.i.d. oral dosing at 12.5 mg/kg.  A single resistant mutant at L138F in fusion protein proved compd. I to be a RSV fusion inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppxigxpJ_FyLVg90H21EOLACvtfcHk0liJRpZnNegS8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFOgu7%252FJ&md5=19190642aedb03d40eb530140530ffaf</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01394%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DJ.%2BZ.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DYun%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520benzoazepinequinoline%2520%2528BAQ%2529%2520derivatives%2520as%2520novel%252C%2520potent%252C%2520orally%2520bioavailable%2520respiratory%2520syncytial%2520virus%2520fusion%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D10228%26epage%3D10241%26doi%3D10.1021%2Facs.jmedchem.8b01394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rothschild, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaniel, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringel-Scaia, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, I. C.</span></span> <span> </span><span class="NLM_article-title">Modulating inflammation through the negative regulation of NF-κB signaling</span>. <i>J. Leukocyte Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1131</span>– <span class="NLM_lpage">1150</span>, <span class="refDoi"> DOI: 10.1002/JLB.3MIR0817-346RRR</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2FJLB.3MIR0817-346RRR" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlaltr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2018&pages=1131-1150&author=D.+E.+Rothschildauthor=D.+K.+McDanielauthor=V.+M.+Ringel-Scaiaauthor=I.+C.+Allen&title=Modulating+inflammation+through+the+negative+regulation+of+NF-%CE%BAB+signaling&doi=10.1002%2FJLB.3MIR0817-346RRR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Modulating inflammation through the negative regulation of NF-κB signaling</span></div><div class="casAuthors">Rothschild, Daniel E.; McDaniel, Dylan K.; Ringel-Scaia, Veronica M.; Allen, Irving C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Leukocyte Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1131-1150</span>CODEN:
                <span class="NLM_cas:coden">JLBIE7</span>;
        ISSN:<span class="NLM_cas:issn">1938-3673</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Immune system activation is essential to thwart the invasion of pathogens and respond appropriately to tissue damage.  However, uncontrolled inflammation can result in extensive collateral damage underlying a diverse range of auto-inflammatory, hyper-inflammatory, and neoplastic diseases.  The NF-κB signaling pathway lies at the heart of the immune system and functions as a master regulator of gene transcription.  Thus, this signaling cascade is heavily targeted by mechanisms designed to attenuate overzealous inflammation and promote resoln.  Mechanisms assocd. with the neg. regulation of NF-κB signaling are currently under intense investigation and have yet to be fully elucidated.  Here, we provide an overview of mechanisms that neg. regulate NF-κB signaling through either attenuation of signal transduction, inhibition of posttranscriptional signaling, or interference with posttranslational modifications of key pathway components.  While the regulators discussed for each group are far from comprehensive, they exemplify common mechanistic approaches that inhibit this crit. biochem. signaling cascade.  Despite their diversity, a commonality among these regulators is their selection of specific targets at key inflection points in the pathway, such as TNF-receptor-assocd. factor family members or essential kinases.  A better understanding of these neg. regulatory mechanisms will be essential to gain greater insight related to the maintenance of immune system homeostasis and inflammation resoln.  These processes are vital elements of disease pathol. and have important implications for targeted therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAg41CDsjMGrVg90H21EOLACvtfcHk0lj1HVRk5ZOa-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlaltr7E&md5=a9f54694e4b65078255cfac5b7123781</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1002%2FJLB.3MIR0817-346RRR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252FJLB.3MIR0817-346RRR%26sid%3Dliteratum%253Aachs%26aulast%3DRothschild%26aufirst%3DD.%2BE.%26aulast%3DMcDaniel%26aufirst%3DD.%2BK.%26aulast%3DRingel-Scaia%26aufirst%3DV.%2BM.%26aulast%3DAllen%26aufirst%3DI.%2BC.%26atitle%3DModulating%2520inflammation%2520through%2520the%2520negative%2520regulation%2520of%2520NF-%25CE%25BAB%2520signaling%26jtitle%3DJ.%2520Leukocyte%2520Biol.%26date%3D2018%26volume%3D103%26spage%3D1131%26epage%3D1150%26doi%3D10.1002%2FJLB.3MIR0817-346RRR" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busch-Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muratore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullion, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakdawala, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cousins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Field, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborn, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonchuk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rumsey, W. L.</span></span> <span> </span><span class="NLM_article-title">3,5-Disubstituted-indole-7-carboxamides as IKKbeta inhibitors: Optimization of oral activity via the C3 substituent</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1164</span>– <span class="NLM_lpage">1169</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00291</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00291" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVCisbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1164-1169&author=J.+K.+Kernsauthor=J.+Busch-Petersenauthor=W.+Fuauthor=J.+C.+Boehmauthor=H.+Nieauthor=M.+Muratoreauthor=A.+Bullionauthor=G.+Linauthor=H.+Liauthor=R.+Davisauthor=X.+Linauthor=A.+S.+Lakdawalaauthor=R.+Cousinsauthor=R.+Fieldauthor=J.+Payneauthor=D.+D.+Millerauthor=P.+Bamboroughauthor=J.+A.+Christopherauthor=I.+Baldwinauthor=R.+R.+Osbornauthor=J.+Yonchukauthor=E.+Webbauthor=W.+L.+Rumsey&title=3%2C5-Disubstituted-indole-7-carboxamides+as+IKKbeta+inhibitors%3A+Optimization+of+oral+activity+via+the+C3+substituent&doi=10.1021%2Facsmedchemlett.8b00291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">3,5-Disubstituted-indole-7-carboxamides as IKKβ Inhibitors: Optimization of Oral Activity via the C3 Substituent</span></div><div class="casAuthors">Kerns, Jeffrey K.; Busch-Petersen, Jakob; Fu, Wei; Boehm, Jeffrey C.; Nie, Hong; Muratore, Michael; Bullion, Ann; Lin, Guoliang; Li, Huijie; Davis, Roderick; Lin, Xichen; Lakdawala, Ami S.; Cousins, Rick; Field, Rita; Payne, Jeremy; Miller, David D.; Bamborough, Paul; Christopher, John A.; Baldwin, Ian; Osborn, Ruth R.; Yonchuk, John; Webb, Edward; Rumsey, William L.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1164-1169</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">IκB kinase β (IKKβ or IKK2) is a key regulator of nuclear factor kappa B (NF-κB) and has received attention as a therapeutic target.  Herein the authors report on the optimization of a series of 3,5-disubstituted-indole-7-carboxamides for oral activity.  In doing so, the authors focused attention on potency, ligand efficiency (LE), and physicochem. properties and have identified compds. I and II as having robust in vivo activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHiHQpGSkcarVg90H21EOLACvtfcHk0lj1HVRk5ZOa-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVCisbzF&md5=65b74893bd7ec4766dad7447f9b3dfda</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00291%26sid%3Dliteratum%253Aachs%26aulast%3DKerns%26aufirst%3DJ.%2BK.%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DBoehm%26aufirst%3DJ.%2BC.%26aulast%3DNie%26aufirst%3DH.%26aulast%3DMuratore%26aufirst%3DM.%26aulast%3DBullion%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DLakdawala%26aufirst%3DA.%2BS.%26aulast%3DCousins%26aufirst%3DR.%26aulast%3DField%26aufirst%3DR.%26aulast%3DPayne%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DChristopher%26aufirst%3DJ.%2BA.%26aulast%3DBaldwin%26aufirst%3DI.%26aulast%3DOsborn%26aufirst%3DR.%2BR.%26aulast%3DYonchuk%26aufirst%3DJ.%26aulast%3DWebb%26aufirst%3DE.%26aulast%3DRumsey%26aufirst%3DW.%2BL.%26atitle%3D3%252C5-Disubstituted-indole-7-carboxamides%2520as%2520IKKbeta%2520inhibitors%253A%2520Optimization%2520of%2520oral%2520activity%2520via%2520the%2520C3%2520substituent%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D1164%26epage%3D1169%26doi%3D10.1021%2Facsmedchemlett.8b00291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samatar, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">Targeting RAS-ERK signalling in cancer: promises and challenges</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">928</span>– <span class="NLM_lpage">942</span>, <span class="refDoi"> DOI: 10.1038/nrd4281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2Fnrd4281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=25435214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2lsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=928-942&author=A.+A.+Samatarauthor=P.+I.+Poulikakos&title=Targeting+RAS-ERK+signalling+in+cancer%3A+promises+and+challenges&doi=10.1038%2Fnrd4281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAS-ERK signalling in cancer: promises and challenges</span></div><div class="casAuthors">Samatar, Ahmed A.; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">928-942</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumors, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes.  Recently, the use of compds. targeting components of ERK signalling, such as RAF or MEK inhibitors, has led to substantial improvement in clin. outcome in metastatic melanoma and has shown promising clin. activity in addnl. tumor types.  However, response rates are highly variable and the efficacy of these drugs is primarily limited by the development of resistance.  Both intrinsic and acquired resistance to RAF and MEK inhibitors are frequently assocd. with the persistence of ERK signalling in the presence of the drug, implying the need for more innovative approaches to target the pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL4UeXNUJnYbVg90H21EOLACvtfcHk0lj1HVRk5ZOa-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2lsrrI&md5=ab4038893612f438cf4406680ab2e4f4</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1038%2Fnrd4281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4281%26sid%3Dliteratum%253Aachs%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DTargeting%2520RAS-ERK%2520signalling%2520in%2520cancer%253A%2520promises%2520and%2520challenges%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D928%26epage%3D942%26doi%3D10.1038%2Fnrd4281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morris, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Restaino, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayananth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinunzio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windsor, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angagaw, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinheiro, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipps, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paliwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daublain, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutterbach, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philippar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siliphaivanh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschmeier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicklin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliland, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fawell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samatar, A. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1158%2F2159-8290.CD-13-0070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=23614898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=742-750&author=E.+J.+Morrisauthor=S.+Jhaauthor=C.+R.+Restainoauthor=P.+Dayananthauthor=H.+Zhuauthor=A.+Cooperauthor=D.+Carrauthor=Y.+Dengauthor=W.+Jinauthor=S.+Blackauthor=B.+Longauthor=J.+Liuauthor=E.+Dinunzioauthor=W.+Windsorauthor=R.+Zhangauthor=S.+Zhaoauthor=M.+H.+Angagawauthor=E.+M.+Pinheiroauthor=J.+Desaiauthor=L.+Xiaoauthor=G.+Shippsauthor=A.+Hruzaauthor=J.+Wangauthor=J.+Kellyauthor=S.+Paliwalauthor=X.+Gaoauthor=B.+S.+Babuauthor=L.+Zhuauthor=P.+Daublainauthor=L.+Zhangauthor=B.+A.+Lutterbachauthor=M.+R.+Pelletierauthor=U.+Philipparauthor=P.+Siliphaivanhauthor=D.+Witterauthor=P.+Kirschmeierauthor=W.+R.+Bishopauthor=D.+Hicklinauthor=D.+G.+Gillilandauthor=L.+Jayaramanauthor=L.+Zawelauthor=S.+Fawellauthor=A.+A.+Samatar&title=Discovery+of+a+novel+ERK+inhibitor+with+activity+in+models+of+acquired+resistance+to+BRAF+and+MEK+inhibitors&doi=10.1158%2F2159-8290.CD-13-0070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors</span></div><div class="casAuthors">Morris, Erick J.; Jha, Sharda; Restaino, Clifford R.; Dayananth, Priya; Zhu, Hugh; Cooper, Alan; Carr, Donna; Deng, Yongi; Jin, Weihong; Black, Stuart; Long, Brian; Liu, Jenny; DiNunzio, Edward; Windsor, William; Zhang, Rumin; Zhao, Shuxia; Angagaw, Minilik H.; Pinheiro, Elaine M.; Desai, Jagdish; Xiao, Li; Shipps, Gerald; Hruza, Alan; Wang, James; Kelly, Joe; Paliwal, Sunil; Gao, Xiaolei; Babu, Boga Sobhana; Zhu, Liang; Daublain, Pierre; Zhang, Ling; Lutterbach, Bart A.; Pelletier, Marc R.; Philippar, Ulrike; Siliphaivanh, Phieng; Witter, David; Kirschmeier, Paul; Bishop, W. Robert; Hicklin, Daniel; Gilliland, D. Gary; Jayaraman, Lata; Zawel, Leigh; Fawell, Stephen; Samatar, Ahmed A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">742-750</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The high frequency of activating RAS or BRAF mutations in cancer provides strong rationale for targeting the mitogen-activated protein kinase (MAPK) pathway.  Selective BRAF and MAP-ERK kinase (MEK) inhibitors have shown clin. efficacy in patients with melanoma.  However, the majority of responses are transient, and resistance is often assocd. with pathway reactivation of the extracellular signal-regulated kinase (ERK) signaling pathway.  Here, we describe the identification and characterization of SCH772984, a novel and selective inhibitor of ERK1/2 that displays behaviors of both type I and type II kinase inhibitors.  SCH772984 has nanomolar cellular potency in tumor cells with mutations in BRAF, NRA5, or KRAS and induces tumor regressions in xenograft models at tolerated doses.  Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in BRAF or MEK inhibitor-resistant models as well as in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors.  These data support the clin. development of ERK inhibitors for tumors refractory to MAPK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4HJ4HhYmLL7Vg90H21EOLACvtfcHk0lhVde5_rUpeUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnE&md5=1f26a4a5bb1fab64bdd6c38c16b3f4e3</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0070%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DE.%2BJ.%26aulast%3DJha%26aufirst%3DS.%26aulast%3DRestaino%26aufirst%3DC.%2BR.%26aulast%3DDayananth%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DCooper%26aufirst%3DA.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DW.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDinunzio%26aufirst%3DE.%26aulast%3DWindsor%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DAngagaw%26aufirst%3DM.%2BH.%26aulast%3DPinheiro%26aufirst%3DE.%2BM.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DShipps%26aufirst%3DG.%26aulast%3DHruza%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DBabu%26aufirst%3DB.%2BS.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDaublain%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLutterbach%26aufirst%3DB.%2BA.%26aulast%3DPelletier%26aufirst%3DM.%2BR.%26aulast%3DPhilippar%26aufirst%3DU.%26aulast%3DSiliphaivanh%26aufirst%3DP.%26aulast%3DWitter%26aufirst%3DD.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DBishop%26aufirst%3DW.%2BR.%26aulast%3DHicklin%26aufirst%3DD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DJayaraman%26aufirst%3DL.%26aulast%3DZawel%26aufirst%3DL.%26aulast%3DFawell%26aufirst%3DS.%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520ERK%2520inhibitor%2520with%2520activity%2520in%2520models%2520of%2520acquired%2520resistance%2520to%2520BRAF%2520and%2520MEK%2520inhibitors%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D742%26epage%3D750%26doi%3D10.1158%2F2159-8290.CD-13-0070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boga, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipps, G. W.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doll, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paliwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhassan, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muppalla, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudipati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buevich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dayananth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherborne, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hruza, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschmeier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windsor, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samatar, A. A.</span></span> <span> </span><span class="NLM_article-title">MK-8353: Discovery of an orally bioavailable dual mechanism ERK inhibitor for oncology</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">767</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00220</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00220" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFenur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=761-767&author=S.+B.+Bogaauthor=Y.+Dengauthor=L.+Zhuauthor=Y.+Nanauthor=A.+B.+Cooperauthor=G.+W.+Shippsauthor=R.+Dollauthor=N.+Y.+Shihauthor=H.+Zhuauthor=R.+Sunauthor=T.+Wangauthor=S.+Paliwalauthor=H.+C.+Tsuiauthor=X.+Gaoauthor=X.+Yaoauthor=J.+Desaiauthor=J.+Wangauthor=A.+B.+Alhassanauthor=J.+Kellyauthor=M.+Patelauthor=K.+Muppallaauthor=S.+Gudipatiauthor=L.+K.+Zhangauthor=A.+Buevichauthor=D.+Heskauthor=D.+Carrauthor=P.+Dayananthauthor=S.+Blackauthor=H.+Meiauthor=K.+Coxauthor=B.+Sherborneauthor=A.+W.+Hruzaauthor=L.+Xiaoauthor=W.+Jinauthor=B.+Longauthor=G.+Liuauthor=S.+A.+Taylorauthor=P.+Kirschmeierauthor=W.+T.+Windsorauthor=R.+Bishopauthor=A.+A.+Samatar&title=MK-8353%3A+Discovery+of+an+orally+bioavailable+dual+mechanism+ERK+inhibitor+for+oncology&doi=10.1021%2Facsmedchemlett.8b00220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology</span></div><div class="casAuthors">Boga, Sobhana Babu; Deng, Yongqi; Zhu, Liang; Nan, Yang; Cooper, Alan B.; Shipps, Gerald W.; Doll, Ronald; Shih, Neng-Yang; Zhu, Hugh; Sun, Robert; Wang, Tong; Paliwal, Sunil; Tsui, Hon-Chung; Gao, Xiaolei; Yao, Xin; Desai, Jagdish; Wang, James; Alhassan, Abdul Basit; Kelly, Joseph; Patel, Mehul; Muppalla, Kiran; Gudipati, Subrahmanyam; Zhang, Li-Kang; Buevich, Alexei; Hesk, David; Carr, Donna; Dayananth, Priya; Black, Stuart; Mei, Hong; Cox, Kathleen; Sherborne, Bradley; Hruza, Alan W.; Xiao, Li; Jin, Weihong; Long, Brian; Liu, Gongjie; Taylor, Stacey A.; Kirschmeier, Paul; Windsor, William T.; Bishop, Robert; Samatar, Ahmed A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">761-767</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The emergence and evolution of new immunol. cancer therapies has sparked a rapidly growing interest in discovering novel pathways to treat cancer.  Toward this aim, a novel series of pyrrolidine derivs. were identified as potent inhibitors of ERK1/2 with excellent kinase selectivity and dual mechanism of action but suffered from poor pharmacokinetics (PK).  The challenge of PK was overcome by the discovery of a novel 3(S)-thiomethyl pyrrolidine analog.  Lead optimization through focused SAR led to the discovery of a clin. candidate MK-8353 suitable for twice daily oral dosing as a potential new cancer therapeutic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzQqYMfaHvG7Vg90H21EOLACvtfcHk0lhiy9kN6AGa0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFenur7M&md5=60d002186bc44c1fc6f0eff8658e0163</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00220%26sid%3Dliteratum%253Aachs%26aulast%3DBoga%26aufirst%3DS.%2BB.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DNan%26aufirst%3DY.%26aulast%3DCooper%26aufirst%3DA.%2BB.%26aulast%3DShipps%26aufirst%3DG.%2BW.%26aulast%3DDoll%26aufirst%3DR.%26aulast%3DShih%26aufirst%3DN.%2BY.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DPaliwal%26aufirst%3DS.%26aulast%3DTsui%26aufirst%3DH.%2BC.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DX.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAlhassan%26aufirst%3DA.%2BB.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DMuppalla%26aufirst%3DK.%26aulast%3DGudipati%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%2BK.%26aulast%3DBuevich%26aufirst%3DA.%26aulast%3DHesk%26aufirst%3DD.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DDayananth%26aufirst%3DP.%26aulast%3DBlack%26aufirst%3DS.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DSherborne%26aufirst%3DB.%26aulast%3DHruza%26aufirst%3DA.%2BW.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DJin%26aufirst%3DW.%26aulast%3DLong%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DTaylor%26aufirst%3DS.%2BA.%26aulast%3DKirschmeier%26aufirst%3DP.%26aulast%3DWindsor%26aufirst%3DW.%2BT.%26aulast%3DBishop%26aufirst%3DR.%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26atitle%3DMK-8353%253A%2520Discovery%2520of%2520an%2520orally%2520bioavailable%2520dual%2520mechanism%2520ERK%2520inhibitor%2520for%2520oncology%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D761%26epage%3D767%26doi%3D10.1021%2Facsmedchemlett.8b00220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cee, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavez, F.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastwood, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herberich, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laszlo, J.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipford, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rex, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamayo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winston, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurz, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasker, A. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of (<i>R</i>)-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4- b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4 (3<i>H</i>)-one, a potent and selective Pim-1/2 kinase inhibitor for hematological malignancies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1523</span>– <span class="NLM_lpage">1540</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01733</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01733" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnslSksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1523-1540&author=H.+L.+Wangauthor=K.+L.+Andrewsauthor=S.+K.+Bookerauthor=J.+Canonauthor=V.+J.+Ceeauthor=F.+Chavezauthor=Y.+Chenauthor=H.+Eastwoodauthor=N.+Guerreroauthor=B.+Herberichauthor=D.+Hickmanauthor=B.+A.+Lanmanauthor=J.+Laszloauthor=M.+R.+Leeauthor=J.+R.+Lipfordauthor=B.+Mattsonauthor=C.+Mohrauthor=Y.+Nguyenauthor=M.+H.+Normanauthor=L.+H.+Pettusauthor=D.+Powersauthor=A.+B.+Reedauthor=K.+Rexauthor=C.+Sastriauthor=N.+Tamayoauthor=P.+Wangauthor=J.+T.+Winstonauthor=B.+Wuauthor=Q.+Wuauthor=T.+Wuauthor=R.+P.+Wurzauthor=Y.+Xuauthor=Y.+Zhouauthor=A.+S.+Tasker&title=Discovery+of+%28R%29-8-%286-methyl-4-oxo-1%2C4%2C5%2C6-tetrahydropyrrolo%5B3%2C4-+b%5Dpyrrol-2-yl%29-3-%281-methylcyclopropyl%29-2-%28%281-methylcyclopropyl%29amino%29quinazolin-4+%283H%29-one%2C+a+potent+and+selective+Pim-1%2F2+kinase+inhibitor+for+hematological+malignancies&doi=10.1021%2Facs.jmedchem.8b01733"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (R)-8-(6-methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4-b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3H)-one, a potent and selective Pim-1/2 kinase inhibitor for hematological malignancies</span></div><div class="casAuthors">Wang, Hui-Ling; Andrews, Kristin L.; Booker, Shon K.; Canon, Jude; Cee, Victor J.; Chavez, Frank, Jr.; Chen, Yuping; Eastwood, Heather; Guerrero, Nadia; Herberich, Brad; Hickman, Dean; Lanman, Brian A.; Laszlo, Jimmy, III; Lee, Matthew R.; Lipford, J. Russell; Mattson, Bethany; Mohr, Christopher; Nguyen, Yen; Norman, Mark H.; Pettus, Liping H.; Powers, David; Reed, Anthony B.; Rex, Karen; Sastri, Christine; Tamayo, Nuria; Wang, Paul; Winston, Jeffrey T.; Wu, Bin; Wu, Qiong; Wu, Tian; Wurz, Ryan P.; Xu, Yang; Zhou, Yihong; Tasker, Andrew S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1523-1540</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pim kinases are a family of constitutively active serine/threonine kinases that are partially redundant and regulate multiple pathways important for cell growth and survival.  In human disease, high expression of the three Pim isoforms has been implicated in the progression of hematopoietic and solid tumor cancers, which suggests that Pim kinase inhibitors could provide patients with therapeutic benefit.  Herein, we describe the structure-guided optimization of a series of quinazolinone-pyrrolodihydropyrrolone analogs leading to the identification of potent pan-Pim inhibitor I with improved potency, soly., and drug-like properties.  I demonstrated on-target Pim activity in an in vivo pharmacodynamic assay with significant inhibition of BAD phosphorylation in KMS-12-BM multiple myeloma tumors for 16 h postdose.  In a 2-wk mouse xenograft model, daily dosing of I resulted in 33% tumor regression at 100 mg/kg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz60Rl1mRubrVg90H21EOLACvtfcHk0lhiy9kN6AGa0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnslSksw%253D%253D&md5=a7d7dbe1f106b6f5cf8c81bb5660cb3f</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01733%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%2BL.%26aulast%3DAndrews%26aufirst%3DK.%2BL.%26aulast%3DBooker%26aufirst%3DS.%2BK.%26aulast%3DCanon%26aufirst%3DJ.%26aulast%3DCee%26aufirst%3DV.%2BJ.%26aulast%3DChavez%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DEastwood%26aufirst%3DH.%26aulast%3DGuerrero%26aufirst%3DN.%26aulast%3DHerberich%26aufirst%3DB.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DLanman%26aufirst%3DB.%2BA.%26aulast%3DLaszlo%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DLipford%26aufirst%3DJ.%2BR.%26aulast%3DMattson%26aufirst%3DB.%26aulast%3DMohr%26aufirst%3DC.%26aulast%3DNguyen%26aufirst%3DY.%26aulast%3DNorman%26aufirst%3DM.%2BH.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DPowers%26aufirst%3DD.%26aulast%3DReed%26aufirst%3DA.%2BB.%26aulast%3DRex%26aufirst%3DK.%26aulast%3DSastri%26aufirst%3DC.%26aulast%3DTamayo%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWinston%26aufirst%3DJ.%2BT.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DWurz%26aufirst%3DR.%2BP.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26atitle%3DDiscovery%2520of%2520%2528R%2529-8-%25286-methyl-4-oxo-1%252C4%252C5%252C6-tetrahydropyrrolo%255B3%252C4-%2520b%255Dpyrrol-2-yl%2529-3-%25281-methylcyclopropyl%2529-2-%2528%25281-methylcyclopropyl%2529amino%2529quinazolin-4%2520%25283H%2529-one%252C%2520a%2520potent%2520and%2520selective%2520Pim-1%252F2%2520kinase%2520inhibitor%2520for%2520hematological%2520malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1523%26epage%3D1540%26doi%3D10.1021%2Facs.jmedchem.8b01733" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Penning, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinghofer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donawho, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bontcheva-Diaz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouska, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osterling, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giranda, V. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(<i>R</i>)-2-methylpyrrolidin-2-yl]-1<i>H</i>-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">514</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.1021/jm801171j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801171j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFals7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=514-523&author=T.+D.+Penningauthor=G.+D.+Zhuauthor=V.+B.+Gandhiauthor=J.+Gongauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=C.+K.+Donawhoauthor=D.+J.+Frostauthor=V.+Bontcheva-Diazauthor=J.+J.+Bouskaauthor=D.+J.+Osterlingauthor=A.+M.+Olsonauthor=K.+C.+Marshauthor=Y.+Luoauthor=V.+L.+Giranda&title=Discovery+of+the+poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+2-%5B%28R%29-2-methylpyrrolidin-2-yl%5D-1H-benzimidazole-4-carboxamide+%28ABT-888%29+for+the+treatment+of+cancer&doi=10.1021%2Fjm801171j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer</span></div><div class="casAuthors">Penning, Thomas D.; Zhu, Gui-Dong; Gandhi, Viraj B.; Gong, Jianchun; Liu, Xuesong; Shi, Yan; Klinghofer, Vered; Johnson, Eric F.; Donawho, Cherrie K.; Frost, David J.; Bontcheva-Diaz, Velitchka; Bouska, Jennifer J.; Osterling, Donald J.; Olson, Amanda M.; Marsh, Kennan C.; Luo, Yan; Giranda, Vincent L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">514-523</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of cyclic amine-contg. benzimidazole carboxamide PARP inhibitors with a methyl-substituted quaternary center at the point of attachment to the benzimidazole ring system has been developed.  These compds. exhibit excellent PARP enzyme potency as well as single-digit nanomolar cellular potency.  These efforts led to the identification of (I)·2HCl (2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, ABT-888), currently in human phase I clin. trials.  Compd. I·2HCl displayed excellent potency against both the PARP-1 and PARP-2 enzymes with a Ki of 5 nM and in a C41 whole cell assay with an EC50 of 2 nM.  In addn., I·2HCl is aq. sol., orally bioavailable across multiple species, and demonstrated good in vivo efficacy in a B16F10 s.c. murine melanoma model in combination with temozolomide (TMZ) and in an MX-1 breast cancer xenograft model in combination with either carboplatin or cyclophosphamide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaBVnNi7EZcbVg90H21EOLACvtfcHk0lgTIfWqtYd8Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFals7bL&md5=283eddd2e8220740c48865e4e8269a95</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Fjm801171j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801171j%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DDiscovery%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%25202-%255B%2528R%2529-2-methylpyrrolidin-2-yl%255D-1H-benzimidazole-4-carboxamide%2520%2528ABT-888%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D514%26epage%3D523%26doi%3D10.1021%2Fjm801171j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munck
Af Rosenschold, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johannesson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikitidis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrchan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikitidis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glader, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kack, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonn, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagberg, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorkstrand, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swedin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreasson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergstrom, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundqvist, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, A. M.</span></span> <span> </span><span class="NLM_article-title">Discovery of the oral leukotriene C4 synthase inhibitor (1S,2S)-2-({5-[(5-chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic acid (AZD9898) as a new treatment for asthma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7769</span>– <span class="NLM_lpage">7787</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00555</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00555" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A280%3ADC%252BB3Mvot1ehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7769-7787&author=M.+Munck%0AAf+Rosenscholdauthor=P.+Johannessonauthor=A.+Nikitidisauthor=C.+Tyrchanauthor=H.+F.+Changauthor=R.+Ronnauthor=D.+Chapmanauthor=V.+Ullahauthor=G.+Nikitidisauthor=P.+Gladerauthor=H.+Kackauthor=B.+Bonnauthor=F.+Wagbergauthor=E.+Bjorkstrandauthor=U.+Anderssonauthor=L.+Swedinauthor=M.+Rohmanauthor=T.+Andreassonauthor=E.+L.+Bergstromauthor=F.+Jiangauthor=X.+H.+Zhouauthor=A.+J.+Lundqvistauthor=A.+Malmbergauthor=M.+Ekauthor=E.+Gordonauthor=A.+Pettersenauthor=L.+Ripaauthor=A.+M.+Davis&title=Discovery+of+the+oral+leukotriene+C4+synthase+inhibitor+%281S%2C2S%29-2-%28%7B5-%5B%285-chloro-2%2C4-difluorophenyl%29%282-fluoro-2-methylpropyl%29amino%5D-3-methoxypyrazin-2-yl%7Dcarbonyl%29cyclopropanecarboxylic+acid+%28AZD9898%29+as+a+new+treatment+for+asthma&doi=10.1021%2Facs.jmedchem.9b00555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic Acid (AZD9898) as a New Treatment for Asthma</span></div><div class="casAuthors">Munck Af Rosenschold Magnus; Johannesson Petra; Nikitidis Antonios; Tyrchan Christian; Chang Hui-Fang; Chapman Dave; Ullah Victoria; Nikitidis Grigorios; Glader Pernilla; Kack Helena; Bonn Britta; Wagberg Fredrik; Andersson Ulf; Swedin Linda; Rohman Mattias; Andreasson Theresa; Bergstrom Eva Lamm; Jiang Fanyi; Zhou Xiao-Hong; Lundqvist Anders J; Malmberg Anna; Ek Margareta; Gordon Euan; Pettersen Anna; Ripa Lena; Davis Andrew M; Ronn Robert; Bjorkstrand Eva</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7769-7787</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">While bronchodilators and inhaled corticosteroids are the mainstay of asthma treatment, up to 50% of asthmatics remain uncontrolled.  Many studies show that the cysteinyl leukotriene cascade remains highly activated in some asthmatics, even those on high-dose inhaled or oral corticosteroids.  Hence, inhibition of the leukotriene C4 synthase (LTC4S) enzyme could provide a new and differentiated core treatment for patients with a highly activated cysteinyl leukotriene cascade.  Starting from a screening hit (3), a program to discover oral inhibitors of LTC4S led to (1S,2S)-2-({5-[(5-chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic acid (AZD9898) (36), a picomolar LTC4S inhibitor (IC50 = 0.28 nM) with high lipophilic ligand efficiency (LLE = 8.5), which displays nanomolar potency in cells (peripheral blood mononuclear cell, IC50,free = 6.2 nM) and good in vivo pharmacodynamics in a calcium ionophore-stimulated rat model after oral dosing (in vivo, IC50,free = 34 nM).  Compound 36 mitigates the GABA binding, hepatic toxicity signal, and in vivo toxicology findings of an early lead compound 7 with a human dose predicted to be 30 mg once daily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQUEHXJSfcFdwwxfk_AGB-EfW6udTcc2eZFWliW_2739bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mvot1ehug%253D%253D&md5=cb13c3632bd4d56be5dd6acdc3638f8f</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00555%26sid%3Dliteratum%253Aachs%26aulast%3DMunck%2BAf%2BRosenschold%26aufirst%3DM.%26aulast%3DJohannesson%26aufirst%3DP.%26aulast%3DNikitidis%26aufirst%3DA.%26aulast%3DTyrchan%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DH.%2BF.%26aulast%3DRonn%26aufirst%3DR.%26aulast%3DChapman%26aufirst%3DD.%26aulast%3DUllah%26aufirst%3DV.%26aulast%3DNikitidis%26aufirst%3DG.%26aulast%3DGlader%26aufirst%3DP.%26aulast%3DKack%26aufirst%3DH.%26aulast%3DBonn%26aufirst%3DB.%26aulast%3DWagberg%26aufirst%3DF.%26aulast%3DBjorkstrand%26aufirst%3DE.%26aulast%3DAndersson%26aufirst%3DU.%26aulast%3DSwedin%26aufirst%3DL.%26aulast%3DRohman%26aufirst%3DM.%26aulast%3DAndreasson%26aufirst%3DT.%26aulast%3DBergstrom%26aufirst%3DE.%2BL.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DZhou%26aufirst%3DX.%2BH.%26aulast%3DLundqvist%26aufirst%3DA.%2BJ.%26aulast%3DMalmberg%26aufirst%3DA.%26aulast%3DEk%26aufirst%3DM.%26aulast%3DGordon%26aufirst%3DE.%26aulast%3DPettersen%26aufirst%3DA.%26aulast%3DRipa%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DA.%2BM.%26atitle%3DDiscovery%2520of%2520the%2520oral%2520leukotriene%2520C4%2520synthase%2520inhibitor%2520%25281S%252C2S%2529-2-%2528%257B5-%255B%25285-chloro-2%252C4-difluorophenyl%2529%25282-fluoro-2-methylpropyl%2529amino%255D-3-methoxypyrazin-2-yl%257Dcarbonyl%2529cyclopropanecarboxylic%2520acid%2520%2528AZD9898%2529%2520as%2520a%2520new%2520treatment%2520for%2520asthma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7769%26epage%3D7787%26doi%3D10.1021%2Facs.jmedchem.9b00555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5822</span>– <span class="NLM_lpage">5880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5822-5880&author=N.+A.+Meanwell&title=Fluorine+and+fluorinated+motifs+in+the+design+and+application+of+bioisosteres+for+drug+design&doi=10.1021%2Facs.jmedchem.7b01788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5822-5880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The electronic properties and relatively small size of fluorine endow it with considerable versatility as a bioisostere and it has found application as a substitute for lone pairs of electrons, the hydrogen atom, and the Me group while also acting as a functional mimetic of the carbonyl, carbinol, andnitrile moieties.  In this context, fluorine substitution can influence the potency, conformation, metab., membrane permeability, and P-gp recognition of a mol. and temper inhibition of the hERG channel by basic amines.  However, as a consequence of the unique properties of fluorine, it features prominently in the design of higher order structural metaphors that are more esoteric in their conception and which reflect a more sophisticated mol. construction that broadens biol. mimesis.  In this Perspective, applications of fluorine in the construction of bioisosteric elements designed to enhance the in vitro and in vivo properties of a mol. are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoQvY950L3LVg90H21EOLACvtfcHk0lgTIfWqtYd8Jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D&md5=2d0ce3326c7ff932da8d7d26972ced14</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01788%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DFluorine%2520and%2520fluorinated%2520motifs%2520in%2520the%2520design%2520and%2520application%2520of%2520bioisosteres%2520for%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5822%26epage%3D5880%26doi%3D10.1021%2Facs.jmedchem.7b01788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinkerton, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peddibhotla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slosky, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hershberger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falter, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardecky, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, T. D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caron, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barak, L. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of beta-arrestin biased, orally bioavailable, and CNS penetrant neurotensin receptor 1 (NTR1) allosteric modulators</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8357</span>– <span class="NLM_lpage">8363</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00340</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00340" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFemtLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8357-8363&author=A.+B.+Pinkertonauthor=S.+Peddibhotlaauthor=F.+Yamamotoauthor=L.+M.+Sloskyauthor=Y.+Baiauthor=P.+Maloneyauthor=P.+Hershbergerauthor=M.+P.+Hedrickauthor=B.+Falterauthor=R.+J.+Ardeckyauthor=L.+H.+Smithauthor=T.+D.+Y.+Chungauthor=M.+R.+Jacksonauthor=M.+G.+Caronauthor=L.+S.+Barak&title=Discovery+of+beta-arrestin+biased%2C+orally+bioavailable%2C+and+CNS+penetrant+neurotensin+receptor+1+%28NTR1%29+allosteric+modulators&doi=10.1021%2Facs.jmedchem.9b00340"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators</span></div><div class="casAuthors">Pinkerton, Anthony B.; Peddibhotla, Satyamaheshwar; Yamamoto, Fusayo; Slosky, Lauren M.; Bai, Yushi; Maloney, Patrick; Hershberger, Paul; Hedrick, Michael P.; Falter, Bekhi; Ardecky, Robert J.; Smith, Layton H.; Chung, Thomas D. Y.; Jackson, Michael R.; Caron, Marc G.; Barak, Lawrence S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8357-8363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Neurotensin receptor 1 (NTR1) is a G protein coupled receptor that is widely expressed throughout the central nervous system where it acts as a neuromodulator.  Neurotensin receptors have been implicated in a wide variety of CNS disorders but despite extensive efforts to develop small mol. ligands there are few reports of such compds.  Herein we describe the optimization of a quinazoline based lead to give 18 (SBI-553(I)), a potent and brain penetrant NTR1 allosteric modulator.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomN2_a2gmsHLVg90H21EOLACvtfcHk0lhu1J2K_0nlAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFemtLfM&md5=aa466e6b4be397a8712d3b5ecf28457b</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00340%26sid%3Dliteratum%253Aachs%26aulast%3DPinkerton%26aufirst%3DA.%2BB.%26aulast%3DPeddibhotla%26aufirst%3DS.%26aulast%3DYamamoto%26aufirst%3DF.%26aulast%3DSlosky%26aufirst%3DL.%2BM.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DMaloney%26aufirst%3DP.%26aulast%3DHershberger%26aufirst%3DP.%26aulast%3DHedrick%26aufirst%3DM.%2BP.%26aulast%3DFalter%26aufirst%3DB.%26aulast%3DArdecky%26aufirst%3DR.%2BJ.%26aulast%3DSmith%26aufirst%3DL.%2BH.%26aulast%3DChung%26aufirst%3DT.%2BD.%2BY.%26aulast%3DJackson%26aufirst%3DM.%2BR.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DBarak%26aufirst%3DL.%2BS.%26atitle%3DDiscovery%2520of%2520beta-arrestin%2520biased%252C%2520orally%2520bioavailable%252C%2520and%2520CNS%2520penetrant%2520neurotensin%2520receptor%25201%2520%2528NTR1%2529%2520allosteric%2520modulators%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8357%26epage%3D8363%26doi%3D10.1021%2Facs.jmedchem.9b00340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">La, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez
Botella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazdoba, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quirk, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A. J.</span></span> <span> </span><span class="NLM_article-title">Neuroactive steroid N-methyl-D-aspartate receptor positive allosteric modulators: Synthesis, SAR, and pharmacological activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7526</span>– <span class="NLM_lpage">7542</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00591</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00591" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFemtL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7526-7542&author=D.+S.+Laauthor=F.+G.+Salituroauthor=G.+Martinez%0ABotellaauthor=A.+M.+Griffinauthor=Z.+Baiauthor=M.+A.+Ackleyauthor=J.+Daiauthor=J.+J.+Dohertyauthor=B.+L.+Harrisonauthor=E.+C.+Hoffmannauthor=T.+M.+Kazdobaauthor=M.+C.+Lewisauthor=M.+C.+Quirkauthor=A.+J.+Robichaud&title=Neuroactive+steroid+N-methyl-D-aspartate+receptor+positive+allosteric+modulators%3A+Synthesis%2C+SAR%2C+and+pharmacological+activity&doi=10.1021%2Facs.jmedchem.9b00591"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroactive Steroid N-Methyl-D-aspartate Receptor Positive Allosteric Modulators: Synthesis, SAR, and Pharmacological Activity</span></div><div class="casAuthors">La, Daniel S.; Salituro, Francesco G.; Martinez Botella, Gabriel; Griffin, Andrew M.; Bai, Zhu; Ackley, Michael A.; Dai, Jing; Doherty, James J.; Harrison, Boyd L.; Hoffmann, Ethan C.; Kazdoba, Tatiana M.; Lewis, Michael C.; Quirk, Michael C.; Robichaud, Albert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7526-7542</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Neuroactive steroids (NASs) play a pivotal role in maintaining homeostasis is the CNS.  We have discovered that one NAS in particular, 24(S)-hydroxycholesterol (I, 24(S)-HC), is a pos. allosteric modulator (PAM) of NMDA receptors.  Using 24(S)-HC as a chem. starting point, we have identified other NASs that have good in vitro potency and efficacy.  Herein, we describe the structure activity relationship and pharmacokinetic optimization of this series that ultimately led to II (SGE-301).  We demonstrate that SGE-301 enhances long-term potentiation (LTP) in rat hippocampal slices and, in a dose-dependent manner, improves cognition in a rat social recognition study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbfB83uVi2QbVg90H21EOLACvtfcHk0lhu1J2K_0nlAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFemtL3E&md5=a5e35b2c292c746cc9e2d9b0014bcdcc</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00591%26sid%3Dliteratum%253Aachs%26aulast%3DLa%26aufirst%3DD.%2BS.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DMartinez%2BBotella%26aufirst%3DG.%26aulast%3DGriffin%26aufirst%3DA.%2BM.%26aulast%3DBai%26aufirst%3DZ.%26aulast%3DAckley%26aufirst%3DM.%2BA.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DDoherty%26aufirst%3DJ.%2BJ.%26aulast%3DHarrison%26aufirst%3DB.%2BL.%26aulast%3DHoffmann%26aufirst%3DE.%2BC.%26aulast%3DKazdoba%26aufirst%3DT.%2BM.%26aulast%3DLewis%26aufirst%3DM.%2BC.%26aulast%3DQuirk%26aufirst%3DM.%2BC.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26atitle%3DNeuroactive%2520steroid%2520N-methyl-D-aspartate%2520receptor%2520positive%2520allosteric%2520modulators%253A%2520Synthesis%252C%2520SAR%252C%2520and%2520pharmacological%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7526%26epage%3D7542%26doi%3D10.1021%2Facs.jmedchem.9b00591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burks, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekete, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubicka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peukert, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of an acrylic acid based tetrahydroisoquinoline as an orally bioavailable selective estrogen receptor degrader for ERalpha+ breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2790</span>– <span class="NLM_lpage">2818</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01468</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01468" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1WktLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2790-2818&author=H.+E.+Burksauthor=T.+Abramsauthor=C.+A.+Kirbyauthor=J.+Bairdauthor=A.+Feketeauthor=L.+G.+Hamannauthor=S.+Kimauthor=F.+Lombardoauthor=A.+Looauthor=D.+Lubickaauthor=K.+Macchiauthor=D.+P.+McDonnellauthor=Y.+Mishinaauthor=J.+D.+Norrisauthor=J.+Nunezauthor=C.+Saranauthor=Y.+Sunauthor=N.+M.+Thomsenauthor=C.+Wangauthor=J.+Wangauthor=S.+Peukert&title=Discovery+of+an+acrylic+acid+based+tetrahydroisoquinoline+as+an+orally+bioavailable+selective+estrogen+receptor+degrader+for+ERalpha%2B+breast+cancer&doi=10.1021%2Facs.jmedchem.6b01468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer</span></div><div class="casAuthors">Burks, Heather E.; Abrams, Tinya; Kirby, Christina A.; Baird, Jason; Fekete, Alexander; Hamann, Lawrence G.; Kim, Sunkyu; Lombardo, Franco; Loo, Alice; Lubicka, Danuta; Macchi, Kaitlin; McDonnell, Donald P.; Mishina, Yuji; Norris, John D.; Nunez, Jill; Saran, Chitra; Sun, Yingchuan; Thomsen, Noel M.; Wang, Chunrong; Wang, Jianling; Peukert, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2790-2818</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tetrahydroisoquinoline 40 has been identified as a potent ERα antagonist and selective estrogen receptor degrader (SERD), exhibiting good oral bioavailability, antitumor efficacy, and SERD activity in vivo.  We outline the discovery and chem. optimization of the THIQ scaffold leading to THIQ 40 and showcase the racemization of the scaffold, pharmacokinetic studies in preclin. species, and the in vivo efficacy of THIQ 40 in a MCF-7 human breast cancer xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6N78pDzgcpLVg90H21EOLACvtfcHk0lhPfsy1veulVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1WktLc%253D&md5=51ce5c93fb6dcaebb3e81fbb3ca67657</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01468%26sid%3Dliteratum%253Aachs%26aulast%3DBurks%26aufirst%3DH.%2BE.%26aulast%3DAbrams%26aufirst%3DT.%26aulast%3DKirby%26aufirst%3DC.%2BA.%26aulast%3DBaird%26aufirst%3DJ.%26aulast%3DFekete%26aufirst%3DA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DLubicka%26aufirst%3DD.%26aulast%3DMacchi%26aufirst%3DK.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DMishina%26aufirst%3DY.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DNunez%26aufirst%3DJ.%26aulast%3DSaran%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DThomsen%26aufirst%3DN.%2BM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPeukert%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520an%2520acrylic%2520acid%2520based%2520tetrahydroisoquinoline%2520as%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520for%2520ERalpha%252B%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2790%26epage%3D2818%26doi%3D10.1021%2Facs.jmedchem.6b01468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degorce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFaul, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingell, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabow, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. D.</span></span> <span> </span><span class="NLM_article-title">Tetrahydroisoquinoline phenols: Selective estrogen receptor downregulator antagonists with oral bioavailability in rat</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00413</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00413" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGku7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=94-99&author=J.+S.+Scottauthor=A.+Baileyauthor=R.+D.+Daviesauthor=S.+L.+Degorceauthor=P.+A.+MacFaulauthor=H.+Gingellauthor=T.+Mossauthor=R.+A.+Normanauthor=J.+H.+Pinkauthor=A.+A.+Rabowauthor=B.+Robertsauthor=P.+D.+Smith&title=Tetrahydroisoquinoline+phenols%3A+Selective+estrogen+receptor+downregulator+antagonists+with+oral+bioavailability+in+rat&doi=10.1021%2Facsmedchemlett.5b00413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat</span></div><div class="casAuthors">Scott, James S.; Bailey, Andrew; Davies, Robert D. M.; Degorce, Sebastien L.; MacFaul, Philip A.; Gingell, Helen; Moss, Thomas; Norman, Richard A.; Pink, Jennifer H.; Rabow, Alfred A.; Roberts, Bryan; Smith, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-99</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of tetrahydroisoquinoline phenols was modified to give an estrogen receptor downregulator-antagonist profile.  Optimization around the core, alkyl side chain, and pendant aryl ring resulted in compds. I [R = Ph, PhCH2, i-Bu, etc.] with subnanomolar levels of potency.  The phenol functionality was shown to be required to achieve highly potent compds., but unusually this was compatible with obtaining high oral bioavailabilities in rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXOiEPK5ofVLVg90H21EOLACvtfcHk0lhPfsy1veulVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGku7bK&md5=8c573b4e96e70cf61d40f349a7c19967</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00413%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBailey%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DR.%2BD.%26aulast%3DDegorce%26aufirst%3DS.%2BL.%26aulast%3DMacFaul%26aufirst%3DP.%2BA.%26aulast%3DGingell%26aufirst%3DH.%26aulast%3DMoss%26aufirst%3DT.%26aulast%3DNorman%26aufirst%3DR.%2BA.%26aulast%3DPink%26aufirst%3DJ.%2BH.%26aulast%3DRabow%26aufirst%3DA.%2BA.%26aulast%3DRoberts%26aufirst%3DB.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26atitle%3DTetrahydroisoquinoline%2520phenols%253A%2520Selective%2520estrogen%2520receptor%2520downregulator%2520antagonists%2520with%2520oral%2520bioavailability%2520in%2520rat%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D94%26epage%3D99%26doi%3D10.1021%2Facsmedchemlett.5b00413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbajo, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polanski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nissink, J. W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varnes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span> <span> </span><span class="NLM_article-title">Building bridges in a series of estrogen receptor degraders: An application of metathesis in medicinal chemistry</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1492</span>– <span class="NLM_lpage">1497</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00370</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00370" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVentr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1492-1497&author=J.+S.+Scottauthor=J.+Breedauthor=R.+J.+Carbajoauthor=P.+R.+Daveyauthor=R.+Greenwoodauthor=H.+K.+Huynhauthor=T.+Klinowskaauthor=C.+J.+Morrowauthor=T.+A.+Mossauthor=R.+Polanskiauthor=J.+W.+M.+Nissinkauthor=J.+Varnesauthor=B.+Yang&title=Building+bridges+in+a+series+of+estrogen+receptor+degraders%3A+An+application+of+metathesis+in+medicinal+chemistry&doi=10.1021%2Facsmedchemlett.9b00370"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry</span></div><div class="casAuthors">Scott, James S.; Breed, Jason; Carbajo, Rodrigo J.; Davey, Paul R.; Greenwood, Ryan; Huynh, Hoan K.; Klinowska, Teresa; Morrow, Christopher J.; Moss, Thomas A.; Polanski, Radoslaw; Nissink, J. Willem M.; Varnes, Jeffrey; Yang, Bin</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1492-1497</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Herein the authors report the use of metathesis to construct a novel tetracyclic core in a series of estrogen receptor degraders.  This improved the chem. stability, as assessed using an NMR-MS based assay, and gave a mol. with excellent physicochem. properties and pharmacokinetics in rat.  X-ray crystallog. established minimal perturbation of the bridged compds. relative to the unbridged analogs in the receptor binding pocket.  Unfortunately, despite retaining excellent binding to ERα, this adversely affected the ability of the compds. to degrade the receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEcZlsyjk417Vg90H21EOLACvtfcHk0lhPfsy1veulVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVentr3E&md5=76a10d7bedd883966fb7106ccf08a0f0</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00370%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BS.%26aulast%3DBreed%26aufirst%3DJ.%26aulast%3DCarbajo%26aufirst%3DR.%2BJ.%26aulast%3DDavey%26aufirst%3DP.%2BR.%26aulast%3DGreenwood%26aufirst%3DR.%26aulast%3DHuynh%26aufirst%3DH.%2BK.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DMorrow%26aufirst%3DC.%2BJ.%26aulast%3DMoss%26aufirst%3DT.%2BA.%26aulast%3DPolanski%26aufirst%3DR.%26aulast%3DNissink%26aufirst%3DJ.%2BW.%2BM.%26aulast%3DVarnes%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DB.%26atitle%3DBuilding%2520bridges%2520in%2520a%2520series%2520of%2520estrogen%2520receptor%2520degraders%253A%2520An%2520application%2520of%2520metathesis%2520in%2520medicinal%2520chemistry%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1492%26epage%3D1497%26doi%3D10.1021%2Facsmedchemlett.9b00370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaPorte, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bulfer, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alverez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkin, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wipf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huryn, D. M.</span></span> <span> </span><span class="NLM_article-title">Optimization of phenyl indole inhibitors of the AAA+ ATPase p97</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1075</span>– <span class="NLM_lpage">1081</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00372</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00372" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslaqsbnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1075-1081&author=M.+G.+LaPorteauthor=J.+C.+Burnettauthor=R.+Colomboauthor=S.+L.+Bulferauthor=C.+Alverezauthor=T.+F.+Chouauthor=R.+J.+Neitzauthor=N.+Greenauthor=W.+J.+Mooreauthor=Z.+Yueauthor=S.+Liauthor=M.+R.+Arkinauthor=P.+Wipfauthor=D.+M.+Huryn&title=Optimization+of+phenyl+indole+inhibitors+of+the+AAA%2B+ATPase+p97&doi=10.1021%2Facsmedchemlett.8b00372"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Phenyl Indole Inhibitors of the AAA+ ATPase p97</span></div><div class="casAuthors">LaPorte, Matthew G.; Burnett, James C.; Colombo, Raffaele; Bulfer, Stacie L.; Alverez, Celeste; Chou, Tsui-Fen; Neitz, R. Jeffrey; Green, Neal; Moore, William J.; Yue, Zhizhou; Li, Shan; Arkin, Michelle R.; Wipf, Peter; Huryn, Donna M.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1075-1081</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Starting from a hit identified from a high-throughput screening campaign for inhibitors of the AAA+ ATPase p97, optimization of the side-chain of Ph indole scaffold, in particular the addn. of an N-alkyl piperazine, led to high potency of this series in a biochem. assay, activity in cell-based assays, and excellent pharmaceutical properties.  Mol. modeling based on a subsequently obtained cryo-EM structure of p97 in complex with a Ph indole was used to rationalize the potency of these allosteric inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroJA4x7rXttLVg90H21EOLACvtfcHk0liAAWuST5hc0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslaqsbnL&md5=e43c1732377a21bdc6f7253d1834f4c2</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00372%26sid%3Dliteratum%253Aachs%26aulast%3DLaPorte%26aufirst%3DM.%2BG.%26aulast%3DBurnett%26aufirst%3DJ.%2BC.%26aulast%3DColombo%26aufirst%3DR.%26aulast%3DBulfer%26aufirst%3DS.%2BL.%26aulast%3DAlverez%26aufirst%3DC.%26aulast%3DChou%26aufirst%3DT.%2BF.%26aulast%3DNeitz%26aufirst%3DR.%2BJ.%26aulast%3DGreen%26aufirst%3DN.%26aulast%3DMoore%26aufirst%3DW.%2BJ.%26aulast%3DYue%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DArkin%26aufirst%3DM.%2BR.%26aulast%3DWipf%26aufirst%3DP.%26aulast%3DHuryn%26aufirst%3DD.%2BM.%26atitle%3DOptimization%2520of%2520phenyl%2520indole%2520inhibitors%2520of%2520the%2520AAA%252B%2520ATPase%2520p97%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D1075%26epage%3D1081%26doi%3D10.1021%2Facsmedchemlett.8b00372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozaki, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muramatsu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizumi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichikawa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuji, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inazawa, J.</span></span> <span> </span><span class="NLM_article-title">Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1139</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1093/carcin/bgp116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1093%2Fcarcin%2Fbgp116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=19423649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXot1CisLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=1139-1146&author=S.+Komatsuauthor=I.+Imotoauthor=H.+Tsudaauthor=K.+I.+Kozakiauthor=T.+Muramatsuauthor=Y.+Shimadaauthor=S.+Aikoauthor=Y.+Yoshizumiauthor=D.+Ichikawaauthor=E.+Otsujiauthor=J.+Inazawa&title=Overexpression+of+SMYD2+relates+to+tumor+cell+proliferation+and+malignant+outcome+of+esophageal+squamous+cell+carcinoma&doi=10.1093%2Fcarcin%2Fbgp116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma</span></div><div class="casAuthors">Komatsu, Shuhei; Imoto, Issei; Tsuda, Hitoshi; Kozaki, Ken-ich; Muramatsu, Tomoki; Shimada, Yutaka; Aiko, Satoshi; Yoshizumi, Yutaka; Ichikawa, Daisuke; Otsuji, Eigo; Inazawa, Johji</div><div class="citationInfo"><span class="NLM_cas:title">Carcinogenesis</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1139-1146</span>CODEN:
                <span class="NLM_cas:coden">CRNGDP</span>;
        ISSN:<span class="NLM_cas:issn">0143-3334</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Although we have identified two putative targets, ATF3 and CENPF, for a frequently gained/amplified region around 1q32-q41 in esophageal squamous cell carcinoma (ESCC), it is possible that other amplification targets remain to be identified.  In this study, we tested whether SET and MYND domain-contg. protein 2 (SMYD2), located between those two genes and encoding a lysine methyltransferase for histone H3K36 and p53K370 that regulates transcription and inhibits transactivation activity, resp., acts as a cancer-promoting gene through activation/overexpression in ESCC.  Frequent overexpression of SMYD2 mRNA and protein was obsd. in KYSE150 cells with remarkable amplification at 1q32-41.1 and other ESCC cell lines (11/43 lines, 25.6%).  Overexpression of SMYD2 protein was frequently detected in primary tumor samples of ESCC (117/153 cases, 76.5%) as well and significantly correlated with gender, venous invasion, the pT category in the tumor-lymph node-metastases classification and status of recurrence.  Patients with SMYD2-overexpressing tumors had a worse overall rate of survival than those with non-expressing tumors, and SMYD2 positivity was independently assocd. with a worse outcome in the multivariate anal.  Knockdown of SMYD2 expression inhibited and ectopic overexpression of SMYD2 promoted the proliferation of ESCC cells in a TP53 mutation-independent but SMYD2 expression-dependent manner.  These findings suggest that SMYD2 plays an important role in tumor cell proliferation through its activation/overexpression and highlight its usefulness as a prognosticator and potential therapeutic target in ESCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGuuMnL7IjzbVg90H21EOLACvtfcHk0liAAWuST5hc0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXot1CisLs%253D&md5=7eb396b256c9ec2b182fd999796527b5</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgp116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgp116%26sid%3Dliteratum%253Aachs%26aulast%3DKomatsu%26aufirst%3DS.%26aulast%3DImoto%26aufirst%3DI.%26aulast%3DTsuda%26aufirst%3DH.%26aulast%3DKozaki%26aufirst%3DK.%2BI.%26aulast%3DMuramatsu%26aufirst%3DT.%26aulast%3DShimada%26aufirst%3DY.%26aulast%3DAiko%26aufirst%3DS.%26aulast%3DYoshizumi%26aufirst%3DY.%26aulast%3DIchikawa%26aufirst%3DD.%26aulast%3DOtsuji%26aufirst%3DE.%26aulast%3DInazawa%26aufirst%3DJ.%26atitle%3DOverexpression%2520of%2520SMYD2%2520relates%2520to%2520tumor%2520cell%2520proliferation%2520and%2520malignant%2520outcome%2520of%2520esophageal%2520squamous%2520cell%2520carcinoma%26jtitle%3DCarcinogenesis%26date%3D2009%26volume%3D30%26spage%3D1139%26epage%3D1146%26doi%3D10.1093%2Fcarcin%2Fbgp116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swewczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trush, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira de Freitas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatlock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumpf, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wythes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casimiro-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsyte-Lovejoy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, D. R.</span></span> <span> </span><span class="NLM_article-title">Selective, small-molecule co-factor binding site inhibition of a Su(var)3-9, enhancer of zeste, trithorax domain containing lysine methyltransferase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7669</span>– <span class="NLM_lpage">7683</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00112</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00112" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyrur7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7669-7683&author=A.+P.+Taylorauthor=M.+Swewczykauthor=S.+Kennedyauthor=V.+V.+Trushauthor=H.+Wuauthor=H.+Zengauthor=A.+Dongauthor=R.+Ferreira+de+Freitasauthor=J.+Tatlockauthor=R.+A.+Kumpfauthor=M.+Wythesauthor=A.+Casimiro-Garciaauthor=R.+A.+Dennyauthor=M.+D.+Parikhauthor=F.+Liauthor=D.+Barsyte-Lovejoyauthor=M.+Schapiraauthor=M.+Vedadiauthor=P.+J.+Brownauthor=C.+H.+Arrowsmithauthor=D.+R.+Owen&title=Selective%2C+small-molecule+co-factor+binding+site+inhibition+of+a+Su%28var%293-9%2C+enhancer+of+zeste%2C+trithorax+domain+containing+lysine+methyltransferase&doi=10.1021%2Facs.jmedchem.9b00112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3-9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase</span></div><div class="casAuthors">Taylor, Alexandria P.; Swewczyk, Magdalena; Kennedy, Steven; Trush, Viacheslav V.; Wu, Hong; Zeng, Hong; Dong, Aiping; Ferreira de Freitas, Renato; Tatlock, John; Kumpf, Robert A.; Wythes, Martin; Casimiro-Garcia, Agustin; Denny, Rajiah Aldrin; Parikh, Mihir D.; Li, Fengling; Barsyte-Lovejoy, Dalia; Schapira, Matthieu; Vedadi, Masoud; Brown, Peter J.; Arrowsmith, Cheryl H.; Owen, Dafydd R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7669-7683</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The first chem. probe to primarily occupy the co-factor binding site of a Su(var)3-9, enhancer of a zeste, trithorax (SET) domain contg. protein lysine methyltransferase (PKMT) is reported.  Protein methyltransferases require S-adenosylmethionine (SAM) as a co-factor (Me donor) for enzymic activity.  However, SAM itself represents a poor medicinal chem. starting point for a selective, cell-active inhibitor given its extreme physicochem. properties and its role in multiple cellular processes.  A previously untested medicinal chem. strategy of deliberate file enrichment around mols. bearing the hallmarks of SAM, but with improved lead-like properties from the outset, yielded viable hits against SET and MYND domain-contg. protein 2 (SMYD2) that were shown to bind in the co-factor site.  These leads were optimized to identify a highly biochem. potent, PKMT-selective, and cell-active chem. probe.  While substrate-based inhibitors of PKMTs are known, this represents a novel, co-factor-derived strategy for the inhibition of SMYD2 which may also prove applicable to lysine methyltransferase family members previously thought of as intractable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrayuqhEmC-MLVg90H21EOLACvtfcHk0ljjmVJ2BEs0Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyrur7N&md5=6a9f875b93804141716a85d77b93c5ee</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00112%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DA.%2BP.%26aulast%3DSwewczyk%26aufirst%3DM.%26aulast%3DKennedy%26aufirst%3DS.%26aulast%3DTrush%26aufirst%3DV.%2BV.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZeng%26aufirst%3DH.%26aulast%3DDong%26aufirst%3DA.%26aulast%3DFerreira%2Bde%2BFreitas%26aufirst%3DR.%26aulast%3DTatlock%26aufirst%3DJ.%26aulast%3DKumpf%26aufirst%3DR.%2BA.%26aulast%3DWythes%26aufirst%3DM.%26aulast%3DCasimiro-Garcia%26aufirst%3DA.%26aulast%3DDenny%26aufirst%3DR.%2BA.%26aulast%3DParikh%26aufirst%3DM.%2BD.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DBarsyte-Lovejoy%26aufirst%3DD.%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DP.%2BJ.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DOwen%26aufirst%3DD.%2BR.%26atitle%3DSelective%252C%2520small-molecule%2520co-factor%2520binding%2520site%2520inhibition%2520of%2520a%2520Su%2528var%25293-9%252C%2520enhancer%2520of%2520zeste%252C%2520trithorax%2520domain%2520containing%2520lysine%2520methyltransferase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7669%26epage%3D7683%26doi%3D10.1021%2Facs.jmedchem.9b00112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakane, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minamino, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kangawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of a human neuromedin U receptor 1-selective hexapeptide agonist with enhanced serum stability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5228</span>– <span class="NLM_lpage">5234</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00694</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00694" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1Sns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5228-5234&author=K.+Takayamaauthor=K.+Moriauthor=A.+Tanakaauthor=E.+Nomuraauthor=Y.+Sohmaauthor=M.+Moriauthor=A.+Taguchiauthor=A.+Taniguchiauthor=T.+Sakaneauthor=A.+Yamamotoauthor=N.+Minaminoauthor=M.+Miyazatoauthor=K.+Kangawaauthor=Y.+Hayashi&title=Discovery+of+a+human+neuromedin+U+receptor+1-selective+hexapeptide+agonist+with+enhanced+serum+stability&doi=10.1021%2Facs.jmedchem.7b00694"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Human Neuromedin U Receptor 1-Selective Hexapeptide Agonist with Enhanced Serum Stability</span></div><div class="casAuthors">Takayama, Kentaro; Mori, Kenji; Tanaka, Akiko; Nomura, Erina; Sohma, Yuko; Mori, Miwa; Taguchi, Akihiro; Taniguchi, Atsuhiko; Sakane, Toshiyasu; Yamamoto, Akira; Minamino, Naoto; Miyazato, Mikiya; Kangawa, Kenji; Hayashi, Yoshio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5228-5234</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Neuromedin U (NMU) activates two NMU receptors (NMUR1 and NMUR2) and is a useful antiobesity drug lead.  We report discovery of a hexapeptide agonist, 2-thienylacetyl-Trp1-Phe(4-F)2-Arg3-Pro4-Arg5-Asn6-NH2 (4).  However, the NMUR1 selectivity and serum stability of this agonist were unsatisfactory.  Through a structure-activity relationship study focused on residue 2 of agonist 4, serum stability, and pharmacokinetic properties, we report here the discovery of a novel NMUR1 selective hexapeptide agonist 7b that suppresses body wt. gain in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqONktrt1VB-LVg90H21EOLACvtfcHk0ljjmVJ2BEs0Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1Sns7k%253D&md5=6bc1a560eff4c7b013fb9caccd0cd644</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00694%26sid%3Dliteratum%253Aachs%26aulast%3DTakayama%26aufirst%3DK.%26aulast%3DMori%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DNomura%26aufirst%3DE.%26aulast%3DSohma%26aufirst%3DY.%26aulast%3DMori%26aufirst%3DM.%26aulast%3DTaguchi%26aufirst%3DA.%26aulast%3DTaniguchi%26aufirst%3DA.%26aulast%3DSakane%26aufirst%3DT.%26aulast%3DYamamoto%26aufirst%3DA.%26aulast%3DMinamino%26aufirst%3DN.%26aulast%3DMiyazato%26aufirst%3DM.%26aulast%3DKangawa%26aufirst%3DK.%26aulast%3DHayashi%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520a%2520human%2520neuromedin%2520U%2520receptor%25201-selective%2520hexapeptide%2520agonist%2520with%2520enhanced%2520serum%2520stability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5228%26epage%3D5234%26doi%3D10.1021%2Facs.jmedchem.7b00694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourbeau, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of AM-6494: A potent and orally efficacious β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with in vivo selectivity over BACE2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2263</span>– <span class="NLM_lpage">2281</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01034</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A280%3ADC%252BB3MnlsFemug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2263-2281&author=L.+H.+Pettusauthor=M.+P.+Bourbeauauthor=J.+Bradleyauthor=M.+D.+Bartbergerauthor=K.+Chenauthor=D.+Hickmanauthor=M.+Johnsonauthor=Q.+Liuauthor=J.+R.+Manningauthor=A.+Nanezauthor=A.+C.+Siegmundauthor=P.+H.+Wenauthor=D.+A.+Whittingtonauthor=J.+R.+Allenauthor=S.+Wood&title=Discovery+of+AM-6494%3A+A+potent+and+orally+efficacious+%CE%B2-site+amyloid+precursor+protein+cleaving+enzyme+1+%28BACE1%29+inhibitor+with+in+vivo+selectivity+over+BACE2&doi=10.1021%2Facs.jmedchem.9b01034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2</span></div><div class="casAuthors">Pettus Liping H; Bourbeau Matthew P; Bradley Jodi; Bartberger Michael D; Chen Kui; Hickman Dean; Johnson Michael; Liu Qingyian; Manning James R; Nanez Adrian; Siegmund Aaron C; Wen Paul H; Whittington Douglas A; Allen Jennifer R; Wood Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2263-2281</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) is an aspartyl protease that plays a key role in the production of amyloid β (Aβ) in the brain and has been extensively pursued as a target for the treatment of Alzheimer's disease (AD).  BACE2, an aspartyl protease that is structurally related to BACE1, has been recently reported to be involved in melanosome maturation and pigmentation.  Herein, we describe the development of a series of cyclopropylthiazines as potent and orally efficacious BACE1 inhibitors.  Lead optimization led to the identification of 20, a molecule with biochemical IC50 BACE2/BACE1 ratio of 47.  Administration of 20 resulted in no skin/fur color change in a 13-day mouse hypopigmentation study and demonstrated robust and sustained reduction of CSF and brain Aβ40 levels in rat and monkey pharmacodynamic models.  On the basis of a compelling data package, 20 (AM-6494) was advanced to preclinical development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQmgrDHvGragzjk2McQZ6XmfW6udTcc2eZJVhiKcVjSCLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnlsFemug%253D%253D&md5=abc7ed1f6b97a705d9b43ea992712a97</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01034%26sid%3Dliteratum%253Aachs%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DBourbeau%26aufirst%3DM.%2BP.%26aulast%3DBradley%26aufirst%3DJ.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DManning%26aufirst%3DJ.%2BR.%26aulast%3DNanez%26aufirst%3DA.%26aulast%3DSiegmund%26aufirst%3DA.%2BC.%26aulast%3DWen%26aufirst%3DP.%2BH.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DAllen%26aufirst%3DJ.%2BR.%26aulast%3DWood%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520AM-6494%253A%2520A%2520potent%2520and%2520orally%2520efficacious%2520%25CE%25B2-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%25201%2520%2528BACE1%2529%2520inhibitor%2520with%2520in%2520vivo%2520selectivity%2520over%2520BACE2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D2263%26epage%3D2281%26doi%3D10.1021%2Facs.jmedchem.9b01034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsoi, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Threapleton, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, F. K.</span></span> <span> </span><span class="NLM_article-title">Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity</span>. <i>Aliment. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1262</span>– <span class="NLM_lpage">1275</span>, <span class="refDoi"> DOI: 10.1111/apt.13642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1111%2Fapt.13642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=27121479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsFWiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2016&pages=1262-1275&author=J.+Q.+Yuanauthor=K.+K.+Tsoiauthor=M.+Yangauthor=J.+Y.+Wangauthor=D.+E.+Threapletonauthor=Z.+Y.+Yangauthor=B.+Zouauthor=C.+Maoauthor=J.+L.+Tangauthor=F.+K.+Chan&title=Systematic+review+with+network+meta-analysis%3A+comparative+effectiveness+and+safety+of+strategies+for+preventing+NSAID-associated+gastrointestinal+toxicity&doi=10.1111%2Fapt.13642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity</span></div><div class="casAuthors">Yuan, J. Q.; Tsoi, K. K. F.; Yang, M.; Wang, J. Y.; Threapleton, D. E.; Yang, Z. Y.; Zou, B.; Mao, C.; Tang, J. L.; Chan, F. K. L.</div><div class="citationInfo"><span class="NLM_cas:title">Alimentary Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1262-1275</span>CODEN:
                <span class="NLM_cas:coden">APTHEN</span>;
        ISSN:<span class="NLM_cas:issn">0269-2813</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Many strategies are used to prevent nonsteroidal anti-inflammatory drug (NSAID)-assocd. gastrointestinal toxicity, but the comparative effectiveness remains unclear.  Aim : To evaluate the comparative effectiveness of clin. strategies for preventing gastrointestinal toxicity induced by NSAIDs.  Methods : MEDLINE, EMBASE and the Cochrane Library (from their inception to May 2015) were searched for randomized controlled trials comparing the risk of gastrointestinal adverse events in patients taking nonselective NSAIDs, selective cyclooxygenase(COX)-2 inhibitors or nonselective NSAIDs/COX-2 inhibitors plus gastroprotective agents [proton pump inhibitors (PPIs), histamine-2 receptor antagonists, misoprostol].  Both pairwise meta-anal. and Bayesian network meta-anal. were performed.  Results : Analyses were based on 82 trials including 125 053 participants.  Network meta-anal. demonstrated that selective COX-2 inhibitors + PPIs [Risk ratio (RR), 95% Credible Interval (CrI): ulcer complications 0.07, 0.02-0.18], selective COX-2 inhibitors (RR, 95% CrI: ulcer complications 0.25, 0.15- 0.38; symptomatic ulcer 0.12, 0.04-0.30), nonselective NSAIDs + PPIs (RR, 95% CrI: ulcer complications 0.28, 0.18-0.41; symptomatic ulcer 0.11, 0.04-0.23), nonselective NSAIDs + misoprostol (RR, 95% CrI: ulcer complications 0.47, 0.24-0.81; symptomatic ulcer 0.41, 0.13-1.00) were assocd. with significantly lower risk of clin. gastrointestinal events compared with nonselective NSAIDs.  For all effectiveness endpoints, selective COX-2 inhibitors + PPIs was assocd. with the lowest abs. event probability and the highest rank, followed by selective COX-2 inhibitors and thirdly by nonselective NSAIDs + PPIs.  Conclusion : The combination of selective COX-2 inhibitors plus PPIs provides the best gastrointestinal protection, followed by selective COX-2 inhibitors, and thirdly by nonselective NSAIDs plus PPIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJmKaEIMhfobVg90H21EOLACvtfcHk0ljTqSSeg6uyLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsFWiur8%253D&md5=48e32a90a90f52070b11bab75b59705b</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1111%2Fapt.13642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fapt.13642%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DJ.%2BQ.%26aulast%3DTsoi%26aufirst%3DK.%2BK.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DJ.%2BY.%26aulast%3DThreapleton%26aufirst%3DD.%2BE.%26aulast%3DYang%26aufirst%3DZ.%2BY.%26aulast%3DZou%26aufirst%3DB.%26aulast%3DMao%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DJ.%2BL.%26aulast%3DChan%26aufirst%3DF.%2BK.%26atitle%3DSystematic%2520review%2520with%2520network%2520meta-analysis%253A%2520comparative%2520effectiveness%2520and%2520safety%2520of%2520strategies%2520for%2520preventing%2520NSAID-associated%2520gastrointestinal%2520toxicity%26jtitle%3DAliment.%2520Pharmacol.%2520Ther.%26date%3D2016%26volume%3D43%26spage%3D1262%26epage%3D1275%26doi%3D10.1111%2Fapt.13642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarathnam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rachakonda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espiritu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steuer, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7202</span>– <span class="NLM_lpage">7218</span>, <span class="refDoi"> DOI: 10.1021/jm100863x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100863x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKmtb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7202-7218&author=M.+J.+Sofiaauthor=D.+Baoauthor=W.+Changauthor=J.+Duauthor=D.+Nagarathnamauthor=S.+Rachakondaauthor=P.+G.+Reddyauthor=B.+S.+Rossauthor=P.+Wangauthor=H.+R.+Zhangauthor=S.+Bansalauthor=C.+Espirituauthor=M.+Keilmanauthor=A.+M.+Lamauthor=H.+M.+Steuerauthor=C.+Niuauthor=M.+J.+Ottoauthor=P.+A.+Furman&title=Discovery+of+a+beta-d-2%E2%80%B2-deoxy-2%E2%80%B2-alpha-fluoro-2%E2%80%B2-beta-C-methyluridine+nucleotide+prodrug+%28PSI-7977%29+for+the+treatment+of+hepatitis+C+virus&doi=10.1021%2Fjm100863x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a β-D-2'-Deoxy-2'-α-fluoro-2'-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus</span></div><div class="casAuthors">Sofia, Michael J.; Bao, Donghui; Chang, Wonsuk; Du, Jinfa; Nagarathnam, Dhanapalan; Rachakonda, Suguna; Reddy, P. Ganapati; Ross, Bruce S.; Wang, Peiyuan; Zhang, Hai-Ren; Bansal, Shalini; Espiritu, Christine; Keilman, Meg; Lam, Angela M.; Steuer, Holly M. Micolochick; Niu, Congrong; Otto, Michael J.; Furman, Phillip A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7202-7218</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) is a global health problem requiring novel approaches for effective treatment of this disease.  The HCV NS5B polymerase has been demonstrated to be a viable target for the development of HCV therapies.  β-D-2'-Deoxy-2'-α-fluoro-2'-β-C-Me nucleosides are selective inhibitors of the HCV NS5B polymerase and have demonstrated potent activity in the clinic.  Phosphoramidate prodrugs of the 5'-phosphate deriv. of the β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleoside were prepd. and showed significant potency in the HCV subgenomic replicon assay (<1 μM) and produced high levels of triphosphate 6 in primary hepatocytes and in the livers of rats, dogs, and monkeys when administered in vivo.  The single diastereomer 51 of diastereomeric mixt. 14 was crystd., and an X-ray structure was detd. establishing the phosphoramidate stereochem. as Sp, thus correlating for the first time the stereochem. of a phosphoramidate prodrug with biol. activity.  51 (PSI-7977) was selected as a clin. development candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWAkLi9-odWbVg90H21EOLACvtfcHk0ljTqSSeg6uyLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKmtb%252FO&md5=33d371e557e9d70562a326f97798f45c</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fjm100863x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100863x%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DBao%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DNagarathnam%26aufirst%3DD.%26aulast%3DRachakonda%26aufirst%3DS.%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.%2BR.%26aulast%3DBansal%26aufirst%3DS.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DKeilman%26aufirst%3DM.%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DSteuer%26aufirst%3DH.%2BM.%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26atitle%3DDiscovery%2520of%2520a%2520beta-d-2%25E2%2580%25B2-deoxy-2%25E2%2580%25B2-alpha-fluoro-2%25E2%2580%25B2-beta-C-methyluridine%2520nucleotide%2520prodrug%2520%2528PSI-7977%2529%2520for%2520the%2520treatment%2520of%2520hepatitis%2520C%2520virus%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7202%26epage%3D7218%26doi%3D10.1021%2Fjm100863x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Migliaccio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomassini, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomew, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosserman, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceccacci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colwell, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortese, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Francesco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eldrup, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getty, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFemina, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludmerer, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacCoss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMasters, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlhut, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flores, O. A.</span></span> <span> </span><span class="NLM_article-title">Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">49164</span>– <span class="NLM_lpage">49170</span>, <span class="refDoi"> DOI: 10.1074/jbc.M305041200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1074%2Fjbc.M305041200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=12966103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptlGrsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=49164-49170&author=G.+Migliaccioauthor=J.+E.+Tomassiniauthor=S.+S.+Carrollauthor=L.+Tomeiauthor=S.+Altamuraauthor=B.+Bhatauthor=L.+Bartholomewauthor=M.+R.+Bossermanauthor=A.+Ceccacciauthor=L.+F.+Colwellauthor=R.+Corteseauthor=R.+De+Francescoauthor=A.+B.+Eldrupauthor=K.+L.+Gettyauthor=X.+S.+Houauthor=R.+L.+LaFeminaauthor=S.+W.+Ludmererauthor=M.+MacCossauthor=D.+R.+McMastersauthor=M.+W.+Stahlhutauthor=D.+B.+Olsenauthor=D.+J.+Hazudaauthor=O.+A.+Flores&title=Characterization+of+resistance+to+non-obligate+chain-terminating+ribonucleoside+analogs+that+inhibit+hepatitis+C+virus+replication+in+vitro&doi=10.1074%2Fjbc.M305041200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of Resistance to Non-obligate Chain-terminating Ribonucleoside Analogs That Inhibit Hepatitis C Virus Replication in Vitro</span></div><div class="casAuthors">Migliaccio, Giovanni; Tomassini, Joanne E.; Carroll, Steven S.; Tomei, Licia; Altamura, Sergio; Bhat, Balkrishen; Bartholomew, Linda; Bosserman, Michele R.; Ceccacci, Alessandra; Colwell, Lawrence F.; Cortese, Riccardo; De Francesco, Raffaele; Eldrup, Anne B.; Getty, Krista L.; Hou, Xiaoli S.; LaFemina, Robert L.; Ludmerer, Steven W.; MacCoss, Malcolm; McMasters, Daniel R.; Stahlhut, Mark W.; Olsen, David B.; Hazuda, Daria J.; Flores, Osvaldo A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">49164-49170</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The urgent need for efficacious drugs to treat chronic hepatitis C virus (HCV) infection requires a concerted effort to develop inhibitors specific for virally encoded enzymes.  We demonstrate that 2'-C-Me ribonucleosides are efficient chain-terminating inhibitors of HCV genome replication.  Characterization of drug-resistant HCV replicons defined a single S282T mutation within the active site of the viral polymerase that conferred loss of sensitivity to structurally related compds. in both replicon and isolated polymerase assays.  Biochem. analyses demonstrated that resistance at the level of the enzyme results from a combination of reduced affinity of the mutant polymerase for the drug and an increased ability to extend the incorporated nucleoside analog.  Importantly, the combination of these agents with interferon-α results in synergistic inhibition of HCV genome replication in cell culture.  Furthermore, 2'-C-methyl-substituted ribonucleosides also inhibited replication of genetically related viruses such as bovine diarrhea virus, yellow fever, and West African Nile viruses.  These observations, together with the finding that 2'-C-methyl-guanosine in particular has a favorable pharmacol. profile, suggest that this class of compds. may have broad utility in the treatment of HCV and other flavivirus infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7Zeuc5zFmbbVg90H21EOLACvtfcHk0liCnkQyYSjIlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptlGrsL4%253D&md5=a7183ce208fe008e48c7a1a83ef66e85</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M305041200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M305041200%26sid%3Dliteratum%253Aachs%26aulast%3DMigliaccio%26aufirst%3DG.%26aulast%3DTomassini%26aufirst%3DJ.%2BE.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DTomei%26aufirst%3DL.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DBhat%26aufirst%3DB.%26aulast%3DBartholomew%26aufirst%3DL.%26aulast%3DBosserman%26aufirst%3DM.%2BR.%26aulast%3DCeccacci%26aufirst%3DA.%26aulast%3DColwell%26aufirst%3DL.%2BF.%26aulast%3DCortese%26aufirst%3DR.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DEldrup%26aufirst%3DA.%2BB.%26aulast%3DGetty%26aufirst%3DK.%2BL.%26aulast%3DHou%26aufirst%3DX.%2BS.%26aulast%3DLaFemina%26aufirst%3DR.%2BL.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMacCoss%26aufirst%3DM.%26aulast%3DMcMasters%26aufirst%3DD.%2BR.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DFlores%26aufirst%3DO.%2BA.%26atitle%3DCharacterization%2520of%2520resistance%2520to%2520non-obligate%2520chain-terminating%2520ribonucleoside%2520analogs%2520that%2520inhibit%2520hepatitis%2520C%2520virus%2520replication%2520in%2520vitro%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D49164%26epage%3D49170%26doi%3D10.1074%2Fjbc.M305041200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Appleby, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barauskas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, D.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wetmore, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, T. E.</span></span> <span> </span><span class="NLM_article-title">Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase</span>. <i>Science (Washington, DC, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">771</span>– <span class="NLM_lpage">775</span>, <span class="refDoi"> DOI: 10.1126/science.1259210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1126%2Fscience.1259210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=25678663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitlKktrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2015&pages=771-775&author=T.+C.+Applebyauthor=J.+K.+Perryauthor=E.+Murakamiauthor=O.+Barauskasauthor=J.+Fengauthor=A.+Choauthor=D.+Foxauthor=D.+R.+Wetmoreauthor=M.+E.+McGrathauthor=A.+S.+Rayauthor=M.+J.+Sofiaauthor=S.+Swaminathanauthor=T.+E.+Edwards&title=Viral+replication.+Structural+basis+for+RNA+replication+by+the+hepatitis+C+virus+polymerase&doi=10.1126%2Fscience.1259210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for RNA replication by the hepatitis C virus polymerase</span></div><div class="casAuthors">Appleby, Todd C.; Perry, Jason K.; Murakami, Eisuke; Barauskas, Ona; Feng, Joy; Cho, Aesop; Fox, David, III; Wetmore, Diana R.; McGrath, Mary E.; Ray, Adrian S.; Sofia, Michael J.; Swaminathan, S.; Edwards, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">6223</span>),
    <span class="NLM_cas:pages">771-775</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Nucleotide analog inhibitors have shown clin. success in the treatment of hepatitis C virus (HCV) infection, despite an incomplete mechanistic understanding of NS5B, the viral RNA-dependent RNA polymerase.  Here we study the details of HCV RNA replication by detg. crystal structures of stalled polymerase ternary complexes with enzymes, RNA templates, RNA primers, incoming nucleotides, and catalytic metal ions during both primed initiation and elongation of RNA synthesis.  Our anal. revealed that highly conserved active-site residues in NS5B position the primer for in-line attack on the incoming nucleotide.  A β loop and a C-terminal membrane-anchoring linker occlude the active-site cavity in the apo state, retract in the primed initiation assembly to enforce replication of the HCV genome from the 3' terminus, and vacate the active-site cavity during elongation.  We investigated the incorporation of nucleotide analog inhibitors, including the clin. active metabolite formed by sofosbuvir, to elucidate key mol. interactions in the active site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvMC7Wt9bjr7Vg90H21EOLACvtfcHk0liCnkQyYSjIlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitlKktrk%253D&md5=aeebcacedf36a44ae80c972100c80c24</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1126%2Fscience.1259210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1259210%26sid%3Dliteratum%253Aachs%26aulast%3DAppleby%26aufirst%3DT.%2BC.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DMurakami%26aufirst%3DE.%26aulast%3DBarauskas%26aufirst%3DO.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DA.%26aulast%3DFox%26aufirst%3DD.%26aulast%3DWetmore%26aufirst%3DD.%2BR.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DEdwards%26aufirst%3DT.%2BE.%26atitle%3DViral%2520replication.%2520Structural%2520basis%2520for%2520RNA%2520replication%2520by%2520the%2520hepatitis%2520C%2520virus%2520polymerase%26jtitle%3DScience%2520%2528Washington%252C%2520DC%252C%2520U.%2520S.%2529%26date%3D2015%26volume%3D347%26spage%3D771%26epage%3D775%26doi%3D10.1126%2Fscience.1259210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jonckers, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijgen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachau-Durand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoops, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snoeys, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leclercq, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tambuyzer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raboisson, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-((2<i>R</i>,4a<i>R</i>,6<i>R</i>,7<i>R</i>,7a<i>R</i>)-2-isopropoxy-2-oxidodihydro-4<i>H</i>,6<i>H</i>-spiro[furo[3,2-d][1,3,2]dioxaphosphinine-7,2′-oxetan]-6-yl)pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione (JNJ-54257099), a 3′-5′-cyclic phosphate ester prodrug of 2′-deoxy-2′-spirooxetane uridine triphosphate useful for HCV inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5790</span>– <span class="NLM_lpage">5798</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00382</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00382" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFKisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5790-5798&author=T.+H.+Jonckersauthor=A.+Tahriauthor=L.+Vijgenauthor=J.+M.+Berkeauthor=S.+Lachau-Durandauthor=B.+Stoopsauthor=J.+Snoeysauthor=L.+Leclercqauthor=L.+Tambuyzerauthor=T.+I.+Linauthor=K.+Simmenauthor=P.+Raboisson&title=Discovery+of+1-%28%282R%2C4aR%2C6R%2C7R%2C7aR%29-2-isopropoxy-2-oxidodihydro-4H%2C6H-spiro%5Bfuro%5B3%2C2-d%5D%5B1%2C3%2C2%5Ddioxaphosphinine-7%2C2%E2%80%B2-oxetan%5D-6-yl%29pyrimidine-2%2C4%281H%2C3H%29-dione+%28JNJ-54257099%29%2C+a+3%E2%80%B2-5%E2%80%B2-cyclic+phosphate+ester+prodrug+of+2%E2%80%B2-deoxy-2%E2%80%B2-spirooxetane+uridine+triphosphate+useful+for+HCV+inhibition&doi=10.1021%2Facs.jmedchem.6b00382"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-((2R,4aR,6R,7R,7aR)-2-Isopropoxy-2-oxidodihydro-4H,6H-spiro[furo[3,2-d][1,3,2]dioxaphosphinine-7,2'-oxetan]-6-yl)pyrimidine-2,4(1H,3H)-dione (JNJ-54257099), a 3'-5'-Cyclic Phosphate Ester Prodrug of 2'-Deoxy-2'-Spirooxetane Uridine Triphosphate Useful for HCV Inhibition</span></div><div class="casAuthors">Jonckers, Tim H. M.; Tahri, Abdellah; Vijgen, Leen; Berke, Jan Martin; Lachau-Durand, Sophie; Stoops, Bart; Snoeys, Jan; Leclercq, Laurent; Tambuyzer, Lotke; Lin, Tse-I.; Simmen, Kenny; Raboisson, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5790-5798</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">JNJ-54257099 (9) is a novel cyclic phosphate ester deriv. that belongs to the class of 2'-deoxy-2'-spirooxetane uridine nucleotide prodrugs which are known as inhibitors of the HCV NS5B RNA-dependent RNA polymerase (RdRp).  In the Huh-7 HCV genotype (GT) 1b replicon-contg. cell line 9 is devoid of any anti-HCV activity, an observation attributable to inefficient prodrug metab. which was found to be CYP3A4-dependent.  In contrast, in vitro incubation of 9 in primary human hepatocytes as well as pharmacokinetic evaluation thereof in different preclin. species reveals the formation of substantial levels of 2'-deoxy-2'-spirooxetane uridine triphosphate (8), a potent inhibitor of the HCV NS5B polymerase.  Overall, it was found that 9 displays a superior profile compared to its phosphoramidate prodrug analogs (e.g., 4) described previously.  Of particular interest is the in vivo dose dependent redn. of HCV RNA obsd. in HCV infected (GT1a and GT3a) human hepatocyte chimeric mice after 7 days of oral administration of 9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpipEonNiweI7Vg90H21EOLACvtfcHk0liCnkQyYSjIlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFKisLg%253D&md5=d7d294da5d1adb1e6d576a708e6779fe</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00382&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00382%26sid%3Dliteratum%253Aachs%26aulast%3DJonckers%26aufirst%3DT.%2BH.%26aulast%3DTahri%26aufirst%3DA.%26aulast%3DVijgen%26aufirst%3DL.%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26aulast%3DLachau-Durand%26aufirst%3DS.%26aulast%3DStoops%26aufirst%3DB.%26aulast%3DSnoeys%26aufirst%3DJ.%26aulast%3DLeclercq%26aufirst%3DL.%26aulast%3DTambuyzer%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.%2BI.%26aulast%3DSimmen%26aufirst%3DK.%26aulast%3DRaboisson%26aufirst%3DP.%26atitle%3DDiscovery%2520of%25201-%2528%25282R%252C4aR%252C6R%252C7R%252C7aR%2529-2-isopropoxy-2-oxidodihydro-4H%252C6H-spiro%255Bfuro%255B3%252C2-d%255D%255B1%252C3%252C2%255Ddioxaphosphinine-7%252C2%25E2%2580%25B2-oxetan%255D-6-yl%2529pyrimidine-2%252C4%25281H%252C3H%2529-dione%2520%2528JNJ-54257099%2529%252C%2520a%25203%25E2%2580%25B2-5%25E2%2580%25B2-cyclic%2520phosphate%2520ester%2520prodrug%2520of%25202%25E2%2580%25B2-deoxy-2%25E2%2580%25B2-spirooxetane%2520uridine%2520triphosphate%2520useful%2520for%2520HCV%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5790%26epage%3D5798%26doi%3D10.1021%2Facs.jmedchem.6b00382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutgesell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskyi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, R.</span></span> <span> </span><span class="NLM_article-title">Novel pyrrolopyridone bromodomain and extra-terminal motif (BET) inhibitors effective in endocrine-resistant ER+ breast cancer with acquired resistance to fulvestrant and palbociclib</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">7186</span>– <span class="NLM_lpage">7210</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00456</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00456" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVSht7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=7186-7210&author=Y.+Liauthor=J.+Zhaoauthor=L.+M.+Gutgesellauthor=Z.+Shenauthor=K.+Ratiaauthor=K.+Dyeauthor=O.+Dubrovskyiauthor=H.+Zhaoauthor=F.+Huangauthor=D.+A.+Tonettiauthor=G.+R.+J.+Thatcherauthor=R.+Xiong&title=Novel+pyrrolopyridone+bromodomain+and+extra-terminal+motif+%28BET%29+inhibitors+effective+in+endocrine-resistant+ER%2B+breast+cancer+with+acquired+resistance+to+fulvestrant+and+palbociclib&doi=10.1021%2Facs.jmedchem.0c00456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib</span></div><div class="casAuthors">Li, Yangfeng; Zhao, Jiong; Gutgesell, Lauren M.; Shen, Zhengnan; Ratia, Kiira; Dye, Katherine; Dubrovskyi, Oleksii; Zhao, Huiping; Huang, Fei; Tonetti, Debra A.; Thatcher, Gregory R. J.; Xiong, Rui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">7186-7210</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acquired resistance to fulvestrant and palbociclib is a new challenge to treatment of estrogen receptor pos. (ER+) breast cancer.  ER is expressed in most resistance settings; thus, bromodomain and extra-terminal protein inhibitors (BETi) that target BET-amplified ER-mediated transcription have therapeutic potential.  Novel pyrrolopyridone BETi leveraged novel interactions with L92/L94 confirmed by a cocrystal structure of 27 with BRD4.  Optimization of BETi using growth inhibition in fulvestrant-resistant (MCF-7:CFR) cells was confirmed in endocrine-resistant, palbociclib-resistant, and ESR1 mutant cell lines. 27 was more potent in MCF-7:CFR cells than six BET inhibitors in clin. trials.  Transcriptomic anal. differentiated 27 from the benchmark BETi, JQ-1, showing downregulation of oncogenes and upregulation of tumor suppressors and apoptosis.  The therapeutic approach was validated by oral administration of 27 in orthotopic xenografts of endocrine-resistant breast cancer in monotherapy and in combination with fulvestrant.  Importantly, at an equiv. dose in rats, thrombocytopenia was mitigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDIuIaC34dxbVg90H21EOLACvtfcHk0lgMbQBt-yebwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVSht7jM&md5=b44638b7c6db7998abd72b50f09382ca</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00456%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DGutgesell%26aufirst%3DL.%2BM.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DRatia%26aufirst%3DK.%26aulast%3DDye%26aufirst%3DK.%26aulast%3DDubrovskyi%26aufirst%3DO.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26aulast%3DXiong%26aufirst%3DR.%26atitle%3DNovel%2520pyrrolopyridone%2520bromodomain%2520and%2520extra-terminal%2520motif%2520%2528BET%2529%2520inhibitors%2520effective%2520in%2520endocrine-resistant%2520ER%252B%2520breast%2520cancer%2520with%2520acquired%2520resistance%2520to%2520fulvestrant%2520and%2520palbociclib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D7186%26epage%3D7210%26doi%3D10.1021%2Facs.jmedchem.0c00456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertoletti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, C.</span></span> <span> </span><span class="NLM_article-title">Adaptive immunity in HBV infection</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">S71</span>– <span class="NLM_lpage">s83</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2016.01.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.jhep.2016.01.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=27084039" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVart7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=S71-s83&author=A.+Bertolettiauthor=C.+Ferrari&title=Adaptive+immunity+in+HBV+infection&doi=10.1016%2Fj.jhep.2016.01.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Adaptive immunity in HBV infection</span></div><div class="casAuthors">Bertoletti, Antonio; Ferrari, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1_Suppl.</span>),
    <span class="NLM_cas:pages">S71-S83</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">During hepatitis B virus (HBV) infection, the presence of HBV-specific antibody producing B cells and functional HBV-specific T cells (with helper or cytotoxic effects) ultimately dets. HBV infection outcome.  In this review, in addn. to summarizing the present state of knowledge of HBV-adaptive immunity, we will highlight controversies and uncertainties concerning the HBV-specific B and T lymphocyte response, and propose future directions for research aimed at the generation of more efficient immunotherapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0DCzFYSMYqLVg90H21EOLACvtfcHk0lgMbQBt-yebwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVart7w%253D&md5=a212ced9423f2e1db502572b049290ad</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2016.01.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2016.01.026%26sid%3Dliteratum%253Aachs%26aulast%3DBertoletti%26aufirst%3DA.%26aulast%3DFerrari%26aufirst%3DC.%26atitle%3DAdaptive%2520immunity%2520in%2520HBV%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2016%26volume%3D64%26spage%3DS71%26epage%3Ds83%26doi%3D10.1016%2Fj.jhep.2016.01.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleby, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aktoudianakis, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metobo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daffis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villasenor, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zablocki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suekawa-Pirrone, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaney, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of GS-9688 (Selgantolimod) as a potent and selective oral Toll-like receptor 8 agonist for the treatment of chronic hepatitis B</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00100</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00100" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=R.+L.+Mackmanauthor=M.+Mishauthor=G.+Chinauthor=J.+K.+Perryauthor=T.+Applebyauthor=V.+Aktoudianakisauthor=S.+Metoboauthor=P.+Pyunauthor=C.+Niuauthor=S.+Daffisauthor=H.+Yuauthor=J.+Zhengauthor=A.+G.+Villasenorauthor=J.+Zablockiauthor=J.+Chamberlainauthor=H.+Jinauthor=G.+Leeauthor=K.+Suekawa-Pirroneauthor=R.+Santosauthor=W.+E.+Delaneyauthor=S.+P.+Fletcher&title=Discovery+of+GS-9688+%28Selgantolimod%29+as+a+potent+and+selective+oral+Toll-like+receptor+8+agonist+for+the+treatment+of+chronic+hepatitis+B&doi=10.1021%2Facs.jmedchem.0c00100"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00100%26sid%3Dliteratum%253Aachs%26aulast%3DMackman%26aufirst%3DR.%2BL.%26aulast%3DMish%26aufirst%3DM.%26aulast%3DChin%26aufirst%3DG.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DAppleby%26aufirst%3DT.%26aulast%3DAktoudianakis%26aufirst%3DV.%26aulast%3DMetobo%26aufirst%3DS.%26aulast%3DPyun%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DDaffis%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DVillasenor%26aufirst%3DA.%2BG.%26aulast%3DZablocki%26aufirst%3DJ.%26aulast%3DChamberlain%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DSuekawa-Pirrone%26aufirst%3DK.%26aulast%3DSantos%26aufirst%3DR.%26aulast%3DDelaney%26aufirst%3DW.%2BE.%26aulast%3DFletcher%26aufirst%3DS.%2BP.%26atitle%3DDiscovery%2520of%2520GS-9688%2520%2528Selgantolimod%2529%2520as%2520a%2520potent%2520and%2520selective%2520oral%2520Toll-like%2520receptor%25208%2520agonist%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520B%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26doi%3D10.1021%2Facs.jmedchem.0c00100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pi-Sunyer, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kissileff, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. P.</span></span> <span> </span><span class="NLM_article-title">C-terminal octapeptide of cholecystokinin decreases food intake in obese men</span>. <i>Physiol. Behav.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1016/0031-9384(82)90230-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2F0031-9384%2882%2990230-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=6294699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaL38XlvFemsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1982&pages=627-630&author=X.+Pi-Sunyerauthor=H.+R.+Kissileffauthor=J.+Thorntonauthor=G.+P.+Smith&title=C-terminal+octapeptide+of+cholecystokinin+decreases+food+intake+in+obese+men&doi=10.1016%2F0031-9384%2882%2990230-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">C-terminal octapeptide of cholecystokinin decreases food intake in obese men</span></div><div class="casAuthors">Pi-Sunyer, Xavier; Kissileff, Harry R.; Thornton, John; Smith, Gerard P.</div><div class="citationInfo"><span class="NLM_cas:title">Physiology & Behavior</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">627-30</span>CODEN:
                <span class="NLM_cas:coden">PHBHA4</span>;
        ISSN:<span class="NLM_cas:issn">0031-9384</span>.
    </div><div class="casAbstract">Six of 8 obese men ate less food during an i.v. infusion of the C-terminal octapeptide of cholecystokinin (CCK-8)  [25126-32-3] (4 ng/kg/min) than during a saline infusion.  Subjects stopped eating sooner during CCK-8.  CCK-8 did not change the rate of eating.  No overt side effects were reported or obsd.  This is the 1st report of the satiety effect of CCK-8 in obese humans and it suggests that the therapeutic potential of CCK-8 for the treatment of obesity deserves investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof8-0MPTyHYLVg90H21EOLACvtfcHk0ljF9miZwFMb9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XlvFemsb8%253D&md5=a4e2a45bf5082f00b5efe25b7459b8eb</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2F0031-9384%2882%2990230-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0031-9384%252882%252990230-X%26sid%3Dliteratum%253Aachs%26aulast%3DPi-Sunyer%26aufirst%3DX.%26aulast%3DKissileff%26aufirst%3DH.%2BR.%26aulast%3DThornton%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DG.%2BP.%26atitle%3DC-terminal%2520octapeptide%2520of%2520cholecystokinin%2520decreases%2520food%2520intake%2520in%2520obese%2520men%26jtitle%3DPhysiol.%2520Behav.%26date%3D1982%26volume%3D29%26spage%3D627%26epage%3D630%26doi%3D10.1016%2F0031-9384%2882%2990230-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henke, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momtahen, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugg, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croom, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grizzle, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queen, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimele, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yingling, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M. K.</span></span> <span> </span><span class="NLM_article-title">3-[2-(N-phenylacetamide)]-1,5-benzodiazepines: orally active, binding selective CCK-A agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">3030</span>– <span class="NLM_lpage">3034</span>, <span class="refDoi"> DOI: 10.1021/jm960205b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960205b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaK28XjvVartbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=3030-3034&author=T.+M.+Willsonauthor=B.+R.+Henkeauthor=T.+M.+Momtahenauthor=P.+L.+Myersauthor=E.+E.+Suggauthor=R.+J.+Unwallaauthor=D.+K.+Croomauthor=R.+W.+Doughertyauthor=M.+K.+Grizzleauthor=M.+F.+Johnsonauthor=K.+L.+Queenauthor=T.+J.+Rimeleauthor=J.+D.+Yinglingauthor=M.+K.+James&title=3-%5B2-%28N-phenylacetamide%29%5D-1%2C5-benzodiazepines%3A+orally+active%2C+binding+selective+CCK-A+agonists&doi=10.1021%2Fjm960205b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">3-[2-(N-Phenylacetamide)]-1,5-benzodiazepines: Orally Active, Binding Selective CCK-A Agonists</span></div><div class="casAuthors">Willson, Timothy M.; Henke, Brad R.; Momtahen, Tanya M.; Myers, Peter L.; Sugg, Elizabeth E.; Unwalla, Rayomand J.; Croom, Dallas K.; Dougherty, Robert W.; Grizzle, Mary K.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3030-3034</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of modifications were made to the C-3 substituent of the 1,5-benzodiazepine CCK-A agonist I.  Replacement of the inner urea NH and addn. of a Me group to generate a C-3 quaternary carbon resulted in acetamide II, which showed CCK-A receptor binding selectivity and sub-micromolar agonist activity in vitro.  II was active in an in vivo mouse gallbladder emptying assay and represents a novel orally active, binding selective CCK-A agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-xv3tWIdKmLVg90H21EOLACvtfcHk0ljF9miZwFMb9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjvVartbc%253D&md5=c2b8e49fc0307b720ef0256a72f05ee7</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fjm960205b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960205b%26sid%3Dliteratum%253Aachs%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DHenke%26aufirst%3DB.%2BR.%26aulast%3DMomtahen%26aufirst%3DT.%2BM.%26aulast%3DMyers%26aufirst%3DP.%2BL.%26aulast%3DSugg%26aufirst%3DE.%2BE.%26aulast%3DUnwalla%26aufirst%3DR.%2BJ.%26aulast%3DCroom%26aufirst%3DD.%2BK.%26aulast%3DDougherty%26aufirst%3DR.%2BW.%26aulast%3DGrizzle%26aufirst%3DM.%2BK.%26aulast%3DJohnson%26aufirst%3DM.%2BF.%26aulast%3DQueen%26aufirst%3DK.%2BL.%26aulast%3DRimele%26aufirst%3DT.%2BJ.%26aulast%3DYingling%26aufirst%3DJ.%2BD.%26aulast%3DJames%26aufirst%3DM.%2BK.%26atitle%3D3-%255B2-%2528N-phenylacetamide%2529%255D-1%252C5-benzodiazepines%253A%2520orally%2520active%252C%2520binding%2520selective%2520CCK-A%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D3030%26epage%3D3034%26doi%3D10.1021%2Fjm960205b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S. B.</span></span> <span> </span><span class="NLM_article-title">The use of spirocyclic scaffolds in drug discovery</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3673</span>– <span class="NLM_lpage">3682</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.06.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.bmcl.2014.06.081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=25052427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFykt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3673-3682&author=Y.+Zhengauthor=C.+M.+Ticeauthor=S.+B.+Singh&title=The+use+of+spirocyclic+scaffolds+in+drug+discovery&doi=10.1016%2Fj.bmcl.2014.06.081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">The use of spirocyclic scaffolds in drug discovery</span></div><div class="casAuthors">Zheng, Yajun; Tice, Colin M.; Singh, Suresh B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3673-3682</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Owing to their inherent three-dimensionality and structural novelty, spiro scaffolds have been increasingly utilized in drug discovery.  In this brief review, we highlight selected examples from the primary medicinal chem. literature during the last three years to demonstrate the versatility of spiro scaffolds.  With recent progress in synthetic methods providing access to spiro building blocks, spiro scaffolds are likely to be used more frequently in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqzTjJrsRkyLVg90H21EOLACvtfcHk0ljF9miZwFMb9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFykt7bM&md5=9a2a644cf2b97edf7876b43b6457f6d5</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.06.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.06.081%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DTice%26aufirst%3DC.%2BM.%26aulast%3DSingh%26aufirst%3DS.%2BB.%26atitle%3DThe%2520use%2520of%2520spirocyclic%2520scaffolds%2520in%2520drug%2520discovery%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3673%26epage%3D3682%26doi%3D10.1016%2Fj.bmcl.2014.06.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, C. M.</span></span> <span> </span><span class="NLM_article-title">The utilization of spirocyclic scaffolds in novel drug discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">834</span>, <span class="refDoi"> DOI: 10.1080/17460441.2016.1195367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1080%2F17460441.2016.1195367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=27233084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FktVGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=831-834&author=Y.+J.+Zhengauthor=C.+M.+Tice&title=The+utilization+of+spirocyclic+scaffolds+in+novel+drug+discovery&doi=10.1080%2F17460441.2016.1195367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">The utilization of spirocyclic scaffolds in novel drug discovery</span></div><div class="casAuthors">Zheng Ya-Jun; Tice Colin M</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on drug discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">831-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYAtKgZnFeprYtC3U5jeOifW6udTcc2eZWAD3dk73tVrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FktVGkug%253D%253D&md5=a736a7ecb934f323069bef58eaed9bbe</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1195367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1195367%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%2BJ.%26aulast%3DTice%26aufirst%3DC.%2BM.%26atitle%3DThe%2520utilization%2520of%2520spirocyclic%2520scaffolds%2520in%2520novel%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26spage%3D831%26epage%3D834%26doi%3D10.1080%2F17460441.2016.1195367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkenbosch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benningshof, J. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumpfe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span> <span> </span><span class="NLM_article-title">Charting biologically relevant spirocyclic compound space</span>. <i>Chem. - Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">703</span>– <span class="NLM_lpage">710</span>, <span class="refDoi"> DOI: 10.1002/chem.201604714</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fchem.201604714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=27859909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVWmsb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=703-710&author=G.+M%C3%BCllerauthor=T.+Berkenboschauthor=J.+C.+J.+Benningshofauthor=D.+Stumpfeauthor=J.+Bajorath&title=Charting+biologically+relevant+spirocyclic+compound+space&doi=10.1002%2Fchem.201604714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Charting Biologically Relevant Spirocyclic Compound Space</span></div><div class="casAuthors">Mueller, Gerhard; Berkenbosch, Tim; Benningshof, Jorg C. J.; Stumpfe, Dagmar; Bajorath, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">703-710</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Spirocycles frequently occur in natural products and experience increasing interest in drug discovery, given their richness in Sp3 centers and distinct three-dimensionality.  The authors have systematically explored chem. space populated with currently available bioactive spirocycles.  Compds. contg. spiro systems were classified and their scaffolds and spirocyclic ring combinations analyzed.  Nearly 47,000 compds. were identified that contained spirocycles in different structural contexts and were active against roughly 200 targets, among which several pharmaceutically relevant members of the G protein-coupled receptor (GPCR) family were identified.  Spirocycles and corresponding compds. displayed notable scaffold diversity but contained only limited nos. of combinations of differently sized rings.  These observations indicate that there should be significant potential to further expand spirocyclic chem. space for drug discovery, exploiting the privileged substructure concept.  Inspired by those findings, the authors embarked on the design and chem. synthesis of three distinct novel spirocyclic scaffolds that qualify for downstream library synthesis, thus exploring principally new chem. space with high potential for pharmaceutical research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUvVwE8kzXULVg90H21EOLACvtfcHk0lg3uhSG8tCA0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVWmsb3O&md5=92293477499539b602abd928891de11b</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1002%2Fchem.201604714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201604714%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller%26aufirst%3DG.%26aulast%3DBerkenbosch%26aufirst%3DT.%26aulast%3DBenningshof%26aufirst%3DJ.%2BC.%2BJ.%26aulast%3DStumpfe%26aufirst%3DD.%26aulast%3DBajorath%26aufirst%3DJ.%26atitle%3DCharting%2520biologically%2520relevant%2520spirocyclic%2520compound%2520space%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2017%26volume%3D23%26spage%3D703%26epage%3D710%26doi%3D10.1002%2Fchem.201604714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flisiak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horban, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvarajah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiercinska-Drapalo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siwak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cielniak, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higersberger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kierkus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aeschlimann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosgurin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolas-Métral, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumont, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porchet, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabbé, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scalfaro, P.</span></span> <span> </span><span class="NLM_article-title">The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">826</span>, <span class="refDoi"> DOI: 10.1002/hep.22131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fhep.22131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=18302285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktVOiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=817-826&author=R.+Flisiakauthor=A.+Horbanauthor=P.+Gallayauthor=M.+Bobardtauthor=S.+Selvarajahauthor=A.+Wiercinska-Drapaloauthor=E.+Siwakauthor=I.+Cielniakauthor=J.+Higersbergerauthor=J.+Kierkusauthor=C.+Aeschlimannauthor=P.+Grosgurinauthor=V.+Nicolas-M%C3%A9tralauthor=J.-M.+Dumontauthor=H.+Porchetauthor=R.+Crabb%C3%A9author=P.+Scalfaro&title=The+cyclophilin+inhibitor+Debio-025+shows+potent+anti-hepatitis+C+effect+in+patients+coinfected+with+hepatitis+C+and+human+immunodeficiency+virus&doi=10.1002%2Fhep.22131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">The cyclophilin inhibitor Debio-O25 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus</span></div><div class="casAuthors">Flisiak, Robert; Horban, Andrzej; Gallay, Philippe; Bobardt, Michael; Selvarajah, Suganya; Wiercinska-Drapalo, Alicja; Siwak, Ewa; Cielniak, Iwona; Higersberger, Jozef; Kierkus, Jarek; Aeschlimann, Christian; Grosgurin, Pierre; Nicolas-Metral, Valerie; Dumont, Jean-Maurice; Porchet, Herve; Crabbe, Raf; Scalfaro, Pietro</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">817-826</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Debio-025 is an oral cyclophilin (Cyp) inhibitor with potent anti-hepatitis C virus activity in vitro.  Its effect on viral load as well as its influence on intracellular Cyp levels was investigated in a randomized, double-blind, placebo-controlled study.  Mean hepatitis C viral load decreased significantly by 3.6 log10 after a 14-day oral treatment with 1200 mg twice daily (P < 0.0001) with an effect against the 3 genotypes (1, 3, and 4) represented in the study.  In addn., the absence of viral rebound during treatment indicates that Debio-025 has a high barrier for the selection of resistance.  In Debio-025-treated patients, cydophilin B (CypB) levels in peripheral blood mononuclear cells decreased from 67 ± 6 (std. error) ng/mg protein (baseline) to 5 ± 1 ng/mg protein at day 15 (P < 0.01).  Conclusion: Debio-025 induced a strong drop in CypB levels, coinciding with the decrease in hepatitis C viral load.  These are the first preliminary human data supporting the hypothesis that CypB may play an important role in hepatitis C virus replication and that Cyp inhibition is a valid target for the development of anti-hepatitis C drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxguJagRjm8bVg90H21EOLACvtfcHk0lg3uhSG8tCA0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktVOiu7o%253D&md5=8b864afa2a4d2b55fc90650d5ac4e30b</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1002%2Fhep.22131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.22131%26sid%3Dliteratum%253Aachs%26aulast%3DFlisiak%26aufirst%3DR.%26aulast%3DHorban%26aufirst%3DA.%26aulast%3DGallay%26aufirst%3DP.%26aulast%3DBobardt%26aufirst%3DM.%26aulast%3DSelvarajah%26aufirst%3DS.%26aulast%3DWiercinska-Drapalo%26aufirst%3DA.%26aulast%3DSiwak%26aufirst%3DE.%26aulast%3DCielniak%26aufirst%3DI.%26aulast%3DHigersberger%26aufirst%3DJ.%26aulast%3DKierkus%26aufirst%3DJ.%26aulast%3DAeschlimann%26aufirst%3DC.%26aulast%3DGrosgurin%26aufirst%3DP.%26aulast%3DNicolas-M%25C3%25A9tral%26aufirst%3DV.%26aulast%3DDumont%26aufirst%3DJ.-M.%26aulast%3DPorchet%26aufirst%3DH.%26aulast%3DCrabb%25C3%25A9%26aufirst%3DR.%26aulast%3DScalfaro%26aufirst%3DP.%26atitle%3DThe%2520cyclophilin%2520inhibitor%2520Debio-025%2520shows%2520potent%2520anti-hepatitis%2520C%2520effect%2520in%2520patients%2520coinfected%2520with%2520hepatitis%2520C%2520and%2520human%2520immunodeficiency%2520virus%26jtitle%3DHepatology%26date%3D2008%26volume%3D47%26spage%3D817%26epage%3D826%26doi%3D10.1002%2Fhep.22131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMassimo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalezari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sluder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scorneaux, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalczyk, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeill, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baugh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallay, P.</span></span> <span> </span><span class="NLM_article-title">The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2012.02.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.jhep.2012.02.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=22425702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC38XovV2nsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2012&pages=47-54&author=S.+Hopkinsauthor=B.+DiMassimoauthor=P.+Rusnakauthor=D.+Heumanauthor=J.+Lalezariauthor=A.+Sluderauthor=B.+Scorneauxauthor=S.+Mosierauthor=P.+Kowalczykauthor=Y.+Ribeillauthor=J.+Baughauthor=P.+Gallay&title=The+cyclophilin+inhibitor+SCY-635+suppresses+viral+replication+and+induces+endogenous+interferons+in+patients+with+chronic+HCV+genotype+1+infection&doi=10.1016%2Fj.jhep.2012.02.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection</span></div><div class="casAuthors">Hopkins, Sam; DiMassimo, Betty; Rusnak, Pamela; Heuman, Douglas; Lalezari, Jacob; Sluder, Ann; Scorneaux, Bernard; Mosier, Sarah; Kowalczyk, Paul; Ribeill, Yves; Baugh, James; Gallay, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-54</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Background & Aims: SCY-635 is a non-immunosuppressive analog of cyclosporin A that inhibits cyclophilins A and B and hepatitis C virus (HCV) replication in vitro.  In a phase 1b multi-dose escalation study, we evaluated the safety, plasma pharmacokinetics, and antiviral activity of 15 days of monotherapy with SCY-635 in adults with chronic genotype 1 HCV infection.  Methods: Twenty adults with chronic HCV genotype 1 were randomized to SCY-635 oral doses of 100, 200, or 300 mg three times daily for 15 days.  Results: No dose-limiting clin. or lab. toxicities were identified.  On day 15, the mean decline in plasma viremia was 2.24 ± 1.74 log10 IU/mL with SCY-635 900 mg/d.  Individual antiviral responses correlated with host IL28B genotype.  Post hoc analyses indicated treatment with SCY-635 increased plasma protein concns. of interferon α (IFNα), IFNs λ1 and λ3, and 2'5' oligoadenylate synthetase 1 (2'5'OAS-1), with the greatest increases in IL28B CC and CT subjects.  Changes in plasma concns. for all markers were coincident with changes in the plasma concn. of SCY-635.  Peaks of IFNs α, λ1, and λ3 and 2'5'OAS-1 were obsd. within 2 h after drug administration.  In replicon cells, SCY-635 enhanced secretion of type I and type III IFNs and increased the expression of IFN-stimulated genes (ISG).  Conclusions: These studies establish clin. proof of concept for SCY-635 as a novel antiviral agent and suggest that restoration of the host innate immune response to chronic hepatitis C infection may represent a major mechanism through which cyclophilin inhibitors exert clin. antiviral activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOeLKHF7TNQLVg90H21EOLACvtfcHk0li5hSWNWnJrbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovV2nsLc%253D&md5=43dcadacaaef7efd63d3d823f53ad514</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.02.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.02.024%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DS.%26aulast%3DDiMassimo%26aufirst%3DB.%26aulast%3DRusnak%26aufirst%3DP.%26aulast%3DHeuman%26aufirst%3DD.%26aulast%3DLalezari%26aufirst%3DJ.%26aulast%3DSluder%26aufirst%3DA.%26aulast%3DScorneaux%26aufirst%3DB.%26aulast%3DMosier%26aufirst%3DS.%26aulast%3DKowalczyk%26aufirst%3DP.%26aulast%3DRibeill%26aufirst%3DY.%26aulast%3DBaugh%26aufirst%3DJ.%26aulast%3DGallay%26aufirst%3DP.%26atitle%3DThe%2520cyclophilin%2520inhibitor%2520SCY-635%2520suppresses%2520viral%2520replication%2520and%2520induces%2520endogenous%2520interferons%2520in%2520patients%2520with%2520chronic%2520HCV%2520genotype%25201%2520infection%26jtitle%3DJ.%2520Hepatol.%26date%3D2012%26volume%3D57%26spage%3D47%26epage%3D54%26doi%3D10.1016%2Fj.jhep.2012.02.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steadman, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dean, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poullennec, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleby, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakemore, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannizzaro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiva, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunbar, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fliri, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Highton, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keats, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazarides, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liclican, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettit, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanvoisin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitz, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperandio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent and orally bioavailable cyclophilin inhibitor derived from the sanglifehrin macrocycle</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9473</span>– <span class="NLM_lpage">9499</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00802</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00802" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVChtbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9473-9499&author=R.+L.+Mackmanauthor=V.+A.+Steadmanauthor=D.+K.+Deanauthor=P.+Jansaauthor=K.+G.+Poullennecauthor=T.+Applebyauthor=C.+Austinauthor=C.+A.+Blakemoreauthor=R.+Caiauthor=C.+Cannizzaroauthor=G.+Chinauthor=J.+C.+Chivaauthor=N.+A.+Dunbarauthor=H.+Fliriauthor=A.+J.+Hightonauthor=H.+Huiauthor=M.+Jiauthor=H.+Jinauthor=K.+Karkiauthor=A.+J.+Keatsauthor=L.+Lazaridesauthor=Y.+J.+Leeauthor=A.+Liclicanauthor=M.+Mishauthor=B.+Murrayauthor=S.+B.+Pettitauthor=P.+Pyunauthor=M.+Sangiauthor=R.+Santosauthor=J.+Sanvoisinauthor=U.+Schmitzauthor=A.+Schrierauthor=D.+Siegelauthor=D.+Sperandioauthor=G.+Stepanauthor=Y.+Tianauthor=G.+M.+Wattauthor=H.+Yangauthor=B.+E.+Schultz&title=Discovery+of+a+potent+and+orally+bioavailable+cyclophilin+inhibitor+derived+from+the+sanglifehrin+macrocycle&doi=10.1021%2Facs.jmedchem.8b00802"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a potent and orally bioavailable cyclophilin inhibitor derived from the sanglifehrin macrocycle</span></div><div class="casAuthors">Mackman, Richard L.; Steadman, Victoria A.; Dean, David K.; Jansa, Petr; Poullennec, Karine G.; Appleby, Todd; Austin, Carol; Blakemore, Caroline A.; Cai, Ruby; Cannizzaro, Carina; Chin, Gregory; Chiva, Jean-Yves C.; Dunbar, Neil A.; Fliri, Hans; Highton, Adrian J.; Hui, Hon; Ji, Mingzhe; Jin, Haolun; Karki, Kapil; Keats, Andrew J.; Lazarides, Linos; Lee, Yu-Jen; Liclican, Albert; Mish, Michael; Murray, Bernard; Pettit, Simon B.; Pyun, Peter; Sangi, Michael; Santos, Rex; Sanvoisin, Jonathan; Schmitz, Uli; Schrier, Adam; Siegel, Dustin; Sperandio, David; Stepan, George; Tian, Yang; Watt, Gregory M.; Yang, Hai; Schultz, Brian E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9473-9499</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclophilins are a family of peptidyl-prolyl isomerases that are implicated in a wide range of diseases including hepatitis C.  Our aim was to discover through total synthesis an orally bioavailable, non-immunosuppressive cyclophilin (Cyp) inhibitor with potent anti-hepatitis C virus (HCV) activity that could serve as part of an all oral antiviral combination therapy.  An initial lead (I) derived from the sanglifehrin A macrocycle was optimized using structure based design to produce a potent and orally bioavailable inhibitor (II).  The macrocycle ring size was reduced by one atom, and an internal hydrogen bond drove improved permeability and drug-like properties. II demonstrates potent Cyp inhibition (Kd = 5 nM), potent anti-HCV 2a activity (EC50 = 98 nM), and high oral bioavailability in rat (100%) and dog (55%).  The synthetic accessibility and properties of II support its potential as an anti-HCV agent and for interrogating the role of Cyp inhibition in a variety of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEpEZcwXK8z7Vg90H21EOLACvtfcHk0li5hSWNWnJrbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVChtbrI&md5=616cf72e0d2766e159769166c98a9e86</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00802%26sid%3Dliteratum%253Aachs%26aulast%3DMackman%26aufirst%3DR.%2BL.%26aulast%3DSteadman%26aufirst%3DV.%2BA.%26aulast%3DDean%26aufirst%3DD.%2BK.%26aulast%3DJansa%26aufirst%3DP.%26aulast%3DPoullennec%26aufirst%3DK.%2BG.%26aulast%3DAppleby%26aufirst%3DT.%26aulast%3DAustin%26aufirst%3DC.%26aulast%3DBlakemore%26aufirst%3DC.%2BA.%26aulast%3DCai%26aufirst%3DR.%26aulast%3DCannizzaro%26aufirst%3DC.%26aulast%3DChin%26aufirst%3DG.%26aulast%3DChiva%26aufirst%3DJ.%2BC.%26aulast%3DDunbar%26aufirst%3DN.%2BA.%26aulast%3DFliri%26aufirst%3DH.%26aulast%3DHighton%26aufirst%3DA.%2BJ.%26aulast%3DHui%26aufirst%3DH.%26aulast%3DJi%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DKarki%26aufirst%3DK.%26aulast%3DKeats%26aufirst%3DA.%2BJ.%26aulast%3DLazarides%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DY.%2BJ.%26aulast%3DLiclican%26aufirst%3DA.%26aulast%3DMish%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DB.%26aulast%3DPettit%26aufirst%3DS.%2BB.%26aulast%3DPyun%26aufirst%3DP.%26aulast%3DSangi%26aufirst%3DM.%26aulast%3DSantos%26aufirst%3DR.%26aulast%3DSanvoisin%26aufirst%3DJ.%26aulast%3DSchmitz%26aufirst%3DU.%26aulast%3DSchrier%26aufirst%3DA.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DSperandio%26aufirst%3DD.%26aulast%3DStepan%26aufirst%3DG.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DWatt%26aufirst%3DG.%2BM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520orally%2520bioavailable%2520cyclophilin%2520inhibitor%2520derived%2520from%2520the%2520sanglifehrin%2520macrocycle%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9473%26epage%3D9499%26doi%3D10.1021%2Facs.jmedchem.8b00802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsumura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yashiroda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niwa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chikada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washizuka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirama, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umehara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirouzu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shitara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muramatsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seimiya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel spiroindoline derivatives as selective tankyrase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">3407</span>– <span class="NLM_lpage">3427</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01888</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01888" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltFertbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3407-3427&author=F.+Shiraiauthor=T.+Tsumuraauthor=Y.+Yashirodaauthor=H.+Yukiauthor=H.+Niwaauthor=S.+Satoauthor=T.+Chikadaauthor=Y.+Kodaauthor=K.+Washizukaauthor=N.+Yoshimotoauthor=M.+Abeauthor=T.+Onukiauthor=Y.+Mazakiauthor=C.+Hiramaauthor=T.+Fukamiauthor=H.+Watanabeauthor=T.+Honmaauthor=T.+Umeharaauthor=M.+Shirouzuauthor=M.+Okueauthor=Y.+Kanoauthor=T.+Watanabeauthor=K.+Kitamuraauthor=E.+Shitaraauthor=Y.+Muramatsuauthor=H.+Yoshidaauthor=A.+Mizutaniauthor=H.+Seimiyaauthor=M.+Yoshidaauthor=H.+Koyama&title=Discovery+of+novel+spiroindoline+derivatives+as+selective+tankyrase+inhibitors&doi=10.1021%2Facs.jmedchem.8b01888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors</span></div><div class="casAuthors">Shirai, Fumiyuki; Tsumura, Takeshi; Yashiroda, Yoko; Yuki, Hitomi; Niwa, Hideaki; Sato, Shin; Chikada, Tsubasa; Koda, Yasuko; Washizuka, Kenichi; Yoshimoto, Nobuko; Abe, Masako; Onuki, Tetsuo; Mazaki, Yui; Hirama, Chizuko; Fukami, Takehiro; Watanabe, Hirofumi; Honma, Teruki; Umehara, Takashi; Shirouzu, Mikako; Okue, Masayuki; Kano, Yuko; Watanabe, Takashi; Kitamura, Kouichi; Shitara, Eiki; Muramatsu, Yukiko; Yoshida, Haruka; Mizutani, Anna; Seimiya, Hiroyuki; Yoshida, Minoru; Koyama, Hiroo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3407-3427</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The canonical WNT pathway plays an important role in cancer pathogenesis.  Inhibition of poly(ADP-ribose) polymerase catalytic activity of the tankyrases (TNKS/TNKS2) has been reported to reduce the Wnt/β-catenin signal by preventing poly ADP-ribosylation dependent degrdn. of AXIN, a neg. regulator of Wnt/β-catenin signaling.  With the goal of investigating the effects of tankyrase and Wnt pathway inhibition on tumor growth, we set out to find small mol. inhibitors of TNKS/TNKS2 with suitable drug-like properties.  Starting from 1a(I), a high-throughput screening hit, the spiroindoline deriv. 40c(II) (RK-287107) was discovered as a potent TNKS/TNKS2 inhibitor with >7,000-fold selectivity against the PARP1 enzyme, which inhibits WNT-responsive TCF reporter activity and proliferation of human colorectal cancer cell line COLO-320DM.  II also demonstrated dose-dependent tumor growth inhibition in a mouse xenograft model.  These observations suggest that II is a promising lead compd. for the development of novel tankyrase inhibitors as anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb10HXpjf717Vg90H21EOLACvtfcHk0lhMM20ricPu3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltFertbg%253D&md5=7877414ff5e5cfc908b1248017867639</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01888%26sid%3Dliteratum%253Aachs%26aulast%3DShirai%26aufirst%3DF.%26aulast%3DTsumura%26aufirst%3DT.%26aulast%3DYashiroda%26aufirst%3DY.%26aulast%3DYuki%26aufirst%3DH.%26aulast%3DNiwa%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DChikada%26aufirst%3DT.%26aulast%3DKoda%26aufirst%3DY.%26aulast%3DWashizuka%26aufirst%3DK.%26aulast%3DYoshimoto%26aufirst%3DN.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DOnuki%26aufirst%3DT.%26aulast%3DMazaki%26aufirst%3DY.%26aulast%3DHirama%26aufirst%3DC.%26aulast%3DFukami%26aufirst%3DT.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DHonma%26aufirst%3DT.%26aulast%3DUmehara%26aufirst%3DT.%26aulast%3DShirouzu%26aufirst%3DM.%26aulast%3DOkue%26aufirst%3DM.%26aulast%3DKano%26aufirst%3DY.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DKitamura%26aufirst%3DK.%26aulast%3DShitara%26aufirst%3DE.%26aulast%3DMuramatsu%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DMizutani%26aufirst%3DA.%26aulast%3DSeimiya%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DKoyama%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520novel%2520spiroindoline%2520derivatives%2520as%2520selective%2520tankyrase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D3407%26epage%3D3427%26doi%3D10.1021%2Facs.jmedchem.8b01888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yashiroda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsumura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muramatsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chikada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niwa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washizuka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazaki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, M.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shitara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umehara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirouzu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seimiya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koyama, H.</span></span> <span> </span><span class="NLM_article-title">Design and discovery of an orally efficacious spiroindolinone-based tankyrase inhibitor for the treatment of colon cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">4183</span>– <span class="NLM_lpage">4204</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00045</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00045" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BB3cXltl2mt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4183-4204&author=F.+Shiraiauthor=A.+Mizutaniauthor=Y.+Yashirodaauthor=T.+Tsumuraauthor=Y.+Kanoauthor=Y.+Muramatsuauthor=T.+Chikadaauthor=H.+Yukiauthor=H.+Niwaauthor=S.+Satoauthor=K.+Washizukaauthor=Y.+Kodaauthor=Y.+Mazakiauthor=M.-K.+Jangauthor=H.+Yoshidaauthor=A.+Nagamoriauthor=M.+Okueauthor=T.+Watanabeauthor=K.+Kitamuraauthor=E.+Shitaraauthor=T.+Honmaauthor=T.+Umeharaauthor=M.+Shirouzuauthor=T.+Fukamiauthor=H.+Seimiyaauthor=M.+Yoshidaauthor=H.+Koyama&title=Design+and+discovery+of+an+orally+efficacious+spiroindolinone-based+tankyrase+inhibitor+for+the+treatment+of+colon+cancer&doi=10.1021%2Facs.jmedchem.0c00045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer</span></div><div class="casAuthors">Shirai, Fumiyuki; Mizutani, Anna; Yashiroda, Yoko; Tsumura, Takeshi; Kano, Yuko; Muramatsu, Yukiko; Chikada, Tsubasa; Yuki, Hitomi; Niwa, Hideaki; Sato, Shin; Washizuka, Kenichi; Koda, Yasuko; Mazaki, Yui; Jang, Myung-Kyu; Yoshida, Haruka; Nagamori, Akiko; Okue, Masayuki; Watanabe, Takashi; Kitamura, Kouichi; Shitara, Eiki; Honma, Teruki; Umehara, Takashi; Shirouzu, Mikako; Fukami, Takehiro; Seimiya, Hiroyuki; Yoshida, Minoru; Koyama, Hiroo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4183-4204</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tankyrases (TNKS/TNKS2) belong to the poly(ADP-ribose) polymerase family.  Inhibition of their enzymic activities attenuates the Wnt/β-catenin signaling, which plays an important role in cancer pathogenesis.  We previously reported the discovery of RK-287107, a spiroindoline-based, highly selective, potent tankyrase inhibitor.  Herein we describe the optimization process of RK-287107 leading to RK-582, which exhibits a markedly improved robust tumor growth inhibition in a COLO-320DM mouse xenograft model when orally administered.  In addn. to the dose-dependent elevation and attenuation of the levels of biomarkers AXIN2 and β-catenin, resp., results of the TCF reporter and cell proliferation studies on COLO-320DM are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnxMuxDScpWLVg90H21EOLACvtfcHk0lhMM20ricPu3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXltl2mt7g%253D&md5=8c55fd054daf7ccc91975379c2d8085b</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00045%26sid%3Dliteratum%253Aachs%26aulast%3DShirai%26aufirst%3DF.%26aulast%3DMizutani%26aufirst%3DA.%26aulast%3DYashiroda%26aufirst%3DY.%26aulast%3DTsumura%26aufirst%3DT.%26aulast%3DKano%26aufirst%3DY.%26aulast%3DMuramatsu%26aufirst%3DY.%26aulast%3DChikada%26aufirst%3DT.%26aulast%3DYuki%26aufirst%3DH.%26aulast%3DNiwa%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DWashizuka%26aufirst%3DK.%26aulast%3DKoda%26aufirst%3DY.%26aulast%3DMazaki%26aufirst%3DY.%26aulast%3DJang%26aufirst%3DM.-K.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DNagamori%26aufirst%3DA.%26aulast%3DOkue%26aufirst%3DM.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DKitamura%26aufirst%3DK.%26aulast%3DShitara%26aufirst%3DE.%26aulast%3DHonma%26aufirst%3DT.%26aulast%3DUmehara%26aufirst%3DT.%26aulast%3DShirouzu%26aufirst%3DM.%26aulast%3DFukami%26aufirst%3DT.%26aulast%3DSeimiya%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DKoyama%26aufirst%3DH.%26atitle%3DDesign%2520and%2520discovery%2520of%2520an%2520orally%2520efficacious%2520spiroindolinone-based%2520tankyrase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520colon%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D4183%26epage%3D4204%26doi%3D10.1021%2Facs.jmedchem.0c00045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newhouse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhodes, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otten, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geck
Do, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutcher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLisle, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groneberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scearce-Levie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purkey, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J. P.</span></span> <span> </span><span class="NLM_article-title">8-Tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">10112</span>– <span class="NLM_lpage">10129</span>, <span class="refDoi"> DOI: 10.1021/jm5015132</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5015132" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKqurnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10112-10129&author=A.+A.+Thomasauthor=K.+W.+Huntauthor=B.+Newhouseauthor=R.+J.+Wattsauthor=X.+Liuauthor=G.+Vigersauthor=D.+Smithauthor=S.+P.+Rhodesauthor=K.+D.+Brownauthor=J.+N.+Ottenauthor=M.+Burkardauthor=A.+A.+Coxauthor=M.+K.+Geck%0ADoauthor=D.+Dutcherauthor=S.+Ranaauthor=R.+K.+DeLisleauthor=K.+Regalauthor=A.+D.+Wrightauthor=R.+Gronebergauthor=J.+Liaoauthor=K.+Scearce-Levieauthor=M.+Siuauthor=H.+E.+Purkeyauthor=J.+P.+Lyssikatos&title=8-Tetrahydropyran-2-yl+chromans%3A+highly+selective+beta-site+amyloid+precursor+protein+cleaving+enzyme+1+%28BACE1%29+inhibitors&doi=10.1021%2Fjm5015132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">8-Tetrahydropyran-2-yl Chromans: Highly Selective Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors</span></div><div class="casAuthors">Thomas, Allen A.; Hunt, Kevin W.; Newhouse, Brad; Watts, Ryan J.; Liu, Xingrong; Vigers, Guy; Smith, Darin; Rhodes, Susan P.; Brown, Karin D.; Otten, Jennifer N.; Burkard, Michael; Cox, April A.; Geck Do, Mary K.; Dutcher, Darrin; Rana, Sumeet; DeLisle, Robert K.; Regal, Kelly; Wright, Albion D.; Groneberg, Robert; Liao, Jiangpeng; Scearce-Levie, Kimberly; Siu, Michael; Purkey, Hans E.; Lyssikatos, Joseph P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10112-10129</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hexahydropyrano[3,2-b]chromenes such as I were prepd. as inhibitors of β-site amyloid cleaving enzyme 1 (BACE1) selective for BACE1 over cathepsin D (CatD).  Three different Asp-binding moieties were examd. (spirocyclic acyl guanidines, spirocyclic aminooxazolines, and spirocyclic aminothiazolines) in order to modulate potency, selectivity, efflux, and permeability; changes to the aryl substituents of the pyranochromene moiety and substitution of a ring junction proton with a Me group were also studied.  In particular, spirocyclic aminooxazoline and aminothiazoline inhibitors with Me substituents possessed excellent cellular potency (37-137 nM) for inhibiting BACE1 and high selectivity (435 to >2000-fold) for BACE1 vs CatD.  These efforts led to nonracemic I, which demonstrated a 69% redn. in rat CSF Aβ1-40 at a dosage of 60 mg/kg (PO).  The complexes of four hexahydropyrano[3,2-b]chromenes bound to BACE-1 were detd. by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKJ3ssfyhPHrVg90H21EOLACvtfcHk0lhMM20ricPu3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKqurnK&md5=827f89cabdaa149283d04f030a3d5568</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Fjm5015132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5015132%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DA.%2BA.%26aulast%3DHunt%26aufirst%3DK.%2BW.%26aulast%3DNewhouse%26aufirst%3DB.%26aulast%3DWatts%26aufirst%3DR.%2BJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DRhodes%26aufirst%3DS.%2BP.%26aulast%3DBrown%26aufirst%3DK.%2BD.%26aulast%3DOtten%26aufirst%3DJ.%2BN.%26aulast%3DBurkard%26aufirst%3DM.%26aulast%3DCox%26aufirst%3DA.%2BA.%26aulast%3DGeck%2BDo%26aufirst%3DM.%2BK.%26aulast%3DDutcher%26aufirst%3DD.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DDeLisle%26aufirst%3DR.%2BK.%26aulast%3DRegal%26aufirst%3DK.%26aulast%3DWright%26aufirst%3DA.%2BD.%26aulast%3DGroneberg%26aufirst%3DR.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DScearce-Levie%26aufirst%3DK.%26aulast%3DSiu%26aufirst%3DM.%26aulast%3DPurkey%26aufirst%3DH.%2BE.%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26atitle%3D8-Tetrahydropyran-2-yl%2520chromans%253A%2520highly%2520selective%2520beta-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%25201%2520%2528BACE1%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D10112%26epage%3D10129%26doi%3D10.1021%2Fjm5015132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchino, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanegawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moechars, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gijsen, H. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusakabe, K. I.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: Targeting the flap to gain selectivity over BACE2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5080</span>– <span class="NLM_lpage">5095</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00309</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXotl2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5080-5095&author=K.+Fujimotoauthor=E.+Matsuokaauthor=N.+Asadaauthor=G.+Tadanoauthor=T.+Yamamotoauthor=K.+Nakaharaauthor=K.+Fuchinoauthor=H.+Itoauthor=N.+Kanegawaauthor=D.+Moecharsauthor=H.+J.+M.+Gijsenauthor=K.+I.+Kusakabe&title=Structure-based+design+of+selective+beta-site+amyloid+precursor+protein+cleaving+enzyme+1+%28BACE1%29+inhibitors%3A+Targeting+the+flap+to+gain+selectivity+over+BACE2&doi=10.1021%2Facs.jmedchem.9b00309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of Selective β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2</span></div><div class="casAuthors">Fujimoto, Kazuki; Matsuoka, Eriko; Asada, Naoya; Tadano, Genta; Yamamoto, Takahiko; Nakahara, Kenji; Fuchino, Kouki; Ito, Hisanori; Kanegawa, Naoki; Moechars, Diederik; Gijsen, Harrie J. M.; Kusakabe, Ken-ichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5080-5095</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">BACE1 inhibitors hold potential as agents in disease-modifying treatment for Alzheimer's disease.  BACE2 cleaves the melanocyte protein PMEL in pigment cells of the skin and eye, generating melanin pigments.  This role of BACE2 implies that nonselective and chronic inhibition of BACE1 may cause side effects derived from BACE2.  Herein, we describe the discovery of potent and selective BACE1 inhibitors using structure-based drug design.  We targeted the flap region, where the shape and flexibility differ between these enzymes.  Anal. of the cocrystal structures of an initial lead 8 prompted us to incorporate spirocycles followed by its fine-tuning, culminating in highly selective compds. 21 and 22.  The structures of 22 bound to BACE1 and BACE2 revealed that a relatively high energetic penalty in the flap of the 22-bound BACE2 structure may cause a loss in BACE2 potency, thereby leading to its high selectivity.  These findings and insights should contribute to responding to the challenges in exploring selective BACE1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGdAN0ejWNyrVg90H21EOLACvtfcHk0ljINPc1L02WRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXotl2nt7w%253D&md5=9ceba959612bdac96dfdda689ad6f0e8</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00309%26sid%3Dliteratum%253Aachs%26aulast%3DFujimoto%26aufirst%3DK.%26aulast%3DMatsuoka%26aufirst%3DE.%26aulast%3DAsada%26aufirst%3DN.%26aulast%3DTadano%26aufirst%3DG.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DNakahara%26aufirst%3DK.%26aulast%3DFuchino%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DH.%26aulast%3DKanegawa%26aufirst%3DN.%26aulast%3DMoechars%26aufirst%3DD.%26aulast%3DGijsen%26aufirst%3DH.%2BJ.%2BM.%26aulast%3DKusakabe%26aufirst%3DK.%2BI.%26atitle%3DStructure-based%2520design%2520of%2520selective%2520beta-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%25201%2520%2528BACE1%2529%2520inhibitors%253A%2520Targeting%2520the%2520flap%2520to%2520gain%2520selectivity%2520over%2520BACE2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5080%26epage%3D5095%26doi%3D10.1021%2Facs.jmedchem.9b00309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sherwood, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paton, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggerstaff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuenswander, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivell, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prisinzano, T. E.</span></span> <span> </span><span class="NLM_article-title">Addressing structural flexibility at the A-ring on salvinorin A: Discovery of a potent kappa-opioid agonist with enhanced metabolic stability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">3866</span>– <span class="NLM_lpage">3878</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00148</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00148" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1Gls7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3866-3878&author=A.+M.+Sherwoodauthor=R.+S.+Crowleyauthor=K.+F.+Patonauthor=A.+Biggerstaffauthor=B.+Neuenswanderauthor=V.+W.+Dayauthor=B.+M.+Kivellauthor=T.+E.+Prisinzano&title=Addressing+structural+flexibility+at+the+A-ring+on+salvinorin+A%3A+Discovery+of+a+potent+kappa-opioid+agonist+with+enhanced+metabolic+stability&doi=10.1021%2Facs.jmedchem.7b00148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability</span></div><div class="casAuthors">Sherwood, Alexander M.; Crowley, Rachel Saylor; Paton, Kelly F.; Biggerstaff, Andrew; Neuenswander, Benjamin; Day, Victor W.; Kivell, Bronwyn M.; Prisinzano, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3866-3878</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Previous structure-activity studies on the neoclerodane diterpenoid salvinorin A have demonstrated the importance of the acetoxy functionality on the A-ring in its activity as a kappa opioid receptor agonist.  Few studies have focused on understanding the role of conformation in these interactions.  Herein we describe the synthesis and evaluation of both flexible and conformationally restricted compds. derived from salvinorin A.  One such compd., spirobutyrolactone (I), was synthesized in a single step from salvinorin B and had similar potency and selectivity to salvinorin A (EC50 = 0.6 ± 0.2 nM at κ >10,000 nM at μ and δ).  Microsomal stability studies demonstrated that 14 was more metabolically resistant than salvinorin A.  Evaluation of analgesic and anti-inflammatory properties revealed similar in vivo effects between 14 and salvinorin A.  To our knowledge, this study represents the first example of bioisosteric replacement of an acetate group by a spirobutyrolactone to produce a metabolically resistant deriv.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphQfDVKsiZz7Vg90H21EOLACvtfcHk0ljINPc1L02WRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1Gls7s%253D&md5=32073a4c5da4fb19e2d9adc0bba34d2d</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00148%26sid%3Dliteratum%253Aachs%26aulast%3DSherwood%26aufirst%3DA.%2BM.%26aulast%3DCrowley%26aufirst%3DR.%2BS.%26aulast%3DPaton%26aufirst%3DK.%2BF.%26aulast%3DBiggerstaff%26aufirst%3DA.%26aulast%3DNeuenswander%26aufirst%3DB.%26aulast%3DDay%26aufirst%3DV.%2BW.%26aulast%3DKivell%26aufirst%3DB.%2BM.%26aulast%3DPrisinzano%26aufirst%3DT.%2BE.%26atitle%3DAddressing%2520structural%2520flexibility%2520at%2520the%2520A-ring%2520on%2520salvinorin%2520A%253A%2520Discovery%2520of%2520a%2520potent%2520kappa-opioid%2520agonist%2520with%2520enhanced%2520metabolic%2520stability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D3866%26epage%3D3878%26doi%3D10.1021%2Facs.jmedchem.7b00148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michaelides, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluge, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Drie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risi, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karukurichi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nesterov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElligott, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langston, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmorstein, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bromberg, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesicki, E. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of spiro oxazolidinediones as selective, orally bioavailable inhibitors of p300/CBP histone acetyltransferases</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00395</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00395" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFOqsrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=28-33&author=M.+R.+Michaelidesauthor=A.+Klugeauthor=M.+Pataneauthor=J.+H.+Van+Drieauthor=C.+Wangauthor=T.+M.+Hansenauthor=R.+M.+Risiauthor=R.+Manteiauthor=C.+Hertelauthor=K.+Karukurichiauthor=A.+Nesterovauthor=D.+McElligottauthor=P.+de+Vriesauthor=J.+W.+Langstonauthor=P.+A.+Coleauthor=R.+Marmorsteinauthor=H.+Liuauthor=L.+Laskoauthor=K.+D.+Brombergauthor=A.+Laiauthor=E.+A.+Kesicki&title=Discovery+of+spiro+oxazolidinediones+as+selective%2C+orally+bioavailable+inhibitors+of+p300%2FCBP+histone+acetyltransferases&doi=10.1021%2Facsmedchemlett.7b00395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases</span></div><div class="casAuthors">Michaelides, Michael R.; Kluge, Arthur; Patane, Michael; Van Drie, John H.; Wang, Ce; Hansen, T. Matthew; Risi, Roberto M.; Mantei, Robert; Hertel, Carmen; Karukurichi, Kannan; Nesterov, Alexandre; McElligott, David; de Vries, Peter; Langston, J. William; Cole, Philip A.; Marmorstein, Ronen; Liu, Hong; Lasko, Loren; Bromberg, Kenneth D.; Lai, Albert; Kesicki, Edward A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-33</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P300 and its paralog CBP can acetylate histones and other proteins and have been implicated in a no. of diseases characterized by aberrant gene activation, such as cancer.  A novel, highly selective, orally bioavailable histone acetyltransferase (HAT) domain inhibitor has been identified through virtual ligand screening and subsequent optimization of a unique hydantoin screening hit.  Conformational restraint in the form of a spirocyclization followed by substitution with a urea led to a significant improvement in potency.  Replacement of the hydantoin moiety with an oxazolidinedione followed by fluoro substitution led to A-485, which exhibits potent cell activity, low clearance, and high oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ091OW0sfXbVg90H21EOLACvtfcHk0lh8K6WHP2bWrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOqsrnE&md5=3ba083fc5e148d06457d2e4015ac7475</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00395%26sid%3Dliteratum%253Aachs%26aulast%3DMichaelides%26aufirst%3DM.%2BR.%26aulast%3DKluge%26aufirst%3DA.%26aulast%3DPatane%26aufirst%3DM.%26aulast%3DVan%2BDrie%26aufirst%3DJ.%2BH.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHansen%26aufirst%3DT.%2BM.%26aulast%3DRisi%26aufirst%3DR.%2BM.%26aulast%3DMantei%26aufirst%3DR.%26aulast%3DHertel%26aufirst%3DC.%26aulast%3DKarukurichi%26aufirst%3DK.%26aulast%3DNesterov%26aufirst%3DA.%26aulast%3DMcElligott%26aufirst%3DD.%26aulast%3Dde%2BVries%26aufirst%3DP.%26aulast%3DLangston%26aufirst%3DJ.%2BW.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DMarmorstein%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLasko%26aufirst%3DL.%26aulast%3DBromberg%26aufirst%3DK.%2BD.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DKesicki%26aufirst%3DE.%2BA.%26atitle%3DDiscovery%2520of%2520spiro%2520oxazolidinediones%2520as%2520selective%252C%2520orally%2520bioavailable%2520inhibitors%2520of%2520p300%252FCBP%2520histone%2520acetyltransferases%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D28%26epage%3D33%26doi%3D10.1021%2Facsmedchemlett.7b00395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Escobar-Alvarez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manfredi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouerfelli, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heaney, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheinberg, D. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of human peptide deformylase disrupts mitochondrial function</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">5099</span>– <span class="NLM_lpage">5109</span>, <span class="refDoi"> DOI: 10.1128/MCB.00469-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1128%2FMCB.00469-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=20805355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVams77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=5099-5109&author=S.+Escobar-Alvarezauthor=J.+Gardnerauthor=A.+Shethauthor=G.+Manfrediauthor=G.+Yangauthor=O.+Ouerfelliauthor=M.+L.+Heaneyauthor=D.+A.+Scheinberg&title=Inhibition+of+human+peptide+deformylase+disrupts+mitochondrial+function&doi=10.1128%2FMCB.00469-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human peptide deformylase disrupts mitochondrial function</span></div><div class="casAuthors">Escobar-Alvarez, Sindy; Gardner, Jeffrey; Sheth, Aneesh; Manfredi, Giovanni; Yang, Guangli; Ouerfelli, Ouathek; Heaney, Mark L.; Scheinberg, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5099-5109</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Deformylases are metalloproteases in bacteria, plants, and humans that remove the N-formyl-methionine off peptides in vitro.  The human homolog of peptide deformylase (HsPDF) resides in the mitochondria, along with its putative formylated substrates; however, the cellular function of HsPDF remains elusive.  Here we report on the function of HsPDF in mitochondrial translation and oxidative phosphorylation complex biogenesis.  Functional HsPDF appears to be necessary for the accumulation of mitochondrial DNA-encoded proteins and assembly of new respiratory complexes contg. these proteins.  Consequently, inhibition of HsPDF reduces respiratory function and cellular ATP levels, causing dependence on aerobic glycolysis for cell survival.  A series of structurally different HsPDF inhibitors and control peptidase inhibitors confirmed that inhibition of HsPDF decreases mtDNA-encoded protein accumulation.  Therefore, HsPDF appears to have a role in maintenance of mitochondrial respiratory function, and this function is analogous to that of chloroplast PDF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZERhqg9LoibVg90H21EOLACvtfcHk0lh8K6WHP2bWrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVams77N&md5=e10c8db4910169d431baa07f6d6a2675</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1128%2FMCB.00469-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00469-10%26sid%3Dliteratum%253Aachs%26aulast%3DEscobar-Alvarez%26aufirst%3DS.%26aulast%3DGardner%26aufirst%3DJ.%26aulast%3DSheth%26aufirst%3DA.%26aulast%3DManfredi%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DOuerfelli%26aufirst%3DO.%26aulast%3DHeaney%26aufirst%3DM.%2BL.%26aulast%3DScheinberg%26aufirst%3DD.%2BA.%26atitle%3DInhibition%2520of%2520human%2520peptide%2520deformylase%2520disrupts%2520mitochondrial%2520function%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2010%26volume%3D30%26spage%3D5099%26epage%3D5109%26doi%3D10.1128%2FMCB.00469-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Randhawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chikara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehring, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yildirim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reindl, K. M.</span></span> <span> </span><span class="NLM_article-title">Overexpression of peptide deformylase in breast, colon, and lung cancers</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">321</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-13-321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1186%2F1471-2407-13-321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=23815882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1ert7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=321&author=H.+Randhawaauthor=S.+Chikaraauthor=D.+Gehringauthor=T.+Yildirimauthor=J.+Menonauthor=K.+M.+Reindl&title=Overexpression+of+peptide+deformylase+in+breast%2C+colon%2C+and+lung+cancers&doi=10.1186%2F1471-2407-13-321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of peptide deformylase in breast, colon, and lung cancers</span></div><div class="casAuthors">Randhawa, Harsharan; Chikara, Shireen; Gehring, Drew; Yildirim, Tuba; Menon, Jyotsana; Reindl, Katie M.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">321</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Human mitochondrial peptide deformylase (PDF) has been proposed as a novel cancer therapeutic target.  However, very little is known about its expression and regulation in human tissues.  The purpose of this study was to characterize the expression pattern of PDF in cancerous tissues and to identify mechanisms that regulate its expression.  Methods: The mRNA expression levels of PDF and methionine aminopeptidase 1D (MAP1D), an enzyme involved in a related pathway with PDF, were detd. using tissue panels contg. cDNA from patients with various types of cancer (breast, colon, kidney, liver, lung, ovarian, prostate, or thyroid) and human cell lines.  Protein levels of PDF were also detd. in 2 colon cancer patients via western blotting.  Colon cancer cells were treated with inhibitors of ERK, Akt, and mTOR signaling pathways and the resulting effects on PDF and MAP1D mRNA levels were detd. by qPCR for colon and lung cancer cell lines.  Finally, the effects of a PDF inhibitor, actinonin, on the proliferation of breast, colon, and prostate cell lines were detd. using the CyQUANT assay.  Results: PDF and MAP1D mRNA levels were elevated in cancer cell lines compared to non-cancer lines.  PDF mRNA levels were significantly increased in breast, colon, and lung cancer samples while MAP1D mRNA levels were increased in just colon cancers.  The expression of PDF and MAP1D varied with stage in these cancers.  Further, PDF protein expression was elevated in colon cancer tissue samples.  Inhibition of the MEK/ERK, but not PI3K or mTOR, pathway reduced the expression of PDF and MAP1D in both colon and lung cancer cell lines.  Further, inhibition of PDF with actinonin resulted in greater redn. of breast, colon, and prostate cancer cell proliferation than non-cancer cell lines.  Conclusions: This is the first report showing that PDF is over-expressed in breast, colon, and lung cancers, and the first evidence that the MEK/ERK pathway plays a role in regulating the expression of PDF and MAP1D.  The over expression of PDF in several cancers and the inhibition of cancer cell growth by a PDF inhibitor suggest this enzyme may act as an oncogene to promote cancer cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4-itOPYaIi7Vg90H21EOLACvtfcHk0lh8K6WHP2bWrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1ert7fM&md5=525b45c0c0147d4abf2a25c8ce7e3191</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-13-321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-13-321%26sid%3Dliteratum%253Aachs%26aulast%3DRandhawa%26aufirst%3DH.%26aulast%3DChikara%26aufirst%3DS.%26aulast%3DGehring%26aufirst%3DD.%26aulast%3DYildirim%26aufirst%3DT.%26aulast%3DMenon%26aufirst%3DJ.%26aulast%3DReindl%26aufirst%3DK.%2BM.%26atitle%3DOverexpression%2520of%2520peptide%2520deformylase%2520in%2520breast%252C%2520colon%252C%2520and%2520lung%2520cancers%26jtitle%3DBMC%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D321%26doi%3D10.1186%2F1471-2407-13-321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and anticancer activity of novel actinonin derivatives as HsPDF inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">6959</span>– <span class="NLM_lpage">6978</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00079</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00079" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Slt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=6959-6978&author=L.+Huauthor=X.+Caiauthor=S.+Dongauthor=Y.+Zhenauthor=J.+Huauthor=S.+Wangauthor=J.+Jiangauthor=J.+Huangauthor=Y.+Hanauthor=Y.+Qianauthor=Y.+Yuanauthor=W.+Hu&title=Synthesis+and+anticancer+activity+of+novel+actinonin+derivatives+as+HsPDF+inhibitors&doi=10.1021%2Facs.jmedchem.0c00079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and anticancer activity of novel Actinonin derivatives as HsPDF inhibitors</span></div><div class="casAuthors">Hu, Liu; Cai, Xing; Dong, Suzhen; Zhen, Yongjia; Hu, Jidi; Wang, Shenjun; Jiang, Jingwen; Huang, Jiawu; Han, Yuqiao; Qian, Yu; Yuan, Yanqiu; Hu, Wenhao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6959-6978</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human mitochondrial peptide deformylase (HsPDF) is responsible for removing the formyl group from N-terminal formylmethionines of newly synthesized mitochondrial proteins and plays important roles in maintaining mitochondria function.  It is overexpressed in various cancers and has been proposed as a novel therapeutic target.  Actinonin, a naturally occurring peptidomimetic HsPDF inhibitor, was reported to inhibit the proliferation of a broad spectrum of human cancer cells in vitro.  However, its efficacy and pharmacokinetic profile requires significant improvement for therapeutic purposes.  To obtain HsPDF inhibitors as anticancer therapeutics, we screened an inhouse collection of actinonin derivs. and found two initial hits with antiproliferation activity.  Further optimization along the peptidomimetic backbone lead to two series of compds. contg. substituted Ph moieties.  They are potent HsPDF inhibitors and exhibited greatly improved antiproliferation activity in selected cancer cell lines.  Finally, compd. (I) significantly inhibited the growth of human colon cancer in xenograft animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVqwuMEsV71bVg90H21EOLACvtfcHk0lj88WRoeMkOpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Slt7vP&md5=33ed3163f3be5502ca7f3be61de48a96</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00079%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DL.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DS.%26aulast%3DZhen%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DW.%26atitle%3DSynthesis%2520and%2520anticancer%2520activity%2520of%2520novel%2520actinonin%2520derivatives%2520as%2520HsPDF%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D6959%26epage%3D6978%26doi%3D10.1021%2Facs.jmedchem.0c00079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goadsby, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edvinsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekman, R.</span></span> <span> </span><span class="NLM_article-title">Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1002/ana.410230214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fana.410230214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=2454066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaL1cXhsVeqsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1988&pages=193-196&author=P.+J.+Goadsbyauthor=L.+Edvinssonauthor=R.+Ekman&title=Release+of+vasoactive+peptides+in+the+extracerebral+circulation+of+humans+and+the+cat+during+activation+of+the+trigeminovascular+system&doi=10.1002%2Fana.410230214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system</span></div><div class="casAuthors">Goadsby, P. J.; Edvinsson, L.; Ekman, R.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">193-6</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    </div><div class="casAbstract">The trigeminal ganglion was activated, in humans by thermocoagulation as part of the treatment of trigeminal neuralgia and in cats by elec. stimulation, and blood samples were taken from the external jugular vein for ests. of plasma levels of substance P and calcitonin gene-related peptide (CGRP).  In those patients who were noted at the time of coagulation to have flushed there were marked elevations of the local (cranial) levels of both peptides.  However, in the nonflushing patients no changes in the peptide levels were obsd.  Parallel expts. in the cat revealed that the levels of substance P-like and CGRP-like immunoreactivity were increased during elec. stimulation of the trigeminal ganglion.  The observation of elevation of substance P-like and CGRP-like immunoreactivity after activation of the nociceptive afferent system of the head provides new insights into a putative role of peptides in the pathophysiol. of migraine and cluster headache, and suggests new areas of possible therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPF6kxitFWh7Vg90H21EOLACvtfcHk0lj88WRoeMkOpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXhsVeqsLo%253D&md5=429d3f356dca62e015608b76b40ac533</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1002%2Fana.410230214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.410230214%26sid%3Dliteratum%253Aachs%26aulast%3DGoadsby%26aufirst%3DP.%2BJ.%26aulast%3DEdvinsson%26aufirst%3DL.%26aulast%3DEkman%26aufirst%3DR.%26atitle%3DRelease%2520of%2520vasoactive%2520peptides%2520in%2520the%2520extracerebral%2520circulation%2520of%2520humans%2520and%2520the%2520cat%2520during%2520activation%2520of%2520the%2520trigeminovascular%2520system%26jtitle%3DAnn.%2520Neurol.%26date%3D1988%26volume%3D23%26spage%3D193%26epage%3D196%26doi%3D10.1002%2Fana.410230214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edvinsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanes, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warfvinge, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, D. N.</span></span> <span> </span><span class="NLM_article-title">CGRP as the target of new migraine therapies - successful translation from bench to clinic</span>. <i>Nat. Rev. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">350</span>, <span class="refDoi"> DOI: 10.1038/s41582-018-0003-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2Fs41582-018-0003-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=29691490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXos1Knsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=338-350&author=L.+Edvinssonauthor=K.+A.+Haanesauthor=K.+Warfvingeauthor=D.+N.+Krause&title=CGRP+as+the+target+of+new+migraine+therapies+-+successful+translation+from+bench+to+clinic&doi=10.1038%2Fs41582-018-0003-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">CGRP as the target of new migraine therapies - successful translation from bench to clinic</span></div><div class="casAuthors">Edvinsson, Lars; Haanes, Kristian Agmund; Warfvinge, Karin; Krause, Diana N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neurology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">338-350</span>CODEN:
                <span class="NLM_cas:coden">NRNACP</span>;
        ISSN:<span class="NLM_cas:issn">1759-4758</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Treatment of migraine is on the cusp of a new era with the development of drugs that target the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its receptor.  Several of these drugs are expected to receive approval for use in migraine headache in 2018 and 2019.  CGRP-related therapies offer considerable improvements over existing drugs as they are the first to be designed specifically to act on the trigeminal pain system, they are more specific and they seem to have few or no adverse effects.  CGRP receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively prevent migraine attacks.  As these drugs come into clin. use, we provide an overview of knowledge that has led to successful development of these drugs.  We describe the biol. of CGRP signalling, summarize key clin. evidence for the role of CGRP in migraine headache, including the efficacy of CGRP-targeted treatment, and synthesize what is known about the role of CGRP in the trigeminovascular system.  Finally, we consider how the latest findings provide new insight into the central role of the trigeminal ganglion in the pathophysiol. of migraine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMGVuYa3fHurVg90H21EOLACvtfcHk0lj88WRoeMkOpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXos1Knsrk%253D&md5=bd946d0558d71beb2cf78ca43d56c78c</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fs41582-018-0003-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41582-018-0003-1%26sid%3Dliteratum%253Aachs%26aulast%3DEdvinsson%26aufirst%3DL.%26aulast%3DHaanes%26aufirst%3DK.%2BA.%26aulast%3DWarfvinge%26aufirst%3DK.%26aulast%3DKrause%26aufirst%3DD.%2BN.%26atitle%3DCGRP%2520as%2520the%2520target%2520of%2520new%2520migraine%2520therapies%2520-%2520successful%2520translation%2520from%2520bench%2520to%2520clinic%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2018%26volume%3D14%26spage%3D338%26epage%3D350%26doi%3D10.1038%2Fs41582-018-0003-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubowchik, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, A. W.</span></span> <span> </span><span class="NLM_article-title">Blocking the CGRP pathway for acute and preventive treatment of migraine: The evolution of success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">6600</span>– <span class="NLM_lpage">6623</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01810</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01810" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFGitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=6600-6623&author=G.+M.+Dubowchikauthor=C.+M.+Conwayauthor=A.+W.+Xin&title=Blocking+the+CGRP+pathway+for+acute+and+preventive+treatment+of+migraine%3A+The+evolution+of+success&doi=10.1021%2Facs.jmedchem.9b01810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success</span></div><div class="casAuthors">Dubowchik, Gene M.; Conway, Charles M.; Xin, Alison W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6600-6623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The pivotal role of calcitonin gene-related peptide (CGRP) in migraine pathophysiol. was identified over 30 years ago, but the successful clin. development of targeted therapies has only recently been realized.  This Perspective traces the decades long evolution of medicinal chem. required to advance small mol. CGRP receptor antagonists, also called gepants, including the current clin. agents rimegepant, vazegepant, ubrogepant, and atogepant.  Providing clin. effective blockade of CGRP signaling required surmounting multiple challenging hurdles, including defeating a sizable ligand with subnanomolar affinity for its receptor, designing antagonists with an extended confirmation and multiple pharmacophores while retaining soly. and oral bioavailability, and achieving circulating free plasma levels that provided near maximal CGRP receptor coverage.  The clin. efficacy of oral and intranasal gepants and the injectable CGRP monoclonal antibodies (mAbs) are described, as are recent synthetic developments that have benefited from new structural biol. data.  The first oral gepant was recently approved and heralds a new era in the treatment of migraine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM4FYBpPD8oLVg90H21EOLACvtfcHk0ljgu0eH4zwo3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFGitLY%253D&md5=f275362ece230e78851612557fec04f8</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01810%26sid%3Dliteratum%253Aachs%26aulast%3DDubowchik%26aufirst%3DG.%2BM.%26aulast%3DConway%26aufirst%3DC.%2BM.%26aulast%3DXin%26aufirst%3DA.%2BW.%26atitle%3DBlocking%2520the%2520CGRP%2520pathway%2520for%2520acute%2520and%2520preventive%2520treatment%2520of%2520migraine%253A%2520The%2520evolution%2520of%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D6600%26epage%3D6623%26doi%3D10.1021%2Facs.jmedchem.9b01810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, D.</span></span> <span> </span><span class="NLM_article-title">Sorbinil, an aldose reductase inhibitor, in fighting against diabetic complications</span>. <i>Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.2174/1573406414666180524082445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.2174%2F1573406414666180524082445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=29792152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsF2ht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=3-7&author=Q.+Huangauthor=Q.+Liuauthor=D.+Ouyang&title=Sorbinil%2C+an+aldose+reductase+inhibitor%2C+in+fighting+against+diabetic+complications&doi=10.2174%2F1573406414666180524082445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Sorbinil, an Aldose Reductase Inhibitor, in Fighting Against Diabetic Complications</span></div><div class="casAuthors">Huang, Qi; Liu, Qiong; Ouyang, Dongsheng</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-7</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: Aldose reductase (AR) is involved in the pathogenesis of diabetes, which is one of the major threats to global public health.  Objective: In this review article, we have discussed the role of sorbinil, an AR inhibitor (ARI), in preventing diabetic complications.  Results: AR contributes in diabetes by generating excess intracellular superoxide and other mediators of oxidative stress through polyol pathway.  Inhibition of AR activity thus might be a potential approach for the management of diabetic complications.  Exptl. evidences indicated that sorbinil can decrease AR activity and inhibit polyol pathway.  Both in vitro and animal model studies reported the efficacy of sorbinil in controlling the progression of diabetes.  Moreover, Sorbinil has been found to be comparatively safer than other ARIs for human use.  But, it is still in earlyphase testing for the treatment of diabetic complications clin.  Conclusion: Sorbinil is an effective ARI, which could play therapeutic role in treating diabetes and diabetic complications.  However, advanced clin. trials are required for sorbinil so that it could be applied with the lowest efficacious dose in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo868R204lrp7Vg90H21EOLACvtfcHk0ljgu0eH4zwo3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsF2ht70%253D&md5=ade5a79e7b1f01c47cc9367854103714</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.2174%2F1573406414666180524082445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1573406414666180524082445%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DOuyang%26aufirst%3DD.%26atitle%3DSorbinil%252C%2520an%2520aldose%2520reductase%2520inhibitor%252C%2520in%2520fighting%2520against%2520diabetic%2520complications%26jtitle%3DMed.%2520Chem.%26date%3D2019%26volume%3D15%26spage%3D3%26epage%3D7%26doi%3D10.2174%2F1573406414666180524082445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El-Kabbani, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darmanin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazemann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joachimiak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze-Briese, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomizaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitschler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podjarny, A.</span></span> <span> </span><span class="NLM_article-title">Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with fidarestat and minalrestat: Implications for the binding of cyclic imide inhibitors</span>. <i>Proteins: Struct., Funct., Genet.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">805</span>– <span class="NLM_lpage">813</span>, <span class="refDoi"> DOI: 10.1002/prot.20001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fprot.20001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=15146479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkslCjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2004&pages=805-813&author=O.+El-Kabbaniauthor=C.+Darmaninauthor=T.+R.+Schneiderauthor=I.+Hazemannauthor=F.+Ruizauthor=M.+Okaauthor=A.+Joachimiakauthor=C.+Schulze-Brieseauthor=T.+Tomizakiauthor=A.+Mitschlerauthor=A.+Podjarny&title=Ultrahigh+resolution+drug+design.+II.+Atomic+resolution+structures+of+human+aldose+reductase+holoenzyme+complexed+with+fidarestat+and+minalrestat%3A+Implications+for+the+binding+of+cyclic+imide+inhibitors&doi=10.1002%2Fprot.20001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: Implications for the binding of cyclic imide inhibitors</span></div><div class="casAuthors">El-Kabbani, Ossama; Darmanin, Connie; Schneider, Thomas R.; Hazemann, Isabelle; Ruiz, Federico; Oka, Mitsuru; Joachimiak, Andrzejj; Schulze-Briese, Clemens; Tomizaki, Takashi; Mitschler, Andre; Podjarny, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">805-813</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The x-ray structures of human aldose reductase holoenzyme in complex with the inhibitors Fidarestat (SNK-860) and Minalrestat (WAY-509) were detd. at at. resolns. of 0.92 Å and 1.1 Å, resp.  The hydantoin and succinimide moieties of the inhibitors interacted with the conserved anion-binding site located between the nicotinamide ring of the coenzyme and active site residues Tyr48, His110, and Trp111.  Minalrestat's hydrophobic isoquinoline ring was bound in an adjacent pocket lined by residues Trp20, Phe122, and Trp219, with the bromo-fluorobenzyl group inside the "specificity" pocket.  The interactions between Minalrestat's bromo-fluorobenzyl group and the enzyme include the stacking against the side-chain of Trp111 as well as hydrogen bonding distances with residues Leu300 and Thr113.  The carbamoyl group in Fidarestat formed a hydrogen bond with the main-chain nitrogen atom of Leu300.  The at. resoln. refinement allowed the positioning of hydrogen atoms and accurate detn. of bond lengths of the inhibitors, coenzyme NADP+ and active-site residue His110.  The 1'-position nitrogen atom in the hydantoin and succinimide moieties of Fidarestat and Minalrestat, resp., form a hydrogen bond with the Nε2 atom of His 110.  For Fidarestat, the electron d. indicated two possible positions for the H-atom in this bond.  Furthermore, both native and anomalous difference maps indicated the replacement of a water mol. linked to His110 by a CI-ion.  These observations suggest a mechanism in which Fidarestat is bound protonated and becomes neg. charged by donating the proton to His110, which may have important implications on drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9xAk-M-tpubVg90H21EOLACvtfcHk0ljgu0eH4zwo3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkslCjtLo%253D&md5=de972dd5f58825024773742f346de1cc</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1002%2Fprot.20001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.20001%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Kabbani%26aufirst%3DO.%26aulast%3DDarmanin%26aufirst%3DC.%26aulast%3DSchneider%26aufirst%3DT.%2BR.%26aulast%3DHazemann%26aufirst%3DI.%26aulast%3DRuiz%26aufirst%3DF.%26aulast%3DOka%26aufirst%3DM.%26aulast%3DJoachimiak%26aufirst%3DA.%26aulast%3DSchulze-Briese%26aufirst%3DC.%26aulast%3DTomizaki%26aufirst%3DT.%26aulast%3DMitschler%26aufirst%3DA.%26aulast%3DPodjarny%26aufirst%3DA.%26atitle%3DUltrahigh%2520resolution%2520drug%2520design.%2520II.%2520Atomic%2520resolution%2520structures%2520of%2520human%2520aldose%2520reductase%2520holoenzyme%2520complexed%2520with%2520fidarestat%2520and%2520minalrestat%253A%2520Implications%2520for%2520the%2520binding%2520of%2520cyclic%2520imide%2520inhibitors%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2004%26volume%3D55%26spage%3D805%26epage%3D813%26doi%3D10.1002%2Fprot.20001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El-Kabbani, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbone, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darmanin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitschler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podjarny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze-Briese, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, R. P.</span></span> <span> </span><span class="NLM_article-title">Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">5536</span>– <span class="NLM_lpage">5542</span>, <span class="refDoi"> DOI: 10.1021/jm050412o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050412o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmsFWntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5536-5542&author=O.+El-Kabbaniauthor=V.+Carboneauthor=C.+Darmaninauthor=M.+Okaauthor=A.+Mitschlerauthor=A.+Podjarnyauthor=C.+Schulze-Brieseauthor=R.+P.+Chung&title=Structure+of+aldehyde+reductase+holoenzyme+in+complex+with+the+potent+aldose+reductase+inhibitor+fidarestat%3A+implications+for+inhibitor+binding+and+selectivity&doi=10.1021%2Fjm050412o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of Aldehyde Reductase Holoenzyme in Complex with the Potent Aldose Reductase Inhibitor Fidarestat: Implications for Inhibitor Binding and Selectivity</span></div><div class="casAuthors">El-Kabbani, Ossama; Carbone, Vincenzo; Darmanin, Connie; Oka, Mitsuru; Mitschler, Andre; Podjarny, Alberto; Schulze-Briese, Clemens; Chung, Roland P.-T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5536-5542</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure detn. of porcine aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat was carried out to explain the difference in the potency of the inhibitor for aldose and aldehyde reductases.  The hydrogen bonds between the active-site residues Tyr50, His113, and Trp114 and fidarestat are conserved in the two enzymes.  In aldose reductase, Leu300 forms a hydrogen bond through its main-chain nitrogen atom with the exocyclic amide group of the inhibitor, which when replaced with a Pro in aldehyde reductase, cannot form a hydrogen bond, thus causing a loss in binding energy.  Furthermore, in aldehyde reductase, the side chain of Trp220 occupies a disordered split conformation that is not obsd. in aldose reductase.  Mol. modeling and inhibitory activity measurements suggest that the difference in the interaction between the side chain of Trp220 and fidarestat may contribute to the difference in the binding of the inhibitor to the enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgas3h39we_rVg90H21EOLACvtfcHk0ljzdOnOViHV7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmsFWntr4%253D&md5=675d54ec62f286d84e31b9b0a5ab03e3</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1021%2Fjm050412o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050412o%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Kabbani%26aufirst%3DO.%26aulast%3DCarbone%26aufirst%3DV.%26aulast%3DDarmanin%26aufirst%3DC.%26aulast%3DOka%26aufirst%3DM.%26aulast%3DMitschler%26aufirst%3DA.%26aulast%3DPodjarny%26aufirst%3DA.%26aulast%3DSchulze-Briese%26aufirst%3DC.%26aulast%3DChung%26aufirst%3DR.%2BP.%26atitle%3DStructure%2520of%2520aldehyde%2520reductase%2520holoenzyme%2520in%2520complex%2520with%2520the%2520potent%2520aldose%2520reductase%2520inhibitor%2520fidarestat%253A%2520implications%2520for%2520inhibitor%2520binding%2520and%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5536%26epage%3D5542%26doi%3D10.1021%2Fjm050412o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Negoro, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujitani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuromiya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komiya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, J.</span></span> <span> </span><span class="NLM_article-title">Novel, highly potent aldose reductase inhibitors: (<i>R</i>)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3′-pyrrolidine-1,2′,3,5′-tetrone (AS-3201) and its congeners</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">4118</span>– <span class="NLM_lpage">4129</span>, <span class="refDoi"> DOI: 10.1021/jm9802968</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9802968" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaK1cXlvFGitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=4118-4129&author=T.+Negoroauthor=M.+Murataauthor=S.+Uedaauthor=B.+Fujitaniauthor=Y.+Onoauthor=A.+Kuromiyaauthor=M.+Komiyaauthor=K.+Suzukiauthor=J.+Matsumoto&title=Novel%2C+highly+potent+aldose+reductase+inhibitors%3A+%28R%29-%28-%29-2-%284-bromo-2-fluorobenzyl%29-1%2C2%2C3%2C4-tetrahydropyrrolo%5B1%2C2-a%5Dpyrazine-4-spiro-3%E2%80%B2-pyrrolidine-1%2C2%E2%80%B2%2C3%2C5%E2%80%B2-tetrone+%28AS-3201%29+and+its+congeners&doi=10.1021%2Fjm9802968"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Novel, Highly Potent Aldose Reductase Inhibitors: (R)-(-)-2-(4-Bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine- 4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and Its Congeners</span></div><div class="casAuthors">Negoro, Toshiyuki; Murata, Makoto; Ueda, Shozo; Fujitani, Buichi; Ono, Yoshiyuki; Kuromiya, Akemi; Komiya, Masanobu; Suzuki, Kenji; Matsumoto, Jun-ichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4118-4129</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of novel tetrahydropyrrolo[1,2-a]pyrazine derivs. were synthesized and evaluated as aldose reductase inhibitors on the basis of their abilities to inhibit porcine lens aldose reductase in vitro and to inhibit sorbitol accumulation in the sciatic nerve of streptozotocin-induced diabetic rats in vivo.  Of these compds., spirosuccinimide-fused tetrahydropyrrolo[1,2-a]pyrazine-1,3-dione derivs. showed significantly potent aldose reductase inhibitory activity.  In the in vivo activity of these derivs., 2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (I) (SX-3030) showed the best oral activity.  The enantiomers of I were synthesized, and the biol. activities were evaluated.  It was found that aldose reductase inhibitory activity resides in the (-)-I (AS-3201), which was 10 times more potent in inhibition of the aldose reductase (IC50 = 1.5 × 10-8 M) and 500 times more potent in the in vivo activity (ED50 = 0.18 mg/kg/day for 5 days) than the corresponding (+)-I (SX-3202).  From these results, AS-3201 was selected as the candidate for clin. development.  The abs. configuration of AS-3201 was also established to be (R)-form by single-crystal X-ray anal.  In this article we report the prepn. and structure-activity relationship of tetrahydropyrrolopyrazine derivs. including a novel aldose reductase inhibitor, AS-3201.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxzCKd8YdPTbVg90H21EOLACvtfcHk0ljzdOnOViHV7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlvFGitL4%253D&md5=6793771a43992b477d2fbf48caf7f207</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Fjm9802968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9802968%26sid%3Dliteratum%253Aachs%26aulast%3DNegoro%26aufirst%3DT.%26aulast%3DMurata%26aufirst%3DM.%26aulast%3DUeda%26aufirst%3DS.%26aulast%3DFujitani%26aufirst%3DB.%26aulast%3DOno%26aufirst%3DY.%26aulast%3DKuromiya%26aufirst%3DA.%26aulast%3DKomiya%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DMatsumoto%26aufirst%3DJ.%26atitle%3DNovel%252C%2520highly%2520potent%2520aldose%2520reductase%2520inhibitors%253A%2520%2528R%2529-%2528-%2529-2-%25284-bromo-2-fluorobenzyl%2529-1%252C2%252C3%252C4-tetrahydropyrrolo%255B1%252C2-a%255Dpyrazine-4-spiro-3%25E2%2580%25B2-pyrrolidine-1%252C2%25E2%2580%25B2%252C3%252C5%25E2%2580%25B2-tetrone%2520%2528AS-3201%2529%2520and%2520its%2520congeners%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D4118%26epage%3D4129%26doi%3D10.1021%2Fjm9802968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urzhumtsev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tete-Favier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitschler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbanton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urzhumtseva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biellmann, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podjarny, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moras, D.</span></span> <span> </span><span class="NLM_article-title">A ‘specificity’ pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">612</span>, <span class="refDoi"> DOI: 10.1016/S0969-2126(97)00216-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2FS0969-2126%2897%2900216-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=9195881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaK2sXjvFamt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1997&pages=601-612&author=A.+Urzhumtsevauthor=F.+Tete-Favierauthor=A.+Mitschlerauthor=J.+Barbantonauthor=P.+Barthauthor=L.+Urzhumtsevaauthor=J.+F.+Biellmannauthor=A.+Podjarnyauthor=D.+Moras&title=A+%E2%80%98specificity%E2%80%99+pocket+inferred+from+the+crystal+structures+of+the+complexes+of+aldose+reductase+with+the+pharmaceutically+important+inhibitors+tolrestat+and+sorbinil&doi=10.1016%2FS0969-2126%2897%2900216-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">A "specificity" pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil</span></div><div class="casAuthors">Urzhumtsev, A.; Tete-Favier, F.; Mitschler, A.; Barbanton, J.; Barth, P.; Urzhumtseva, L.; Biellmann, J.F.; Podjarny, A.D.; Moras, D.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">601-612</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Current Biology</span>)
        </div><div class="casAbstract">Aldose reductase (AR) is an NADPH-dependent enzyme implicated in long-term diabetic complications.  Buried at the bottom of a deep hydrophobic cleft, the NADPH coenzyme is surrounded by the conserved hydrophilic residues of the AR active site.  The existence of an anionic binding site near the NADP+ has been detd. from the structures of the complexes of AR with citrate, cacodylate and glucose-6-phosphate.  The inhibitor zopolrestat binds to this anionic site, and in the hydrophobic cleft, after a change of conformation which opens a "specificity" pocket.  The crystal structures of the porcine AR holoenzyme and its complexes with the inhibitors tolrestat and sorbinil have been solved; these structures are important as tolrestat and sorbinil are, pharmaceutically, the most well-studied AR inhibitors.  The active site of the holoenzyme was analyzed, and binding of the inhibitors was found to involve two contact zones in the active site; first, a recognition region for hydrogen-bond acceptors near the coenzyme, with three centers, including the anionic site; and second, a hydrophobic contact zone in the active-site cleft, which in the case of tolrestat includes the specificity pocket.  The conformational change leading to the opening of the specificity pocket upon tolrestat binding is different to the one seen upon zopolrestat binding; this pocket binds inhibitors that are more effective against AR than against aldehyde reductase.  The active site of AR adapts itself to bind tightly to different inhibitors; this happens both upon binding to the inhibitor's hydrophilic heads, and at the hydrophobic and specificity pockets of AR, which can change their shape through different conformational change of the same residues.  This flexibility could explain the large variety of possible substrates of AR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryQrSqGzZR_7Vg90H21EOLACvtfcHk0ljzdOnOViHV7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjvFamt7o%253D&md5=309b86f73d9cacb2667c6b8d609fca28</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2FS0969-2126%2897%2900216-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0969-2126%252897%252900216-5%26sid%3Dliteratum%253Aachs%26aulast%3DUrzhumtsev%26aufirst%3DA.%26aulast%3DTete-Favier%26aufirst%3DF.%26aulast%3DMitschler%26aufirst%3DA.%26aulast%3DBarbanton%26aufirst%3DJ.%26aulast%3DBarth%26aufirst%3DP.%26aulast%3DUrzhumtseva%26aufirst%3DL.%26aulast%3DBiellmann%26aufirst%3DJ.%2BF.%26aulast%3DPodjarny%26aufirst%3DA.%26aulast%3DMoras%26aufirst%3DD.%26atitle%3DA%2520%25E2%2580%2598specificity%25E2%2580%2599%2520pocket%2520inferred%2520from%2520the%2520crystal%2520structures%2520of%2520the%2520complexes%2520of%2520aldose%2520reductase%2520with%2520the%2520pharmaceutically%2520important%2520inhibitors%2520tolrestat%2520and%2520sorbinil%26jtitle%3DStructure%26date%3D1997%26volume%3D5%26spage%3D601%26epage%3D612%26doi%3D10.1016%2FS0969-2126%2897%2900216-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El-Kabbani, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darmanin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulze-Briese, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomizaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazemann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitschler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podjarny, A.</span></span> <span> </span><span class="NLM_article-title">High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor Fidarestat: stereospecific interaction between the enzyme and a cyclic imide type inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">4530</span>– <span class="NLM_lpage">4537</span>, <span class="refDoi"> DOI: 10.1021/jm0497794</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0497794" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVeiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=4530-4537&author=O.+El-Kabbaniauthor=C.+Darmaninauthor=M.+Okaauthor=C.+Schulze-Brieseauthor=T.+Tomizakiauthor=I.+Hazemannauthor=A.+Mitschlerauthor=A.+Podjarny&title=High-resolution+structures+of+human+aldose+reductase+holoenzyme+in+complex+with+stereoisomers+of+the+potent+inhibitor+Fidarestat%3A+stereospecific+interaction+between+the+enzyme+and+a+cyclic+imide+type+inhibitor&doi=10.1021%2Fjm0497794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">High-Resolution Structures of Human Aldose Reductase Holoenzyme in Complex with Stereoisomers of the Potent Inhibitor Fidarestat: Stereospecific Interaction between the Enzyme and a Cyclic Imide Type Inhibitor</span></div><div class="casAuthors">El-Kabbani, Ossama; Darmanin, Connie; Oka, Mitsuru; Schulze-Briese, Clemens; Tomizaki, Takashi; Hazemann, Isabelle; Mitschler, Andre; Podjarny, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4530-4537</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure detns. of human aldose reductase holoenzyme in complex with the 2S,4R-, 2R,4S- and 2R,4R-isomers of the potent inhibitor Fidarestat ((2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazoline]-2-carboxamide) were carried out to elucidate the binding modes responsible for the differences in their inhibitory potencies.  In the complex structure with the 2R4S-isomer the cyclic imide moiety formed hydrogen bonds with the side-chains of Trp-111, Tyr-48 and His-110.  In the attempt to det. the complex structure with the least potent 2R4R-isomer this ligand was not obsd., and instead, the active site was simultaneously occupied by two citrate mols. (occupancies of 60% and 40%).  In the case of 2S4R, the active site was occupied by a citrate mol. which anchors the 2S4R-isomer from its carbamoyl group.  The structures of the complexes suggest that the differences in the interactions between the cyclic imide rings and carbamoyl groups of the compds. with residues His-110, Trp-111, Trp-219 and Cys-298 account for differences in their inhibitory potencies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-nKSIwDdmorVg90H21EOLACvtfcHk0lg0QhELSpqOTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVeiur8%253D&md5=3e66fa908fcb38393800c7d33e5d916f</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Fjm0497794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0497794%26sid%3Dliteratum%253Aachs%26aulast%3DEl-Kabbani%26aufirst%3DO.%26aulast%3DDarmanin%26aufirst%3DC.%26aulast%3DOka%26aufirst%3DM.%26aulast%3DSchulze-Briese%26aufirst%3DC.%26aulast%3DTomizaki%26aufirst%3DT.%26aulast%3DHazemann%26aufirst%3DI.%26aulast%3DMitschler%26aufirst%3DA.%26aulast%3DPodjarny%26aufirst%3DA.%26atitle%3DHigh-resolution%2520structures%2520of%2520human%2520aldose%2520reductase%2520holoenzyme%2520in%2520complex%2520with%2520stereoisomers%2520of%2520the%2520potent%2520inhibitor%2520Fidarestat%253A%2520stereospecific%2520interaction%2520between%2520the%2520enzyme%2520and%2520a%2520cyclic%2520imide%2520type%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D4530%26epage%3D4537%26doi%3D10.1021%2Fjm0497794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohtake, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmori, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of tofogliflozin, a novel C-arylglucoside with an <i>O</i>-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7828</span>– <span class="NLM_lpage">7840</span>, <span class="refDoi"> DOI: 10.1021/jm300884k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300884k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOrurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7828-7840&author=Y.+Ohtakeauthor=T.+Satoauthor=T.+Kobayashiauthor=M.+Nishimotoauthor=N.+Takaauthor=K.+Takanoauthor=K.+Yamamotoauthor=M.+Ohmoriauthor=M.+Yamaguchiauthor=K.+Takamiauthor=S.+Y.+Yeuauthor=K.+H.+Ahnauthor=H.+Matsuokaauthor=K.+Morikawaauthor=M.+Suzukiauthor=H.+Hagitaauthor=K.+Ozawaauthor=K.+Yamaguchiauthor=M.+Katoauthor=S.+Ikeda&title=Discovery+of+tofogliflozin%2C+a+novel+C-arylglucoside+with+an+O-spiroketal+ring+system%2C+as+a+highly+selective+sodium+glucose+cotransporter+2+%28SGLT2%29+inhibitor+for+the+treatment+of+type+2+diabetes&doi=10.1021%2Fjm300884k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tofogliflozin, a Novel C-Arylglucoside with an O-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes</span></div><div class="casAuthors">Ohtake, Yoshihito; Sato, Tsutomu; Kobayashi, Takamitsu; Nishimoto, Masahiro; Taka, Naoki; Takano, Koji; Yamamoto, Keisuke; Ohmori, Masayuki; Yamaguchi, Marina; Takami, Kyoko; Yeu, Sang-Yong; Ahn, Koo-Hyeon; Matsuoka, Hiroharu; Morikawa, Kazumi; Suzuki, Masayuki; Hagita, Hitoshi; Ozawa, Kazuharu; Yamaguchi, Koji; Kato, Motohiro; Ikeda, Sachiya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7828-7840</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of sodium glucose cotransporter 2 (SGLT2) has been proposed as a novel therapeutic approach to treat type 2 diabetes.  In our efforts to discover novel inhibitors of SGLT2, we first generated a 3D pharmacophore model based on the superposition of known inhibitors.  A search of the Cambridge Structural Database using a series of pharmacophore queries led to the discovery of an O-spiroketal C-arylglucoside scaffold.  Subsequent chem. examn. combined with computational modeling resulted in the identification of the clin. candidate CSG452 (tofogliflozin), which is currently under phase III clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeIDNjd6qaWLVg90H21EOLACvtfcHk0lg0QhELSpqOTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOrurfN&md5=174a0538c13a286dd320a52395e1dd85</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1021%2Fjm300884k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300884k%26sid%3Dliteratum%253Aachs%26aulast%3DOhtake%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DNishimoto%26aufirst%3DM.%26aulast%3DTaka%26aufirst%3DN.%26aulast%3DTakano%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DK.%26aulast%3DOhmori%26aufirst%3DM.%26aulast%3DYamaguchi%26aufirst%3DM.%26aulast%3DTakami%26aufirst%3DK.%26aulast%3DYeu%26aufirst%3DS.%2BY.%26aulast%3DAhn%26aufirst%3DK.%2BH.%26aulast%3DMatsuoka%26aufirst%3DH.%26aulast%3DMorikawa%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DHagita%26aufirst%3DH.%26aulast%3DOzawa%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DIkeda%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520tofogliflozin%252C%2520a%2520novel%2520C-arylglucoside%2520with%2520an%2520O-spiroketal%2520ring%2520system%252C%2520as%2520a%2520highly%2520selective%2520sodium%2520glucose%2520cotransporter%25202%2520%2528SGLT2%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520type%25202%2520diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7828%26epage%3D7840%26doi%3D10.1021%2Fjm300884k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patchett, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nargund, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tata, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barakat, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacks, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pong, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaung, L. Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, S. H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, R. G.</span></span> <span> </span><span class="NLM_article-title">Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">7001</span>– <span class="NLM_lpage">7005</span>, <span class="refDoi"> DOI: 10.1073/pnas.92.15.7001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1073%2Fpnas.92.15.7001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=7624358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADyaK2MXntVSktLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1995&pages=7001-7005&author=A.+A.+Patchettauthor=R.+P.+Nargundauthor=J.+R.+Tataauthor=M.+H.+Chenauthor=K.+J.+Barakatauthor=D.+B.+Johnstonauthor=K.+Chengauthor=W.+W.+Chanauthor=B.+Butlerauthor=G.+Hickeyauthor=T.+Jacksauthor=K.+Schleimauthor=S.+S.+Pongauthor=L.+Y.+P.+Chaungauthor=H.+Y.+Chenauthor=E.+Frazierauthor=K.+H.+Leungauthor=S.+H.+L.+Chiuauthor=R.+G.+Smith&title=Design+and+biological+activities+of+L-163%2C191+%28MK-0677%29%3A+a+potent%2C+orally+active+growth+hormone+secretagogue&doi=10.1073%2Fpnas.92.15.7001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue</span></div><div class="casAuthors">Patchett, A. A.; Nargund, R. P.; Tata, J. R.; Chen, M.-H.; Barakat, K. J.; Johnston, D. B. R.; Cheng, K.; Chan, W. W.-S.; Butler, B.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7001-5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A potent, orally active growth hormone (GH) secretagogue L-163,191 belonging to a recently synthesized structural class has been characterized.  L-163,191 releases GH from rat pituitary cells in culture with EC50 = 1.3 nM and is mechanistically indistinguishable from the GH-releasing peptide GHRP-6 and the prototypical nonpeptide GH secretagogue L-692,429 but clearly distinguishable from the natural GH secretagogue, GH-releasing hormone.  L-163,191 elevates GH in dogs after oral doses as low as 0.125 mg/kg and was shown to be specific in its release of GH without significant effect on plasma levels of aldosterone, LH, thyroxine, and prolactin after oral administration of 1 mg/kg.  Only modest increases in cortisol were obsd.  Based on these properties, L-163,191 has been selected for clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3UFEi4P46gbVg90H21EOLACvtfcHk0lg0QhELSpqOTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXntVSktLw%253D&md5=4e008b20d4713e41d2f0ee4b2113d851</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1073%2Fpnas.92.15.7001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.92.15.7001%26sid%3Dliteratum%253Aachs%26aulast%3DPatchett%26aufirst%3DA.%2BA.%26aulast%3DNargund%26aufirst%3DR.%2BP.%26aulast%3DTata%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DM.%2BH.%26aulast%3DBarakat%26aufirst%3DK.%2BJ.%26aulast%3DJohnston%26aufirst%3DD.%2BB.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DW.%2BW.%26aulast%3DButler%26aufirst%3DB.%26aulast%3DHickey%26aufirst%3DG.%26aulast%3DJacks%26aufirst%3DT.%26aulast%3DSchleim%26aufirst%3DK.%26aulast%3DPong%26aufirst%3DS.%2BS.%26aulast%3DChaung%26aufirst%3DL.%2BY.%2BP.%26aulast%3DChen%26aufirst%3DH.%2BY.%26aulast%3DFrazier%26aufirst%3DE.%26aulast%3DLeung%26aufirst%3DK.%2BH.%26aulast%3DChiu%26aufirst%3DS.%2BH.%2BL.%26aulast%3DSmith%26aufirst%3DR.%2BG.%26atitle%3DDesign%2520and%2520biological%2520activities%2520of%2520L-163%252C191%2520%2528MK-0677%2529%253A%2520a%2520potent%252C%2520orally%2520active%2520growth%2520hormone%2520secretagogue%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1995%26volume%3D92%26spage%3D7001%26epage%3D7005%26doi%3D10.1073%2Fpnas.92.15.7001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carpino, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefker, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toler, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadcock, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiBrino, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campeta, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeNinno, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chidsey-Frink, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hada, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inthavongsay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangano, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullins, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickerson, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirie, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tess, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawistoski, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DaSilva-Jardine, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D. D.</span></span> <span> </span><span class="NLM_article-title">Pyrazolinone-piperidine dipeptide growth hormone secretagogues (GHSs). Discovery of capromorelin</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">590</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(02)00433-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2FS0968-0896%2802%2900433-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=12538023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlt1OltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2003&pages=581-590&author=P.+A.+Carpinoauthor=B.+A.+Lefkerauthor=S.+M.+Tolerauthor=L.+C.+Panauthor=J.+R.+Hadcockauthor=E.+R.+Cookauthor=J.+N.+DiBrinoauthor=A.+M.+Campetaauthor=S.+L.+DeNinnoauthor=K.+L.+Chidsey-Frinkauthor=W.+A.+Hadaauthor=J.+Inthavongsayauthor=F.+M.+Manganoauthor=M.+A.+Mullinsauthor=D.+F.+Nickersonauthor=O.+Ngauthor=C.+M.+Pirieauthor=J.+A.+Raganauthor=C.+R.+Roseauthor=D.+A.+Tessauthor=A.+S.+Wrightauthor=L.+Yuauthor=M.+P.+Zawistoskiauthor=P.+A.+DaSilva-Jardineauthor=T.+C.+Wilsonauthor=D.+D.+Thompson&title=Pyrazolinone-piperidine+dipeptide+growth+hormone+secretagogues+%28GHSs%29.+Discovery+of+capromorelin&doi=10.1016%2FS0968-0896%2802%2900433-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolinone-piperidine dipeptide growth hormone secretagogues (GHSs): discovery of capromorelin</span></div><div class="casAuthors">Carpino, Philip A.; Lefker, Bruce A.; Toler, Steven M.; Pan, Lydia C.; Hadcock, John R.; Cook, Ewell R.; DiBrino, Joseph N.; Campeta, Anthony M.; DeNinno, Shari L.; Chidsey-Frink, Kristin L.; Hada, William A.; Inthavongsay, John; Mangano, F. Michael; Mullins, Michelle A.; Nickerson, David F.; Ng, Oicheng; Pirie, Christine M.; Ragan, John A.; Rose, Colin R.; Tess, David A.; Wright, Ann S.; Yu, Li; Zawistoski, Michael P.; DaSilva-Jardine, Paul A.; Wilson, Theresa C.; Thompson, David D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">581-590</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Novel pyrazolinone-piperidine dipeptide derivs. were synthesized and evaluated as growth hormone secretagogues (GHSs).  Two analogs, capromorelin (5, CP-424391-18, hGHS-R1a Ki=7 nM, rat pituicyte EC50=3 nM) and the des-Me analog 5c (hGHS-R1a Ki=17 nM, rat pituicyte EC50=3 nM), increased plasma GH levels in an anesthetized rat model, with ED50 values less than 0.05 mg/kg iv.  Capromorelin showed enhanced intestinal absorption in rodent models and exhibited superior pharmacokinetic properties, including high bioavailabilities in two animal species [F(rat)=65%, F(dog)=44%].  This short-duration GHS was orally active in canine models and was selected as a development candidate for the treatment of musculoskeletal frailty in elderly adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomT-CMS1N-_7Vg90H21EOLACvtfcHk0lj0-KT2vk76vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlt1OltQ%253D%253D&md5=bc0b258bb650a827188bf33fb1399cc1</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2802%2900433-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252802%252900433-9%26sid%3Dliteratum%253Aachs%26aulast%3DCarpino%26aufirst%3DP.%2BA.%26aulast%3DLefker%26aufirst%3DB.%2BA.%26aulast%3DToler%26aufirst%3DS.%2BM.%26aulast%3DPan%26aufirst%3DL.%2BC.%26aulast%3DHadcock%26aufirst%3DJ.%2BR.%26aulast%3DCook%26aufirst%3DE.%2BR.%26aulast%3DDiBrino%26aufirst%3DJ.%2BN.%26aulast%3DCampeta%26aufirst%3DA.%2BM.%26aulast%3DDeNinno%26aufirst%3DS.%2BL.%26aulast%3DChidsey-Frink%26aufirst%3DK.%2BL.%26aulast%3DHada%26aufirst%3DW.%2BA.%26aulast%3DInthavongsay%26aufirst%3DJ.%26aulast%3DMangano%26aufirst%3DF.%2BM.%26aulast%3DMullins%26aufirst%3DM.%2BA.%26aulast%3DNickerson%26aufirst%3DD.%2BF.%26aulast%3DNg%26aufirst%3DO.%26aulast%3DPirie%26aufirst%3DC.%2BM.%26aulast%3DRagan%26aufirst%3DJ.%2BA.%26aulast%3DRose%26aufirst%3DC.%2BR.%26aulast%3DTess%26aufirst%3DD.%2BA.%26aulast%3DWright%26aufirst%3DA.%2BS.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DZawistoski%26aufirst%3DM.%2BP.%26aulast%3DDaSilva-Jardine%26aufirst%3DP.%2BA.%26aulast%3DWilson%26aufirst%3DT.%2BC.%26aulast%3DThompson%26aufirst%3DD.%2BD.%26atitle%3DPyrazolinone-piperidine%2520dipeptide%2520growth%2520hormone%2520secretagogues%2520%2528GHSs%2529.%2520Discovery%2520of%2520capromorelin%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2003%26volume%3D11%26spage%3D581%26epage%3D590%26doi%3D10.1016%2FS0968-0896%2802%2900433-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorneloe, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsaid, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenhard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jian, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maniscalco-Hauk, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawiec, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olzinski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozinskaya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elefante, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matasic, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tunstead, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waszkiewicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davenport, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casillas, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquis, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidam, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toomey, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roethke, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jucker, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnackenberg, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsley, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepore, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willette, R. N.</span></span> <span> </span><span class="NLM_article-title">An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">159ra148</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.3004276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1126%2Fscitranslmed.3004276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=23136043" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&author=K.+S.+Thorneloeauthor=M.+Cheungauthor=W.+Baoauthor=H.+Alsaidauthor=S.+Lenhardauthor=M.+Y.+Jianauthor=M.+Costellauthor=K.+Maniscalco-Haukauthor=J.+A.+Krawiecauthor=A.+Olzinskiauthor=E.+Gordonauthor=I.+Lozinskayaauthor=L.+Elefanteauthor=P.+Qinauthor=D.+S.+Matasicauthor=C.+Jamesauthor=J.+Tunsteadauthor=B.+Donovanauthor=L.+Kallalauthor=A.+Waszkiewiczauthor=K.+Vaidyaauthor=E.+A.+Davenportauthor=J.+Larkinauthor=M.+Burgertauthor=L.+N.+Casillasauthor=R.+W.+Marquisauthor=G.+Yeauthor=H.+S.+Eidamauthor=K.+B.+Goodmanauthor=J.+R.+Toomeyauthor=T.+J.+Roethkeauthor=B.+M.+Juckerauthor=C.+G.+Schnackenbergauthor=M.+I.+Townsleyauthor=J.+J.+Leporeauthor=R.+N.+Willette&title=An+orally+active+TRPV4+channel+blocker+prevents+and+resolves+pulmonary+edema+induced+by+heart+failure&doi=10.1126%2Fscitranslmed.3004276"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3004276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3004276%26sid%3Dliteratum%253Aachs%26aulast%3DThorneloe%26aufirst%3DK.%2BS.%26aulast%3DCheung%26aufirst%3DM.%26aulast%3DBao%26aufirst%3DW.%26aulast%3DAlsaid%26aufirst%3DH.%26aulast%3DLenhard%26aufirst%3DS.%26aulast%3DJian%26aufirst%3DM.%2BY.%26aulast%3DCostell%26aufirst%3DM.%26aulast%3DManiscalco-Hauk%26aufirst%3DK.%26aulast%3DKrawiec%26aufirst%3DJ.%2BA.%26aulast%3DOlzinski%26aufirst%3DA.%26aulast%3DGordon%26aufirst%3DE.%26aulast%3DLozinskaya%26aufirst%3DI.%26aulast%3DElefante%26aufirst%3DL.%26aulast%3DQin%26aufirst%3DP.%26aulast%3DMatasic%26aufirst%3DD.%2BS.%26aulast%3DJames%26aufirst%3DC.%26aulast%3DTunstead%26aufirst%3DJ.%26aulast%3DDonovan%26aufirst%3DB.%26aulast%3DKallal%26aufirst%3DL.%26aulast%3DWaszkiewicz%26aufirst%3DA.%26aulast%3DVaidya%26aufirst%3DK.%26aulast%3DDavenport%26aufirst%3DE.%2BA.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DBurgert%26aufirst%3DM.%26aulast%3DCasillas%26aufirst%3DL.%2BN.%26aulast%3DMarquis%26aufirst%3DR.%2BW.%26aulast%3DYe%26aufirst%3DG.%26aulast%3DEidam%26aufirst%3DH.%2BS.%26aulast%3DGoodman%26aufirst%3DK.%2BB.%26aulast%3DToomey%26aufirst%3DJ.%2BR.%26aulast%3DRoethke%26aufirst%3DT.%2BJ.%26aulast%3DJucker%26aufirst%3DB.%2BM.%26aulast%3DSchnackenberg%26aufirst%3DC.%2BG.%26aulast%3DTownsley%26aufirst%3DM.%2BI.%26aulast%3DLepore%26aufirst%3DJ.%2BJ.%26aulast%3DWillette%26aufirst%3DR.%2BN.%26atitle%3DAn%2520orally%2520active%2520TRPV4%2520channel%2520blocker%2520prevents%2520and%2520resolves%2520pulmonary%2520edema%2520induced%2520by%2520heart%2520failure%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2012%26volume%3D4%26doi%3D10.1126%2Fscitranslmed.3004276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behm, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eidam, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoang, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilfiker, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawhorn, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roethke, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorneloe, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of GSK2798745: A clinical candidate for inhibition of transient receptor potential vanilloid 4 (TRPV4)</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1228</span>– <span class="NLM_lpage">1233</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00274</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00274" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOhurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1228-1233&author=C.+A.+Brooksauthor=L.+S.+Bartonauthor=D.+J.+Behmauthor=H.+S.+Eidamauthor=R.+M.+Foxauthor=M.+Hammondauthor=T.+H.+Hoangauthor=D.+A.+Holtauthor=M.+A.+Hilfikerauthor=B.+G.+Lawhornauthor=J.+R.+Pattersonauthor=P.+Stoyauthor=T.+J.+Roethkeauthor=G.+Yeauthor=S.+Zhaoauthor=K.+S.+Thorneloeauthor=K.+B.+Goodmanauthor=M.+Cheung&title=Discovery+of+GSK2798745%3A+A+clinical+candidate+for+inhibition+of+transient+receptor+potential+vanilloid+4+%28TRPV4%29&doi=10.1021%2Facsmedchemlett.9b00274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4)</span></div><div class="casAuthors">Brooks, Carl A.; Barton, Linda S.; Behm, David J.; Eidam, Hilary S.; Fox, Ryan M.; Hammond, Marlys; Hoang, Tram H.; Holt, Dennis A.; Hilfiker, Mark A.; Lawhorn, Brian G.; Patterson, Jaclyn R.; Stoy, Patrick; Roethke, Theresa J.; Ye, Guosen; Zhao, Steve; Thorneloe, Kevin S.; Goodman, Krista B.; Cheung, Mui</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1228-1233</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">GSK2798745, a clin. candidate, was identified as an inhibitor of the transient receptor potential vanilloid 4 (TRPV4) ion channel for the treatment of pulmonary edema assocd. with congestive heart failure.  The lead optimization of this novel spirocarbamate series and specifically focus on the authors' strategies and solns. for achieving desirable potency, rat pharmacokinetics, and physicochem. properties are discussed.  The authors highlight the use of conformational bias to deliver potency and optimization of vol. of distribution and unbound clearance to enable desirable in vivo mean residence times.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeTgvHBnx5ObVg90H21EOLACvtfcHk0ljTIk__XhaKPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOhurfK&md5=fce123551c6d6d336cfb1270c2513a18</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00274%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DC.%2BA.%26aulast%3DBarton%26aufirst%3DL.%2BS.%26aulast%3DBehm%26aufirst%3DD.%2BJ.%26aulast%3DEidam%26aufirst%3DH.%2BS.%26aulast%3DFox%26aufirst%3DR.%2BM.%26aulast%3DHammond%26aufirst%3DM.%26aulast%3DHoang%26aufirst%3DT.%2BH.%26aulast%3DHolt%26aufirst%3DD.%2BA.%26aulast%3DHilfiker%26aufirst%3DM.%2BA.%26aulast%3DLawhorn%26aufirst%3DB.%2BG.%26aulast%3DPatterson%26aufirst%3DJ.%2BR.%26aulast%3DStoy%26aufirst%3DP.%26aulast%3DRoethke%26aufirst%3DT.%2BJ.%26aulast%3DYe%26aufirst%3DG.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DThorneloe%26aufirst%3DK.%2BS.%26aulast%3DGoodman%26aufirst%3DK.%2BB.%26aulast%3DCheung%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520GSK2798745%253A%2520A%2520clinical%2520candidate%2520for%2520inhibition%2520of%2520transient%2520receptor%2520potential%2520vanilloid%25204%2520%2528TRPV4%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1228%26epage%3D1233%26doi%3D10.1021%2Facsmedchemlett.9b00274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span> <span> </span><span class="NLM_article-title">Expression of polo-like kinase 4 (PLK4) in breast cancer and its response to taxane-based neoadjuvant chemotherapy</span>. <i>J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1125</span>– <span class="NLM_lpage">1132</span>, <span class="refDoi"> DOI: 10.7150/jca.14307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.7150%2Fjca.14307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=27326256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmsFGltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1125-1132&author=Z.+Liauthor=K.+Daiauthor=C.+Wangauthor=Y.+Songauthor=F.+Guauthor=F.+Liuauthor=L.+Fu&title=Expression+of+polo-like+kinase+4+%28PLK4%29+in+breast+cancer+and+its+response+to+taxane-based+neoadjuvant+chemotherapy&doi=10.7150%2Fjca.14307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of Polo-Like Kinase 4(PLK4) in breast cancer and its response to taxane-based neoadjuvant chemotherapy</span></div><div class="casAuthors">Li, Zhenhua; Dai, Kun; Wang, Chijuan; Song, Yawen; Gu, Feng; Liu, Fangfang; Li, Fu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer (Wyoming, Australia)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1125-1132</span>CODEN:
                <span class="NLM_cas:coden">JCWAAL</span>;
        ISSN:<span class="NLM_cas:issn">1837-9664</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher Pty Ltd.</span>)
        </div><div class="casAbstract">Purpose: Polo-like kinase 4(PLK4) is an important evolutionarily regulator involved in centrosome duplication.  We here investigated the expression of PLK4 mRNA and PLK4 in breast cancer, and evaluated its predictive value for response to taxane-based neoadjuvant chemotherapy.  Method: The PLK4 mRNA expression was measured in breast cancer tissues and corresponding normal breast tissues from 30 breast cancer patients by quant. real-time polymerase chain reaction (PCR).The assocn. of the expression of PLK4 with clinicopathol. parameters and prognostic significance was evaluated in 154 cases of invasive breast cancer.  In addn., we immunohistochem. examd. the changes of PLK4 expression in biopsy and postoperative tumor specimens of another 64 breast cancer patients who received taxane-based neoadjuvant chemotherapy.  Results: The level of PLK4 mRNA expression in cancerous tissues had a significant difference compared to the corresponding normal breast tissues (P=0.021).  There is a correlation of PLK4 expression with higher incidence of lymph node metastasis and distant metastasis or surrounding recurrence (P=0.043; P=0.006).  High PLK4 expression was found to be a detrimental prognostic factor measured by overall survival (OS) (P=0.003) and progress-free survival (PFS) (P=0.003).  Moreover, the results demonstrated that PLK4 expression was a neg. predictor of response to taxane-based neoadjuvant chemotherapy (rs= - 0.253, P=0.044).  Conclusion: The findings of this current study indicated that PLK4 expression in breast cancer could be a potential prognostic factor and a neg. predictor of response to taxane-based neoadjuvant chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAAGxqawou-7Vg90H21EOLACvtfcHk0ljTIk__XhaKPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmsFGltrc%253D&md5=ba87450f801327b59e0efa3369750fce</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.7150%2Fjca.14307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fjca.14307%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DDai%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DFu%26aufirst%3DL.%26atitle%3DExpression%2520of%2520polo-like%2520kinase%25204%2520%2528PLK4%2529%2520in%2520breast%2520cancer%2520and%2520its%2520response%2520to%2520taxane-based%2520neoadjuvant%2520chemotherapy%26jtitle%3DJ.%2520Cancer%26date%3D2016%26volume%3D7%26spage%3D1125%26epage%3D1132%26doi%3D10.7150%2Fjca.14307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forrest, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ban, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awrey, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnikova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiarash, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirgadze, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mak, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, H. W.</span></span> <span> </span><span class="NLM_article-title">The discovery of polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3′[3<i>H</i>]indol]-2′(1′<i>H</i>).ones as orally bioavailable antitumor agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1021/jm500537u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500537u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1Wktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=130-146&author=P.+B.+Sampsonauthor=Y.+Liuauthor=N.+K.+Patelauthor=M.+Feherauthor=B.+Forrestauthor=S.+W.+Liauthor=L.+Edwardsauthor=R.+Lauferauthor=Y.+Langauthor=F.+Banauthor=D.+E.+Awreyauthor=G.+Maoauthor=O.+Plotnikovaauthor=G.+Leungauthor=R.+Hodgsonauthor=J.+M.+Masonauthor=X.+Weiauthor=R.+Kiarashauthor=E.+Greenauthor=W.+Qiuauthor=N.+Y.+Chirgadzeauthor=T.+W.+Makauthor=G.+Panauthor=H.+W.+Pauls&title=The+discovery+of+polo-like+kinase+4+inhibitors%3A+design+and+optimization+of+spiro%5Bcyclopropane-1%2C3%E2%80%B2%5B3H%5Dindol%5D-2%E2%80%B2%281%E2%80%B2H%29.ones+as+orally+bioavailable+antitumor+agents&doi=10.1021%2Fjm500537u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">The Discovery of Polo-Like Kinase 4 Inhibitors: Design and Optimization of Spiro[cyclopropane-1,3'[3H]indol]-2'(1'H)-ones as Orally Bioavailable Antitumor Agents</span></div><div class="casAuthors">Sampson, Peter B.; Liu, Yong; Patel, Narendra Kumar; Feher, Miklos; Forrest, Bryan; Li, Sze-Wan; Edwards, Louise; Laufer, Radoslaw; Lang, Yunhui; Ban, Fuqiang; Awrey, Donald E.; Mao, Guodong; Plotnikova, Olga; Leung, Genie; Hodgson, Richard; Mason, Jacqueline; Wei, Xin; Kiarash, Reza; Green, Erin; Qiu, Wei; Chirgadze, Nickolay Y.; Mak, Tak W.; Pan, Guohua; Pauls, Henry W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">130-146</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polo-like kinase 4 (PLK4), a unique member of the polo-like kinase family of serine-threonine kinases, is a master regulator of centriole duplication that is important for maintaining genome integrity.  Overexpression of PLK4 is found in several human cancers and is linked with a predisposition to tumorigenesis.  Previous efforts to identify potent and efficacious PLK4 inhibitors resulted in the discovery of (E)-3-((1H-indazol-6-yl)methylene)indolin-2-ones, which are superseded by the bioisosteric 2-(1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones reported herein.  Optimization of this new cyclopropane-linked series was based on a computational model of a PLK4 x-ray structure and SAR attained from the analogous alkene-linked series.  The racemic cyclopropane-linked compds. showed PLK4 affinity and antiproliferative activity comparable to their alkene-linked congeners with improved physicochem., ADME, and pharmacokinetic properties.  Pos. xenograft results from the MDA-MB-468 human breast cancer xenograft model for compd. I support the investigation of PLK4 inhibitors as anticancer therapeutics.  A PLK4 x-ray co-structure with compd. I revealed preferential binding of the 1R,2S enantiomer to the PLK4 kinase domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_nQjbJy_sMLVg90H21EOLACvtfcHk0lhHZ_4tsUCQfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1Wktro%253D&md5=90d60867ee5d6c27f597ebe32db64278</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1021%2Fjm500537u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500537u%26sid%3Dliteratum%253Aachs%26aulast%3DSampson%26aufirst%3DP.%2BB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DPatel%26aufirst%3DN.%2BK.%26aulast%3DFeher%26aufirst%3DM.%26aulast%3DForrest%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%2BW.%26aulast%3DEdwards%26aufirst%3DL.%26aulast%3DLaufer%26aufirst%3DR.%26aulast%3DLang%26aufirst%3DY.%26aulast%3DBan%26aufirst%3DF.%26aulast%3DAwrey%26aufirst%3DD.%2BE.%26aulast%3DMao%26aufirst%3DG.%26aulast%3DPlotnikova%26aufirst%3DO.%26aulast%3DLeung%26aufirst%3DG.%26aulast%3DHodgson%26aufirst%3DR.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DKiarash%26aufirst%3DR.%26aulast%3DGreen%26aufirst%3DE.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DChirgadze%26aufirst%3DN.%2BY.%26aulast%3DMak%26aufirst%3DT.%2BW.%26aulast%3DPan%26aufirst%3DG.%26aulast%3DPauls%26aufirst%3DH.%2BW.%26atitle%3DThe%2520discovery%2520of%2520polo-like%2520kinase%25204%2520inhibitors%253A%2520design%2520and%2520optimization%2520of%2520spiro%255Bcyclopropane-1%252C3%25E2%2580%25B2%255B3H%255Dindol%255D-2%25E2%2580%25B2%25281%25E2%2580%25B2H%2529.ones%2520as%2520orally%2520bioavailable%2520antitumor%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D130%26epage%3D146%26doi%3D10.1021%2Fjm500537u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beisner, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langerak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otero, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirot, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiltshire, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodendorf, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martoglio, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, M. P.</span></span> <span> </span><span class="NLM_article-title">The intramembrane protease SPPL2a is required for B cell and DC development and survival via cleavage of the invariant chain</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.1084/jem.20121072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1084%2Fjem.20121072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=23267013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Oitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2013&pages=23-30&author=D.+R.+Beisnerauthor=P.+Langerakauthor=A.+E.+Parkerauthor=C.+Dahlbergauthor=F.+J.+Oteroauthor=S.+E.+Suttonauthor=L.+Poirotauthor=W.+Barnesauthor=M.+A.+Youngauthor=S.+Niessenauthor=T.+Wiltshireauthor=U.+Bodendorfauthor=B.+Martoglioauthor=B.+Cravattauthor=M.+P.+Cooke&title=The+intramembrane+protease+SPPL2a+is+required+for+B+cell+and+DC+development+and+survival+via+cleavage+of+the+invariant+chain&doi=10.1084%2Fjem.20121072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">The intramembrane protease Sppl2a is required for B cell and DC development and survival via cleavage of the invariant chain</span></div><div class="casAuthors">Beisner, Daniel R.; Langerak, Petra; Parker, Albert E.; Dahlberg, Carol; Otero, Francella J.; Sutton, Sue E.; Poirot, Laurent; Barnes, Whitney; Young, Michael A.; Niessen, Sherry; Wiltshire, Tim; Bodendorf, Ursula; Martoglio, Bruno; Cravatt, Benjamin; Cooke, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-30</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">B cell development requires tight regulation to allow for the generation of a diverse repertoire while preventing the development of autoreactive cells.  We report, using N-ethyl-N-nitrosourea (ENU)-induced mutagenesis, the identification of a mutant mouse (chompB) with a block in early B cell development.  The blockade occurs after the transitional 1 (T1) stage and leads to a decrease in mature B cell subsets and deficits in T cell-dependent antibody responses.  Addnl., chompB mice have decreases in myeloid dendritic cells (DCs).  The mutation was mapped to the intramembrane protease signal peptide peptidase-like 2a (Sppl2a), a gene not previously implicated in immune cell development.  Proteomic anal. identified the invariant chain (CD74) as a key substrate of Sppl2a and suggests that regulated intramembrane proteolysis of CD74 by Sppl2a contributes to B cell and DC survival.  Moreover, these data suggest that modulation of Sppl2a may be a useful therapeutic strategy for treatment of B cell dependent autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz5IaIoDFCJrVg90H21EOLACvtfcHk0lhHZ_4tsUCQfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Oitbs%253D&md5=001a2fe7aca2a8d5bb669833e155dff9</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1084%2Fjem.20121072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20121072%26sid%3Dliteratum%253Aachs%26aulast%3DBeisner%26aufirst%3DD.%2BR.%26aulast%3DLangerak%26aufirst%3DP.%26aulast%3DParker%26aufirst%3DA.%2BE.%26aulast%3DDahlberg%26aufirst%3DC.%26aulast%3DOtero%26aufirst%3DF.%2BJ.%26aulast%3DSutton%26aufirst%3DS.%2BE.%26aulast%3DPoirot%26aufirst%3DL.%26aulast%3DBarnes%26aufirst%3DW.%26aulast%3DYoung%26aufirst%3DM.%2BA.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DWiltshire%26aufirst%3DT.%26aulast%3DBodendorf%26aufirst%3DU.%26aulast%3DMartoglio%26aufirst%3DB.%26aulast%3DCravatt%26aufirst%3DB.%26aulast%3DCooke%26aufirst%3DM.%2BP.%26atitle%3DThe%2520intramembrane%2520protease%2520SPPL2a%2520is%2520required%2520for%2520B%2520cell%2520and%2520DC%2520development%2520and%2520survival%2520via%2520cleavage%2520of%2520the%2520invariant%2520chain%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2013%26volume%3D210%26spage%3D23%26epage%3D30%26doi%3D10.1084%2Fjem.20121072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velcicky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodendorf, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigollier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epple, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beisner, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feifel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wipfli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aichholz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couttet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widmer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandl, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of the first potent, selective, and orally bioavailable signal peptide peptidase-like 2a (SPPL2a) inhibitor displaying pronounced immunomodulatory effects in vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">865</span>– <span class="NLM_lpage">880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01371</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01371" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=865-880&author=J.+Velcickyauthor=U.+Bodendorfauthor=P.+Rigollierauthor=R.+Eppleauthor=D.+R.+Beisnerauthor=D.+Gueriniauthor=P.+Smithauthor=B.+Liuauthor=R.+Feifelauthor=P.+Wipfliauthor=R.+Aichholzauthor=P.+Couttetauthor=I.+Dixauthor=T.+Widmerauthor=B.+Wenauthor=T.+Brandl&title=Discovery+of+the+first+potent%2C+selective%2C+and+orally+bioavailable+signal+peptide+peptidase-like+2a+%28SPPL2a%29+inhibitor+displaying+pronounced+immunomodulatory+effects+in+vivo&doi=10.1021%2Facs.jmedchem.7b01371"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the First Potent, Selective, and Orally Bioavailable Signal Peptide Peptidase-Like 2a (SPPL2a) Inhibitor Displaying Pronounced Immunomodulatory Effects In Vivo</span></div><div class="casAuthors">Velcicky, Juraj; Bodendorf, Ursula; Rigollier, Pascal; Epple, Robert; Beisner, Daniel R.; Guerini, Danilo; Smith, Philip; Liu, Bo; Feifel, Roland; Wipfli, Peter; Aichholz, Reiner; Couttet, Philippe; Dix, Ina; Widmer, Toni; Wen, Ben; Brandl, Trixi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">865-880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Signal Peptide Peptidase-Like 2a (SPPL2a) is an aspartic intramembrane protease which has recently been shown to play an important role in the development and function of antigen presenting cells such as B lymphocytes and dendritic cells.  In this paper the authors describe the discovery of the first selective and orally active SPPL2a inhibitor (S)-2-cyclopropyl-N1-((S)-5,11-dioxo-10,11-dihydro-1H,3H,5H-spiro[benzo[d]pyrazolo[1,2-a][1,2]diazepine-2,1'-cyclopropan]-10-yl)-N4-(5-fluoro-2-methylpyridin-3-yl)succinamide (40) (SPL-707).  This compd. shows adequate selectivity against the closely related enzymes γ secretase and SPP and a good pharmacokinetic profile in mouse and rat.  Compd. 40 significantly inhibited processing of the SPPL2a substrate CD74/p8 fragment in rodents at doses ≤10 mg/kg b.i.d. po.  Oral dosing of 40 for 11 days at ≥10 mg/kg b.i.d. recapitulated the phenotype seen in Sppl2a k.o. and ENU-mutant mice (reduced no. of specific B cells and myeloid dendritic cells).  Thus, the authors believe that SPPL2a represents an interesting and druggable pharmacol. target potentially providing a novel approach for the treatment of autoimmune diseases by targeting B cells and dendritic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-3mN1wPBrf7Vg90H21EOLACvtfcHk0liG7ZB_pzb2Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyiuro%253D&md5=3076c11b3b83e2c3e1cf23ed69d8455e</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01371%26sid%3Dliteratum%253Aachs%26aulast%3DVelcicky%26aufirst%3DJ.%26aulast%3DBodendorf%26aufirst%3DU.%26aulast%3DRigollier%26aufirst%3DP.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DBeisner%26aufirst%3DD.%2BR.%26aulast%3DGuerini%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DFeifel%26aufirst%3DR.%26aulast%3DWipfli%26aufirst%3DP.%26aulast%3DAichholz%26aufirst%3DR.%26aulast%3DCouttet%26aufirst%3DP.%26aulast%3DDix%26aufirst%3DI.%26aulast%3DWidmer%26aufirst%3DT.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DBrandl%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520the%2520first%2520potent%252C%2520selective%252C%2520and%2520orally%2520bioavailable%2520signal%2520peptide%2520peptidase-like%25202a%2520%2528SPPL2a%2529%2520inhibitor%2520displaying%2520pronounced%2520immunomodulatory%2520effects%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D865%26epage%3D880%26doi%3D10.1021%2Facs.jmedchem.7b01371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vassilev, L. T.</span></span> <span> </span><span class="NLM_article-title">p53 Activation by small molecules: application in oncology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">4491</span>– <span class="NLM_lpage">4499</span>, <span class="refDoi"> DOI: 10.1021/jm058174k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058174k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlarsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=4491-4499&author=L.+T.+Vassilev&title=p53+Activation+by+small+molecules%3A+application+in+oncology&doi=10.1021%2Fjm058174k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">p53 Activation by Small Molecules: Application in Oncology</span></div><div class="casAuthors">Vassilev, Lyubomir T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4491-4499</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  P53 activation by small mols. and their application in chemoprevention are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO8McGVTfuxrVg90H21EOLACvtfcHk0liG7ZB_pzb2Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlarsLc%253D&md5=44ee6a039c0c5ad69e218de742de0d53</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Fjm058174k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058174k%26sid%3Dliteratum%253Aachs%26aulast%3DVassilev%26aufirst%3DL.%2BT.%26atitle%3Dp53%2520Activation%2520by%2520small%2520molecules%253A%2520application%2520in%2520oncology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D4491%26epage%3D4499%26doi%3D10.1021%2Fjm058174k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shargary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5553</span>– <span class="NLM_lpage">5561</span>, <span class="refDoi"> DOI: 10.1021/jm4005708</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4005708" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslCisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5553-5561&author=Y.+Zhaoauthor=S.+Yuauthor=W.+Sunauthor=L.+Liuauthor=J.+Luauthor=D.+McEachernauthor=S.+Shargaryauthor=D.+Bernardauthor=X.+Liauthor=T.+Zhaoauthor=P.+Zouauthor=D.+Sunauthor=S.+Wang&title=A+potent+small-molecule+inhibitor+of+the+MDM2-p53+interaction+%28MI-888%29+achieved+complete+and+durable+tumor+regression+in+mice&doi=10.1021%2Fjm4005708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">A Potent Small-Molecule Inhibitor of the MDM2-p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice</span></div><div class="casAuthors">Zhao, Yujun; Yu, Shanghai; Sun, Wei; Liu, Liu; Lu, Jianfeng; McEachern, Donna; Shargary, Sanjeev; Bernard, Denzil; Li, Xiaoqin; Zhao, Ting; Zou, Peng; Sun, Duxin; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5553-5561</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors previously reported the discovery of a class of spirooxindoles as potent and selective small-mol. inhibitors of the MDM2-p53 interaction (MDM2 inhibitors).  The authors report herein the authors' efforts to improve their pharmacokinetic properties and in vivo antitumor activity.  The authors' efforts led to the identification of MI-888 as a potent MDM2 inhibitor (Ki = 0.44 nM) with a superior pharmacokinetic profile and enhanced in vivo efficacy.  MI-888 is capable of achieving rapid, complete, and durable tumor regression in two types of xenograft models of human cancer with oral administration and represents the most potent and efficacious MDM2 inhibitor reported to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr06DpGqpt0TLVg90H21EOLACvtfcHk0liG7ZB_pzb2Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslCisb4%253D&md5=a53931e3f91a1c1a302ac88bbb4d5c0d</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1021%2Fjm4005708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4005708%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DShargary%26aufirst%3DS.%26aulast%3DBernard%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DT.%26aulast%3DZou%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DA%2520potent%2520small-molecule%2520inhibitor%2520of%2520the%2520MDM2-p53%2520interaction%2520%2528MI-888%2529%2520achieved%2520complete%2520and%2520durable%2520tumor%2520regression%2520in%2520mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5553%26epage%3D5561%26doi%3D10.1021%2Fjm4005708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meaux, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barriere, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meagher, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman-Luca, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shangary, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dos-Santos, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besret, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerif, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorge-Bernat, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debussche, L.</span></span> <span> </span><span class="NLM_article-title">SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">5855</span>– <span class="NLM_lpage">5865</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-0799</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1158%2F0008-5472.CAN-14-0799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=25145672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslGjsr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=5855-5865&author=S.+Wangauthor=W.+Sunauthor=Y.+Zhaoauthor=D.+McEachernauthor=I.+Meauxauthor=C.+Barriereauthor=J.+A.+Stuckeyauthor=J.+L.+Meagherauthor=L.+Baiauthor=L.+Liuauthor=C.+G.+Hoffman-Lucaauthor=J.+Luauthor=S.+Shangaryauthor=S.+Yuauthor=D.+Bernardauthor=A.+Aguilarauthor=O.+Dos-Santosauthor=L.+Besretauthor=S.+Guerifauthor=P.+Pannierauthor=D.+Gorge-Bernatauthor=L.+Debussche&title=SAR405838%3A+an+optimized+inhibitor+of+MDM2-p53+interaction+that+induces+complete+and+durable+tumor+regression&doi=10.1158%2F0008-5472.CAN-14-0799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression</span></div><div class="casAuthors">Wang, Shaomeng; Sun, Wei; Zhao, Yujun; McEachern, Donna; Meaux, Isabelle; Barriere, Cedric; Stuckey, Jeanne A.; Meagher, Jennifer L.; Bai, Longchuan; Liu, Liu; Hoffman-Luca, Cassandra Gianna; Lu, Jianfeng; Shangary, Sanjeev; Yu, Shanghai; Bernard, Denzil; Aguilar, Angelo; Dos-Santos, Odette; Besret, Laurent; Guerif, Stephane; Pannier, Pascal; Gorge-Bernat, Dimitri; Debussche, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5855-5865</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Despite the risk of applying a selection for p53 mutations that escape MDM2 control, blocking MDM2-p53 protein-protein interaction has long been considered by many to offer an attractive cancer therapeutic strategy, a position strongly supported by the findings of this preclin. study.  Blocking the oncoprotein murine double minute 2 (MDM2)-p53 protein-protein interaction has long been considered to offer a broad cancer therapeutic strategy, despite the potential risks of selecting tumors harboring p53 mutations that escape MDM2 control.  In this study, we report a novel small-mol. inhibitor of the MDM2-p53 interaction, SAR405838 (MI-77301), that has been advanced into phase I clin. trials.  SAR405838 binds to MDM2 with Ki = 0.88 nmol/L and has high specificity over other proteins.  A cocrystal structure of the SAR405838:MDM2 complex shows that, in addn. to mimicking three key p53 amino acid residues, the inhibitor captures addnl. interactions not obsd. in the p53-MDM2 complex and induces refolding of the short, unstructured MDM2 N-terminal region to achieve its high affinity.  SAR405838 effectively activates wild-type p53 in vitro and in xenograft tumor tissue of leukemia and solid tumors, leading to p53-dependent cell-cycle arrest and/or apoptosis.  At well-tolerated dose schedules, SAR405838 achieves either durable tumor regression or complete tumor growth inhibition in mouse xenograft models of SJSA-1 osteosarcoma, RS4;11 acute leukemia, LNCaP prostate cancer, and HCT-116 colon cancer.  Remarkably, a single oral dose of SAR405838 is sufficient to achieve complete tumor regression in the SJSA-1 model.  Mechanistically, robust transcriptional upregulation of PUMA induced by SAR405838 results in strong apoptosis in tumor tissue, leading to complete tumor regression.  Our findings provide a preclin. basis upon which to evaluate SAR405838 as a therapeutic agent in patients whose tumors retain wild-type p53.  Cancer Res; 74(20); 5855-65. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptKSwfNhNzNLVg90H21EOLACvtfcHk0lhG7tTPV-HvVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslGjsr7M&md5=5b35759e14fe4c1ae4e734775c4334a0</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-0799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-0799%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DMeaux%26aufirst%3DI.%26aulast%3DBarriere%26aufirst%3DC.%26aulast%3DStuckey%26aufirst%3DJ.%2BA.%26aulast%3DMeagher%26aufirst%3DJ.%2BL.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DHoffman-Luca%26aufirst%3DC.%2BG.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DShangary%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DBernard%26aufirst%3DD.%26aulast%3DAguilar%26aufirst%3DA.%26aulast%3DDos-Santos%26aufirst%3DO.%26aulast%3DBesret%26aufirst%3DL.%26aulast%3DGuerif%26aufirst%3DS.%26aulast%3DPannier%26aufirst%3DP.%26aulast%3DGorge-Bernat%26aufirst%3DD.%26aulast%3DDebussche%26aufirst%3DL.%26atitle%3DSAR405838%253A%2520an%2520optimized%2520inhibitor%2520of%2520MDM2-p53%2520interaction%2520that%2520induces%2520complete%2520and%2520durable%2520tumor%2520regression%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D5855%26epage%3D5865%26doi%3D10.1158%2F0008-5472.CAN-14-0799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rew, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span> <span> </span><span class="NLM_article-title">Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">6332</span>– <span class="NLM_lpage">6341</span>, <span class="refDoi"> DOI: 10.1021/jm500627s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500627s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVGlu7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6332-6341&author=Y.+Rewauthor=D.+Sun&title=Discovery+of+a+small+molecule+MDM2+inhibitor+%28AMG+232%29+for+treating+cancer&doi=10.1021%2Fjm500627s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Small Molecule MDM2 Inhibitor (AMG 232) for Treating Cancer</span></div><div class="casAuthors">Rew, Yosup; Sun, Daqing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6332-6341</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  We recently reported the discovery of AMG 232 (1), a potent and selective piperidinone inhibitor of the MDM2-p53 protein-protein interaction.  Compd. 1 is currently being evaluated in human clin. trials for the treatment of cancer.  This article provides an overview of its discovery from the de novo design of the piperidinone series to the structure-activity studies leading to the identification of 1.  In addn., this article also describes the preclin. pharmacol. and pharmacokinetics of 1, along with its drug metab. and safety assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_6moQsRdmtLVg90H21EOLACvtfcHk0lhG7tTPV-HvVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVGlu7jM&md5=07628b602fba44634add7d235751daf7</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1021%2Fjm500627s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500627s%26sid%3Dliteratum%253Aachs%26aulast%3DRew%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520a%2520small%2520molecule%2520MDM2%2520inhibitor%2520%2528AMG%2520232%2529%2520for%2520treating%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6332%26epage%3D6341%26doi%3D10.1021%2Fjm500627s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gehling, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duplessis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brucelle, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaswani, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Côté, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmange, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Audia, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levell, J. R.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of styrenylcyclopropylamine LSD1 inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1213</span>– <span class="NLM_lpage">1220</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00060</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00060" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BB3cXoslals78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1213-1220&author=V.+S.+Gehlingauthor=J.+P.+McGrathauthor=M.+Duplessisauthor=A.+Khannaauthor=F.+Brucelleauthor=R.+G.+Vaswaniauthor=A.+C%C3%B4t%C3%A9author=J.+Stuckeyauthor=V.+Watsonauthor=R.+T.+Cummingsauthor=S.+Balasubramanianauthor=P.+Iyerauthor=P.+Sawantauthor=A.+C.+Goodauthor=B.+K.+Albrechtauthor=J.-C.+Harmangeauthor=J.+E.+Audiaauthor=S.+F.+Bellonauthor=P.+Trojerauthor=J.+R.+Levell&title=Design+and+synthesis+of+styrenylcyclopropylamine+LSD1+inhibitors&doi=10.1021%2Facsmedchemlett.0c00060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Styrenylcyclopropylamine LSD1 Inhibitors</span></div><div class="casAuthors">Gehling, Victor S.; McGrath, John P.; Duplessis, Martin; Khanna, Avinash; Brucelle, Francois; Vaswani, Rishi G.; Cote, Alexandre; Stuckey, Jacob; Watson, Venita; Cummings, Richard T.; Balasubramanian, Srividya; Iyer, Priyadarshini; Sawant, Priyanka; Good, Andrew C.; Albrecht, Brian K.; Harmange, Jean-Christophe; Audia, James E.; Bellon, Steven F.; Trojer, Patrick; Levell, Julian R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1213-1220</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Leveraging the catalytic machinery of LSD1 (KDM1A), a series of covalent styrenylcyclopropane LSD1 inhibitors were identified.  These inhibitors represent a new class of mechanism-based inhibitors that target and covalently label the FAD cofactor of LSD1.  The series was rapidly progressed to potent biochem. and cellular LSD1 inhibitors with good phys. properties.  This effort resulted in the identification of 34, a highly potent (<4 nM biochem., 2 nM cell, and 1 nM GI50), and selective LSD1 inhibitor.  In-depth kinetic profiling of 34 confirmed its covalent mechanism of action, validated the styrenylcyclopropane as an FAD-directed warhead, and demonstrated that the potency of this inhibitor is driven by improved non-covalent binding (KI). 34 demonstrated robust cell-killing activity in a panel of AML cell lines and robust antitumor activity in a Kasumi-1 xenograft model of AML when dosed orally at 1.5 mg/kg once daily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXdKSi11wzG7Vg90H21EOLACvtfcHk0lhG7tTPV-HvVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXoslals78%253D&md5=77d6d1674b5ec70bcbf4627a20417120</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00060%26sid%3Dliteratum%253Aachs%26aulast%3DGehling%26aufirst%3DV.%2BS.%26aulast%3DMcGrath%26aufirst%3DJ.%2BP.%26aulast%3DDuplessis%26aufirst%3DM.%26aulast%3DKhanna%26aufirst%3DA.%26aulast%3DBrucelle%26aufirst%3DF.%26aulast%3DVaswani%26aufirst%3DR.%2BG.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DA.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DWatson%26aufirst%3DV.%26aulast%3DCummings%26aufirst%3DR.%2BT.%26aulast%3DBalasubramanian%26aufirst%3DS.%26aulast%3DIyer%26aufirst%3DP.%26aulast%3DSawant%26aufirst%3DP.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DAlbrecht%26aufirst%3DB.%2BK.%26aulast%3DHarmange%26aufirst%3DJ.-C.%26aulast%3DAudia%26aufirst%3DJ.%2BE.%26aulast%3DBellon%26aufirst%3DS.%2BF.%26aulast%3DTrojer%26aufirst%3DP.%26aulast%3DLevell%26aufirst%3DJ.%2BR.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520styrenylcyclopropylamine%2520LSD1%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1213%26epage%3D1220%26doi%3D10.1021%2Facsmedchemlett.0c00060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5992</span>– <span class="NLM_lpage">6000</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.08.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2Fj.bmcl.2013.08.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=24054120" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVOns73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5992-6000&author=M.+D.+Shultz&title=The+thermodynamic+basis+for+the+use+of+lipophilic+efficiency+%28LipE%29+in+enthalpic+optimizations&doi=10.1016%2Fj.bmcl.2013.08.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5992-6000</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Approaches to improve the efficiency of mol. optimizations have received great attention and numerous efficiency metrics have been introduced to assist in this effort.  Optimization of properties is equally important to optimization of potency and therefore these metrics contain potency vs. property calcns.  Widespread use of a metric does not guarantee its accuracy and a further understanding of which, if any, metric increases the probability of success was sought.  An anal. of LE, LELP and LipE based on theor. and exptl. data was performed demonstrating that LipE most strongly correlates with compd. quality as defined by enthalpy-driven binding.  The basis for the prioritization of LipE over other metrics in enthalpic optimizations is described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobuMO74LdKnbVg90H21EOLACvtfcHk0lhh0BqdO059qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVOns73P&md5=23d948d1135eeefdfebc60846f28ec2b</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.030%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DThe%2520thermodynamic%2520basis%2520for%2520the%2520use%2520of%2520lipophilic%2520efficiency%2520%2528LipE%2529%2520in%2520enthalpic%2520optimizations%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5992%26epage%3D6000%26doi%3D10.1016%2Fj.bmcl.2013.08.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beumer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puhalla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swartz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owonikoko, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donald Harvey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoller, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petro, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawbi, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argiris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strychor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouquet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiesel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belani, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramalingam, S. S.</span></span> <span> </span><span class="NLM_article-title">Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">1289</span>– <span class="NLM_lpage">1301</span>, <span class="refDoi"> DOI: 10.1007/s00280-019-03960-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1007%2Fs00280-019-03960-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=31549216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVarsbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2019&pages=1289-1301&author=L.+J.+Applemanauthor=J.+H.+Beumerauthor=Y.+Jiangauthor=Y.+Linauthor=F.+Dingauthor=S.+Puhallaauthor=L.+Swartzauthor=T.+K.+Owonikokoauthor=R.+Donald+Harveyauthor=R.+Stollerauthor=D.+P.+Petroauthor=H.+A.+Tawbiauthor=A.+Argirisauthor=S.+Strychorauthor=M.+Pouquetauthor=B.+Kieselauthor=A.+P.+Chenauthor=D.+Gandaraauthor=C.+P.+Belaniauthor=E.+Chuauthor=S.+S.+Ramalingam&title=Phase+1+study+of+veliparib+%28ABT-888%29%2C+a+poly+%28ADP-ribose%29+polymerase+inhibitor%2C+with+carboplatin+and+paclitaxel+in+advanced+solid+malignancies&doi=10.1007%2Fs00280-019-03960-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies</span></div><div class="casAuthors">Appleman, Leonard J.; Beumer, Jan H.; Jiang, Yixing; Lin, Yan; Ding, Fei; Puhalla, Shannon; Swartz, Leigh; Owonikoko, Taofeek K.; Donald Harvey, R.; Stoller, Ronald; Petro, Daniel P.; Tawbi, Hussein A.; Argiris, Athanassios; Strychor, Sandra; Pouquet, Marie; Kiesel, Brian; Chen, Alice P.; Gandara, David; Belani, Chandra P.; Chu, Edward; Ramalingam, Suresh S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1289-1301</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Veliparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP)-1 and -2.  We aimed to det. the recommended phase 2 dose (RP2D), max. tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics (PK) of veliparib combined with paclitaxel and carboplatin.  Methods: Eligibility criteria included patients with advanced solid tumors treated with = 3 prior regimens.  Paclitaxel and carboplatin were administered on day 3 of a 21-day cycle.  Veliparib was given PO BID days 1-7, except for cycle 1 in the first 46 patients to serve as control for toxicity and PK.  The pharmacokinetic (PK) disposition of veliparib, paclitaxel, and carboplatin was detd. by LC-MS/MS and AAS during cycles 1 and 2.  Results: Seventy-three patients were enrolled.  Toxicities were as expected with carboplatin/paclitaxel chemotherapy, including neutropenia, thrombocytopenia, and peripheral neuropathy.  DLTs were seen in two of seven evaluable patients at the max. administered dose (MAD): veliparib 120 mg BID, paclitaxel 200 mg/m2, and carboplatin AUC 6 (febrile neutropenia, hyponatremia).  The MTD and RP2D were detd. to be veliparib 100 mg BID, paclitaxel 200 mg/m2, and carboplatin AUC 6.  Median no. of cycles of the three-agent combination was 4 (1-16).  Veliparib did not affect paclitaxel or carboplatin PK disposition.  Conclusion: Veliparib, paclitaxel, and carboplatin were well tolerated and demonstrated promising antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtG2HmKirpWbVg90H21EOLACvtfcHk0lhh0BqdO059qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVarsbvJ&md5=bea92fafcc14ba9047195eb3c149454a</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1007%2Fs00280-019-03960-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-019-03960-w%26sid%3Dliteratum%253Aachs%26aulast%3DAppleman%26aufirst%3DL.%2BJ.%26aulast%3DBeumer%26aufirst%3DJ.%2BH.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DF.%26aulast%3DPuhalla%26aufirst%3DS.%26aulast%3DSwartz%26aufirst%3DL.%26aulast%3DOwonikoko%26aufirst%3DT.%2BK.%26aulast%3DDonald%2BHarvey%26aufirst%3DR.%26aulast%3DStoller%26aufirst%3DR.%26aulast%3DPetro%26aufirst%3DD.%2BP.%26aulast%3DTawbi%26aufirst%3DH.%2BA.%26aulast%3DArgiris%26aufirst%3DA.%26aulast%3DStrychor%26aufirst%3DS.%26aulast%3DPouquet%26aufirst%3DM.%26aulast%3DKiesel%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DA.%2BP.%26aulast%3DGandara%26aufirst%3DD.%26aulast%3DBelani%26aufirst%3DC.%2BP.%26aulast%3DChu%26aufirst%3DE.%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26atitle%3DPhase%25201%2520study%2520of%2520veliparib%2520%2528ABT-888%2529%252C%2520a%2520poly%2520%2528ADP-ribose%2529%2520polymerase%2520inhibitor%252C%2520with%2520carboplatin%2520and%2520paclitaxel%2520in%2520advanced%2520solid%2520malignancies%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2019%26volume%3D84%26spage%3D1289%26epage%3D1301%26doi%3D10.1007%2Fs00280-019-03960-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorbunova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofheinz, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Alfonso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nechaeva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cubillo Gracian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elez Fernandez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deming, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanathan, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, J. D.</span></span> <span> </span><span class="NLM_article-title">A phase 2 randomised study of veliparib plus FOLFIRI+/-bevacizumab versus placebo plus FOLFIRI+/-bevacizumab in metastatic colorectal cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1038/s41416-018-0343-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2Fs41416-018-0343-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=30531832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFWrtbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2019&pages=183-189&author=V.+Gorbunovaauthor=J.+T.+Beckauthor=R.+D.+Hofheinzauthor=P.+Garcia-Alfonsoauthor=M.+Nechaevaauthor=A.+Cubillo+Gracianauthor=L.+Mangelauthor=E.+Elez+Fernandezauthor=D.+A.+Demingauthor=R.+K.+Ramanathanauthor=A.+H.+Torresauthor=D.+Sullivanauthor=Y.+Luoauthor=J.+D.+Berlin&title=A+phase+2+randomised+study+of+veliparib+plus+FOLFIRI%2B%2F-bevacizumab+versus+placebo+plus+FOLFIRI%2B%2F-bevacizumab+in+metastatic+colorectal+cancer&doi=10.1038%2Fs41416-018-0343-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer</span></div><div class="casAuthors">Gorbunova, Vera; Beck, J. Thaddeus; Hofheinz, Ralf-Dieter; Garcia-Alfonso, Pilar; Nechaeva, Marina; Cubillo Gracian, Antonio; Mangel, Laszlo; Elez Fernandez, Elena; Deming, Dustin A.; Ramanathan, Ramesh K.; Torres, Alison H.; Sullivan, Danielle; Luo, Yan; Berlin, Jordan D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">183-189</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Background: Metastatic colorectal cancer (mCRC) has low survival rates.  We assessed if addn. of veliparib, concurrent to FOLFIRI, improves survival in patients with previously untreated mCRC.  Methods: This study compared veliparib (200 mg BID for 7 days of each 14-day cycle) to placebo, each with FOLFIRI.  Bevacizumab was allowed in both arms.  The primary endpoint was progression-free survival (PFS).  Results: Patients were randomised to receive veliparib (n = 65) or placebo (n = 65) in combination with FOLFIRI.  Median PFS was 12 vs 11 mo (veliparib vs placebo) [HR = 0.94 (95% CI: 0.60, 1.48)].  Median OS was 25 vs 27 mo [HR = 1.26 (95% CI: 0.74, 2.16)].  Response rate was 57% vs 62%.  Median DOR was 11 vs 9 mo [HR = 0.73 (95% CI: 0.38, 1.40)].  AEs with significantly higher frequency (p < 0.05) in the veliparib group were anemia (39% vs 19%, p = 0.019) and neutropenia (66% vs 37%, p = 0.001) for common AEs (≥20%); neutropenia (59% vs 22%, p < 0.001) for common Grade 3/4 AEs (≥5%); none in serious AEs.  Haematopoietic cytopenias were more common with veliparib (79% vs 52%, p = 0.003).  Fourteen percent of patients on veliparib and 15% on placebo discontinued treatment due to AEs.  Conclusion: Veliparib added to FOLFIRI ± bevacizumab demonstrated similar efficacy as FOLFIRI ± bevacizumab in frontline mCRC patients.  No unexpected safety concerns occurred.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyqNMJBiQPG7Vg90H21EOLACvtfcHk0lhh0BqdO059qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFWrtbvM&md5=07f1c62412daf5dca8627422a2b26d68</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1038%2Fs41416-018-0343-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41416-018-0343-z%26sid%3Dliteratum%253Aachs%26aulast%3DGorbunova%26aufirst%3DV.%26aulast%3DBeck%26aufirst%3DJ.%2BT.%26aulast%3DHofheinz%26aufirst%3DR.%2BD.%26aulast%3DGarcia-Alfonso%26aufirst%3DP.%26aulast%3DNechaeva%26aufirst%3DM.%26aulast%3DCubillo%2BGracian%26aufirst%3DA.%26aulast%3DMangel%26aufirst%3DL.%26aulast%3DElez%2BFernandez%26aufirst%3DE.%26aulast%3DDeming%26aufirst%3DD.%2BA.%26aulast%3DRamanathan%26aufirst%3DR.%2BK.%26aulast%3DTorres%26aufirst%3DA.%2BH.%26aulast%3DSullivan%26aufirst%3DD.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DBerlin%26aufirst%3DJ.%2BD.%26atitle%3DA%2520phase%25202%2520randomised%2520study%2520of%2520veliparib%2520plus%2520FOLFIRI%252B%252F-bevacizumab%2520versus%2520placebo%2520plus%2520FOLFIRI%252B%252F-bevacizumab%2520in%2520metastatic%2520colorectal%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2019%26volume%3D120%26spage%3D183%26epage%3D189%26doi%3D10.1038%2Fs41416-018-0343-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pishvaian, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hankin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorsch-Vogel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukadiya, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiner, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brody, J. R.</span></span> <span> </span><span class="NLM_article-title">A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">2337</span>– <span class="NLM_lpage">2346</span>, <span class="refDoi"> DOI: 10.1002/cncr.31309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fcncr.31309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=29579325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOqsLzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2018&pages=2337-2346&author=M.+J.+Pishvaianauthor=R.+S.+Slackauthor=W.+Jiangauthor=A.+R.+Heauthor=J.+J.+Hwangauthor=A.+Hankinauthor=K.+Dorsch-Vogelauthor=D.+Kukadiyaauthor=L.+M.+Weinerauthor=J.+L.+Marshallauthor=J.+R.+Brody&title=A+phase+2+study+of+the+PARP+inhibitor+veliparib+plus+temozolomide+in+patients+with+heavily+pretreated+metastatic+colorectal+cancer&doi=10.1002%2Fcncr.31309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer</span></div><div class="casAuthors">Pishvaian, Michael J.; Slack, Rebecca S.; Jiang, Wei; He, A. Ruth; Hwang, Jimmy J.; Hankin, Amy; Dorsch-Vogel, Karen; Kukadiya, Divyesh; Weiner, Louis M.; Marshall, John L.; Brody, Jonathan R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2337-2346</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">BACKGROUND : Poly(ADP ribose) polymerase (PARP) inhibitors such as veliparib are potent sensitizing agents and have been safely combined with DNA-damaging agents such as temozolomide.  The sensitizing effects of PARP inhibitors are magnified when cells harbor DNA repair defects.  METHODS : A single-arm, open-label, phase 2 study was performed to investigate the disease control rate (DCR) after 2 cycles of veliparib plus temozolomide in patients with metastatic colorectal cancer (mCRC) refractory to all std. therapies.  Fifty patients received temozolomide (150 mg/m2/d) on days 1 to 5 and veliparib (40 mg twice daily) on days 1 to 7 of each 28-day cycle.  Another 5 patients with mismatch repair-deficient (dMMR) tumors were also enrolled.  Twenty addnl. patients were then treated with temozolomide at 200 mg/m2/d.  Archived tumor specimens were used for immunohistochem. to assess mismatch repair, phosphatase and tensin homolog deleted on chromosome 10 (PTEN), and O(6)-methylguanine-DNA methyltransferase (MGMT) protein expression levels.  RESULTS : The combination was well tolerated, although some patients required dose redns. for myelosuppression.  The primary endpoint was successfully met with a DCR of 24% and 2 confirmed partial responses.  The median progression-free survival was 1.8 mo, and the median overall survival was 6.6 mo.  PTEN protein expression and MGMT protein expression were not predictors of DCR.  There was also a suggestion of worse outcomes for patients with dMMR tumors.  CONCLUSIONS : In this heavily pretreated mCRC population, a combination of veliparib and temozolomide was well tolerated with temozolomide doses up to 200 mg/m2/d, and it was clin. active.  PARP inhibitor-based therapy merits further exploration in patients with mCRC.  Cancer 2018;124:2337-46. © 2018 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0pPe3laOHHLVg90H21EOLACvtfcHk0lj3sio_MLS-wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOqsLzM&md5=6b3ed55b93609f62c5c4dc566da2bee0</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1002%2Fcncr.31309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.31309%26sid%3Dliteratum%253Aachs%26aulast%3DPishvaian%26aufirst%3DM.%2BJ.%26aulast%3DSlack%26aufirst%3DR.%2BS.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DA.%2BR.%26aulast%3DHwang%26aufirst%3DJ.%2BJ.%26aulast%3DHankin%26aufirst%3DA.%26aulast%3DDorsch-Vogel%26aufirst%3DK.%26aulast%3DKukadiya%26aufirst%3DD.%26aulast%3DWeiner%26aufirst%3DL.%2BM.%26aulast%3DMarshall%26aufirst%3DJ.%2BL.%26aulast%3DBrody%26aufirst%3DJ.%2BR.%26atitle%3DA%2520phase%25202%2520study%2520of%2520the%2520PARP%2520inhibitor%2520veliparib%2520plus%2520temozolomide%2520in%2520patients%2520with%2520heavily%2520pretreated%2520metastatic%2520colorectal%2520cancer%26jtitle%3DCancer%26date%3D2018%26volume%3D124%26spage%3D2337%26epage%3D2346%26doi%3D10.1002%2Fcncr.31309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loibl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shaughnessy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Untch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikov, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKee, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huober, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golshan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Minckwitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maag, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolmark, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponce Lorenzo, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzger Filho, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastogi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symmans, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, C. E.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(18)30111-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2FS1470-2045%2818%2930111-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=29501363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=497-509&author=S.+Loiblauthor=J.+O%E2%80%99Shaughnessyauthor=M.+Untchauthor=W.+M.+Sikovauthor=H.+S.+Rugoauthor=M.+D.+McKeeauthor=J.+Huoberauthor=M.+Golshanauthor=G.+von+Minckwitzauthor=D.+Maagauthor=D.+Sullivanauthor=N.+Wolmarkauthor=K.+McIntyreauthor=J.+J.+Ponce+Lorenzoauthor=O.+Metzger+Filhoauthor=P.+Rastogiauthor=W.+F.+Symmansauthor=X.+Liuauthor=C.+E.+Geyer&title=Addition+of+the+PARP+inhibitor+veliparib+plus+carboplatin+or+carboplatin+alone+to+standard+neoadjuvant+chemotherapy+in+triple-negative+breast+cancer+%28BrighTNess%29%3A+a+randomised%2C+phase+3+trial&doi=10.1016%2FS1470-2045%2818%2930111-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomized, phase 3 trial</span></div><div class="casAuthors">Loibl, Sibylle; O'Shaughnessy, Joyce; Untch, Michael; Sikov, William M.; Rugo, Hope S.; McKee, Mark D.; Huober, Jens; Golshan, Mehra; von Minckwitz, Gunter; Maag, David; Sullivan, Danielle; Wolmark, Norman; McIntyre, Kristi; Ponce Lorenzo, Jose J.; Metzger Filho, Otto; Rastogi, Priya; Symmans, W. Fraser; Liu, Xuan; Geyer, Charles E., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">497-509</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Background: Although several randomized trials in patients with triple-neg. breast cancer have shown that the addn. of carboplatin, with or without poly(ADP-ribose) polymerase (PARP) inhibitors, to neoadjuvant chemotherapy increases the likelihood of achieving a pathol. complete response, the use of these therapies in this setting has remained controversial.  The BrighTNess trial was designed to assess the addn. of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to std. neoadjuvant chemotherapy in triple-neg. breast cancer.  Methods: We did a phase 3, randomized, double-blind, placebo-controlled trial (BrighTNess) across 145 sites in 15 countries.  Patients aged 18 years and older with previously untreated histol. or cytol. confirmed clin. stage II-III triple-neg. breast cancer, who were candidates for potentially curative surgery and had an Eastern Cooperative Oncol. Group performance status of 0 or 1, were randomly assigned (2:1:1) by an interactive response technol. system via permuted blocks (block size of four) within strata to receive one of three segment 1 regimens: paclitaxel (80 mg/m2 i.v. weekly for 12 doses) plus carboplatin (area under the curve 6 mg/mL per min, i.v. every 3 wk, for four cycles) plus veliparib (50 mg orally, twice a day); paclitaxel plus carboplatin plus veliparib placebo (twice a day); or paclitaxel plus carboplatin placebo (every 3 wk for four cycles) plus veliparib placebo.  Following segment 1, all patients were assigned to segment 2 in which they received doxorubicin and cyclophosphamide every 2-3 wk for four cycles.  Randomisation for segment 1 was stratified by germline BRCA mutation status, nodal stage, and planned schedule of doxorubicin and cyclophosphamide administration.  The primary endpoint was pathol. complete response in breast and lymph nodes as detd. by site pathologists following completion of neoadjuvant therapy.  Efficacy analyses were done by intention to treat and safety analyses included all patients who received at least one dose of study treatment.  These are the first results of an ongoing clin. trial; the data cutoff for the analyses presented was Dec 8, 2016.  This study is registered with ClinicalTrials.gov, no. NCT02032277.  Findings: Between Apr. 4, 2014, and March 18, 2016, 634 patients were randomly assigned: 316 to paclitaxel plus carboplatin plus veliparib, 160 to paclitaxel plus carboplatin, and 158 to paclitaxel alone.  The proportion of patients who achieved a pathol. complete response was higher in the paclitaxel, carboplatin, and veliparib group than in patients receiving paclitaxel alone (168 [53%] of 316 patients vs 49 [31%] of 158, p<0·0001), but not compared with patients receiving paclitaxel plus carboplatin (92 [58%] of 160 patients, p=0·36).  Grade 3 or 4 toxicities, and serious adverse events were more common in patients receiving carboplatin, whereas veliparib did not substantially increase toxicity.  The most common grade 3 or 4 events overall were neutropenia (352 [56%] of 628 patients), anemia (180 [29%]), and thrombocytopenia (75 [12%]) through complete treatment, and febrile neutropenia (88 [15%] of 601 patients) during segment 2.  The most common serious adverse events were febrile neutropenia (80 [13%] of 628 patients) and anemia (20 [3%]).  Interpretation: Although the addn. of veliparib and carboplatin to paclitaxel followed by doxorubicin and cyclophosphamide improved the proportion of patients with triple-neg. breast cancer who achieved a pathol. complete response, the addn. of veliparib to carboplatin and paclitaxel did not.  Increased toxicities with the addn. of carboplatin (with or without veliparib) to paclitaxel were manageable and did not substantially affect treatment delivery of paclitaxel followed by doxorubicin and cyclophosphamide.  Given the consistent results with previous studies, the addn. of carboplatin appears to have a favorable risk to benefit profile and might be considered as a potential component of neoadjuvant chemotherapy for patients with high-risk, triple-neg. breast cancer.AbbVie.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8o10fhEXh6LVg90H21EOLACvtfcHk0lj3sio_MLS-wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGgur4%253D&md5=38b22907e32c3bab5faeaf9bf1a96719</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2818%2930111-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252818%252930111-6%26sid%3Dliteratum%253Aachs%26aulast%3DLoibl%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Shaughnessy%26aufirst%3DJ.%26aulast%3DUntch%26aufirst%3DM.%26aulast%3DSikov%26aufirst%3DW.%2BM.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DMcKee%26aufirst%3DM.%2BD.%26aulast%3DHuober%26aufirst%3DJ.%26aulast%3DGolshan%26aufirst%3DM.%26aulast%3Dvon%2BMinckwitz%26aufirst%3DG.%26aulast%3DMaag%26aufirst%3DD.%26aulast%3DSullivan%26aufirst%3DD.%26aulast%3DWolmark%26aufirst%3DN.%26aulast%3DMcIntyre%26aufirst%3DK.%26aulast%3DPonce%2BLorenzo%26aufirst%3DJ.%2BJ.%26aulast%3DMetzger%2BFilho%26aufirst%3DO.%26aulast%3DRastogi%26aufirst%3DP.%26aulast%3DSymmans%26aufirst%3DW.%2BF.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DGeyer%26aufirst%3DC.%2BE.%26atitle%3DAddition%2520of%2520the%2520PARP%2520inhibitor%2520veliparib%2520plus%2520carboplatin%2520or%2520carboplatin%2520alone%2520to%2520standard%2520neoadjuvant%2520chemotherapy%2520in%2520triple-negative%2520breast%2520cancer%2520%2528BrighTNess%2529%253A%2520a%2520randomised%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2018%26volume%3D19%26spage%3D497%26epage%3D509%26doi%3D10.1016%2FS1470-2045%2818%2930111-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horn, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baran, P. S.</span></span> <span> </span><span class="NLM_article-title">Synthetic organic electrochemistry: An enabling and innately sustainable method</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">302</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1021/acscentsci.6b00091</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.6b00091" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC28XntFyrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=302-308&author=E.+J.+Hornauthor=B.+R.+Rosenauthor=P.+S.+Baran&title=Synthetic+organic+electrochemistry%3A+An+enabling+and+innately+sustainable+method&doi=10.1021%2Facscentsci.6b00091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Organic Electrochemistry: An Enabling and Innately Sustainable Method</span></div><div class="casAuthors">Horn, Evan J.; Rosen, Brandon R.; Baran, Phil S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">302-308</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  While preparative electrolysis of org. mols. has been an active area of research over the past century, modern synthetic chemists have generally been reluctant to adopt this technol.  In fact, electrochem. methods possess many benefits over traditional reagent-based transformations, such as high functional group tolerance, mild conditions, and innate scalability and sustainability.  In this Outlook, we highlight illustrative examples of electrochem. reactions in the context of the synthesis of complex mols., showcasing the intrinsic benefits of electrochem. reactions vs. traditional reagent-based approaches.  Our hope is that this field will soon see widespread adoption in the synthetic community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGJWhmoi1pj7Vg90H21EOLACvtfcHk0lj3sio_MLS-wQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntFyrsLg%253D&md5=3ab155779f3a0a3b407e5197bcb67a37</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.6b00091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.6b00091%26sid%3Dliteratum%253Aachs%26aulast%3DHorn%26aufirst%3DE.%2BJ.%26aulast%3DRosen%26aufirst%3DB.%2BR.%26aulast%3DBaran%26aufirst%3DP.%2BS.%26atitle%3DSynthetic%2520organic%2520electrochemistry%253A%2520An%2520enabling%2520and%2520innately%2520sustainable%2520method%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2016%26volume%3D2%26spage%3D302%26epage%3D308%26doi%3D10.1021%2Facscentsci.6b00091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRoy, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perreault, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larivée, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harran, P. G.</span></span> <span> </span><span class="NLM_article-title">Electrolytic macrocyclizations: scalable synthesis of a diazonamide-based drug development candidate</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4818</span>– <span class="NLM_lpage">4822</span>, <span class="refDoi"> DOI: 10.1002/anie.201411663</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1002%2Fanie.201411663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvF2nu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=4818-4822&author=H.+Dingauthor=P.+L.+DeRoyauthor=C.+Perreaultauthor=A.+Lariv%C3%A9eauthor=A.+Siddiquiauthor=C.+G.+Caldwellauthor=S.+Harranauthor=P.+G.+Harran&title=Electrolytic+macrocyclizations%3A+scalable+synthesis+of+a+diazonamide-based+drug+development+candidate&doi=10.1002%2Fanie.201411663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Electrolytic Macrocyclizations: Scalable Synthesis of a Diazonamide-Based Drug Development Candidate</span></div><div class="casAuthors">Ding, Hui; DeRoy, Patrick L.; Perreault, Christian; Larivee, Alexandre; Siddiqui, Arshad; Caldwell, Charles G.; Harran, Susan; Harran, Patrick G.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4818-4822</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">An electrochem. method to synthesize the core macrolactam of diazonamides is described.  Large ring-forming dehydrogenation is initiated by anodic oxidn. at a graphite surface.  The reaction requires no tailoring of the substrate and occurs at ambient temp. in aq. DMF in an undivided cell open to air.  This unique chem. has enabled a concise, scalable prepn. of DZ-2384; a refined analog of diazonamide A slated for clin. development as a cancer therapeutic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR84QAkxXvorVg90H21EOLACvtfcHk0lgg7J6673vVVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvF2nu78%253D&md5=45c53b65fe3cf1b39f16e8966e6dfad9</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1002%2Fanie.201411663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201411663%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%26aulast%3DDeRoy%26aufirst%3DP.%2BL.%26aulast%3DPerreault%26aufirst%3DC.%26aulast%3DLariv%25C3%25A9e%26aufirst%3DA.%26aulast%3DSiddiqui%26aufirst%3DA.%26aulast%3DCaldwell%26aufirst%3DC.%2BG.%26aulast%3DHarran%26aufirst%3DS.%26aulast%3DHarran%26aufirst%3DP.%2BG.%26atitle%3DElectrolytic%2520macrocyclizations%253A%2520scalable%2520synthesis%2520of%2520a%2520diazonamide-based%2520drug%2520development%2520candidate%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D4818%26epage%3D4822%26doi%3D10.1002%2Fanie.201411663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maddess, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alorati, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremeyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleator, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dieguez-Vazquez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibb, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klapars, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span> <span> </span><span class="NLM_article-title">Enantioselective synthesis of a highly substituted tetrahydrofluorene derivative as a potent and selective estrogen receptor beta agonist</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">528</span>– <span class="NLM_lpage">538</span>, <span class="refDoi"> DOI: 10.1021/op5000489</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op5000489" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlOksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=528-538&author=M.+L.+Maddessauthor=J.+P.+Scottauthor=A.+Aloratiauthor=C.+Baxterauthor=N.+Bremeyerauthor=S.+Brewerauthor=K.+Camposauthor=E.+Cleatorauthor=A.+Dieguez-Vazquezauthor=A.+Gibbauthor=A.+Gibsonauthor=M.+Howardauthor=S.+Keenauthor=A.+Klaparsauthor=J.+Leeauthor=J.+Liauthor=J.+Lynchauthor=P.+Mullensauthor=D.+Wallaceauthor=R.+Wilson&title=Enantioselective+synthesis+of+a+highly+substituted+tetrahydrofluorene+derivative+as+a+potent+and+selective+estrogen+receptor+beta+agonist&doi=10.1021%2Fop5000489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective Synthesis of a Highly Substituted Tetrahydrofluorene Derivative as a Potent and Selective Estrogen Receptor Beta Agonist</span></div><div class="casAuthors">Maddess, Matthew L.; Scott, Jeremy P.; Alorati, Anthony; Baxter, Carl; Bremeyer, Nadine; Brewer, Sarah; Campos, Kevin; Cleator, Ed; Dieguez-Vazquez, Alejandro; Gibb, Andrew; Gibson, Andrew; Howard, Melissa; Keen, Stephen; Klapars, Artis; Lee, Jaemoon; Li, Jing; Lynch, Joseph; Mullens, Peter; Wallace, Debra; Wilson, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">528-538</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A practical asym. synthesis of an estrogen receptor β-selective agonist methanocycloheptaindenotriazolone I on multikilogram scale was developed using the diastereoselective alkylation of a phenoxyethyl indenopyridooxazolone II incorporating an aminoindanol chiral auxiliary with a bromomethylbenzotriazole III as the key step.  More than 30 kg of I in >99% ee was prepd. by a route with a longest linear sequence of thirteen steps in 21% overall yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRZ1TGpTmOubVg90H21EOLACvtfcHk0lgg7J6673vVVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlOksbs%253D&md5=6b441a45b5955c68815aa77b3fda75da</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1021%2Fop5000489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop5000489%26sid%3Dliteratum%253Aachs%26aulast%3DMaddess%26aufirst%3DM.%2BL.%26aulast%3DScott%26aufirst%3DJ.%2BP.%26aulast%3DAlorati%26aufirst%3DA.%26aulast%3DBaxter%26aufirst%3DC.%26aulast%3DBremeyer%26aufirst%3DN.%26aulast%3DBrewer%26aufirst%3DS.%26aulast%3DCampos%26aufirst%3DK.%26aulast%3DCleator%26aufirst%3DE.%26aulast%3DDieguez-Vazquez%26aufirst%3DA.%26aulast%3DGibb%26aufirst%3DA.%26aulast%3DGibson%26aufirst%3DA.%26aulast%3DHoward%26aufirst%3DM.%26aulast%3DKeen%26aufirst%3DS.%26aulast%3DKlapars%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLynch%26aufirst%3DJ.%26aulast%3DMullens%26aufirst%3DP.%26aulast%3DWallace%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DR.%26atitle%3DEnantioselective%2520synthesis%2520of%2520a%2520highly%2520substituted%2520tetrahydrofluorene%2520derivative%2520as%2520a%2520potent%2520and%2520selective%2520estrogen%2520receptor%2520beta%2520agonist%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2014%26volume%3D18%26spage%3D528%26epage%3D538%26doi%3D10.1021%2Fop5000489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sclafani, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reese, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudipalli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neville, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakale, R. P.</span></span> <span> </span><span class="NLM_article-title">The first asymmetric pilot-scale synthesis of TV-45070</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1616</span>– <span class="NLM_lpage">1624</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.7b00237</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.7b00237" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVGhsr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=1616-1624&author=J.+A.+Sclafaniauthor=J.+Chenauthor=D.+V.+Levyauthor=H.+Reeseauthor=M.+Dimitriauthor=P.+Mudipalliauthor=M.+Christieauthor=C.+J.+Nevilleauthor=M.+Olsenauthor=R.+P.+Bakale&title=The+first+asymmetric+pilot-scale+synthesis+of+TV-45070&doi=10.1021%2Facs.oprd.7b00237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">The First Asymmetric Pilot-Scale Synthesis of TV-45070</span></div><div class="casAuthors">Sclafani, Joseph A.; Chen, Jian; Levy, Daniel V.; Reese, Harlan; Dimitri, Mina; Mudipalli, Partha; Christie, Michael; Neville, Christopher J.; Olsen, Mark; Bakale, Roger P.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1616-1624</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">TV-45070 (formerly XEN-402) is a small-mol. lactam contg. a chiral spiro-ether that is reported as a potential topical therapy for pain assocd. with the Nav1.7 Na ion channel encoded by the gene SCN9A.  A pilot-scale synthesis is presented that is highlighted by an asym. aldol coupling at ambient temp., used to create a quaternary chiral center.  Although only a moderate ee was obtained, the removal of the undesired isomer is achieved through preferential pptn. of a near racemic mixt. from the reaction, leaving the enantiopure isomer in soln.  Cyclization to form the final API uses an uncommon diphenylphosphine-based leaving group which proved successful on the neopentyl system when other traditional leaving groups failed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvvJXHK7roRLVg90H21EOLACvtfcHk0lij3PoBisEO5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVGhsr3E&md5=0be4812d90881ccd423f3b70a64ea395</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.7b00237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.7b00237%26sid%3Dliteratum%253Aachs%26aulast%3DSclafani%26aufirst%3DJ.%2BA.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLevy%26aufirst%3DD.%2BV.%26aulast%3DReese%26aufirst%3DH.%26aulast%3DDimitri%26aufirst%3DM.%26aulast%3DMudipalli%26aufirst%3DP.%26aulast%3DChristie%26aufirst%3DM.%26aulast%3DNeville%26aufirst%3DC.%2BJ.%26aulast%3DOlsen%26aufirst%3DM.%26aulast%3DBakale%26aufirst%3DR.%2BP.%26atitle%3DThe%2520first%2520asymmetric%2520pilot-scale%2520synthesis%2520of%2520TV-45070%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2017%26volume%3D21%26spage%3D1616%26epage%3D1624%26doi%3D10.1021%2Facs.oprd.7b00237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scalabrino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankish, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, H.</span></span> <span> </span><span class="NLM_article-title">Investigation of the stereoselective synthesis of the indane dimer PH46A, a new potential anti-inflammatory agent</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1972</span>– <span class="NLM_lpage">1979</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.7b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.7b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVKisrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=1972-1979&author=G.+R.+Cummingauthor=T.+Zhangauthor=G.+Scalabrinoauthor=N.+Frankishauthor=H.+Sheridan&title=Investigation+of+the+stereoselective+synthesis+of+the+indane+dimer+PH46A%2C+a+new+potential+anti-inflammatory+agent&doi=10.1021%2Facs.oprd.7b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of the Stereoselective Synthesis of the Indane Dimer PH46A, a New Potential Anti-inflammatory Agent</span></div><div class="casAuthors">Cumming, Graham R.; Zhang, Tao; Scalabrino, Gaia; Frankish, Neil; Sheridan, Helen</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1972-1979</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PH46A, belonging to a class of 1,2-Indane dimers, has been developed by our research group as a potential therapeutic agent for the treatment of inflammatory and autoimmune diseases.  The initial synthetic route to PH46A gave a low overall yield, due in large part to the generation of undesired diastereoisomer I and the unwanted enantiomer (R,R)-II during the synthesis.  The aim of this work was to carry out a comprehensive investigation into the stereoselective synthesis of PH46A.  Significant progress was made on the ketone redn. step, where the use of triisobutylaluminum [TiBA, Al(iBu)3] afforded high selectivity for the target diastereoisomer (rac)-III, compared to the unfavorable ratio obtained using a previous process.  This enabled a multikilo scale synthesis of PH46A in a GMP environment.  Further, a brief proof-of-principle investigation was carried out using an achiral phase transfer catalyst (PTC) for alkylation at the methine carbon of the parent indanone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow1yX3lGQF-7Vg90H21EOLACvtfcHk0lij3PoBisEO5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVKisrvI&md5=a48530087953d2ac9cadb6771cc46908</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.7b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.7b00258%26sid%3Dliteratum%253Aachs%26aulast%3DCumming%26aufirst%3DG.%2BR.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DScalabrino%26aufirst%3DG.%26aulast%3DFrankish%26aufirst%3DN.%26aulast%3DSheridan%26aufirst%3DH.%26atitle%3DInvestigation%2520of%2520the%2520stereoselective%2520synthesis%2520of%2520the%2520indane%2520dimer%2520PH46A%252C%2520a%2520new%2520potential%2520anti-inflammatory%2520agent%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2017%26volume%3D21%26spage%3D1972%26epage%3D1979%26doi%3D10.1021%2Facs.oprd.7b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entwistle, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossop, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laity, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Praquin, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strang, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C. A. L.</span></span> <span> </span><span class="NLM_article-title">Development of a scaleable synthesis of a geminal dimethyl tertiary amine as an inhaled muscarinic antagonist for the treatment of COPD</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1021/op200233r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op200233r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVKlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=195-203&author=B.+R.+Dillonauthor=D.+F.+Robertsauthor=D.+A.+Entwistleauthor=P.+A.+Glossopauthor=C.+J.+Knightauthor=D.+A.+Laityauthor=K.+Jamesauthor=C.+F.+Praquinauthor=R.+S.+Strangauthor=C.+A.+L.+Watson&title=Development+of+a+scaleable+synthesis+of+a+geminal+dimethyl+tertiary+amine+as+an+inhaled+muscarinic+antagonist+for+the+treatment+of+COPD&doi=10.1021%2Fop200233r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a scaleable synthesis of a geminal dimethyl tertiary amine as an inhaled muscarinic antagonist for the treatment of COPD</span></div><div class="casAuthors">Dillon, Barry R.; Roberts, Dannielle F.; Entwistle, David A.; Glossop, Paul A.; Knight, Craig J.; Laity, Daniel A.; James, Kim; Praquin, Celine F.; Strang, Ross S.; Watson, Christine A. L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-203</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An efficient and scaleable process for the synthesis of muscarinic antagonist, PF-3635659 (I), is described, illustrating redesign of an analog-targeted synthesis which contained a scale-limiting rhodium-activated C-H amination step.  The final route includes a reproducible modified Bouveault reaction which has not previously been reported on a substrate of this complexity, or on such a scale with over 5 kg of the requisite gem-dimethylamine prepd. via this methodol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFXTINg0pelLVg90H21EOLACvtfcHk0lij3PoBisEO5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVKlug%253D%253D&md5=11262a71aaceed3259dc98bb73810bbe</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Fop200233r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop200233r%26sid%3Dliteratum%253Aachs%26aulast%3DDillon%26aufirst%3DB.%2BR.%26aulast%3DRoberts%26aufirst%3DD.%2BF.%26aulast%3DEntwistle%26aufirst%3DD.%2BA.%26aulast%3DGlossop%26aufirst%3DP.%2BA.%26aulast%3DKnight%26aufirst%3DC.%2BJ.%26aulast%3DLaity%26aufirst%3DD.%2BA.%26aulast%3DJames%26aufirst%3DK.%26aulast%3DPraquin%26aufirst%3DC.%2BF.%26aulast%3DStrang%26aufirst%3DR.%2BS.%26aulast%3DWatson%26aufirst%3DC.%2BA.%2BL.%26atitle%3DDevelopment%2520of%2520a%2520scaleable%2520synthesis%2520of%2520a%2520geminal%2520dimethyl%2520tertiary%2520amine%2520as%2520an%2520inhaled%2520muscarinic%2520antagonist%2520for%2520the%2520treatment%2520of%2520COPD%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2012%26volume%3D16%26spage%3D195%26epage%3D203%26doi%3D10.1021%2Fop200233r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Polster, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burcham, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaborenko, N.</span></span> <span> </span><span class="NLM_article-title">Pilot-scale continuous production of LY2886721: Amide formation and reactive crystallization</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1295</span>– <span class="NLM_lpage">1309</span>, <span class="refDoi"> DOI: 10.1021/op500204z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op500204z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslChtr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=1295-1309&author=C.+S.+Polsterauthor=K.+P.+Coleauthor=C.+L.+Burchamauthor=B.+M.+Campbellauthor=A.+L.+Frederickauthor=M.+M.+Hansenauthor=M.+Hardingauthor=M.+R.+Hellerauthor=M.+T.+Millerauthor=J.+L.+Phillipsauthor=P.+M.+Pollockauthor=N.+Zaborenko&title=Pilot-scale+continuous+production+of+LY2886721%3A+Amide+formation+and+reactive+crystallization&doi=10.1021%2Fop500204z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Pilot-Scale Continuous Production of LY2886721: Amide Formation and Reactive Crystallization</span></div><div class="casAuthors">Polster, Christopher S.; Cole, Kevin P.; Burcham, Christopher L.; Campbell, Bradley M.; Frederick, Andrea L.; Hansen, Marvin M.; Harding, Molly; Heller, Michael R.; Miller, Michael T.; Phillips, Joseph L.; Pollock, Patrick M.; Zaborenko, Nikolay</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1295-1309</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, development, and implementation of a pilot-scale continuous Schotten-Baumann amide bond formation and reactive crystn. to afford LY2886721 is described.  The material met all API quality attributes and was comparable to material produced by a defined batch process.  The scalability of the reaction and crystn. processes was confirmed during the development process.  The pilot-scale equipment set was contained in a walk-in fume hood and operated at a prodn. rate of 3 kg/day in a 72 h continuous run.  Significant tech. and business drivers for running the process in continuous flow mode were proposed and examd. during development.  The continuous process provided for lab hood commercialization and provided for minimal material at risk in the process.  The demonstration also confirmed the risk inherent to operation of a tubular reactor under supersatd. conditions, and fouling occurred in the plug flow reactor.  Fouling also occurred in the crystallizer.  Recognizing these deficiencies, the process operated within the footprint of a std. walk-in fume hood, providing a successful demonstration of the opportunities afforded by continuous processing for low vol. pharmaceuticals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzl8U-JufDgLVg90H21EOLACvtfcHk0liGIPK_aVjsKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslChtr7E&md5=2777d9d7600b877872d5bc74e367daf9</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Fop500204z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop500204z%26sid%3Dliteratum%253Aachs%26aulast%3DPolster%26aufirst%3DC.%2BS.%26aulast%3DCole%26aufirst%3DK.%2BP.%26aulast%3DBurcham%26aufirst%3DC.%2BL.%26aulast%3DCampbell%26aufirst%3DB.%2BM.%26aulast%3DFrederick%26aufirst%3DA.%2BL.%26aulast%3DHansen%26aufirst%3DM.%2BM.%26aulast%3DHarding%26aufirst%3DM.%26aulast%3DHeller%26aufirst%3DM.%2BR.%26aulast%3DMiller%26aufirst%3DM.%2BT.%26aulast%3DPhillips%26aufirst%3DJ.%2BL.%26aulast%3DPollock%26aufirst%3DP.%2BM.%26aulast%3DZaborenko%26aufirst%3DN.%26atitle%3DPilot-scale%2520continuous%2520production%2520of%2520LY2886721%253A%2520Amide%2520formation%2520and%2520reactive%2520crystallization%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2014%26volume%3D18%26spage%3D1295%26epage%3D1309%26doi%3D10.1021%2Fop500204z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giulianotti, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinilla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghten, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina-Franco, J. L.</span></span> <span> </span><span class="NLM_article-title">Chemoinformatic analysis of combinatorial libraries, drugs, natural products, and molecular libraries small molecule repository</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1010</span>– <span class="NLM_lpage">1024</span>, <span class="refDoi"> DOI: 10.1021/ci800426u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci800426u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjsVKktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=1010-1024&author=N.+Singhauthor=R.+Guhaauthor=M.+A.+Giulianottiauthor=C.+Pinillaauthor=R.+A.+Houghtenauthor=J.+L.+Medina-Franco&title=Chemoinformatic+analysis+of+combinatorial+libraries%2C+drugs%2C+natural+products%2C+and+molecular+libraries+small+molecule+repository&doi=10.1021%2Fci800426u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoinformatic Analysis of Combinatorial Libraries, Drugs, Natural Products, and Molecular Libraries Small Molecule Repository</span></div><div class="casAuthors">Singh, Narender; Guha, Rajarshi; Giulianotti, Marc A.; Pinilla, Clemencia; Houghten, Richard A.; Medina-Franco, Jose L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1010-1024</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A multiple criteria approach is presented, that is used to perform a comparative anal. of four recently developed combinatorial libraries to drugs, Mol. Libraries Small Mol. Repository (MLSMR) and natural products.  The compd. databases were assessed in terms of physicochem. properties, scaffolds, and fingerprints.  The approach enables the anal. of property space coverage, degree of overlap between collections, scaffold and structural diversity, and overall structural novelty.  The degree of overlap between combinatorial libraries and drugs was assessed using the R-NN curve methodol., which measures the d. of chem. space around a query mol. embedded in the chem. space of a target collection.  The combinatorial libraries studied in this work exhibit scaffolds that were not obsd. in the drug, MLSMR, and natural products databases.  The fingerprint-based comparisons indicate that these combinatorial libraries are structurally different than current drugs.  The R-NN curve methodol. revealed that a proportion of mols. in the combinatorial libraries is located within the property space of the drugs.  However, the R-NN anal. also showed that there are a significant no. of mols. in several combinatorial libraries that are located in sparse regions of the drug space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcwu-N7ebOhLVg90H21EOLACvtfcHk0liGIPK_aVjsKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjsVKktLY%253D&md5=4c246e6c66780516f596a7b398fc337b</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1021%2Fci800426u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci800426u%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DN.%26aulast%3DGuha%26aufirst%3DR.%26aulast%3DGiulianotti%26aufirst%3DM.%2BA.%26aulast%3DPinilla%26aufirst%3DC.%26aulast%3DHoughten%26aufirst%3DR.%2BA.%26aulast%3DMedina-Franco%26aufirst%3DJ.%2BL.%26atitle%3DChemoinformatic%2520analysis%2520of%2520combinatorial%2520libraries%252C%2520drugs%252C%2520natural%2520products%252C%2520and%2520molecular%2520libraries%2520small%2520molecule%2520repository%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2009%26volume%3D49%26spage%3D1010%26epage%3D1024%26doi%3D10.1021%2Fci800426u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, J.</span></span> <span> </span><span class="NLM_article-title">Will combinatorial chemistry keep its promise?</span>. <i>Biotechnol. Healthcare</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">32</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=23393460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A280%3ADC%252BC3szmslWlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=26-32&author=J.+Carroll&title=Will+combinatorial+chemistry+keep+its+promise%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Will combinatorial chemistry keep its promise?</span></div><div class="casAuthors">Carroll John</div><div class="citationInfo"><span class="NLM_cas:title">Biotechnology healthcare</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">26-32</span>
        ISSN:<span class="NLM_cas:issn">1554-169X</span>.
    </div><div class="casAbstract">Although this technology has come under fire, it isn't being abandoned.  Biotechs that use combichem are developing new strategies - replacing diverse compound libraries with smaller, targeted libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS83ZdOHnrtdXO4gDb7JggCfW6udTcc2eZiD0qhFlMHh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szmslWlsQ%253D%253D&md5=2de10527093d0e78140e7c3aa9d94478</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCarroll%26aufirst%3DJ.%26atitle%3DWill%2520combinatorial%2520chemistry%2520keep%2520its%2520promise%253F%26jtitle%3DBiotechnol.%2520Healthcare%26date%3D2005%26volume%3D2%26spage%3D26%26epage%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kodadek, T.</span></span> <span> </span><span class="NLM_article-title">The rise, fall and reinvention of combinatorial chemistry</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">9757</span>– <span class="NLM_lpage">9763</span>, <span class="refDoi"> DOI: 10.1039/c1cc12102b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1039%2Fc1cc12102b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=21701754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVGms7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=9757-9763&author=T.+Kodadek&title=The+rise%2C+fall+and+reinvention+of+combinatorial+chemistry&doi=10.1039%2Fc1cc12102b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">The rise, fall and reinvention of combinatorial chemistry</span></div><div class="casAuthors">Kodadek, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">9757-9763</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Combinatorial chem. provides a powerful tool for the rapid creation of large nos. of synthetic compds.  Ideally, these libraries should be a rich source of bioactive mols., but there is the general feeling that the initial promise of combinatorial chem. has not yet been realized.  In particular, enthusiasm for conducting unbiased (non-structure-guided) screens of large libraries for protein or RNA ligands has waned.  A central challenge in this area is to devise methods for the synthesis of chem. diverse, high-quality libraries of mols. with many of the desirable features of natural products.  These include diverse functionality, a significant representation of chiral sp3 centers that provide conformational bias to the mol., significant skeletal diversity, and good pharmacokinetic properties.  However, these libraries must be easy to make from cheap, readily available building blocks, ideally those that would support convenient hit optimization/structure reactivity relationship studies.  Meeting these challenges will not be easy.  Here I review some recent advances in this area and provide some thoughts on likely important developments in the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ-foGwWRw_7Vg90H21EOLACvtfcHk0lioWsv4zzMMmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVGms7rN&md5=7f511292a501b50ff78bb497021b87e0</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1039%2Fc1cc12102b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1cc12102b%26sid%3Dliteratum%253Aachs%26aulast%3DKodadek%26aufirst%3DT.%26atitle%3DThe%2520rise%252C%2520fall%2520and%2520reinvention%2520of%2520combinatorial%2520chemistry%26jtitle%3DChem.%2520Commun.%26date%3D2011%26volume%3D47%26spage%3D9757%26epage%3D9763%26doi%3D10.1039%2Fc1cc12102b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thorpe, D. S.</span></span> <span> </span><span class="NLM_article-title">Combinatorial chemistry: starting the second decade</span>. <i>Pharmacogenomics J.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1038/sj.tpj.6500045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1038%2Fsj.tpj.6500045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=11908762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjtlamtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=229-232&author=D.+S.+Thorpe&title=Combinatorial+chemistry%3A+starting+the+second+decade&doi=10.1038%2Fsj.tpj.6500045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial chemistry: Starting the second decade</span></div><div class="casAuthors">Thorpe, D. S.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacogenomics Journal</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">229-233</span>CODEN:
                <span class="NLM_cas:coden">PJHOAZ</span>;
        ISSN:<span class="NLM_cas:issn">1470-269X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review introduces the basic concepts of combinatorial chem., describe its strengths and weaknesses with an eye to efficiencies, and emphasize some ongoing changes to enhance performance.  The scope is restricted to small compds. made by synthetic chem., and not biol. generated libraries such as phage display.  The first generation of combinatorial chem. was based on polymer chem.  The high-diversity second-generation libraries were effective in generating hits and leads for only certain types of screens.  The current third generation of combinatorial chem. is building on its strength.  Design of the collections now employs empirical knowledge, sophisticated algorithms, and medicinal chem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx1sxCVdJh7bVg90H21EOLACvtfcHk0lgsFXuoVyj5Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjtlamtg%253D%253D&md5=f6e3e01f8b715b52827394d42fc038d3</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1038%2Fsj.tpj.6500045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.tpj.6500045%26sid%3Dliteratum%253Aachs%26aulast%3DThorpe%26aufirst%3DD.%2BS.%26atitle%3DCombinatorial%2520chemistry%253A%2520starting%2520the%2520second%2520decade%26jtitle%3DPharmacogenomics%2520J.%26date%3D2001%26volume%3D1%26spage%3D229%26epage%3D232%26doi%3D10.1038%2Fsj.tpj.6500045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P. J.</span></span> <span> </span><span class="NLM_article-title">Moving beyond combinatorial chemistry for greater efficiency in lead discovery</span>. <i>JALA</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1016/S1535-5535-04-00175-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=10.1016%2FS1535-5535-04-00175-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;key=1%3ACAS%3A528%3ADC%252BD38Xit1amtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2002&pages=59-63&author=P.+J.+Edwards&title=Moving+beyond+combinatorial+chemistry+for+greater+efficiency+in+lead+discovery&doi=10.1016%2FS1535-5535-04-00175-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Moving beyond combinatorial chemistry for greater efficiency in lead discovery</span></div><div class="casAuthors">Edwards, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">JALA</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-63</span>CODEN:
                <span class="NLM_cas:coden">JALLFO</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">JALA</span>)
        </div><div class="casAbstract">A review.  Pfizer Inc. is a research based global pharmaceutical company committed to the discovery and development of innovative medicines that improve the quality of life of individuals throughout the world.  In order to gain a competitive advantage over competitor companies in the discovery of new medicines, we must speed up drug discovery and drive down costs.  Using non-combinatorial chem. techniques increases the efficiency with which we discover new "leads," leveraging our drug discovery efforts through retaining complete control over the properties of each product made.  Compd. purifn., managed through inhouse software, augments the quality of data obtained upon biol. screening of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL8vaIVL65QrVg90H21EOLACvtfcHk0lgsFXuoVyj5Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xit1amtLY%253D&md5=ac35620cd2d245fa458331a2ee786b65</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2FS1535-5535-04-00175-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1535-5535-04-00175-3%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DP.%2BJ.%26atitle%3DMoving%2520beyond%2520combinatorial%2520chemistry%2520for%2520greater%2520efficiency%2520in%2520lead%2520discovery%26jtitle%3DJALA%26date%3D2002%26volume%3D7%26spage%3D59%26epage%3D63%26doi%3D10.1016%2FS1535-5535-04-00175-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00829&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00829%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-22" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00829" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a7ec2deaf3d8e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
